PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FEDER, HM				FEDER, HM			IMAGES IN CLINICAL MEDICINE - 5TH DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FEDER, HM (corresponding author), UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06030, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1062	1062						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090166				2022-12-28	WOS:A1994PL56000005
J	PASRICHA, PJ; RAVICH, WJ; HENDRIX, TR; SOSTRE, S; JONES, B; KALLOO, AN				PASRICHA, PJ; RAVICH, WJ; HENDRIX, TR; SOSTRE, S; JONES, B; KALLOO, AN			TREATMENT OF ACHALASIA WITH INTRASPHINCTERIC INJECTION OF BOTULINUM TOXIN - A PILOT TRIAL	ANNALS OF INTERNAL MEDICINE			English	Note							DILATATION; DISORDERS				PASRICHA, PJ (corresponding author), JOHNS HOPKINS UNIV HOSP, 600 N WOLFE ST, BLALOCK 4, BALTIMORE, MD 21287 USA.		Kalloo, Anthony/AAY-9380-2020					COCCIA G, 1991, GUT, V32, P604, DOI 10.1136/gut.32.6.604; CSENDES A, 1989, GUT, V30, P299, DOI 10.1136/gut.30.3.299; ECKARDT VF, 1992, GASTROENTEROLOGY, V103, P1732, DOI 10.1016/0016-5085(92)91428-7; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; PASRICHA PJ, 1993, GASTROENTEROLOGY, V105, P1045, DOI 10.1016/0016-5085(93)90947-B; RICHTER JE, 1991, TXB GASTROENTEROLOGY, P1083; ROBERTSON CS, 1989, GUT, V30, P768, DOI 10.1136/gut.30.6.768; STUART RC, 1989, BRIT J SURG, V76, P1111, DOI 10.1002/bjs.1800761104; VANTRAPPEN G, 1980, GASTROENTEROLOGY, V79, P144; WONG RKH, 1992, ESOPHAGUS, P233	10	128	135	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					590	591		10.7326/0003-4819-121-8-199410150-00006	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085691				2022-12-28	WOS:A1994PL48600006
J	BRITTBERG, M; LINDAHL, A; NILSSON, A; OHLSSON, C; ISAKSSON, O; PETERSON, L				BRITTBERG, M; LINDAHL, A; NILSSON, A; OHLSSON, C; ISAKSSON, O; PETERSON, L			TREATMENT OF DEEP CARTILAGE DEFECTS IN THE KNEE WITH AUTOLOGOUS CHONDROCYTE TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RABBIT ARTICULAR-CARTILAGE; PERICHONDRIAL GRAFTS; PERIOSTEAL GRAFTS; OSTEO-ARTHRITIS; REPAIR; RECONSTRUCTION; SURFACES	Background. Full-thickness defects of articular cartilage in the knee have a poor capacity for repair. They may progress to osteoarthritis and require total knee replacement. We performed autologous chondrocyte transplantation in 23 people with deep cartilage defects in the knee. Methods. The patients ranged in age from 14 to 48 years and had full-thickness cartilage defects that ranged in size from 1.6 to 6.5 cm(2). Healthy chondrocytes obtained from an uninvolved area of the injured knee during arthroscopy were isolated and cultured in the laboratory for 14 to 21 days. The cultured chondrocytes were then injected into the area of the defect. The defect was covered with a sutured periosteal flap taken from the proximal medial tibia. Evaluation included clinical examination according to explicit criteria and arthroscopic examination with a biopsy of the transplantation site. Results. Patients were followed for 16 to 66 months (mean, 39). initially, the transplants eliminated knee locking and reduced pain and swelling in all patients. After three months, arthroscopy showed that the transplants were level with the surrounding tissue and spongy when probed, with visible borders. A second arthroscopic examination showed that in many instances the transplants had the same macroscopic appearance as they had earlier but were firmer when probed and similar in appearance to the surrounding cartilage. Two years after transplantation, 14 of the 16 patients with femoral condylar transplants had good-to-excellent results. Two patients required a second operation because of severe central wear in the transplants, with locking and pain. A mean of 36 months after transplantation, the results were excellent or good in two of the seven patients with patellar transplants, fair in three, and poor in two; two patients required a second operation because of severe chondromalacia. Biopsies showed that 11 of the 15 femoral transplants and 1 of the 7 patellar transplants had the appearance of hyaline cartilage. Conclusions. Cultured autologous chondrocytes can be used to repair deep cartilage defects in the femorotibial articular surface of the knee joint.	GOTHENBURG UNIV, SAHLGRENS UNIV HOSP, DEPT CLIN CHEM, ENDOCRINOL & METAB RES CTR, S-41345 GOTHENBURG, SWEDEN; UNIV GOTHENBURG, SAHLGRENS UNIV HOSP, DEPT ORTHOPED SURG, GOTHENBURG, SWEDEN; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT INTERNAL MED, S-41345 GOTHENBURG, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg			Lindahl, Anders/H-9550-2014; Ohlsson, Claes/AGP-3544-2022; Ohlsson, Claes/HIR-6959-2022	Lindahl, Anders/0000-0003-2871-5166; Ohlsson, Claes/0000-0002-9633-2805; Ohlsson, Claes/0000-0002-9633-2805				AMIEL D, 1985, J BONE JOINT SURG AM, V67A, P911, DOI 10.2106/00004623-198567060-00013; AMSTUTZ HC, 1986, CLIN ORTHOP RELAT R, V213, P92; ASTON JE, 1986, J BONE JOINT SURG BR, V68, P29, DOI 10.1302/0301-620X.68B1.3941138; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BRITTBERG M, 1989, 1989 BAT SHEV SEM ME, V1, P28; BUCHWALTER JA, 1990, ARTICULAR CARTILAGE, P19; CHESTERMAN P J, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P184; COLETTI JM, 1972, J BONE JOINT SURG AM, VA 54, P147, DOI 10.2106/00004623-197254010-00014; DANDY DJ, 1975, J BONE JOINT SURG BR, V57, P346, DOI 10.1302/0301-620X.57B3.346; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; ELVES MW, 1974, J BONE JOINT SURG BR, VB 56, P178; ENGKVIST O, 1979, SCAND J PLAST RECONS, V13, P361, DOI 10.3109/02844317909013084; ENGKVIST O, 1979, SCAND J PLAST RECONS, V13, P269, DOI 10.3109/02844317909013069; FICAT RP, 1979, CLIN ORTHOP RELAT R, V144, P74; FURUKAWA T, 1980, J BONE JOINT SURG AM, V62, P79, DOI 10.2106/00004623-198062010-00012; GRANDE DA, 1989, J ORTHOP RES, V7, P208, DOI 10.1002/jor.1100070208; GREEN WT, 1977, CLIN ORTHOP RELAT R, V124, P237; GYLYSMORIN VM, 1987, AM J ROENTGENOL, V148, P1153, DOI 10.2214/ajr.148.6.1153; Hunter W., 1743, SURGEON, V42, P514, DOI [10.1098/rstl.1742.0079, DOI 10.1098/RSTL.1742.0079)]; INSALL J, 1974, CLIN ORTHOP RELAT R, P61; Johnson L, 1991, OPERATIVE ARTHROSCOP, P341; JOHNSONNURSE C, 1985, J BONE JOINT SURG BR, V67, P42, DOI 10.1302/0301-620X.67B1.3968141; KAWABE N, 1991, CLIN ORTHOP RELAT R, V268, P279; KLARESKOG L, 1986, ARTHRITIS RHEUM, V29, P730, DOI 10.1002/art.1780290605; LANDON GC, 1985, CLIN ORTHOP RELAT R, V192, P69; LANGER F, 1974, J BONE JOINT SURG AM, VA 56, P297, DOI 10.2106/00004623-197456020-00007; MITCHELL N, 1976, J BONE JOINT SURG AM, V58, P230, DOI 10.2106/00004623-197658020-00012; MUCKLE DS, 1990, J BONE JOINT SURG BR, V72, P60, DOI 10.1302/0301-620X.72B1.2404987; NIEDERMANN B, 1985, ACTA ORTHOP SCAND, V56, P457, DOI 10.3109/17453678508993034; NOYES FR, 1980, J BONE JOINT SURG AM, V62, P687, DOI 10.2106/00004623-198062050-00001; ODRISCOLL SW, 1986, CLIN ORTHOP RELAT R, V208, P131; OUTERBRIDGE RE, 1961, J BONE JOINT SURG BR, V43, P752; PETERSON L, 1984, 30TH T ANN ORTH RES, P218; PRAEMER A, 1992, MUSCULOSKELETAL COND, P125; RADIN EL, 1978, CLIN ORTHOP RELAT R, P288; RADIN EL, 1992, OSTEOARTHRITIS DIAGN, P341; ROTHWELL AG, 1990, ORTHOPEDICS, V13, P433; RUBAK JM, 1982, ACTA ORTHOP SCAND, V53, P175, DOI 10.3109/17453678208992197; WAKITANI S, 1989, J BONE JOINT SURG BR, V71, P74, DOI 10.1302/0301-620X.71B1.2915011; WOJTYS E, 1987, AM J SPORT MED, V15, P455, DOI 10.1177/036354658701500505	40	4005	4278	14	368	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					889	895		10.1056/NEJM199410063311401	http://dx.doi.org/10.1056/NEJM199410063311401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078550				2022-12-28	WOS:A1994PJ41900001
J	BIDANI, A; TZOUANAKIS, AE; CARDENAS, VJ; ZWISCHENBERGER, JB				BIDANI, A; TZOUANAKIS, AE; CARDENAS, VJ; ZWISCHENBERGER, JB			PERMISSIVE HYPERCAPNIA IN ACUTE RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE-PRESSURE VENTILATION; END-EXPIRATORY PRESSURE; CRITICALLY ILL PATIENTS; HIGH AIRWAY PRESSURE; HIGH TIDAL VOLUME; MECHANICAL VENTILATION; STATUS-ASTHMATICUS; DISTRESS SYNDROME; PULMONARY-EDEMA; LACTIC-ACIDOSIS	Objective.-To evaluate the potential efficacy of pressure limitation with permissive hypercapnia in the treatment of acute respiratory failure/adult respiratory distress syndrome on the basis of current theories of ventilator-induced lung injury, potential complications of systemic hypercarbia, and available human outcome studies. Data Sources.-Articles were identified through MEDLINE, reference citations of published data, and consultation with authorities in their respective fields. Study Selection.-Animal model experimentation and human clinical trials were selected on the basis of whether they addressed the questions of pressure limitation with or without hypercapnia, the pathophysiologic effects of hypercapnia, or the concept of ventilator-induced parenchymal lung injury. Frequently cited references were preferentially included. Data Extraction.-Data were analyzed with particular emphasis on obtaining the following variables from the clinical studies: peak inspiratory pressures, tidal volumes, minute ventilation, and PCO2. Quantitative aspects of respiratory physiology were used to analyze the theoretical effects of permissive hypercapnia on ventilatory requirements in normal and injured lungs. Data Synthesis.-Extensive animal model data support the hypothesis that ventilator-driven alveolar overdistention can induce significant parenchymal lung injury. The heterogeneous nature of lung injury in adult respiratory distress syndrome, with its small physiologic lung volume, may render the lung susceptible to this type of injury through the use of conventional tidal volumes (10 to 15 mL/kg). Permissive hypercapnia is an approach whereby alveolar overdistention is minimized through either pressure or volume limitation, and the potential deleterious consequences of respiratory acidosis are accepted. Uncontrolled human trials of explicit or implicit permissive hypercapnia have demonstrated improved survival in comparison with models of predictive mortality. Conclusions.-Avoidance of alveolar overdistention through pressure or volume limitation has significant support based on animal models and computer simulation. Deleterious effects of the associated hypercarbia in severe lung injury do not appear to be a significant limiting factor in preliminary human clinical trials. Although current uncontrolled studies suggest benefit, controlled trials are urgently needed to confirm these findings before adoption of the treatment can be endorsed.	UNIV TEXAS,MED BRANCH,DEPT THORAC SURG,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	BIDANI, A (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV PULM,0561,GALVESTON,TX 77555, USA.							ARIEFF AI, 1982, AM J PHYSIOL, V242, pF586, DOI 10.1152/ajprenal.1982.242.6.F586; ASHBAUGH DG, 1967, LANCET, V2, P319; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; BIDANI A, FLUID ELECTROLYTE AC; BOWTON DL, 1989, CRIT CARE MED, V17, P908, DOI 10.1097/00003246-198909000-00014; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; COOPER DJ, 1990, ANN INTERN MED, V112, P492, DOI 10.7326/0003-4819-112-7-492; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DAUGHERTY RM, 1967, AM J PHYSIOL, V5, P1102; DOUGLASS JA, 1992, AM REV RESPIR DIS, V146, P517, DOI 10.1164/ajrccm/146.2.517; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1992, INTENS CARE MED, V18, P139, DOI 10.1007/BF01709236; EPSTEIN RM, 1966, ANESTHESIOLOGY, V27, P654, DOI 10.1097/00000542-196609000-00017; FOEX P, 1972, CARDIOVASC RES, V6, P257, DOI 10.1093/cvr/6.3.257; FUJITA Y, 1989, ANESTH ANALG, V69, P152; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; HERNANDEZ LA, 1989, J APPL PHYSIOL, V66, P2364, DOI 10.1152/jappl.1989.66.5.2364; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HICKLING KG, 1993, RESPIR CARE, V38, P379; HOKA S, 1992, CAN J PHYSIOL PHARM, V70, P1032, DOI 10.1139/y92-142; HURST JM, 1990, ANN SURG, V211, P486, DOI 10.1097/00000658-199004000-00017; IRWIN RL, 1957, ANESTHESIOLOGY, V18, P594, DOI 10.1097/00000542-195707000-00007; KAWANO T, 1987, J APPL PHYSIOL, V62, P27, DOI 10.1152/jappl.1987.62.1.27; KNABE U, 1972, VASCULAR SMOOTH MUSC, P83; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; KUPTER Y, 1992, ANN INTERN MED, V117, P484; LASSEN NA, 1968, SCAND J CLIN LAB INV, V22, P247, DOI 10.3109/00365516809167060; LEWANDOWSKI K, 1992, YB INTENSIVE CARE EM, P372; MATALON S, 1983, J APPL PHYSIOL, V54, P803, DOI 10.1152/jappl.1983.54.3.803; MENITOVE SM, 1983, AM J MED, V74, P898, DOI 10.1016/0002-9343(83)91082-3; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS LR, 1986, ANN INTERN MED, V105, P836, DOI 10.7326/0003-4819-105-6-836; MORRIS ME, 1962, BRIT J ANAESTH, V34, P672, DOI 10.1093/bja/34.10.672; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OTT NT, 1973, CIRC RES, V33, P160, DOI 10.1161/01.RES.33.2.160; POTKIN RT, 1992, CHEST, V102, P1742, DOI 10.1378/chest.102.6.1742; PRYSROBERTS C, 1971, GENERAL ANESTHESIA, P224; PRYSROBERTS C, 1980, GENERAL ANAESTHESIA, P435; RAHN H, 1976, B EUR PHYSIOPATH RES, V12, P5; RAHN H, 1975, AM REV RESPIR DIS, V112, P165; RAICHLE ME, 1971, BRAIN BLOOD FLOW, P223; ROBIN ED, 1963, NEW ENGL J MED, V268, P917, DOI 10.1056/NEJM196304252681703; SCHIEVE JF, 1953, J CLIN INVEST, V32, P33, DOI 10.1172/JCI102707; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SHAPIRO JM, 1993, INTENS CARE MED, V8, P144; SIEJO BK, 1972, J NEUROCHEM, V19, P2483; SIEJO BK, 1971, SCAND J CLIN LAB INV, V28, P113; TENNEY SM, 1967, RESP PHYSIOL, V3, P130, DOI 10.1016/0034-5687(67)90002-3; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; TZOUANAKIS AE, 1993, AM REV RESPIR DIS, V147, pA891; WALLEY KR, 1990, CIRC RES, V67, P628, DOI 10.1161/01.RES.67.3.628; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	56	116	125	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					957	962		10.1001/jama.272.12.957	http://dx.doi.org/10.1001/jama.272.12.957			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084064				2022-12-28	WOS:A1994PG73700024
J	WANG, L; MIURA, M; BERGERON, L; ZHU, H; YUAN, JY				WANG, L; MIURA, M; BERGERON, L; ZHU, H; YUAN, JY			ICH-1, AN ICE/CED-3-RELATED GENE, ENCODES BOTH POSITIVE AND NEGATIVE REGULATORS OF PROGRAMMED CELL-DEATH	CELL			English	Article							CAENORHABDITIS-ELEGANS; ENZYME; CED-3; INHIBITORS; PROTEASE; LINE	We report here the isolation and characterization of Ich-1, a gene related to the C. elegans cell death gene ced-3 and the mammalian homolog of ced-3, interleukin-1 beta-converting enzyme (ICE). Alternative splicing results in two distinct Ich-1 mRNA species. One mRNA species encodes a protein product of 435 amino acids (ICH-1(L)) that is homologous to both the P20 and P10 subunits of ICE (27% identity) and the entire CED-3 protein (28% identity). The other mRNA encodes a 312 amino acid truncated version of ICH-1(L) protein (ICH-1(s)). Overexpression of Ich(L) induces programmed cell death, suggesting that Ich-1 is also a mammalian programmed cell death gene. More interestingly, overexpression of the Ich-1(s) suppresses Rat-1 cell death induced by serum deprivation. These observations suggest that Ich-1 plays an important role in both positive and negative regulation of programmed cell death in vertebrate animals.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	WANG, L (corresponding author), MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129, USA.			Zhu, Hong/0000-0002-2575-4031				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DINARELLO CA, 1991, BLOOD, V77, P1627; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VUX DL, 1994, CELL, V76, P777; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	19	831	879	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					739	750		10.1016/S0092-8674(94)90422-7	http://dx.doi.org/10.1016/S0092-8674(94)90422-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087842				2022-12-28	WOS:A1994PG29600004
J	HASHIMOTO, L; HABITA, C; BERESSI, JP; DELEPINE, M; BESSE, C; CAMBONTHOMSEN, A; DESCHAMPS, I; ROTTER, JI; DJOULAH, S; JAMES, MR; FROGUEL, P; WEISSENBACH, J; LATHROP, GM; JULIER, C				HASHIMOTO, L; HABITA, C; BERESSI, JP; DELEPINE, M; BESSE, C; CAMBONTHOMSEN, A; DESCHAMPS, I; ROTTER, JI; DJOULAH, S; JAMES, MR; FROGUEL, P; WEISSENBACH, J; LATHROP, GM; JULIER, C			GENETIC-MAPPING OF A SUSCEPTIBILITY LOCUS FOR INSULIN-DEPENDENT DIABETES-MELLITUS ON CHROMOSOME 11Q	NATURE			English	Article							BB RAT; REGION; MARKER; RT6	LOCI in the major histocompatibility complex (MHC) on chromosome 6 and the insulin (INS) region on chromosome 11 have been implicated in susceptibility to insulin-dependent diabetes mellitus (IDDM) through candidate gene investigations(1-5), but they may account for less than 50% of genetic risk for the disease(6). Genome-wide linkage studies have led to localization of more than 10 susceptibility loci for insulin-dependent diabetes in the non-obese diabetic (NOD) mouse(7) and the BB rat(8). Similar studies are now possible in humans through the development of dense genetic maps of highly informative microsatellite loci obtained using polymerase chain reaction analysis(9). We have applied microsatellite markers from recent Genethon maps(10,11), and other highly informative markers, in a genome-wide linkage study in IDDM. Here we report evidence for the localization of a previously undetected susceptibility locus for IDDM in the region of the FGF3 gene on chromosome 11q. Our result shows the potential of genome-wide linkage studies to detect susceptibility loci in IDDM and other multifactorial disorders.	HOP ST LOUIS,INSERM,U358,F-75010 PARIS,FRANCE; WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; HOP ST LOUIS,INSERM,U93,F-75010 PARIS,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; HOP PURPAN,CTR IMMUNOPATHOL & GENET HUMAINE,CNRS,UPR 8291,F-31300 TOULOUSE,FRANCE; HOP NECKER ENFANTS MALAD,SERV ENDOCRINOL & DIABET ENFANT,F-75015 PARIS,FRANCE; CEDARS SINAI MED CTR,DIV MED GENET,LOS ANGELES,CA 90048; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90048; GENETHON,F-91002 EVRY,FRANCE; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			JULIER, Cécile/M-9824-2017; FROGUEL, Philippe/O-6799-2017	JULIER, Cécile/0000-0002-1538-0240; FROGUEL, Philippe/0000-0003-2972-0784	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIN SC, 1992, NAT GENET, V2, P212, DOI 10.1038/ng1192-212; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; GOSH S, 1993, NAT GENET, V4, P404; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HYER RN, 1991, AM J HUM GENET, V48, P243; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; JAMES M, IN PRESS NATURE GENE; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; LANG F, 1989, EUR J IMMUNOL, V19, P1785, DOI 10.1002/eji.1830191004; LATHROP GM, 1994, NAT GENET, V6, P327; PROCHAZKA M, 1991, IMMUNOGENETICS, V33, P152, DOI 10.1007/BF00210829; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; RISCH N, 1988, AM J HUM GENET, V40, P1; THOMSON G, 1988, AM J HUM GENET, V43, P799; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; VADHEIM CM, 1992, INT TXB DIABETES MEL, P31; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; 1989, SAGE STATISTICAL ANA	22	384	392	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					161	164		10.1038/371161a0	http://dx.doi.org/10.1038/371161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072544				2022-12-28	WOS:A1994PF19100065
J	HOGE, CW; REICHLER, MR; DOMINGUEZ, EA; BREMER, JC; MASTRO, TD; HENDRICKS, KA; MUSHER, DM; ELLIOTT, JA; FACKLAM, RR; BREIMAN, RF				HOGE, CW; REICHLER, MR; DOMINGUEZ, EA; BREMER, JC; MASTRO, TD; HENDRICKS, KA; MUSHER, DM; ELLIOTT, JA; FACKLAM, RR; BREIMAN, RF			AN EPIDEMIC OF PNEUMOCOCCAL DISEASE IN AN OVERCROWDED, INADEQUATELY VENTILATED JAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICK BUILDING SYNDROME; RESISTANT STREPTOCOCCUS-PNEUMONIAE; POLYSACCHARIDE VACCINE; OUTBREAK; TUBERCULOSIS; TRANSMISSION; CARRIAGE; FAMILIES; SYMPTOMS; EFFICACY	Background. In the United States many correctional facilities now operate at far over capacity, with the potential for living conditions that permit outbreaks of respiratory infections. We investigated an outbreak that was identified in an overcrowded Houston jail after two inmates died of pneumococcal sepsis on the same day. Outbreaks of pneumococcal disease have been rare in the era of antibiotics. Methods. We assessed risk factors for pneumococcal disease in both a case-control and a cohort study. Ventilation was evaluated by measuring carbon dioxide levels and air flow to the living areas of the jail. The extent of asymptomatic infection was determined by culturing pharyngeal specimens from a random sample of inmates. Type-specific immunity was determined with an enzyme immunoassay. Results. Over a four-week period, 46 inmates had either acute pneumonia or invasive pneumococcal disease due to Streptococcus pneumoniae serotype 12F. The jail's capacity had been set at 3500 inmates, but it housed 6700 at the time of the outbreak; the inmates had a median living area of only 34 ft(2) (3.2 m(2)) (interquartile range, 28 to 56 ft(2) [2.6 to 5.2 m(2)]) per person. There were significantly fewer cases of disease among inmates with 80 ft(2) (7.4 m(2)) per person or more (P = 0.030). Carbon dioxide levels ranged from 1100 to 2500 ppm (acceptable, <1000), and the ventilation system delivered a median of only 6.1 ft(3) of outside air per minute per person (interquartile range, 4.4 to 8.5 ft(3); recommended, greater than or equal to 20 ft(3)). The attack rate was highest among inmates in cells with the highest carbon dioxide levels and the lowest volume of outside air delivered by the ventilation system (relative risk, 1.94; 95 percent confidence interval, 1.08 to 3.48). Of underlying medical conditions, intravenous drug use was most strongly associated with disease (odds ratio, 4.50). The epidemic strain (serotype 12F) was cultured from 7 percent of the asymptomatic inmates. Of 11 case patients tested with the enzyme immunoassay, 9 (82 percent) lacked preexisting immunity to this strain. Conclusions. Severe overcrowding, inadequate ventilation, and altered host susceptibility all contributed to this outbreak of pneumococcal disease in a large urban jail.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,ATLANTA,GA; VET AFFAIRS MED CTR,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030; HARRIS CTY HLTH DEPT,HOUSTON,TX; TEXAS DEPT HLTH,AUSTIN,TX	Centers for Disease Control & Prevention - USA; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Texas Department of State Health Services			Dominguez, Edward A./AAL-6119-2020					AUSTRIAN R, 1992, INFECTIOUS DISEASES; BERK SL, 1985, SOUTHERN MED J, V78, P159, DOI 10.1097/00007611-198502000-00010; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; BROOME CV, 1981, REV INFECT DIS, V3, P277; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; Dallal GE, 1988, AM STAT, V42, P272; DEAN AG, 1990, EPIINFO VERSION 5 WO; DOWLING JN, 1971, J INFECT DIS, V124, P9, DOI 10.1093/infdis/124.1.9; ERDMAN DD, 1990, J CLIN MICROBIOL, V28, P2744, DOI 10.1128/JCM.28.12.2744-2749.1990; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573, DOI 10.1136/bmj.289.6458.1573; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; Heffron R, 1979, PNEUMONIA SPECIAL RE; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; HODGES RG, 1946, AM J HYG, V44, P183, DOI 10.1093/oxfordjournals.aje.a119088; HUGHES RT, 1986, AM IND HYG ASSOC J, V47, P207, DOI 10.1080/15298668691389630; JORGENSEN JH, 1991, J INFECT DIS, V163, P644, DOI 10.1093/infdis/163.3.644; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; MACKENZIE GM, 1940, T ASSOC AM PHYSICIAN, V55, P199; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MOORE EP, 1988, J INFECTION, V16, P199, DOI 10.1016/S0163-4453(88)94147-3; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; REICHLER M, 1991, 31ST INT C ANT AG CH, P107; RIEDO F, 1991, 31ST INT C ANT AG CH, P106; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221, DOI 10.1164/ajrccm/137.1.221; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Smillie WG, 1936, AM J HYG, V24, P522, DOI 10.1093/oxfordjournals.aje.a118281; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; 1989, MMWR-MORBID MORTAL W, V38, P635; 1992, ANN INTERN MED, V117, P71; 1981, ASHRAE551981 AM SOC; 1989, MMWR-MORBID MORTAL W, V38, P64; 1989, ASHRAE621989 AM SOC; 1985, MMWR-MORBID MORTAL W, V34, P615; 1988, AM C GOVT IND HYGIEN; 1981, STANDARDIZED DIAGNOS; 1989, MMWR-MORBID MORTAL W, V38, P73; 1992, MMWR-MORBID MORTAL W, V41, P927; 1989, MMWR-MORBID MORTAL W, V38, P733; 1992, MMWR-MORBID MORTAL W, V41, P507; 1989, MMWR-MORBID MORTAL W, V38, P641	51	185	188	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					643	648		10.1056/NEJM199409083311004	http://dx.doi.org/10.1056/NEJM199409083311004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052273				2022-12-28	WOS:A1994PE38200004
J	SOUMERAI, SB; MCLAUGHLIN, TJ; ROSSDEGNAN, D; CASTERIS, CS; BOLLINI, P				SOUMERAI, SB; MCLAUGHLIN, TJ; ROSSDEGNAN, D; CASTERIS, CS; BOLLINI, P			EFFECTS OF LIMITING MEDICAID DRUG-REIMBURSEMENT BENEFITS ON THE USE OF PSYCHOTROPIC AGENTS AND ACUTE MENTAL-HEALTH-SERVICES BY PATIENTS WITH SCHIZOPHRENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECONOMIC COSTS; PAYMENT; THERAPY; POLICY; NEED; CARE; ILL	Background. We examined the effects of a three-prescription monthly payment limit (cap) on the use of psychotropic drugs and acute mental health care by noninstitutionalized patients with schizophrenia. We hypothesized that reducing access to such drugs would increase the use of emergency mental health services and the rate of partial hospitalizations (full-day or half-day treatment programs) and psychiatric-hospital admissions. Methods. We linked Medicaid claims data for a period of 42 months with clinical records from two community mental health centers (CMHCs) and the single state psychiatric hospital in New Hampshire, where Medicaid imposed a three-prescription limit on reimbursement for drugs during 11 months (months 15 through 25) of the study. For comparison, we used Medicaid claims for a period of 42 months in New Jersey, which had no limit on drug reimbursement. The study patients (n = 268) and the comparison patients (n = 1959) were permanently disabled, noninstitutionalized patients with schizophrenia, 19 through 60 years of age, who were insured by Medicaid. We conducted interrupted time-series regression analyses to estimate the effects of the cap on the use of medications and mental health services. Results. The cap resulted in immediate reductions (range, 15 to 49 percent) in the use of antipsychotic drugs, antidepressants and lithium, and anxiolytic and hypnotic drugs (P<0.01). It also resulted in coincident increases of one to two visits per patient per month to CMHCs (range of increase, 43 to 57 percent; P<0.001) and sharp increases in the use of emergency mental health services and partial hospitalization (1.2 to 1.4 episodes per patient per month), but no change in the frequency of hospital admissions. After the cap was discontinued, the use of medications and most mental health services reverted to base-line levels (measured in the first 14 months of the study). The estimated average increase in mental health care costs per patient during the cap ($1,530) exceeded the savings in drug costs to Medicaid by a factor of 17. Conclusions. Limits on coverage for the costs of prescription drugs can increase the use of acute mental health services among low-income patients with chronic mental illnesses and increase costs to the government, even aside from the increases caused in pain and suffering on the part of patients.	HARVARD UNIV,SCH MED,DEPT PREVENT & SOCIAL MED,BOSTON,MA; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA; INT ORG MIGRAT,GENEVA,SWITZERLAND	Harvard University; Harvard Medical School; International Organization for Migration	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE,BOSTON,MA, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044881] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH44881] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREWS G, 1985, ARCH GEN PSYCHIAT, V42, P537; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; Cook T.C., 1979, QUASIEXPERIMENTATION; CRANE GE, 1973, SCIENCE, V181, P124, DOI 10.1126/science.181.4095.124; DAVIS JM, 1984, TREATMENT CARE SCHIZ; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; ENNA SJ, 1983, NEUROLEPTICS NEUROCH, P1; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; HAAIJERRUSKAMP FM, 1991, DRUGS MONEY PROBLEM; JABLENSKY A, 1988, SCHIZOPHRENIA MAJOR, P19; JOHNSON DAW, 1988, SCHIZOPHRENIA MAJOR, P158; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; LIEBERMAN AA, 1986, COMMUNITY MENT HLT J, V22, P104, DOI 10.1007/BF00754549; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MCGUIRE TG, 1991, SCHIZOPHRENIA BULL, V17, P375, DOI 10.1093/schbul/17.3.375; MECHANIC D, 1992, HEALTH AFFAIR, V11, P128, DOI 10.1377/hlthaff.11.1.128; Mohr L., 1992, IMPACT ANAL PROGRAM; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SHAPIRO S, 1985, MED CARE, V23, P1033, DOI 10.1097/00005650-198509000-00002; SHARFSTEIN SS, 1992, HEALTH AFFAIR, V11, P84, DOI 10.1377/hlthaff.11.3.84; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Torrey EF, 1990, CARE SERIOUSLY MENTA; 1979, SCHIZOPHRENIA INT FO; 1973, INT PILOT STUDY SCHI, V1; 1984, MED CARE S, V22, pS1	32	403	404	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					650	655		10.1056/NEJM199409083311006	http://dx.doi.org/10.1056/NEJM199409083311006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PE382	8052275	Green Published			2022-12-28	WOS:A1994PE38200006
J	COOPER, RA				COOPER, RA			SEEKING A BALANCED PHYSICIAN WORKFORCE FOR THE 21ST-CENTURY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE REFORM; UNITED-STATES; MEDICAL SPECIALTIES; SPECIALISTS; 21ST-CENTURY; EDUCATION; OUTCOMES; SERVICES; SYSTEMS; DOCTOR				COOPER, RA (corresponding author), MED COLL WISCONSIN, INST HLTH POLICY, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.							AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; [Anonymous], 1993, ACAD MED, V68, P1; CAWLEY JF, 1993, GENERAL INTERNIST WH, P117; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; Cooper R A, 1994, Internist, V35, P10; DEANGELIS CD, 1994, JAMA-J AM MED ASSOC, V271, P868, DOI 10.1001/jama.271.11.868; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FEIL EC, 1993, JAMA-J AM MED ASSOC, V269, P2659, DOI 10.1001/jama.269.20.2659; FOSTER EA, 1994, ACAD MED, V69, P501, DOI 10.1097/00001888-199406000-00019; FOWKES V, 1993, ASSESSMENT PHYSICIAN; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; GATES PR, 1994, ALTERNATIVE MED J, V1, P12; GINZBERG E, 1989, HEALTH AFFAIR, V8, P84, DOI 10.1377/hlthaff.8.2.84; GINZBERG E, 1994, JAMA-J AM MED ASSOC, V271, P464, DOI 10.1001/jama.271.6.464; GINZBERG E, 1993, IS PRIMARY CARE ANSW, P77; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; Hendee W R, 1994, Wis Med J, V93, P159; IGLEHART JK, 1994, NEW ENGL J MED, V330, P1167, DOI 10.1056/NEJM199404213301628; JOHNS MME, 1993, JAMA-J AM MED ASSOC, V269, P3156, DOI 10.1001/jama.269.24.3156; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; KASSEBAUM DG, 1993, ACAD MED, V68, P866, DOI 10.1097/00001888-199311000-00018; KASSEBAUM DG, 1994, ACAD MED, V69, P164; KASSIRER JP, 1994, NEW ENGL J MED, V330, P204, DOI 10.1056/NEJM199401203300310; KENNEDY P, 1993, PREPARING 21ST CENTU, P21; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V271, P1505, DOI 10.1001/jama.271.19.1505; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1101; MEYER CT, 1993, GENERAL INTERNIST WH, P97; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; MUNDINGER MO, 1994, NEW ENGL J MED, V330, P211, DOI 10.1056/NEJM199401203300314; Nolan J, 1994, Internist, V35, P14; Petersdorf R G, 1994, Internist, V35, P7; PETERSDORF RG, 1993, NEW ENGL J MED, V328, P651, DOI 10.1056/NEJM199303043280911; PETERSDORF RG, 1993, ACAD MED, V68, P113, DOI 10.1097/00001888-199302000-00001; REINHARDT UE, 1994, NEW ENGL J MED, V330, P1452, DOI 10.1056/NEJM199405193302012; REINHARDT UE, 1991, KEY HLTH POLICY; REUBEN DB, 1993, J AM GERIATR SOC, V41, P444, DOI 10.1111/j.1532-5415.1993.tb06955.x; RICH EC, 1994, J GEN INTERN MED, V9, pS115, DOI 10.1007/BF02598126; RIVO ML, 1994, JAMA-J AM MED ASSOC, V271, P1499, DOI 10.1001/jama.271.19.1499; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; ROGERS DE, 1994, J ROY SOC MED, V87, P2; ROGERS JF, 1992, TRENDS US HLTH CARE, P68; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SCHERR L, 1993, TAKING CHARGE GRADUA, P151; SCHROEDER SA, 1987, ANN INTERN MED, V106, P768, DOI 10.7326/0003-4819-106-5-768; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; SCHROEDER SA, 1993, B NEW YORK ACAD MED, V70, P103; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; SPIEGEL JS, 1983, NEW ENGL J MED, V308, P1208, DOI 10.1056/NEJM198305193082007; Starfield B., 1992, PRIMARY CARE CONCEPT; STEINBROOK R, 1994, NEW ENGL J MED, V330, P1311, DOI 10.1056/NEJM199405053301813; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P53, DOI 10.1001/jama.272.1.53; TARLOV AR, 1983, NEW ENGL J MED, V308, P1235, DOI 10.1056/NEJM198305193082028; WALL EM, 1994, ACAD MED, V69, P261, DOI 10.1097/00001888-199404000-00002; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1993, HLTH AFF MILLWOOD, V12, P90; WHITCOMB ME, 1994, 23577 RW JOHNS F REP; WHITCOMB ME, 1994, MED ED PHYSICIAN WOR; WILLIAMS AP, 1983, NEW ENGL J MED, V309, P958, DOI 10.1056/NEJM198310203091606; 1993, PHYSICIAN CHARACTERI; 1994, MATRICULATING STUDEN; 1993, ANN REPORT C, P55; 1992, P251092 US BUR CENS; 1992, IMPROVING ACCESS HLT; 1994, TRACKING CENSUS SAIM; 1992, DHHS PHS921232 US DE, P19; 1994, NATIONAL MED EXPENDI, P18; 1981, DHHS HRA81651 US DEP; 1993, 1993 ASS AM MED COLL	80	140	140	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					680	687		10.1001/jama.272.9.680	http://dx.doi.org/10.1001/jama.272.9.680			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064983				2022-12-28	WOS:A1994PE32700012
J	WEINBERG, E; OSULLIVAN, P; BOLL, AG; NELSON, TR				WEINBERG, E; OSULLIVAN, P; BOLL, AG; NELSON, TR			THE COST OF 3RD-YEAR CLERKSHIPS AT LARGE NONUNIVERSITY TEACHING HOSPITALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIME ALLOCATION	Background.-Large nonuniversity teaching hospitals are major providers of the clinical training component of undergraduate medical education, yet little information is available to policymakers, participating hospitals, or sponsoring medical schools on the institutional costs of this service. Objective.-To determine the costs associated with teaching students in required third-year clerkships for a group of large nonuniversity teaching hospitals. Setting/Participants.-A total of 201 medical students from nine large nonuniversity teaching hospitals affiliated with nine medical schools that participate in required third-year clerkships. Methods.-During a typical week, students completed 24-hour time and activity logs that classified each activity, instructor, and audience. From these logs, the number of teaching hours by full-time faculty and others were estimated and costs were calculated. Results.-Full-time faculty provided a mean of 0.242 h/d of formal teaching, 0.326 h/d of informal teaching, and 0.581 h/d of supervised patient care training per student, an estimated direct faculty cost of $412 per week per student. The cost of direct and indirect departmental and academic administration, as well as other direct out-of-pocket medical education costs, added $250 per week per student. The average annual clinical program cost of third-year clerkships to nonuniversity hospitals and their full-time faculties was $31 776 per student. This figure does not include the substantial contributions of teaching by other than paid faculty (eg, volunteer physicians and residents), which was important in terms of activity and service provided. Conclusions.-Direct and indirect costs of third-year medical student education for most hospitals in this study was more than $1 million per year, well in excess of the average support provided by sponsoring medical schools.	BAYSTATE HLTH SYST,DIV ACAD AFFAIRS,SPRINGFIELD,MA; DELOITTE & TOUCHE,CINCINNATI,OH	Deloitte Touche Tohmatsu Limited				O'Sullivan, Patricia/0000-0002-8706-4095				BOEX JR, 1992, ACAD MED, V67, P80, DOI 10.1097/00001888-199202000-00004; COOK RL, 1992, ACAD MED, V67, P279, DOI 10.1097/00001888-199204000-00020; DRUCKER WR, 1965, AM J SURG, V149, P315; FINCHER RME, 1989, ACAD MED, V64, P691, DOI 10.1097/00001888-198911000-00023; FISHER LA, 1965, J MED EDUC, V40, P125; FRIEDMAN CP, 1978, J MED EDUC, V53, P565; GINZBERG E, 1993, EC MED ED; LAPALIO LR, 1983, J MED EDUC, V58, P328; MULHAUSEN R, 1989, ACAD MED, V69, P314; PETERSDORF RG, 1985, JAMA-J AM MED ASSOC, V253, P2543, DOI 10.1001/jama.253.17.2543; RELMAN AS, 1984, SCIENCE, V26, P20; SCHWARTZ WB, 1985, NEW ENGL J MED, V313, P157, DOI 10.1056/NEJM198507183130305; 1991, REPORT MED SCH FACUL; MEDICARE COST REPORT	14	15	15	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					669	673						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064982				2022-12-28	WOS:A1994PE32700010
J	PLOTKIN, SA				PLOTKIN, SA			VACCINES FOR VARICELLA-ZOSTER VIRUS AND CYTOMEGALOVIRUS - RECENT PROGRESS	SCIENCE			English	Editorial Material							IMMUNIZATION; LIVE; GLYCOPROTEIN; RECOMBINANT; INFECTION; CHILDREN				PLOTKIN, SA (corresponding author), PASTEUR MERIEUX CONNAUGHT, 3 AVE LOUIS PASTEUR, F-92430 MARNES COQUETTE, FRANCE.							ADLER SP, 1994, PEDIATR RES, V35, pA173; ARVIN AM, 1992, J INFECT DIS, V166, pS35, DOI 10.1093/infdis/166.Supplement_1.S35; ARVIN AM, 1992, J INFECT DIS, pS13; BRITT WJ, 1988, J VIROL, V62, P3308; ELEK SD, 1991, TRANSPLANT P, V23, P85; FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003; GERSHON AA, 1992, J INFECT DIS, V166, pS63, DOI 10.1093/infdis/166.Supplement_1.S63; GONCZOL E, 1990, VACCINE, V8, P130, DOI 10.1016/0264-410X(90)90135-9; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; LEVIN MJ, 1992, J INFECT DIS, V166, P253, DOI 10.1093/infdis/166.2.253; LIEU TA, 1994, PEDIATR INFECT DIS J, V13, P173, DOI 10.1097/00006454-199403000-00001; MARSHALL GS, 1990, J INFECT DIS, V162, P1177, DOI 10.1093/infdis/162.5.1177; PEREIRA L, 1991, INT CONGR SER, V978, P195; PLOTKIN SA, 1975, INFECT IMMUN, V12, P521, DOI 10.1128/IAI.12.3.521-527.1975; RIDDELL SR, 1993, CURR OPIN IMMUNOL, V5, P484, DOI 10.1016/0952-7915(93)90027-P; SABELLA C, 1993, J VIROL, V67, P7673, DOI 10.1128/JVI.67.12.7673-7676.1993; SPAETE RR, 1993, VIROLOGY, V193, P853, DOI 10.1006/viro.1993.1194; SPAETE RR, 1991, TRANSPLANT P, V23, P90; SPERBER SJ, 1992, ANTIVIR RES, V17, P213, DOI 10.1016/0166-3542(92)90042-4; TAKAHASHI M, 1994, VACCINES, P387; WATSON B, 1994, J INFECT DIS, V169, P197, DOI 10.1093/infdis/169.1.197; WATSON BM, 1993, PEDIATRICS, V91, P17; WHITE CJ, 1992, PEDIATRICS, V89, P354; YOW MD, 1992, NEW ENGL J MED, V326, P702, DOI 10.1056/NEJM199203053261010	24	44	48	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1383	1385		10.1126/science.8073277	http://dx.doi.org/10.1126/science.8073277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073277				2022-12-28	WOS:A1994PE73300029
J	MALENKA, RC				MALENKA, RC			SYNAPTIC PLASTICITY IN THE HIPPOCAMPUS - LTP AND LTD	CELL			English	Review							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; NITRIC-OXIDE; AREA CA1; MEMORY; TRANSMISSION; ACTIVATION; DEPRESSION; INDUCTION; MAINTENANCE		UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	MALENKA, RC (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143, USA.		Sancheti, Harsh/H-3538-2012					ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DAVIS S, 1992, J NEUROSCI, V12, P21; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MOSER EI, 1994, LEARN MEMORY, V1, P55; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	32	516	527	2	46	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					535	538		10.1016/0092-8674(94)90517-7	http://dx.doi.org/10.1016/0092-8674(94)90517-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069904				2022-12-28	WOS:A1994PD69300001
J	SAITZ, R; MAYOSMITH, MF; ROBERTS, MS; REDMOND, HA; BERNARD, DR; CALKINS, DR				SAITZ, R; MAYOSMITH, MF; ROBERTS, MS; REDMOND, HA; BERNARD, DR; CALKINS, DR			INDIVIDUALIZED TREATMENT FOR ALCOHOL-WITHDRAWAL - A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCALE; CHLORDIAZEPOXIDE; DETOXIFICATION; MANAGEMENT; CLONIDINE; CARE	Objective.-To assess the effect of an individualized treatment regimen on the intensity and duration of medication treatment for alcohol withdrawal. Design.-A randomized double-blind, controlled trial. Setting.-An inpatient detoxification unit in a Veterans Affairs medical center. Patients.-One hundred one patients admitted for the treatment of alcohol withdrawal who could give informed consent and had no history of seizures or medication use that might alter the clinical course of withdrawal. Intervention.-Patients were randomized to either a standard course of chlor-diazepoxide four times daily with additional medication as needed (fixed-schedule therapy) or to a treatment regimen that provided chlordiazepoxide only in response to the development of the signs and symptoms of alcohol withdrawal (symptom-triggered therapy). The need for administration of ''as-needed'' medication was determined using a validated measure of the severity of alcohol withdrawal. Main Outcome Measures.-Duration of medication treatment and total chlor-diazepoxide administered. Results.-The median duration of treatment in the symptom-triggered group was 9 hours compared with 68 hours in the fixed-schedule group (P<.001). The symptom-triggered group received 100 mg of chlordiazepoxide, and the fixed-schedule group received 425 mg (P<.001). There were no significant differences in the severity of withdrawal during treatment or in the incidence of seizures or delirium tremens. Conclusions.-Symptom-triggered therapy individualizes treatment, decreases both treatment duration and the amount of benzodiazepine used, and is as efficacious as standard fixed-schedule therapy for alcohol withdrawal.	NEW ENGLAND DEACONESS HOSP,DIV GEN INTERNAL MED,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; VET AFFAIRS MED CTR,DEPT MED,ALCOHOL DETOXIFICAT UNIT,MANCHESTER,NH; DARTMOUTH COLL SCH MED,LEBANON,NH	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College				/0000-0002-2535-1427				BAUMGARTNER GR, 1987, ARCH INTERN MED, V147, P1223, DOI 10.1001/archinte.147.7.1223; BAUMGARTNER GR, 1991, SOUTHERN MED J, V84, P312, DOI 10.1097/00007611-199103000-00006; FOY A, 1988, ALCOHOL CLIN EXP RES, V12, P360, DOI 10.1111/j.1530-0277.1988.tb00208.x; GREENBLATT DJ, 1983, NEW ENGL J MED, V309, P410; KAIM SC, 1969, AM J PSYCHIAT, V125, P1640, DOI 10.1176/ajp.125.12.1640; MALCOLM R, 1989, AM J PSYCHIAT, V146, P617; NARANJO CA, 1983, CLIN PHARMACOL THER, V34, P214, DOI 10.1038/clpt.1983.155; SAITZ R, 1993, CLIN RES, V41, pA549; SELLERS EM, 1991, ARCH GEN PSYCHIAT, V48, P442; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHAW JM, 1981, J CLIN PSYCHOPHARM, V1, P382, DOI 10.1097/00004714-198111000-00006; Stinnett J L, 1982, Am J Drug Alcohol Abuse, V9, P413, DOI 10.3109/00952998209002643; SULLIVAN JT, 1991, J CLIN PSYCHOPHARM, V11, P291; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; TURNER RC, 1989, J GEN INTERN MED, V4, P432, DOI 10.1007/BF02599697; Victor M, 1953, RES PUBL ASSOC RES N, V32, P526; WARTENBERG AA, 1990, ALCOHOL CLIN EXP RES, V14, P71, DOI 10.1111/j.1530-0277.1990.tb00449.x; WHITFIELD CL, 1978, JAMA-J AM MED ASSOC, V239, P1409, DOI 10.1001/jama.239.14.1409; WILFORD BB, 1990, SYLLABUS REV COURSE, P182; WILSON JD, 1991, HARRISONS PRINCIPLES, P2150; WYNGAARDEN JB, 1988, CECIL TXB MED, P46; 1989, SAS STAT USERS GUIDE; 1987, DIAGNOSTIC STATISTIC, P130; 1990, PREVENTION TREATMENT, P268	24	241	244	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					519	523		10.1001/jama.272.7.519	http://dx.doi.org/10.1001/jama.272.7.519			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB229	8046805				2022-12-28	WOS:A1994PB22900028
J	CROWLEY, KS; LIAO, SR; WORRELL, VE; REINHART, GD; JOHNSON, AE				CROWLEY, KS; LIAO, SR; WORRELL, VE; REINHART, GD; JOHNSON, AE			SECRETORY PROTEINS MOVE THROUGH THE ENDOPLASMIC-RETICULUM MEMBRANE VIA AN AQUEOUS, GATED PORE	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; LIPID BILAYER; TRANSLOCATION; INSERTION; SEQUENCE; BINDING; ER; FLUORESCENCE; RIBOSOMES	The environment of secretory proteins undergoing translocation across the ER membrane was determined by incorporating fluorescent probes into nascent chains during translation. Dyes were positioned at various locations across the entire bilayer and inside the ribosome, and in each case the probes were in an aqueous milieu, as shown both by their fluorescence lifetimes and by collisional quenching of their fluorescence by iodide ions introduced into the ER lumen. The nascent chain therefore occupies an aqueous pore that spans the entire membrane. Since the pore is sealed off from the cytoplasm, cotranslational translocation is effected topographically. This pore is not open to the lumen after targeting is completed; it opens only after the nascent chain length reaches about 70 residues.			CROWLEY, KS (corresponding author), UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019, USA.		Johnson, Arthur E/G-3457-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033216, R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 33216, R01 GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1993, TRANSLATIONAL APPARATUS, P359; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MCKNIGHT CJ, 1991, BIOCHEMISTRY-US, V30, P6241, DOI 10.1021/bi00239a023; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OKUN MM, 1990, J BIOL CHEM, V265, P7478; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SASAVAGE NL, 1982, J BIOL CHEM, V267, P678; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TWETEN RK, 1988, INFECT IMMUN, V56, P3228, DOI 10.1128/IAI.56.12.3228-3234.1988; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211	42	299	303	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					461	471		10.1016/0092-8674(94)90424-3	http://dx.doi.org/10.1016/0092-8674(94)90424-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062388				2022-12-28	WOS:A1994PC40500012
J	KIM, SG; UGURBIL, K; STRICK, PL				KIM, SG; UGURBIL, K; STRICK, PL			ACTIVATION OF A CEREBELLAR OUTPUT NUCLEUS DURING COGNITIVE PROCESSING	SCIENCE			English	Article							MOTOR CORTEX; ARCUATE PREMOTOR; EYE-MOVEMENTS; MENTAL SKILLS; CELL ACTIVITY; BRAIN; DISCHARGE; NEURONS; MONKEY; ORGANIZATION	Magnetic resonance imaging was used to examine the involvement of the dentate nucleus of the cerebellum in cognitive operations. All seven people examined displayed a large bilateral activation in the dentate during their attempts to solve a pegboard puzzle. The area activated was three to four times greater than that activated during simple movements of the pegs. These results provide support for the concept that the computational power of the cerebellum is applied not only to the control of movement but also to cognitive functions.	VET ADM MED CTR, RES SERV 151, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA; UNIV MINNESOTA, SCH MED, DEPT RADIOL, CTR MAGNET RESONANCE RES, MINNEAPOLIS, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities			Ugurbil, Kamil/AAD-6058-2022		NCRR NIH HHS [RR08079] Funding Source: Medline; NINDS NIH HHS [NS24328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BLOEDEL JR, 1992, BEHAV BRAIN SCI, V15, P666; BRACKETOLKMITT R, 1989, BEHAV NEUROSCI, V103, P442, DOI 10.1037/0735-7044.103.2.442; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; DAVIS R, 1984, CEREBELLAR STIMULATI; DECETY J, 1990, BRAIN RES, V535, P313, DOI 10.1016/0006-8993(90)91615-N; Dow RS, 1942, BIOL REV CAMB PHILOS, V17, P179, DOI 10.1111/j.1469-185X.1942.tb00437.x; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; GARDNER EP, 1975, J NEUROPHYSIOL, V38, P627, DOI 10.1152/jn.1975.38.3.627; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; HU XP, 1994, MAGN RESON MED, V31, P495, DOI 10.1002/mrm.1910310505; Ito M, 1984, CEREBELLUM NEURAL CO; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEINER HC, 1987, ITAL J NEUROL SCI, V8, P425; LEINER HC, 1989, BEHAV NEUROSCI, V103, P998, DOI 10.1037/0735-7044.103.5.998; LEINER HC, 1986, BEHAV NEUROSCI, V100, P443, DOI 10.1037/0735-7044.100.4.443; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LYNCH JC, IN PRESS EXP BRAIN R; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; MUSHIAKE H, 1993, J NEUROPHYSIOL, V70, P2660, DOI 10.1152/jn.1993.70.6.2660; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ORIOLI PJ, 1989, J COMP NEUROL, V288, P612, DOI 10.1002/cne.902880408; PASSINGHAM RE, 1975, BRAIN BEHAV EVOLUT, V11, P73, DOI 10.1159/000123626; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SCHELL GR, 1984, J NEUROSCI, V4, P539; SCHIEBER MH, 1985, J NEUROPHYSIOL, V54, P1228, DOI 10.1152/jn.1985.54.5.1228; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; STONE LS, 1990, J NEUROPHYSIOL, V63, P1262, DOI 10.1152/jn.1990.63.5.1262; STRICK PL, 1993, INT CONGR SER, V1024, P171; STRICK PL, 1983, J NEUROSCI, V3, P2007; THACH WT, 1993, REV NEUROL, V149, P607; THACH WT, 1975, BRAIN RES, V88, P233, DOI 10.1016/0006-8993(75)90387-X; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; THACH WT, 1970, J NEUROPHYSIOL, V33, P527, DOI 10.1152/jn.1970.33.4.527; THACH WT, 1968, J NEUROPHYSIOL, V31, P785, DOI 10.1152/jn.1968.31.5.785; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; WETTS R, 1985, J NEUROPHYSIOL, V54, P231, DOI 10.1152/jn.1985.54.2.231; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105; WOOTEN GF, 1981, J NEUROSCI, V1, P285; YEO CH, 1985, EXP BRAIN RES, V60, P99, DOI 10.1007/BF00237023	51	410	419	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					949	951		10.1126/science.8052851	http://dx.doi.org/10.1126/science.8052851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052851				2022-12-28	WOS:A1994PB49900041
J	ANNAS, GJ				ANNAS, GJ			WHEN SHOULD PREVENTIVE TREATMENT BE PAID FOR BY HEALTH-INSURANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OVARIAN-CANCER; BREAST; CARE							Annas, George/0000-0001-5836-7831				BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P782, DOI 10.1001/jama.265.6.782; FERGUSON JH, 1993, JAMA-J AM MED ASSOC, V269, P2116, DOI 10.1001/jama.269.16.2116; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; MARINER WK, 1994, AM J PUBLIC HEALTH, V84, P1515, DOI 10.2105/AJPH.84.9.1515; Ozar David T, 1983, Theor Med, V4, P129, DOI 10.1007/BF00562886; PAYER L, 1992, DISEASE MONOGERS; Pear Robert, 1994, NY TIMES        0309, pA13; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707	11	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					1027	1030		10.1056/NEJM199410133311521	http://dx.doi.org/10.1056/NEJM199410133311521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK504	8084353	Green Published			2022-12-28	WOS:A1994PK50400035
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA SEEKS COMMENTS ON HOW TO ENHANCE FOOD SAFETY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V271, P812; 1994, FED REGISTER, V59, P39888	2	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					995	995		10.1001/jama.272.13.995	http://dx.doi.org/10.1001/jama.272.13.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089899				2022-12-28	WOS:A1994PH77500008
J	WEYAND, CM; HICOK, KC; HUNDER, GG; GORONZY, JJ				WEYAND, CM; HICOK, KC; HUNDER, GG; GORONZY, JJ			TISSUE CYTOKINE PATTERNS IN PATIENTS WITH POLYMYALGIA-RHEUMATICA AND GIANT-CELL ARTERITIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYTOKINES; TEMPORAL ARTERITIS; POLYMYALGIA RHEUMATICA; VASCULITIS; INFLAMMATION	TEMPORAL ARTERITIS; RESPONSES; DISEASE; INTERLEUKIN-2; LYMPHOCYTES; MACROPHAGES; VASCULITIS; MECHANISMS; INDUCTION; IMMUNE	Objective: To analyze temporal artery specimens from patients with giant cell arteritis and polymyalgia rheumatica for the presence of inflammatory cytokines and to ascertain whether a specific cytokine pattern exists for the two conditions. Design: Case series of patients having temporal artery biopsy procedures. Setting: The outpatient clinic and the research laboratories of the Division of Rheumatology, Mayo Clinic. Patients: 34 patients having temporal artery biopsy procedures: 15 patients had giant cell arteritis, 9 had polymyalgia rheumatica without evidence of vasculitis, and 10 had neither polymyalgia rheumatica nor vasculitis. Measurement: Temporal artery specimens were analyzed for in vivo presence of cytokine messenger RNA (mRNA) by polymerase chain reaction with cytokine-specific primer sets. Results: Vasculitic lesions in giant cell arteritis samples were characterized by in situ production of interleukin-1 beta, interleukin-6, and transforming growth factor-beta 1 mRNA (indicative of macrophage activation) and by interferon-gamma and interleukin-2 mRNA (indicative of selective T-cell activation). However, macrophage- and T-cell-derived cytokines were also detected in temporal artery biopsy specimens from patients with polymyalgia rheumatica. Tissue-infiltrating T cells in giant cell arteritis and polymyalgia rheumatica samples each had distinctive lymphokine profiles. Although interferon-gamma was found in 67% of giant cell arteritis samples, polymyalgia rheumatica samples had only interleukin-2. Conclusions: Patients with polymyalgia rheumatica have vascular involvement. Patients with polymyalgia rheumatica and giant cell arteritis share in situ production of mRNA specific for macrophage-derived cytokines. T cells recruited to vasculitic lesions in patients with giant cell arteritis predominantly produce interleukin-2 and interferon-gamma. Patients with polymyalgia rheumatica do not have interferon-gamma production, suggesting that interferon-gamma may be involved in the progression to overt arteritis.			WEYAND, CM (corresponding author), MAYO CLIN & MAYO FDN, 401 GUGGENHEIM BLDG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BANKS PM, 1983, ARTHRITIS RHEUM, V26, P1201, DOI 10.1002/art.1780261005; BETZ M, 1991, J IMMUNOL, V146, P108; Boros D.L., 1980, BASIC CLIN ASPECTS G, P1; CALAMIA K, 1920, CLIN RHEUM DIS, V6, P389; CHENSUE SW, 1989, J IMMUNOL, V142, P1281; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; Dinarello C A, 1992, Semin Immunol, V4, P133; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; GOLD KN, 1994, ARTHRITIS RHEUM, V37, P925, DOI 10.1002/art.1780370623; HUNDER GG, 1985, CLIN RHEUM DIS, V11, P471; HUNDER GG, 1993, ARTHRITIS RHEUM-US, V36, P757, DOI 10.1002/art.1780360604; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; LIE JT, 1990, ARTHRITIS RHEUM-US, V33, P1074; MATHEW RC, 1986, INFECT IMMUN, V54, P820, DOI 10.1128/IAI.54.3.820-826.1986; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; POSTLETHWAITE AE, 1982, J EXP MED, V155, P168, DOI 10.1084/jem.155.1.168; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SHAW J, 1988, J IMMUNOL, V140, P2243; WAGNER AD, 1994, IN PRESS J CLIN INVE; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; WEYAND CM, 1992, J CLIN INVEST, V90, P2355, DOI 10.1172/JCI116125; WEYAND CM, 1994, ARTHRITIS RHEUM, V37, P514, DOI 10.1002/art.1780370411; WEYAND CM, 1994, J EXP MED, V179, P951, DOI 10.1084/jem.179.3.951; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; YOKOTA T, 1990, PEPTIDE GROWTH FACTO, P576	31	314	327	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					484	491		10.7326/0003-4819-121-7-199410010-00003	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067646				2022-12-28	WOS:A1994PJ10200003
J	HELD, PJ; KAHAN, BD; HUNSICKER, LG; LISKA, D; WOLFE, RA; PORT, FK; GAYLIN, DS; GARCIA, JR; AGODOA, LYC; KRAKAUER, H				HELD, PJ; KAHAN, BD; HUNSICKER, LG; LISKA, D; WOLFE, RA; PORT, FK; GAYLIN, DS; GARCIA, JR; AGODOA, LYC; KRAKAUER, H			THE IMPACT OF HLA MISMATCHES ON THE SURVIVAL OF FIRST CADAVERIC KIDNEY-TRANSPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; CYCLOSPORINE; RECIPIENTS; EXPERIENCE; THERAPY	Background. The benefits of HLA-A, B, and DR matching of cadaveric kidney grafts and recipients remain controversial when viewed from the perspective of social equity and graft survival. Methods. We estimated graft survival using proportional-hazards techniques, adjusting for patient and donor characteristics, for a series of 30,564 Medicare patients receiving a first cadaveric kidney transplant between 1984 and 1990. The effects of minimal achievable HLA mismatches and maximal matching on graft survival were estimated by simulated allocation of a sample of organs to a sample of 20,000 candidates for transplantation. Results. The adjusted one-year graft survival was 84.3 percent for grafts with no mismatches and 77.0 percent for grafts with four mismatches. National rationing of donor organs to achieve minimal mismatching and maximal matching could potentially decrease the average number of HLA mismatches from 3.6 to 1.2, with a corresponding increase in the number of matches, As a consequence, projected five-year graft survival could potentially increase from 58.5 percent to 62.9 percent. This would be associated with a decrease in the proportion of kidneys allocated to black recipients from 22.2 to 15.0 percent. Conclusions, Under ideal circumstances, a policy of maximal matching of cadaveric renal transplants would increase five-year graft survival by a comparatively small 4.4 percentage points, but the actual benefit is likely to be smaller.	UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109; UNIV TEXAS,SCH MED,DIV IMMUNOL & ORGAN TRANSPLANTAT,HOUSTON,TX 77030; UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242; URBAN INST,CTR HLTH POLICY,WASHINGTON,DC 20037; NIDDKD,BETHESDA,MD 20892; PRINCETON UNIV,WOODROW WILSON SCH,PRINCETON,NJ 08544; UNIFORMED SERV UNIV HLTH SCI,SCH MED,DEPT PREVENT MED,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,SCH MED,DIV BIOMETR,BETHESDA,MD 20814	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; University of Iowa; Urban Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Princeton University; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	HELD, PJ (corresponding author), UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,315 W HURON ST,SUITE 240,ANN ARBOR,MI 48103, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK082234] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-8-2234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER JW, 1987, TRANSPLANT P, V19, P672; BAILEY RC, 1977, TRANSPLANTATION, V24, P309, DOI 10.1097/00007890-197711000-00001; BARGER B, 1992, TRANSPLANTATION, V53, P770, DOI 10.1097/00007890-199204000-00013; BRYNGER H, 1988, TRANSPLANT P, V20, P261; CARPENTER CB, 1989, TRANSPLANT P, V21, P663; Cicciarelli J, 1991, Clin Transpl, P325; COX DR, 1972, J R STAT SOC B, V34, P187; ELLISON MD, 1992, AM J KIDNEY DIS, V20, pA3; FESTENSTEIN H, 1986, NEW ENGL J MED, V314, P7, DOI 10.1056/NEJM198601023140102; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Gjertson D W, 1991, Clin Transpl, P225; HUI SL, 1983, J AM STAT ASSOC, V78, P753, DOI 10.2307/2288179; KAHAN BD, 1985, SURGERY, V97, P125; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; OPELZ G, 1988, LANCET, V2, P61; PERSIJN GG, 1989, TRANSPLANT P, V21, P656; PORT FK, 1991, AM J KIDNEY DIS, V17, P519, DOI 10.1016/S0272-6386(12)80492-6; SANFILIPPO F, 1984, NEW ENGL J MED, V311, P358, DOI 10.1056/NEJM198408093110603; TERASAKI PI, 1991, KIDNEY INT, V39, P557, DOI 10.1038/ki.1991.64; 1993, NIH1993 NAT I DIAB D; 1983, E ENGL J MED, V309, P809; 1992, NIH923176 NAT I DIAB; 1991, SAS USERS GUIDE STAT	24	174	176	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					765	770		10.1056/NEJM199409223311203	http://dx.doi.org/10.1056/NEJM199409223311203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065404				2022-12-28	WOS:A1994PG30100003
J	ROSSING, MA; DALING, JR; WEISS, NS; MOORE, DE; SELF, SG				ROSSING, MA; DALING, JR; WEISS, NS; MOORE, DE; SELF, SG			OVARIAN-TUMORS IN A COHORT OF INFERTILE WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STATES CASE-CONTROL; UNITED-STATES; CANCER RISK; COLLABORATIVE ANALYSIS; FERTILITY DRUGS; WHITE WOMEN; STIMULATION	Background. Case reports and the results of a recent case-control study have raised questions about the potential neoplastic effects of medications used as treatment for infertility. Methods. We examined the risk of ovarian tumors in a cohort of 3837 women evaluated for infertility between 1974 and 1985 in Seattle. Computer linkage with a population-based tumor registry was used to identify women in whom tumors were diagnosed before January 1, 1992. Data on infertility testing and treatment were abstracted from the medical records of women who had ovarian cancer and those of a randomly selected comparison group. The risk of ovarian tumors associated with exposure to ovulation-inducing medications was assessed through an age-standardized comparison with the rate of ovarian tumors in the general population, and Cox regression analysis was used to compare the risk of cancer among women who received these medications with the risk among infertile women who did not receive them. Results. There were 11 invasive or borderline malignant ovarian tumors, as compared with an expected number of 4.4 (standardized incidence ratio, 2.5; 95 percent confidence interval, 1.3 to 4.5). Nine of the women in whom ovarian tumors developed had taken clomiphene; the adjusted relative risk among these women, as compared with that among infertile women who had not taken this drug, was 2.3 (95 percent confidence interval, 0.5 to 11.4). Five of the nine women had taken the drug during 12 or more monthly cycles. This period of treatment was associated with an increased risk of ovarian tumors among both women with ovarian abnormalities and those without apparent abnormalities (relative risk, 11.1; 95 percent confidence interval, 1.5 to 82.3), whereas treatment with the drug for less than one year was not associated with an increased risk. Conclusions. Prolonged use of clomiphene may increase the risk of a borderline or invasive ovarian tumor.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	ROSSING, MA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R35CA039779] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-05230, R35 CA-39779] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRINTON LA, 1989, AM J EPIDEMIOL, V129, P712, DOI 10.1093/oxfordjournals.aje.a115186; FISHEL S, 1989, BRIT MED J, V299, P309, DOI 10.1136/bmj.299.6694.309; HARRIS R, 1992, AM J EPIDEMIOL, V136, P1204, DOI 10.1093/oxfordjournals.aje.a116428; HORNROSS PL, 1992, EPIDEMIOLOGY, V3, P490, DOI 10.1097/00001648-199211000-00005; PRESTON DL, 1993, EPICURE RISK REGRESS; RICHARDSON GS, 1985, NEW ENGL J MED, V312, P415, DOI 10.1056/NEJM198502143120706; RON E, 1987, AM J EPIDEMIOL, V125, P780, DOI 10.1093/oxfordjournals.aje.a114595; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; SPIRTAS R, 1993, FERTIL STERIL, V59, P291; WACHOLDER S, 1987, AM J EPIDEMIOL, V126, P1198, DOI 10.1093/oxfordjournals.aje.a114759; Wacholder S, 1991, Epidemiology, V2, P155, DOI 10.1097/00001648-199103000-00013; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; WYSOWSKI DK, 1993, FERTIL STERIL, V60, P1096	15	507	522	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					771	776		10.1056/NEJM199409223311204	http://dx.doi.org/10.1056/NEJM199409223311204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065405				2022-12-28	WOS:A1994PG30100004
J	WIBLE, BA; TAGLIALATELA, M; FICKER, E; BROWN, AM				WIBLE, BA; TAGLIALATELA, M; FICKER, E; BROWN, AM			GATING OF INWARDLY RECTIFYING K+ CHANNELS LOCALIZED TO A SINGLE NEGATIVELY CHARGED RESIDUE	NATURE			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ION CHANNELS; RECTIFICATION; CONDUCTANCE; DEPENDENCE; BLOCKING; MG-2+; CELLS	INWARDLY rectifying K+ channels (IRKs) conduct current preferentially in the inward direction. This inward rectification has two components: voltage-dependent blockade by intracellular Mg2+ (Mg-i(2+))(1-7) and intrinsic gating(8,9). Two members of this channel family, IRK1 (ref. 10) and ROMK1 (ref. 11), differ markedly in affinity for Mg-i(2+) (ref. 12). We found that IRK1 and ROMK1 differ in voltage-dependent gating and searched for the gating structure by large-scale and site-directed mutagenesis. We found that a single amino-acid change within the putative transmembrane domain M2, aspartate (D) in IRK1 to the corresponding asparagine (N) in ROMK1, controls the gating phenotype. Mutation D172N in IRK1 produced ROMK1-like gating whereas the reverse mutation in ROMK1-N171D-produced IRK1-like gating. Thus, a single negatively charged residue seems to be a crucial determinant of gating.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT HUMAN COMMUN SCI,PHARMACOL SECT,I-80121 NAPLES,ITALY	Baylor College of Medicine; University of Naples Federico II			Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/A-2062-2019	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ANUMONWO JMB, 1991, CARDIOVASC DRUG REV, V9, P299, DOI 10.1111/j.1527-3466.1991.tb00418.x; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CIANI S, 1980, BIOPHYS J, V30, P199, DOI 10.1016/S0006-3495(80)85089-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; HILLE B, 1992, IONIC CHANNELS EXCIT, V2, P83; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUGLER JL, 1994, BIOPHYS J, V66, pA427; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1991, MG2PLUS EXCITABLE ME, V53, P289; PENNEFATHER P, 1992, BIOPHYS J, V61, P448, DOI 10.1016/S0006-3495(92)81850-7; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	27	216	218	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					246	249		10.1038/371246a0	http://dx.doi.org/10.1038/371246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078584				2022-12-28	WOS:A1994PG29000052
J	FEHLING, HJ; SWAT, W; LAPLACE, C; KUHN, R; RAJEWSKY, K; MULLER, U; VONBOEHMER, H				FEHLING, HJ; SWAT, W; LAPLACE, C; KUHN, R; RAJEWSKY, K; MULLER, U; VONBOEHMER, H			MHC CLASS-I EXPRESSION IN MICE LACKING THE PROTEASOME SUBUNIT LMP-7	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN PRESENTATION; VIRAL PEPTIDES; MOLECULES; GENE; REGION; CELLS	Proteasomes degrade endogenous proteins. Two subunits, LMP-2 and LMP-7, are encoded in a region of the major histocompatibility complex (MHC) that is critical for class I-restricted antigen presentation. Mice with a targeted deletion of the gene encoding LMP-7 have reduced levels of MHC class I cell-surface expression and present the endogenous antigen HY inefficiently; addition of peptides to splenocytes deficient in LMP-7 restores wild-type class I expression levels. This demonstrates the involvement of LMP-7 in the MHC class I presentation pathway and suggests that LMP-7 functions as an integral part of the peptide supply machinery.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne	FEHLING, HJ (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4058 BASEL,SWITZERLAND.		Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Fehling, Hans Joerg/0000-0002-4580-1990; Rajewsky, Klaus/0000-0002-6633-6370				ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; DRISCOLL J, 1993, IMMUNOL TODAY, V365, P262; GACZYNSKA M, 1993, IMMUNOL TODAY, V365, P264; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Kaer LV, 1992, CELL, V71, P1205; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; YANG Y, 1992, J BIOL CHEM, V267, P11669; ZANELLI E, 1993, IMMUNOGENETICS, V38, P400, DOI 10.1007/BF00184520	25	461	472	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1234	1237		10.1126/science.8066463	http://dx.doi.org/10.1126/science.8066463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066463				2022-12-28	WOS:A1994PD42200038
J	KOVACS, I; JULESZ, B				KOVACS, I; JULESZ, B			PERCEPTUAL SENSITIVITY MAPS WITHIN GLOBALLY DEFINED VISUAL SHAPES	NATURE			English	Article							CHANNELS	AN unsolved problem of biology is the processing of global shape in natural vision. The known processes of early vision are spatially restricted (or local) operations, and little is known about their interactions in organizing the visual image into functionally coherent (or global) objects. Here we introduce a human psychophysical method which allows us to measure the effect of perceptual organization on the activity pattern of local visual detectors, We map differential contrast sensitivity for a target across regions enclosed by a boundary. We show that local contrast sensitivity is enhanced within the boundary even for large distances between the boundary and the target. Furthermore, the locations of maximal sensitivity enhancement in the sensitivity maps are determined by global shape properties. Our data support a class of models which describe shapes by the means of a medial axis transformation(1-3), implying that the visual system extracts 'skeletons' as an intermediate-lever representation of objects. The skeletal representation offers a structurally simplified shape description which can be used for higher-level operations and for coding into memory.			KOVACS, I (corresponding author), RUTGERS STATE UNIV,VIS RES LAB,BUSCH CAMPUS,PSYCHOL BLDG,PISCATAWAY,NJ 08854, USA.		Kovacs, Ilona/A-2372-2009	Kovacs, Ilona/0000-0002-1772-2697				BLUM H, 1973, J THEOR BIOL, V38, P205, DOI 10.1016/0022-5193(73)90175-6; BLUM H, 1978, PATTERN RECOGN, V10, P167, DOI 10.1016/0031-3203(78)90025-0; BLUM H, 1967, PERSPECT BIOL MED, V10, P381; Blum H., 1967, MODELS PERCEPTION SP, P362, DOI DOI 10.1142/S0218654308001154; BURBECK CA, 1994, INVEST OPHTH VIS SCI, V35, P1626; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; Gabor D., 1946, J I ELECT ENG LOND, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; GRINVALD A, 1994, J NEUROSCI, V14, P2545; KIMIA BB, IN PRESS INT J COMP; KOENDERINK JJ, 1986, BIOL CYBERN, V53, P383, DOI 10.1007/BF00318204; KOVACS I, 1993, P NATL ACAD SCI USA, V90, P7495, DOI 10.1073/pnas.90.16.7495; LAMME VAF, 1994, INVEST OPHTH VIS SCI, V35, P1489; MARCELJA S, 1980, J OPT SOC AM, V70, P1297, DOI 10.1364/JOSA.70.001297; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, 1994, VISION RES, V34, P73, DOI 10.1016/0042-6989(94)90258-5; TOLHURST DJ, 1978, VISION RES, V18, P951, DOI 10.1016/0042-6989(78)90023-8; ZIPSER K, 1994, INVEST OPHTH VIS SCI, V35, P1973	17	173	174	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					644	646		10.1038/370644a0	http://dx.doi.org/10.1038/370644a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065449				2022-12-28	WOS:A1994PD31000048
J	SCHACHTMAN, DP; SCHROEDER, JI				SCHACHTMAN, DP; SCHROEDER, JI			STRUCTURE AND TRANSPORT MECHANISM OF A HIGH-AFFINITY POTASSIUM UPTAKE TRANSPORTER FROM HIGHER-PLANTS	NATURE			English	Article							ARABIDOPSIS-THALIANA; SALT TOLERANCE; BARLEY ROOTS; K+ CHANNELS; EXPRESSION; MEMBRANE; CDNA	POTASSIUM is the most abundant cation in higher plants and is crucial for plant nutrition, growth, tropisms, enzyme homeostasis and osmoregulation(1-4). K+ accumulation can be rate-limiting for agricultural production(2-4). K+ uptake from soils into roots is largely mediated by high-affinity K+ uptake (K-m approximate to 10-40 mu M) (refs 1, 2, 5-7). But although K+ channels allow low-affinity K+ uptake(8-10), both the transport mechanism and structure of the high-affinity K+ nutrition pathway remain unknown. Here we use expression cloning to isolate a complementary DNA encoding a membrane protein (HKT1) from wheat roots which confers the ability to take up K+. The substrate affinity, saturation and cation selectivity of HKT1 correspond to hallmark properties of classical high-affinity K+ uptake in plants(1,2,11). The transport mechanism of HKT1 uses K+-H+ co-uptake. Expression of HKT1 is localized to specific root and leaf regions which represent primary sites for K+ uptake in plants(2,3). HKT1 is important for plant nutrition and could possibly contribute to environmental alkali metal toxicities(11-13).	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego				Schachtman, Daniel/0000-0003-1807-4369; Schroeder, Julian/0000-0002-3283-5972				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; DREW MC, 1984, PLANTA, V160, P490, DOI 10.1007/BF00411136; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; EPSTEIN E, 1966, NATURE, V212, P1324, DOI 10.1038/2121324a0; FERNANDO M, 1992, PLANT PHYSIOL, V100, P1269, DOI 10.1104/pp.100.3.1269; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GASSMANN W, IN PRESS PLANT PHYSL; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KOCHIAN LV, 1988, ADV BOT RES, V15, P93; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; MAATHUIS FJM, 1993, PLANTA, V191, P302, DOI 10.1007/BF00195686; MAATHUIS FJM, IN PRESS P NATN ACAD; NEWMAN IA, 1987, PLANT PHYSIOL, V84, P1177, DOI 10.1104/pp.84.4.1177; POOLE RJ, 1978, ANNU REV PLANT PHYS, V29, P437, DOI 10.1146/annurev.pp.29.060178.002253; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; SCHACHTMAN DP, 1991, CROP SCI, V31, P992, DOI 10.2135/cropsci1991.0011183X003100040030x; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SHEAHAN JJ, 1993, PLANT J, V3, P647, DOI 10.1111/j.1365-313X.1993.00647.x; SPANSWICK RM, 1981, ANNU REV PLANT PHYS, V32, P267, DOI 10.1146/annurev.pp.32.060181.001411; WELCH RM, 1968, P NATL ACAD SCI USA, V61, P447, DOI 10.1073/pnas.61.2.447	30	460	528	4	116	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					655	658		10.1038/370655a0	http://dx.doi.org/10.1038/370655a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065452				2022-12-28	WOS:A1994PD31000052
J	NAKANO, T; KODAMA, H; HONJO, T				NAKANO, T; KODAMA, H; HONJO, T			GENERATION OF LYMPHOHEMATOPOIETIC CELLS FROM EMBRYONIC STEM-CELLS IN CULTURE	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; COLONY-STIMULATING FACTOR; HEMATOPOIETIC DEVELOPMENT; YOLK-SAC; INVITRO; DIFFERENTIATION; GENE; INTERLEUKIN-7; EXPRESSION; INVIVO	An efficient system was developed that induced the differentiation of embryonic stem (ES) cells into blood cells of erythroid, myeloid, and B cell lineages by coculture with the stromal cell line OP9. This cell line does not express functional macrophage colony-stimulating factor (M-CSF). The presence of M-CSF had inhibitory effects on the differentiation of ES cells to blood cells other than macrophages. Embryoid body formation or addition of exogenous growth factors was not required, and differentiation was highly reproducible even after the selection of ES cells with the antibiotic G418. Combined with the ability to genetically manipulate ES cells, this system will facilitate the study of molecular mechanisms involved in development and differentiation of hematopoietic cells.	OHU UNIV,SCH DENT,DEPT ANAT,FUKUSHIMA 963,JAPAN		NAKANO, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BURKERT U, 1991, NEW BIOL, V3, P698; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN U, 1992, P NATL ACAD SCI USA, V89, P2541, DOI 10.1073/pnas.89.7.2541; Chen U, 1992, Dev Immunol, V2, P29, DOI 10.1155/1992/79518; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JACKS T, 1992, NATURE, V359, P328; KAWAKAMI T, 1980, NUCLEIC ACIDS RES, V8, P3933, DOI 10.1093/nar/8.17.3933; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KINCADE PW, 1988, J IMMUNOL, V18, P97; KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KODAMA H, IN PRESS EXP HEMATOL; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKANO T, UNPUB; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; SUDA T, 1989, BLOOD, V74, P1936; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; WILES MV, 1991, DEVELOPMENT, V111, P259; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	32	641	686	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1098	1101		10.1126/science.8066449	http://dx.doi.org/10.1126/science.8066449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066449				2022-12-28	WOS:A1994PC53900038
J	CHOI, KY; SATTERBERG, B; LYONS, DM; ELION, EA				CHOI, KY; SATTERBERG, B; LYONS, DM; ELION, EA			STE5 TETHERS MULTIPLE PROTEIN-KINASES IN THE MAP KINASE CASCADE REQUIRED FOR MATING IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; THREONINE KINASE; YEAST; FUS3; COMPONENTS; CLONING; FAR1; PHOSPHORYLATION	Ste5 is a Zn2+ finger-like protein thought to function before three kinases, Ste11 (a MEKK), Ste7 (a MEK), and Fus3 (a MAPK), in a conserved MAP kinase cascade required for mating in S. cerevisiae. Here, we present evidence that Ste5 forms a multikinase complex that joins these kinases for efficient Fus3 activation. By two-hybrid analysis, Ste11, Ste7, and Fus3 associate with different domains of Ste5, while Kss1, another MAPK, associates with the same domain as Fus3, thus implying that Ste5 simultaneously binds a MEKK, MEK, and MAPK. Ste5 copurifies with Ste11, Fus3, and a hypophosphorylated form of Ste7, and all four proteins cosediment in a glycerol gradient as if in a large complex. Ste5 also increases the amount of Ste11 complexed to Ste7 and Fus3 and is required for Ste11 to function. These results substantiate a novel signal transduction component that physically links multiple kinases within a single cascade.			CHOI, KY (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM46962-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACKAY VL, 1983, METHOD ENZYMOL, V101, P325; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUDA S, 1993, J BIOL CHEM, V268, P2377; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKAI Y, 1993, MOL CELL BIOL, V13, P2050, DOI 10.1128/MCB.13.4.2050; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NIEMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1990, New Biologist, V2, P389; PINES J, 1992, J CELL BIOL, V115, P1; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SEGER R, 1992, J BIOL CHEM, V267, P25628; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Sprague G. F., 1993, MOL CELLULAR BIOL YE, P657; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	48	442	453	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					499	512						14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062390				2022-12-28	WOS:A1994PC40500015
J	IMBALZANO, AN; KWON, H; GREEN, MR; KINGSTON, RE				IMBALZANO, AN; KWON, H; GREEN, MR; KINGSTON, RE			FACILITATED BINDING OF TATA-BINDING PROTEIN TO NUCLEOSOMAL DNA	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMATIN STRUCTURE; CRYSTAL-STRUCTURE; MINOR-GROOVE; TFIID BINDS; BOX COMPLEX; MAJOR LATE; YEAST; INVITRO	BINDING of the TATA-binding protein (TBP) to the TATA box is required for transcription from many eukaryotic promoters in gene expression. Regulation of this binding is therefore likely to be an important determinant of promoter activity. Incorporation of the TATA sequence into nucleosomes dramatically reduces transcription initiation(1-3), presumably because of stereochemical constraints on binding of general transcription factors. Biochemical and genetic studies imply that cellular factors such as yeast SWI/SNF are required for activator function and might alter chromatin structure(4-11). One step that could be regulated during the activation process is TBP binding in chromatin(12,13) We show here that binding of TBP to the TATA sequence is severely inhibited by incorporation of this sequence into a nucleosome. Inhibition can be overcome by ATP-dependent alterations in nucleosomal DNA structure mediated by hSWI/SNF, a putative human homologue of the yeast SWI/SNF complex. Additionally, the orientation of the TATA sequence relative to the surface of the histone core affects the access of TBP. We propose that the dynamic remodelling of chromatin structure to allow TBP binding is a key step in the regulation of eukaryotic gene expression.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	30	527	535	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					481	485		10.1038/370481a0	http://dx.doi.org/10.1038/370481a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047170				2022-12-28	WOS:A1994PB40700062
J	HOWARD, RS				HOWARD, RS			RECENT ADVANCES - NEUROLOGY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; GUILLAIN-BARRE-SYNDROME; HUMAN IMMUNE GLOBULIN; MULTIPLE-SCLEROSIS; MOLECULAR-GENETICS; STATUS EPILEPTICUS; SERUM ANTIBODIES; DISEASE; BRAIN; TRIAL				HOWARD, RS (corresponding author), ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, LONDON SE1 7EH, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1993, Lancet, V341, P586; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; CASTRO LHM, 1993, NEUROLOGY, V43, P1034, DOI 10.1212/WNL.43.5.1034; CHADWICK D, 1993, BRIT MED J, V306, P1374; CHANCELLOR AM, 1993, J NEUROL NEUROSUR PS, V56, P1200, DOI 10.1136/jnnp.56.11.1200; CHAUDHRY V, 1993, ANN NEUROL, V33, P237, DOI 10.1002/ana.410330303; CORNBLATH DR, 1994, J NEUROL NEUROSUR PS, V57, P256; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; EDELMAN RR, 1993, AM J ROENTGENOL, V161, P1, DOI 10.2214/ajr.161.1.8517285; HARDING AE, 1993, J NEUROL NEUROSUR PS, V56, P229, DOI 10.1136/jnnp.56.3.229; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; HUGHES R, 1994, J NEUROL NEUROSUR PS, V57, P3, DOI 10.1136/jnnp.57.1.3; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; LEES AJ, 1993, BRIT MED J, V307, P469; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1993, ANN NEUROL, V34, P757, DOI 10.1002/ana.410340603; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; MILLIGAN NM, 1994, J NEUROL NEUROSUR PS, V57, P164, DOI 10.1136/jnnp.57.2.164; MORRISSEY SP, 1993, BRAIN, V116, P135, DOI 10.1093/brain/116.1.135; MUMFORD CJ, 1994, NEUROLOGY, V44, P11, DOI 10.1212/WNL.44.1.11; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PTACEK LJ, 1993, NEW ENGL J MED, V328, P482; RAYMOND AA, 1994, J NEUROL NEUROSUR PS, V57, P1195, DOI 10.1136/jnnp.57.10.1195; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENBERG RN, 1993, ARCH NEUROL-CHICAGO, V50, P1123, DOI 10.1001/archneur.1993.00540110005001; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROULLET E, 1993, J NEUROL NEUROSUR PS, V56, P1062, DOI 10.1136/jnnp.56.10.1062; SHORVON S, 1993, J NEUROL NEUROSUR PS, V56, P125, DOI 10.1136/jnnp.56.2.125; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VONKUMMER R, 1993, THROMBOLYTIC THERAPY, V2, P53; WEINER HL, 1993, NEUROLOGY, V43, P910, DOI 10.1212/WNL.43.5.910; WILES CM, 1994, J NEUROL NEUROSUR PS, V57, P154, DOI 10.1136/jnnp.57.2.154; WILLISON HJ, 1993, J NEUROL NEUROSUR PS, V56, P204, DOI 10.1136/jnnp.56.2.204	38	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	1994	309	6951					392	395		10.1136/bmj.309.6951.392	http://dx.doi.org/10.1136/bmj.309.6951.392			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081146	Green Published			2022-12-28	WOS:A1994PB31600029
J	STREETLY, A; GRANT, C; BICKLER, G; ELDRIDGE, P; BIRD, S; GRIFFITHS, W				STREETLY, A; GRANT, C; BICKLER, G; ELDRIDGE, P; BIRD, S; GRIFFITHS, W			VARIATION IN COVERAGE BY ETHNIC-GROUP OF NEONATAL (GUTHRIE) SCREENING-PROGRAM IN SOUTH LONDON	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL HYPOTHYROIDISM; PHENYLKETONURIA; PREVALENCE	Objectives-To determine whether coverage of the neonatal (Guthrie) screening programme in Britain is different for groups at highest risk of sickle cell disease and to identify possible reasons for incomplete coverage. Design-Descriptive study of coverage of screening programme and its variation by mobility, district of residence, and ethnic group. Subjects-1727 infants born between 1 October and 31 December 1991. Setting-Former West Lambeth and Camberwell District Health Authorities, London. Main outcome measure-Proportion of infants with an identifiable screening test result. Results-Screening covered 1663/1727 (96.3%) infants overall (745/786 (94.8%) in West Lambeth; 918/941 (97.6%) in Camberwell). The relative odds ratio of an African infant not having been tested compared with a white infant was 3.05 (95% confidence interval 1.30 to 7.14) (2.08 (0.86 to 5.01) after adjustment for mobility and district of residence). For infants whose families moved into the districts after the birth compared with those born and resident in the districts the relative odds ratio of having been tested was 10.16 (4.85 to 21.29). The odds ratio of locally delivered infants in West Lambeth not having been tested compared with those in Camberwell was 2.12 (1.08 to 4.16) after adjustment for ethnic group. Conclusion-Coverage of the screening programme is incomplete and poorer in infants of African ethnic group than in white infants. Poorer coverage is also associated with mobility of the family around the time of birth. The findings have implications for using the neonatal programme for testing for sickle cell disease and other disorders. Arrangements for monitoring the existing screening programme are inadequate and an improved system should be established, similar to the scheme that monitors the immunisation programme.	UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND; LAMBETH SOUTHWARK & LEWISHAM HLTH COMMISS,LONDON SE1 7RJ,ENGLAND; LEWISHAM HOSP NHS TRUST,DEPT CLIN CHEM,LONDON SE13 6LH,ENGLAND; GUYS HOSP,DEPT CLIN BIOCHEM,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust				Bickler, Graham/0000-0001-8935-2368				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; Dean A. G., 1990, EPI INFO VERSION 5 W; DHONDT JL, 1991, J INHERIT METAB DIS, V14, P633, DOI 10.1007/BF01797933; ELLIMAN D, 1991, BRIT MED J, V303, P471, DOI 10.1136/bmj.303.6800.471; FERNHOFF PM, 1987, LANCET, V2, P490; FISHER DA, 1987, PEDIATR CLIN N AM, V34, P881; GRIFFITHS PD, 1987, ADV NEONATAL SCREENI, P513; HENDERSON SJ, 1993, BRIT J HAEMATOL, V84, P20; HUNTER R, 1989, HEEL HEAL SCREENING; PASS KA, 1991, AM J PUBLIC HEALTH, V81, P22, DOI 10.2105/AJPH.81.Suppl.22; PHAROAH POD, 1992, ARCH DIS CHILD, V67, P1073, DOI 10.1136/adc.67.9.1073; POLLITT RJ, 1993, J CLIN PATHOL, V46, P497, DOI 10.1136/jcp.46.6.497; RATTENBURY JM, 1978, LANCET, V2, P482; SMITH I, 1991, BRIT MED J, V303, P333, DOI 10.1136/bmj.303.6798.333; STREETLY A, 1993, BRIT MED J, V306, P1491, DOI 10.1136/bmj.306.6891.1491; 1981, SCREENING EARLY DETE; 1989, SAS STAT USES GUIDE, V2; 1969, SCREENING EARLY DETE	18	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					372	374		10.1136/bmj.309.6951.372	http://dx.doi.org/10.1136/bmj.309.6951.372			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081135	Green Published			2022-12-28	WOS:A1994PB31600017
J	BRUNNER, D; DUCKER, K; OELLERS, N; HAFEN, E; SCHOLZ, H; KLAMBT, C				BRUNNER, D; DUCKER, K; OELLERS, N; HAFEN, E; SCHOLZ, H; KLAMBT, C			THE ETS DOMAIN PROTEIN POINTED-P2 IS A TARGET OF MAP KINASE IN THE SEVENLESS SIGNAL-TRANSDUCTION PATHWAY	NATURE			English	Article							RECEPTOR TYROSINE KINASE; FUNCTIONS DOWNSTREAM; GENETIC DISSECTION; DROSOPHILA EYE; GROWTH-FACTOR; ACTIVATION; EXPRESSION; CELLS; LOCALIZATION; PATTERN	The fate of the R7 photoreceptor cell in the developing eye of Drosophila is controlled by the Sevenless (Sev) receptor tyrosine kinase(1,2). Sev activates a highly conserved signal transduction cascade involving the proteins Ras1 and Raf and the Rolled/mitogen-activated protein (Rl/hlAP) kinase(3). Here we show that the ETS domain protein encoded by the P2 transcript of the pointed (pnt) gene is a nuclear target of this signalling cascade which acts downstream of RI/MAP kinase. The PntP2 protein is phosphorylated by Rl/MAP kinase in vitro at a single site and this site is required for its function in vivo. Furthermore, we present genetic and biochemical data suggesting that MAP kinase controls neural development through phosphorylation of two antagonizing transcription factors of the ETS family, Yan and PntP2.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND; UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY	University of Zurich; University of Cologne			Brunner, Damian/F-2024-2011; Scholz, Henrike/ABE-1063-2020	Brunner, Damian/0000-0001-5250-492X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON B, 1993, DEV DROSOPHILA; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JURGENS G, 1984, W ROUXS ARCH DEV BIO, V193, P183; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SCHOLZ H, 1993, GENETICS, V135, P455; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	30	318	320	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					386	389		10.1038/370386a0	http://dx.doi.org/10.1038/370386a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047146				2022-12-28	WOS:A1994PA30400060
J	BOREN, SD				BOREN, SD			I HAD A TOUGH DAY TODAY, HILLARY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LEFT HEART SYNDROME; BREAST-CANCER; TRANSPLANTATION				BOREN, SD (corresponding author), CNA INSURANCE CO,CHICAGO,IL 60685, USA.							ALLAN LD, 1991, LANCET, V337, P959, DOI 10.1016/0140-6736(91)91582-F; ARMITAGE JO, 1992, HIGH DOSE CANCER THE; CLINTON B, 1992, NEW ENGL J MED, V327, P804, DOI 10.1056/NEJM199209103271112; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; DEAN M, 1991, LANCET, V338, P1133, DOI 10.1016/0140-6736(91)91977-3; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; FERGUSON JH, 1993, JAMA-J AM MED ASSOC, V269, P2116, DOI 10.1001/jama.269.16.2116; HARKER C, 1993, SELF FUNDING HLTH CA; HARRUS HR, 1993, CANCER PRINCIPLES PR, V1, P1322; HAUBOLDT R, 1993, RES REPORT COST IMPL, P30; MCCARTNEY S, 1993, WALL STREET J   0401, pA1; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; MICHAELS MG, 1993, JAMA-J AM MED ASSOC, V269, P401, DOI 10.1001/jama.269.3.401; Pear Robert, 1993, N Y Times Web, pB7; PETERS WP, 1992, P AM SOC CLIN ONCOL, V11, pA59; STARNES VA, 1992, J THORAC CARDIOV SUR, V104, P189; STOUT J, 1993, WALL ST J       0422, pA1; STUART AG, 1991, LANCET, V337, P957, DOI 10.1016/0140-6736(91)91581-E; WARTZMAN R, 1993, WALL STREET J, pA3; 1993, LANCET, V341, P343; 1992, 1991 HLTH CARE BENEF, P15; 1992, DIGEST HLTH INSURANC; 1988, GROUP LIFE HLTH IN C, P39	23	21	21	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					500	502		10.1056/NEJM199402173300712	http://dx.doi.org/10.1056/NEJM199402173300712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8068069				2022-12-28	WOS:A1994MW48000012
J	HARRISON, MR; ADZICK, NS; ESTES, JM; HOWELL, LJ				HARRISON, MR; ADZICK, NS; ESTES, JM; HOWELL, LJ			A PROSPECTIVE-STUDY OF THE OUTCOME FOR FETUSES WITH DIAPHRAGMATIC-HERNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							EXTRACORPOREAL MEMBRANE-OXYGENATION; INITIAL CLINICAL-EXPERIENCE; PRENATAL-DIAGNOSIS	Objective.-To establish the natural history and outcome of isolated congenital diaphragmatic hernia (CDH) diagnosed before birth. The mortality of CDH with currently available postnatal care, including extracorporeal membrane oxygenation (ECMO), reported in retrospective studies ranges from less than 25% to greater than 75%. This variation is attributable to a ''hidden mortality (infants who die with CDH that is not recognized) of unknown magnitude. Design.-Prospectively followed case series. Setting.-Patients were referred from practitioners in 18 slates and evaluated and followed up by the University of California, San Francisco, Fetal Treatment Center. Arrangements were made for planned delivery at tertiary perinatal centers with ECMO capability. Patients.-All 83 fetuses with isolated, potentially correctable CDH diagnosed prior to 24 weeks' gestation referred to the University of California, San Francisco, Fetal Treatment Center between January 1989 and October 1993. Main Outcome Measures.-Survival beyond 2 months after optimal postnatal care. Results.-Fifty-eight percent (48 of 83) died despite optimal postnatal care (95% confidence interval, 41% to 75%). Of the 48 nonsurvivors, seven suffered intrauterine fetal demise, four were too premature for ECMO, 16 died before ECMO could be started, and 21 died despite ECMO therapy. Twenty-two of the 35 survivors received ECMO, and nine of these have severe chronic illness attributable to the intensive management. Conclusions.-In this study, the mortality for potentially correctable CDH diagnosed before 24 weeks' gestation is 58%, despite optimal care presently available after birth. Infants who die in utero and soon after birth constitute a substantial hidden mortality.			HARRISON, MR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT SURG,DIV PEDIAT SURG,513 PARNASSUS AVE,ROOM 1601-HSW,SAN FRANCISCO,CA 94143, USA.		Harrison, Michael/GYD-8608-2022					ADZICK NS, 1985, J PEDIATR SURG, V20, P357, DOI 10.1016/S0022-3468(85)80219-0; ATKINSON JB, 1991, J PEDIATR SURG, V26, P791, DOI 10.1016/0022-3468(91)90140-O; BENJAMIN DR, 1988, J PEDIATR SURG, V23, P899, DOI 10.1016/S0022-3468(88)80380-4; BUTLER N, 1962, LANCET, V1, P659; CRAWFORD DC, 1989, BRIT J OBSTET GYNAEC, V96, P705, DOI 10.1111/j.1471-0528.1989.tb03286.x; FLEISS JL, 1981, STATISTICAL METHODS, P13; HARRISON MR, 1990, J PEDIATR SURG, V25, P47, DOI 10.1016/S0022-3468(05)80163-0; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1993, J PEDIATR SURG, V28, P1411, DOI 10.1016/S0022-3468(05)80338-0; HARRISON MR, 1990, LANCET, V336, P965, DOI 10.1016/0140-6736(90)92420-M; HARRISON MR, 1979, J PEDIATR SURG, V13, P227; Harrison MR, 1991, UNBORN PATIENT PRENA, P328; HEISS K, 1989, ANN SURG, V209, P225, DOI 10.1097/00000658-198902000-00014; KAMATA S, 1992, PEDIATR SURG INT, V7, P109, DOI 10.1007/BF00183914; NAKAYAMA DK, 1985, J PEDIATR SURG, V20, P118, DOI 10.1016/S0022-3468(85)80282-7; SHARLAND GK, 1992, AM J OBSTET GYNECOL, V166, P9, DOI 10.1016/0002-9378(92)91817-T; STOLAR C, 1988, J PEDIATR SURG, V23, P207, DOI 10.1016/S0022-3468(88)80723-1; THORPE-BEESTON J G, 1989, Fetal Therapy, V4, P21; TORFS CP, 1992, TERATOLOGY, V46, P555, DOI 10.1002/tera.1420460605; VANMEURS KP, 1990, J PEDIATR-US, V117, P954, DOI 10.1016/S0022-3476(05)80144-1; WENSTROM KD, 1991, AM J OBSTET GYNECOL, V165, P838, DOI 10.1016/0002-9378(91)90425-Q	21	264	272	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					382	384		10.1001/jama.271.5.382	http://dx.doi.org/10.1001/jama.271.5.382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8054005				2022-12-28	WOS:A1994MR98300034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			REPORTS OF PROBLEMS WITH USE OF LIQUID-DOSING DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					995	995		10.1001/jama.272.13.995	http://dx.doi.org/10.1001/jama.272.13.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089899				2022-12-28	WOS:A1994PH77500006
J	HOHNLOSER, SH; KLINGENHEBEN, T; SINGH, BN				HOHNLOSER, SH; KLINGENHEBEN, T; SINGH, BN			AMIODARONE-ASSOCIATED PROARRHYTHMIC EFFECTS - A REVIEW WITH SPECIAL REFERENCE TO TORSADE-DE-POINTES TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Review							SUSTAINED VENTRICULAR-TACHYCARDIA; ARRHYTHMIA SUPPRESSION TRIAL; ANTIARRHYTHMIC DRUG-THERAPY; ACUTE MYOCARDIAL-INFARCTION; PLACEBO-CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; LOW-DOSE AMIODARONE; LONG QT SYNDROME; TERM FOLLOW-UP; DE-POINTES	Purpose: To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of new arrhythmias, such as torsade de pointes, in patients with cardiac disease. Data Sources and Study Selection: A MEDLINE literature search was done to identify articles published during the last 20 years that presented data on amiodarone-associated proarrhythmic events. The articles were divided into three categories: case reports, uncontrolled retrospective studies, and prospective controlled trials. In addition, articles were identified that examined the effects of amiodarone in patients with previously documented drug-induced torsade de pointes. Results: 65 English-language case reports dealing with torsade de pointes during amiodarone therapy were found in the literature. In many of these cases, other predisposing factors for the development of torsade de pointes were reported. Seventeen studies each reported data from at least 50 patients who were treated with amiodarone for at least 6 months. Of 2878 patients included in these trials, 57 were reported to have a proarrhythmic event while exposed to the drug (an overall incidence of 2%). Torsade de pointes was observed in one third of these patients (an overall incidence of 0.7%). In seven placebo-controlled trials in which the drug was given as monotherapy, amiodarone was not associated with the development of a proarrhythmic event in any patient. Finally, in three reports, 31 patients with previous drug-mediated torsade de pointes were exposed to amiodarone during short- and long-term therapy. In none of these patients did a recurrent episode of torsade de pointes develop, despite the amiodarone-induced prolongation of the QTc interval, which was equivalent to that observed at the time of torsade de pointes during exposure to previous drugs. Conclusions: Amiodarone appears to be associated with a remarkably low frequency of proarrhythmic events and an incidence of torsade de pointes of less than 1.0%. This low arrhythmogenicity and the negligible negative inotropic effect of the compound constitute properties that make amiodarone particularly useful in treating high-risk patients prone to sudden cardiac death. Its potential to reduce this risk is currently being evaluated in several large prospective trials.	W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	HOHNLOSER, SH (corresponding author), UNIV FREIBURG, DEPT CARDIOL, HUGSTETTER STR 55, D-79106 FREIBURG, GERMANY.							AKHTAR M, 1990, CIRCULATION, V81, P1123, DOI 10.1161/01.CIR.81.3.1123; ANDRIVET P, 1990, INTENS CARE MED, V16, P342, DOI 10.1007/BF01706367; BAJAJ BP, 1991, INT J CARDIOL, V33, P335, DOI 10.1016/0167-5273(91)90369-Z; BALESTRA B, 1993, SCHWEIZ MED WSCHR, V123, P20; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BANSAL AM, 1986, AM HEART J, V112, P618, DOI 10.1016/0002-8703(86)90533-8; BAUMAN JL, 1987, AM HEART J, V114, P1436, DOI 10.1016/0002-8703(87)90549-7; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1993, AM J CARDIOL, V72, pF87, DOI 10.1016/0002-9149(93)90969-J; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CAMM AJ, 1993, AM J CARDIOL, V72, pF95, DOI 10.1016/0002-9149(93)90970-N; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; COLATSKY TJ, 1990, CIRCULATION, V82, P2235, DOI 10.1161/01.CIR.82.6.2235; CONNOLLY SJ, 1993, AM J CARDIOL, V72, pF103, DOI 10.1016/0002-9149(93)90972-F; CUI GG, 1994, J AM COLL CARDIOL, pA179; CUI GG, 1992, CIRCULATION, V86, P393; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EL-SHERIF N, 1990, Journal of Cardiovascular Electrophysiology, V1, P145, DOI 10.1111/j.1540-8167.1990.tb01057.x; ELSHERIF N, 1989, J AM COLL CARDIOL, V14, P252, DOI 10.1016/0735-1097(89)90082-X; FOGOROS RN, 1983, CIRCULATION, V68, P88, DOI 10.1161/01.CIR.68.1.88; GARGUICHEVICH J, 1992, EUR HEART J, V13, pP1581; GREENE HL, 1993, AM J CARDIOL, V72, P280; GREENE HL, 1983, J AM COLL CARDIOL, V2, P1114, DOI 10.1016/S0735-1097(83)80338-6; GUCCIONE P, 1990, J AM COLL CARDIOL, V15, P1118, DOI 10.1016/0735-1097(90)90251-J; HAFFAJEE CI, 1983, CIRCULATION, V67, P1347, DOI 10.1161/01.CIR.67.6.1347; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HII JTY, 1992, CIRCULATION, V86, P1376, DOI 10.1161/01.CIR.86.5.1376; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOCKINGS BEF, 1987, AM J CARDIOL, V60, P967, DOI 10.1016/0002-9149(87)90334-1; HONDEGHEM LM, 1992, J CARDIOVASC PHARM, V20, pS17, DOI 10.1097/00005344-199220002-00004; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JORENS PG, 1989, ACTA CARDIOL, V44, P411; KERIN NZ, 1988, J ELECTROPHYSIOL, V2, P289; MASON JW, 1987, NEW ENGL J MED, V316, P455; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1983, PFLUG ARCH EUR J PHY, V396, P79, DOI 10.1007/BF00584702; MATTIONI TA, 1989, ANN INTERN MED, V111, P574, DOI 10.7326/0003-4819-111-7-574; MCGOVERN B, 1983, BRIT MED J, V287, P175, DOI 10.1136/bmj.287.6386.175; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MORADY F, 1983, AM J CARDIOL, V52, P975, DOI 10.1016/0002-9149(83)90515-5; MORGAN JM, 1991, EUR HEART J, V12, P1144, DOI 10.1093/oxfordjournals.eurheartj.a059849; MOSTOW ND, 1986, AM HEART J, V111, P178, DOI 10.1016/0002-8703(86)90573-9; MYERS M, 1990, AM HEART J, V119, P8, DOI 10.1016/S0002-8703(05)80074-2; NADEMANEE K, 1993, CIRCULATION, V88, P764, DOI 10.1161/01.CIR.88.2.764; NADEMANEE K, 1983, ANN INTERN MED, V98, P577, DOI 10.7326/0003-4819-98-5-577; NATTEL S, 1987, CIRCULATION, V76, P442, DOI 10.1161/01.CIR.76.2.442; NGUYEN PT, 1986, CIRCULATION, V74, P340, DOI 10.1161/01.CIR.74.2.340; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; PETER T, 1983, AM HEART J, V106, P943, DOI 10.1016/0002-8703(83)90020-0; PFISTERER ME, 1993, CIRCULATION, V87, P309, DOI 10.1161/01.CIR.87.2.309; POLSTER P, 1976, BIOCHEM PHARMACOL, V25, P131, DOI 10.1016/0006-2952(76)90279-3; POSER RF, 1985, AM HEART J, V110, P9, DOI 10.1016/0002-8703(85)90507-1; RAE AP, 1988, J AM COLL CARDIOL, V12, P131, DOI 10.1016/0735-1097(88)90366-X; RAEDER EA, 1985, AM HEART J, V109, P975, DOI 10.1016/0002-8703(85)90238-8; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SAGER PT, 1993, CIRCULATION, V88, P1063, DOI 10.1161/01.CIR.88.3.1063; Schlienger R G, 1993, Schweiz Rundsch Med Prax, V82, P173; SINGH BN, 1992, ANN NY ACAD SCI, V644, P187, DOI 10.1111/j.1749-6632.1992.tb31011.x; SINGH BN, 1989, PROG CARDIOVASC DIS, V31, P249, DOI 10.1016/0033-0620(89)90033-9; SINGH BN, 1993, AM J CARDIOL, V72, pF114, DOI 10.1016/0002-9149(93)90974-H; SINGH BN, 1989, AM J CARDIOL, V63, P867, DOI 10.1016/0002-9149(89)90059-3; SINGH BN, 1990, CARDIAC ELECTROPHYSI, P882; SINGH SN, 1993, AM J CARDIOL, V72, pF99, DOI 10.1016/0002-9149(93)90971-E; SLATER W, 1988, AM J CARDIOL, V61, P349, DOI 10.1016/0002-9149(88)90943-5; SMITH WM, 1986, AM J CARDIOL, V57, P1288, DOI 10.1016/0002-9149(86)90206-7; SOYKA LF, 1990, AM J CARDIOL, V65, pA74; TAKANAKA C, 1990, J AM COLL CARDIOL, V15, P213, DOI 10.1016/0735-1097(90)90205-4; VELEBIT V, 1982, CIRCULATION, V65, P886, DOI 10.1161/01.CIR.65.5.886; VROBEL TR, 1989, PROG CARDIOVASC DIS, V31, P393, DOI 10.1016/0033-0620(89)90016-9; WAXMAN HL, 1982, AM J CARDIOL, V50, P1066, DOI 10.1016/0002-9149(82)90419-2; WEINBERG BA, 1993, AM HEART J, V125, P109, DOI 10.1016/0002-8703(93)90063-F; ZIPES DP, 1984, J AM COLL CARDIOL, V3, P1059, DOI 10.1016/S0735-1097(84)80367-8	79	283	290	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					529	535		10.7326/0003-4819-121-7-199410010-00009	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067651				2022-12-28	WOS:A1994PJ10200009
J	SPACH, DH; FRITSCHE, TR				SPACH, DH; FRITSCHE, TR			NORWEGIAN SCABIES IN A PATIENT WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SPACH, DH (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98122, USA.								0	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					777	777						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065406				2022-12-28	WOS:A1994PG30100005
J	HAAHTELA, T; JARVINEN, M; KAVA, T; KIVIRANTA, K; KOSKINEN, S; LEHTONEN, K; NIKANDER, K; PERSSON, T; SELROOS, O; SOVIJARVI, A; STENIUSAARNIALA, B; SVAHN, T; TAMMIVAARA, R; LAITINEN, LA				HAAHTELA, T; JARVINEN, M; KAVA, T; KIVIRANTA, K; KOSKINEN, S; LEHTONEN, K; NIKANDER, K; PERSSON, T; SELROOS, O; SOVIJARVI, A; STENIUSAARNIALA, B; SVAHN, T; TAMMIVAARA, R; LAITINEN, LA			EFFECTS OF REDUCING OR DISCONTINUING INHALED BUDESONIDE IN PATIENTS WITH MILD ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL ASTHMA	Background. In a previous study, we found that two years of treatment with an inhaled corticosteroid, budesonide, was more effective than treatment with an inhaled beta(2)-agonist, terbutaline, in patients with newly diagnosed, generally mild asthma. We continued this study for a third year to investigate whether the steroid dose could be reduced or discontinued and what effect crossover of patients from beta(2)-agonist therapy to corticosteroid therapy would have. Methods. A total of 37 patients treated for two years with inhaled budesonide at a dose of 1200 mu g per day were randomly assigned to treatment with 400 mu g of budesonide per day (19 patients) or placebo (18 patients) in a double-blind manner. Another 37 patients, who had received terbutaline during the first two years, were crossed over in an open-label manner to treatment with 1200 mu g of budesonide per day during the third year. Results. Treatment with the reduced dose of budesonide was sufficiently effective in 74 percent of the patients to maintain bronchial responsiveness at a level similar to that achieved with the higher dose. In contrast, improvement was maintained in only 33 percent of the patients receiving placebo, and the differences in pulmonary function between the steroid and placebo groups were significant (for forced expiratory volume in one second, P = 0.007; for bronchial responsiveness to histamine, P = 0.025; and for peak expiratory flow in the morning, P = 0.040). The condition of patients who were crossed over from terbutaline therapy to treatment with 1200 mu g of budesonide per day improved. However, the degree of improvement in these patients appeared to be less than in those who were treated with budesonide at the beginning of the three-year study. Conclusions. Early treatment with inhaled budesonide results in long-lasting control of mild asthma. Maintenance therapy can usually be given at a reduced dose, but discontinuation of treatment is often accompanied by exacerbation of the disease.	KANTA HAME CENT HOSP, HAMEENLINNA, FINLAND; POHJOIS KARJALA CENT HOSP, JOENSUU, FINLAND; KILJAVA HOSP, KILJAVA, FINLAND; ETELA SAIMAA CENT HOSP, LAPPEENRANTA, FINLAND; ASTRO DRACO AB, LUND, SWEDEN		HAAHTELA, T (corresponding author), UNIV HELSINKI, CENT HOSP, DEPT ALLERG DIS, MEILAHDENTIE 2, SF-00250 HELSINKI, FINLAND.		Sovijärvi, Anssi Raimo Antero/AAE-9512-2021					BROGDEN RN, 1983, STEROIDS ASTHMA, P154; ENGEL T, 1989, ALLERGY, V44, P220, DOI 10.1111/j.1398-9995.1989.tb02266.x; GREGG I, 1973, BMJ-BRIT MED J, V3, P282, DOI 10.1136/bmj.3.5874.282; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; MAYNARD DE, 1966, ANN INTERN MED, V64, P552, DOI 10.7326/0003-4819-64-3-552; OSTERMAN K, 1993, EUR RESPIR J S17, V6, pS119; PAGE C, 1992, RESP MED, V86, P477, DOI 10.1016/S0954-6111(96)80005-9; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5	12	596	606	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					700	705		10.1056/NEJM199409153311103	http://dx.doi.org/10.1056/NEJM199409153311103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058076				2022-12-28	WOS:A1994PF33200003
J	LYTTLE, CS; LEVEY, GS				LYTTLE, CS; LEVEY, GS			THE NATIONAL-STUDY-OF-INTERNAL-MEDICINE-MANPOWER .10. THE CHANGING DEMOGRAPHICS OF INTERNAL-MEDICINE RESIDENCY TRAINING-PROGRAMS	ANNALS OF INTERNAL MEDICINE			English	Article							YOUNG PHYSICIANS; FUTURE	Three annual physician workforce surveys of internal medicine residency programs from 1990-1991, 1991-1992, and 1992-1993 show that changes in the demographic characteristics of internal medicine residents detected in the period 1986-1989 have been sustained; specifically, more women and international medical graduates are entering internal medicine. Women and international medical graduates now compose 32% and 36% of internal medicine trainees, respectively. The percentage of U.S. medical graduates was lower in traditional 3-year (categorical) tracks (64%) and highest in preliminary tracks (1 year of internal medicine leading to another specialty) (87%). Approximately 1500 more first-year residents than positions offered through the National Residency Matching Program were reported in 1992-1993. This suggests that many programs concentrate their recruiting efforts outside the Matching Program. The data also show a continuing high subspecialization rate for residents who complete 3 years of training in internal medicine (approximately 60%), although about one third do not go directly into subspecialty training. We discuss the implications of these findings for the national goal of increasing the number of primary care physicians.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LYTTLE, CS (corresponding author), UNIV CHICAGO, CTR HLTH ADM STUDIES, 969 E 60TH ST, CHICAGO, IL 60637 USA.							ANDERSEN RM, 1990, ANN INTERN MED, V113, P243, DOI 10.7326/0003-4819-113-3-243; ANDERSEN RM, 1992, ANN INTERN MED, V117, P243, DOI 10.7326/0003-4819-117-3-243; BLANK LL, 1992, ANN INTERN MED, V117, P778; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; COHEN JJ, 1993, ANN INTERN MED, V119, P1125, DOI 10.7326/0003-4819-119-11-199312010-00010; GLICKMAN RM, 1993, ANN INTERN MED, V118, P903, DOI 10.7326/0003-4819-118-11-199306010-00014; HADLEY J, 1992, ACAD MED, V67, P180, DOI 10.1097/00001888-199203000-00010; HARRINGTON WJ, 1991, ACAD MED, V66, P707, DOI 10.1097/00001888-199111000-00018; KLETKE PR, 1990, AM J PUBLIC HEALTH, V80, P300, DOI 10.2105/AJPH.80.3.300; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; PETERSDORF RG, 1993, ANN INTERN MED, V119, P1130, DOI 10.7326/0003-4819-119-11-199312010-00011; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; SCHROEDER SA, 1993, ACAD MED, V68, P118, DOI 10.1097/00001888-199302000-00002; 1993, PHYSICIAN PAYMENT RE; 1992, NATIONAL INTERN RESI; 1992, IMPROVING ACCESS HLT	17	19	18	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					435	441		10.7326/0003-4819-121-6-199409150-00008	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053618				2022-12-28	WOS:A1994PF33700008
J	KENT, RJ; UTTLEY, AHC; STOKER, NG; MILLER, R; POZNIAK, AL				KENT, RJ; UTTLEY, AHC; STOKER, NG; MILLER, R; POZNIAK, AL			TRANSMISSION OF TUBERCULOSIS IN BRITISH CENTER FOR PATIENTS INFECTED WITH HIV	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GENITOURINARY MED,LONDON SE5 9PT,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON SE5 9PT,ENGLAND; DULWICH PUBL HLTH LAB,REG TB CTR,LONDON SE22 8QF,ENGLAND; LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND; MIDDLESEX HOSP,LONDON W1N 8AA,ENGLAND	University of London; King's College London; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London			Stoker, Neil G/L-8812-2016	Stoker, Neil G/0000-0001-7055-6184; Miller, Robert/0000-0003-2067-4291				DIPERRI G, 1989, LANCET, V2, P1502; UTTLEY AHC, 1993, J HOSP INFECT, V23, P249, DOI 10.1016/0195-6701(93)90141-L; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; 1990, BRIT MED J, V300, P995; 1990, MORBIDITY MORTALITY, V39, P1	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					639	640		10.1136/bmj.309.6955.639	http://dx.doi.org/10.1136/bmj.309.6955.639			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086987	Green Published			2022-12-28	WOS:A1994PG02000020
J	HEDDLE, NM; KLAMA, L; SINGER, J; RICHARDS, C; FEDAK, P; WALKER, I; KELTON, JG				HEDDLE, NM; KLAMA, L; SINGER, J; RICHARDS, C; FEDAK, P; WALKER, I; KELTON, JG			THE ROLE OF THE PLASMA FROM PLATELET CONCENTRATES IN TRANSFUSION REACTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEBRILE	Background. Febrile, nonhemolytic transfusion reactions are the most frequent adverse reactions to platelets. A number of observations argue against the widely held view that these reactions result from the interaction between antileukocyte antibodies in the recipient and leukocytes in the platelet product. We sought to determine whether substances in the plasma or the cells in the product cause reactions to transfused platelets. Methods. We separated standard platelet concentrates into their plasma and cellular components and then transfused both portions in random order. Patients were monitored for reactions during all transfusions. Before each transfusion, the concentration of cytokines (interleukin-1 beta and interleukin-6) was measured in the platelet products. Studies were also performed on the platelet products to determine the effect of storage on the concentration of cytokines. Results. Sixty-four pairs of platelet-product components (the plasma supernatant and the cells) were administered to 12 patients. There were 20 reactions to the plasma supernatant and 6 reactions to the cells (chi-square = 6.50, P = 0.009). Eight transfusions were associated with reactions to both products. The plasma component was more likely to cause severe reactions than the cells (chi-square = 9.6, P < 0.01). A strong positive correlation was observed between the reactions and the concentration of interleukin-1 beta and interleukin-6 in the plasma supernatant (P < 0.001 and P = 0.034, respectively). In vitro studies demonstrated that interleukin-1 beta and interleukin-6 concentrations rise progressively in stored platelets and that these concentrations are related to the leukocyte count in the platelet product. Conclusions. Bioreactive substances in the plasma supernatant of the platelet product cause most febrile reactions associated with platelet transfusions. Removing the plasma supernatant before transfusion can minimize or prevent these reactions.	MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA; CHEDOKE MCMASTER HOSP,TRANSFUS MED SERV,HAMILTON,ON,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA; CANADIAN RED CROSS BLOOD TRANSFUS SERV,HAMILTON CTR,HAMILTON,ON,CANADA	McMaster University; McMaster University; University of British Columbia	HEDDLE, NM (corresponding author), MCMASTER UNIV,MED CTR,DEPT PATHOL,RM 2N38,1200 MAIN ST W,HAMILTON L8N 3Z5,ON,CANADA.			Fedak, Paul/0000-0003-0658-9381; Richards, Carl/0000-0002-0081-2231				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AVE MT, 1993, BLOOD S1, V82, pA336; CHAMBERS LA, 1990, TRANSFUSION, V30, P219, DOI 10.1046/j.1537-2995.1990.30390194340.x; HEDDLE NM, 1993, TRANSFUSION, V33, P794, DOI 10.1046/j.1537-2995.1993.331094054613.x; KALMIN ND, 1987, TRANSFUSION, V27, P281, DOI 10.1046/j.1537-2995.1987.27387235641.x; LENG B, 1990, 1990 P ISBT AABB JOI, P17; MANGANO MM, 1991, AM J CLIN PATHOL, V95, P733, DOI 10.1093/ajcp/95.5.733; MUYLLE L, 1992, TRANSFUSION MED, V2, P289, DOI 10.1111/j.1365-3148.1992.tb00172.x; MUYLLE L, 1993, TRANSFUSION, V33, P195, DOI 10.1046/j.1537-2995.1993.33393174443.x; PAYNE R, 1957, Vox Sang, V2, P233; PAYNE R, 1960, AM J MED, V29, P449, DOI 10.1016/0002-9343(60)90041-3; PERKINS HA, 1966, VOX SANG, V11, P578, DOI 10.1111/j.1423-0410.1966.tb04256.x; SILLIMAN C, 1992, BLOOD, V80, pA365; STACK G, 1994, TRANSFUSION, V34, P20, DOI 10.1046/j.1537-2995.1994.34194098597.x; WALKER RH, 1990, TECHNICAL MANUAL, P420	15	369	386	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					625	628		10.1056/NEJM199409083311001	http://dx.doi.org/10.1056/NEJM199409083311001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052271				2022-12-28	WOS:A1994PE38200001
J	MILLS, M; DAVIES, HTO; MACRAE, WA				MILLS, M; DAVIES, HTO; MACRAE, WA			CARE OF DYING PATIENTS IN-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							TERMINAL CANCER; DEATH; FAMILIES; SYMPTOMS; PAIN	Objective-To study the process of care of dying patients in general hospitals. Design-Non-participant observer (MM) carried out regular periods of continuous comprehensive observation in wards where there were dying patients, recording the quantity and quality of care given. Observations were made in 1983. Setting-13 wards (six surgical, six medical, and one specialist unit) in four large teaching hospitals Cbed capacity 503-796) in west of Scotland. Sujects-50 dying patients (29 female, 21 male) with mean age of 66 (range 40-89); 29 were dying from cancer and 21 from non-malignant disease. Results-Final period of hospitalisation ranged from 6 hours to 24 weeks. More than half of all patients retained consciousness until shortly before death. Basic interventions to maintain patients' comfort were often not provided: oral hygiene was often poor, thirst remained unquenched, and little assistance was given to encourage eating, Contact between nurses and the dying patients was minimal; distancing and isolation of patients by most medical and nursing staff were evident; this isolation increased as death approached. Conclusions-Care of many of the dying patients observed in these hospitals was poor. We need to identify and implement practical steps to facilitate high quality care of the dying. Much can be learned from the hospice movement, but such knowledge and skills must be replicated in all settings.	GREATER GLASGOW HLTH BOARD,GLASGOW G1 1PT,LANARK,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT ANAESTHET,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee				Davies, Huw/0000-0002-2653-3695				ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; BOWLING A, 1983, J MED ETHICS, V9, P158, DOI 10.1136/jme.9.3.158; BUCKINGHAM RW, 1976, CAN MED ASSOC J, V115, P1211; CAMERON J, 1983, POSTGRAD MED J, V59, P73, DOI 10.1136/pgmj.59.688.73; CARTWRIGHT A, 1991, J PUBLIC HEALTH MED, V13, P81; Conboy-Hill S, 1986, Int Nurs Rev, V33, P19; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; FOX D, 1976, FUNDAMENTALS RES NUR; HIGGINSON I, 1989, J ROY SOC MED, V82, P264, DOI 10.1177/014107688908200507; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; Higginson I, 1993, Qual Health Care, V2, P112, DOI 10.1136/qshc.2.2.112; HINTON J, 1979, LANCET, V1, P29; HOCKLEY JM, 1988, BRIT MED J, V296, P1715, DOI 10.1136/bmj.296.6638.1715; KANE RL, 1984, LANCET, V1, P890; MAGUIRE P, 1985, BRIT MED J, V291, P1711, DOI 10.1136/bmj.291.6510.1711; OBRIEN T, 1993, MANAGEMENT TERMINAL, P33; PARKES CM, 1984, POSTGRAD MED J, V60, P120, DOI 10.1136/pgmj.60.700.120; RAY M, 1981, CARING ESSENTIAL HUM, P25; SAMAREL N, 1989, INT J NURS STUD, V26, P313, DOI 10.1016/0020-7489(89)90018-7; SAUNDERS C, 1993, MANAGEMENT TERMINAL; SEALE C, 1991, SOC SCI MED, V32, P147, DOI 10.1016/0277-9536(91)90054-G; SIMPSON K H, 1991, Palliative Medicine, V5, P122; SUDNOW D, 1967, PASSONG SOCIAL ORG D; SYKES N P, 1992, Palliative Medicine, V6, P227, DOI 10.1177/026921639200600307; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; Ventafridda V, 1990, J Palliat Care, V6, P7; Webster M E, 1981, Nurs Times, V77, P999; WILKES E, 1984, LANCET, V1, P950; 1993, 1992 GEN REG OFF ANN; 1991, J R COLL PHYSICIANS, V25, P325; 1967, SCOTTISH HLTH SERVIC, V3	32	99	99	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					583	586		10.1136/bmj.309.6954.583	http://dx.doi.org/10.1136/bmj.309.6954.583			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PF330	8086948	Green Published			2022-12-28	WOS:A1994PF33000023
J	NUSSENZWEIG, RS; LONG, CA				NUSSENZWEIG, RS; LONG, CA			MALARIA VACCINES - MULTIPLE TARGETS	SCIENCE			English	Editorial Material							PLASMODIUM-FALCIPARUM SPOROZOITES; ASEXUAL BLOOD STAGES; CD8+ T-CELLS; CIRCUMSPOROZOITE PROTEIN; SYNTHETIC VACCINE; PROTECTIVE IMMUNITY; PARASITE CHITINASE; IMMUNOGENICITY; MEMBRANE; ANTIGEN		HAHNEMANN UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19102 USA	Drexel University	NUSSENZWEIG, RS (corresponding author), NYU, MED CTR, DEPT MED & MOLEC PARASITOL, NEW YORK, NY 10010 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021089, P01AI035703, U01AI037542] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37542-01, AI35703-01, AI21089] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADOR R, 1992, J INFECT DIS, V166, P139, DOI 10.1093/infdis/166.1.139; [Anonymous], 1991, MALARIA OBSTACLES OP; BALLOU WR, 1987, LANCET, V1, P1277; BROOK JH, 1994, NEW ENGL J MED, V331, P22, DOI 10.1056/NEJM199407073310105; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; CLYDE DF, 1975, AM J TROP MED HYG, V24, P397, DOI 10.4269/ajtmh.1975.24.397; COOPER JA, 1993, PARASITOL TODAY, V9, P50, DOI 10.1016/0169-4758(93)90031-A; CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703; DALY T, UNPUB; DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; HERRERA S, 1992, AM J TROP MED HYG, V47, P682, DOI 10.4269/ajtmh.1992.47.682; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; HERRINGTON D, 1992, AM J TROP MED HYG, V49, P166; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOLDER AA, 1988, PROG ALLERGY, V41, P72; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; INSELBURG J, 1993, INFECT IMMUN, V61, P2048, DOI 10.1128/IAI.61.5.2048-2052.1993; KASLOW DC, 1993, CURR OPIN IMMUNOL, V5, P557, DOI 10.1016/0952-7915(93)90037-S; KHUSMITH S, 1994, INFECT IMMUN, V62, P2979, DOI 10.1128/IAI.62.7.2979-2983.1994; LI SQ, 1993, P NATL ACAD SCI USA, V90, P5214, DOI 10.1073/pnas.90.11.5214; LING IT, 1994, PARASITE IMMUNOL, V16, P63, DOI 10.1111/j.1365-3024.1994.tb00324.x; LONG CA, 1993, CURR OPIN IMMUNOL, V5, P548, DOI 10.1016/0952-7915(93)90036-R; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PASVOL G, 1982, NATURE, V297, P64, DOI 10.1038/297064a0; PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; RIDLEY RG, 1990, PARASITOLOGY, V101, P187, DOI 10.1017/S0031182000063228; RIECKMANN KH, 1974, T ROY SOC TROP MED H, V68, P258, DOI 10.1016/0035-9203(74)90129-1; RODRIGUES M, 1992, J EXP MED, V175, P895, DOI 10.1084/jem.175.4.895; ROMERO P, 1992, CURR OPIN IMMUNOL, V4, P432, DOI 10.1016/S0952-7915(06)80035-X; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; RUEBUSH TK, 1990, AM J TROP MED HYG, V43, P355, DOI 10.4269/ajtmh.1990.43.355; SADOFF JC, 1988, SCIENCE, V240, P336, DOI 10.1126/science.3281260; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573	52	63	69	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1381	1383		10.1126/science.8073276	http://dx.doi.org/10.1126/science.8073276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073276				2022-12-28	WOS:A1994PE73300028
J	HARLOS, K; MARTIN, DMA; OBRIEN, DP; JONES, EY; STUART, DI; POLIKARPOV, I; MILLER, A; TUDDENHAM, EGD; BOYS, CWG				HARLOS, K; MARTIN, DMA; OBRIEN, DP; JONES, EY; STUART, DI; POLIKARPOV, I; MILLER, A; TUDDENHAM, EGD; BOYS, CWG			CRYSTAL-STRUCTURE OF THE EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR	NATURE			English	Article							FACTOR-VII; PROTEIN CRYSTALLOGRAPHY; HUMAN CD4; DOMAINS; RECEPTOR; FRAGMENT; COMPLEX; BINDING	TISSUE factor is a cell-surface glycoprotein receptor which initiates the blood coagulation cascade after vessel injury by interacting with blood clotting factor VII/VIIa and which is implicated in various pathological processes(1). When bound to tissue factor, factor VII is readily converted to the active protease factor VIIa by trace amounts of factors Xa, IXa or VIIa. Human tissue factor consists of 263 residues, the first 219 of which comprise the extracellular region(2). We have determined the crystal structure of the extracellular region at a resolution of 2.2 Angstrom. Tissue factor consists of two immunoglobulin-like domains associated through an extensive, novel, interdomain interface region. The binding site for factor VII lies at the interface region and involves residues from domain 1 and an extended loop (binding 'finger') of domain 2. This is the first reported structure of a representative of the class 2 cytokine receptor family, which also includes interferon-alpha, interferon-gamma (refs 2, 3) and interleukin-10 (ref. 4) receptors.	UNIV EDINBURGH, SCH MED, DEPT BIOCHEM, EDINBURGH EH8 9XD, SCOTLAND; UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; MRC, CLIN RES CTR, HAEMOSTASIS RES GRP, HARROW HA1 3UJ, MIDDX, ENGLAND	University of Edinburgh; University of Oxford; University of Oxford; Medical Research Council Clinical Trials Unit			Jones, Yvonne/J-2293-2016; Tuddenham, Edward/AAS-6196-2020; Jones, Yvonne/N-8111-2019; Martin, David/C-2984-2009; Polikarpov, Igor/D-2575-2012	Jones, Yvonne/0000-0002-3834-1893; Tuddenham, Edward/0000-0001-8955-2909; Jones, Yvonne/0000-0002-3834-1893; Polikarpov, Igor/0000-0001-9496-4174; Stuart, David/0000-0002-3426-4210; Martin, David/0000-0002-8732-204X				BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOYS CWG, 1993, J MOL BIOL, V234, P1263, DOI 10.1006/jmbi.1993.1678; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GIBBS CS, 1993, BLOOD, V82, pA451; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOLDEN HM, 1991, ARCH BIOCHEM BIOPHYS, V291, P187, DOI 10.1016/0003-9861(91)90122-Y; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; OBRIEN DP, 1993, BIOCHEM J, V292, P7, DOI 10.1042/bj2920007; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	29	211	220	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					662	666		10.1038/370662a0	http://dx.doi.org/10.1038/370662a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065454				2022-12-28	WOS:A1994PD31000054
J	NURNBERGER, T; NENNSTIEL, D; JABS, T; SACKS, WR; HAHLBROCK, K; SCHEEL, D				NURNBERGER, T; NENNSTIEL, D; JABS, T; SACKS, WR; HAHLBROCK, K; SCHEEL, D			HIGH-AFFINITY BINDING OF A FUNGAL OLIGOPEPTIDE ELICITOR TO PARSLEY PLASMA-MEMBRANES TRIGGERS MULTIPLE DEFENSE RESPONSES	CELL			English	Article							PHENYLALANINE AMMONIA-LYASE; PHYTOALEXIN ACCUMULATION; PROTEIN-PHOSPHORYLATION; HYPERSENSITIVE REACTION; PETROSELINUM-CRISPUM; SOYBEAN MEMBRANES; OXIDATIVE BURST; GENE-EXPRESSION; PLANT-CELLS; UV-LIGHT	An oligopeptide of 13 amino acids (Pep-13) identified within a 42 kDa glycoprotein elicitor from P. megasperma was shown to be necessary and sufficient to stimulate a complex defense response in parsley cells comprising H+/Ca2+ influxes, K+/Cl- effluxes, an oxidative burst, defense-related gene activation, and phytoalexin formation. Binding of radiolabeled Pep-13 to parsley microsomes and protoplasts was specific, reversible, and saturable. Identical structural features of Pep-13 were found to be responsible for specific binding and initiation of all plant responses analyzed. The high affinity binding site recognizing the peptide ligand (K-D = 2.4 nM) may therefore represent a novel class of receptors in plants, and the rapidly induced ion fluxes may constitute elements of the signal transduction cascade triggering pathogen defense in plants.			NURNBERGER, T (corresponding author), MAX PLANCK INST ZUCHTUNGSFORSCH,BIOCHEM ABT,CARL VON LINNE WEG 10,D-50829 COLOGNE,GERMANY.							APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ATKINSON MM, 1993, ADV PLANT PATHOL, V10, P35; BASSE CW, 1993, J BIOL CHEM, V268, P14724; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; CHAPPELL J, 1984, PLANTA, V161, P475, DOI 10.1007/BF00394581; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHEONG JJ, 1991, PLANT CELL, V3, P127, DOI 10.1105/tpc.3.2.127; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; CONRATH U, 1991, FEBS LETT, V279, P141, DOI 10.1016/0014-5793(91)80269-9; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; COSIO EG, 1988, EUR J BIOCHEM, V175, P309, DOI 10.1111/j.1432-1033.1988.tb14198.x; DANGL JL, 1987, EMBO J, V6, P2551, DOI 10.1002/j.1460-2075.1987.tb02543.x; DEVLIN WS, 1992, PLANT PHYSIOL, V100, P1189, DOI 10.1104/pp.100.3.1189; DIEKMANN W, 1994, IN PRESS PLANTA; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DIXON RA, 1990, PLANT MOL BIOL, V41, P339; DOUGLAS C, 1987, EMBO J, V6, P1189, DOI 10.1002/j.1460-2075.1987.tb02353.x; DRON M, 1988, P NATL ACAD SCI USA, V85, P6738, DOI 10.1073/pnas.85.18.6738; EBEL J, 1994, INT REV CYTOL, V148, P1; EBEL J, 1992, GENES INVOLVED PLANT, V1, P184; FARMER EE, 1989, P NATL ACAD SCI USA, V86, P1539, DOI 10.1073/pnas.86.5.1539; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HE YS, 1993, CELL, V73, P1255; HULME EC, 1992, RECEPTOR LIGAND INTE, V1, P63; JAHNEN W, 1988, PLANTA, V173, P197, DOI 10.1007/BF00958957; JAKOBEK JL, 1993, PLANT CELL, V5, P49, DOI 10.1105/tpc.5.1.49; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; KAUSS H, 1989, SIGNAL MOL PLANTS PL, V1, P107; KAWALLECK P, 1993, PLANT MOL BIOL, V21, P673, DOI 10.1007/BF00014550; KAWALLECK P, 1993, J BIOL CHEM, V268, P2189; KNOGGE W, 1991, Z NATURFORSCH C, V46, P969; KOMBRINK E, 1986, PLANT PHYSIOL, V81, P216, DOI 10.1104/pp.81.1.216; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; LOZOYA E, 1991, PLANT J, V1, P227, DOI 10.1111/j.1365-313X.1991.00227.x; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; NURNBERGER T, 1994, IN PRESS SIGNALS ENV; PARKER JE, 1991, MOL PLANT MICROBE IN, V4, P19, DOI 10.1094/MPMI-4-019; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, 1993, J BIOL CHEM, V268, P212; RENELT A, 1993, J EXP BOT, V44, P257; RYAN CA, 1994, P NATL ACAD SCI USA, V91, P1, DOI 10.1073/pnas.91.1.1; Sacks W. R., 1993, Advances in molecular genetics of plant-microbe interactions. Vol. 2. Proceedings of the 6th International Symposium of Molecular Plant-Microbe Interactions, Seattle, Washington, USA, July 1992., P485; SACKS WR, IN PRESS MOL GEN GEN; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWACKE R, 1992, PLANTA, V187, P136, DOI 10.1007/BF00201635; SHIBUYA N, 1993, FEBS LETT, V329, P75, DOI 10.1016/0014-5793(93)80197-3; SILVA ODE, 1993, PLANT J, V4, P125, DOI 10.1046/j.1365-313X.1993.04010125.x; SOMSSICH IE, 1989, PLANT MOL BIOL, V12, P227, DOI 10.1007/BF00020507; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; YU LM, 1993, PLANT J, V3, P805, DOI 10.1111/j.1365-313X.1993.00805.x	55	443	461	2	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					449	460		10.1016/0092-8674(94)90423-5	http://dx.doi.org/10.1016/0092-8674(94)90423-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062387				2022-12-28	WOS:A1994PC40500011
J	ZARRINKAR, PP; WILLIAMSON, JR				ZARRINKAR, PP; WILLIAMSON, JR			KINETIC INTERMEDIATES IN RNA FOLDING	SCIENCE			English	Article							GROUP-I INTRON; TETRAHYMENA-THERMOPHILA RIBOZYME; RIBOSOMAL-RNA; CONFORMATIONAL-CHANGES; TERTIARY STRUCTURE; ACTIVE-SITE; SUBSTRATE; CATALYSIS; BINDING; SEQUENCE	The folding pathways of large, highly structured RNA molecules are largely unexplored. Insight into both the kinetics of folding and the presence of intermediates was provided in a study of the Mg2+-induced folding of the Tetrahymena ribozyme by hybridization of complementary oligodeoxynucleotide probes. This RNA folds via a complex mechanism involving both Mg2+-dependent and Mg2+-independent steps. A hierarchical model for the folding pathway is proposed in which formation of one helical domain (P4-P6) precedes that of a second helical domain (P3-P7). The overall rate-limiting step is formation of P3-P7, and takes place with an observed rate constant of 0.72 +/- 0.14 minute(-1). The folding mechanism of large RNAs appears similar to that of many multidomain proteins in that formation of independently stable substructures precedes their association into the final conformation.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X				BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CECH TR, 1993, RNA WORLD, P239; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4368, DOI 10.1021/bi00773a025; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOUDNA JA, 1993, P NATL ACAD SCI USA, V90, P7829, DOI 10.1073/pnas.90.16.7829; EMERICK VL, 1993, BIOCHEMISTRY-US, V32, P14062, DOI 10.1021/bi00213a040; FELDEN B, 1994, RNA WORLD, V235, P508; Garel Jean-Renaud, 1992, P405; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LECUYER KA, 1994, P NATL ACAD SCI USA, V91, P3373, DOI 10.1073/pnas.91.8.3373; LYNCH DC, 1974, BIOCHEMISTRY-US, V13, P1841, DOI 10.1021/bi00706a012; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466; Pan  T., 1993, RNA WORLD, P271; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RESTELAND RF, 1993, RNA WORLD; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; SCHEFFLE.IE, 1968, J MOL BIOL, V36, P291, DOI 10.1016/0022-2836(68)90156-3; SCHIMMEL PR, 1980, ANNU REV BIOPHYS BIO, V9, P181, DOI 10.1146/annurev.bb.09.060180.001145; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; UHLENBEC.OC, 1970, NATURE, V225, P508, DOI 10.1038/225508a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG JF, 1994, J AM CHEM SOC, V116, P4178, DOI 10.1021/ja00089a005; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WESTHOF E, 1992, STRUCTURAL TOOLS ANA, P255; WOODWARD CK, 1994, CURR OPIN STRUC BIOL, V4, P112, DOI 10.1016/S0959-440X(94)90068-X; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	46	307	315	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					918	924		10.1126/science.8052848	http://dx.doi.org/10.1126/science.8052848			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052848				2022-12-28	WOS:A1994PB49900032
J	LI, YZ; HUNTER, RL; MCIVER, RT				LI, YZ; HUNTER, RL; MCIVER, RT			HIGH-RESOLUTION MASS-SPECTROMETER FOR PROTEIN CHEMISTRY	NATURE			English	Article							ASSISTED LASER-DESORPTION; ION-CYCLOTRON RESONANCE; BIOLOGICAL MOLECULES; SEQUENCE DATABASES; MATRIX; PEPTIDES; SPECTROSCOPY; FIELD	Matrix-assisted laser desorption/ionization is an accurate and sensitive method for measuring the molecular weights of peptides and proteins. Usually time-of-flight mass spectrometry is used to detect the laser-produced ions, but a new method called Fourier transform mass spectrometry offers greater sensitivity and much higher mass measurement accuracy.	IONSPEC CORP,IRVINE,CA 92714		LI, YZ (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							ARNOTT D, 1993, CLIN CHEM, V39, P2005; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BEAVIS RC, 1991, CHEM PHYS LETT, V181, P479, DOI 10.1016/0009-2614(91)90384-L; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BILLECI TM, 1993, ANAL CHEM, V65; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAMBERS DM, 1993, ANAL CHEM, V65, P14, DOI 10.1021/ac00049a005; COMISARO.MB, 1974, CHEM PHYS LETT, V26, P489, DOI 10.1016/0009-2614(74)80397-0; COMISAROW MB, 1978, J CHEM PHYS, V69, P4097, DOI 10.1063/1.437143; COTTER RJ, 1992, ANAL CHEM, V64, pA1027, DOI 10.1021/ac00045a002; EKSTROM P, 1980, SCI AM, V243, P105, DOI 10.1038/scientificamerican0880-104; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KARAS M, 1989, INT J MASS SPECTROM, V92, P231, DOI 10.1016/0168-1176(89)83030-7; Karas M., 1988, ANAL CHEM, V60, P2291; LEBRILLA CB, 1989, J AM CHEM SOC, V111, P8593, DOI 10.1021/ja00205a006; LEBRILLA CB, 1989, INT J MASS SPECTROM, V87, pR7, DOI 10.1016/0168-1176(89)80014-X; LI YZ, 1994, ANAL CHEM, V66, P2077, DOI 10.1021/ac00085a024; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MARSHALL AG, 1985, ACCOUNTS CHEM RES, V18, P316, DOI 10.1021/ar00118a006; MCIVER RT, 1990, INT J MASS SPECTROM, V98, P35, DOI 10.1016/0168-1176(90)85046-5; MCIVER RT, 1994, P NATL ACAD SCI USA, V91, P4801, DOI 10.1073/pnas.91.11.4801; MCIVER RT, 1994, INT J MASS SPECTROM, V132, pL1, DOI 10.1016/0168-1176(94)85003-8; MCIVER RT, 1981, INT J MASS SPECTROM, V39, P65, DOI 10.1016/0020-7381(81)80122-2; MCIVER RT, 1994, RAPID COMMUN MASS SP, V8, P237, DOI 10.1002/rcm.1290080303; MCIVER RT, 1985, INT J MASS SPECTROM, V64, P67, DOI 10.1016/0168-1176(85)85037-0; MEIVER R, 1985, Patent No. 4535235; PAN Y, 1992, ORG MASS SPECTROM, V27, P3, DOI 10.1002/oms.1210270103; SCHWARTZ JC, 1993, RAPID COMMUN MASS SP, V7, P27, DOI 10.1002/rcm.1290070107; SPENGLER B, 1991, RAPID COMMUN MASS SP, V5, P198, DOI 10.1002/rcm.1290050412; STRUPAT K, 1991, INT J MASS SPECTROM, V111, P89, DOI 10.1016/0168-1176(91)85050-V; WINELAND D, 1973, PHYS REV LETT, V31, P1279, DOI 10.1103/PhysRevLett.31.1279; ZHOU J, 1992, RAPID COMMUN MASS SP, V6, P671, DOI 10.1002/rcm.1290061109	35	11	11	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					393	395		10.1038/370393a0	http://dx.doi.org/10.1038/370393a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047148				2022-12-28	WOS:A1994PA30400066
J	CARBON, R				CARBON, R			ABC OF SPORTS MEDICINE - FEMALE ATHLETES	BRITISH MEDICAL JOURNAL			English	Article											CARBON, R (corresponding author), LONDON HOSP,COLL MED,DEPT SPORTS MED,LONDON E1 1BB,ENGLAND.								0	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					254	258		10.1136/bmj.309.6949.254	http://dx.doi.org/10.1136/bmj.309.6949.254			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069144	Green Published			2022-12-28	WOS:A1994NZ18000023
J	HOTH, DF; BOLOGNESI, DP; COREY, L; VERMUND, SH				HOTH, DF; BOLOGNESI, DP; COREY, L; VERMUND, SH			HIV VACCINE DEVELOPMENT - A PROGRESS REPORT	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TOXIC LYMPHOCYTES-T; SEROPOSITIVE INDIVIDUALS; RECOMBINANT GP160; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEIN; SERUM NEUTRALIZATION; UNITED-STATES; INFECTION; AIDS	The development of a safe, effective preventive vaccine for human immunodeficiency virus (HIV) infection remains an area of vigorous research. Several highly innovative vaccine candidates are being developed, and more than 13 vaccine candidates have been tested in human phase I or II trials. All have produced antibody and several have produced modest neutralizing titers, but to date no reproducible evidence has suggested prolonged, high-titer neutralization across a diversity of HIV strains. Furthermore, only the live recombinant vector approaches have produced some evidence of cytotoxic T-cell responses. The principal obstacle to progress is the lack of definitive information on what constitutes a protective immune response. There is no animal model for HIV-induced disease. Hence, the identification of the correlates of immunity and more useful animal models is among the highest priorities for HIV vaccine research. Large-scale efficacy trials raise daunting scientific, ethical, and resource issues. Nonetheless, preparation in such trials is underway in order to be in a position to evaluate the most promising vaccine candidate.	DUKE UNIV, MED CTR, CTR AIDS RES, DURHAM, NC 27710 USA; UNIV WASHINGTON, SEATTLE, WA 98144 USA; UNIV ALABAMA, DEPT EPIDEMIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA	Duke University; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	HOTH, DF (corresponding author), CELL GENESYS, 322 LAKESIDE DR, FOSTER CITY, CA 94404 USA.		Corey, Lawrence/AAE-1796-2020; Vermund, Sten/AAD-3592-2020	Corey, Lawrence/0000-0002-2179-2436; Vermund, Sten/0000-0001-7289-8698				ADA GL, 1990, LANCET, V335, P523, DOI 10.1016/0140-6736(90)90748-T; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ALTMAN LK, 1994, NY TIMES        0628; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; ANDERSON DJ, 1991, LANCET, V338, P573, DOI 10.1016/0140-6736(91)91139-L; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291; BELSHE RB, 1993, J INFECT DIS, V168, P1387, DOI 10.1093/infdis/168.6.1387; BOWLER S, 1992, J ADOLESCENCE, V15, P345, DOI 10.1016/0140-1971(92)90069-H; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; CAMERON DW, 1989, LANCET, V2, P403; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLAYTON EW, 1990, J PEDIATR-US, V116, P508, DOI 10.1016/S0022-3476(05)81594-X; CLERICI M, 1991, J IMMUNOL, V146, P2214; COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635; COOMBS RW, 1990, NEW ENGL J MED, V322, P1467; COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DIXON DO, 1993, J ACQ IMMUN DEF SYND, V6, P485; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; DUBLER NN, 1989, MILBANK Q, V67, P171, DOI 10.2307/3350137; ELIAS CJ, 1993, 6 POP COUNC PROGR DI; English Abigail, 1992, P262; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; FAUCI AS, 1989, ANN INTERN MED, V110, P373, DOI 10.7326/0003-4819-110-5-373; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FULTZ PN, 1987, J VIROL, V61, P4026, DOI 10.1128/JVI.61.12.4026-4029.1987; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GRAHAM B, 1993, 9 INT C AIDS 4 SEX T; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; GROOPMAN JE, 1987, AIDS RES HUM RETROV, V3, P71, DOI 10.1089/aid.1987.3.71; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HALLORAN ME, 1994, STAT MED, V13, P357, DOI 10.1002/sim.4780130404; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; HILLEMAN MR, 1985, J INFECT DIS, V151, P407, DOI 10.1093/infdis/151.3.407; HILLEMAN MR, 1992, VACCINE, V10, P1053, DOI 10.1016/0264-410X(92)90115-Z; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOFF R, 1993, AIDS RES HUM RETROV, V9, pS71; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; JONES JH, 1981, BAD BLOOD; KAPLAN EH, 1992, INFECT AGENT DIS, V1, P92; KARZON DT, 1992, VACCINE, V10, P1039, DOI 10.1016/0264-410X(92)90114-Y; KATZENSTEIN DA, 1990, J ACQ IMMUN DEF SYND, V3, P810; KEEFER M, 1992, 8 INT C AIDS AMST; KEEFER M, 1993, 9 INT C AIDS 4 SEX T; KHAN J, 1993, 9 INT C AIDS 4 SEX T; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; KOUP RA, 1989, BLOOD, V73, P1909; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; KRIEGER JN, 1991, J INFECT DIS, V164, P464, DOI 10.1093/infdis/164.3.464; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; Mann J., 1992, AIDS WORLD GLOBAL RE; MANN JM, 1992, J INFECT DIS, V165, P245, DOI 10.1093/infdis/165.2.245; MCELRATH MJ, 1994, AIDS RES HUM RETROV, V10, P541, DOI 10.1089/aid.1994.10.541; MOSIER DE, 1993, P NATL ACAD SCI USA, V90, P2443, DOI 10.1073/pnas.90.6.2443; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; RIVIERE Y, 1989, J VIROL, V63, P2270, DOI 10.1128/JVI.63.5.2270-2277.1989; ROBERTGUROFF M, 1993, J INFECT DIS, V167, P538, DOI 10.1093/infdis/167.3.538; RODRIGUEZ EM, 1993, J ACQ IMMUN DEF SYND, V6, P313; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; SCHULTZ AM, 1993, AIDS, V7, pS161, DOI 10.1097/00002030-199301001-00021; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; SETHI KK, 1988, NATURE, V335, P178, DOI 10.1038/335178a0; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STEIN RE, 1993, AIDS RES HUM RETROV, V9, pS157; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; STRAUS SE, 1993, J INFECT DIS, V167, P1045, DOI 10.1093/infdis/167.5.1045; TAYLOR R, 1992, J NIH RES, V4, P65; VASQUEZ R, 1993, AIDS RES HUM RETRO S, V9, pS23; VERMUND SH, 1993, AIDS RES HUM RETROV, V9, pS127; VERMUND SH, 1992, 8 INT C AIDS AMST, V2, pC329; VERMUND SH, 1991, ANN REV AIDS RES, P81; VONGEGERFELT A, 1991, VIROLOGY, V185, P162, DOI 10.1016/0042-6822(91)90764-3; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WAWER MJ, 1990, 6 INT C AIDS SAN FRA, V6, P232; WEINHOLD KJ, 1988, LANCET, V1, P902; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X; 1992, WHO A45304 DOC	94	25	26	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					603	611		10.7326/0003-4819-121-8-199410150-00008	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085693				2022-12-28	WOS:A1994PL48600008
J	REYES, VP; RAJU, BS; WYNNE, J; STEPHENSON, LW; RAJU, R; FROMM, BS; RAJAGOPAL, P; MEHTA, P; SINGH, S; RAO, DP; SATYANARAYANA, PV; TURI, ZG				REYES, VP; RAJU, BS; WYNNE, J; STEPHENSON, LW; RAJU, R; FROMM, BS; RAJAGOPAL, P; MEHTA, P; SINGH, S; RAO, DP; SATYANARAYANA, PV; TURI, ZG			PERCUTANEOUS BALLOON VALVULOPLASTY COMPARED WITH OPEN SURGICAL COMMISSUROTOMY FOR MITRAL-STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; INOUE BALLOON; SINGLE INOUE; VALVOTOMY; IMMEDIATE; CATHETER; VALVE; REGURGITATION; RESTENOSIS; COMPLICATIONS	Background. Percutaneous balloon mitral valvuloplasty has been proposed as an alternative to open surgical commissurotomy for the treatment of rheumatic mitral-valve stenosis. Methods. We enrolled 60 patients with severe mitral stenosis and favorable valvular anatomy in a prospective, randomized trial comparing the two procedures. All patients underwent cardiac catheterization before the procedure and one week, six months, and three years thereafter. Hemodynamic data were analyzed by investigators who were blinded to the patients' treatment assignments. Results. Mitral-valve areas improved initially in both groups, from a mean (+/-SD) of 0.9+/-0.3 cm(2) to 2.l+/-0.6 cm(2) in the balloon-valvuloplasty group (30 patients; P<0.01) and from 0.9+/-0.3 cm(2) to 2.0+/-0.6 cm(2) in the surgical group (30 patients; P<0.001). Although improvement was maintained in both groups, mitral-valve areas were greater in the patients in the balloon-valvuloplasty group at three years (2.4+/-0.6 cm(2), vs. 1.8+/-0.4 cm(2) in the surgery group; P<0.001). Restenosis occurred in three patients in the balloon-valvuloplasty group and four in the surgery group. One patient in the balloon-valvuloplasty group died of an apparent stroke after 2.5 years; four patients in the balloon-valvuloplasty group had residual atrial septal defects, and three patients (two in the balloon-valvuloplasty group and one in the surgery group) were judged to have severe mitral regurgitation. Seventy-two percent of the patients who underwent balloon valvuloplasty and 57 percent of the surgically treated patients were in New York Heart Association functional class I (i.e., they had no cardiovascular symptoms) at three years. No patient was lost to follow-up. Conclusions. In the treatment of mitral stenosis, balloon valvuloplasty and open surgical commissurotomy have comparable initial results and low rates of restenosis, and both produce good functional capacity for at least three years. The potential complications associated with balloon valvuloplasty should be noted. The better hemodynamic results at three years, lower cost, and elimination of the need for thoracotomy suggest that balloon valvuloplasty should be considered for all patients with favorable mitral-valve anatomy.	WAYNE STATE UNIV,HARPER HOSP,SCH MED,DEPT INTERNAL MED,DIV CARDIOL,DETROIT,MI 48201; WAYNE STATE UNIV,HARPER HOSP,SCH MED,DEPT INTERNAL MED,DIV CARDIOTHORAC SURG,DETROIT,MI 48201; WAYNE STATE UNIV,HARPER HOSP,SCH MED,DEPT SURG,DETROIT,MI 48201; NIZAMS INST MED SCI,DEPT CARDIOL,HYDERABAD,ANDHRA PRADESH,INDIA; NIZAMS INST MED SCI,DEPT CARDIAC SURG,HYDERABAD,ANDHRA PRADESH,INDIA; MEDICITI,HYDERABAD,ANDHRA PRADESH,INDIA	Wayne State University; Wayne State University; Wayne State University; Nizam's Institute of Medical Sciences; Nizam's Institute of Medical Sciences								ABASCAL VM, 1988, J AM COLL CARDIOL, V11, P257, DOI 10.1016/0735-1097(88)90089-7; ABDULLAH M, 1992, AM HEART J, V123, P1581, DOI 10.1016/0002-8703(92)90813-B; ALZAIBAG M, 1986, LANCET, V1, P757; BASSAND JP, 1991, J AM COLL CARDIOL, V18, P982, DOI 10.1016/0735-1097(91)90757-Z; BLOCK PC, 1992, AM J CARDIOL, V69, P537, DOI 10.1016/0002-9149(92)91000-T; CHAVEZ AM, 1988, AM J CARDIOL, V62, P253, DOI 10.1016/0002-9149(88)90221-4; CHENG TO, 1992, AM J CARDIOL, V69, P574, DOI 10.1016/0002-9149(92)91015-V; COHEN DJ, 1992, NEW ENGL J MED, V327, P1329, DOI 10.1056/NEJM199211053271901; COME PC, 1988, AM J CARDIOL, V61, P817, DOI 10.1016/0002-9149(88)91073-9; DEAN LS, 1990, CIRCULATION, V82, P545; DESIDERI A, 1992, AM J CARDIOL, V69, P1602, DOI 10.1016/0002-9149(92)90711-7; ESSOP MR, 1991, CIRCULATION, V84, P1669, DOI 10.1161/01.CIR.84.4.1669; FLAMM MD, 1969, AM J CARDIOL, V23, P258, DOI 10.1016/0002-9149(69)90075-7; GORLIN R, 1951, AM HEART J, V41, P1, DOI 10.1016/0002-8703(51)90002-6; HERRMANN HC, 1993, J AM COLL CARDIOL, V22, P783, DOI 10.1016/0735-1097(93)90191-3; HERRMANN HC, 1992, AM HEART J, V124, P160, DOI 10.1016/0002-8703(92)90935-O; HICKEY MSJ, 1991, J AM COLL CARDIOL, V17, P29, DOI 10.1016/0735-1097(91)90701-A; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; INOUE K, 1984, J THORAC CARDIOV SUR, V87, P394; ISHIKURA F, 1990, AM HEART J, V120, P873, DOI 10.1016/0002-8703(90)90203-A; JOHN S, 1983, CIRCULATION, V68, P891, DOI 10.1161/01.CIR.68.5.891; LOCK JE, 1985, NEW ENGL J MED, V313, P1515, DOI 10.1056/NEJM198512123132405; PALACIOS IF, 1989, CIRCULATION, V79, P573, DOI 10.1161/01.CIR.79.3.573; PAN JP, 1991, AM J CARDIOL, V67, P264; PARK SJ, 1993, AM J CARDIOL, V71, P938, DOI 10.1016/0002-9149(93)90910-5; RIBEIRO PA, 1991, AM J CARDIOL, V68, P687, DOI 10.1016/0002-9149(91)90369-V; SERRA A, 1990, CIRCULATION, V82, P546; SHARMA S, 1993, CATHETER CARDIO DIAG, V29, P18, DOI 10.1002/ccd.1810290104; SPENCER FC, 1990, SURGERY CHEST, V2, P1517; THOMAS MR, 1993, BRIT HEART J, V69, P418; Turi Z G, 1993, Cardiovasc Clin, V23, P293; TURI ZG, 1991, CIRCULATION, V83, P1179, DOI 10.1161/01.CIR.83.4.1179; TUZCU EM, 1991, J AM COLL CARDIOL, V17, P1121, DOI 10.1016/0735-1097(91)90841-V; TUZCU EM, 1992, CIRCULATION, V85, P963, DOI 10.1161/01.CIR.85.3.963; VAHANIAN A, 1991, EUR HEART J, V12, P84, DOI 10.1093/eurheartj/12.suppl_B.84; VILLANOVA C, 1993, INT J CARDIOL, V38, P315, DOI 10.1016/0167-5273(93)90251-B; WILKINS GT, 1988, BRIT HEART J, V60, P299; YOSHIDA K, 1989, CIRCULATION, V80, P1521, DOI 10.1161/01.CIR.80.6.1521; 1990, SAS STAT USERS GUIDE; 1992, CIRCULATION, V85, P448	40	272	289	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					961	967		10.1056/NEJM199410133311501	http://dx.doi.org/10.1056/NEJM199410133311501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	8084354				2022-12-28	WOS:A1994PK50400001
J	CORTI, MC; GURALNIK, JM; SALIVE, ME; SORKIN, JD				CORTI, MC; GURALNIK, JM; SALIVE, ME; SORKIN, JD			SERUM-ALBUMIN LEVEL AND PHYSICAL-DISABILITY AS PREDICTORS OF MORTALITY IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HOSPITAL STAY; COMPLICATIONS; AGE	Objectives.-To study the relationship between serum albumin level and all-cause mortality in an elderly population and to evaluate the role of albumin level in combination with physical disability status in predicting mortality. Design.-Cohort study with a mean follow-up of 3.7 years. Setting.-Three communities: East Boston, Mass, New Haven, Conn, and Iowa and Washington counties, Iowa. Subjects.-A total of 1486 men and 2630 women aged 71 years and older who consented to have blood drawn. Results.-During follow-up, 447 men and 488 women died. In both sexes, there was a graded increase in mortality rate with decreasing albumin level. After adjusting for age, race, education, chronic conditions, and disability status, hypoalbuminemia (<35 g/L) was associated with a significantly increased risk of mortality in comparison with the reference group tie, those with albumin levels greater than 43 g/L) (men: relative risk [RR], 1.9; 95% confidence interval [Cl], 1.1 to 3.1; women: RR, 3.7; 95% Cl, 2.5 to 5.5). Among those with albumin levels in the range usually considered normal (35 g/L to 50 g/L), there was a graded increase in mortality risk from the highest normal to the lowest normal groups. For women, results were similar in separate analyses that considered deaths occurring during the first year end 1 year or more after baseline, while for men the relationship decreased after 1 year. Lower albumin level was associated with an elevated risk of mortality for all categories of causes of death. A 15-lever measure that characterized participants according to albumin level and disability status demonstrated that mortality increased with decreasing albumin level and increasing disability lever. Conclusions.-Serum albumin level is an independent risk factor for all-cause mortality in older persons. A combined measure of albumin and disability reveals a strong gradient in mortality risk and may serve as a simple but useful index of frailty that can identify a high-risk group of older men and women who could be targeted for preventive and treatment efforts.			CORTI, MC (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WISCONSIN AVE,ROOM 3C-309,BETHESDA,MD 20892, USA.				NIA NIH HHS [N01-AG-0-2106, N01-AG-0-2107, N01-AG-0-2105] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG002107, N01AG002106, N01AG002105] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON CF, 1984, MAYO CLIN PROC, V59, P477, DOI 10.1016/S0025-6196(12)60437-6; [Anonymous], 1988, INT CLASSIFICATION D; BADLEY EM, 1986, INT REHABIL MED, V8, P118; BRAY GA, 1978, INT J OBESITY, V2, P99; Buchner D M, 1992, Clin Geriatr Med, V8, P1; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; CAMPION EW, 1988, J GERONTOL, V43, pM18, DOI 10.1093/geronj/43.1.M18; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DELORGERIL M, 1990, LANCET, V335, P349; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; DOWEIKO JP, 1991, JPEN-PARENTER ENTER, V15, P207, DOI 10.1177/0148607191015002207; FRIED LP, 1992, AGING-CLIN EXP RES, V4, P251, DOI 10.1007/BF03324099; FRIEDMAN P J, 1985, Journal of Clinical and Experimental Gerontology, V7, P191; GILLUM RF, 1992, AM HEART J, V123, P507, DOI 10.1016/0002-8703(92)90667-K; GRIMBLE R, 1990, LANCET, V335, P350; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURALNIK JM, 1991, REDUCING FRAILTY FAL; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; HERMANN FR, 1992, ARCH INTERN MED, V152, P125; HEYMSFIELD SB, 1988, MODERN NUTRITION HLT; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASL SV, 1981, AGING BIOL BEHAVIOR, P345; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813, DOI 10.1093/oxfordjournals.aje.a117078; KLONOFFCOHEN H, 1992, J CLIN EPIDEMIOL, V45, P207, DOI 10.1016/0895-4356(92)90080-7; KULLER LH, 1991, AM J EPIDEMIOL, V134, P1266, DOI 10.1093/oxfordjournals.aje.a116030; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MCLAREN DS, 1988, NUTRITION, V4, P1; PHILLIPS A, 1989, LANCET, V2, P1434; RICH MW, 1989, AM J CARDIOL, V63, P714, DOI 10.1016/0002-9149(89)90257-9; ROSOW I, 1966, J GERONTOL, V39, P686; ROTSCHILD MA, 1988, HEPATOLOGY, V8, P385; SALIVE ME, 1992, J CLIN EPIDEMIOL, V45, P213, DOI 10.1016/0895-4356(92)90081-W; SOETERS PB, 1990, LANCET, V335, P348, DOI 10.1016/0140-6736(90)90633-G; WILLIAMS TF, 1992, J CLIN EPIDEMIOL, V45, P205; WILLIAMS WR, 1990, LANCET, V335, P348; 1991, SAS P217 SAS I INC T; 1991, NIH91397 PUBL	38	460	465	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1036	1042		10.1001/jama.272.13.1036	http://dx.doi.org/10.1001/jama.272.13.1036			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089886				2022-12-28	WOS:A1994PH77500029
J	MURPHY, FL; WANG, YH; GRIFFITH, JD; CECH, TR				MURPHY, FL; WANG, YH; GRIFFITH, JD; CECH, TR			COAXIALLY STACKED RNA HELICES IN THE CATALYTIC CENTER OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							GROUP-I INTRON; PHENYLALANINE TRANSFER-RNA; PERMUTED TRANSFER-RNAS; SECONDARY STRUCTURE; RIBOSOMAL-RNA; TERTIARY STRUCTURE; TARGET SEQUENCE; REV PROTEIN; ACTIVE-SITE; DNA	Coaxial stacking of helical elements is a determinant of three-dimensional structure in RNA. In the catalytic center of the Tetrahymena group I intron, helices P4 and P6 are part of a tertiary structural domain that folds independently of the remainder of the intron. When P4 and P6 were fused with a phosphodiester linkage, the resulting RNA retained the detailed tertiary interactions characteristic of the native P4-P6 domain and even required lower magnesium ion concentrations for folding. These results indicate that P4 and P6 are coaxial in the P4-P6 domain and, therefore, in the native ribozyme. Helix fusion could provide a general method for identifying pairs of coaxially stacked helices in biological RNA molecules.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1993, RNA WORLD, P239; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHASTAIN M, 1992, BIOCHEMISTRY-US, V31, P12733, DOI 10.1021/bi00166a004; CHASTAIN M, 1993, BIOCHEMISTRY-US, V32, P14220, DOI 10.1021/bi00214a022; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; FELDSTEIN PA, 1993, NUCLEIC ACIDS RES, V21, P1991, DOI 10.1093/nar/21.8.1991; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; Gold L., 1993, RNA WORLD, P497; GREEN R, 1994, J MOL BIOL, V235, P140, DOI 10.1016/S0022-2836(05)80022-1; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; JARRELL KA, 1993, P NATL ACAD SCI USA, V90, P8624, DOI 10.1073/pnas.90.18.8624; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LATHAM JA, 1990, METHOD ENZYMOL, V181, P558; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; MURPHY FL, 1992, THESIS U COLORADO; MURPHY FL, UNPUB; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5257; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG YH, 1994, J MOL BIOL, V236, P64, DOI 10.1006/jmbi.1994.1118; WARING RB, 1983, J MOL BIOL, V167, P595, DOI 10.1016/S0022-2836(83)80100-4; WOESE CR, 1993, RNA WORLD, P91; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAUG AJ, 1993, BIOCHEMISTRY-US, V32, P7946, DOI 10.1021/bi00082a016	58	61	62	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1709	1712		10.1126/science.8085157	http://dx.doi.org/10.1126/science.8085157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085157				2022-12-28	WOS:A1994PG28400031
J	MCGARRY, GW; GATEHOUSE, S; HINNIE, J				MCGARRY, GW; GATEHOUSE, S; HINNIE, J			RELATION BETWEEN ALCOHOL AND NOSE BLEEDS	BRITISH MEDICAL JOURNAL			English	Article							EPISTAXIS		GLASGOW ROYAL INFIRM,MED RES COUNCIL,INST HEARING RES,GLASGOW,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT BIOCHEM,GLASGOW G4 0SF,SCOTLAND	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Glasgow; University of Glasgow	MCGARRY, GW (corresponding author), GLASGOW ROYAL INFIRM,DEPT OTOLARYNGOL,GLASGOW G4 0SF,SCOTLAND.							DIGHT S, 1976, SCOTTISH DRINKING HA; HART MJ, 1974, AM J MED, V56, P22; JACKSON KR, 1988, ARCH OTOLARYNGOL, V114, P862; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; STELL PM, 1977, CLIN OTOLARYNGOL, V2, P263, DOI 10.1111/j.1365-2273.1977.tb01365.x	5	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					640	640		10.1136/bmj.309.6955.640	http://dx.doi.org/10.1136/bmj.309.6955.640			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086988	Green Published			2022-12-28	WOS:A1994PG02000021
J	RADMACHER, M; FRITZ, M; HANSMA, HG; HANSMA, PK				RADMACHER, M; FRITZ, M; HANSMA, HG; HANSMA, PK			DIRECT OBSERVATION OF ENZYME-ACTIVITY WITH THE ATOMIC-FORCE MICROSCOPE	SCIENCE			English	Article								The height fluctuations on top of the protein lysozyme adsorbed on mica were measured locally with an atomic force microscope operated in tapping mode in liquid. Height fluctuations of an apparent size of 1 nanometer that lasted for about 50 milliseconds were observed over lysozyme molecules when a substrate (oligoglycoside) was present. In the presence of the inhibitor chitobiose, these height fluctuations decreased to the level without the oligoglycoside. The most straightforward interpretation of these results is that the height fluctuations correspond to the conformational changes of lysozyme during hydrolysis. It is also possible, however, that the height fluctuations are, at least in part, the result of a different height or elasticity of the transient complex of lysozyme plus the substrate.	UNIV CALIF SANTA BARBARA,INST MARINE SCI,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara	RADMACHER, M (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106, USA.		Radmacher, Manfred/A-3956-2012	Radmacher, Manfred/0000-0001-8744-4541				AMDUR I, 1966, CHEM KINETICS PRINCI; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRITZ M, 1994, BIOPHYS J, V66, P1328, DOI 10.1016/S0006-3495(94)80963-4; GOLANDER CG, 1990, COLLOID SURFACE, V50, P113, DOI 10.1016/0166-6622(90)80257-5; HANSMA HG, 1994, ANNU REV BIOPH BIOM, V23, P115, DOI 10.1146/annurev.bb.23.060194.000555; HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795; HENDERSON E, 1994, PROG SURF SCI, V46, P39, DOI 10.1016/0079-6816(94)90006-X; HENDERSON E, 1992, NUCLEIC ACIDS RES, V20, P445, DOI 10.1093/nar/20.3.445; Imoto T., 1972, ENZYMES, V7, P665; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; JACKSON MB, 1993, J CHEM PHYS, V99, P7253, DOI 10.1063/1.465418; KARRASCH S, 1994, P NATL ACAD SCI USA, V91, P836, DOI 10.1073/pnas.91.3.836; KEATON A, 1994, MAR P NATO ADV STUD; KELLER D, 1992, P SOC PHOTO-OPT INS, V1639, P91, DOI 10.1117/12.58194; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; RUPLEY JA, 1967, PROC R SOC SER B-BIO, V167, P416, DOI 10.1098/rspb.1967.0038; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WENZEL M, 1961, Z PHYSIOL CHEM, V327, P13; YANG J, 1993, J MOL BIOL, V229, P286, DOI 10.1006/jmbi.1993.1033; YANG Y, 1980, J BIOCHEM-TOKYO, V87, P1003; [No title captured]	28	329	335	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1577	1579		10.1126/science.8079171	http://dx.doi.org/10.1126/science.8079171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079171				2022-12-28	WOS:A1994PF33600034
J	HARLAN, JE; HAJDUK, PJ; YOON, HS; FESIK, SW				HARLAN, JE; HAJDUK, PJ; YOON, HS; FESIK, SW			PLECKSTRIN HOMOLOGY DOMAINS BIND TO PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE	NATURE			English	Article							ADRENERGIC-RECEPTOR KINASE; PHOSPHOLIPASE C-DELTA-1; SIGNALING PROTEINS; PH DOMAIN; EXPRESSION	THE pleckstrin homology (PH) domain is a new protein module of around 100 amino acids found in several proteins involved in signal transduction(1-5). Although its specific function has yet to be elucidated, the carboxy-terminal regions of many PH domains bind to the beta gamma subunits of G proteins(6,7). On the basis of structural similarities between PH domains and Lipid-binding proteins, we have proposed that PH domains may be binding to lipophilic molecules(8). indeed, many of the proteins that contain this domain associate with phospholipid membrane(6,9,10), and disruption of this domain can interfere with membrane association(6,11). Here we report that PH domains bind to phosphatidylinositol-4,5-bisphosphate and show that the lipid-binding site is located at the Lip of the beta-barrel. This suggests that PH domains may be important for membrane localization of proteins through interactions with phosphatidylinositol-4,5-bisphosphate.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,NMR RES,ABBOTT PK,IL 60064	Abbott Laboratories			Yoon, Ho Sup/A-2193-2011	Yoon, Ho Sup/0000-0002-8243-3904				CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; GIBSON S, 1993, BLOOD, V82, P1561; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MANO H, 1993, ONCOGENE, V8, P417; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	19	673	682	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					168	170		10.1038/371168a0	http://dx.doi.org/10.1038/371168a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072546	Green Accepted			2022-12-28	WOS:A1994PF19100067
J	COLEMAN, DE; BERGHUIS, AM; LEE, E; LINDER, ME; GILMAN, AG; SPRANG, SR				COLEMAN, DE; BERGHUIS, AM; LEE, E; LINDER, ME; GILMAN, AG; SPRANG, SR			STRUCTURES OF ACTIVE CONFORMATIONS OF G(I-ALPHA-1) AND THE MECHANISM OF GTP HYDROLYSIS	SCIENCE			English	Article							ELONGATION-FACTOR TU; H-RAS P21; ALPHA-SUBUNITS; G-PROTEINS; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; TRIPHOSPHATE CONFORMATION; STEREOCHEMICAL COURSE; REGULATORY COMPONENT; SIGNAL TRANSDUCTION	Mechanisms of guanosine triphosphate (GTP) hydrolysis by members of the G protein alpha subunit-p21(ras) superfamily of guanosine triphosphatases have been studied extensively but have not been well understood. High-resolution x-ray structures of the GTP gamma S and GDP.AlF4- complexes formed by the G protein G(i alpha 1) demonstrate specific roles in transition-state stabilization for two highly conserved residues. Glutamine(204)(Gln(61) in p21(ras)) stabilizes and orients the hydrolytic water in the trigonal-bipyramidal transition state. Arginine 178 stabilizes the negative charge at the equatorial oxygen atoms of the pentacoordinate phosphate intermediate. Conserved only in the G(alpha) family, this residue may account for the higher hydrolytic rate of G(alpha) proteins relative to those of the p21(ras) family members. The fold of G(i alpha 1) differs from that of the homologous G(t alpha) subunit in the conformation of a helix-loop sequence located in the alpha-helical domain that is characteristic of these proteins; this site may participate in effector binding. The amino-terminal 33 residues are disordered in GTP gamma S-G(i alpha 1), suggesting a mechanism that may promote release of the beta gamma subunit complex when the a subunit is activated by GTP.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Berghuis, Albert M/A-6495-2008; Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Berghuis, Albert/0000-0002-2663-025X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KLEUSS C, IN PRESS P NATL ACAD; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIXON M, UNPUB; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH JL, 1991, ISOMORPHOUS REPLACEM, P96; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VANDOP C, 1984, J BIOL CHEM, V259, P696; 1991, CCP4 SERC UK COLLABO	61	740	755	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1405	1412		10.1126/science.8073283	http://dx.doi.org/10.1126/science.8073283			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073283				2022-12-28	WOS:A1994PE73300037
J	SIBER, GR				SIBER, GR			PNEUMOCOCCAL DISEASE - PROSPECTS FOR A NEW-GENERATION OF VACCINES	SCIENCE			English	Editorial Material							MEMBRANE PROTEIN COMPLEX; STREPTOCOCCUS-PNEUMONIAE; NEISSERIA-MENINGITIDIS; POLYSACCHARIDE VACCINE; CONJUGATE VACCINES; B POLYSACCHARIDE; INFANTS; IMMUNOGENICITY; INFECTIONS; ANTIBODIES		HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02111	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	SIBER, GR (corresponding author), MASSACHUSETTS PUBL HLTH BIOL LABS,BOSTON,MA 02111, USA.							BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BRILES DE, 1992, INFECT IMMUN, V60, P1957, DOI 10.1128/IAI.60.5.1957-1962.1992; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; DAGAN R, 1992, JAMA-J AM MED ASSOC, V268, P3328, DOI 10.1001/jama.268.23.3328; GRANOFF DM, 1993, J INFECT DIS, V168, P663, DOI 10.1093/infdis/168.3.663; LIU MA, 1992, P NATL ACAD SCI USA, V89, P4633, DOI 10.1073/pnas.89.10.4633; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; NIELSEN SV, 1993, MICROB PATHOGENESIS, V14, P299, DOI 10.1006/mpat.1993.1029; PATON JC, 1993, ANNU REV MICROBIOL, V47, P89, DOI 10.1146/annurev.mi.47.100193.000513; PEETERS CCAM, 1991, INFECT IMMUN, V59, P3504, DOI 10.1128/IAI.59.10.3504-3510.1991; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHAPPERT SM, 1992, VITAL HLTH STATISTIC, V214, P1; SCHNEERSON R, 1992, INFECT IMMUN, V60, P3528, DOI 10.1128/IAI.60.9.3528-3532.1992; SHAPIRO ED, 1994, J INFECT DIS, V169, P212, DOI 10.1093/infdis/169.1.212; SHAPIRO ED, 1989, J INFECT DIS, V160, P1064, DOI 10.1093/infdis/160.6.1064; STANSFIELD SK, 1987, PEDIATR INFECT DIS J, V6, P622, DOI 10.1097/00006454-198707000-00002; SZU SC, 1986, INFECT IMMUN, V54, P448, DOI 10.1128/IAI.54.2.448-455.1986; WELBY PL, 1994, PEDIATR INFECT DIS J, V13, P281, DOI 10.1097/00006454-199404000-00007	20	159	176	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1385	1387		10.1126/science.8073278	http://dx.doi.org/10.1126/science.8073278			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073278				2022-12-28	WOS:A1994PE73300030
J	BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW				BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW			EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHELATION-THERAPY; CARDIAC-FUNCTION; DESFERRIOXAMINE; STORES; ANEMIA; SURVIVAL	Background. To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we evaluated 59 patients (30 were female and 29 male; age range, 7 to 31 years) periodically for 4 to 10 years or until death. Methods. At each follow-up visit, we performed a detailed clinical and laboratory evaluation and measured hepatic iron stores with a noninvasive magnetic device. Results. The body iron burden as assessed by magnetic measurement of hepatic iron stores was closely correlated (R = 0.89, P < 0.001) with the ratio of cumulative transfusional iron load to cumulative deferoxamine use (expressed in millimoles of iron per kilogram of body weight, in relation to grams of deferoxamine per kilogram, transformed into the natural logarithm). Each increase of one unit in the natural logarithm of the ratio (transfusional iron load to deferoxamine use) was associated with an increased risk of impaired glucose tolerance (relative risk, 19.3; 95 percent confidence interval, 4.8 to 77.4), diabetes mellitus (relative risk, 9.2; 95 percent confidence interval, 1.8 to 47.7), cardiac disease (relative risk, 9.9; 95 percent confidence interval, 1.9 to 51.2), and death (relative risk, 12.6; 95 percent confidence interval, 2.4 to 65.4). All nine deaths during the study occurred among the 23 patients who had begun chelation therapy later and used less deferoxamine in relation to their transfusional iron load (P < 0.001). Conclusions. The early use of deferoxamine in an amount proportional to the transfusional iron load reduces the body iron burden and helps protect against diabetes mellitus, cardiac disease, and early death in patients with thalassemia major.	CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHYS, CLEVELAND, OH 44106 USA; MOORHEAD STATE UNIV, DEPT MATH, MOORHEAD, MN 56560 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; Minnesota State Colleges & Universities; Minnesota State University Moorhead; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM025105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K06DK014370] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-25105] Funding Source: Medline; NIDDK NIH HHS [DK-14370] Funding Source: Medline; FDA HHS [FD-U-000532] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FDA HHS		BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BORGNAPIGNATTI C, 1985, J PEDIATR-US, V106, P150, DOI 10.1016/S0022-3476(85)80488-1; BRITTENHAM GM, 1988, ANN NY ACAD SCI, V526, P199, DOI 10.1111/j.1749-6632.1988.tb55506.x; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRITTENHAM GM, 1992, BLOOD, V80, P569; BRITTENHAM GM, 1994, IRON METABOLISM HLTH, P31; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COHEN A, 1990, J PEDIATR-US, V117, P326, DOI 10.1016/S0022-3476(05)80556-6; COX DR, 1972, J R STAT SOC B, V34, P187; DESANCTIS V, 1988, ARCH DIS CHILD, V63, P58, DOI 10.1136/adc.63.1.58; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; Fleiss JL, 1981, STAT METHODS RATES P; FOSBURG MT, 1990, BLOOD, V76, P435; FREEDMAN MH, 1990, AM J DIS CHILD, V144, P565, DOI 10.1001/archpedi.1990.02150290059028; FREEMAN AP, 1989, CLIN LAB HAEMATOL, V11, P299, DOI 10.1111/j.1365-2257.1989.tb00227.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P740; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; MARCUS RE, 1984, LANCET, V1, P392; Modell B., 1984, CLIN APPROACH THALAS; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIOMELLI S, 1993, BAILLIERE CLIN HAEM, V6, P287, DOI 10.1016/S0950-3536(05)80073-3; Pippard M J, 1989, Prog Clin Biol Res, V309, P85; POOTRAKUL P, 1988, BLOOD, V71, P1124; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; PROPPER RD, 1976, NEW ENGL J MED, V294, P1421, DOI 10.1056/NEJM197606242942603; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SMITH RS, 1962, BMJ-BRIT MED J, P1577, DOI 10.1136/bmj.2.5319.1577; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	32	648	668	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					567	573		10.1056/NEJM199409013310902	http://dx.doi.org/10.1056/NEJM199409013310902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047080	Bronze			2022-12-28	WOS:A1994PD69900002
J	NICOLAIDES, NC; PAPADOPOULOS, N; LIU, B; WEI, YF; CARTER, KC; RUBEN, SM; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; DUNLOP, MG; HAMILTON, SR; PETERSEN, GM; DELACHAPELLE, A; VOGELSTEIN, B; KINZLER, KW				NICOLAIDES, NC; PAPADOPOULOS, N; LIU, B; WEI, YF; CARTER, KC; RUBEN, SM; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; DUNLOP, MG; HAMILTON, SR; PETERSEN, GM; DELACHAPELLE, A; VOGELSTEIN, B; KINZLER, KW			MUTATIONS OF 2 PMS HOMOLOGS IN HEREDITARY NONPOLYPOSIS COLON-CANCER	NATURE			English	Article							DNA MISMATCH REPAIR; COLORECTAL-CANCER; SEQUENCE	HEREDITARY nonpolyposis colorectal cancer (HNPCC) is one of man's commonest hereditary diseases(1). Several studies have implicated a defect in DNA mismatch repair in the pathogenesis of this disease(2-8). In particular, hMSH2 and hMLH1 homologues of the bacterial DNA mismatch repair genes mutS and mutL, respectively, were shown to be mutated in a subset of HNPCC cases(9-16). Here we report the nucleotide sequence, chromosome localization and mutational analysis of hPMS1 and hPMS2, two additional homologues of the prokaryotic mutL gene. Both hPMS1 and hPMS2 were found to be mutated in the germline of HNPCC patients. This doubles the number of genes implicated in HNPCC and may help explain the relatively high incidence of this disease.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; INST GENOM RES,GAITHERSBURG,MD 20878; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND	Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline; Human Genome Sciences Inc; J. Craig Venter Institute; University of Edinburgh; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Helsinki			Dunlop, Malcolm G/F-1973-2011; Papadopoulos, Nickolas/K-7272-2012	Dunlop, Malcolm G/0000-0002-3033-5851; Fraser, Claire/0000-0003-1462-2428				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, INPRESS CANCER RES; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; NYSTROMLAHTI M, 1994, P NATL ACAD SCI USA, V91, P6054, DOI 10.1073/pnas.91.13.6054; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PROLLA TA, IN PRESS SCIENCE; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VANDERLUIJT R, 1994, GENOMICS, V208, P1	29	1384	1440	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					75	80		10.1038/371075a0	http://dx.doi.org/10.1038/371075a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072530				2022-12-28	WOS:A1994PE38100055
J	ABRAHAMS, JP; LESLIE, AGW; LUTTER, R; WALKER, JE				ABRAHAMS, JP; LESLIE, AGW; LUTTER, R; WALKER, JE			STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF F1-ATPASE FROM BOVINE HEART-MITOCHONDRIA	NATURE			English	Article							ATP SYNTHASE; BETA-SUBUNIT; OXIDATIVE-PHOSPHORYLATION; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; F1-ATPASE; PROTEIN; BINDING; MECHANISM	In the crystal structure of bovine mitochondrial F-1-ATPase determined at 2.8 Angstrom resolution, the three catalytic beta-subunits differ in conformation and in the bound nucleotide. The structure supports a catalytic mechanism in intact ATP synthase in which the three catalytic subunits are in different states of the catalytic cycle at any instant. Interconversion of the states may be achieved by rotation of the alpha(3) beta(3) subassembly relative to an alpha-helical domain of the gamma-subunit.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Abrahams, Jan Pieter/G-7287-2016; Abrahams, Jan Pieter/AAE-4319-2020	Abrahams, Jan Pieter/0000-0001-8216-1868; Abrahams, Jan Pieter/0000-0001-8216-1868; Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH DA, 1989, BIOCHIM BIOPHYS ACTA, V975, P377, DOI 10.1016/S0005-2728(89)80346-9; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COLLINSON IR, IN PRESS BIOCH J; COLLINSON IR, IN PRESS J MOL BIOL; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; ESCH FS, 1978, J BIOL CHEM, V253, P6100; ESCH FS, 1981, J BIOL CHEM, V256, P9084; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GANN J, 1986, BIOCHEMISTRY-US, V25, P4431; GARIN J, 1994, BIOCHEMISTRY-US, V33, P3772, DOI 10.1021/bi00178a038; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JACKSON PJ, 1986, BIOCHEM J, V235, P577, DOI 10.1042/bj2350577; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1993, STRUCTURE, V1, P350; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MILLBURN MV, 1990, SCIENCE, V247, P939; MITCHELL P, 1985, FEBS LETT, V182, P1, DOI 10.1016/0014-5793(85)81142-X; Mitchell P, 1966, BIOL REV, V41, P455; MUELLER C W, 1992, Journal of Molecular Biology, V224, P159; NICOLLS A, 1991, PROTEINS, V11, P281; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PENEFSKY HS, 1991, ADV ENZYMOL RELATED, V64, P173; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1990, PHILOS T ROY SOC B, V326, P367, DOI 10.1098/rstb.1990.0018; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013; 1979, SERC4 DAR LAB COLL C	50	2714	2776	7	225	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					621	628		10.1038/370621a0	http://dx.doi.org/10.1038/370621a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065448				2022-12-28	WOS:A1994PD31000041
J	CLARKE, RW; GRAY, C				CLARKE, RW; GRAY, C			OPTIONS FOR CHANGE IN THE NHS CONSULTANT CONTRACT	BRITISH MEDICAL JOURNAL			English	Article								The lead negotiators for the management and consultant sides in an NHS trust in northern England responded to debate in their trust about consultant contracts by offering to research the attitudes of their peers towards st variety of contract options. The options tested included the current contract; models already examined in the trust and elsewhere, such as time sensitive and mild performance related contracts; and some more radical and speculative possibilities, including consultants franchising their services to the trust. Beyond the predictable conclusion that consultants would prefer no change while managers desired it, a time sensitive contract emerged as having potential for successful negotiation. On the other hand, neither consultants nor managers favoured a strict performance related contract or a fee for service contract. There was a strong similarity of opinion between the two groups on the relative salary values of the options, though the consultants consistently priced these higher than the managers.	HARROGATE DIST HOSP,HARROGATE HG2 7ND,W YORKSHIRE,ENGLAND; UNIV NOTTINGHAM,CTR HLTH SERV MANAGEMENT,NOTTINGHAM,ENGLAND	University of Nottingham								Armstrong David, 1983, POLITICAL ANATOMY BO, P114; BLOOR K, 1992, 98 U YORK CTR HLTH E; BOYCE J, 1992, BRIT MED J, V305, P131, DOI 10.1136/bmj.305.6846.131; Jacobson SL, 1992, PERFORMANCE RELATED, P34; THOMPSON M, 1992, IMS218 I MANP STUD R; 1994, 23RD REP 1994; 1993, HOSPITAL DOCTORS TRA	7	4	4	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					528	530		10.1136/bmj.309.6953.528	http://dx.doi.org/10.1136/bmj.309.6953.528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086915	Green Published			2022-12-28	WOS:A1994PD30800031
J	PENDERGRAST, PS; EBRIGHT, YW; EBRIGHT, RH				PENDERGRAST, PS; EBRIGHT, YW; EBRIGHT, RH			HIGH-SPECIFICITY DNA CLEAVAGE AGENT - DESIGN AND APPLICATION TO KILOBASE AND MEGABASE DNA SUBSTRATES	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; TRIPLE-HELIX FORMATION; SITE-SPECIFIC CLEAVAGE; ESCHERICHIA-COLI; SINGLE-SITE; DUPLEX DNA; CRYSTAL-STRUCTURE; TRANSCRIPTION ACTIVATION; NUCLEASE ACTIVITY; RECEPTOR PROTEIN	Strategies to cleave double-stranded DNA at specific DNA sites longer than those of restriction endonucleases (longer than 8 base pairs) have applications in chromosome mapping, chromosome cloning, and chromosome sequencing-provided that the strategies yield high DNA-cleavage efficiency and high DNA-cleavage specificity. In this report, the DNA-cleaving moiety copper:o-phenanthroline was attached to the sequence-specific DNA binding protein catabolite activator protein (CAP) at an amino acid that, because of a difference in DNA bending, is close to DNA in the specific CAP-DNA complex but is not close to DNA in the nonspecific CAP-DNA complex. The resulting CAP derivative, OP(26)CAP, cleaved kilobase and megabase DNA substrates at a 22- base pair consensus DNA site with high efficiency and exhibited no detectable nonspecific DNA-deavage activity.	RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTAGLIA LP, 1977, ACTA CRYSTALLOGR B, V33, P3886, DOI 10.1107/S0567740877012321; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; CHEN CHB, 1987, SCIENCE, V237, P1197, DOI 10.1126/science.2820056; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FRANCOIS JC, 1989, P NATL ACAD SCI USA, V86, P9702, DOI 10.1073/pnas.86.24.9702; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; KANG C, 1993, BIOTECHNIQUES, V15, P659; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; KOOB M, 1992, NUCLEIC ACIDS RES, V20, P5831, DOI 10.1093/nar/20.21.5831; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; PEI D, 1991, J AM CHEM SOC, V113, P9398, DOI 10.1021/ja00024a072; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1992, J AM CHEM SOC, V114, P5934, DOI 10.1021/ja00041a005; SAXE SA, 1979, BIOCHEMISTRY-US, V18, P255, DOI 10.1021/bi00569a003; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P118, DOI 10.1073/pnas.91.1.118; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; TAKAHASHI M, 1979, NUCLEIC ACIDS RES, V7, P1699, DOI 10.1093/nar/7.6.1699; VIPOND IB, 1993, MOL MICROBIOL, V9, P225, DOI 10.1111/j.1365-2958.1993.tb01685.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1984, NUCLEIC ACIDS RES, V12, P8475, DOI 10.1093/nar/12.22.8475; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	45	51	52	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					959	962		10.1126/science.8052855	http://dx.doi.org/10.1126/science.8052855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052855				2022-12-28	WOS:A1994PB49900045
J	FENN, P; HERMANS, D; DINGWALL, R				FENN, P; HERMANS, D; DINGWALL, R			ESTIMATING THE COST OF COMPENSATING VICTIMS OF MEDICAL NEGLIGENCE	BRITISH MEDICAL JOURNAL			English	Article								The current system in Britain for compensating victims of medical injury depends on an assessment of negligence. Despite the sporadic pressure on the government to adopt a ''no fault'' approach, such as exists in Sweden, the negligence system will probably remain for the immediate future. The cost of this system was estimated to be pound 52.3m for England 1990-1. The problem for the future, however, is one of forecasting accuracy at provider level: too high a guess and current patient care will suffer; too low a guess and future patient care will suffer. The introduction of a mutual insurance scheme may not resolve these difficulties, as someone will have to set the rates. Moreover, the figures indicate that if a no fault scheme was introduced the cost might be four times that of the current system, depending on the type of scheme adopted.	UNIV NOTTINGHAM,SCH SOCIAL STUDIES,NOTTINGHAM NG7 2RD,ENGLAND; UNIV OXFORD,CTR SOCIOLEGAL STUDIES,OXFORD OX2 6UD,ENGLAND	University of Nottingham; University of Oxford	FENN, P (corresponding author), UNIV NOTTINGHAM,SCH MANAGEMENT & FINANCE,NOTTINGHAM NG7 2RD,ENGLAND.		Dingwall, Robert WJ/A-9348-2008	Dingwall, Robert WJ/0000-0002-1588-3796				[Anonymous], 1983, REPORT WORKING PARTY; ESPERSSON C, 1992, SWEDISH PATIENT INSU; Ham Christopher, 1988, MED NEGLIGENCE COMPE; Harris D., 1984, COMPENSATION SUPPORT; MAWHINNEY B, 1994, MED NEGLIGENCE CLAIM, P239; Weiler PC, 1993, MEASURE MALPRACTICE; 1991, ARBITRATION MED NEGL; 1990, COMPENSATION ADVERSE; 1991, REPORT WORKING PARTY	9	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					389	391		10.1136/bmj.309.6951.389	http://dx.doi.org/10.1136/bmj.309.6951.389			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081145	Green Published			2022-12-28	WOS:A1994PB31600028
J	NICOLL, A; MCGARRIGLE, C; HEPTONSTALL, J; PARRY, J; MAHONEY, A; NICHOLAS, S; HUTCHINSON, E; GILL, ON				NICOLL, A; MCGARRIGLE, C; HEPTONSTALL, J; PARRY, J; MAHONEY, A; NICHOLAS, S; HUTCHINSON, E; GILL, ON			PREVALENCE OF HIV-INFECTION IN PREGNANT-WOMEN IN LONDON AND ELSEWHERE IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article									CENT PUBL HLTH LAB,HEPATITIS & RETROVIRUS LAB,LONDON,ENGLAND; PUBL HLTH LAB SERV,STAT UNIT,LONDON,ENGLAND	Public Health England; Public Health England	NICOLL, A (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.		McGarrigle, Christine/J-8331-2017	McGarrigle, Christine/0000-0001-5814-5673				COUTURIER E, 1993, B EPIDEMIOL HEBDOM, V38, P175; Gilbart V L, 1992, Commun Dis Rep CDR Rev, V2, pR55; NICOLL A, IN PRESS COMMUNICABL; PARKER S, 1992, AIDS, V6, P1031; PERUCCI CA, 1993, 9TH P INT C AIDS BER	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					376	377		10.1136/bmj.309.6951.376a	http://dx.doi.org/10.1136/bmj.309.6951.376a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081138	Green Published			2022-12-28	WOS:A1994PB31600020
J	SEAGROATT, V; GOLDACRE, M				SEAGROATT, V; GOLDACRE, M			MEASURES OF EARLY POSTOPERATIVE MORTALITY - BEYOND HOSPITAL FATALITY RATES	BRITISH MEDICAL JOURNAL			English	Article							DISCHARGE	Objective-To quantify the short term risk of postoperative mortality in ways which take account of deaths after discharge and the background risks of death in patients who come to operation. Design-Analysis of linked abstracts of hospital admission records and death certificates for common operations. Setting-Six health districts in the Oxford region. Subjects-Records of 223529 operations performed in 1980-6. Main outcome measures-In hospital fatality rates, case fatality rates, and standardised mortality ratios at selected time periods during the year after operation and the ratio of early ( < 30 days) to late (90-364 days after operation) fatality rates. Results-Fatality rates throughout the year after operations performed after emergency admissions were generally higher than those for similar operations performed after elective admissions and higher than expected from population rates. Examples were prostatectomy, hip arthroplasty, inguinal herniorrhaphy, and cholecystectomy. Common elective operations such as inguinal herniorrhaphy and cataract operations showed no early peak in mortality, but others did. These included transurethral prostatectomy (ratio of early to late mortality 2.0; 95% confidence interval 1.3 to 2.6), hysterectomy (3.2; 1.5 to 6.6), hip arthroplasty (3.8; 2.5 to 5.4), and cholecystectomy (6.9; 4.3 to 11.1). Conclusions-Temporal profiles of death rates in the year after operation show which operations have early peaks in mortality and which do not. Emergency and elective operations have very different profiles and should be analysed separately. For elective operations for conditions which pose no immediate threat to life the ratio of early to later fatality rates provides a measure of increase in mortality after operation while allowing for the background risk of death in the patient groups.			SEAGROATT, V (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.							Acheson E.D., 1967, MED RECORD LINKAGE; ALDERSON MR, 1975, THEORY PRACTICE PUBL, P29; Breslow N. E., 1987, STATISTICAL METHODS, VII; Buck N, 1987, REPORT CONFIDENTIAL; GARDNER MJ, 1989, STATISTICS CONFIDENC; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldacre M J, 1981, Community Med, V3, P60, DOI 10.1007/BF02549440; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; LOFT A, 1991, BRIT J OBSTET GYNAEC, V98, P147, DOI 10.1111/j.1471-0528.1991.tb13360.x; Lubitz J, 1985, Health Care Financ Rev, V6, P103; MACKAY D, 1951, HOSPITAL MORBIDITY S, P7; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; VERHEUL HA, 1993, LANCET, V341, P872, DOI 10.1016/0140-6736(93)93073-A; 1975, CLASSIFICATION SURGI; 1840, LANCET, P597; 1993, LANCET, V341, P1183	17	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					361	365		10.1136/bmj.309.6951.361	http://dx.doi.org/10.1136/bmj.309.6951.361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081132	Green Published			2022-12-28	WOS:A1994PB31600013
J	OPELZ, G; WUJCIAK, T				OPELZ, G; WUJCIAK, T			THE INFLUENCE OF HLA COMPATIBILITY ON GRAFT-SURVIVAL AFTER HEART-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC ALLOGRAFT RECIPIENTS; RISK-FACTORS; REJECTION; HISTOCOMPATIBILITY	Background. In cardiac transplantation, it is standard practice for donor hearts to be allocated to recipients without consideration of the extent of HLA matching. Because the HLA system is highly polymorphic, the likelihood that donor hearts will be well matched to their recipients by chance alone is extremely small. It has therefore not been possible in the past to analyze adequately the success rate of transplantation with HLA matched hearts. Methods. We initiated a collaborative study in 1985 to evaluate the influence of HLA compatibility on graft survival in heart transplantation. Data were collected from 104 centers in 24 countries. Results. Of the 8331 patients, 128 received a graft with no HLA-A, B, or DR mismatches or only one mismatch. This frequency (1.5 percent) corresponds to the rate that would be expected from a random allocation of donor organs. The three-year rate of graft survival correlated strongly with HLA compatibility, decreasing from a mean (+/-SE) of 83+/-4 percent for the 128 donor hearts with no mismatches or only one mismatch to 76+/-2 percent for the 439 hearts with two mismatches and 71+/-1 percent for the 7764 hearts with three to six mismatches (P<0.001). Multifactorial Cox regression analysis showed that this effect was independent of the age and sex of the donor and recipient, the type of underlying disease, the duration of cold ischemia, and the use of prophylaxis with antilymphocyte antibodies (P = 0.005). Conclusions. Graft survival in heart transplantation is Significantly influenced by the extent of HLA compatibility.			OPELZ, G (corresponding author), UNIV HEIDELBERG,INST IMMUNOL,DEPT TRANSPLANTAT IMMUNOL,NEUENHEIMER FELD 305,D-69120 HEIDELBERG,GERMANY.							COCHRANE A, 1992, TRANSPLANT P, V24, P169; COX DR, 1972, J R STAT SOC B, V34, P187; DISESA VJ, 1990, ANN THORAC SURG, V49, P220, DOI 10.1016/0003-4975(90)90141-R; DUNN OJ, 1974, APPLIED STATISTICS A, P236; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAGHANI A, 1989, TRANSPLANT P, V21, P799; LAUFER G, 1989, J THORAC CARDIOV SUR, V98, P1113; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; OPELZ G, 1989, TRANSPLANT P, V21, P794; OPELZ G, 1991, TRANSPLANT P, V23, P46; OPELZ G, 1992, TRANSPLANT INT S1, V5, P621; PFEFFER PF, 1988, TRANSPLANT P, V20, P367; RAFFOUX C, 1987, TRANSPLANT P, V19, P3559; TERASAKI P, 1989, TRANSPLANT P, V21, P615; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; WUJCIAK T, 1993, TRANSPLANTATION, V55, P516; ZERBE TR, 1991, TRANSPLANTATION, V52, P485, DOI 10.1097/00007890-199109000-00019; 1993, EUROTRANSPLANT NEWSL, V101, P2; 1992, COLLABORATIVE T 1110	20	161	166	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					816	819		10.1056/NEJM199403243301203	http://dx.doi.org/10.1056/NEJM199403243301203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8068075				2022-12-28	WOS:A1994NB80300003
J	GREENGOLD, NL				GREENGOLD, NL			BY THE NUMBERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					890	890		10.1001/jama.271.12.890	http://dx.doi.org/10.1001/jama.271.12.890			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8080507				2022-12-28	WOS:A1994NA74300002
J	VERDER, H; ROBERTSON, B; GREISEN, G; EBBESEN, F; ALBERTSEN, P; LUNDSTROM, K; JACOBSEN, T; AGERTOFT, L; HOBOLTH, N; DJERNES, B; GRYTTER, C; HERTEL, J; HOLM, V; HANSEN, US; KAMPER, J; JOHANSEN, KH; NATHAN, E; LANGE, A; PEITERSEN, B; PEDERSENBJERGAARD, L; SKOV, L; SVENNINGSEN, N; CURSTEDT, T; BERTELSEN, A; VESTERGAARD, A; PETERSEN, E				VERDER, H; ROBERTSON, B; GREISEN, G; EBBESEN, F; ALBERTSEN, P; LUNDSTROM, K; JACOBSEN, T; AGERTOFT, L; HOBOLTH, N; DJERNES, B; GRYTTER, C; HERTEL, J; HOLM, V; HANSEN, US; KAMPER, J; JOHANSEN, KH; NATHAN, E; LANGE, A; PEITERSEN, B; PEDERSENBJERGAARD, L; SKOV, L; SVENNINGSEN, N; CURSTEDT, T; BERTELSEN, A; VESTERGAARD, A; PETERSEN, E			SURFACTANT THERAPY AND NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE FOR NEWBORNS WITH RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; HYALINE-MEMBRANE DISEASE; REPLACEMENT; TRIAL; LUNG; LESS	Background. In southern Scandinavia most babies with respiratory distress syndrome are initially treated with nasal continuous positive airway pressure. We performed a multicenter trial to investigate whether the addition of a single dose of porcine surfactant administered during a short intubation before the occurrence of serious deterioration could reduce the subsequent need for mechanical ventilation. Methods. We randomly assigned 35 infants with moderate-to-severe respiratory distress syndrome to surfactant therapy (Curosurf, 200 mg per kilogram of body weight) plus nasal continuous positive airway pressure and 33 infants to nasal continuous positive airway pressure alone. The study was not blinded. The indications for mechanical ventilation were a ratio of arterial to alveolar oxygen tension of less than 0.15, severe apneic attacks, or both. Results. Six hours after randomization, when the median age of the babies was 18 hours, the mean ratio of arterial to alveolar oxygen tension was 0.37 in the surfactant-treated babies, as compared with 0.25 in the controls (P<0.001). The need for subsequent mechanical ventilation was reduced with surfactant therapy (to 43 percent of the surfactant-treated babies, as compared with 85 percent of the controls; P = 0.003). When 17 infants with ratios of arterial-to-alveolar oxygen tension of less than 0.15 at randomization were excluded, the need for mechanical ventilation was still significantly reduced in the surfactant-treated group (to 33 percent [9 of 27 babies], as compared with 83 percent [20 of 24 babies] in the control group; P<0.001). After 28 days, two of the surfactant-treated babies had died, as compared with five of the control babies. Conclusions. In babies with moderate-to-severe respiratory distress syndrome treated with nasal continuous positive airway pressure, a single dose of surfactant reduced the need for subsequent mechanical ventilation.	KAROLINSKA HOSP,PERINATAL PATHOL RES UNIT,STOCKHOLM,SWEDEN; UNIV COPENHAGEN HOSP,DEPT PEDIAT,DK-2100 COPENHAGEN,DENMARK; AALBORG HOSP,DEPT PEDIAT,AALBORG,DENMARK	Karolinska Institutet; Karolinska University Hospital; University of Copenhagen; Aalborg University; Aalborg University Hospital	VERDER, H (corresponding author), HOLBAEK CENT HOSP,DEPT PEDIAT,DK-4300 HOLBAEK,DENMARK.		Greisen, Gorm/AAA-6463-2022	Greisen, Gorm/0000-0001-8042-3262				ALLEN LP, 1977, ARCH DIS CHILD, V52, P373, DOI 10.1136/adc.52.5.373; Altman DG, 1991, PRACTICAL STATISTICS; AVERY ME, 1987, PEDIATRICS, V79, P26; BENVENIS.D, 1968, BRIT J ANAESTH, V40, P464, DOI 10.1093/bja/40.6.464; BENVENISTE D, 1976, J PEDIATR-US, V88, P1015, DOI 10.1016/S0022-3476(76)81066-9; BEVILACQUA G, 1993, J PERINAT MED, V21, P329, DOI 10.1515/jpme.1993.21.5.329; BOS J, 1991, SURFACTANT SYSTEM OF THE LUNG, P96; BRENDSTRUP A, 1975, BRIT J ANAESTH, V47, P1335, DOI 10.1093/bja/47.12.1335; FARRELL EE, 1989, AM J OBSTET GYNECOL, V161, P628, DOI 10.1016/0002-9378(89)90367-0; FUJIWARA T, 1980, LANCET, V1, P55; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; HALLIDAY HL, 1993, ARCH DIS CHILD-FETAL, V69, P276, DOI 10.1136/adc.69.3_Spec_No.276; HILL A, 1982, PEDIATRICS, V69, P282; JACOBSEN T, 1993, ACTA PAEDIATR, V82, P934, DOI 10.1111/j.1651-2227.1993.tb12603.x; JOBE AH, 1993, NEW ENGL J MED, V328, P861; KAMPER J, 1978, ACTA ANAESTH SCAND, V22, P367, DOI 10.1111/j.1399-6576.1978.tb01312.x; KAMPER J, 1993, ACTA PAEDIATR, V82, P193, DOI 10.1111/j.1651-2227.1993.tb12637.x; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; LUNDSTROM KE, 1993, ACTA PAEDIATR, V82, P856, DOI 10.1111/j.1651-2227.1993.tb12579.x; MORTENSSON W, 1987, ACTA RADIOL, V28, P389; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; ROBERTSON B, 1990, PROG R RES, V25, P237; SPEER CP, 1992, PEDIATRICS, V89, P13; SVENNINGSEN N, 1987, CRIT CARE MED, V15, P918, DOI 10.1097/00003246-198710000-00005; TARNOWMORDI W, 1991, ARCH DIS CHILD-FETAL, V66, P374, DOI 10.1136/adc.66.4_Spec_No.374; VERDER H, 1992, UGESKRIFT LAEGER, V154, P2136; VICTORIN LH, 1990, BIOL NEONATE, V58, P121; 1988, PEDIATRICS, V82, P683; 1992, LANCET, V340, P1363	31	286	305	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1051	1055		10.1056/NEJM199410203311603	http://dx.doi.org/10.1056/NEJM199410203311603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090164				2022-12-28	WOS:A1994PL56000003
J	CAMPMAN, SC				CAMPMAN, SC			A NOVEL IDEA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					990	990						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089895				2022-12-28	WOS:A1994PH77500002
J	BODENHEIMER, T; GRUMBACH, K				BODENHEIMER, T; GRUMBACH, K			REIMBURSING PHYSICIANS AND HOSPITALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; PAYMENT; INCENTIVES		UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BODENHEIMER, T (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,BOX 1364,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016					BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; CASALINO LP, 1992, JAMA-J AM MED ASSOC, V267, P403; COOK JV, 1988, J FAM PRACTICE, V26, P325; DAY P, 1991, HEALTH AFFAIR, V10, P39, DOI 10.1377/hlthaff.10.3.39; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; HORNBROOK MC, 1991, RISK BASED CONTRIBUT, V12; IGLEHART JK, 1983, NEW ENGL J MED, V308, P1428, DOI 10.1056/NEJM198306093082331; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; JENCKS SF, 1985, NEW ENGL J MED, V312, P1492, DOI 10.1056/NEJM198506063122306; Langwell K M, 1986, Med Care Rev, V43, P5, DOI 10.1177/107755878604300102; Law Sylvia, 1974, BLUE CROSS WHAT WENT; LEE PR, 1989, JAMA-J AM MED ASSOC, V261, P2382, DOI 10.1001/jama.261.16.2382; LEE PR, 1990, ANNU REV PUBL HEALTH, V11, P297; MARDER WD, 1988, HEALTH AFFAIR, V7, P137, DOI 10.1377/hlthaff.7.5.137; MELIA EP, 1983, NEW ENGL J MED, V308, P788, DOI 10.1056/NEJM198303313081337; Relman A S, 1983, Health Aff (Millwood), V2, P5, DOI 10.1377/hlthaff.2.2.5; SCOVERN H, 1988, NEW ENGL J MED, V319, P787, DOI 10.1056/NEJM198809223191211; WELCH WP, 1990, MILBANK Q, V68, P221, DOI 10.2307/3350097	19	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					971	977		10.1001/jama.272.12.971	http://dx.doi.org/10.1001/jama.272.12.971			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG737	8084067				2022-12-28	WOS:A1994PG73700028
J	DZIK, WH				DZIK, WH			BLOOD USAGE REVIEWS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRANSFUSION				DZIK, WH (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA, USA.							BABINEAU TJ, 1992, AM J SURG, V164, P22, DOI 10.1016/S0002-9610(05)80640-3; DZIK WH, 1992, CURRENT ISSUES CREAT; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					896	896		10.1001/jama.272.11.896	http://dx.doi.org/10.1001/jama.272.11.896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078172				2022-12-28	WOS:A1994PG18200034
J	PAULSHOCK, BZ				PAULSHOCK, BZ			UNTIL THE PEPPERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					836	836						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078150				2022-12-28	WOS:A1994PG18200001
J	MINOR, DL; KIM, PS				MINOR, DL; KIM, PS			CONTEXT IS A MAJOR DETERMINANT OF BETA-SHEET PROPENSITY	NATURE			English	Article							HELIX-FORMING TENDENCIES; STREPTOCOCCAL PROTEIN-G; OCCURRING AMINO-ACIDS; STABILITY; PARAMETERS; ALANINE; GLYCINE; PEPTIDE; WATER	RESIDUES in B-sheets occur in two distinct tertiary contexts: central strands, bordered on both sides by other beta-strands, and edge strands, bordered on only a single side by another beta-strand(1). The Delta Delta G values for beta-sheet formation measured at an edge beta-strand of the IgG-binding domain of protein G(GB1) are suite different from those obtained previously(2,3) at a central position in the same protein. In particular, there is no correlation at the edge position with statistically determined beta-sheet-forming preferences(4). The differences between beta-sheet propensities measured at central and edge beta-strands, Delta Delta Delta G values, correlate with the values of water/octanol transfer free energies(5) and side-chain non-polar surface area for the amino acids(6). These results strongly suggest that, unlike alpha-helix formation, beta-sheet formation is determined in large part by tertiary context, even at solvent-accessible sites, and not by intrinsic secondary structure preferences.	MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	MINOR, DL (corresponding author), MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT CHEM,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; GRONENBORN AM, 1993, J MOL BIOL, V233, P331, DOI 10.1006/jmbi.1993.1514; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIFSON S, 1980, J MOL BIOL, V139, P627, DOI 10.1016/0022-2836(80)90052-2; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	321	335	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					264	267		10.1038/371264a0	http://dx.doi.org/10.1038/371264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078589				2022-12-28	WOS:A1994PG29000058
J	RABASSA, AA; TREY, G; SHUKLA, U; SAMO, T; ANAND, BS				RABASSA, AA; TREY, G; SHUKLA, U; SAMO, T; ANAND, BS			ISONIAZID-INDUCED ACUTE-PANCREATITIS	ANNALS OF INTERNAL MEDICINE			English	Note							TUBERCULOSIS; INFECTION		BAYLOR COLL MED, GASTROENTEROL SECT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INFECT DIS SERV, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine								BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BONACINI M, 1991, J CLIN GASTROENTEROL, V13, P58, DOI 10.1097/00004836-199102000-00013; DAVIDSON PT, 1992, DRUGS, V43, P651, DOI 10.2165/00003495-199243050-00003; GOLDMAN AL, 1972, CHEST, V62, P71, DOI 10.1378/chest.62.1.71; GUERRA M, 1967, J AMER MED ASSOC, V200, P552, DOI 10.1001/jama.200.6.552; KVALE PA, 1975, CHEST, V68, P271; LARSEN R R, 1962, N Y State J Med, V62, P2397; MATTSON K, 1973, SCAND J RESPIR DIS, P1; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; 1989, MMMWR MORB MORTAL WK, V38, P236	10	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					433	434		10.7326/0003-4819-121-6-199409150-00007	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053617				2022-12-28	WOS:A1994PF33700007
J	TACCIOLI, GE; GOTTLIEB, TM; BLUNT, T; PRIESTLEY, A; DEMENGEOT, J; MIZUTA, R; LEHMANN, AR; ALT, FW; JACKSON, SP; JEGGO, PA				TACCIOLI, GE; GOTTLIEB, TM; BLUNT, T; PRIESTLEY, A; DEMENGEOT, J; MIZUTA, R; LEHMANN, AR; ALT, FW; JACKSON, SP; JEGGO, PA			KU80 - PRODUCT OF THE XRCC5 GENE AND ITS ROLE IN DNA-REPAIR AND V(D)J RECOMBINATION	SCIENCE			English	Article							STRAND BREAK-REPAIR; RAY-SENSITIVE MUTANTS; COMBINED IMMUNE-DEFICIENCY; PRE-B CELLS; IONIZING-RADIATION; PROTEIN-KINASE; HUMAN CHROMOSOME-8; SCID MUTATION; BINDING; COMPLEMENTATION	The radiosensitive mutant xrs-6, derived from Chinese hamster ovary cells, is defective in DNA double-strand break repair and in ability to undergo V(D)J recombination. The human XRCC5 DNA repair gene, which complements this mutant, is shown here through genetic and biochemical evidence to be the 80-kilodalton subunit of the Ku protein. Ku binds to free double-stranded DNA ends and is the DNA-binding component of the DNA-dependent protein kinase. Thus, the Ku protein is involved in DNA repair and in V(D)J recombination, and these results may also indicate a role for the Ku-DNA-dependent protein kinase complex in those same processes.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,ENGLAND; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA; UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Sussex; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Cambridge; University of Cambridge			demengeot, jocelyne/K-8072-2014; Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	demengeot, jocelyne/0000-0002-4761-614X; Jackson, Stephen Philip/0000-0001-9317-7937; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20047] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		AKROYD JE, 1986, NUCLEIC ACIDS RES, V14, P6901, DOI 10.1093/nar/14.17.6901; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTLIEB TM, UNPUB; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HISEH CL, 1993, J BIOL CHEM, V268, P20105; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1989, MUTAT RES, V218, P75, DOI 10.1016/0921-8777(89)90013-X; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MIMORI T, 1986, J BIOL CHEM, V261, P2274; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THACKER J, 1991, MUTAT RES, V254, P135, DOI 10.1016/0921-8777(91)90004-9; THACKER J, 1994, MUTAGENESIS, V9, P163, DOI 10.1093/mutage/9.2.163; THALER DS, 1987, EMBO J, V6, P3171, DOI 10.1002/j.1460-2075.1987.tb02628.x; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	48	584	592	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1442	1445		10.1126/science.8073286	http://dx.doi.org/10.1126/science.8073286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073286				2022-12-28	WOS:A1994PE73300047
J	RAVETCH, JV				RAVETCH, JV			FC-RECEPTORS - RUBOR REDUX	CELL			English	Review							NATURAL-KILLER-CELLS; HIGH-AFFINITY RECEPTOR; CYTOPLASMIC DOMAIN HETEROGENEITY; GAMMA-RIII CD16; T-CELL; IGG FC; SIGNAL-TRANSDUCTION; LYMPHOCYTES-T; ZETA-CHAIN; EXPRESSION				RAVETCH, JV (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				ALBER G, 1991, J BIOL CHEM, V266, P22613; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; BROOKS DG, 1994, THESIS CORNELL U MED; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; ERNST LK, 1992, J BIOL CHEM, V267, P15692; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Gallin John I., 1993, P1015; GUYGRAND D, 1993, CURR OPIN IMMUNOL, V5, P247, DOI 10.1016/0952-7915(93)90012-H; GUYGRAND D, 1994, IN PRESS J EXP MED; HA TY, 1987, EXP CELL BIOL, V55, P63; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1989, NATURE, V326, P292; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEFRANCOIS L, 1991, IMMUNOL TODAY, V12, P436, DOI 10.1016/0167-5699(91)90015-L; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MARTIN TM, IN PRESS J IMMUNOL; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; OAKEY RJ, 1992, IMMUNOGENETICS, V35, P279, DOI 10.1007/BF00166834; OETTINGEN HC, 1994, IN PRESS NATURE; OHNO H, 1993, INT IMMUNOL, V5, P1403, DOI 10.1093/intimm/5.11.1403; OHNO H, 1994, J EXP MED, V179, P365, DOI 10.1084/jem.179.1.365; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1994, IN PRESS J EXP MED; PERLMUTTER DH, 1986, ANNU REV IMMUNOL, V4, P231, DOI 10.1146/annurev.iy.04.040186.001311; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RAVETCH JV, 1994, NAT GENET, V7, P117, DOI 10.1038/ng0694-117; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SELDIN MF, 1993, MAMM GENOME, V4, P1; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SHIBATA T, 1990, INT IMMUNOL, V2, P1133, DOI 10.1093/intimm/2.12.1133; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; STETSON CA, 1951, J EXP MED, V94, P349; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; SU Y, 1993, P NATL ACAD SCI USA, V90, P10856, DOI 10.1073/pnas.90.22.10856; SYLVESTRE DL, 1994, IN PRESS SCIENCE; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WARD PA, 1964, FED PROC, V23, P509; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	66	344	384	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					553	560		10.1016/0092-8674(94)90521-5	http://dx.doi.org/10.1016/0092-8674(94)90521-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069908				2022-12-28	WOS:A1994PD69300005
J	OH, VMS				OH, VMS			KETOPROFEN GEL AND DELAYED-HYPERSENSITIVITY DERMATITIS	BRITISH MEDICAL JOURNAL			English	Letter											OH, VMS (corresponding author), NATL UNIV SINGAPORE HOSP,SINGAPORE 0511,SINGAPORE.							CYRIAX J, 1969, TXB ORTHOPAEDIC MED, V1, P307; FRITH P, 1978, LANCET, V2, P847	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					512	512		10.1136/bmj.309.6953.512b	http://dx.doi.org/10.1136/bmj.309.6953.512b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086908	Green Published			2022-12-28	WOS:A1994PD30800023
J	ZHOU, GW; GUO, JC; HUANG, W; FLETTERICK, RJ; SCANLAN, TS				ZHOU, GW; GUO, JC; HUANG, W; FLETTERICK, RJ; SCANLAN, TS			CRYSTAL-STRUCTURE OF A CATALYTIC ANTIBODY WITH A SERINE-PROTEASE ACTIVE-SITE	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; TRYPSIN; SPECIFICITY; TRIAD; FAB; HISTIDINE-159; SPECTROSCOPY; BINDING; PAPAIN	The three-dimensional structure of an unusually active hydrolytic antibody with a phosphonate transition state analog (hapten) bound to the active site has been solved to 2.5 Angstrom resolution. The antibody (17E8) catalyzes the hydrolysis of norleucine and methionine phenyl esters and is selective for amino acid esters that have the natural alpha-carbon L configuration. A plot of the pH-dependence of the antibody-catalyzed reaction is bell-shaped with an activity maximum at pH 9.5; experiments on mechanism lend support to the formation of a covalent acyl-antibody intermediate. The structural and kinetic data are complementary and support a hydrolytic mechanism for the antibody that is remarkably similar to that of the serine proteases. The antibody active site contains a Ser-His dyad structure proximal to the phosphorous atom of the bound hapten that resembles two of the three components of the Ser-His-Asp catalytic triad of serine proteases. The antibody active site also contains a Lys residue to stabilize oxyanion formation, and a hydrophobic binding pocket for specific substrate recognition of norleucine and methionine side chains. The structure identifies active site residues that mediate catalysis and suggests specific mutations that may improve the catalytic efficiency of the antibody. This high resolution structure of a catalytic antibody-hapten complex shows that antibodies can converge on active site structures that have arisen through natural enzyme evolution.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39304] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; BLACKBURN S, 1976, ENZYME STRUCTURE FUN; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; COREY DR, 1992, J AM CHEM SOC, V114, P4905, DOI 10.1021/ja00038a067; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; CRONIN CN, 1987, J AM CHEM SOC, V109, P2222, DOI 10.1021/ja00241a072; Fersht A., 1985, ENZYME STRUCTURE MEC; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; Guo Jincan, 1994, Journal of the American Chemical Society, V116, P6062, DOI 10.1021/ja00093a002; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HUSAIN SS, 1968, BIOCHEM J, V108, P855, DOI 10.1042/bj1080855; JANARIK J, 1991, J APPL CRYSTALLOGR, V24, P409; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P52, DOI 10.1021/bi00504a600; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P44, DOI 10.1021/bi00504a008; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P48; Kabat EA, 1991, SEQUENCES PROTEINS I; KOSSIAKOFF AA, 1987, BIOL MACROMOLECULES, V3; KRIEGER M, 1974, J MOL BIOL, V83, P209, DOI 10.1016/0022-2836(74)90388-X; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; POLLACK SJ, 1987, COLD SPRING HARB SYM, V52, P97, DOI 10.1101/SQB.1987.052.01.014; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SCANLAN TS, UNPUB; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STROUD RM, 1971, COLD SPRING HARB SYM, V36, P125, DOI 10.1101/SQB.1972.036.01.018; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261	39	178	182	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1059	1064		10.1126/science.8066444	http://dx.doi.org/10.1126/science.8066444			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066444				2022-12-28	WOS:A1994PC53900024
J	RODRIGUEZVICIANA, P; WARNE, PH; DHAND, R; VANHAESEBROECK, B; GOUT, I; FRY, MJ; WATERFIELD, MD; DOWNWARD, J				RODRIGUEZVICIANA, P; WARNE, PH; DHAND, R; VANHAESEBROECK, B; GOUT, I; FRY, MJ; WATERFIELD, MD; DOWNWARD, J			PHOSPHATIDYLINOSITOL-3-OH KINASE AS A DIRECT TARGET OF RAS	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTOR; DIFFERENT SIGNALING PATHWAYS; SH3 DOMAIN; 3-KINASE; BIND; ASSOCIATION; EXPRESSION; 3'-KINASE; COMPLEX	Ras (p21(ras)) interacts directly with the catalytic subunit of phosphatidylinositol-3-OH kinase in a GTP-dependent manner through the Ras effector site. In vivo, dominant negative Ras mutant N17 inhibits growth factor induced production of 3' phosphorylated phosphoinositides in PC12 cells, and transfection of Ras, but not Raf, into COS cells results in a large elevation in the level of these lipids. Therefore Ras can probably regulate phosphatidylinositol-3-OH kinase, providing a point of divergence in signalling pathways downstream of Ras.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Fry, Michael/0000-0001-8518-1370				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DOWNWARD J, 1991, Current Biology, V1, P353, DOI 10.1016/0960-9822(91)90190-8; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REIF K, 1993, J BIOL CHEM, V268, P10780; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VATANI A, 1990, CELL, V61, P769; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAME PH, 1993, NATURE, V364, P352; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	1632	1664	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					527	532		10.1038/370527a0	http://dx.doi.org/10.1038/370527a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052307				2022-12-28	WOS:A1994PC53700046
J	KAPHINGST, K; KUNES, S				KAPHINGST, K; KUNES, S			PATTERN-FORMATION IN THE VISUAL CENTERS OF THE DROSOPHILA BRAIN - WINGLESS ACTS VIA DECAPENTAPLEGIC TO SPECIFY THE DORSOVENTRAL AXIS	CELL			English	Article							SEGMENT-POLARITY GENE; CELL-CELL COMMUNICATION; MOLECULAR-ORGANIZATION; INT-1 PROTOONCOGENE; NERVOUS-SYSTEM; HEDGEHOG GENE; BETA FAMILY; MELANOGASTER; EXPRESSION; PROTEIN	A stepwise morphogenetic program of cell division and cell fate determination generates the precise neuronal architecture of the visual centers of the Drosophila brain. Here, we show that the assembly of the target structure for ingrowing retinal axons involves cell-cell interactions mediated by the secreted product of the wingless (wg) gene. wg, expressed in two symmetrical domains of the developing brain, is required to induce and maintain the expression of the secreted decapentaplegic (dpp) gene product in adjacent domains. wg and dpp function are required for target field neurons to adapt their proper fates and to send axons into the developing target structure. These observations implicate a cascade of diffusible signaling molecules in patterning the visual centers of the Drosophila brain.			KAPHINGST, K (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GMO-7598-16] Funding Source: Medline; PHS HHS [R01-10112-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAITENBERG V, 1967, EXP BRAIN RES, V3, P271; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; GELBART WM, 1989, DEVELOPMENT, V107, P65; GIERER A, 1987, DEVELOPMENT, V101, P479; Goodman Corey S., 1993, P1131; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KUNES S, 1993, J NEUROSCI, V13, P752; Kunes Samuel, 1993, Current Opinion in Neurobiology, V3, P53, DOI 10.1016/0959-4388(93)90035-W; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Martinez Arias Alfonso, 1993, P517; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meinertzhagen Ian A., 1993, P1363; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; Sharma R. P., 1973, DROS INF SER, V50, P134; SKAER H, 1992, DEVELOPMENT, V116, P745; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TRUJILLOCENOZ O, 1973, J ULTRA MOL STRUCT R, V42, P554, DOI 10.1016/S0022-5320(73)80027-9; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WHITE K, 1978, DEV BIOL, V65, P296, DOI 10.1016/0012-1606(78)90029-5	61	97	97	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	1994	78	3					437	448		10.1016/0092-8674(94)90422-7	http://dx.doi.org/10.1016/0092-8674(94)90422-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062386				2022-12-28	WOS:A1994PC40500010
J	LADER, M				LADER, M			FORTNIGHTLY REVIEW - TREATMENT OF ANXIETY	BRITISH MEDICAL JOURNAL			English	Review							BENZODIAZEPINES; DISORDER; ANTIDEPRESSANTS; EFFICACY; MEMORY				LADER, M (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							Bruce M. S., 1986, Human Psychopharmacology, V1, P63, DOI 10.1002/hup.470010203; CLARK DM, 1988, PANIC PHOBIAS, V2, P149; CURRAN HV, 1991, PSYCHOPHARMACOLOGY, V105, P1; DAVIS JD, 1991, INT REV PSYCHIATR, V3, P5; DEAKIN JFW, 1993, J PSYCHOPHARMACOL, V7, P283, DOI 10.1177/026988119300700308; DIETCH JT, 1988, J CLIN PSYCHIAT, V49, P184; DONNAN P, 1990, BRIT J GEN PRACT, V40, P498; DURHAM RC, 1987, BEHAV RES THER, V25, P229, DOI 10.1016/0005-7967(87)90051-9; DURHAM RC, 1993, BRIT J PSYCHIAT, V163, P19, DOI 10.1192/bjp.163.1.19; FITTON A, 1992, DRUGS, V43, P561, DOI 10.2165/00003495-199243040-00009; GHONEIM MM, 1990, ANESTHESIOLOGY, V72, P926; Goldberg DP., 1992, COMMON MENTAL DISORD; HALLSTROM C, 1993, BENZODIAZEPINE DEPEN; JANNOUN L, 1982, BEHAV THER, V13, P103, DOI 10.1016/S0005-7894(82)80053-1; LADER M, 1992, PSYCHIAT B, V6, P650; RASKIN M, 1980, ARCH GEN PSYCHIAT, V37, P93; RICKELS K, 1993, ARCH GEN PSYCHIAT, V50, P884; SALZMAN C, 1992, ADVERSE EFFECTS PSYC, P139; SERFATY M, 1993, BRIT J PSYCHIAT, V163, P386, DOI 10.1192/bjp.163.3.386; SHEEHAN DV, 1980, ARCH GEN PSYCHIAT, V37, P51; TILLER JWG, 1992, DRUGS, V44, P165, DOI 10.2165/00003495-199244020-00001; TYRER P, 1988, LANCET, V2, P235; TYRER P, 1988, DRUGS, V36, P773, DOI 10.2165/00003495-198836060-00006; WESTENBERG HGM, 1989, PSYCHOPHARMACOL BULL, V25, P119; 1987, DIAGNOSTIC STATISTIC; 1992, BR J PSYCHAITRY, V160, P191; 1986, MORBID STATISTICS GE; 1985, AUST NZ J PSYCHIAT, V19, P138	28	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					321	324		10.1136/bmj.309.6950.321	http://dx.doi.org/10.1136/bmj.309.6950.321			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA373	8086871	Green Published			2022-12-28	WOS:A1994PA37300023
J	PEAR, SM; WILLIAMSON, TH; BETTIN, KM; GERDING, DN; GALGIANI, JN				PEAR, SM; WILLIAMSON, TH; BETTIN, KM; GERDING, DN; GALGIANI, JN			DECREASE IN NOSOCOMIAL CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHEA BY RESTRICTING CLINDAMYCIN USE	ANNALS OF INTERNAL MEDICINE			English	Article						CROSS INFECTION; CLINDAMYCIN; DIARRHEA; CLOSTRIDIUM-DIFFICILE; CLOSTRIDIUM INFECTIONS	TOXIN-ASSOCIATED DIARRHEA; RISK-FACTORS; CROSS-INFECTION; COLITIS; OUTBREAK; ACQUISITION; SUSCEPTIBILITY; TRANSMISSION; DISEASE	Objective: To report the investigation and effective control of a nosocomial epidemic of Clostridium difficile-associated diarrhea. Design: Concurrent surveillance for identification of new nosocomial cases, retrospective case-control analysis, and hospital formulary control of antibiotic use. Setting: University-affiliated Veterans Affairs Medical Center located in southwestern United States. Patients: Hospitalized patients who developed diarrhea submitted stool specimens for cytotoxin assay. Patients who were positive for cytotoxin were compared with control patients without infection. Measurements: Isolates of C. difficile were typed by restriction endonuclease analysis. Antimicrobial agent use from hospital pharmacy records and selected patient data from chart review were correlated with frequency of specific laboratory abnormalities. Results: For 13 months, the monthly incidence of C. difficile infection averaged more than five times that for the previous 21 months. Stool specimens from 34 patients (59%) contained a single strain (restriction enzyme analysis type J7). Clindamycin was statistically associated with the epidemic as shown by the following: clindamycin use at our center compared with national normal values, clindamycin use for years before compared with during the epidemic, monthly use of clindamycin compared with monthly frequency of infection, frequency of infection in patients receiving clindamycin compared with that in patients receiving other antimicrobial agents, and amount of clindamycin used by infected patients compared with that used by control patients. Restricting clindamycin use led to a prompt decrease in infection rate and the type J7 organisms. Conclusion: A nosocomial epidemic of C. difficile diarrhea was controlled by analysis of antibiotic use patterns and by subsequent restriction of clindamycin.	VET AFFAIRS MED CTR, MED SERV 111, 6TH & AJO, TUCSON, AZ 85723 USA; VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55417 USA; VET AFFAIRS LAKESIDE MED CTR, CHICAGO, IL 60611 USA; UNIV ARIZONA, TUCSON, AZ 85721 USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Arizona; Northwestern University			williamson, tom/AAP-3801-2020; Galgiani, John/GLT-7012-2022	williamson, tom/0000-0002-1879-449X				BARTLETT J, 1988, CLOSTRIDIUM DIFFICIL; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1981, JOHNS HOPKINS MED J, V149, P6; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; CLABOTS CR, 1988, J INFECT DIS, V158, P731, DOI 10.1093/infdis/158.4.731; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1987, DIAGN MICR INFEC DIS, V6, P49, DOI 10.1016/0732-8893(87)90113-1; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; COHEN LE, 1973, JAMA-J AM MED ASSOC, V223, P1379, DOI 10.1001/jama.223.12.1379; CUMMING AD, 1986, BRIT MED J, V292, P238, DOI 10.1136/bmj.292.6515.238; DELMEE M, 1986, J INFECTION, V13, P5, DOI 10.1016/S0163-4453(86)92095-5; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GEORGE WL, 1978, CURR MICROBIOL, V1, P55, DOI 10.1007/BF02601709; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; HEARD SR, 1986, J INFECT DIS, V153, P159, DOI 10.1093/infdis/153.1.159; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KOFSKY P, 1991, DIS COLON RECTUM, V34, P244, DOI 10.1007/BF02090164; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; PETERSON LR, 1988, DIAGN MICR INFEC DIS, V10, P85, DOI 10.1016/0732-8893(88)90045-4; POXTON IR, 1984, J MED MICROBIOL, V17, P317, DOI 10.1099/00222615-17-3-317; SCHIFMAN RB, 1991, PROBES ANTIMICROBIAL, pA90; STRUELENS MJ, 1991, AM J MED, V91, pS138, DOI 10.1016/0002-9343(91)90359-6; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; ZIMMERMAN RK, 1991, INFECT CONT HOSP EP, V12, P96; 1990, SAS STAT USERS GUIDE, V2, P495	27	176	178	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					272	277		10.7326/0003-4819-120-4-199402150-00003	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8080497				2022-12-28	WOS:A1994MW10300003
J	SOX, HC; SCOTT, HD; GINSBURG, JA				SOX, HC; SCOTT, HD; GINSBURG, JA			THE ROLE OF THE FUTURE GENERAL-INTERNIST DEFINED	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL SPECIALTIES; CURRICULUM; OUTCOMES; SYSTEMS; CARE	In this position paper, the American College of Physicians Task Force on Physician Supply examines the current and future roles of the ideal general internist. Discussed are the characteristics shared by all internists, whether engaged in general or subspecialty practice; current trends and the growing crisis in the supply of primary care physicians; and the practices and patient characteristics of both general internists and family physicians. The Task Force considered four options for the future general internist but rejected them because they either maintained the status quo or were retrogressive: 1) allowing the community-based general internist to disappear; 2) strengthening the generalist's identity as a primary care-oriented physician who provides no subspecialty care; 3) becoming hospital-based generalists who act principally as consultants; or 4) becoming fully trained subspecialists who also provide primary care. The Task Force proposes a new definition that reaffirms fundamental characteristics of today's general internists and adds characteristics that should be the hallmark of the general internist of the future. The paper describes characteristics that are shared by other generalist physicians and those that are distinctive to today's general internist. It then addresses characteristics that will be needed to prepare for the environment of medical care in the future. The new definition reaffirms that the general internist is an expert in the general care of the adult, but it also revives the concept of the general internist as a local authority on a specific topic in which he or she has special expertise. The paper concludes with a discussion of some of the questions that its definition poses for graduate medical education. The Task Force suggests that changes in the educational system to produce the desired mix of skills required for the general internist of the future will increase the attractiveness of general internal medicine.										BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; LEVEY GS, 1992, ANN INTERN MED, V116, P1046, DOI 10.7326/0003-4819-116-12-1046; NUCKOLLS JG, 1992, ANN INTERN MED, V116, P1051, DOI 10.7326/0003-4819-116-12-1051; STEIN JH, 1991, ANN INTERN MED, V114, P79, DOI 10.7326/0003-4819-114-1-79; 1992, ESSENTIALS ACCREDITE	9	35	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					616	622		10.7326/0003-4819-121-8-199410150-00011	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085695				2022-12-28	WOS:A1994PL48600011
J	SZERSZEN, JB; SZCZYGLOWSKI, K; BANDURSKI, RS				SZERSZEN, JB; SZCZYGLOWSKI, K; BANDURSKI, RS			IAGLU, A GENE FROM ZEA-MAYS INVOLVED IN CONJUGATION OF GROWTH-HORMONE INDOLE-3-ACETIC	SCIENCE			English	Article							ENZYMATIC-HYDROLYSIS; ENZYMIC-SYNTHESIS; BOUND AUXINS; 6-O-INDOL-3-YLACETYL-BETA-D-GLUCOSE; PURIFICATION; EXPRESSION; SEQUENCE; CLONING; ESTERS; FAMILY	Plants contain most of the growth hormone indole-3-acetic acid (IAA) in conjugated forms believed to be inactive in promoting growth. The iaglu gene, which controls the first step in the biosynthesis of the IAA conjugates of Zea mays, encodes (uridine 5'-diphosphate-glucose:indol-3-ylacetyl)-beta-D-glucosyl transferase. Protein synthesized by Escherichia coli that contained cloned 1-O-beta-D-indol-3-ylacetyt-glucose complementary DNA (cDNA) was catalytically active. The predicted amino acid sequence of the cDNA was confirmed by amino-terminal sequencing of the purified enzyme. Homologous nucleotide sequences were found in all plants tested. The blockage or enhancement of iaglu expression may permit regulation of plant growth.	MICHIGAN STATE UNIV, DEPT BOT & PLANT PATHOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT ENERGY, PLANT RES LAB, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								BANDURSK.RS, 1974, PLANT PHYSIOL, V54, P257, DOI 10.1104/pp.54.3.257; BANDURSKI RS, 1988, PLANT GROWTH SUBSTAN, P341; BANDURSKI RS, 1991, PROGR PLANT GROWTH R, P1; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; COHEN JD, 1978, PLANTA, V139, P203, DOI 10.1007/BF00388631; FURTEK D, 1988, PLANT MOL BIOL, V11, P473, DOI 10.1007/BF00039028; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; JACKSON MR, 1986, NUCLEIC ACIDS RES, V14, P779, DOI 10.1093/nar/14.2.779; JAKUBOWSKA A, 1993, J PLANT PHYSIOL, V142, P61, DOI 10.1016/S0176-1617(11)80108-2; KEGLEVIC D, 1971, CARBOHYD RES, V20, P293, DOI 10.1016/S0008-6215(00)81383-X; KESY JM, 1990, PLANT PHYSIOL, V94, P1598, DOI 10.1104/pp.94.4.1598; KOWALCZYK S, 1991, BIOCHEM J, V279, P509, DOI 10.1042/bj2790509; KOWALCZYK S, 1990, PLANT PHYSIOL, V94, P4, DOI 10.1104/pp.94.1.4; LEZNICKI AJ, 1988, PLANT PHYSIOL, V88, P1481, DOI 10.1104/pp.88.4.1481; MICHALCZUK L, 1982, BIOCHEM J, V207, P273, DOI 10.1042/bj2070273; NOWACKI J, 1980, PLANT PHYSIOL, V65, P422, DOI 10.1104/pp.65.3.422; Reinecke D. M., 1987, Plant hormones and their role in plant growth and development., P24; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P758; SZERSZEN JB, UNPUB; TUKEY RH, 1993, J BIOL CHEM, V268, P15260; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465	23	165	180	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1699	1701		10.1126/science.8085154	http://dx.doi.org/10.1126/science.8085154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085154				2022-12-28	WOS:A1994PG28400028
J	EDDY, DM				EDDY, DM			RATIONING RESOURCES WHILE IMPROVING QUALITY - HOW TO GET MORE FOR LESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; TRIALS		KAISER PERMANENTE SO CALIF,PASADENA,CA	Kaiser Permanente								ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P324, DOI 10.1001/jama.272.4.324; EDDY DM, 1994, JAMA-J AM MED ASSOC, V271, P1792, DOI 10.1001/jama.271.22.1792; EDDY DM, 1986, NCI MONOGRAPHS, V2, P75; Elwood JM, 1993, ONLINE J CURR CLIN T; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; LORD M, 1994, US NEWS WORLD R 0509, P63; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Pear Robert, 1994, NY TIMES        0119, pA12; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; 1984, JAMA-J AM MED ASSOC, V251, P351; 1993, JAMA-J AM MED ASSOC, V269, P3015	16	61	64	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					817	824		10.1001/jama.272.10.817	http://dx.doi.org/10.1001/jama.272.10.817			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078149				2022-12-28	WOS:A1994PF18800034
J	WILSON, P; WATSON, R; RALSTON, GE				WILSON, P; WATSON, R; RALSTON, GE			METHADONE-MAINTENANCE IN GENERAL-PRACTICE - PATIENTS, WORKLOAD, AND OUTCOMES	BRITISH MEDICAL JOURNAL			English	Article							INJECTING DRUG-USERS; HIV-INFECTION; PRACTITIONERS; MISUSE; GLASGOW; CLIENTS; LONDON	Objective-To assess recruitment to and workload associated with methadone maintenance clinics in general practice; to investigate the characteristics of patients and outcomes associated with treatment. Design-Study of case notes. Setting-Methadone maintenance clinics run jointly by general practitioners and drug counsellors in two practices in Glasgow, Participants-46 injecting drug users receiving methadone maintenance during an 18 month period, 31 of whom were recruited to clinic based methadone maintenance treatment and 15 of whom were already receiving methadone maintenance treatment from the general practitioners. Mean (SD) age of patients entering treatment was 29.6 (5.5) years'; 29 were male. They had been injecting opiates for a mean 9.9 (5.1) years, and most had a concurrent history of benzodiazepine misuse. Average reported daily intake of heroin was approximately 0.75 g. Participants in treatment had high levels of preexisting morbidity, and most stated that they committed crime daily. Results-2232 patient weeks of treatment were studied. Mean duration of treatment during the study period was 50.7 (21.1) weeks and retention in treatment at 26 weeks was 83%. No evidence of illicit opiate use was obtained at an average of 78% of patients' consultations where methadone had been prescribed in the previous week; for opiate injection the corresponding figure was 86%. Conclusions-Providing methadone maintenance in general practice is feasible. Although costs are considerable, the reduction in drug use, especially of intravenous opiates, is encouraging. Attending clinics also allows this population, in which morbidity is considerable, to receive other health care.	LANSDOWNE CLIN,DEPT CLIN PSYCHOL,GLASGOW,LANARK,SCOTLAND; THE SURGERY,GLASGOW G72 8RW,LANARK,SCOTLAND	University of Glasgow	WILSON, P (corresponding author), THE SURGERY,GLASGOW G42 9JT,LANARK,SCOTLAND.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248				Ball J.C., 2012, EFFECTIVENESS METHAD; BELL J, 1990, BRIT J ADDICT, V85, P1599; BENNETT T, 1986, BRIT J ADDICT, V81, P757; CHALMERS J W T, 1990, Health Bulletin (Edinburgh), V48, P62; COHEN J, 1992, BRIT MED J, V304, P1158, DOI 10.1136/bmj.304.6835.1158; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; FRISCHER M, 1992, AIDS, V6, P1371, DOI 10.1097/00002030-199211000-00022; FRISCHER M, 1992, BRIT J ADDICT, V87, P235; GLANZ A, 1986, BRIT MED J, V293, P543, DOI 10.1136/bmj.293.6546.543; GLASS RM, 1993, JAMA-J AM MED ASSOC, V269, P1995, DOI 10.1001/jama.269.15.1995; GREENWOOD J, 1992, DRUGLINK         JUL, P8; KIDD BA, 1992, BRIT J GEN PRACT, V42, P441; KIDD BA, 1993, BRIT MED J, V306, P1414, DOI 10.1136/bmj.306.6889.1414; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; LEAVER EJ, 1992, BRIT J GEN PRACT, V42, P465; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; ROBERTSON JR, 1989, BRIT J ADDICT, V84, P377; ROZEWICZ L, 1992, BRIT MED J, V304, P1442, DOI 10.1136/bmj.304.6839.1442; STARK MJ, 1990, AM J DRUG ALCOHOL AB, V16, P67, DOI 10.3109/00952999009001573; TANTAM D, 1993, BRIT J GEN PRACT, V43, P470; WARD J, 1992, BRIT J ADDICT, V87, P447; 1993, SCOTTISH DRUG MISUSE, P8; 1990, GAOHRD90104 GEN ACC	24	64	64	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					641	644		10.1136/bmj.309.6955.641	http://dx.doi.org/10.1136/bmj.309.6955.641			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG020	8086989	Green Published			2022-12-28	WOS:A1994PG02000022
J	POPE, CE				POPE, CE			CURRENT CONCEPTS - ACID-REFLUX DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEVERE PEPTIC ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; CONTROLLED TRIAL; DOUBLE-BLIND; CISAPRIDE; DISEASE; RANITIDINE; OMEPRAZOLE; CIMETIDINE; RELAPSE		VET AFFAIRS MED CTR, DEPT MED, SEATTLE, WA 98108 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	POPE, CE (corresponding author), UNIV WASHINGTON, DEPT MED, DIV GASTROENTEROL RG24, SEATTLE, WA 98195 USA.							BALDI F, 1990, ITAL J GASTROENTEROL, V22, P29; BARDHAN KD, 1990, GUT, V31, P745, DOI 10.1136/gut.31.7.745; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BLUM AL, 1993, DIGEST DIS SCI, V38, P551, DOI 10.1007/BF01316514; CHAMPION G, 1993, GASTROENTEROLOGY, V104, pA51; CRAUSAZ FM, 1988, CHEST, V93, P376, DOI 10.1378/chest.93.2.376; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503; GALMICHE JP, 1988, GUT, V29, P675, DOI 10.1136/gut.29.5.675; GAYNOR EB, 1991, AM J GASTROENTEROL, V86, P801; HARDY SC, 1993, GASTROENTEROLOGY, V104, pA95; HARVEY RF, 1987, LANCET, V2, P1200; HELM JF, 1984, NEW ENGL J MED, V310, P284, DOI 10.1056/NEJM198402023100503; HERVE P, 1986, AM REV RESPIR DIS, V134, P986, DOI 10.1164/arrd.1986.134.5.986; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; HILLMAN AL, 1992, ARCH INTERN MED, V152, P1467, DOI 10.1001/archinte.152.7.1467; HOLLOWAY RH, 1991, DIGEST DIS SCI, V36, P1034, DOI 10.1007/BF01297443; HUBERT D, 1988, J ALLERGY CLIN IMMUN, V81, P1168, DOI 10.1016/0091-6749(88)90886-X; INAUEN W, 1993, GUT, V34, P1025, DOI 10.1136/gut.34.8.1025; IRELAND A, 1990, Gastroenterology, V98, pA361; JACOB P, 1991, GASTROENTEROLOGY, V100, P305, DOI 10.1016/0016-5085(91)90196-R; KAMEL P, 1992, Gastroenterology, V102, pA93; KLINKENBERGKNOL EC, 1992, HEPATO-GASTROENTEROL, V39, P27; LARRAIN A, 1991, CHEST, V99, P1330, DOI 10.1378/chest.99.6.1330; Mittal RK, 1987, GASTROENTEROLOGY, V92, P130, DOI 10.1016/0016-5085(87)90849-3; MITTAL RK, 1990, AM J PHYSIOL, V258, pG624, DOI 10.1152/ajpgi.1990.258.4.G624; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; ORLANDO RC, 1991, TXB GASTROENTEROLOGY, V1, P1123; POPE CE, 1992, WORLD J SURG, V16, P355, DOI 10.1007/BF02071548; POPE CE, 1989, SCAND J GASTROENTERO, V24, P67; REID BJ, 1991, GASTROENTEROL CLIN N, V20, P817; SAFAIESHIRAZI S, 1975, GASTROENTEROLOGY, V68, P728; SILVERSTEIN FE, 1991, ATLAS GASTROINTESTIN; SLOAN S, 1991, GASTROENTEROLOGY, V100, P596, DOI 10.1016/0016-5085(91)80003-R; SOLVELL L, 1990, DIGESTION, V47, P59, DOI 10.1159/000200519; SPECHLER SJ, 1992, NEW ENGL J MED, V326, P786, DOI 10.1056/NEJM199203193261202; TOUSSAINT J, 1991, GUT, V32, P1280, DOI 10.1136/gut.32.11.1280; TYTGAT GNJ, 1990, GASTROENTEROLOGY, V99, P629, DOI 10.1016/0016-5085(90)90947-Y; TYTGAT GNJ, 1990, SCAND J GASTROENTERO, V25, P1, DOI 10.3109/00365529009093121; WIENER GJ, 1989, AM J GASTROENTEROL, V84, P1503; WILSON JA, 1989, ANN OTO RHINOL LARYN, V98, P405	41	90	93	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					656	660		10.1056/NEJM199409083311007	http://dx.doi.org/10.1056/NEJM199409083311007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052276				2022-12-28	WOS:A1994PE38200007
J	KAMINER, RK				KAMINER, RK			CHILDREN WITH DISABILITIES - MY PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Freud S, INTERPRETATION DREAM	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					652	652						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PE327	8064976				2022-12-28	WOS:A1994PE32700002
J	BLOT, WJ; LI, JY; TAYLOR, PR; LI, B				BLOT, WJ; LI, JY; TAYLOR, PR; LI, B			LUNG-CANCER AND VITAMIN SUPPLEMENTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									CHINESE ACAD MED SCI,BEIJING 100021,PEOPLES R CHINA	Chinese Academy of Medical Sciences - Peking Union Medical College	BLOT, WJ (corresponding author), NCI,BETHESDA,MD 20892, USA.							BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Li B, 1993, Ann Epidemiol, V3, P577, DOI 10.1016/1047-2797(93)90078-I; 1994, NEW ENGL J MED, V330, P1029	3	32	33	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					614	614		10.1056/NEJM199409013310913	http://dx.doi.org/10.1056/NEJM199409013310913			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047094				2022-12-28	WOS:A1994PD69900020
J	AKIYAMA, KY; YOKOTA, KY; KAGAWA, S; SHIMBARA, N; TAMURA, T; AKIOKA, H; NOTHWANG, HG; NODA, C; TANAKA, K; ICHIHARA, A				AKIYAMA, KY; YOKOTA, KY; KAGAWA, S; SHIMBARA, N; TAMURA, T; AKIOKA, H; NOTHWANG, HG; NODA, C; TANAKA, K; ICHIHARA, A			CDNA CLONING AND INTERFERON-GAMMA DOWN-REGULATION OF PROTEASOMAL SUBUNIT-X AND SUBUNIT-Y	SCIENCE			English	Article							LINKED LMP GENE; CLASS-II REGION; ANTIGEN PRESENTATION; YEAST PROTEASOME; HUMAN MHC; PROTEINASE; PROTEOLYSIS; DISTINCT; CODES	Proteasomes are the proteolytic complex responsible for major histocompatibility complex (MHC) class I-restricted antigen presentation. Interferon gamma treatment increases expression of MHC-encoded LMP2 and LMP7 subunits of the proteasome and decreases expression of two proteasome subunits, named X and Y, which alters the proteolytic specificity of proteasomes. Molecular cloning of complementary DNAs encoding X and Y showed that their proteins are proteasomal subunits with high amino acid similarity to LMP7 and LMP2, respectively. Thus, interferon gamma may induce subunit replacements of X and Y by LMP7 and LMP2, respectively, producing proteasomes perhaps more appropriate for the immunological processing of endogenous antigens.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT UROL,TOKUSHIMA 770,JAPAN; SUMITOMO ELECT IND LTD,DEPT BIOMED RES & DEV,SAKAE KU,YOKOHAMA 244,JAPAN	Tokushima University; Tokushima University; Sumitomo Electric Industries			Nothwang, Hans G/C-5847-2011; Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556; Nothwang, Hans Gerd/0000-0001-7695-6437				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; BEY F, 1993, MOL GEN GENET, V237, P193, DOI 10.1007/BF00282801; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BROWN MG, 1993, J IMMUNOL, V151, P1193; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1993, NATURE, V365, P267; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; HUANG J, COMMUNICATION; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LARSEN F, 1993, HUM MOL GENET, V2, P1559; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NISHIMURA C, 1993, FEBS LETT, V336, P462, DOI 10.1016/0014-5793(93)80856-P; NOTHWANG HG, IN PRESS BIOCH BIOPH; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1992, NEW BIOL, V4, P173; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4978; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	30	185	192	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1231	1234		10.1126/science.8066462	http://dx.doi.org/10.1126/science.8066462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066462				2022-12-28	WOS:A1994PD42200037
J	SADEGHNASSERI, S; STERN, LJ; WILEY, DC; GERMAIN, RN				SADEGHNASSERI, S; STERN, LJ; WILEY, DC; GERMAIN, RN			MHC CLASS-II FUNCTION PRESERVED BY LOW-AFFINITY PEPTIDE INTERACTIONS PRECEDING STABLE BINDING	NATURE			English	Article							ANTIGENIC PEPTIDE; INVARIANT-CHAIN; HISTOCOMPATIBILITY MOLECULES; MICE LACKING; HLA-DR; EXPRESSION; COMPLEXES; HLA-DR1	MAJOR histocompatibility complex class II molecules and their peptide ligands show unusual interaction kinetics, with slow association and dissociation rates that yield an apparent equilibrium constant of similar to 10(-6)-10(-8) M (refs 1-5). However, there is evidence for a specific, rapidly formed, short-lived complex(6). The altered migration on SDS-polyacrylamide gel electrophoresis of class II molecules upon stable peptide binding(7-9) has led to the hypothesis that the two kinetically distinguishable types of class II-peptide complexes correspond to different structures. In accord with this model, we demonstrate here that insert cell-derived HLA-DR1 class II molecules show fast, almost stoichiometric occupancy with rapidly dissociating peptide while remaining sensitive to SDS-induced chain dissociation. The same DR1 molecules slowly and quantitatively form long-lived complexes resistant to SDS-induced denaturation. Surprisingly, low-affinity interaction with peptide protects class II from denaturation at physiological temperature, a finding that has implications for understanding the role of invariant chain in the intracellular behaviour of class II molecules.	NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard University; Howard Hughes Medical Institute			Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019	Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; FAIRCHILD PJ, 1993, INT IMMUNOL, V5, P1151, DOI 10.1093/intimm/5.9.1151; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROMAGNOLI P, IN PRESS J EXP MED; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; Sadegh-Nasseri S, 1994, ANTIGEN PROCESSING P, P170; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	22	130	130	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					647	650		10.1038/370647a0	http://dx.doi.org/10.1038/370647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065450				2022-12-28	WOS:A1994PD31000049
J	BITHELL, JF; DUTTON, SJ; DRAPER, GJ; NEARY, NM				BITHELL, JF; DUTTON, SJ; DRAPER, GJ; NEARY, NM			DISTRIBUTION OF CHILDHOOD LEUKEMIAS AND NON-HODGKINS-LYMPHOMAS NEAR NUCLEAR INSTALLATIONS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							WEST-BERKSHIRE; POWER STATION; YOUNG-PEOPLE; LEUKEMIA; CANCER; VICINITY; MORTALITY; CHILDREN; CUMBRIA; SITES	Objective-To examine the relation between the risk of childhood leukaemia and non-Hodgkin's lymphoma and proximity of residence to nuclear installations in England and Wales. Design-Observed and expected numbers of cases were calculated and analysed by standard methods based on ratios of observed to expected counts and by a new statistical test, the linear risk score test, based on ranks and designed to be sensitive to excess incidence in close proximity to a putative source of risk. Setting-Electoral wards within 25 km of 23 nuclear installations and six control sites that had been investigated for suitability for generating stations but never used. Subjects-Children below age 15 in England and Wales, 1966-87. Main outcome measure-Registration of any leukaemia or non-Hodgkin's lymphoma. Results-In none of the 25 km circles around the installations was the incidence ratio significantly greater than 1.0. The only significant results for the linear risk score test were for Sellafield (P=0.00002) and Burghfield (P=0.031). The circles for Aldermaston and Burghfield overlap; the incidence ratio was 1.10 in each. One of the control sites gave a significant linear risk score test result (P=0.020). All the tests carried but were one sided with P values estimated by simulation. Conclusion-There is no evidence of a general increase of childhood leukaemia or non-Hodgkin's lymphoma around nuclear installations. Apart from Sellafield, the evidence for distance related risk is very weak.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	BITHELL, JF (corresponding author), UNIV OXFORD,DEPT STAT,OXFORD OX1 3TG,ENGLAND.							ALEXANDER FE, 1989, BRIT MED J, V299, P565; BARCLAY R, 1987, COMMUNITY MED, V9, P279; BARON JA, 1984, BRIT J CANCER, V50, P815, DOI 10.1038/bjc.1984.261; BITHELL JF, 1989, J EPIDEMIOL COMMUN H, V43, P79, DOI 10.1136/jech.43.1.79; BLACK D, 1984, INVESTIGATION POSSIB; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI P, 1987, STUDIES MED POPULATI, V51; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; DOBSON AJ, 1990, INTRO STATISTICAL MO; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; EWINGS PD, 1989, BRIT MED J, V299, P289, DOI 10.1136/bmj.299.6694.289; EWINGS PD, 1988, LEUKAEMIA INCIDENCE; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; STONE RA, 1988, STAT MED, V7, P649, DOI 10.1002/sim.4780070604; TAYLOR RH, 1989, BRIT MED J, V299, P565, DOI 10.1136/bmj.299.6698.565-a; Townsend PP., 1988, HLTH DEPRIVATION INE; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1989, 3RD REPORT INCIDENCE; 1988, 2ND REPORT INVESTIGA; [No title captured]	26	77	77	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					501	505		10.1136/bmj.309.6953.501	http://dx.doi.org/10.1136/bmj.309.6953.501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086902	Green Published			2022-12-28	WOS:A1994PD30800014
J	LAWRENCE, M; GRIEW, K; DERRY, J; ANDERSON, J; HUMPHREYS, J				LAWRENCE, M; GRIEW, K; DERRY, J; ANDERSON, J; HUMPHREYS, J			AUDITING AUDITS - USE AND DEVELOPMENT OF THE OXFORDSHIRE-MEDICAL-AUDIT-ADVISORY-GROUP RATING SYSTEM	BRITISH MEDICAL JOURNAL			English	Article							TRAINING PRACTICES; APPROVAL; TRAINERS; REGION; HEALTH	Objectives-To assess the value of the Oxfordshire Medical Audit Advisory Group rating system in monitoring and stimulating audit activity, and to implement a development of the system. Design-Use of the rating system for assessment of practice audits on three annual visits in Oxfordshire; development and use of an ''audit grid'' as a refinement of the system; questionnaire to all medical audit advisory groups in England and Wales. Setting-All 85 general practices in Oxfordshire; all 95 medical audit advisory groups in England and Wales. Main outcome measures-Level of practices' audit activity as measured by rating scale and grid. Use of scale nationally together with perceptions of strengths and weaknesses as perceived by chairs of medical audit advisory groups. Results-After one year Oxfordshire practices more than attained the target standards set in 1991, with 72% doing audit involving setting target Planning standards or implementing change; by 1993 this had No audit risen to 78%. Most audits were confined to chronic disease management, preventive care, and appointments. 38 of 92 medical audit advisory groups used the Oxfordshire group's rating scale. Its main weaknesses were insensitivity in assessing the quality of audits and failure to measure team involvement. Conclusions-The rating system is effective educationally in helping practices improve and summatively for providing feedback to family health service authorities. The grid showed up weakness in the breadth of audit topics studied. Implications and action-Oxfordshire practices achieved targets set for 1991-2 but need to broaden the scope of their audits and the topics studied. The advisory group's targets for 1994-5 are for 50% of practices to achieve an audit in each of the areas of clinical care, access, communication, and professional values and for 80% of audits to include setting targets or implementing change.			LAWRENCE, M (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORDSHIRE MED AUDIT ADVISORY GRP,OXFORD OX2 6HE,ENGLAND.							BAKER R, 1994, J ROY SOC MED, V87, P228; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; DEMING WE, 1986, CRISIS; DERRY J, 1991, BRIT MED J, V303, P1247, DOI 10.1136/bmj.303.6812.1247; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; Lawrence M, 1993, MED AUDIT PRIMARY HL; MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470; SCHOFIELD TPC, 1984, BRIT MED J, V288, P538, DOI 10.1136/bmj.288.6416.538; SCHOFIELD TPC, 1984, BRIT MED J, V288, P612, DOI 10.1136/bmj.288.6417.612; SCHOFIELD TPC, 1984, BRIT MED J, V288, P688, DOI 10.1136/bmj.288.6418.688; 1990, RCGP50 ROYAL COLL GE; 1985, 23 REP GEN PRACT; 1983, JR COLL GEN PRACT, V33, P521; 1989, MED AUDIT 1ST REPORT; 1990, MED AUDIT FAMILY PRA	17	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					513	516		10.1136/bmj.309.6953.513	http://dx.doi.org/10.1136/bmj.309.6953.513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086911	Green Published			2022-12-28	WOS:A1994PD30800025
J	BLANCHARD, DG; KIMURA, BJ; DITTRICH, HC; DEMARIA, AN				BLANCHARD, DG; KIMURA, BJ; DITTRICH, HC; DEMARIA, AN			TRANSESOPHAGEAL ECHOCARDIOGRAPHY OF THE AORTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; PENETRATING ATHEROSCLEROTIC ULCERS; CODED DOPPLER ECHOCARDIOGRAPHY; DESCENDING THORACIC AORTA; EHLERS-DANLOS SYNDROME; COMPUTED-TOMOGRAPHY; SACCULAR ANEURYSM; MARFAN-SYNDROME; CHEST TRAUMA; FOLLOW-UP	Transesophageal echocardiography (TEE) has become a widely used imaging technique for evaluating cardiac structure, function, and valvular anatomy. Transesophageal echocardiography has also provided a new perspective on the thoracic aorta, and there is growing evidence that the technique contributes valuable and sometimes unique information about aortic structure and pathology. Recently introduced multiplane transesophageal probes have improved visualization of the proximal and transverse aorta, but few comprehensive discussions of TEE's application in aortic disease exist. Therefore, we have reviewed the published literature and our institutional experience in transesophageal aortic ultrasonography. The available evidence strongly supports the use of TEE in aortic dissection and atherosclerosis and suggests potential utility in additional diseases of the aorta such as aneurysm, ulceration, trauma, and congenital or inherited malformation.	UNIV CALIF SAN DIEGO, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego	BLANCHARD, DG (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, 200 W ARBOR ST, 8411, SAN DIEGO, CA 92103 USA.							ALBOLIRAS ET, 1988, AM J CARDIOL, V61, P166, DOI 10.1016/0002-9149(88)91324-0; AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; APPELBE AF, 1993, J AM COLL CARDIOL, V21, P754, DOI 10.1016/0735-1097(93)90109-E; BALLAL RS, 1991, CIRCULATION, V84, P1903, DOI 10.1161/01.CIR.84.5.1903; Bansal R C, 1993, J Am Soc Echocardiogr, V6, P319; BANSAL RC, 1990, CURR PROB CARDIOLOGY, V15, pU643; BARBANT SD, 1992, AM HEART J, V124, P541, DOI 10.1016/0002-8703(92)90632-6; Blanchard D G, 1992, J Am Soc Echocardiogr, V5, P525; BROOKS SW, 1992, J TRAUMA, V32, P761, DOI 10.1097/00005373-199206000-00015; BYERS PH, 1989, METABOLIC BASIS INHE, P2824; CIGARROA JE, 1993, NEW ENGL J MED, V328, P35, DOI 10.1056/NEJM199301073280107; COOKE JP, 1988, MAYO CLIN PROC, V63, P718, DOI 10.1016/S0025-6196(12)65534-7; Daily P O, 1970, Ann Thorac Surg, V10, P237; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DEBAKEY ME, 1982, SURGERY, V92, P1118; DELROSSI AJ, 1990, SURGERY, V108, P864; DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; DORSA FB, 1992, AM HEART J, V123, P1398, DOI 10.1016/0002-8703(92)91057-8; EAGLE KA, 1989, CURR PROB CARDIOLOGY, V14, P225, DOI 10.1016/S0146-2806(89)80010-6; EAGLE KA, 1992, HEART DISEASE TXB CA, P1533; EDDY AC, 1990, AM J SURG, V159, P500, DOI 10.1016/S0002-9610(05)81255-3; ENIA F, 1989, CHEST, V95, P124, DOI 10.1378/chest.95.1.124; ERBEL R, 1989, LANCET, V1, P457; ERBEL R, 1993, CIRCULATION, V87, P1604, DOI 10.1161/01.CIR.87.5.1604; ERBEL R, 1987, THORAC CARDIOV SURG, V35, P126, DOI 10.1055/s-2007-1020273; FAZIO GP, 1993, J AM COLL CARDIOL, V21, P144, DOI 10.1016/0735-1097(93)90729-K; FINE MJ, 1987, ANGIOLOGY, V38, P769, DOI 10.1177/000331978703801007; FYFE DA, 1991, ECHOCARDIOGR-J CARD, V8, P573, DOI 10.1111/j.1540-8175.1991.tb01019.x; GALVIN IF, 1991, ANN THORAC SURG, V51, P310, DOI 10.1016/0003-4975(91)90811-4; GOARIN JP, 1993, CHEST, V103, P618, DOI 10.1378/chest.103.2.618; GRANATO JE, 1985, AM J CARDIOL, V56, P123, DOI 10.1016/0002-9149(85)90579-X; GREENDYKE RM, 1966, J AMER MED ASSOC, V195, P527, DOI 10.1001/jama.195.7.527; HELLENBRAND WE, 1990, AM J CARDIOL, V66, P207, DOI 10.1016/0002-9149(90)90590-W; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; HOFMANN T, 1990, LANCET, V336, P1421; HUNTER GC, 1982, ARCH SURG-CHICAGO, V117, P495; HUSSAIN S, 1989, J VASC SURG, V9, P710, DOI 10.1067/mva.1989.vs0090710; KAMP O, 1991, INT J CARDIOL, V33, P330, DOI 10.1016/0167-5273(91)90367-X; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; KAZEROONI EA, 1992, RADIOLOGY, V183, P759, DOI 10.1148/radiology.183.3.1584933; KEARNEY PA, 1993, J TRAUMA, V34, P696, DOI 10.1097/00005373-199305000-00012; KRAM HB, 1987, J VASC SURG, V6, P168, DOI 10.1067/mva.1987.avs0060168; Kronzon I, 1990, J Am Soc Echocardiogr, V3, P145; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MARSH DG, 1976, ANN THORAC SURG, V21, P337, DOI 10.1016/S0003-4975(10)64323-8; MATSUMOTO M, 1980, AM J CARDIOL, V46, P95, DOI 10.1016/0002-9149(80)90611-6; MCKENNEY PA, 1992, AM HEART J, V123, P228, DOI 10.1016/0002-8703(92)90774-P; MITCHELL MM, 1992, CLIN TRANSESOPHAGEAL, P97; MOHRKAHALY S, 1989, CIRCULATION, V80, P24, DOI 10.1161/01.CIR.80.1.24; MOHRKAHALY S, 1994, J AM COLL CARDIOL, V23, P658, DOI 10.1016/0735-1097(94)90751-X; MUGGE A, 1989, AM HEART J, V117, P474, DOI 10.1016/0002-8703(89)90795-3; MUGGE A, 1991, CIRCULATION, V83, P70, DOI 10.1161/01.CIR.83.1.70; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; NISHIMURA RA, 1985, MAYO CLIN PROC, V60, P321, DOI 10.1016/S0025-6196(12)60540-0; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; PYERITZ RE, 1992, HEART DIS TXB CARDIO, P1641; ROSS JJ, 1993, AM J CARDIOL, V71, P1000, DOI 10.1016/0002-9149(93)90924-2; RYAN K, 1992, ECHOCARDIOGR-J CARD, V9, P277, DOI 10.1111/j.1540-8175.1992.tb00470.x; SCHLUTER M, 1982, BRIT HEART J, V48, P67; SHAPIRO MJ, 1991, J TRAUMA, V31, P835, DOI 10.1097/00005373-199106000-00015; SIMONS AJ, 1992, AM HEART J, V123, P224, DOI 10.1016/0002-8703(92)90772-N; SINGH H, 1986, BRIT HEART J, V56, P171; SPARKS MB, 1991, ARCH SURG-CHICAGO, V126, P711; Stanson A W, 1986, Ann Vasc Surg, V1, P15, DOI 10.1016/S0890-5096(06)60697-3; STEINMANN B, 1989, AM J MED GENET, V34, P68, DOI 10.1002/ajmg.1320340113; STURM JT, 1985, ANN THORAC SURG, V39, P418, DOI 10.1016/S0003-4975(10)61947-9; TAAMS MA, 1988, CHEST, V93, P436, DOI 10.1378/chest.93.2.436; TOBLER HG, 1988, J THORAC CARDIOV SUR, V96, P304; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; WAGGONER A D, 1990, Cardiology Clinics, V8, P173; WHITE RD, 1986, AM J CARDIOL, V57, P282, DOI 10.1016/0002-9149(86)90906-9; YUCEL EK, 1990, RADIOLOGY, V177, P779, DOI 10.1148/radiology.177.3.2243989	78	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					546	551		10.1001/jama.272.7.546	http://dx.doi.org/10.1001/jama.272.7.546			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046810				2022-12-28	WOS:A1994PB22900033
J	KING, DE; LAHIRI, K				KING, DE; LAHIRI, K			SOCIOECONOMIC-FACTORS AND THE ODDS OF VAGINAL BIRTH AFTER CESAREAN DELIVERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SECTION RATES; PROGRAM; HEALTH	Objective.-To determine the independent effect of socioeconomic, organizational, and professional liability factors on the odds of vaginal birth after cesarean delivery (VBAC) while controlling for important clinical factors. Design.-A retrospective study of 1989 New York State vital statistics data, supplemented with additional information on county- and hospital-specific variables. Using multiple logistic regression analysis, odds ratios (ORs) and 95% confidence intervals (Cls) were derived for 15 independent variables. Setting.-Births occurring in 104 New York State hospitals. Data Set.-A total of 13944 births occurring to New York State residents with a history of cesarean delivery of which 3068 (22%) were vaginal deliveries. Results.-The odds of VBAC increased with maternal education. The ORs were 1.15 (95% Cl, 0.99 to 1.34) for 12 years of education; 1.36 (95% Cl, 1.16 to 1.60) for 13 to 15 years; 1.59 (95% Cl, 1.32 to 1.93) for 16 years, and 2.00 (95% Cl, 1.64 to 2.45) for 17 years or more. The ORs also increased with the level of care provided by the hospital; they were 1.55 (95% Cl, 1.34 to 1.81) and 1.30 (95% Cl, 1.18 to 1.44) for hospitals with intensive and intermediate neonatal care facilities, respectively. The ORs were 1.15 (95% Cl, 1.02 to 1.30) for health maintenance organization participants and 0.77 (95% Cl, 0.63 to 0.94) for women giving birth in government hospitals. The ORs of VBAC for African-American and Hispanic mothers were 0.80 (95% Cl, 0.70 to 0.93) and 0.61 (95% Cl, 0.51 to 0.73), respectively. The ORs for a $5000 increase in physician's yearly malpractice premium and the hospital's paid loss due to malpractice claim settlements were 0.98 (95% Cl, 0.97 to 0.99) and 1.01 (95% Cl, 0.99 to 1.03), respectively. Conclusions.-ln addition to clinical factors, a mother's level of education and ethnicity and specific characteristics of the hospital in which she delivers affect the odds of a vaginal delivery after a previous cesarean delivery. From our analysis, we cannot conclude that professional liability factors affected VBAC rates.	SUNY ALBANY, DEPT ECON, ALBANY, NY 12222 USA; SUNY ALBANY, DEPT BIOMETRY & STAT, ALBANY, NY 12222 USA; SUNY ALBANY, DEPT HLTH POLICY & MANAGEMENT, ALBANY, NY 12222 USA; US SOCIAL SECUR ADM, WASHINGTON, DC USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany								ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; [Anonymous], 1981, Obstet Gynecol, V57, P537; BAPTISTI LR, 1987, VAGINAL BIRTH CESARE; BERGER MC, 1989, J HUM RESOUR, V24, P433, DOI 10.2307/145822; DILLON WP, 1992, OBSTET GYNECOL, V80, P731; DOMINICKPIERRE K, 1991, SOC SCI MED, V83, P1104; FLAMM BL, 1990, BIRTH CESAREAN MED F; Fuchs V.R., 1982, EC ASPECTS HLTH, P93; GLEICHER N, 1984, JAMA-J AM MED ASSOC, V252, P3273; GOLDMAN G, 1993, AM J PUBLIC HEALTH, V83, P1104, DOI 10.2105/AJPH.83.8.1104; GOLDMAN G, 1990, CAN MED ASSOC J, V143, P1017; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; HACK M, 1989, NEW ENGL J MED, V321, P1642, DOI 10.1056/NEJM198912143212405; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KENKEL DS, 1991, J POLIT ECON, V99, P287, DOI 10.1086/261751; KIRK EP, 1990, AM J OBSTET GYNECOL, V162, P1398, DOI 10.1016/0002-9378(90)90898-H; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; LEWIT M, 1992, 4221 NAT BUR EC RES; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARIESKIND HI, 1989, BIRTH-ISS PERINAT C, V16, P196, DOI 10.1111/j.1523-536X.1989.tb00898.x; MARTIN JN, 1988, OBSTET GYN CLIN N AM, V15, P719; MCCLAIN CS, 1990, SOC SCI MED, V31, P203, DOI 10.1016/0277-9536(90)90062-W; MYERS SA, 1990, NEW ENGL J MED, V323, P200; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; PARRISH KM, 1994, JAMA-J AM MED ASSOC, V271, P443, DOI 10.1001/jama.271.6.443; PORRECO RP, 1985, OBSTET GYNECOL, V65, P307; Rosen Mortimer, 1989, CESAREAN MYTH; SANCHEZRAMOS L, 1990, AM J OBSTET GYNECOL, V163, P1081, DOI 10.1016/0002-9378(90)91132-V; SILVER L, 1989, UNNECESSARY CESAREAN; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; TAFFEL SM, 1991, BIRTH-ISS PERINAT C, V18, P73, DOI 10.1111/j.1523-536X.1991.tb00063.x; TAFFEL SM, 1992, BIRTH-ISS PERINAT C, V19, P21, DOI 10.1111/j.1523-536X.1992.tb00367.x; VANTUINEN I, 1992, UNNECESSARY CESAREAN; ZDEB MS, 1989, BIRTH-ISS PERINAT C, V16, P203, DOI 10.1111/j.1523-536X.1989.tb00899.x; 1993, BIRTH-ISS PERINAT C, V20, P164; 1992, COST MATERNITY CARE; 1988, COMMMITTEE OPINION 6; 1990, SAS STAT USERS GUIDE; 1990, HLTH PEOPLE 2000 NAT; 1990, APPROPRIATENESS REV; 1987, CESAREAN CHILDBIRTH	44	46	46	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					524	529		10.1001/jama.272.7.524	http://dx.doi.org/10.1001/jama.272.7.524			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046806				2022-12-28	WOS:A1994PB22900029
J	HAJNOCZKY, G; THOMAS, AP				HAJNOCZKY, G; THOMAS, AP			THE INOSITOL TRISPHOSPHATE CALCIUM-CHANNEL IS INACTIVATED BY INOSITOL TRISPHOSPHATE	NATURE			English	Article							PERMEABILIZED HEPATOCYTES; CA2+ MOBILIZATION; RELEASE; 1,4,5-TRISPHOSPHATE; STORES; CELLS	ACTIVATION Of intracellular Ca2+ channels by inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) represents the initial Ca2+ mobilization step in response to many extracellular signals(1). Here we report that Ins(1,4,5)P-3-induced channel activation in permeabilized hepatocytes is followed by a time-dependent inactivation, which is a direct consequence of ligand binding. The inactivation by Ins(1,4,5)P-3 parallels the quantal character of channel opening, giving rise to a unique process of incremental inactivation whereby discrete channel populations are inhibited at each Ins(1,4,5)P-3 dose. Ins(1,4,5)P-3 can induce inactivation in the absence of stored Ca2+, but the inactivation rate is enhanced by increases of cytosolic Ca2+. The inhibitory effect of Ins(1,4,5)P-3 can be reversed by Ins(1,4,5)P-3 washout, or by chelation of cytosolic Ca2+. Thus, Ins(1,4,5)P-3 and Ca2+ act as coinhibitors of the Ins(1,4,5)P-3-sensitive Ca2+ channel. Inactivation is an inherent consequence of Ins(1,4,5)P-3-induced channel opening which can terminate increases of cytosolic Ca2+.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601	16	156	157	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					474	477		10.1038/370474a0	http://dx.doi.org/10.1038/370474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047168				2022-12-28	WOS:A1994PB40700060
J	BAIN, J				BAIN, J			THE NEW NHS - THE 3RD YEAR - FUNDHOLDING - A 2-TIER SYSTEM	BRITISH MEDICAL JOURNAL			English	Article								The Calverton practice is one of 30 fundholding practices in Nottinghamshire. Three years after the inception of fundholding, it has achieved a lower outpatient waiting time for its specialist clinics than non-fundholding practices in the region. Its district nursing and health visiting services have been strengthened. Prescribing costs remain below the national average, and making further cost reductions has not been easy. The business plan has allowed the practice to work within a defined budget and develop expertise in the purchasing of services. Through the provision of specialist clinics and increased patient demand the workload of general practitioners has risen by 15% in the past year. But fundholding is still a minority activity in Nottinghamshire-a non-fundholders' group has been set up to ensure that purchasing of good quality secondary care is equitably distributed among all patients, and this group is extremely active.			BAIN, J (corresponding author), WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.								0	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					396	399		10.1136/bmj.309.6951.396	http://dx.doi.org/10.1136/bmj.309.6951.396			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081147	Green Published			2022-12-28	WOS:A1994PB31600031
J	DING, HF; RIMSKY, S; BATSON, SC; BUSTIN, M; HANSEN, U				DING, HF; RIMSKY, S; BATSON, SC; BUSTIN, M; HANSEN, U			STIMULATION OF RNA-POLYMERASE-II ELONGATION BY CHROMOSOMAL PROTEIN HMG-14	SCIENCE			English	Article							ASSEMBLED CHROMATIN TEMPLATES; MOBILITY GROUP PROTEIN-14; ACCURATE TRANSCRIPTION; NUCLEOSOMES; GENES; DNA; EXPRESSION; SEQUENCE; INVITRO; CELLS	The high-mobility group protein 14 (HMG-14) is a non-histone chromosomal protein that is preferentially associated with transcriptionally active chromatin. To assess the effect of HMG-14 on transcription by RNA polymerase II, in vivo-assembled chromatin with elevated amounts of HMG-14 was obtained. Here it is shown that HMG-14 enhanced transcription on chromatin templates but not on DNA templates. This protein stimulated the rate of elongation by RNA polymerase II but not the level of initiation of transcription. These findings suggest that the association of HMG-14 with nucleosomes is part of the cellular process involved in the generation of transcriptionally active chromatin.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bustin, Michael/G-6155-2015	Hansen, Ulla/0000-0001-9803-4185; Rimsky, Sylvie/0000-0003-2654-3014; Ding, Han-Fei/0000-0001-5702-3439; Bustin, Michael/0000-0002-5147-7242	NIGMS NIH HHS [GM-36667] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; AUSUBEL FM, 1989, CURRENT PROTOCOLSIN; BATSON SC, 1993, NUCLEIC ACIDS RES, V21, P3459; BATSON SC, 1992, MOL CELL BIOL, V12, P1639, DOI 10.1128/MCB.12.4.1639; BUSTIN M, 1991, NUCLEIC ACIDS RES, V19, P3115, DOI 10.1093/nar/19.11.3115; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; Ding H, UNPUB; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; GIRI C, 1987, J BIOL CHEM, V262, P9839; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Johns EW, 1982, HMG CHROMOSOMAL PROT; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; NICOLAS RH, 1983, NUCLEIC ACIDS RES, V11, P753, DOI 10.1093/nar/11.3.753; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PASH JM, 1993, J BIOL CHEM, V268, P13632; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; STEIN A, 1983, NUCLEIC ACIDS RES, V11, P6803, DOI 10.1093/nar/11.19.6803; SWERDLOW PS, 1983, NUCLEIC ACIDS RES, V11, P387, DOI 10.1093/nar/11.2.387; TOMASETTO C, 1993, J CELL BIOL, V122, P157, DOI 10.1083/jcb.122.1.157; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WEISBROD S, 1979, P NATL ACAD SCI USA, V76, P630, DOI 10.1073/pnas.76.2.630	33	77	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					796	799		10.1126/science.8047885	http://dx.doi.org/10.1126/science.8047885			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047885				2022-12-28	WOS:A1994PA37200037
J	FRIEDMAN, RC; DOWNEY, JI				FRIEDMAN, RC; DOWNEY, JI			HOMOSEXUALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MALE SEXUAL ORIENTATION; CROSS-GENDER BEHAVIOR; GAY MEN; UNITED-STATES; CEREBRAL LATERALIZATION; BIOLOGICAL MECHANISMS; LESBIAN MOTHERS; PRENATAL STRESS; MATERNAL STRESS; RISK BEHAVIOR		COLUMBIA UNIV, COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY USA; NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY USA; ADELPHI UNIV, DEPT PSYCHOL, NEW YORK, NY USA	Columbia University; New York State Psychiatry Institute; Adelphi University								ACOSTA FX, 1975, ARCH SEX BEHAV, V4, P9, DOI 10.1007/BF01541883; ALLEN LS, 1992, P NATL ACAD SCI USA, V89, P7199, DOI 10.1073/pnas.89.15.7199; Allport G.W., 1954, NATURE PREJUDICE; [Anonymous], 1990, HARVARD LAW REV; [Anonymous], 1984, MALE COUPLE RELATION; BAILEY JM, 1993, ARCH GEN PSYCHIAT, V50, P217; BAILEY JM, 1991, ARCH GEN PSYCHIAT, V48, P1089; BAILEY JM, 1991, ARCH SEX BEHAV, V20, P277, DOI 10.1007/BF01541847; BAILEY JM, IN PRESS DEV PSYCHOL; Bayer R., 1981, HOMOSEXUALITY AM PSY; BEACH RK, 1993, PEDIATRICS, V92, P631; Bell Alan P., 1981, SEXUAL PREFERENCE IT; Bell AP, 1978, HOMOSEXUALITIES STUD; Bieber, 1962, HOMOSEXUALITY PSYCHO; BILLY JOG, 1993, FAM PLANN PERSPECT, V25, P52, DOI 10.2307/2136206; BLANCHARD R, 1994, AM J PSYCHIAT, V151, P1375; Blumstein Philip, 1983, AM COUPLES; Bozett F., 1987, GAY LESBIAN PARENTS, P39; BUHRICH N, 1991, BEHAV GENET, V21, P75, DOI 10.1007/BF01067668; BYNE W, 1993, ARCH GEN PSYCHIAT, V50, P228; CHU SY, 1990, AM J PUBLIC HEALTH, V80, P1380, DOI 10.2105/AJPH.80.11.1380; Coates S., 1992, INTERFACE PSYCHOANAL, P245, DOI [DOI 10.1037/10118-010, 10.1037/10118-010]; DIAMOND M, 1993, ARCH SEX BEHAV, V22, P291, DOI 10.1007/BF01542119; DOUGLAS CJ, 1985, HOSP COMMUNITY PSYCH, V36, P1309; ECKERT ED, 1986, BRIT J PSYCHIAT, V148, P421, DOI 10.1192/bjp.148.4.421; Edwards A, 1990, Int J STD AIDS, V1, P178; ELLIS L, 1988, J SEX RES, V25, P152, DOI 10.1080/00224498809551449; ERIKSON EH, 1959, IDENTITY LIFE CYCLE, V1, P101; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; FREUND K, 1974, ARCH GEN PSYCHIAT, V31, P495; FRIEDMAN RC, 1993, J AM PSYCHOANAL ASS, V41, P1159, DOI 10.1177/000306519304100410; FRIEDMAN RC, 1993, J NEUROPSYCH CLIN N, V5, P131; Friedman RC, 1988, MALE HOMOSEXUALITY C; GARNETS L, 1991, AM PSYCHOL, V46, P964, DOI 10.1037/0003-066X.46.9.964; GARTRELL N, 1974, J NERV MENT DIS, V159, P141, DOI 10.1097/00005053-197408000-00009; GEBHARD PH, 1972, INCIDENCE OVERT HOMO, P22; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P521, DOI 10.1001/archneur.1985.04060060019009; Golden C., 1987, LESBIAN PSYCHOL EXPL, P19; GOLOMBOK S, 1983, J CHILD PSYCHOL PSYC, V24, P551, DOI 10.1111/j.1469-7610.1983.tb00132.x; Gonsiorek J.C., 1991, HOMOSEXUALITY RES IM, P115; Gonsiorek John C., 1991, HOMOSEXUALITY RES IM; Gooren L., 1990, ANN REV SEX RES, V1, P175; GORSKI RA, 1991, BRAIN ENDOCRINOLOGY, P71; GOTTMAN JS, 1990, HOMOSEXUALITY FAMILY, P177, DOI DOI 10.1300/J002v14n03_09; Green G. D., 1991, HOMOSEXUALITY RES IM, P197; GREEN R, 1985, AM J PSYCHIAT, V142, P339; GREEN R, 1986, ARCH SEX BEHAV, V15, P167, DOI 10.1007/BF01542224; Green R, 1987, SISSY BOY SYNDROME D; Greenberg DavidF., 1988, CONSTRUCTION HOMOSEX; GROTH AN, 1978, ARCH SEX BEHAV, V7, P175, DOI 10.1007/BF01542377; Haldeman D.C., 1991, HOMOSEXUALITY RES IM, P149; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANDSFIELD HH, 1990, SEX TRANSM DIS, V17, P211, DOI 10.1097/00007435-199010000-00011; HANLEYHACKENBRU.P, 1993, REV PSYCHIATRY, V12, P59; HART G, 1993, INT J STD AIDS, V4, P102, DOI 10.1177/095646249300400209; HENDIN H, 1992, AM J PSYCHIAT, V149, P1416; HENEK GM, 1991, HOMOSEXUALITY RES IM, P60; HERDT G, 1990, HDB SEXOLOGY, V7; Herdt G., 1989, GAY LESBIAN YOUTH; HEREK GM, 1984, J HOMOSEXUAL, V10, P1, DOI 10.1300/J082v10n01_01; HEREK GM, 1990, J INTERPERSONAL VIOL, V5; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HOOKER E, 1957, J PROJ TECH PERS ASS, V21, P18, DOI 10.1080/08853126.1957.10380742; Isay R.A., 1989, BEING HOMOSEXUAL GAY; Kallmann Franz J., 1953, HEREDITY HLTH MENTAL; KANOUSE D, 1991, AIDS RELATED KNOWLED; KANOUSE DE, 1991, RESPONSE AIDS EPIDEM; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P1335, DOI 10.2105/AJPH.81.10.1335; KELLY JA, 1987, J MED EDUC, V62, P549; KELLY JA, 1992, ARCH INTERN MED, V152, P2293, DOI 10.1001/archinte.152.11.2293; KING M, 1992, BRIT J PSYCHIAT, V160, P407, DOI 10.1192/bjp.160.3.407; King M. B., 1993, AIDS HIV MENTAL HLTH; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA; KINSEY AC, 1953, SEXUAL BEHAVIOR HUMA; KIRKPATRICK M, 1981, AM J ORTHOPSYCHIAT, V51, P545, DOI 10.1111/j.1939-0025.1981.tb01403.x; LEVAY S, 1991, SCIENCE, V253, P1034, DOI 10.1126/science.1887219; LEWIS CE, 1982, J CLIN PSYCHIAT, V43, P277; LINN LS, 1989, ARCH INTERN MED, V149, P2685, DOI 10.1001/archinte.149.12.2685; LISS JL, 1973, AM J PSYCHOTHER, V27, P102, DOI 10.1176/appi.psychotherapy.1973.27.1.102; LOHRENZ LJ, 1978, J STUD ALCOHOL, V39, P1959, DOI 10.15288/jsa.1978.39.1959; LOULAN J, 1988, Women and Therapy, V7, P221, DOI 10.1300/J015v07n02_18; MALYON A, 1982, J HOMOSEXUAL, V17, P59; MARTIN JL, 1988, J CONSULT CLIN PSYCH, V56, P856, DOI 10.1037/0022-006X.56.6.856; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MCCORMICK CM, 1990, PSYCHONEUROENDOCRINO, V15, P69, DOI 10.1016/0306-4530(90)90048-E; MCCORMICK CM, 1991, PSYCHONEUROENDOCRINO, V16, P459, DOI 10.1016/0306-4530(91)90030-W; Meyer-Bahlburg H. F. L., 1993, CHILD ADOLESCENT PSY, V2, P489; MEYERBAHLBURG HFL, 1993, CHILD ADOLESC PSYCHI, V2, P501; MILLER B, 1979, FAM COORD, V28, P544, DOI 10.2307/583517; MONEY J, 1984, PSYCHONEUROENDOCRINO, V9, P405, DOI 10.1016/0306-4530(84)90048-9; MONEY J, 1988, GAY STRAIGHT IN BETW; Money J., 1972, MAN WOMAN BOY GIRL; NICHOLS M, 1990, KINSEY INST, V2, P350; Nicolosi J., 1991, REPARATIVE THERAPY M; PATTERSON CJ, 1992, CHILD DEV, V63, P1025, DOI 10.1111/j.1467-8624.1992.tb01679.x; PATTISON EM, 1980, AM J PSYCHIAT, V137, P1553; PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369, DOI 10.1210/endo-65-3-369; PILLARD RC, 1986, ARCH GEN PSYCHIAT, V43, P808; PILLARD RC, 1988, PSYCHIAT ANN, V18, P52, DOI 10.3928/0048-5713-19880101-15; PILLARD RC, 1982, ARCH SEX BEHAV, V11, P511, DOI 10.1007/BF01542476; PRENZLAUER S, 1992, AM J PSYCHIAT, V149, P1416; Randall C E, 1989, J Nurs Educ, V28, P302; REMAFEDI G, 1991, PEDIATRICS, V87, P869; RICH CL, 1986, SUICIDE LIFE-THREAT, V16, P448; Robins E., 1981, FINAL MONTHS; ROSENSTEIN LD, 1987, PSYCHOL REP, V60, P704, DOI 10.2466/pr0.1987.60.3.704; Ross MW, 1983, MARRIED HOMOSEXUAL M; ROTHERAMBORUS MJ, 1994, J SEX RES, V31, P47, DOI 10.1080/00224499409551729; ROYSE D, 1987, PSYCHOL REP, V61, P867, DOI 10.2466/pr0.1987.61.3.867; Saghir Marcel, 1973, MALE FEMALE HOMOSEXU; SANDERS G, 1987, INT J NEUROSCI, V36, P1, DOI 10.3109/00207458709002134; SCHEIER R, 1989, AM MED NEWS     0113, P29; SEIDMAN SN, 1994, AM J PSYCHIAT, V151, P330; SHAFFER D, 1993, NEW YORKER      0503, P116; SLATER BR, 1988, PROF PSYCHOL-RES PR, V19, P226, DOI 10.1037/0735-7028.19.2.226; Socarides C.W., 1978, HOMOSEXUALITY; STEIN TS, 1993, REV PSYCHIAT, V12, P9; STEVENSON MR, 1988, J SEX RES, V25, P500, DOI 10.1080/00224498809551478; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; TROIDEN RR, 1979, PSYCHIATRY, V42, P362, DOI 10.1080/00332747.1979.11024039; WALLICK MM, 1992, ACAD MED, V67, P601, DOI 10.1097/00001888-199209000-00013; WARD IL, 1985, BEHAV NEUROSCI, V99, P301, DOI 10.1037/0735-7044.99.2.301; WARD IL, 1972, SCIENCE, V175, P82, DOI 10.1126/science.175.4017.82; Weinberg G., 1972, SOC HLTH HOMOSEXUAL; WHITAM FL, 1993, ARCH SEX BEHAV, V22, P187, DOI 10.1007/BF01541765; WHITAM FL, 1991, ARCH SEX BEHAV, V20, P151, DOI 10.1007/BF01541941; WHITAM FL, 1984, ARCH SEX BEHAV, V13, P427, DOI 10.1007/BF01541428; WILLIAMS JBW, 1991, ARCH GEN PSYCHIAT, V48, P124; WISNIEWSKI JJ, 1987, SOC WORK, V32, P454; Zucker K. J., 1993, CHILD ADOLESCENT PSY, V2, P513; 1994, AIDS MENTAL HLTH 2, V10, P1; 1994, AIDS MENTAL HLTH 1, V10, P1; 1987, BOSTON LESBIAN PSYCH; 1993, HIV AIDS SURVEILLANC; [No title captured]	136	67	67	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					923	930		10.1056/NEJM199410063311407	http://dx.doi.org/10.1056/NEJM199410063311407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078554				2022-12-28	WOS:A1994PJ41900007
J	STEFFEN, R; KANE, MA; SHAPIRO, CN; BILLO, N; SCHOELLHORN, KJ; VANDAMME, P				STEFFEN, R; KANE, MA; SHAPIRO, CN; BILLO, N; SCHOELLHORN, KJ; VANDAMME, P			EPIDEMIOLOGY AND PREVENTION OF HEPATITIS-A IN TRAVELERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							UNITED-STATES; A VACCINE; NON-B; PROGNOSTIC ASPECTS; VIRAL-HEPATITIS; IMMUNIZATION; PREVALENCE; COUNTRIES; RISK	Objective.-To assess the risk of hepatitis A in international travelers and to recommend preventive measures. Data Sources.-Index Medicus, 1974 through 1983; MEDLINE, 1984 through 1993; and unpublished data of the Centers for Disease Control and Prevention. Study Selection.-Review of all retrospective and cohort studies on hepatitis A and other vaccine-preventable diseases in travelers, of seroepidemiologic surveys of hepatitis A virus (HAV) antibodies in travelers, of data on the various hepatitis A vaccines, of economic analyses, and of recommendations of recognized organizations. Data Extraction.-Independent analysis by multiple observers. Data Synthesis.-The incidence rate for unprotected travelers, including those staying in luxury hotels, is estimated to be three per 1000 travelers per month of stay in a developing country. Persons eating and drinking under poor hygienic conditions have a rate of 20/1000 per month. This makes hepatitis A the most frequent infection in travelers that may be prevented by immunization. In many industrialized countries persons born after 1945 have an HAV antibody seroprevalence (immunity) of less than 20%. New inactivated HAV vaccines induce protective antibodies in more than 95% of recipients and offer protection estimated to last for 10 years or more, whereas protection by immune globulin lasts only 3 to 5 months. Conclusions.-Hepatitis A vaccine, or immune globulin where HAV vaccine is not available, is recommended for all nonimmune travelers visiting developing countries. Prescreening for antibodies to HAV in travelers living in countries with low prevalence is usually not necessary in persons born after 1945.	WHO,DIV COMMUNICABLE DIS,MICROBIOL & IMMUNOL SUPPORT SERV,CH-1211 GENEVA,SWITZERLAND; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH,ATLANTA,GA 30341; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE; HAWAII DEPT HLTH,EPIDEMIOL BRANCH,HAWAII IMMUNIZAT PROGRAM,HONOLULU,HI; UNIV ANTWERP,DEPT EPIDEMIOL,B-2020 ANTWERP,BELGIUM	World Health Organization; Centers for Disease Control & Prevention - USA; University of Antwerp	STEFFEN, R (corresponding author), UNIV ZURICH,INST SOCIAL & PREVENT MED,DIV EPIDEMIOL & PRIVENT COMMUNICABLE DIS,SUMATRASTR 30,CH-8006 ZURICH,SWITZERLAND.		van damme, pierre/I-4846-2013	Billo, Nils Eric/0000-0002-5735-5107				AMBROSCH F, 1991, VIRAL HEPATITIS LIVE, P89; ANDRE FE, 1992, VACCINE S1, V10, P160; ANSDELL VE, 1994, IN PRESS J TRAVEL ME; APOTHELOZ M, 1982, SOZ PRAVENTIV MED, V27, P264, DOI 10.1007/BF02079664; ARMIGLIATO M, 1986, INFECTION, V14, P283, DOI 10.1007/BF01643963; BEHRENS RH, 1993, LANCET, V341, P972, DOI 10.1016/0140-6736(93)91274-P; BERNARD KW, 1991, VACCINE, V9, P833, DOI 10.1016/0264-410X(91)90221-Q; BIENZLE U, 1993, LANCET, V341, P1028, DOI 10.1016/0140-6736(93)91118-6; BRIEM H, 1994, 6TH INT CINF DIS PRA; COWAN DN, 1984, MIL MED, V149, P260; FORBES A, 1988, J ROY COLL PHYS LOND, V22, P237; FROSNER GG, 1979, AM J EPIDEMIOL, V110, P63; GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141; GREEN MS, 1993, J INFECT DIS, V168, P740, DOI 10.1093/infdis/168.3.740; HALL SM, 1983, LANCET, V2, P1198; HANDSZUH H, 1992, 2ND P C INT TRAV MED, P8; HAWKINS RE, 1992, J INFECT DIS, V165, P716, DOI 10.1093/infdis/165.4.716; IWARSON S, 1983, DEV BIOL STAND, V54, P419; IWARSON S, 1976, SCAND J INFECT DIS, V8, P143, DOI 10.3109/inf.1976.8.issue-3.03; JUST M, 1992, VACCINE S1, V10, P110; Koch, 1994, J Travel Med, V1, P4, DOI 10.1111/j.1708-8305.1994.tb00548.x; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; KUBLI D, 1987, BRIT MED J, V195, P169; LAROUZE B, 1987, AM J EPIDEMIOL, V126, P31, DOI 10.1093/oxfordjournals.aje.a114658; MORGER H, 1983, BRIT MED J, V286, P184, DOI 10.1136/bmj.286.6360.184; NORDENFELT E, 1992, VACCINE S1, V10, P573; NORKRANS G, 1979, SCAND J INFECT DIS, V11, P259, DOI 10.3109/inf.1979.11.issue-4.01; PEETERMANS J, 1992, VACCINE S1, V10, P99; SCHOELLHORN KJ, 1987, THESIS U HAWAII HONO; SCHOTTENHAML C, 1990, THESIS U ZURICH ZURI; SHAPIRO CN, 1990, 1990 INT S VIR HEP L; SIEGL G, 1990, VIRUS RES, V17, P75, DOI 10.1016/0168-1702(90)90070-R; SKINHOJ P, 1981, SCAND J INFECT DIS, V13, P1; STAPLETON JT, 1992, VACCINE S1, V10, P545; STEFFEN R, 1977, SCHWEIZ MED WSCHR, V107, P1300; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; STEFFEN R, 1992, PARASITOL TODAY, V8, P61, DOI 10.1016/0169-4758(92)90091-F; STEFFEN R, 1990, VACCINE, V8, P31; STUDER S, 1993, EUR J EPIDEMIOL, V9, P50, DOI 10.1007/BF00463089; TAYLOR DN, 1983, J INFECT DIS, V148, P599, DOI 10.1093/infdis/148.3.599; TORMANS G, 1992, VACCINE S1, V10, P88; TORMANS G, 1992, 23 U ANTW EP COMM ME; VANDAMME P, 1992, LANCET, V340, P617, DOI 10.1016/0140-6736(92)92157-B; VANDAMME P, 1994, 6TH INT C INF DIS PR; WEBER JT, 1994, ARCH INTERN MED, V154, P551, DOI 10.1001/archinte.154.5.551; WEILAND O, 1981, SCAND J INFECT DIS, V13, P247, DOI 10.3109/inf.1981.13.issue-4.02; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WIDELL A, 1982, SCAND J INFECT DIS, V14, P253, DOI 10.3109/inf.1982.14.issue-4.02; YAP I, 1992, EPIDEMIOL NEWS B SIN, V18, P4; 1994, INT TRAVEL HLTH; 1994, 55 CTR DIS CONTR PRE, P26; 1992, B BUNDESAMT GES 0309, P122; 1992, EPIDEMIOL NEWS B SIN, V18, P63; 1992, HLTH INFORMATION INT	54	134	138	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					885	889		10.1001/jama.272.11.885	http://dx.doi.org/10.1001/jama.272.11.885			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078167				2022-12-28	WOS:A1994PG18200029
J	IRIE, K; GOTOH, Y; YASHAR, BM; ERREDE, B; NISHIDA, E; MATSUMOTO, K				IRIE, K; GOTOH, Y; YASHAR, BM; ERREDE, B; NISHIDA, E; MATSUMOTO, K			STIMULATORY EFFECTS OF YEAST AND MAMMALIAN 14-3-3-PROTEINS ON THE RAF PROTEIN-KINASE	SCIENCE			English	Article							ACTIVATION; IDENTIFICATION; INHIBITORS; DEFINITION; SEQUENCE; PATHWAY; C-RAF-1; CLONING; REGION; CELLS	Intracellular signaling from receptor tyrosine kinases in mammalian cells results in activation of a signal cascade that includes the guanine nucleotide-binding protein Ras and the protein kinases Raf, MEK [mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase (ERK) kinase], and MAPK. MAPK activation that is dependent on the coupling of Ras and Raf was reconstituted in yeast. Yeast genes were isolated that, when overexpressed, enhanced the function of Raf. One of them is identical to BMH1, which encodes a protein similar to members of the mammalian 14-3-3 family. Bacterially synthesized mammalian 14-3-3 protein stimulated the activity of Raf prepared from yeast cells expressing c-Raf-1. Thus, the 14-3-3 protein may participate in or be required for activation of Raf.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Nagoya University; Kyoto University; University of North Carolina; University of North Carolina Chapel Hill				Yashar, Beverly M./0000-0003-0807-3258				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOTOH Y, 1994, ONCOGENE, V9, P1891; GUAN C, 1987, GENE, V67, P21; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YASHAR B, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	288	294	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1716	1719		10.1126/science.8085159	http://dx.doi.org/10.1126/science.8085159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085159				2022-12-28	WOS:A1994PG28400033
J	SMOTHERS, JF; VONDOHLEN, CD; SMITH, LH; SPALL, RD				SMOTHERS, JF; VONDOHLEN, CD; SMITH, LH; SPALL, RD			MOLECULAR EVIDENCE THAT THE MYXOZOAN PROTISTS ARE METAZOANS	SCIENCE			English	Article							EARLY EVOLUTION; RNA; SEQUENCES; MYXOSPOREA; EUKARYOTES; ORIGIN; PHYLA; TREES	The evolutionary origins of the protistan phylum, Myxozoa, have long been questioned. Although these obligate parasites are like protozoans in many features, several aspects of their ontogeny and morphology have implied a closer relationship to metazoan lineages. Phylogenetic analyses of 18S ribosomal RNA sequences from myxozoans and other eukaryotes, with the use of parsimony, distance, and maximum-likelihood methods, support the hypothesis that myxozoans are closely related to the bilateral animals. These results suggest that the Myxozoa, long considered an assemblage of protozoans, should be considered a metazoan phylum.	IDAHO STATE UNIV,DEPT BIOL SCI,POCATELLO,ID 83209; UNIV ARIZONA,DEPT ECOL & EVOLUTIONARY BIOL,TUCSON,AZ 85721	Idaho; Idaho State University; University of Arizona				von Dohlen, Carol/0000-0002-3961-251X				BACKELJAU T, 1993, CLADISTICS, V9, P167, DOI 10.1111/j.1096-0031.1993.tb00216.x; Butschli O, 1881, ZOOL JB F, V1, P162; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; CORLISS JO, 1987, INT REV CYTOL, V100, P319; CORLISS JO, 1984, BIOSYSTEMS, V17, P87, DOI 10.1016/0303-2647(84)90003-0; CORLISS JO, 1994, ACTA PROTOZOOL, V34, P1; DONOGHUE MJ, 1992, ANN MO BOT GARD, V79, P333, DOI 10.2307/2399772; ERNISS DJ, 1992, SYST BIOL, V41, P305; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; Ghiselin M.T., 1988, Oxford Surveys in Evolutionary Biology, V5, P66; GRASSE P-P, 1978, Annales des Sciences Naturelles Zoologie et Biologie Animale, V20, P193; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; JOHNSON AM, 1989, PARASITOL TODAY, V5, P102, DOI 10.1016/0169-4758(89)90046-X; KENT ML, IN PRESS CAN J ZOOL; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KRISTENSEN RM, 1983, Z ZOOL SYST EVOL, V21, P163; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Lee J. J., 1985, ILLUSTRATED GUIDE PR; Lom J., 1990, P36; LOM J, 1989, J FISH DIS, V12, P151, DOI 10.1111/j.1365-2761.1989.tb00287.x; Lom J., 1965, Protistologica, V1, P53; LOM J, 1984, FOLIA PARASIT, V31, P193; LOM J, 1964, 3 P EUR REG C EL MIC, P191; Margulis L., 1982, 5 KINGDOMS ILLUSTRAT; Margulis L, 1990, HDB PROTOCTISTA; Meglitsch P.A., 1991, INVERTEBRATE ZOOLOGY; Mitchell L.G., 1977, PARASITIC PROTOZOA, VIV, P115; MITCHELL LG, 1989, CAN J ZOOL, V67, P1915, DOI 10.1139/z89-274; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; Perkins F.O., 1991, P261; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SPALL RD, 1973, THESIS OKLAHOMA STAT; Stolc A, 1899, B INT ACAD SCI BOHEM, V22, P1; SWOFFORD DL, PAUP PHYLOGENETIC AN; SWOFFORD DL, 1990, MOL SYSTEMATICS, pCH11; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; Weill R, 1938, TRAVAUX STATION ZOOL, V13, P727; Willmer P., 1990, INVERTEBRATE RELATIO; WOLF K, 1984, SCIENCE, V225, P1449, DOI 10.1126/science.225.4669.1449	44	194	215	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1719	1721		10.1126/science.8085160	http://dx.doi.org/10.1126/science.8085160			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085160				2022-12-28	WOS:A1994PG28400034
J	NELSON, CA; PETZOLD, SJ; UNANUE, ER				NELSON, CA; PETZOLD, SJ; UNANUE, ER			PEPTIDES DETERMINE THE LIFE-SPAN OF MHC CLASS-II MOLECULES IN THE ANTIGEN-PRESENTING CELL	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL; IMMUNOGENIC PEPTIDES; SURFACE EXPRESSION; LIVING CELLS; B-CELLS; IA; IDENTIFICATION; BINDING; PROTEIN	ALTHOUGH many peptides are generated during the intracellular processing of protein antigens, only a few are selected for recognition by the immune system(1-5). The immunodominant epitope of hen egg white lysozyme (HEL) for H-2(k) mice is contained in a tryptic fragment of amino-acid residues 46-61 (refs 6, 7). The core of this T-cell epitope, from amino acids 52 to 61 (DYGILQINSR), contains those residues required for binding to the class II molecule I-A(k) (ref. 7). Most of the naturally processed fragments recovered from I-A(k)-bearing antigen-presenting cells (APCs) cultured with HEL contained this 52-61 core sequence, presented as a nested set of peptides with extensions at both the amino and carboxyl termini(8). We now compare the handling by APCs of peptides containing HEL 52-61 to establish whether there is an advantage for the APC in selecting extended peptides: different complexes between peptides and major histocompatibility complex (MHC) molecules varied greatly in the amount of time associated with the APC, and in their immunogenic strength. This difference in persistence is one of the factors contributing to the selection and immune recognition of peptide-MHC complexes by T cells.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)	NELSON, CA (corresponding author), WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110, USA.							ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; DOMMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLIMCHER LH, 1983, J IMMUNOL, V130, P2287; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; KATZ ME, 1982, EUR J IMMUNOL, V12, P535, DOI 10.1002/eji.1830120702; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROSENTHAL AS, 1977, NATURE, V267, P156, DOI 10.1038/267156a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297	24	170	173	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					250	252		10.1038/371250a0	http://dx.doi.org/10.1038/371250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078585				2022-12-28	WOS:A1994PG29000053
J	VLADECK, BC				VLADECK, BC			RACE AND ETHNICITY DATA COLLECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					761	761		10.1001/jama.272.10.761	http://dx.doi.org/10.1001/jama.272.10.761			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PF188	8078126				2022-12-28	WOS:A1994PF18800005
J	ECONOMOU, A; WICKNER, W				ECONOMOU, A; WICKNER, W			SECA PROMOTES PREPROTEIN TRANSLOCATION BY UNDERGOING ATP-DRIVEN CYCLES OF MEMBRANE INSERTION AND DEINSERTION	CELL			English	Article							COLI PLASMA-MEMBRANE; PRECURSOR PROTEIN TRANSLOCATION; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; COAT PROTEIN; CYTOPLASMIC MEMBRANE; ESSENTIAL COMPONENT; SECRETORY PROTEIN; INNER MEMBRANE; TRIGGER FACTOR	SecA, the peripheral subunit of E. coli preprotein translocase, alternates between a membrane inserted and a deinserted state as part of the catalytic cycle of preprotein translocation. When SecA is complexed with SecY/E and preprotein, ATP drives a profound conformational change, leading to membrane insertion of a 30 kDa domain of SecA. The inserted domain is protease-inaccessible from the cytosolic side of the membrane, but becomes accessible upon membrane disruption. Concomitant with 30 kDa domain insertion, similar to 20 aminoacyl residues of the preprotein are translocated. Additional ATP, which may be hydrolyzed at the second ATP site of SecA, releases the translocated preprotein and allows the 30 kDa domain to deinsert, whence it can exchange with cytosolic SecA. Thus, SecA is the mobile subunit of an integral membrane transporter, consuming ATP during both the insertion and deinsertion phases of its catalytic cycle while guiding preprotein segments across the membrane.			ECONOMOU, A (corresponding author), DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.		Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P827, DOI 10.1073/pnas.77.2.827; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KIM YJ, 1994, CELL, V78, P845; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TANI K, 1989, J BIOL CHEM, V264, P18582; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WEAVER AJ, 1992, J STRUCT BIOL, V109, P87, DOI 10.1016/1047-8477(92)90040-H; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1983, METHOD ENZYMOL, V97, P40; YAMADA H, 1989, J BIOL CHEM, V264, P18577	54	488	495	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					835	843		10.1016/S0092-8674(94)90582-7	http://dx.doi.org/10.1016/S0092-8674(94)90582-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087850				2022-12-28	WOS:A1994PG29600012
J	MULROW, CD				MULROW, CD			SYSTEMATIC REVIEWS - RATIONALE FOR SYSTEMATIC REVIEWS .1.	BRITISH MEDICAL JOURNAL			English	Review							MYOCARDIAL-INFARCTION; METAANALYSIS; TRIALS; SCIENCE; STATE	Systematic literature reviews including meta-analyses are invaluable scientific activities, The rationale for such reviews is well established. Health care providers, researchers, and policy makers are inundated with unmanageable amounts of information; they need systematic reviews to efficiently integrate existing information and provide data for rational decision making. Systematic reviews establish whether scientific findings are consistent and can be generalised across populations, settings, and treatment variations, or whether findings vary significantly by particular subsets. Meta-analyses in particular can increase power and precision of estimates of treatment effects and exposure risks, Finally, explicit methods used in systematic reviews limit bias and, hopefully, will improve reliability and accuracy of conclusions.	UNIV TEXAS,HLTH SCI CTR,DIV GERIATR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	MULROW, CD (corresponding author), UNIV TEXAS,HLTH SCI CTR,DIV GEN MED,SAN ANTONIO,TX 78284, USA.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BOSSEL JP, 1989, CONTROLLED CLIN TRIA, V10, P254; CHALMERS I, 1986, CONTROL CLIN TRIALS, V7, P306, DOI 10.1016/0197-2456(86)90038-3; Cooper H, 1986, INTEGRATIVE RES REV, V15, P1718; COOPER HM, 1980, PSYCHOL BULL, V87, P442, DOI 10.1037/0033-2909.87.3.442; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; GARFIELD RE, 1987, CLIN OBSTET GYNECOL, V30, P3, DOI 10.1097/00003081-198703000-00004; GELBER RD, 1991, ANN ONCOL, V2, P461, DOI 10.1093/oxfordjournals.annonc.a057993; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEDERBERG J, 1986, ANN REV COMPUTER SCI, V1, P5; LIGHT RJ, 1984, SUMMING UP SCI REV R; MORGAN PP, 1986, CAN MED ASSOC J, V134, P98; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; 1987, ANN INTERN MED, V106, P598	16	837	862	5	62	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					597	599		10.1136/bmj.309.6954.597	http://dx.doi.org/10.1136/bmj.309.6954.597			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086953	Green Published			2022-12-28	WOS:A1994PF33000032
J	COYNE, JA; CRITTENDEN, AP; MAH, K				COYNE, JA; CRITTENDEN, AP; MAH, K			GENETICS OF A PHEROMONAL DIFFERENCE CONTRIBUTING TO REPRODUCTIVE ISOLATION IN DROSOPHILA	SCIENCE			English	Article							MELANOGASTER SPECIES SUBGROUP; CUTICULAR HYDROCARBONS; SEXUAL ISOLATION; LOCUS; CHROMOSOME; EVOLUTION; SIMULANS; SPECIATION; COURTSHIP; COMPLEX	Although sexual isolation is one of the most important causes of speciation, its genetic basis is largely unknown. Here evidence is presented that suggests that sexual isolation between two closely related species of Drosophila is largely caused by differences in female cuticular hydrocarbons. This difference maps to only one of the three major chromosomes, implying that reproductive isolation might have a fairly simple genetic basis. The effect of the hydrocarbons on courtship may help explain the ubiquitous asymmetry of sexual isolation between many pairs of Drosophila species.			COYNE, JA (corresponding author), UNIV CHICAGO, DEPT ECOL & EVOLUT, 1101 E 57TH ST, CHICAGO, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM050355, R01GM038462] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38462, GM 50355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELT RJ, 1986, COMP BIOCHEM PHYS B, V83, P731, DOI 10.1016/0305-0491(86)90138-0; CARLSON DA, 1971, SCIENCE, V174, P76, DOI 10.1126/science.174.4004.76; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; COBB M, 1990, ANIM BEHAV, V39, P1058, DOI 10.1016/S0003-3472(05)80778-X; COBB M, 1989, J INSECT BEHAV, V2, P63, DOI 10.1007/BF01053619; COYNE JA, 1992, GENET RES, V60, P25, DOI 10.1017/S0016672300030639; COYNE JA, 1989, EVOLUTION, V43, P362, DOI [10.2307/2409213, 10.1111/j.1558-5646.1989.tb04233.x]; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DAVID J, 1974, ANN GENET-PARIS, V17, P235; DORWEILER J, 1993, SCIENCE, V262, P233, DOI 10.1126/science.262.5131.233; FERVEUR JF, 1993, GENETICS, V133, P561; FRANK SA, 1991, EVOLUTION, V45, P262, DOI 10.1111/j.1558-5646.1991.tb04401.x; GIDDINGS LV, 1983, SCIENCE, V220, P372, DOI 10.1126/science.220.4595.372; GRULA JW, 1980, J CHEM ECOL, V6, P241, DOI 10.1007/BF00987543; GRULA JW, 1979, HEREDITY, V42, P359, DOI 10.1038/hdy.1979.39; HOWARD RW, 1982, ANNU REV ENTOMOL, V27, P149, DOI 10.1146/annurev.en.27.010182.001053; JABLONKA E, 1991, P ROY SOC B-BIOL SCI, V243, P203, DOI 10.1098/rspb.1991.0032; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; JALLON JM, 1987, EVOLUTION, V41, P294, DOI 10.1111/j.1558-5646.1987.tb05798.x; KANESHIRO KY, 1987, EVOL BIOL, V21, P29; KLIMAN RM, 1993, GENETICS, V133, P375; LANGLEY PA, 1983, J INSECT PHYSIOL, V29, P825, DOI 10.1016/0022-1910(83)90148-8; LEMEUNIER F, 1976, PROC R SOC SER B-BIO, V193, P275, DOI 10.1098/rspb.1976.0046; LOFSTEDT C, 1993, PHILOS T R SOC B, V340, P167, DOI 10.1098/rstb.1993.0055; Margulis Lynn, 1991, SYMBIOSISOURCE EVO, P1; NAVEIRA H, 1992, GENETICS, V130, P205; OGUMA Y, 1992, CHEMOECOLOGY, V3; ORR HA, 1993, EVOLUTION, V47, P1606, DOI [10.2307/2410171, 10.1111/j.1558-5646.1993.tb02179.x]; ORR HA, 1992, AM NAT, V140, P725, DOI 10.1086/285437; PECHINE JM, 1985, ANAL BIOCHEM, V145, P177, DOI 10.1016/0003-2697(85)90344-6; ROELOFS W, 1987, P NATL ACAD SCI USA, V84, P7585, DOI 10.1073/pnas.84.21.7585; WEIBERGEN P, 1992, EVOLUTION, V46, P1385	33	284	287	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1461	1464		10.1126/science.8073292	http://dx.doi.org/10.1126/science.8073292			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073292				2022-12-28	WOS:A1994PE73300053
J	BRUGGE, WR; LEE, MJ				BRUGGE, WR; LEE, MJ			ADENOCARCINOMA OF THE ESOPHAGUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BRUGGE, WR (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					585	585						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047083				2022-12-28	WOS:A1994PD69900005
J	VONGERSDORFF, H; MATTHEWS, G				VONGERSDORFF, H; MATTHEWS, G			INHIBITION OF ENDOCYTOSIS BY ELEVATED INTERNAL CALCIUM IN A SYNAPTIC TERMINAL	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; VESICLE FUSION; TRANSMITTER RELEASE; CHROMAFFIN CELLS; EXOCYTOSIS; SECRETION; MEMBRANE; ENDINGS; NEURONS; RETINA	DURING synaptic transmission in the nervous system, synaptic vesicles fuse with the plasma membrane of presynaptic terminals, releasing neurotransmitter by exocytosis(1,2). The vesicle membrane is then retrieved by endocytosis and recycled into new transmitter-containing vesicles. Exocytosis in synaptic terminals is calcium-dependent(7-9), and we now report that endocytosis also is regulated by the intracellular calcium concentration ([Ca2+](i)). Capacitance measurements(10,11) in synaptic terminals of retinal bipolar neurons revealed that endocytosis was strongly inhibited by elevated [Ca2+](i) in the range achieved by Ca2+-current activation. The rate of membrane retrieval was steeply dependent on [Ca2+](i), with a Hill coefficient of 4 and half-inhibition at similar to 500 nM. At [Ca2+](i) greater than or equal to 900 nM, endocytosis was entirely absent. The action of internal calcium on endocytosis represents a novel negative-feedback mechanism controlling the rate of membrane recovery in synaptic terminals after neurotransmitter secretion. As membrane retrieval is the first step in vesicle recycling, this mechanism may contribute to activity-dependent synaptic depression.			VONGERSDORFF, H (corresponding author), SUNY STONY BROOK, DEPT NEUROBIOL & BEHAV, STONY BROOK, NY 11794 USA.							AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MULKEY RM, 1991, NATURE, V350, P153, DOI 10.1038/350153a0; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NORDMANN JJ, 1992, NEUROSCIENCE, V49, P201, DOI 10.1016/0306-4522(92)90088-J; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; PYSH JJ, 1974, J CELL BIOL, V60, P365, DOI 10.1083/jcb.60.2.365; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SCHAEFFER SF, 1978, J CELL BIOL, V79, P802, DOI 10.1083/jcb.79.3.802; SHARMA RK, 1988, MOL ASPECTS CELLULAR, V5, P265; SUZUKI S, 1990, VISUAL NEUROSCI, V5, P223, DOI 10.1017/S0952523800000298; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TORRITARELLI F, 1985, J CELL BIOL, V101, P1386, DOI 10.1083/jcb.101.4.1386; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0	31	226	229	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					652	655		10.1038/370652a0	http://dx.doi.org/10.1038/370652a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065451				2022-12-28	WOS:A1994PD31000051
J	JITSUKAWA, M; DJERASSI, C				JITSUKAWA, M; DJERASSI, C			BIRTH-CONTROL IN JAPAN - REALITIES AND PROGNOSIS	SCIENCE			English	Editorial Material							MIFEPRISTONE RU-486		STANFORD UNIV,ASIA PACIFIC RES CTR,DEPT CHEM,STANFORD,CA 94305	Stanford University	JITSUKAWA, M (corresponding author), STANFORD UNIV,ASIA PACIFIC RES CTR,DEPT ANTHROPOL,STANFORD,CA 94305, USA.							BUMILLER E, 1990, WASHINGTON POST 1025, pD6; BUMILLER E, 1990, WASHINGTON POST 1025, pD1; Coleman Samuel, 1983, FAMILY PLANNING JAPA; DJERASSI C, 1990, SCIENCE, V248, P1061, DOI 10.1126/science.2343313; DJERASSI C, 1987, TECHNOL SOC, V9, P157, DOI 10.1016/0160-791X(87)90021-2; DJERASSI C, 1991, SCI PUBLIC AFF LONDO, V6, P5; DJERASSI C, 1993, PILL PYGMY CHIMPS DE, pCH9; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; IKEGAMI C, 1991, HUM SEX, V5, P28; JANSSON Y, 1991, HUM SEX TOKYO, V2, P10; Kobayashi T, 1989, Int J Fertil, V34 Suppl, P14; KOBAYASHI T, 1992, MED FAIRU, V7, P2; Kuwabara Y, 1989, Int J Fertil, V34 Suppl, P18; MATSUMOTO S, 1991, MED FAIRU, V6, P2; MATSUMOTO S, 1988, CURR THER RES, V44, P115; MINAGUCHI H, 1993, NIHON ISHIKAI ZASSHI, V110, P1273; MUNAKATA T, 1992, EIZU TO SEKKUSU REPO; MURAMATSU M, 1974, ABORTION RES INT EXP, P133; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; POTTS M, 1977, ABORTION, P136; Satoh K, 1989, Int J Fertil, V34 Suppl, P8; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; THOMSEN RJ, 1982, ATLAS INTRAUTERINE C, P108; UNO S, 1992, WOMENS MESSAGES JAPA, V9, P26; Weisman Steven R, 1992, N Y Times Web, pA3; YOSHITAKE T, CITED INDIRECTLY; 1987, PIRU WATASHITACHI WA; 1988, POPUL REP SER A, V7, P20; QUIET LOVE RELATIONS; 1992, KIROKU NIPPON NO JIN; 1983, KANASHIMI SABAKEMASU, P266; VITAL STATISTICS EUG; 1992, MED FAIRU, V7, P13; 1987, WKLY EPIDEMIOL REC, V62, P244	35	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1048	1051		10.1126/science.8066442	http://dx.doi.org/10.1126/science.8066442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066442				2022-12-28	WOS:A1994PC53900021
J	DALY, DA				DALY, DA			SPEECH CLUTTERING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALY, DA (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.							DALY D, 1988, FREEDOM FLUENCY; Daly D. A., 1993, STUTTERING RELATED D; DALY DA, 1986, ATYPICAL STUTTERER P; DALY DA, 1992, CLUTTERING CLIN PERS; Weiss D., 1964, CLUTTERING	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					565	565		10.1001/jama.272.7.565	http://dx.doi.org/10.1001/jama.272.7.565			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046816				2022-12-28	WOS:A1994PB22900040
J	FUCHS, VR				FUCHS, VR			HEALTH SYSTEM REFORM - A DIFFERENT APPROACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COST-CONTAINMENT; CARE		STANFORD UNIV,DEPT ECON,STANFORD,CA 94305; STANFORD UNIV,DEPT HLTH RES & POLICY,STANFORD,CA 94305	Stanford University; Stanford University	FUCHS, VR (corresponding author), NATL BUR ECON RES,204 JUNIPERO SERRA BLVD,STANFORD,CA 94305, USA.							BOULDING KE, 1968, ECONOMICS; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; FUCHS VR, 1974, SHALL LIVE HLTH EC S; METCALF GE, 1994, TAX POLICY EC, P45; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; ROMER PM, 1993, BROOKINGS PAP ECO AC, P345; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; WEISBROD BA, 1991, J ECON LIT, V29, P523	8	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					560	563		10.1001/jama.272.7.560	http://dx.doi.org/10.1001/jama.272.7.560			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB229	8046814				2022-12-28	WOS:A1994PB22900037
J	RAWLES, J				RAWLES, J			ATTITUDES OF GENERAL-PRACTITIONERS TO PREHOSPITAL THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION	Objective-To investigate reasons for general practitioners not giving thrombolytic treatment to eligible patients with acute myocardial infarction. Design-Postal questionnaires were sent to 424 general practitioners. Subjects-97 general practitioners who had taken part in the Grampian region early anistreplase trial, 185 whose practices in Scotland were at least 24 km from a district general hospital, and 142 who had attended postgraduate conferences at which thrombolysis had been discussed; 87, 158, and 125 respectively responded. Main outcome measures-Answers to questions about readiness to use thrombolytic treatment. Results-Response rate was 87% (370/424). Almost all respondents (350) were convinced of benefits of thrombolysis for acute myocardial infarction, and 277 were convinced that there were additional benefits from its administration in the community at first opportunity. Most doctors working 16 km or more from hospital thought that giving treatment at home would appreciably save time (200/274). Most doctors agreed that they could make time to give thrombolytic treatment (278), and would be willing to record an electrocardiogram (284), and would be able to interpret it (280). Sixty four respondents (17%) reported using thrombolytic treatment in previous year. Among non-users, 150 (49%) were unwilling to use thrombolytic treatment without further training. While many non-users (210 (69%)) were willing to use thrombolytic treatment without encouragement from Department of Health, 184 (60%) were unwilling to use it unless encouraged to do so by their local cardiologist. Conclusions-The need to become better informed about thrombolysis and lack of encouragement from local cardiologists were important factors preventing wider use of thrombolytic treatment in the community by general practitioners.			RAWLES, J (corresponding author), UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1991, BRIT HEART J, V66, P250; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GEMMILL JD, 1993, BRIT HEART J, V70, P503; GORDON I, 1989, J ROY COLL GEN PRACT, V39, P49; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LIDDELL R, 1990, BRIT J GEN PRACT, V40, P318; MCCREA WA, 1993, BRIT HEART J, V70, P219; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; RULE S, 1993, POSTGRAD MED J, V69, P190, DOI 10.1136/pgmj.69.809.190; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; WILCOX RG, 1988, LANCET, V2, P525; 1992, BRIT HEART J, V68, P621	18	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	1994	309	6951					379	382		10.1136/bmj.309.6951.379	http://dx.doi.org/10.1136/bmj.309.6951.379			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081141	Green Published			2022-12-28	WOS:A1994PB31600024
J	THORNTON, JG; LILFORD, RJ				THORNTON, JG; LILFORD, RJ			ACTIVE MANAGEMENT OF LABOR - CURRENT KNOWLEDGE AND RESEARCH ISSUES	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; PERINATAL-MORTALITY; NULLIPAROUS WOMEN; AMNIOTOMY; DECREASE; DYSTOCIA; DELIVERY; TRIAL	Objectives-To review the evidence that the package of labour interventions collectively called ''active management''-namely, strict diagnostic criteria for labour, early amniotomy, early use of oxytocin, and continuous professional support-reduce rates of caesarean sections and operative vaginal delivery in first labours. Design-Review of observational data, supplemented by evidence from four separate overviews of relevant randomised trials previously published as part of the Cochrane Collaboration pregnancy and childbirth database. Results-Observational data do not permit a clear conclusion. There have been no randomised trials of the total package of active management or of the use of strict diagnostic criteria alone, but trials of early amniotomy, early oxytocin, and these interventions combined do not suggest that these interventions are effective in reducing rates of caesarean sections or operative vaginal deliveries. In contrast, the provision of continuous professional support in labour seems to reduce both types of operative delivery, although the effect on caesarean sections is confined to those settings where non-professional companions are not normally present in labour. Conclusions-Delivery units should endeavour to provide continuous professional support in labour, but routine use of amniotomy and early oxytocin is not recommended.			THORNTON, JG (corresponding author), UNIV LEEDS,INST EPIDEMIOL & HLTH SERV RES,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				AKOURY HA, 1988, AM J OBSTET GYNECOL, V158, P255, DOI 10.1016/0002-9378(88)90133-0; BARRETT JFR, 1992, BRIT J OBSTET GYNAEC, V99, P5, DOI 10.1111/j.1471-0528.1992.tb14382.x; BREART G, 1993, CARE CONCERN CURE PE, P39; Caldeyro-Barcia R, 1972, INT J GYNECOL OBSTET, V10, P169; CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; COHEN GR, 1987, AM J OBSTET GYNECOL, V157, P1174, DOI 10.1016/S0002-9378(87)80288-0; FRASER WD, 1993, NEW ENGL J MED, V328, P1145, DOI 10.1056/NEJM199304223281602; FRASER WD, 1992, PREGNANCY CHILDBIRTH; Friedman EA, 1978, LABOR CLIN EVALUATIO, V2nd; HODNERT ED, 1993, PREGNANCY CHILDBIRTH; KIERSE MJN, 1989, EFFECTIVE CARE PREGN, P951; LEVENO KJ, 1985, AM J OBSTET GYNECOL, V153, P838, DOI 10.1016/0002-9378(85)90686-6; LOPEZZENO JA, 1992, NEW ENGL J MED, V326, P450, DOI 10.1056/NEJM199202133260705; ODRISCOLL K, 1983, OBSTET GYNECOL, V61, P1; ODRISCOLL K, 1984, OBSTET GYNECOL, V63, P485; ODRISCOLL K, 1969, BMJ-BRIT MED J, V2, P477, DOI 10.1136/bmj.2.5655.477; ODRISCOLL K, 1973, BMJ-BRIT MED J, V3, P135, DOI 10.1136/bmj.3.5872.135; ODRISCOLL K, 1980, ACTIVE MANAGEMENT LA; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; ROCHENSCHAUB A, 1990, LANCET, V335, P977; Scott J. L., 1981, BRIT MED J, V282, P1064; STUDD J, 1973, BRIT MED J, V4, P451, DOI 10.1136/bmj.4.5890.451; TURNER MJ, 1986, J OBSTET GYNAECOL, V7, P79, DOI 10.3109/01443618609112275; TURNER MJ, 1988, OBSTET GYNECOL, V71, P150; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; 1994, ONLINE J CURR CLIN T, V3, P122	26	72	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					366	369		10.1136/bmj.309.6951.366	http://dx.doi.org/10.1136/bmj.309.6951.366			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081133	Green Published			2022-12-28	WOS:A1994PB31600015
J	HENRY, JM; MACPHERSON, IA; DONALD, SC				HENRY, JM; MACPHERSON, IA; DONALD, SC			SURVEY OF PRIVATE NURSING-HOMES IN 7 ENGLISH COUNTIES	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen								HENRY JM, 1993, SURVEY NURSING HOMES	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					314	314						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086870				2022-12-28	WOS:A1994PA37300021
J	LEMESHOW, S; LEGALL, JR				LEMESHOW, S; LEGALL, JR			MODELING THE SEVERITY OF ILLNESS OF ICU PATIENTS - A SYSTEMS UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLASSIFICATION-SYSTEM; ACUTE PHYSIOLOGY; APACHE-II; MORTALITY; CARE; PREDICTION; SEPSIS; SCORE	Objective.-To review recent revisions of systems for estimating the probability of hospital mortality of adult intensive care unit (ICU) patients. Emphasis on comparison of components of systems and potential uses. Data Sources.-Published articles in which the systems were presented. Study Selection.-Acute Physiology and Chronic Health Evaluation (APACHE III), Simplified Acute Physiology Score (SAPS II), and Mortality Probability Models (MPM II) are the major severity systems for ICU patients. Data Extraction.-Information on variables collected in the systems, characteristics of databases from which they were developed, and reported performance of models were evaluated from published articles. Data Synthesis.-APACHE III and SAPS II produce a score and probability of hospital mortality based on worst values of several variables during the first 24 hours in ICU. The MPM II system has four models, one at ICU admission and one at 24, 48, and 72 hours into the ICU stay. The SAPS II and MPM II models can be implemented from published information. The APACHE III score can be calculated from published information; weights to convert score to probability are proprietary. All reported good areas under receiver operating characteristic curve. Goodness of fit was good for SAPS II and MPM II models and was not reported for APACHE III models. Conclusions.-All models were based on rigorous research and reported performance is good. AH can be used to assist in assessing prognosis, to compare ICU performance, and to stratify patients for clinical trials. Direct comparison on a common cohort is needed.	HOP ST LOUIS,SERV REANIMAT MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	LEMESHOW, S (corresponding author), UNIV MASSACHUSETTS,SCH PUBL HLTH,ARNOLD HOUSE,AMHERST,MA 01003, USA.				AHRQ HHS [HS06026] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CLEVELAND WS, 1981, AM STAT, V35, P54, DOI 10.2307/2683591; Hadorn DC., 1993, ASSESSING PERFORMANC; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; Le Gall J-R, 1993, REAN URG, V6, P656; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEGALL JR, 1994, HADOJAMA, V271, P1321; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; LOIRAT P, 1994, REANIM URG, V3, P173; MEYER AA, 1992, J TRAUMA, V32, P747, DOI 10.1097/00005373-199206000-00013; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; TERES D, 1994, CRIT CARE CLIN, V10, P93, DOI 10.1016/S0749-0704(18)30147-7; WATTS CM, 1994, CRIT CARE CLIN, V10, P111, DOI 10.1016/S0749-0704(18)30148-9	22	270	281	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1049	1055		10.1001/jama.272.13.1049	http://dx.doi.org/10.1001/jama.272.13.1049			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089888				2022-12-28	WOS:A1994PH77500031
J	POLLACK, MM; CUERDON, TT; PATEL, KM; RUTTIMANN, UE; GETSON, PR; LEVETOWN, M				POLLACK, MM; CUERDON, TT; PATEL, KM; RUTTIMANN, UE; GETSON, PR; LEVETOWN, M			IMPACT OF QUALITY-OF-CARE FACTORS ON PEDIATRIC INTENSIVE-CARE UNIT MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CHARACTERISTICS; VOLUME; OUTCOMES; PERFECT; TIME	Objective.-To determine the importance of the following care factors previously associated with hospital quality on survival from pediatric intensive care: size of the intensive care unit (ICU), medical school teaching status of the hospital housing the ICU, specialist status (pediatric intensivist), and unit coordination. Design.-After a national survey, consecutive case series were collected at 16 sites randomly selected to represent unique combinations of quality-of-care factors. Setting.-Pediatric ICUs. Patients.-Consecutive admissions to each site. Main Outcome Measure.-Patient mortality adjusted for physiologic status, diagnosis, and other mortality risk factors. Results.-There were 5415 pediatric ICU admissions and 248 ICU deaths. The ICUs differed significantly with respect to descriptive variables, including mortality (range, 2.2% to 16.4%). Analysis of risk-adjusted mortality indicated that the hospital teaching status and the presence of a pediatric intensivist were significantly associated with a patient's chance of survival. The probability of patient survival after hospitalization in an ICU located in a teaching hospital was decreased (relative odds of dying, 1.79; 95% confidence interval [CI], 1.23 to 2.61; P=.002). In contrast, the probability of patient survival after hospitalization in an ICU with a pediatric intensivist was improved (relative odds of dying, 0.65; 95% CI, 0.44 to 0.95; P=.027). Post hoc analysis indicated that the higher severity-adjusted mortality in teaching hospitals may be explained by the presence of residents caring for ICU patients. Conclusion.-Characteristics indicative of the best overall hospital quality may not be associated, or may be negatively associated, with quality of care in specialized care areas, including the pediatric ICU.	GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC 20052; GEORGE WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,WASHINGTON,DC; CHILDRENS NATL MED CTR,DEPT PEDIAT,WASHINGTON,DC; CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC; NIAAA,BETHESDA,MD	George Washington University; George Washington University; Children's National Health System; Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	POLLACK, MM (corresponding author), CHILDRENS NATL MED CTR,CHILDRENS RES INST,CTR HLTH SERV & CLIN RES,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.				PHS HHS [MCH-110584] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1993, Pediatrics, V92, P166; ARMITAGE P, 1971, STATISTICAL METHODS; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; BURNS LR, 1991, MED CARE, V29, P251, DOI 10.1097/00005650-199103000-00007; COHEN J, 1988, STATISTICAL POWER BE; DIXON WJ, 1957, INTRO STATISTICAL AN, P412; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; GONNELLA JS, 1986, DISEASE STAGING CLIN; GREENLAND P, 1979, J MED EDUC, V54, P863; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; Hosmer DW, 1989, APPL LOGISTIC REGRES, P141; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; KAY R, 1987, BIOMETRIKA, V74, P495, DOI 10.1093/biomet/74.3.495; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LAFFEL GL, 1992, NEW ENGL J MED, V327, P1220, DOI 10.1056/NEJM199210223271707; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1993, CRIT CARE MED, V21, P607, DOI 10.1097/00003246-199304000-00023; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; SHORTELL SM, 1991, MED CARE, V29, P709, DOI 10.1097/00005650-199108000-00004; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; SIMPSON DE, 1987, SOC SCI MED, V25, P861, DOI 10.1016/0277-9536(87)90044-X; 1990, SAS STAT USERS GUIDE, V2, P1071	30	173	178	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					941	946		10.1001/jama.272.12.941	http://dx.doi.org/10.1001/jama.272.12.941			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084061				2022-12-28	WOS:A1994PG73700021
J	OXMAN, AD				OXMAN, AD			SYSTEMATIC REVIEWS - CHECKLISTS FOR REVIEW ARTICLES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL LITERATURE; CONTROLLED TRIALS; CLINICAL RESEARCH; USERS GUIDES; GUIDELINES; QUALITY	Preparing a review entails many judgments. The focus of the review must be decided. Studies that are relevant to the focus of the review must be identified, selected for inclusion and critically appraised. Information must be collected and synthesised from the relevant studies, and conclusions must be drawn. Checklists can help prevent important errors in this process. Reviewers, editors, content experts, and users of reviews all have a role to play in improving the quality of published reviews and promoting the appropriate use of reviews by decisionmakers. It is essential that both providers and users appraise the validity of review articles.	MCMASTER UNIV, DEPT FAMILY MED, HAMILTON L8S 4L8, ON, CANADA	McMaster University	OXMAN, AD (corresponding author), MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ON, CANADA.		Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061				ALTMAN DG, 1992, ANN INTERN MED S2, V116, pA28; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Becker B. J., 1993, HDB RES SYNTHESIS; COOK DJ, 1992, CHEST S4, V102, P305; COOPER HM, 1982, REV EDUC RES, V52, P291, DOI 10.3102/00346543052002291; COOPER HM, 1986, SOC PSYCHOL EDUC, P341; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; FLETCHER RH, 1979, NEW ENGL J MED, V301, P180, DOI 10.1056/NEJM197907263010403; Glass G. V., 1981, METAANALYSIS SOCIAL; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; JACKSON GB, 1980, REV EDUC RES, V50, P438, DOI 10.3102/00346543050003438; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Light R., 1984, SUMING UP SCI REV RE, P160; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; OXMAN AD, IN PRESS JAMA; OXMAN AD, IN PRESS ANN NY ACAD; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; SACKETT DL, 1983, J CHRON DIS, V36, P545, DOI 10.1016/0021-9681(83)90132-7; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SCHULZ KF, 1993, UNPUB FAILURE CONCEA; WILLIAMSON JW, 1986, MED USE STATISTICS, P370; YSUF S, 1987, STAT MED, V6, P217; YSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93; 1992, JAMA-J AM MED ASSOC, V268, P2420; 1992, ANN INTERN MED, V117, P1038	33	315	328	2	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 10	1994	309	6955					648	651		10.1136/bmj.309.6955.648	http://dx.doi.org/10.1136/bmj.309.6955.648			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086990	Green Published			2022-12-28	WOS:A1994PG02000031
J	PRICE, LH; HENINGER, GR				PRICE, LH; HENINGER, GR			LITHIUM IN THE TREATMENT OF MOOD DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CYCLING AFFECTIVE-DISORDER; BIPOLAR DISORDER; REFRACTORY DEPRESSION; RECEPTOR-BINDING; FOLLOW-UP; CARBAMAZEPINE; ILLNESS; THERAPY; MANIA; HYPOTHESIS				PRICE, LH (corresponding author), YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, CLIN NEUROSCI RES UNIT, NEW HAVEN, CT 06519 USA.		anand, amit/A-7222-2009		NIMH NIH HHS [MH-25642, MH-30929] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH030929, P01MH025642, P50MH030929] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADDONIZIO G, 1985, J CLIN PSYCHOPHARM, V5, P296, DOI 10.1097/00004714-198510000-00008; AMDISEN A, 1977, CLIN PHARMACOKINET, V2, P73, DOI 10.2165/00003088-197702020-00001; [Anonymous], 1985, Am J Psychiatry, V142, P469; BARR RD, 1983, CAN MED ASSOC J, V128, P123; BATLLE DC, 1985, NEW ENGL J MED, V312, P408, DOI 10.1056/NEJM198502143120705; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOCCHETTA A, 1991, ACTA PSYCHIAT SCAND, V83, P193, DOI 10.1111/j.1600-0447.1991.tb05523.x; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; BUNNEY WE, 1987, PSYCHOPHARMACOLOGY 3, P553; CADE JFJ, 1949, MED J AUSTRALIA, V2, P349, DOI 10.5694/j.1326-5377.1949.tb36912.x; CARLSON GA, 1992, J CHILD PSYCHOL PSYC, V33, P411, DOI 10.1111/j.1469-7610.1992.tb00876.x; CHEN Y, 1990, INT CLIN PSYCHOPHARM, V5, P217, DOI 10.1097/00004850-199007000-00007; COHEN LS, 1994, JAMA-J AM MED ASSOC, V271, P146, DOI 10.1001/jama.271.2.146; Collard K.J., 1986, ENDOCRINE METABOLIC; Cooper T., 1987, PSYCHOPHARMACOLOGY 3, P1365; COPPEN A, 1988, ACTA PSYCHIAT SCAND, V78, P754, DOI 10.1111/j.1600-0447.1988.tb06415.x; COPPEN A, 1991, J AFFECT DISORDERS, V23, P1, DOI 10.1016/0165-0327(91)90030-V; CORYELL W, 1992, ARCH GEN PSYCHIAT, V49, P126; DASGUPTA K, 1990, GEN HOSP PSYCHIAT, V12, P83, DOI 10.1016/0163-8343(90)90019-9; DEANDREA D, 1982, J CLIN PSYCHOPHARM, V2, P199; Delgado PL, 1992, HDB AFFECTIVE DISORD, P219; DEMONTIGNY C, 1981, BRIT J PSYCHIAT, V138, P252, DOI 10.1192/bjp.138.3.252; DILSAVER SC, 1984, BIOL PSYCHIAT, V19, P1551; FIEVE RR, 1983, ANTIDEPRESSANTS, V1, P277; FRIEDLANDER AA, 1986, ORAL SURG ORAL MED O, V61, P579, DOI 10.1016/0030-4220(86)90097-6; GELENBERG AJ, 1989, NEW ENGL J MED, V321, P1489, DOI 10.1056/NEJM198911303212201; GHADIRIAN AM, 1980, COMPR PSYCHIAT, V21, P327, DOI 10.1016/0010-440X(80)90013-9; GOODNICK PJ, 1981, CLIN PHARMACOL THER, V29, P47, DOI 10.1038/clpt.1981.8; GOODNICK PJ, 1991, PSYCHOPHARMACOL BULL, V27, P475; Goodwin F, 1990, MANIC DEPRESSIVE ILL; GOODWIN FK, 1969, ARCH GEN PSYCHIAT, V21, P486; HARROW M, 1990, ARCH GEN PSYCHIAT, V47, P665; HAYKAL RF, 1990, J CLIN PSYCHIAT, V51, P450; HENINGER GR, 1983, ARCH GEN PSYCHIAT, V40, P1335; HIMMELHOCH JM, 1991, AM J PSYCHIAT, V148, P910; Holstein-Rathlou N H, 1990, Kidney Int Suppl, V28, pS4; HOSCHL C, 1991, DRUGS, V42, P721; JACOBSON SJ, 1992, LANCET, V339, P530, DOI 10.1016/0140-6736(92)90346-5; JEFFERSON JW, 1979, JAMA-J AM MED ASSOC, V241, P1134, DOI 10.1001/jama.241.11.1134; Jefferson JW, 1987, LITHIUM ENCY CLIN PR; Johnson F. N, 1984, HIST LITHIUM THERAPY; LACHMAN HM, 1989, LIFE SCI, V45, P1413, DOI 10.1016/0024-3205(89)90031-3; LAPIERRE YD, 1976, CAN MED ASSOC J, V114, P619; MANJI HK, 1992, AM J PSYCHIAT, V149, P746; MARTIN BA, 1982, AM J PSYCHIAT, V139, P1326; MELLERUP ET, 1987, PSYCHOPHARMACOLOGY 3, P1443; MELTZER H L, 1990, Pharmacology and Toxicology Supplement, V66, P84; MITCHELL JE, 1982, J CLIN PSYCHIAT, V43, P47; MORK A, 1992, PHARMACOL TOXICOL, V71, P4, DOI 10.1111/j.1600-0773.1992.tb01624.x; MOTOHASHI N, 1989, EUR J PHARMACOL, V166, P95, DOI 10.1016/0014-2999(89)90687-0; MULLEROERLINGHAUSEN B, 1992, ACTA PSYCHIAT SCAND, V86, P218, DOI 10.1111/j.1600-0447.1992.tb03255.x; NAHORSKI SR, 1992, PHARMACOL TOXICOL, V71, P42, DOI 10.1111/j.1600-0773.1992.tb01628.x; OCONNELL RA, 1991, BRIT J PSYCHIAT, V159, P123, DOI 10.1192/bjp.159.1.123; ODAGAKI Y, 1992, LITHIUM, V3, P95; PERRY PJ, 1984, ACTA PSYCHIAT SCAND, V69, P528, DOI 10.1111/j.1600-0447.1984.tb02527.x; POPE HG, 1991, ARCH GEN PSYCHIAT, V48, P62; POST RM, 1990, J CLIN PSYCHOPHARM, V10, P318; POST RM, 1992, AM J PSYCHIAT, V149, P1727; POST RM, 1985, PSYCHOPHARMACOL BULL, V21, P10; PRICE LH, 1986, AM J PSYCHIAT, V143, P1387; PRICE LH, 1990, PSYCHOPHARMACOLOGY, V100, P3, DOI 10.1007/BF02245781; PRIEN RF, 1984, ARCH GEN PSYCHIAT, V41, P1096; PRIEN RF, 1990, PSYCHOPHARMACOL BULL, V26, P409; RAGHEB M, 1990, J CLIN PSYCHOPHARM, V10, P350; RISBY ED, 1991, ARCH GEN PSYCHIAT, V48, P513; SCHOU M, 1954, J NEUROL NEUROSUR PS, V17, P250, DOI 10.1136/jnnp.17.4.250; SHAPIRO DR, 1989, ARCH GEN PSYCHIAT, V46, P401; SHUKLA S, 1984, AM J PSYCHIAT, V141, P1604; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; SOUZA FGM, 1991, BRIT J PSYCHIAT, V158, P666, DOI 10.1192/bjp.158.5.666; STOKES PE, 1971, LANCET, V1, P1319; STOKES PE, 1976, ARCH GEN PSYCHIAT, V33, P1080; SUPPES T, 1991, ARCH GEN PSYCHIAT, V48, P1082; THOMSEN K, 1978, DAN MED BULL, V25, P106; THORNHILL DP, 1981, BIOPHARM DRUG DISPOS, V2, P305, DOI 10.1002/bdd.2510020403; VESTERGAARD P, 1991, J AFFECT DISORDERS, V21, P33, DOI 10.1016/0165-0327(91)90016-L; VESTERGAARD P, 1992, NEUROPSYCHOPHARMACOL, V7, P249; VIEGUT V, 1990, LITHIUM, V1, P9; WALDMEIER P C, 1990, Pharmacology and Toxicology Supplement, V66, P121; WALDMEIER PC, 1987, PHARMACOPSYCHIATRY, V20, P37, DOI 10.1055/s-2007-1017072; WALLER DG, 1989, PSYCHOL MED, V19, P825, DOI 10.1017/S0033291700005535; WEHR TA, 1988, AM J PSYCHIAT, V145, P179; WEHR TA, 1987, PSYCHOPHARMACOL BULL, V23, P61; WOOD AJ, 1987, PSYCHOL MED, V17, P579, DOI 10.1017/S0033291700025836; 1994, DIAGNOSTIC STATISTIC; 1988, BIOL THER PSYCHIATRY, V11, P43	86	213	219	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					591	598						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047085				2022-12-28	WOS:A1994PD69900007
J	FORRESTER, WC; VANGENDEREN, C; JENUWEIN, T; GROSSCHEDL, R				FORRESTER, WC; VANGENDEREN, C; JENUWEIN, T; GROSSCHEDL, R			DEPENDENCE OF ENHANCER-MEDIATED TRANSCRIPTION OF THE IMMUNOGLOBULIN-MU GENE ON NUCLEAR MATRIX ATTACHMENT REGIONS	SCIENCE			English	Article							HEAVY-CHAIN ENHANCER; CHROMOSOMAL LOOP ANCHORAGE; TRANSGENIC MICE; REGULATORY ELEMENTS; BINDING SITES; IGH ENHANCER; C-MYC; PRE-B; EXPRESSION; CHROMATIN	Transcription of the immunoglobulin mu heavy chain locus is regulated by an intronic enhancer that is flanked on both sides by nuclear matrix attachment regions (MARs). These MARs have now been shown to be essential for transcription of a rearranged mu gene in transgenic B lymphocytes, but they were not required in stably transfected tissue culture cells. Normal rates of transcriptional initiation at a variable region promoter and the formation of an extended deoxyribonuclease I (DNase I)-sensitive chromatin domain were dependent on MARs, although DNase I hypersensitivity at the enhancer was detected in the absence of MARs. Thus, transcriptional activation of the mu gene during normal lymphoid development requires a synergistic collaboration between the enhancer and flanking MARs.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BLAZQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; EPNER E, 1992, Current Biology, V2, P262, DOI 10.1016/0960-9822(92)90379-O; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JENUWEIN T, UNPUB; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KIM KJ, 1979, J IMMUNOL, V122, P549; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LIBERMANN TA, 1991, MOL ASPECTS CELL REG, V6, P385; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MOORE BB, 1993, NUCLEIC ACIDS RES, V21, P1481, DOI 10.1093/nar/21.6.1481; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STEIF A, 1989, NATURE, V341, P343; STORB U, 1981, NATURE, V294, P90, DOI 10.1038/294090a0; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XU M, 1989, J BIOL CHEM, V264, P21190; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	48	210	218	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1221	1225		10.1126/science.8066460	http://dx.doi.org/10.1126/science.8066460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066460				2022-12-28	WOS:A1994PD42200034
J	MCGEEHAN, GM; BECHERER, JD; BAST, RC; BOYER, CM; CHAMPION, B; CONNOLLY, KM; CONWAY, JG; FURDON, P; KARP, S; KIDAO, S; MCELROY, AB; NICHOLS, J; PRYZWANSKY, KM; SCHOENEN, F; SEKUT, L; TRUESDALE, A; VERGHESE, M; WARNER, J; WAYS, JP				MCGEEHAN, GM; BECHERER, JD; BAST, RC; BOYER, CM; CHAMPION, B; CONNOLLY, KM; CONWAY, JG; FURDON, P; KARP, S; KIDAO, S; MCELROY, AB; NICHOLS, J; PRYZWANSKY, KM; SCHOENEN, F; SEKUT, L; TRUESDALE, A; VERGHESE, M; WARNER, J; WAYS, JP			REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA PROCESSING BY A METALLOPROTEINASE INHIBITOR	NATURE			English	Article							MURINE TUMOR; MONO MAC-6; ACTIVATION; EXPRESSION; SECRETION; CLONING	TUMOUR necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory agent produced primarily by activated monocytes and macrophages(1). TNF-alpha is synthesized as a precursor protein of M(r) 26,000 (26K) which is processed to a secreted 17K mature form by cleavage of an Ala-Val bond between residues 76-77. The enzyme(s) responsible for processing pro-TNF-alpha has yet to be identified. Here, we describe the capacity of a metalloproteinase inhibitor, GI 129471, to block TNF-alpha secretion both in vitro and in vivo. The inhibition is specific to TNF-alpha; the production of other secreted cytokines, such as the interleukins IL-1 beta, IL-2, or IL-6, is not inhibited. The mechanism of inhibition occurs at a post-translational step in TNF-alpha production. Our data suggest that TNF-alpha processing is mediated by a unique Zn2+ endopeptidase which is inhibited by GI 129471 and would represent a novel target for therapeutic intervention in TNF-alpha associated pathologies.	DUKE UNIV,MED CTR,DUKE COMPREHENS CANC CTR,DEPT MED,DURHAM,NC 27710; MCGILL UNIV,JEWISH GEN HOSP,DEPT ONCOL,MONTREAL H3T 1E2,PQ,CANADA; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27516	Duke University; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	MCGEEHAN, GM (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Schoenen, Frank/0000-0003-2711-1117				BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLACK RA, 1992, CYTOKINE, V3, P480; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; CAMPION C, 1990, Patent No. 05719; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KARP SE, 1992, J IMMUNOL, V149, P2076; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KIM KU, 1993, IMMUNOLOGY, V80, P134; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; NIEHORSTER M, 1990, BIOCHEM PHARMACOL, V40, P1601, DOI 10.1016/0006-2952(90)90461-S; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; SCUDERI P, 1989, J IMMUNOL, V143, P168; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERGHESE MW, 1981, J IMMUNOL, V127, P288; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	26	546	607	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					558	561		10.1038/370558a0	http://dx.doi.org/10.1038/370558a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052311				2022-12-28	WOS:A1994PC53700055
J	CHAISSON, RE				CHAISSON, RE			SMOKING CESSATION IN PATIENTS WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CIGARETTE-SMOKING; HOMOSEXUAL MEN; INFECTION; PROGRESSION; SUBSETS; AIDS				CHAISSON, RE (corresponding author), JOHNS HOPKINS UNIV,BALTIMORE,MD, USA.							BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; BUSHKIN SE, 1992, 8TH INT C AIDS 3 STD; CAIAFFA WT, 1993, 11TH INT C AIDS BERL; CRAIB KJP, 1992, CLIN INVEST MED, V15, P301; HIRSCHTICK R, 1993, AM REV RESPIR DIS, V147, pA1003; NIEMAN R, 1992, 8TH INT C AIDS 3 STD; NIEMAN RB, 1993, AIDS, V7, P705, DOI 10.1097/00002030-199305000-00015; PARK LP, 1992, J ACQ IMMUN DEF SYND, V5, P1124; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P612, DOI 10.1164/ajrccm/144.3_Pt_1.612	11	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					564	564						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046815				2022-12-28	WOS:A1994PB22900038
J	VANSCHAYCK, CP; VANHERWAARDEN, CLA; FOLGERING, H; VANWEEL, C				VANSCHAYCK, CP; VANHERWAARDEN, CLA; FOLGERING, H; VANWEEL, C			BRONCHODILATOR TREATMENT IN ASTHMA AND BRONCHITIS	BRITISH MEDICAL JOURNAL			English	Letter							DEATH						van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				CRANE J, 1989, LANCET, V1, P917; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					271	271		10.1136/bmj.309.6949.271a	http://dx.doi.org/10.1136/bmj.309.6949.271a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069156	Green Published			2022-12-28	WOS:A1994NZ18000049
J	BUNN, PA; HOFFMAN, SJ; NORRIS, D; GOLITZ, LE; AELING, JL				BUNN, PA; HOFFMAN, SJ; NORRIS, D; GOLITZ, LE; AELING, JL			SYSTEMIC THERAPY OF CUTANEOUS T-CELL LYMPHOMAS (MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME)	ANNALS OF INTERNAL MEDICINE			English	Review							T101 MONOCLONAL-ANTIBODY; RECOMBINANT INTERFERON ALFA-2B; CHRONIC LYMPHOCYTIC-LEUKEMIA; SOUTHWEST-ONCOLOGY-GROUP; NON-HODGKINS-LYMPHOMA; PHASE-II TRIAL; COMBINATION CHEMOTHERAPY; FOLLOW-UP; TUMOR STAGE; EXTRACORPOREAL PHOTOCHEMOTHERAPY	Objective: To review recent studies of systemic therapy for mycosis fungoides and the Sezary syndrome (cutaneous T-cell lymphomas). Data Sources: English-language articles indexed in MEDLINE from 1988 through 1994. Study Selection: All therapeutic studies were selected. Data Extraction: The data were abstracted without judgments on response criteria or patient numbers. Data quality and validity were assessed by independent author reviews. Data Synthesis: No systemic therapy cures patients with cutaneous T-cell lymphomas. Single and combined chemotherapeutic agents produce high response rates. Whether any of these is preferred is not established. A randomized trial comparing combination chemotherapy plus radiation therapy with topical therapy showed no survival benefit for the combination. Several adenosine analogs and retinoids were active, but their optimal use is uncertain. Interferons are as active as chemotherapeutic agents and may be less toxic. Interferon combined with psoralen plus ultraviolet A light therapy produces high complete response rates and long-lasting remissions. Combinations with other systemic therapies do not increase response rates. Photopheresis therapy should be regarded as experimental. Promising preliminary results were seen with interleukin-2 fusion toxins and several antibody conjugates. Conclusions: Systemic therapy should be considered effective and palliative. The principles of treating all low-grade lymphomas can be applied. Randomized trials are needed to evaluate new agents (such as a comparison of psoralen plus ultraviolet light with or without interferon), and large phase II trials are needed for new agents such as photopheresis, interleukin-2 fusion toxin, temozolomide, and others.	UNIV COLORADO, HLTH SCI CTR, DEPT DERMATOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BUNN, PA (corresponding author), UNIV COLORADO, CTR CANC, 4200 E 9TH AVE, CAMPUS BOX B-188, DENVER, CO 80262 USA.				NCI NIH HHS [1 P30 CA46934-06, 1 P50 CA58187-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTOMARE GF, 1993, INT J DERMATOL, V32, P138, DOI 10.1111/j.1365-4362.1993.tb01458.x; ARMUS S, 1990, J AM ACAD DERMATOL, V23, P898, DOI 10.1016/0190-9622(90)70312-6; BERNENGO MG, 1988, BRIT J DERMATOL, V119, P207, DOI 10.1111/j.1365-2133.1988.tb03203.x; BERTRAM JH, 1986, BLOOD, V68, P752; BIGLER RD, 1991, BONE MARROW TRANSPL, V7, P133; BRAATHEN LR, 1987, RETINOIDS TODAY TOMO, V9, P17; BRAVERMAN IM, 1987, J AM ACAD DERMATOL, V16, P45, DOI 10.1016/S0190-9622(87)70004-8; BRODER S, 1980, SEMIN ONCOL, V7, P310; BUNN PA, 1984, ANN INTERN MED, V101, P484, DOI 10.7326/0003-4819-101-4-484; BUNN PA, 1990, J INVEST DERMATOL, V95, pS209, DOI 10.1111/1523-1747.ep12875762; BUNN PA, 1988, PRINCIPLES PRACTICE, V2, P1799; BURG G, 1986, JAMA-J AM MED ASSOC, V256, P214, DOI 10.1001/jama.256.2.214; CARRASQUILLO JA, 1987, J NUCL MED, V28, P281; CARRASQUILLO JA, 1986, NEW ENGL J MED, V315, P673, DOI 10.1056/NEJM198609113151104; CASE DC, 1984, AM J CLIN ONCOL-CANC, V7, P453, DOI 10.1097/00000421-198410000-00012; CHATTERJEE M, 1993, ANN NY ACAD SCI, V690, P376; CLAUDY AL, 1983, BRIT J DERMATOL, V109, P49, DOI 10.1111/j.1365-2133.1983.tb03991.x; COHEN RB, 1993, ANN INTERN MED, V118, P114, DOI 10.7326/0003-4819-118-2-199301150-00007; COOPER DL, 1993, CANCER, V71, P2335, DOI 10.1002/1097-0142(19930401)71:7<2335::AID-CNCR2820710727>3.0.CO;2-D; CUMMINGS FJ, 1991, J CLIN ONCOL, V9, P565, DOI 10.1200/JCO.1991.9.4.565; DALLOT A, 1988, OCT INT S CUT LYMPH; DANGVU AP, 1988, J AM ACAD DERMATOL, V19, P692, DOI 10.1016/S0190-9622(88)70224-8; DEARDEN C, 1991, BRIT J CANCER, V64, P903, DOI 10.1038/bjc.1991.423; DILLMAN RO, 1984, J CLIN ONCOL, V2, P881, DOI 10.1200/JCO.1984.2.8.881; DOBERAUER C, 1989, ACTA DERM-VENEREOL, V69, P538; DRENO B, 1993, ACTA HAEMATOL-BASEL, V89, P28; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; ESTRACH T, 1989, J INVEST DERMATOL, V93, P549; FOON K A, 1987, Cancer, V59, P601, DOI 10.1002/1097-0142(19870201)59:3+<601::AID-CNCR2820591304>3.0.CO;2-J; Foss F., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P237; FOSS F, 1993, EUR J HAEMATOL, V51, P63; FOSS FM, 1992, J CLIN ONCOL, V10, P1907, DOI 10.1200/JCO.1992.10.12.1907; GISSELBRECHT C, 1994, BLOOD, V83, P2081; GREVER MR, 1983, BLOOD, V61, P279; GROTH O, 1979, ACTA DERM-VENEREOL, V59, P59; GROZEA PN, 1979, CANCER TREAT REP, V63, P647; HAGBERG H, 1988, EUR J HAEMATOL, V40, P31; HALLAHAN DE, 1988, J CLIN ONCOL, V6, P1177, DOI 10.1200/JCO.1988.6.7.1177; HEALD PW, 1991, ANN NY ACAD SCI, V636, P171, DOI 10.1111/j.1749-6632.1991.tb33448.x; HESKETH P, 1993, J CLIN ONCOL, V11, P1682, DOI 10.1200/JCO.1993.11.9.1682; HO AD, 1988, ONKOLOGIE, V11, P35, DOI 10.1159/000216477; HOLKINGTON MA, 1993, SERAGEN 1993 Q REPOR; HOTING E, 1988, CANCER, V62, P1044, DOI 10.1002/1097-0142(19880915)62:6<1044::AID-CNCR2820620603>3.0.CO;2-1; Jimbow K, 1987, Gan To Kagaku Ryoho, V14, P152; KANOFSKY JR, 1982, AM J CLIN ONCOL-CANC, V5, P179, DOI 10.1097/00000421-198204000-00066; KAPLAN EH, 1990, J NATL CANCER I, V82, P208, DOI 10.1093/jnci/82.3.208; KAYE FJ, 1989, NEW ENGL J MED, V321, P1784, DOI 10.1056/NEJM198912283212603; KEENAN AM, 1987, CANCER RES, V47, P6093; Kemme D J, 1992, Oncology (Williston Park), V6, P31; KESSLER JF, 1987, ARCH DERMATOL, V123, P201, DOI 10.1001/archderm.123.2.201; KNOBLER RM, 1991, J AM ACAD DERMATOL, V24, P247, DOI 10.1016/0190-9622(91)70036-2; KNOX SJ, 1991, BLOOD, V77, P20; KOHN EC, 1990, J CLIN ONCOL, V8, P155, DOI 10.1200/JCO.1990.8.1.155; KUZEL TM, 1990, J NATL CANCER I, V82, P203, DOI 10.1093/jnci/82.3.203; KUZEL TM, 1992, P AN M AM SOC CLIN, V11, pA1089; LANG MH, 1986, Z HAUTKRANKHEITEN, V61, P599; LEAVELL UW, 1976, SOUTHERN MED J, V69, P915, DOI 10.1097/00007611-197607000-00038; LEMAISTRE CF, 1991, BLOOD, V78, P1173; LEMAISTRE CF, 1992, BLOOD, V79, P2547; LEMAISTRE CF, 1993, BLOOD, V82, pA137; MADDOX AM, 1985, J AM ACAD DERMATOL, V12, P952, DOI 10.1016/S0190-9622(85)70121-1; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MCDONALD CJ, 1978, CANCER TREAT REP, V62, P1009; MILLER RA, 1981, LANCET, V2, P226; MOLIN L, 1979, ACTA DERM-VENEREOL, V59, P84; MOLIN L, 1987, ACTA DERM-VENEREOL, V67, P232; MOLIN L, 1987, ACTA DERM-VENEREOL, V67, P179; MOLIN L, 1980, ACTA DERM-VENEREOL, V60, P542; NICOLAS JF, 1989, DERMATOLOGICA, V179, P34, DOI 10.1159/000248098; ODWYER PJ, 1988, ANN INTERN MED, V108, P733, DOI 10.7326/0003-4819-108-5-733; OLSEN EA, 1989, J AM ACAD DERMATOL, V20, P395, DOI 10.1016/S0190-9622(89)70049-9; OREILLY SM, 1992, BR J CANCER S16, V65, P13; OSTERBORG A, 1993, BLOOD, V81, P1428; OTTE HG, 1992, HAUTARZT, V43, P695; PAPA G, 1991, BRIT J HAEMATOL, V79, P48, DOI 10.1111/j.1365-2141.1991.tb08119.x; PUTTICK L, 1983, J ROY SOC MED, V76, P1063, DOI 10.1177/014107688307601216; RESNIK KS, 1993, J AM ACAD DERMATOL, V29, P73, DOI 10.1016/0190-9622(93)70155-M; ROOK AH, 1991, ARCH DERMATOL, V127, P1535, DOI 10.1001/archderm.127.10.1535; ROSEN ST, 1987, J CLIN ONCOL, V5, P562, DOI 10.1200/JCO.1987.5.4.562; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; SAUSVILLE EA, 1988, ANN INTERN MED, V109, P372, DOI 10.7326/0003-4819-109-5-372; SAVEN A, 1992, BLOOD, V80, P587; SCHEMAN AJ, 1986, AM J MED, V80, P1199, DOI 10.1016/0002-9343(86)90687-X; SENTIS HJ, 1985, ACTA DERM-VENEREOL, V65, P179; SMALLEY RV, 1992, NEW ENGL J MED, V327, P1336, DOI 10.1056/NEJM199211053271902; SOLALCELIGNY P, 1993, NEW ENGL J MED, V329, P1608, DOI 10.1056/NEJM199311253292203; STRAVRIANEAS N, 1989, J INVEST DERMATOL, V93, P580; STREET ML, 1990, J AM ACAD DERMATOL, V23, P1084, DOI 10.1016/0190-9622(90)70337-H; THESTRUPPEDERSEN K, 1988, BRIT J DERMATOL, V118, P811, DOI 10.1111/j.1365-2133.1988.tb02600.x; THOMSEN K, 1984, ACTA DERM-VENEREOL, V64, P563; THOMSEN K, 1989, ACTA DERM-VENEREOL, V69, P536; THOMSEN K, 1979, CANCER TREAT REP, V63, P709; TIRELLI U, 1979, TUMORI, V65, P447, DOI 10.1177/030089167906500404; TOTTERMAN TH, 1985, SCAND J HAEMATOL, V34, P196; TURA S, 1987, HAEMATOLOGICA, V72, P337; VANBLADE J, 1993, J CLIN ONCOL, V11, P1165; VANDERMOLEN LA, 1990, JNCI-J NATL CANCER I, V82, P235, DOI 10.1093/jnci/82.3.235; VEGNA ML, 1990, EUR J HAEMATOL, V45, P32; VONDERHEID EC, 1987, ARCH DERMATOL, V123, P757, DOI 10.1001/archderm.123.6.757; VONHOFF DD, 1990, J NATL CANCER I, V82, P1353, DOI 10.1093/jnci/82.16.1353; WINKELMANN RK, 1974, MAYO CLIN PROC, V49, P519; WINKLER CF, 1986, J CLIN ONCOL, V4, P1094, DOI 10.1200/JCO.1986.4.7.1094; ZACHARIAE H, 1982, ACTA DERM-VENEREOL, V62, P162; ZACHARIAE H, 1987, ACTA DERM-VENEREOL, V67, P433; ZACKHEIM HS, 1989, J AM ACAD DERMATOL, V21, P757, DOI 10.1016/S0190-9622(89)70251-6; ZAKEM MH, 1986, CANCER, V58, P2611, DOI 10.1002/1097-0142(19861215)58:12<2611::AID-CNCR2820581210>3.0.CO;2-W; ZIC J, 1992, J AM ACAD DERMATOL, V27, P729, DOI 10.1016/0190-9622(92)70246-C; ZINCANI PL, 1988, OCT INT S CUT LYMPH	109	168	174	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					592	602		10.7326/0003-4819-121-8-199410150-00007	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085692				2022-12-28	WOS:A1994PL48600007
J	CUNNINGHAMRUNDLES, C; KAZBAY, K; HASSETT, J; ZHOU, Z; MAYER, L				CUNNINGHAMRUNDLES, C; KAZBAY, K; HASSETT, J; ZHOU, Z; MAYER, L			ENHANCED HUMORAL IMMUNITY IN COMMON VARIABLE IMMUNODEFICIENCY AFTER LONG-TERM TREATMENT WITH POLYETHYLENE GLYCOL-CONJUGATED INTERLEUKIN-2	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							B-CELL DIFFERENTIATION; HUMAN RECOMBINANT INTERLEUKIN-2; PERIPHERAL-BLOOD LYMPHOCYTES; IMMUNOGLOBULIN SECRETION; VARIED IMMUNODEFICIENCY; INTERFERON-GAMMA; INVIVO TREATMENT; GENE-EXPRESSION; T-CELLS; INVITRO				CUNNINGHAMRUNDLES, C (corresponding author), MT SINAI MED CTR, DEPT MED, DIV CLIN IMMUNOL, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				NCI NIH HHS [CA 53341] Funding Source: Medline; NIAID NIH HHS [AI-23504, AI 24671] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA053341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671, R01AI023504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BICHTHUY LT, 1985, EUR J IMMUNOL, V15, P1075, DOI 10.1002/eji.1830151102; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; CALLARD RE, 1986, EUR J IMMUNOL, V16, P1037, DOI 10.1002/eji.1830160902; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1992, CLIN IMMUNOL IMMUNOP, V64, P46, DOI 10.1016/0090-1229(92)90058-V; CUNNINGHAMRUNDLES C, 1993, CLIN RES, V41, pA369; FISCHER MB, 1993, J ALLERGY CLIN IMMUN, V92, P340, DOI 10.1016/0091-6749(93)90178-I; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; KATRE NV, 1987, P NATL ACAD SCI USA, V84, P1487, DOI 10.1073/pnas.84.6.1487; KATRE NV, 1990, J IMMUNOL, V144, P209; KAZBAY K, 1993, J IMMUNOL, V150, pA95; KRUGER G, 1984, J CLIN IMMUNOL, V4, P295, DOI 10.1007/BF00915297; Lipsky P E, 1988, Scand J Rheumatol Suppl, V76, P229; LOPEZBOTET M, 1982, J IMMUNOL, V128, P679; MAYER L, 1984, J CLIN INVEST, V74, P2115, DOI 10.1172/JCI111636; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; MITTLER R, 1985, J IMMUNOL, V134, P2393; NAKAGAWA N, 1987, J IMMUNOL, V138, P795; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; RALPH P, 1984, J IMMUNOL, V133, P2442; ROBB RI, 1981, IMMUNOL TODAY, V5, P203; RUMP JA, 1992, CLIN EXP IMMUNOL, V89, P204; SCHIFFMAN G, 1980, J IMMUNOL METHODS, V33, P133, DOI 10.1016/S0022-1759(80)80004-4; SHERRIS D, 1989, J IMMUNOL, V142, P2343; SMITH RA, 1993, PROGR IMMUNITY, P269; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPICKETT GP, 1989, IMMUNOL TODAY, V10, P192, DOI 10.1016/0167-5699(89)90323-X; SPLAWSKI JB, 1990, J IMMUNOL, V144, P562; STOHL W, 1988, CLIN IMMUNOL IMMUNOP, V49, P273, DOI 10.1016/0090-1229(88)90117-1; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; VOGELZANG NJ, 1993, J CLIN ONCOL, V11, P1809, DOI 10.1200/JCO.1993.11.9.1809; WHITE WB, 1985, NEW ENGL J MED, V312, P198, DOI 10.1056/NEJM198501243120402; WRIGHT JJ, 1987, NEW ENGL J MED, V317, P1516, DOI 10.1056/NEJM198712103172406; 1992, IMMUNODEFIC REV, V3, P195	36	32	32	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					918	921		10.1056/NEJM199410063311405	http://dx.doi.org/10.1056/NEJM199410063311405			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078552				2022-12-28	WOS:A1994PJ41900005
J	MAKELA, TP; TASSAN, JP; NIGG, EA; FRUTIGER, S; HUGHES, GJ; WEINBERG, RA				MAKELA, TP; TASSAN, JP; NIGG, EA; FRUTIGER, S; HUGHES, GJ; WEINBERG, RA			A CYCLIN ASSOCIATED WITH THE CDK-ACTIVATING KINASE MO15	NATURE			English	Article							PROTEIN-KINASE; CATALYTIC SUBUNIT; CELL-CYCLE; PHOSPHORYLATION; P34CDC2; CDC2; P40(MO15); P34(CDC2); INVITRO; YEAST	THE eukaryotic cell cycle is regulated by the sequential activation of cyclin-dependent kinases (CDKs)(1). CDK activation is dependent on cyclin binding(2-4) and phosphorylation of a conserved threonine (T161 in Cdc2)(5-9) mediated by the CDK-activating kinase CAK(9). A CDK-related kinase, MO15 (ref. 10), has been identified as the catalytic submit of CAK (refs 11-13). Here we use a yeast two-hybrid screen to show that a new human cyclin (cyclin H) is a MO15-associated protein. Cyclin H is a major MO15 partner in vivo and enhances the kinase activity of MO15 towards Cdk2/cyclin A. These findings demonstrate that a cyclin/kinase complex can function as a regulator of other cyclin/kinase complexes, and suggest that cyclin/kinase cascades may exist.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,CTR MED UNIV,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Massachusetts Institute of Technology (MIT); Whitehead Institute; Swiss Institute Experimental Cancer Research; University of Geneva			makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; nigg, erich/0000-0003-4835-5719				CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TASSAN JP, IN PRESS J CELL BIOL; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	26	242	246	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					254	257		10.1038/371254a0	http://dx.doi.org/10.1038/371254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078587				2022-12-28	WOS:A1994PG29000055
J	MARRONI, M; GRESELE, P; LANDONIO, G; LAZZARIN, A; COEN, M; VEZZA, R; SINNONE, MS; BOSCHETTI, E; NOSARI, AM; STAGNI, G; NENCI, GG; PAULUZZI, S				MARRONI, M; GRESELE, P; LANDONIO, G; LAZZARIN, A; COEN, M; VEZZA, R; SINNONE, MS; BOSCHETTI, E; NOSARI, AM; STAGNI, G; NENCI, GG; PAULUZZI, S			INTERFERON-ALPHA IS EFFECTIVE IN THE TREATMENT OF HIV-1-RELATED, SEVERE, ZIDOVUDINE-RESISTANT THROMBOCYTOPENIA - A PROSPECTIVE, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						THROMBOCYTOPENIA; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS; INTERFERON-ALPHA; PLATELET COUNT	HIV-RELATED THROMBOCYTOPENIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INTRAVENOUS-DRUG-USERS; HOMOSEXUAL MEN; VIRUS INFECTION; IMMUNE THROMBOCYTOPENIA; SYNDROME AIDS; PURPURA; THERAPY; SARCOMA	Objective: To determine the effect of interferon-alpha for severe, zidovudine-resistant, HIV-1-related thrombocytopenia. Design: Prospective, randomized, double-blind, placebo-controlled, multicenter, crossover trial. Setting: Outpatient clinics in Central Northern Italy. Patients: 15 sequential patients positive for HIV-1 with platelet counts less than 25 x 10(9)/L who were refractory to 1 month of full-dose (1000 mg/d) zidovudine. Intervention: Interferon-alpha (3 million units) or placebo (1 mL saline) three times a week subcutaneously for 4 weeks, followed by a 4-week washout period. Patients were then switched to the alternative treatment for the next 4 weeks, followed by another 4 weeks of washout, and they were randomly assigned to either sequence of treatment. Patients received zidovudine (200 mg three times daily) throughout the study. Measurements: The primary end point was the platelet count (measured weekly). Secondary end points were qualitative assessment of the platelet response; bleeding time; p24 antigen in serum; CD4/CD8 counts; beta(2)-microglobulin in serum; and platelet-associated IgG. Results: Interferon-alpha significantly increased platelet counts in the 12 patients who completed the study (baseline level, 15.6 +/- 7.1 x 10(9)/L; after 4 weeks of interferon-alpha therapy, 82.2 +/- 52.2 x 10(9)/L). The estimated increase in the platelet count after interferon-alpha compared with placebo was 60.0 x 10(9)/L (95% CI, 23.2 to 96.8 x 10(9)/L). The increase was already statistically significant after 3 weeks (66.6 +/- 49.7 x 10(9)/L) and remained significantly increased 1 week after discontinuing interferon-alpha therapy (58.2 +/- 45.0 x 10(9)/L). Placebo did not modify the platelet count. The bleeding time was significantly shortened by interferon-alpha. Four of 12 patients who had more serious alterations of some measures reflecting disease severity did not respond to interferon-alpha. No relevant side effects were observed. Conclusions: Interferon-alpha is a safe and effective treatment for zidovudine-resistant, HIV-related thrombocytopenia.	UNIV PERUGIA, INST INTERNAL & VASC MED, I-06126 PERUGIA, ITALY; NIGUARDA HOSP, DEPT MED ONCOL FALK, I-20162 MILAN, ITALY; UNIV MILAN, HOSP SAN RAFFAELE, CTR SAN LUIGI, INFECT DIS CLIN, I-20100 MILAN, ITALY; L SACCO HOSP VIALBA, DEPT INFECT DIS, I-20157 MILAN, ITALY	University of Perugia; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Luigi Sacco Hospital			Gresele, Paolo/F-6775-2013; gresele, paolo/AAG-8019-2019; LAZZARIN, Adriano/K-3607-2018	Gresele, Paolo/0000-0001-5365-8445; LAZZARIN, Adriano/0000-0003-2551-7754				ABRAMS DI, 1986, ANN INTERN MED, V104, P47, DOI 10.7326/0003-4819-104-1-47; AGNELLI G, 1984, NEW ENGL J MED, V311, P599; BALLEM PJ, 1992, NEW ENGL J MED, V327, P1779, DOI 10.1056/NEJM199212173272503; BORNE AEGKVD, 1980, BRIT J HAEMATOL, V45, P319, DOI 10.1111/j.1365-2141.1980.tb07151.x; BOYAR A, 1991, AIDS, V5, P1351, DOI 10.1097/00002030-199111000-00011; DURAND JM, 1991, AM J MED, V90, P675, DOI 10.1016/S0002-9343(05)80054-3; ELLIS ME, 1987, BRIT MED J, V295, P1519, DOI 10.1136/bmj.295.6612.1519; FINAZZI G, 1990, EUR J HAEMATOL, V45, P82; GAFA S, 1993, J INFECTION, V26, P33, DOI 10.1016/0163-4453(93)96744-B; GILL PS, 1989, ANN INTERN MED, V110, P937, DOI 10.7326/0003-4819-110-11-937; GOLDSWEIG HG, 1986, AM J HEMATOL, V21, P243, DOI 10.1002/ajh.2830210303; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; HUDSON JG, 1992, BRIT J HAEMATOL, V82, P630, DOI 10.1111/j.1365-2141.1992.tb06483.x; HYMES KB, 1988, NEW ENGL J MED, V318, P516, DOI 10.1056/NEJM198802253180812; IGLEHART D, 1989, 5TH INT C AIDS MONTR; JONES B, 1989, DESIGN ANAL CROSS OV, P1; KARPATKIN S, 1988, SEMIN HEMATOL, V25, P219; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; LANDONIO G, 1990, AIDS, V4, P29, DOI 10.1097/00002030-199001000-00004; LANDONIO G, 1993, AIDS, V7, P209, DOI 10.1097/00002030-199302000-00008; MANOHARAN A, 1991, BRIT J HAEMATOL, V79, P143, DOI 10.1111/j.1365-2141.1991.tb04513.x; MIELKE CH, 1969, BLOOD-J HEMATOL, V34, P204, DOI 10.1182/blood.V34.2.204.204; MIENTJES GHC, 1992, BRIT J HAEMATOL, V82, P615, DOI 10.1111/j.1365-2141.1992.tb06476.x; MONTANER JSG, 1990, J ACQ IMMUN DEF SYND, V3, P565; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; MURPHY KP, 1992, SOUTH MED J, V85, P557, DOI 10.1097/00007611-199205000-00021; NORTHFELT DW, 1991, AM J HEMATOL, V38, P238, DOI 10.1002/ajh.2830380317; OKSENHENDLER E, 1993, BLOOD, V82, P29, DOI 10.1182/blood.V82.1.29.bloodjournal82129; OKSENHENDLER E, 1989, ANN INTERN MED, V110, P365, DOI 10.7326/0003-4819-110-5-365; OKSENHENDLER E, 1988, BLOOD, V71, P1499; RARICK MU, 1991, AIDS, V5, P1357, DOI 10.1097/00002030-199111000-00012; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROSSI E, 1991, HAEMATOLOGICA, V76, P141; ROUTY JP, 1990, PRESSE MED, V19, P674; SCHULHAFER EP, 1987, AM J MED, V82, P313, DOI 10.1016/0002-9343(87)90076-3; SCHVED JF, 1992, J LAB CLIN MED, V120, P411; SHAFER RW, 1985, LANCET, V1, P934; SLOAND EM, 1992, EUR J HAEMATOL, V48, P168; SMITH MS, 1991, ANTIMICROB AGENTS CH, V35, P62, DOI 10.1128/AAC.35.1.62; SNYDER HW, 1991, AIDS, V5, P1257, DOI 10.1097/00002030-199110000-00017; STELLINI R, 1992, HAEMATOLOGICA, V77, P418; 1988, ANN INTERN MED, V107, P718	44	25	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					423	429		10.7326/0003-4819-121-6-199409150-00005	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053616				2022-12-28	WOS:A1994PF33700005
J	FISHER, DE				FISHER, DE			APOPTOSIS IN CANCER-THERAPY - CROSSING THE THRESHOLD	CELL			English	Review							WILD-TYPE P53; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR GENE; ANTICANCER AGENTS; PREVENT APOPTOSIS; CYCLE ARREST; MUTATIONS; BCL-2; AMPLIFICATION; RADIATION		HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School	FISHER, DE (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT HEMATOL ONCOL,BOSTON,MA 02115, USA.		Sebens, Susanne/C-1222-2010					ASKEW DS, 1991, ONCOGENE, V6, P1915; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P245; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADA M, 1993, BLOOD, V82, P3163; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	30	1353	1421	1	70	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					539	542		10.1016/0092-8674(94)90518-5	http://dx.doi.org/10.1016/0092-8674(94)90518-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069905				2022-12-28	WOS:A1994PD69300002
J	IZAURRALDE, E; LEWIS, J; MCGUIGAN, C; JANKOWSKA, M; DARZYNKIEWICZ, E; MATTAJ, IW				IZAURRALDE, E; LEWIS, J; MCGUIGAN, C; JANKOWSKA, M; DARZYNKIEWICZ, E; MATTAJ, IW			A NUCLEAR CAP-BINDING PROTEIN COMPLEX INVOLVED IN PRE-MESSENGER-RNA SPLICING	CELL			English	Article							EUKARYOTIC MESSENGER-RNA; INITIATION FACTOR-4E; POLYMERASE-II; HELA-CELLS; EXPORT; ANALOGS; IDENTIFICATION; PURIFICATION; TRANSLATION; INVITRO	A cap-binding protein complex (CBC) present in the nuclei of HeLa cells has been characterized. Purified CBC consists of two previously identified proteins, CBP80 and CBP20. These proteins are shown to cofractionate to apparent homogeneity and to be coimmunoprecipitable with anti-CBP80 antibodies, Analysis of the inhibition of pre-mRNA splicing in vitro and in vivo by chemically modified analogs of the cap structure, and of the binding of these analogs to CBC in vitro, suggests a role for the complex in splicing. Extracts immunodepleted of CBC do not efficiently splice an adenoviral pre-mRNA owing to blockage of an early step in splicing complex formation. CBC may therefore play a role in pre-mRNA recognition.	UNIV WARSAW,DEPT CHEM,PL-02093 WARSAW,POLAND; UNIV WARSAW,DEPT BIOPHYS,PL-02089 WARSAW,POLAND	University of Warsaw; University of Warsaw	IZAURRALDE, E (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Izaurralde, Elisa/G-3239-2012	Mattaj, Iain/0000-0002-5537-8284; Izaurralde, Elisa/0000-0001-7365-2649				ABOVICH N, 1994, IN PRESS GENES DEV, V8; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; DARZYNKIEWICZ E, 1990, NUCLEOS NUCLEOT, V9, P599, DOI 10.1080/07328319008045191; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FILIPOWICZ W, 1978, FEBS LETT, V96, P1, DOI 10.1016/0014-5793(78)81049-7; Frohman MA, 1990, PCR PROTOCOLS GUIDE; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANG V, 1994, J BIOL CHEM, V269, P6117; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; PATZELT E, 1987, NUCLEIC ACIDS RES, V15, P1387, DOI 10.1093/nar/15.4.1387; PATZELT E, 1983, NUCLEIC ACIDS RES, V11, P5821, DOI 10.1093/nar/11.17.5821; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROZEN F, 1987, NUCLEIC ACIDS RES, V15, P6489, DOI 10.1093/nar/15.16.6489; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; UEMURA H, 1992, J BACTERIOL, V174, P5526, DOI 10.1128/JB.174.17.5526-5532.1992; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	65	427	437	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					657	668		10.1016/0092-8674(94)90530-4	http://dx.doi.org/10.1016/0092-8674(94)90530-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069914				2022-12-28	WOS:A1994PD69300014
J	NISHI, R				NISHI, R			NEUROTROPHIC FACTORS - 2 ARE BETTER THAN ONE	SCIENCE			English	Editorial Material							FIBROBLAST GROWTH-FACTORS; SURVIVAL; NEURONS; LOCALIZATION; MOTONEURONS				NISHI, R (corresponding author), OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1992, J NEUROSCI, V12, P2726; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; STOCK A, 1992, J NEUROSCI, V12, P4688; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; WOODWARD WR, 1992, J NEUROSCI, V12, P142	15	57	64	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1052	1053		10.1126/science.8066443	http://dx.doi.org/10.1126/science.8066443			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066443				2022-12-28	WOS:A1994PC53900022
J	MUHLRAD, D; PARKER, R				MUHLRAD, D; PARKER, R			PREMATURE TRANSLATIONAL TERMINATION TRIGGERS MESSENGER-RNA DECAPPING	NATURE			English	Article							MESSENGER-RNA DECAY; NONSENSE MUTATIONS; ENDONUCLEOLYTIC CLEAVAGE; SACCHAROMYCES-CEREVISIAE; RICH SEQUENCES; DEGRADATION; POLY(A); YEAST; DEADENYLATION; STEP	THE degradation of messenger RNA in eukaryotic cells is initiated by endonucleolytic cleavage(1,2) or by shortening of the poly(A) tail(3-6), which for some mRNAs activates a deadenylation-dependent decapping reaction(7). One type of rapid mRNA degradation in eukaryotes is caused by premature termination of translation(8,9). This turnover process prevents the translation of aberrant mRNAs(10,11), may affect the abundance and splicing pattern of nuclear transcripts(12,13), and may be involved in the aetiology of human genetic disease(14). Here we show that premature translational termination in yeast triggers decapping, independent of deadenylation, thereby exposing the transcript to 5'-to-3' degradation. Inactivation of the 5'-to-3' exonuclease reveals an additional 3'-to-5' pathway of mRNA turnover. These observations provide in vivo evidence for two new mechanisms of mRNA decay.			MUHLRAD, D (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,LIFE SCI S,TUCSON,AZ 85721, USA.							BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEVENS A, 1987, ARCH BIOCHEM BIOPHYS, V252, P339, DOI 10.1016/0003-9861(87)90040-3; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG H, 1992, MOL CELL BIOL, V12, P1553, DOI 10.1128/MCB.12.4.1553	23	330	334	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					578	581		10.1038/370578a0	http://dx.doi.org/10.1038/370578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052314				2022-12-28	WOS:A1994PC53700061
J	KENNEDY, TE; SERAFINI, T; DELATORRE, JR; TESSIERLAVIGNE, M				KENNEDY, TE; SERAFINI, T; DELATORRE, JR; TESSIERLAVIGNE, M			NETRINS ARE DIFFUSIBLE CHEMOTROPIC FACTORS FOR COMMISSURAL AXONS IN THE EMBRYONIC SPINAL-CORD	CELL			English	Article							C-ELEGANS; NERVOUS-SYSTEM; GUIDES CELL; GUIDANCE; EXPRESSION; NEURONS; PROTEIN; DIFFERENTIATION; MIGRATIONS; GRADIENTS	The guidance of axons to their targets in the developing nervous system is believed to involve diffusible chemotropic factors secreted by target cells. Floor plate cells at the ventral midline of the spinal cord secrete a diffusible factor or factors that promotes the outgrowth of spinal commissural axons and attracts these axons in vitro. Two membrane-associated proteins isolated from brain, netrin-1 and netrin-2, possess commissural axon outgrowth-promoting activity. We show here that netrin-1 RNA is expressed by floor plate cells, whereas netrin-2 RNA is detected at lower levels in the ventral two-thirds of the spinal cord, but not the floor plate. Heterologous cells expressing recombinant netrin-1 or netrin-2 secrete diffusible farms of the proteins and can attract commissural axons at a distance. These results show that netrin-1 is a chemotropic factor expressed by floor plate cells and suggest that the two netrin proteins guide commissural axons in the developing spinal cord.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	KENNEDY, TE (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.		de la Torre, Jose R/H-2081-2012	de la Torre, Jose R/0000-0002-9553-6048	NINDS NIH HHS [NS07067] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BOURRAT F, 1990, ARCH ITAL BIOL, V128, P151; BOURRAT F, 1990, J COMP NEUROL, V249, P1; CAJAL SRY, 1892, CELLULE, V9, P119; CAJAL SRY, 1909, HISTOLOGIE SYSTEME N, V1, P1952; COUTINHO LL, 1992, BIOTECHNIQUES, V13, P722; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V2, P61; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HOLLEY JA, 1982, J COMP NEUROL, V205, P371, DOI 10.1002/cne.902050406; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JESSELL TM, 1992, HARVEY LECT, V86, P87; Kingsbury BF, 1920, J COMP NEUROL, V32, P113, DOI 10.1002/cne.900320106; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Sambrook J, 1989, MOL CLONING LABORATO; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tessier-Lavigne M, 1992, Curr Opin Neurobiol, V2, P60, DOI 10.1016/0959-4388(92)90163-F; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; YAGINUMA H, 1990, DEVELOPMENT, V108, P705; YAMAMOTO M, 1986, J NEUROSCI, V6, P3576	36	1050	1075	4	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					425	435		10.1016/0092-8674(94)90421-9	http://dx.doi.org/10.1016/0092-8674(94)90421-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062385				2022-12-28	WOS:A1994PC40500009
J	KRETZSCHMAR, M; KAISER, K; LOTTSPEICH, F; MEISTERERNST, M				KRETZSCHMAR, M; KAISER, K; LOTTSPEICH, F; MEISTERERNST, M			A NOVEL MEDIATOR OF CLASS-II GENE-TRANSCRIPTION WITH HOMOLOGY TO VIRAL IMMEDIATE-EARLY TRANSCRIPTIONAL REGULATORS	CELL			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; SIMPLEX VIRUS TYPE-1; VARICELLA-ZOSTER VIRUS; DNA TOPOISOMERASE-I; ACTIVATION DOMAIN; MOLECULAR-CLONING; FACTOR-TFIIB; COMPLEX; IDENTIFICATION	Our investigations of mammalian class II gene transcription resulted in identification, purification, and cloning of the corresponding cDNA of a cellular factor (p15) that mediates the effects of several distinct activators on transcription in vitro. Functional deletion analyses revealed a bipartite structure of p15 comprising an amino-terminal regulatory domain and a carboxy-terminal cryptic DNA-binding domain. We provide evidence that activity of p15 is controlled by protein kinases that target the regulatory domain. Structural and functional similarities, including sequence homology to domains essential for cofactor function, cofactor activity, promiscuity with respect to transcriptional activators, and interactions with components of the basal transcription machinery, relate this novel cellular cofactor to viral immediate-early transcriptional regulators.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Rockefeller University; Max Planck Society	KRETZSCHMAR, M (corresponding author), UNIV MUNICH, GENZENTRUM, MOLEK BIOL LAB, D-82152 MARTINSRIED, GERMANY.							BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COHEN JI, 1993, J VIROL, V67, P4246, DOI 10.1128/JVI.67.7.4246-4251.1993; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM TK, 1993, J BIOL CHEM, V268, P20866; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MARTIN KJ, 1990, GENE DEV, V4, P2376, DOI 10.1101/gad.4.12b.2376; MEIER UT, 1992, CELL, V70, P127; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NG TI, 1994, J VIROL, V68, P1350, DOI 10.1128/JVI.68.3.1350-1359.1994; PATERSON T, 1990, J GEN VIROL, V71, P1775, DOI 10.1099/0022-1317-71-8-1775; PERERA LP, 1993, J VIROL, V67, P4474, DOI 10.1128/JVI.67.8.4474-4483.1993; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PUGH BF, 1992, J BIOL CHEM, V267, P679; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SHEPARD AA, 1989, J VIROL, V63, P3714, DOI 10.1128/JVI.63.9.3714-3728.1989; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; SOMA GI, 1984, BIOCHEM BIOPH RES CO, V124, P164, DOI 10.1016/0006-291X(84)90931-8; STELZER G, 1994, IN PRESS MOL CELL BI, V14; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WU CL, 1991, J VIROL, V65, P1149, DOI 10.1128/JVI.65.3.1149-1159.1991; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZOPF D, 1987, GENE DEV, V1, P699, DOI 10.1101/gad.1.7.699	52	186	190	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	1994	78	3					525	534		10.1016/0092-8674(94)90429-4	http://dx.doi.org/10.1016/0092-8674(94)90429-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062392				2022-12-28	WOS:A1994PC40500017
J	PENSWICK, J; WRIGHT, AL				PENSWICK, J; WRIGHT, AL			SKIN NECROSIS INDUCED BY STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter											PENSWICK, J (corresponding author), BRADFORD ROYAL INFIRM,BRADFORD BD9 6RJ,ENGLAND.							CIMO PL, 1979, AM J HEMATOL, V6, P125, DOI 10.1002/ajh.2830060204; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; SMITHSON JE, 1993, BRIT MED J, V306, P973, DOI 10.1136/bmj.306.6883.973-b; 1993, ANROIO, P349	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					378	378		10.1136/bmj.309.6951.378	http://dx.doi.org/10.1136/bmj.309.6951.378			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081140	Green Published			2022-12-28	WOS:A1994PB31600021
J	PENTON, A; CHEN, YJ; STAEHLINGHAMPTON, K; WRANA, JL; ATTISANO, L; SZIDONYA, J; CASSILL, JA; MASSAGUE, J; HOFFMANN, FM				PENTON, A; CHEN, YJ; STAEHLINGHAMPTON, K; WRANA, JL; ATTISANO, L; SZIDONYA, J; CASSILL, JA; MASSAGUE, J; HOFFMANN, FM			IDENTIFICATION OF 2 BONE MORPHOGENETIC PROTEIN TYPE-I RECEPTORS IN DROSOPHILA AND EVIDENCE THAT BRK25D IS A DECAPENTAPLEGIC RECEPTOR	CELL			English	Article							GROWTH-FACTOR-BETA; BIOCHEMICAL-CHARACTERIZATION; CYTOGENETIC ANALYSIS; GENE; MELANOGASTER; PATTERN; EMBRYO; MEMBER; FAMILY; SUPERFAMILY	Drosophila sequences at chromosomal positions 25D (Brk25D) and 43E (Brk43E) are similar to the TGF beta type I receptor serine/threonine kinases and are expressed broadly during embryogenesis. Brk25D binds dpp protein and bone morphogenetic protein 2 with high affinity. Mutations affecting Brk25D map to the gene thick veins and block the expression of two decapentaplegic-responsive (dpp-responsive) genes, dpp and labial, in the embryonic midgut. Defects in Brk25D receptor function combined with reduced expression of dpp ligand produce mutant phenotypes in the embryo and adult. Brk43E is the product of the gene saxophone, which also interacts with dpp. We conclude that dpp signaling in vivo is mediated by at least two receptors, Brk25D and Brk43E.	UNIV WISCONSIN, SCH MED, GENET LAB, MADISON, WI 53706 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; UNIV HORT & FOOD IND, DEPT GENET & PLANT BREEDING, H-1518 BUDAPEST, HUNGARY; UNIV TEXAS, DIV LIFE SCI, SAN ANTONIO, TX 78249 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Corvinus University Budapest; University of Texas System	PENTON, A (corresponding author), UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA.		Wrana, Jeffrey/F-8857-2013; Cassill, Aaron/F-5467-2010	Hoffmann, F. Michael/0000-0002-2770-9656; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [P30CA007175, T32CA009135] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006610] Funding Source: NIH RePORTER; NCI NIH HHS [CA09135, CA07175] Funding Source: Medline; NCRR NIH HHS [RR06610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEITZLER P, 1993, GENETICS, V135, P105; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KOENIG BB, 1994, IN PRESS MOL CELL BI; Lawrence P.A., 1986, P229; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1993, DEV BIOL, V159, P276, DOI 10.1006/dbio.1993.1240; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Sambrook J, 1989, MOL CLONING LABORATO; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SEGAL D, 1985, GENETICS, V109, P119; STAEHLINGHAMPTO.K, 1994, IN PRESS DEV BIOL; STAEHLINGHAMPTO.K, 1994, IN PRESS CELL GROWTH; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TERRACOL R, 1994, IN PRESS GENETICS; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	47	235	245	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					239	250		10.1016/0092-8674(94)90294-1	http://dx.doi.org/10.1016/0092-8674(94)90294-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044838				2022-12-28	WOS:A1994NZ24200008
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			STATISTICS NOTES - ONE-SIDED AND 2-SIDED TESTS OF SIGNIFICANCE .8.	BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							GALLOE AM, 1993, BRIT MED J, V307, P585, DOI 10.1136/bmj.307.6904.585; LUND MB, 1991, BRIT J RADIOL, V64, P520, DOI 10.1259/0007-1285-64-762-520; LUTHRA P, 1982, BMJ-BRIT MED J, V284, P1013, DOI 10.1136/bmj.284.6321.1013	3	83	83	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					248	248		10.1136/bmj.309.6949.248	http://dx.doi.org/10.1136/bmj.309.6949.248			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069143	Green Published, Bronze			2022-12-28	WOS:A1994NZ18000020
J	VALIMAKI, MJ; KARKKAINEN, M; LAMBERG-ALLARDT, C; LAITINEN, K; ALHAVA, E; HEIKKINEN, J; IMPIVAARA, O; MAKELA, P; PALMGREN, J; SEPPANEN, R; VUORI, I; AKERBLOM, HK; UHARI, M; VIIKARI, J; DAHL, M; PESONEN, E; PIETIKAINEN, M; SALO, M; AROMAA, A; KANNAS, L; KELTIKANGASJARVINEN, L; KUUSELA, V; PYORALA, K; RONNEMAA, T; RASANEN, L; SAMA, S; SEPPANEN, A; TELAMA, R				VALIMAKI, MJ; KARKKAINEN, M; LAMBERG-ALLARDT, C; LAITINEN, K; ALHAVA, E; HEIKKINEN, J; IMPIVAARA, O; MAKELA, P; PALMGREN, J; SEPPANEN, R; VUORI, I; AKERBLOM, HK; UHARI, M; VIIKARI, J; DAHL, M; PESONEN, E; PIETIKAINEN, M; SALO, M; AROMAA, A; KANNAS, L; KELTIKANGASJARVINEN, L; KUUSELA, V; PYORALA, K; RONNEMAA, T; RASANEN, L; SAMA, S; SEPPANEN, A; TELAMA, R			EXERCISE, SMOKING, AND CALCIUM INTAKE DURING ADOLESCENCE AND EARLY ADULTHOOD AS DETERMINANTS OF PEAK BONE MASS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; WOMEN; CHILDREN; DENSITOMETRY; BALANCE; FEMALES	Objective-To evaluate the contribution to peak bone mass of exercise, smoking, and calcium intake in adolescents and young adults. Design-Prospective cohort study with end point measurement (bane mineral density) after 11 years' follow up for lifestyle. Setting-Five university hospital clinics. Subjects-264 (153 females, 111 males) subjects aged 9 to 18 years at the beginning of the follow up and 20 to 29 years at the time of measurement of bone mineral density. Main outcome measure-Bone mineral density of lumbar spine and femoral neck by dual energy x ray absorptiometry; measures of physical activity and smoking and estimates of calcium intake repeated three times during follow up. Results-In the groups with the lowest and highest levels of exercise the femoral bone mineral densities (adjusted for age and weight) were 0.918 and 0.988 g/cm(2) for women (P = 0.015, analysis of covariance) and 0.943 and 1.042 g/cm(2) for men (P = 0.005), respectively; at the lumbar spine the respective values were 1.045 and 1.131 (P = 0.005) for men. In men the femoral bone mineral densities (adjusted for age, weight, and exercise) were 1.022 and 0.923 g/cm(2) for the groups with the lowest and highest values of smoking index (P = 0.054, analysis of covariance). In women the adjusted femoral. bone mineral density increased by 4.7% together with increasing calcium intake (P = 0.089, analysis of covariance). In multiple regression analysis on bone mineral density of the femoral neck, weight, exercise, age, and smoking were independent predictors for men; with weight, exercise, and age for women. These predictors together explained 38% of the variance in bone mineral density in women and 46% in men. At the lumbar spine, weight, smoking, and exercise were predictors for men; and only weight for women. Conclusions-Regular exercise and not smoking is important in achieving maximal peak bone mass in adolescents and young adults.	MINERVA FDN, INST MED RES, HELSINKI, FINLAND; UNIV HELSINKI, ALCOHOL DIS RES UNIT, HELSINKI, FINLAND; UNIV KUOPIO, CENT HOSP, DEPT SURG, KUOPIO, FINLAND; DEACONESS INST OULU, OSTEOPOROSIS CLIN, OULU, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, TURKU, FINLAND; UNIV HELSINKI, DEPT OBSTET & GYNAECOL, HELSINKI, FINLAND; NATL PUBL HLTH INST, HELSINKI, FINLAND; UKK INST HLTH PROMOT RES, TAMPERE, FINLAND; UNIV HELSINKI, CHILDRENS HOSP, DEPT PAEDIAT 2, HELSINKI, FINLAND; UNIV OULU, DEPT PAEDIAT, OULU, FINLAND; UNIV TURKU, DEPT MED, TURKU, FINLAND; UNIV TURKU, DEPT PAEDIAT, TURKU, FINLAND; UNIV HELSINKI, DEPT PAEDIAT 1, HELSINKI, FINLAND; UNIV KUOPIO, DEPT PAEDIAT, SF-70211 KUOPIO, FINLAND; TAMPERE UNIV, DEPT PAEDIAT, SF-33101 TAMPERE, FINLAND; SOCIAL INSURANCE INST, HELSINKI, FINLAND; UNIV HELSINKI, DEPT PSYCHOL, SF-00100 HELSINKI, FINLAND; STAT CENT BUR, HELSINKI, FINLAND; UNIV KUOPIO, DEPT MED, SF-70210 KUOPIO, FINLAND; UNIV HELSINKI, DEPT APPL CHEM & MICROBIOL, DIV NUTR, HELSINKI, FINLAND; UNIV HELSINKI, DEPT PUBL HLTH, HELSINKI, FINLAND; SOCIAL INSURANCE INST, REHABIL RES CTR, SF-20720 TURKU, FINLAND; UNIV JYVASKYLA, DEPT EDUC PHYS, SF-40100 JYVASKYLA, FINLAND	University of Helsinki; Kuopio University Hospital; University of Eastern Finland; University of Helsinki; Finland National Institute for Health & Welfare; UKK Institute; University of Helsinki; University of Oulu; University of Turku; University of Turku; University of Helsinki; University of Eastern Finland; Tampere University; University of Helsinki; University of Eastern Finland; University of Helsinki; University of Helsinki; University of Jyvaskyla	VALIMAKI, MJ (corresponding author), UNIV HELSINKI, CENT HOSP, DEPT MED 3, SF-00290 HELSINKI, FINLAND.			Palmgren, Juni/0000-0002-9031-8615; Lamberg-Allardt, Christel/0000-0001-7326-1904				ANGUS RM, 1988, BONE MINER, V4, P265; AVIOLI LV, 1991, CALCIFIED TISSUE INT, V48, P221, DOI 10.1007/BF02556371; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BYCKLING T, 1985, ACTA PAEDIATR SCAND, P195; CAULEY JA, 1988, JAMA-J AM MED ASSOC, V260, P3150, DOI 10.1001/jama.260.21.3150; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; HEANEY RP, 1990, J NUTR, V120, P869, DOI 10.1093/jn/120.8.869; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KROGER H, 1992, BONE MINER, V17, P75, DOI 10.1016/0169-6009(92)90712-M; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1992, AM J CLIN NUTR, V55, P992, DOI 10.1093/ajcn/55.5.992; PARFITT AM, 1988, OSTEOPOROSIS ETIOLOG; PICARD D, 1988, BONE MINER, V4, P299; RASANEN L, 1991, ANN MED, V23, P73, DOI 10.3109/07853899109147934; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA CW, 1991, J BONE MINER RES, V6, P1227; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SOWERS MF, 1985, PREV MED, V14, P585, DOI 10.1016/0091-7435(85)90079-9; TELAMA R, 1985, ACTA PAEDIATR SCAND, P169; VAINIO P, 1992, NUCL MED COMMUN, V13, P252, DOI 10.1097/00006231-199204000-00156; 1989, RECOMMENDED DIETARY	23	229	234	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 23	1994	309	6949					230	235		10.1136/bmj.309.6949.230	http://dx.doi.org/10.1136/bmj.309.6949.230			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069139	Green Published			2022-12-28	WOS:A1994NZ18000015
J	UITERWAAL, CSPM; GROBBEE, DE; WITTEMAN, JCM; VANSTIPHOUT, WAHJ; KRAUSS, XH; HAVEKES, LM; DEBRUIJN, AM; VANTOL, A; HOFMAN, A				UITERWAAL, CSPM; GROBBEE, DE; WITTEMAN, JCM; VANSTIPHOUT, WAHJ; KRAUSS, XH; HAVEKES, LM; DEBRUIJN, AM; VANTOL, A; HOFMAN, A			POSTPRANDIAL TRIGLYCERIDE RESPONSE IN YOUNG-ADULT MEN AND FAMILIAL RISK FOR CORONARY ATHEROSCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY ARTERIOSCLEROSIS; TRIGLYCERIDES; CORONARY DISEASE; LIPOPROTEINS; HEREDITARY DISEASES	DENSITY LIPOPROTEIN CHOLESTEROL; ARTERY DISEASE; CHYLOMICRON REMNANTS; RICH LIPOPROTEINS; PLASMA-CLEARANCE; RETINYL ESTERS; METABOLISM; PRECIPITATION; LIPEMIA; VITAMIN	Objective: To determine whether an increased familial risk for coronary artery disease in young adult men is related to changes in postprandial lipoprotein metabolism. Design: Cross-sectional study. Setting: Coronary angiography departments of four central general hospitals in the Netherlands. Patients: 80 sons (mean age, 24.8 years) of men with severe coronary artery disease and 55 sons (mean age, 23.2 years) of controls. Measurements: Postprandial levels of serum triglycerides, retinyl palmitate, and total cholesterol were measured during a 12-hour period after a standardized oral lipid load. Results: Both groups showed a marked increase in levels of serum triglyceride and retinyl palmitate after lipid loading, reaching a maximum 4 to 6 hours postprandially. No changes in postprandial total cholesterol levels were observed in either group. Sons of men with coronary artery disease had prolonged postprandial hypertriglyceridemia when compared with sons of controls. Significant differences in postprandial triglyceride levels were found at 8 hours (difference, 0.35 mmol/L; 95% CI, 0.07 to 0.62 mmol/L), at 10 hours (difference, 0.21 mmol/L; CI, 0.06 to 0.36 mmol/L), and at 12 hours after lipid loading (difference, 0.13 mmol/L; CI, 0.01 to 0.26 mmol/L). Levels of postprandial retinyl palmitate were also slightly, but not statistically, different (mainly after 6 hours). Conclusions: Healthy young adult sons, whose fathers have established coronary artery disease, have prolonged postprandial hypertriglyceridemia. Changes in postprandial lipoprotein metabolism appear to be associated with familial risk for coronary atherosclerosis.	ZUIDERZIEKENHUIS ROTTERDAM, DEPT CARDIOL, 3075 EA ROTTERDAM, NETHERLANDS; TNO, INST AGEING & VASC RES, GAUBIUS LAB, 2300 AK LEIDEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT BIOCHEM, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Netherlands Organization Applied Science Research; Erasmus University Rotterdam	UITERWAAL, CSPM (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BERR F, 1984, J LIPID RES, V25, P805; BERR F, 1986, J LIPID RES, V27, P645; BOERWINKLE E, 1994, AM J HUM GENET, V54, P341; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHEUNG MC, 1977, J CLIN INVEST, V60, P43, DOI 10.1172/JCI108767; COHN JS, 1988, J LIPID RES, V29, P469; COHN JS, 1989, METABOLISM, V38, P484, DOI 10.1016/0026-0495(89)90203-5; DAVIS CE, 1980, CIRCULATION, V62, P24; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; GROVE TH, 1979, CLIN CHEM, V25, P560; HAVEKES LM, 1987, J LIPID RES, V28, P455; HAZZARD WR, 1976, METABOLISM, V25, P777, DOI 10.1016/0026-0495(76)90149-9; KRASINSKI SD, 1990, J CLIN INVEST, V85, P883, DOI 10.1172/JCI114515; KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MORRISON JA, 1982, METABOLISM, V31, P158, DOI 10.1016/0026-0495(82)90129-9; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PARTHASARATHY S, 1989, ARTERIOSCLEROSIS, V9, P398, DOI 10.1161/01.ATV.9.3.398; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; PEARSON TA, 1979, AM J EPIDEMIOL, V109, P285, DOI 10.1093/oxfordjournals.aje.a112682; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; RYU JE, 1992, STROKE, V23, P823, DOI 10.1161/01.STR.23.6.823; SCHLIERF G, 1987, METABOLISM, V36, P726, DOI 10.1016/0026-0495(87)90107-7; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SIMONS LA, 1987, ATHEROSCLEROSIS, V65, P181, DOI 10.1016/0021-9150(87)90020-7; SIMPSON HS, 1990, ATHEROSCLEROSIS, V85, P193, DOI 10.1016/0021-9150(90)90111-U; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; STALENHOEF AFH, 1984, P NATL ACAD SCI-BIOL, V81, P1839, DOI 10.1073/pnas.81.6.1839; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; WEINBERG R, 1982, AM J EPIDEMIOL, V116, P385, DOI 10.1093/oxfordjournals.aje.a113422; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; WILSON DE, 1983, METABOLISM, V32, P514, DOI 10.1016/0026-0495(83)90016-1; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1989, VOORLICHTINGSBUREAU	43	111	113	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					576	+		10.7326/0003-4819-121-8-199410150-00004	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085689				2022-12-28	WOS:A1994PL48600004
J	OSTER, MH; ENDERS, SR; SAMUELS, SJ; CONE, LA; HOOTON, TM; BROWDER, HP; FLYNN, NM				OSTER, MH; ENDERS, SR; SAMUELS, SJ; CONE, LA; HOOTON, TM; BROWDER, HP; FLYNN, NM			MEGESTROL-ACETATE IN PATIENTS WITH AIDS AND CACHEXIA	ANNALS OF INTERNAL MEDICINE			English	Article						MEGESTROL; ACQUIRED IMMUNODEFICIENCY SYNDROME; CACHEXIA; WEIGHT GAIN; APPETITE	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EXOGENOUS ADRENOCORTICOTROPIC HORMONE; CANCER ANOREXIA; CORTISOL RESPONSES; BODY-COMPOSITION; CONTROLLED TRIAL; INFECTION; THERAPY; CATS	Objective: To study the effects of a megestrol acetate liquid formulation (800 mg/d) on body weight, body composition, caloric intake, and mental outlook in patients with the acquired immunodeficiency syndrome (AIDS) who had cachexia. Design: Twelve-week, multicenter, randomized, double-blind, placebo-controlled trial. Setting: Multiple clinical centers. Patients: 100 patients with AIDS who had weight loss of 10% or more of ideal body weight were randomly assigned to placebo (n = 48) or megestrol acetate (n = 52). Measurements: Caloric intake, body weight, body composition, and sense of well-being. Results: Most patients receiving megestrol acetate had increased caloric intake resulting in body weight gain (mainly fat mass). From baseline to week 8, the megestrol acetate group increased their daily caloric intake by 608 calories, whereas the placebo group increased intake by 134 calories (difference, 474 calories; 95% CI, -68 to 880 calories). Body weight in the megestrol acetate group increased by 3.86 kg from baseline to week 8, although it decreased by 0.46 kg in the placebo group (difference, 4.32 kg; CI, 2.42 to 6.22 kg). At week 8 in the megestrol acetate group, patients gained 3.68 kg in fat mass and those in the placebo group lost 0.28 kg (difference, 3.96 kg; CI, 2.49 to 5.43 kg). Body water, lean mass, and patient survival were not statistically different between treatment groups. Patients treated with megestrol acetate had an increased sense of well-being when compared with patients who received placebo. Conclusions: This megestrol acetate liquid formulation is well tolerated, increases food intake, results in body weight gain, and improves the sense of well-being in cachectic patients with AIDS.	UNIV CALIF DAVIS, MED CTR, DIV GEN MED, SACRAMENTO, CA 95817 USA; HARBORVIEW MED CTR, SEATTLE, WA USA; BRISTOL MYERS SQUIBB, PLAINSBORO, NJ USA; EISENHOWER MED CTR, RANCHO MIRAGE, CA USA	University of California System; University of California Davis; Harborview Medical Center; Bristol-Myers Squibb								ANTONY MA, 1988, DIGEST DIS SCI, V33, P1141, DOI 10.1007/BF01535791; BOCK RD, 1975, MULTIVARIATE STATIST, P490; BRUERA E, 1990, CANCER, V66, P1279, DOI 10.1002/1097-0142(19900915)66:6&lt;1279::AID-CNCR2820660630&gt;3.0.CO;2-R; GIBSON RS, 1990, PRINCIPLES NUTRITION, P190; GILLIN JS, 1985, ANN INTERN MED, V102, P619, DOI 10.7326/0003-4819-102-5-619; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5; HENRY K, 1992, ANN INTERN MED, V116, P53, DOI 10.7326/0003-4819-116-1-53; KOTLER DP, 1989, ARCH INTERN MED, V149, P901, DOI 10.1001/archinte.149.4.901; KOTLER DP, 1990, AM J CLIN NUTR, V51, P7, DOI 10.1093/ajcn/51.1.7; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1992, J NUTR, V122, P723, DOI 10.1093/jn/122.suppl_3.723; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LOPRESTI JS, 1989, ANN INTERN MED, V110, P970, DOI 10.7326/0003-4819-110-12-970; LOPRINZI CL, 1992, MAYO CLIN PROC, V67, P1160, DOI 10.1016/S0025-6196(12)61145-8; LOPRINZI CL, 1993, J CLIN ONCOL, V11, P762, DOI 10.1200/JCO.1993.11.4.762; LOPRINZI CL, 1990, JNCI-J NATL CANCER I, V82, P1127, DOI 10.1093/jnci/82.13.1127; MIDDLETON DJ, 1987, CAN J VET RES, V51, P60; NATHWANI D, 1990, ACTA DERM-VENEREOL, V70, P520; OTT M, 1993, AM J CLIN NUTR, V57, P15, DOI 10.1093/ajcn/57.1.15; TCHEKMEDYIAN NS, 1987, JAMA-J AM MED ASSOC, V257, P1195, DOI 10.1001/jama.257.9.1195; TCHEKMEDYIAN NS, 1992, CANCER, V69, P1268; VONROENN JH, 1989, ANN INTERN MED, V110, P667; VONROENN JH, 1988, ANN INTERN MED, V109, P840, DOI 10.7326/0003-4819-109-10-840; VONROENN JH, 1992, INT C AIDS; WATSON ADJ, 1989, RES VET SCI, V47, P374, DOI 10.1016/S0034-5288(18)31264-5; 1987, SAS VERSION 6 04; 1980, METROPOLITAN HEIGHT	28	184	187	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					400	408		10.7326/0003-4819-121-6-199409150-00002	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053613				2022-12-28	WOS:A1994PF33700002
J	HAYLES, J; FISHER, D; WOOLLARD, A; NURSE, P				HAYLES, J; FISHER, D; WOOLLARD, A; NURSE, P			TEMPORAL-ORDER OF S-PHASE AND MITOSIS IN FISSION YEAST IS DETERMINED BY THE STATE OF THE P34(CDC2) MITOTIC B-CYCLIN COMPLEX	CELL			English	Article							CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; PROTEIN-KINASE; BUDDING YEAST; GENE-PRODUCT; G2; FIBROBLASTS; INVOLVEMENT	We show here that the state of the p34(cdc2)-p56(cdc13) mitotic B cyclin complex determines whether a fission yeast cell undergoes S phase or mitosis. Mutants defective for p56(cdc13) reset to G1 and rereplicate their DNA, while cells completely lacking the p34(cdc2)-p56(cdc13) complex undergo multiple rounds of S phase. In contrast, formation of the p34(cdc2)-p56(cdc13) complex in G1 promotes cells inappropriately into mitosis. We propose that the temporal order of S phase and mitosis is maintained by the presence or absence of the p34(cdc2)-p56(cdc13) complex.			HAYLES, J (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Fisher, Daniel/D-6915-2018	Fisher, Daniel/0000-0002-0822-3482	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FORSBURG SL, 1994, J CELL SCI, V107, P601; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Goff LJ., 1990, BIOL RED ALGAE, P43; HAGAN I, 1988, J CELL SCI, V91, P587; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; JOHN B, 1990, MELOSIS; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nagl W., 1985, CELL DIVISION CYCLE, P217; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; OKEEFE SJ, 1991, P NATL ACAD SCI USA, V88, P7869, DOI 10.1073/pnas.88.17.7869; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAZER S, 1990, J CELL SCI, V97, P509; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH AV, 1991, DEVELOPMENT, V112, P997; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	41	336	343	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					813	822		10.1016/S0092-8674(94)90542-8	http://dx.doi.org/10.1016/S0092-8674(94)90542-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087848				2022-12-28	WOS:A1994PG29600010
J	SUSMAN, RL				SUSMAN, RL			FOSSIL EVIDENCE FOR EARLY HOMINID TOOL USE	SCIENCE			English	Article							HAND	Although several Plio-Pleistocene hominids are found in association with stone and bone tools, it has been generally assumed that at any one time the hominid with the largest brain was the toolmaker. Fossils recovered over the last decade suggest that early hominids subsequent to 2.5 million years ago all might have used tools and occupied ''cultural'' niches. A test for humanlike precision grasping (the enhanced ability to manipulate tools) is proposed and applied to australopithecines and early Home. The results indicate that tools were likely to have been used by all early hominids at around 2.0 million years ago. The earliest australopithecines, which predate the appearance of stone tools in the archaeological record, do not show signs of advanced precision grasping.			SUSMAN, RL (corresponding author), SUNY STONY BROOK,SCH MED,DEPT ANAT SCI,STONY BROOK,NY 11794, USA.		Klein, Richard G/B-5910-2009					ASHLEYMONTAGU MF, 1931, AM J PHYS ANTHROPOL, V15, P291; BECK B, 1980, ANIMAL TOOL BEHAVIOR, P4; DAY MH, 1964, NATURE, V201, P969, DOI 10.1038/201969a0; Harris J.W.K., 1983, AFR ARCHAEOL REV, V1, P3, DOI DOI 10.1007/BF01116770; HOWELL FC, 1987, J HUM EVOL, V16, P665; JOLLY CJ, 1970, MAN, V5, P6; le Minor J.-M., 1988, Gegenbaurs Morphologisches Jahrbuch, V134, P693; LEAKEY LSB, 1959, NATURE, V184, P491, DOI 10.1038/184491a0; LEAKEY LSB, 1961, NATURE, V191, P417, DOI 10.1038/191417a0; LEAKEY LSB, 1964, NATURE, V202, P7, DOI 10.1038/202007a0; MARZKE MW, 1986, J HUM EVOL, V15, P439, DOI 10.1016/S0047-2484(86)80027-6; NAPIER J, 1962, NATURE, V196, P409, DOI 10.1038/196409a0; NAPIER JR, 1956, J BONE JOINT SURG BR, V38, P902, DOI 10.1302/0301-620X.38B4.902; NAPIER JR, 1962, SCI AM, V205, P56; OAKLEY KP, 1961, MAN TOOL MAKER, P111; POTTS R, 1988, EARLY HOMINID ACTIVI, P3; ROCHE H, 1977, CR ACAD SCI D NAT, V284, P1871; SCHICK KD, 1993, MAKING SILENT STONES, P102; SCHULTZ AH, 1936, Q REV BIOL, V2, P259; SPINNER M, 1984, KAPLANS FUNCTIONAL S, P159; Straus WL, 1942, Q REV BIOL, V17, P228, DOI 10.1086/394656; SUSMAN RL, 1988, SCIENCE, V240, P781, DOI 10.1126/science.3129783; SUSMAN RL, 1979, AM J PHYS ANTHROPOL, V50, P311; Tobias P. V., 1965, South African Archaeological Bulletin, V20, P167, DOI 10.2307/3887824; TOBIAS PV, 1964, NATURE, V202, P3, DOI 10.1038/202003a0; TOBIAS PV, 1966, CURR ANTHROPOL, V6, P391; Trinkaus, 2014, SHANIDAR NEANDERTALS; Tubiana, 1981, HAND, P427; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0	29	143	148	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1570	1573		10.1126/science.8079169	http://dx.doi.org/10.1126/science.8079169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PF336	8079169				2022-12-28	WOS:A1994PF33600032
J	ROBERDS, SL; LETURCQ, F; ALLAMAND, V; PICCOLO, F; JEANPIERRE, M; ANDERSON, RD; LIM, LE; LEE, JC; TOME, FMS; ROMERO, NB; FARDEAU, M; BECKMANN, JS; KAPLAN, JC; CAMPBELL, KP				ROBERDS, SL; LETURCQ, F; ALLAMAND, V; PICCOLO, F; JEANPIERRE, M; ANDERSON, RD; LIM, LE; LEE, JC; TOME, FMS; ROMERO, NB; FARDEAU, M; BECKMANN, JS; KAPLAN, JC; CAMPBELL, KP			MISSENSE MUTATIONS IN THE ADHALIN GENE LINKED TO AUTOSOMAL RECESSIVE MUSCULAR-DYSTROPHY	CELL			English	Article							GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; CARDIOMYOPATHIC HAMSTER; LINKAGE ANALYSIS; CYSTIC-FIBROSIS; DEFICIENCY; SARCOLEMMA; PROTEINS; HETEROGENEITY; ASSOCIATION	Adhalin, the 50 kDa dystrophin-associated glycoprotein, is deficient in skeletal muscle of patients having severe childhood autosomal recessive muscular dystrophy (SCARMD). In several North African families, SCARMD has been linked to chromosome 13q, but SCARMD has been excluded from linkage to this locus in other families. We have now cloned human adhalin cDNA and mapped the adhalin gene to chromosome 17q12-q21.33, excluding it from involvement in 13q-linked SCARMD. However, one allelic variant of a polymorphic microsatellite located within intron 6 of the adhalin gene cosegregated perfectly with the disease phenotype in a large family. Furthermore, missense mutations were identified within the adhalin gene that might cause SCARMD in this family. Thus, the adhalin gene is involved in at least one form of autosomal recessive muscular dystrophy.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV PARIS 05, CHU COCHIN PORT ROYAL, INSERM, U129, F-75014 PARIS, FRANCE; UNIV PARIS 05, CHU COCHIN PORT ROYAL, BIOCHIM GENET LAB, F-75014 PARIS, FRANCE; CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE; GENETHON, F-91000 EVRY, FRANCE; INSERM, U153, F-75005 PARIS, FRANCE; CNRS, F-75005 PARIS, FRANCE; HOP ROBERT DEBRE, PATHOL MUSCULAIRE LAB, F-75020 PARIS, FRANCE	University of Iowa; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	ROBERDS, SL (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA.		Allamand, Valérie/AAH-6272-2021; Roberds, Steven L/AAP-4985-2020; Allamand, Valerie/M-4333-2017; Beckmann, Jacques S/A-9772-2008	Allamand, Valérie/0000-0001-8997-9742; Roberds, Steven L/0000-0003-0676-272X; Beckmann, Jacques S/0000-0002-9741-1900; Campbell, Kevin/0000-0003-2066-5889				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AZIBI K, 1993, HUM MOL GENET, V2, P1423; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BENJELLOUNDELLAGI S, 1990, NEUROLOGY, V40, P1903; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; ELKERCH F, 1994, J MED GENET, V31, P342, DOI 10.1136/jmg.31.4.342; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FARAG TI, 1990, AM J MED GENET, V37, P290, DOI 10.1002/ajmg.1320370229; FARDEAU M, 1993, CR ACAD SCI III-VIE, V316, P799; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HIGUCHI I, IN PRESS J CLIN INVE; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, FEBS LETT, V329, P227, DOI 10.1016/0014-5793(93)80227-L; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LAZARO C, 1993, HUM MOL GENET, V2, P725, DOI 10.1093/hmg/2.6.725; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; McKusick V.A., 1992, MENDELIAN INHERITANC; MIZUNO Y, 1994, MUSCLE NERVE, V17, P206, DOI 10.1002/mus.880170212; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASSOSBUENO MR, 1993, J MED GENET, V30, P385, DOI 10.1136/jmg.30.5.385; PASSOSBUENO MR, 1993, HUM MOL GENET, V2, P1945, DOI 10.1093/hmg/2.11.1945; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; ROMERO NB, 1994, CR ACAD SCI III-VIE, V317, P70; SALIH MAM, 1983, DEV MED CHILD NEUROL, V25, P43; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAMANOUCHI Y, 1994, NEUROMUSCULAR DISORD, V4, P49, DOI 10.1016/0960-8966(94)90047-7; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	47	430	446	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					625	633		10.1016/0092-8674(94)90527-4	http://dx.doi.org/10.1016/0092-8674(94)90527-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069911				2022-12-28	WOS:A1994PD69300011
J	GUYATT, GH; COOK, DJ				GUYATT, GH; COOK, DJ			HEALTH-STATUS, QUALITY-OF-LIFE, AND THE INDIVIDUAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AIR-FLOW LIMITATION		MCMASTER UNIV,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA	McMaster University	GUYATT, GH (corresponding author), MCMASTER UNIV,HLTH SCI CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,ROOM 2C12,1200 MAIN ST W,HAMILTON L8N 3Z5,ON,CANADA.							GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GUYATT GH, 1987, BRIT J DIS CHEST, V81, P45, DOI 10.1016/0007-0971(87)90107-0; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009	5	158	161	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					630	631		10.1001/jama.272.8.630	http://dx.doi.org/10.1001/jama.272.8.630			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057520				2022-12-28	WOS:A1994PC39800035
J	HAVERKORN, MJ; MANDIGERS, J				HAVERKORN, MJ; MANDIGERS, J			REDUCTION OF BACTERIURIA AND PYURIA USING CRANBERRY JUICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									CATHARINA HOSP, EINDHOVEN, NETHERLANDS	Catharina Hospital								AVORN J, 1994, JAMA-J AM MED ASSOC, V271, P751, DOI 10.1001/jama.271.10.751; MOSKOWITZ E, 1957, J Chronic Dis, V5, P342, DOI 10.1016/0021-9681(57)90092-9; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91	3	40	40	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					590	590						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057506				2022-12-28	WOS:A1994PC39800014
J	SPEVAK, MR; KLEINMAN, PK; BELANGER, PL; PRIMACK, C; RICHMOND, JM				SPEVAK, MR; KLEINMAN, PK; BELANGER, PL; PRIMACK, C; RICHMOND, JM			CARDIOPULMONARY-RESUSCITATION AND RIB FRACTURES IN INFANTS - A POSTMORTEM RADIOLOGIC-PATHOLOGICAL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							COMPLICATIONS; CPR	Objective.-To determine the incidence of rib fractures visible at autopsy or with postmortem radiographs after cardiopulmonary resuscitation (CPR) in infants younger than 1 year. Design.-Retrospective review. Setting.-Medical examiner's office in a county consisting of a medium-sized city, towns, and rural areas. Patients.-Ninety-one infants (56 males, 35 females; mean age, 2.4 months; age range, 26 hours to 8.5 months) without evidence of child abuse who had undergone CPR before death. Methods.-Medical records, skeletal surveys, and autopsy results were reviewed. Results.-No patient had rib fractures. Conclusions.-Cardiopulmonary resuscitation is unlikely to cause rib fractures in infants.	UNIV MASSACHUSETTS,MED CTR,CHIEF MED EXAMINERS OFF,WORCESTER,MA	University of Massachusetts System; University of Massachusetts Worcester	SPEVAK, MR (corresponding author), UNIV MASSACHUSETTS,MED CTR,IMAGING CTR CHILD ABUSE & NEGLECT,DEPT RADIOL,WORCESTER,MA 01655, USA.							BEDELL SE, 1986, ARCH INTERN MED, V146, P1725, DOI 10.1001/archinte.146.9.1725; CAMERON JM, 1975, ATLAS BATTERED CHILD; FELDMAN KW, 1984, PEDIATRICS, V73, P339; KLEINMAN P K, 1989, Investigative Radiology, V24, pS132, DOI 10.1097/00004424-198912000-00235; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P67; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; NAGEL EL, 1981, CRIT CARE MED, V9, P424, DOI 10.1097/00003246-198105000-00037; Patterson R H, 1974, Med Ann Dist Columbia, V43, P389; RIKER WL, 1969, PEDIATR CLIN N AM, V16, P661; THALER MM, 1962, NEW ENGL J MED, V267, P500, DOI 10.1056/NEJM196209062671009; THOMAS PS, 1987, ANN RADIOL, V20, P115	11	75	76	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					617	618		10.1001/jama.272.8.617	http://dx.doi.org/10.1001/jama.272.8.617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057518				2022-12-28	WOS:A1994PC39800032
J	BENDE, BC; PHILPOTT, RM; SALTISSI, S; EDWARDS, RHT; WILLIAMS, G; WYATT, GB; KHAN, K				BENDE, BC; PHILPOTT, RM; SALTISSI, S; EDWARDS, RHT; WILLIAMS, G; WYATT, GB; KHAN, K			GRAND ROUNDS - ROYAL-LIVERPOOL-UNIVERSITY-HOSPITAL - PERSISTENT POSTTRAUMATIC-STRESS-DISORDER	BMJ-BRITISH MEDICAL JOURNAL			English	Discussion									UNIV LIVERPOOL, LIVERPOOL, ENGLAND; ROYAL LIVERPOOL UNIV HOSP TRUST, LIVERPOOL, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL, MERSEYSIDE, ENGLAND; ARROWE PK HOSP, WIRRAL, MERSEYSIDE, ENGLAND	University of Liverpool; Liverpool School of Tropical Medicine; University of Liverpool	BENDE, BC (corresponding author), MOSSLEY HILL HOSP, DEPT PSYCHOGERIATR, LIVERPOOL L18 8BV, MERSEYSIDE, ENGLAND.							DAVIDSON J, 1992, BRIT J PSYCHIAT, V160, P309, DOI 10.1192/bjp.160.3.309; DAVIDSON JRT, 1990, COMPR PSYCHIAT, V31, P162, DOI 10.1016/0010-440X(90)90020-S; DAVIDSON JRT, 1989, DIAGNOSIS TREATMENT, P77; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOULKES SH, 1946, LANCET, V250, P303; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; KEANE TM, 1982, J CONSULT CLIN PSYCH, V50, P138, DOI 10.1037/0022-006X.50.1.138; KIPPER DA, 1977, J CONSULT CLIN PSYCH, V45, P216, DOI 10.1037/0022-006X.45.2.216; LUNDMARK J, 1989, ACTA PSYCHIAT SCAND, V80, P76, DOI 10.1111/j.1600-0447.1989.tb07177.x; ROLLNICK S, 1991, COUNSELING PROBLEM D, P97; ROTH WT, 1988, POST TRAUMATIC THERA, P39; Sargant W, 1940, LANCET, V2, P1; SHERMAN AR, 1972, J ABNORM PSYCHOL, V79, P19, DOI 10.1037/h0032335; VAUGHAN K, 1992, BRIT J PSYCHIAT, V161, P658, DOI 10.1192/bjp.161.5.658; WLAZLO Z, 1990, BEHAV RES THER, V28, P181, DOI 10.1016/0005-7967(90)90001-Y; Worden J. W., 1982, GRIEF COUNSELING GRI; [No title captured]	18	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	1994	309	6953					526	528						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086914				2022-12-28	WOS:A1994PD30800030
J	WOLMAN, RL				WOLMAN, RL			ABC OF SPORTS MEDICINE - OSTEOPOROSIS AND EXERCISE	BRITISH MEDICAL JOURNAL			English	Article											WOLMAN, RL (corresponding author), ROYAL NATL ORTHOPAED HOSP TRUST,STANMORE HA7 4LP,MIDDX,ENGLAND.								0	17	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					400	403		10.1136/bmj.309.6951.400	http://dx.doi.org/10.1136/bmj.309.6951.400			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081148	Green Published			2022-12-28	WOS:A1994PB31600033
J	SHADICK, NA; PHILLIPS, CB; LOGIGIAN, EL; STEERE, AC; KAPLAN, RF; BERARDI, VP; DURAY, PH; LARSON, MG; WRIGHT, EA; GINSBURG, KS; KATZ, JN; LIANG, MH				SHADICK, NA; PHILLIPS, CB; LOGIGIAN, EL; STEERE, AC; KAPLAN, RF; BERARDI, VP; DURAY, PH; LARSON, MG; WRIGHT, EA; GINSBURG, KS; KATZ, JN; LIANG, MH			THE LONG-TERM CLINICAL OUTCOMES OF LYME-DISEASE - A POPULATION-BASED RETROSPECTIVE COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						LYME DISEASE; OUTCOME ASSESSMENT (HEALTH CARE); ARTHRITIS; VERBAL LEARNING; BORRELIA BURGDORFERI	NERVOUS-SYSTEM MANIFESTATIONS; BORRELIA-BURGDORFERI; FIBROMYALGIA; ARTHRITIS; SERODIAGNOSIS; DIAGNOSIS	Objective: To ascertain the prevalence of and risk factors for long-term sequelae from acute Lyme disease. Design: Population-based, retrospective cohort study. Setting: A coastal region endemic for Lyme disease. Participants: Patients with a history of Lyme disease who were previously treated with antibiotics were compared with randomly selected controls. Measurements: A standardized physical examination, health status measure (Short Form 36), psychometric test battery, and serologic analysis. Results: Compared with the control group (n = 43), the Lyme group (n = 38; mean duration from disease onset to study evaluation, 6.2 years) had more arthralgias (61% compared with 16%; P < 0.0001); distal paresthesias (16% compared with 2%; P = 0.03); concentration difficulties (16% compared with 2%; P= 0.03); and fatigue (26% compared with 9%; P = 0.04), and they had poorer global health status scores (P = 0.04). The Lyme group also had more abnormal joints (P = 0.02) and more verbal memory deficits (P = 0.01) than did the control group. Overall, 13 patients (34%; 95% CI, 19% to 49%) had long-term sequelae from Lyme disease (arthritis or recurrent arthralgias [n = 6], neurocognitive impairment [n = 4], and neuropathy or myelopathy [n = 3]). Compared with controls, patients who had long-term sequelae had higher IgG antibody titers to the spirochete (P = 0.03) and received treatment later (34.5 months compared with 2.7 months; P < 0.0001). Conclusions: Persons with a history pf Lyme disease have more musculoskeletal impairment and a higher prevalence of verbal memory impairment when compared with those without a history of Lyme disease. Our findings suggest that disseminated Lyme disease may be associated with long-term morbidity.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR, DEPT MED, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DIV RHEUMATOL IMMUNOL, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DEPT NEUROL, BOSTON, MA 02111 USA; IMUGENE INC, DIV RES, NORWOOD, MA 02062 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR, DEPT PATHOL, BOSTON, MA 02115 USA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA 01701 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Framingham Heart Study	SHADICK, NA (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR, BOSTON, MA 02115 USA.			Larson, Martin/0000-0002-9631-1254; Steere, Allen/0000-0002-5268-9853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530, P60AR036308, R01AR020358] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20358, AR07530, AR36308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERER E, 1991, J CLIN MICROBIOL, V29, P764, DOI 10.1128/JCM.29.4.764-772.1991; Army Individual Test Battery, 1944, MANUAL DIRECTIONS SC; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BURGDORFER W, 1984, YALE J BIOL MED, V57, P515; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Duray P, 1985, LAB MED, V16, P685, DOI DOI 10.1093/LABMED/16.11.685; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HAHN RD, 1959, ARCH NEURO PSYCHIATR, V81, P557, DOI 10.1001/archneurpsyc.1959.02340170023003; HALPERIN JJ, 1988, ANN NY ACAD SCI, V539, P24, DOI 10.1111/j.1749-6632.1988.tb31835.x; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; KRUPP LB, 1991, ARCH NEUROL-CHICAGO, V48, P1125, DOI 10.1001/archneur.1991.00530230033017; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; Ober B. A, 1988, CALIFORNIA VERBAL LE; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SCHMUTZHARD E, 1992, 5TH INT C LYM BORR, P45; Shipley, 1946, I LIVING SCALE; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBER K, 1988, PEDIATR INFECT DIS J, V7, P286, DOI 10.1097/00006454-198804000-00010; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; ZAR JH, 1984, BIOSTAT ANAL, P397; 1990, CONNECTICUT EPIDEMIO, V10, P9; 1948, EXAMINERS MANUAL PUR; 1985, DICT RHEUMATIC DISEA, V1, P78; 1993, MMWR-MORBID MORTAL W, V42, P2; 1990, SAS STAT USERS GUIDE, P175	40	189	193	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					560	+		10.7326/0003-4819-121-8-199410150-00002	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085687				2022-12-28	WOS:A1994PL48600002
J	HAVLIR, D; TORRIANI, F; DUBE, M				HAVLIR, D; TORRIANI, F; DUBE, M			UVEITIS ASSOCIATED WITH RIFABUTIN PROPHYLAXIS	ANNALS OF INTERNAL MEDICINE			English	Note									UNIV SO CALIF, LOS ANGELES CTY MED CTR, LOS ANGELES, CA 90033 USA	University of Southern California	HAVLIR, D (corresponding author), UNIV CALIF SAN DIEGO, CTR TREATMENT, 2760 5TH AVE, SUITE 300, SAN DIEGO, CA 92103 USA.		Torriani, Francesca/HGE-5175-2022					FRANK MO, 1994, NEW ENGL J MED, V330, P868, DOI 10.1056/NEJM199403243301218; FULLER JD, 1994, NEW ENGL J MED, V330, P1315, DOI 10.1056/NEJM199405053301816; LEWIS RC, 1991, PHARMACEUT RES, V8, P1434, DOI 10.1023/A:1015865526655; NARANG PK, 1994, NEW ENGL J MED, V330, P1316, DOI 10.1056/NEJM199405053301817; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; OBRIEN RJ, 1987, REV INFECT DIS, V9, P519; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; SIEGAL FP, 1990, AIDS, V4, P433, DOI 10.1097/00002030-199005000-00009; Trapnell CB, 1993, 9TH P INT C AIDS BER, P504; 1993, MMWR-MORBID MORTAL W, V42, P14	10	59	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					510	512		10.7326/0003-4819-121-7-199410010-00006	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067648				2022-12-28	WOS:A1994PJ10200006
J	STOCKDALE, FE				STOCKDALE, FE			MAMMOGRAPHY, NEEDLE-BIOPSY, AND TUMOR SPREAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BREAST				STOCKDALE, FE (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.							FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; HARTER LP, 1992, RADIOLOGY, V185, P713, DOI 10.1148/radiology.185.3.1343569	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					895	896						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078171				2022-12-28	WOS:A1994PG18200033
J	HANNON, GJ; BEACH, D				HANNON, GJ; BEACH, D			P15(INK4B) IS A POTENTIAL EFFECTOR OF TGF-BETA-INDUCED CELL-CYCLE ARREST	NATURE			English	Article							TRANSFORMING GROWTH-FACTOR; HOMOZYGOUS DELETIONS; INHIBITION; KINASES; LINE; MELANOMA	TRANSFORMING growth factor-beta (TGF-beta) inhibits cell proliferation by inducing a G1-phase cell cycle arrest(1). Normal progression through G1 is promoted by the activity of the cyclin-dependent protein kinases CDK4 and CDK6 (ref. 2), which are inhibited by the protein p16(INK4). We have isolated a new member of the p16(INK4) family, p15(INK4B). p15 expression is induced similar to 30-fold in human keratinocytes by treatment with TGF-beta, suggesting that p15 may act as an effector of TGF-beta-mediated cell cycle arrest. The gene encoding p15 is located on chromosome 9 adjacent to the p16 gene at a frequent site of chromosomal abnormality in human tumours (9p21).	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Hannon, Gregory/AAB-3568-2019					BATES S, 1994, ONCOGENE, V9, P71; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHENG JQ, 1993, CANCER RES, V53, P4761; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MERLO A, 1994, CANCER RES, V54, P640; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1985, CANCER CELL, V3, P65; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PETTY EM, 1993, AM J HUM GENET, V53, P96; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RODECK U, 1994, CANCER RES, V54, P575; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	1913	1989	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					257	261		10.1038/371257a0	http://dx.doi.org/10.1038/371257a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078588				2022-12-28	WOS:A1994PG29000056
J	DOBROWSKY, RT; WERNER, MH; CASTELLINO, AM; CHAO, MV; HANNUN, YA				DOBROWSKY, RT; WERNER, MH; CASTELLINO, AM; CHAO, MV; HANNUN, YA			ACTIVATION OF THE SPHINGOMYELIN CYCLE THROUGH THE LOW-AFFINITY NEUROTROPHIN RECEPTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; NGF RECEPTOR; CELL-DIFFERENTIATION; TRK PROTOONCOGENE; PROTEIN-KINASE; CERAMIDE; BINDING; EXPRESSION; RESPONSIVENESS	The role of the low-affinity neurotrophin receptor (p75(NTR)) in signal transduction is undefined. Nerve growth factor can activate the sphingomyelin cycle, generating the putative-lipid second messenger ceramide. In T9 glioma cells, addition of a cell-permeable ceramide analog mimicked the effects of nerve growth factor on cell growth inhibition and process formation. This signaling pathway appears to be mediated by p75(NTR) in T9 cells and NIH 3T3 cells overexpressing p75(NTR). Expression of an epidermal growth factor receptor-p75(NTR) chimera in T9 cells imparted to epidermal growth factor the ability to activate the sphingomyelin cycle. These data demonstrate that p75(NTR) is capable of signaling independently of the trk neurotrophin receptor (p140(trk)) and that ceramide may be a mediator in neurotrophin biology.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Duke University; Duke University; Cornell University; Cornell University				Chao, Moses/0000-0002-6969-3744	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIA NIH HHS [AG05531] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; Chan-Palay V., 1990, DEMENT GERIATR COGN, V1, P138, DOI [DOI 10.1159/0001, 10.1159/000107133, DOI 10.1159/000107133]; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, UNPUB; FEINSTEIN DL, 1990, FEBS LETT, V272, P7, DOI 10.1016/0014-5793(90)80437-N; GROB PM, 1985, J BIOL CHEM, V260, P8044; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HERMANN JL, 1993, MOL BIOL CELL, V4, P1205; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM MY, 1991, J BIOL CHEM, V266, P484; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MARUSHIGE Y, 1987, CANCER RES, V47, P4109; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TANIUCHI M, 1988, J NEUROSCI, V8, P664; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	45	534	542	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1596	1599		10.1126/science.8079174	http://dx.doi.org/10.1126/science.8079174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079174				2022-12-28	WOS:A1994PF33600041
J	DAVIES, JL; KAWAGUCHI, Y; BENNETT, ST; COPEMAN, JB; CORDELL, HJ; PRITCHARD, LE; REED, PW; GOUGH, SCL; JENKINS, SC; PALMER, SM; BALFOUR, KM; ROWE, BR; FARRALL, M; BARNETT, AH; BAIN, SC; TODD, JA				DAVIES, JL; KAWAGUCHI, Y; BENNETT, ST; COPEMAN, JB; CORDELL, HJ; PRITCHARD, LE; REED, PW; GOUGH, SCL; JENKINS, SC; PALMER, SM; BALFOUR, KM; ROWE, BR; FARRALL, M; BARNETT, AH; BAIN, SC; TODD, JA			A GENOME-WIDE SEARCH FOR HUMAN TYPE-1 DIABETES SUSCEPTIBILITY GENES	NATURE			English	Article							MELLITUS IDDM; INSULIN GENE; LINKAGE ANALYSIS; QUANTITATIVE TRAITS; MENDELIAN FACTORS; HLA; POLYMORPHISM; REGION; LOCUS; MICE	We have searched the human genome for genes that predispose to type 1 (insulin-dependent) diabetes mellitus using semi-automated fluorescence-based technology and linkage analysis. In addition to IDDM1 (in the major histocompatibility complex on chromosome 6p21) and IDDM2 (in the insulin gene region on chromosome 11p15), eighteen different chromosome regions showed some positive evidence of linkage to disease. Linkages to chromosomes iio (IDDM4) and 6q (IDDM5) were confirmed by replication, and chromosome is may encode a fifth disease locus. There are probably no genes with large effects aside from IDDM1. Therefore polygenic inheritance Is indicated, with a major locus at the major histocompatibility complex.	UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; UNIV BIRMINGHAM,BIRMINGHAM HEARTLANDS HOSP,DEPT MED DIABET ENDOCRINOL,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; HAMMERSMITH HOSP,MRC,CLIN RES CTR,LONDON W12 0NN,ENGLAND	University of Oxford; Wellcome Centre for Human Genetics; Heart of England NHS Foundation Trust; University of Birmingham; Imperial College London; Medical Research Council Clinical Trials Unit	DAVIES, JL (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.		Peng, Bo/A-6920-2009; Todd, John A/A-3542-2010	Peng, Bo/0000-0001-8225-2284; Todd, John A/0000-0003-2740-8148; Cordell, Heather/0000-0002-1879-5572	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIN SC, 1990, AUTOIMMUNITY, V7, P83, DOI 10.3109/08916939008993380; BAIN SC, 1992, NAT GENET, V2, P212, DOI 10.1038/ng1192-212; BARBOSA J, 1982, J CLIN ENDOCR METAB, V55, P193, DOI 10.1210/jcem-55-1-193; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BRETT PM, 1991, NUCLEIC ACIDS RES, V19, P6978, DOI 10.1093/nar/19.24.6978-a; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CAILLATZUCMAN S, 1992, J CLIN INVEST, V90, P2242, DOI 10.1172/JCI116110; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; DUNSWORTH TS, 1982, DIABETES, V31, P991, DOI 10.2337/diabetes.31.11.991; EFF C, 1978, DIABETOLOGIA, V15, P169, DOI 10.1007/BF00421234; ELSTON RC, 1994, GENETIC APPROACHES M, P3; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HODGE SE, 1981, LANCET, V2, P893; HODGE SE, 1983, AM J HUM GENET, V35, P1139; HOLMANS P, 1993, AM J HUM GENET, V52, P362; HYER RN, 1991, AM J HUM GENET, V48, P243; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; JUNIEN C, 1991, CYTOGENET CELL GENET, V58, P459, DOI 10.1159/000133171; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; LANDER ES, 1989, GENETICS, V121, P185; LEBEAU MM, 1991, CYTOGENET CELL GENET, V58, P739, DOI 10.1159/000133178; LERNMARK A, 1990, AM J HUM GENET, V47, P1028; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MORTON NE, 1983, AM J HUM GENET, V35, P201; OWERBACH D, 1990, DIABETES, V39, P1504, DOI 10.2337/diabetes.39.12.1504; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PENROSE LS, 1953, ANN EUGENIC, V18, P120; POCIOT F, IN PRESS AUTOIMMUNIT; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; RISCH N, 1990, GENET EPIDEMIOL, V7, P3, DOI 10.1002/gepi.1370070103; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, 1987, AM J HUM GENET, V40, P1; RISCH N, 1991, AM J HUM GENET, V48, P1058; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; SCHWENGEL DA, 1994, GENOMICS, V22, P46, DOI 10.1006/geno.1994.1344; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; TODD JA, 1994, DIABETIC MED, V11, P6, DOI 10.1111/j.1464-5491.1994.tb00222.x; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1992, DIABETES, V41, P1029, DOI 10.2337/diabetes.41.9.1029; VANDEWALLE CL, 1993, DIABETOLOGIA, V36, P1155, DOI 10.1007/BF00401060; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZIEGLE JS, 1992, GENOMICS, V14, P1026, DOI 10.1016/S0888-7543(05)80126-0	50	1212	1250	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					130	136		10.1038/371130a0	http://dx.doi.org/10.1038/371130a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072542				2022-12-28	WOS:A1994PF19100055
J	ANDINO, R; SILVERA, D; SUGGETT, SD; ACHACOSO, PL; MILLER, CJ; BALTIMORE, D; FEINBERG, MB				ANDINO, R; SILVERA, D; SUGGETT, SD; ACHACOSO, PL; MILLER, CJ; BALTIMORE, D; FEINBERG, MB			ENGINEERING POLIOVIRUS AS A VACCINE VECTOR FOR THE EXPRESSION OF DIVERSE ANTIGENS	SCIENCE			English	Article							PROTEIN-SYNTHESIS; 5' END; CHIMERAS; RNA; SEQUENCES; VIRUS	As a step toward developing poliovirus as a vaccine vector, poliovirus recombinants were constructed by fusing exogenous peptides (up to 400 amino acids) and an artificial cleavage site for viral protease 3C(pro) to the amino terminus of the viral polyprotein. Viral replication proceeded normally. An extended polyprotein was produced in infected cells and proteolytically processed into the complete array of viral proteins plus the foreign peptide, which was excluded from mature virions. The recombinants retained exogenous sequences through successive rounds of replication in culture and in vivo. Infection of animals with recombinants elicited a humoral immune response to the foreign peptides.	GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94141; ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV CALIF DAVIS,SCH VET MED,DEPT VET PATHOL,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH VET MED,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Rockefeller University; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California San Francisco	ANDINO, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022346, R01AI035545, R37AI022346] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00169] Funding Source: Medline; NIAID NIH HHS [AI35545, AI22346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, UNPUB; ANSARDI DC, 1992, J VIROL, V66, P4556, DOI 10.1128/JVI.66.7.4556-4563.1992; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CRABBE MJC, 1990, FEBS LETT, V271, P194, DOI 10.1016/0014-5793(90)80404-7; DEDIEU JF, 1992, J VIROL, V66, P3161, DOI 10.1128/JVI.66.5.3161-3167.1992; EVANS DJ, 1989, NATURE, V339, P385, DOI 10.1038/339385a0; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; HEMINGTON DA, 1988, J EXP MED, V168, P1487; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P951, DOI 10.1073/pnas.88.3.951; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MELNICK JL, 1988, VACCINES, P115; NAMOTO A, 1982, P NATL ACAD SCI USA, V79, P5793; NIXON DF, 1991, AIDS, V5, P1049; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PEARSON GDN, 1982, P NATL ACAD SCI-BIOL, V79, P2976, DOI 10.1073/pnas.79.9.2976; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YIM T, UNPUB	24	123	134	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1448	1451		10.1126/science.8073288	http://dx.doi.org/10.1126/science.8073288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073288				2022-12-28	WOS:A1994PE73300049
J	REID, IR; CHIN, K; EVANS, MC; JONES, JG				REID, IR; CHIN, K; EVANS, MC; JONES, JG			RELATION BETWEEN INCREASE IN LENGTH OF HIP AXIS IN OLDER WOMEN BETWEEN 1950S AND 1990S AND INCREASE IN AGE-SPECIFIC RATES OF HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							PROXIMAL FEMUR	Objective-To determine whether length of hip axis in elderly women has increased over the past 40 years and, if so, whether the increase may have contributed to the increase in the age adjusted rate of hip fractures during those years. Design-Retrospective assessment of anteroposterior x ray films of the pelvis. Setting-Radiology department of a rheumatology hospital, New Zealand. Patients-Two cohorts of women aged >60 (mean 70) who were x rayed on the same apparatus in either the 1950s or the 1990s. Main outcome-length of hip axis (distance from the medial aspect of the pelvis to the lateral aspect of the femur along the axis of the femoral neck), length of femoral neck (length of hip axis excluding the femoral head and more medial structures), and width of femoral neck (see figure). Results-Both the mean length of the hip axis and the mean length of the femoral neck were significantly greater in the women whose x ray films were taken in the 1990s than in those in the 1950s (124.0 mm (SE 1) v 130.5 (1), P=0.0002; 79.4 (1) v 84.9 (1), P<0.0001, respectively). The width of the femoral neck did not change, and the lengths expressed as ratios to width were greater in the more recent x ray films, indicating that these findings are not due to an unrecognised change in radiographic technique. Conclusions-An increase in the length of the hip axis in elderly women in New Zealand during the past 40 years has occurred which is large enough to account for the increase in the age adjusted rate of hip fractures during those years.	QUEEN ELIZABETH HOSP,ROTORUA,NEW ZEALAND		REID, IR (corresponding author), UNIV AUCKLAND,DEPT MED,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.							BOYCE WJ, 1985, LANCET, V1, P150; FALCH JA, 1993, BONE, V14, P643, DOI 10.1016/8756-3282(93)90086-P; FAULKNER KG, 1993, J BONE MINER RES, V8, P1211, DOI 10.1002/jbmr.5650081008; JOHNELL O, 1984, ACTA ORTHOP SCAND, V55, P290, DOI 10.3109/17453678408992358; LAU EMC, 1993 OST P 4TH INT S, P58; LEWIS AF, 1981, BMJ-BRIT MED J, V283, P1217, DOI 10.1136/bmj.283.6301.1217; Rockwood P R, 1990, J Orthop Trauma, V4, P388, DOI 10.1097/00005131-199012000-00004; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; WALLACE WA, 1983, LANCET, V1, P1413; ZETTERBERG C, 1982, ACTA ORTHOP SCAND, V53, P419, DOI 10.3109/17453678208992236	10	65	66	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					508	509		10.1136/bmj.309.6953.508	http://dx.doi.org/10.1136/bmj.309.6953.508			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086904	Green Published			2022-12-28	WOS:A1994PD30800017
J	STUCKEY, JA; SCHUBERT, HL; FAUMAN, EB; ZHANG, ZY; DIXON, JE; SAPER, MA				STUCKEY, JA; SCHUBERT, HL; FAUMAN, EB; ZHANG, ZY; DIXON, JE; SAPER, MA			CRYSTAL-STRUCTURE OF YERSINIA PROTEIN-TYROSINE-PHOSPHATASE AT 2.5-ANGSTROM AND THE COMPLEX WITH TUNGSTATE	NATURE			English	Article							VIRULENCE DETERMINANT; PURIFICATION; INTERMEDIATE; CATALYSIS; CYSTEINE; CHARGES; LAR	PROTEIN tyrosine phosphatases (PTPases) and kinases coregulate the critical levels of phosphorylation necessary for intracellular signalling, cell growth and differentiation(1,2). Yersinia, the causative bacteria of the bubonic plague and other enteric diseases, secrete an active PTPase(3), Yop51, that enters and suppresses host immune cells(4,5). Though the catalytic domain is only similar to 20% identical to human PTP1B(6), the Yersinia PTPase contains all of the invariant residues present in eukaryotic PTPases(7), including the nucleophilic Cys 403 which forms a phosphocysteine intermediate during catalysis(3,8-10). We present here structures of the unliganded (2.5 Angstrom resolution) and tungstate-bound (2.6 Angstrom) crystal forms which reveal that Cys 403 is positioned at the centre of a distinctive phosphate-binding loop. This loop is at the hub of several hydrogen-bond arrays that not only stabilize a bound oxyanion, but may activate Cys 403 as a reactive thiolate. Binding of tungstate triggers a conformational change that traps the oxyanion and swings Asp 356, an important catalytic residue(7), by similar to 6 Angstrom into the active site. The same anion-binding loop in PTPases is also found in the enzyme rhodanese(11).	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,WALTHER CANC INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Walther Cancer Institute			Fauman, Eric/AAC-8275-2020	Fauman, Eric/0000-0002-9739-0249				AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUNGER TA, 1993, XPLOR VERSION 3 1 MA; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; STEIGEMANN W, 1974, THESIS TU MUNICH; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WIERENGA RK, 1986, T AM CRYSTALLOGR ASS, V22, P49; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	31	376	383	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					571	575		10.1038/370571a0	http://dx.doi.org/10.1038/370571a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052312	Green Submitted			2022-12-28	WOS:A1994PC53700059
J	GE, H; ROEDER, RG				GE, H; ROEDER, RG			PURIFICATION, CLONING, AND CHARACTERIZATION OF A HUMAN COACTIVATOR, PC4, THAT MEDIATES TRANSCRIPTIONAL ACTIVATION OF CLASS-II GENES	CELL			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; IMMEDIATE EARLY PROTEIN; DNA TOPOISOMERASE-I; MAJOR LATE PROMOTER; PREINITIATION COMPLEX; GAL4 DERIVATIVES; REGULATORY FACTORS; MOLECULAR-CLONING; RIBOSOMAL-PROTEIN	Activator-dependent transcription in mammalian cells requires upstream stimulatory activity (USA)-derived cofactors in addition to those present in TFIID. A novel positive cofactor (PC4) purified from the human USA fraction effected a marked enhancement (up to 85-fold) of GAL4-AH-dependent transcription in conjunction with TFIID and other general factors. Isolation of a corresponding cDNA identified PC4 as a 127 residue single-stranded DNA-binding protein with serine-rich regions near the N-terminus. Recombinant PC4 was functionally equivalent to native PC4, and both proteins markedly enhanced activation by diverse activation domains fused to the DNA-binding domain of GAL4. Recombinant PC4 interacted independently both with free or DNA-bound VP16 activation domains and with free or DNA-bound TFIIA-TBP complexes (but not with Tap alone). These results indicate that PC4 is a general coactivator that functions cooperatively with TAFs and mediates functional interactions between upstream activators and the general transcriptional machinery.			GE, H (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							ABMAYR SM, 1985, CELL, V43, P821, DOI 10.1016/0092-8674(85)90255-7; ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHAMBERS JC, 1985, P NATL ACAD SCI USA, V82, P2115, DOI 10.1073/pnas.82.7.2115; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; GE H, 1994, J BIOL CHEM, V269, P17136; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KONDOH N, 1992, CANCER RES, V52, P791; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PASCOLO S, 1992, YEAST, V8, P987, DOI 10.1002/yea.320081109; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SOMA GI, 1984, BIOCHEM BIOPH RES CO, V124, P164, DOI 10.1016/0006-291X(84)90931-8; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	70	323	333	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					513	523		10.1016/0092-8674(94)90428-6	http://dx.doi.org/10.1016/0092-8674(94)90428-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062391				2022-12-28	WOS:A1994PC40500016
J	KLEIN, PS; MELTON, DA				KLEIN, PS; MELTON, DA			INDUCTION OF MESODERM IN XENOPUS-LAEVIS EMBRYOS BY TRANSLATION INITIATION-FACTOR 4E	SCIENCE			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; 3' UNTRANSLATED REGION; 5' NONCODING REGION; MESSENGER-RNA; SECONDARY STRUCTURE; ACTIVIN RECEPTOR; C-ELEGANS; MALIGNANT TRANSFORMATION; MIDBLASTULA TRANSITION; POLY(A) ADDITION	The microinjection of messenger RNA encoding the eukaryotic translation initiation factor 4E (elF-4E) into early embryos of Xenopus laevis leads to the induction of mesoderm in ectodermal explants. This induction occurs without a stimulation of overall protein synthesis and is blocked by the co-expression of a dominant negative mutant of the proto-oncogene ras or a truncated activin type II receptor. Although other translation factors have been studied in vertebrate and invertebrate embryos, none have been shown to play a direct role in development. The results here suggest a mechanism for relaying and amplifying signals for mesoderm induction.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BU X, 1993, J BIOL CHEM, V268, P4975; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1992, DEVELOPMENT, V115, P573; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMATIBRIVANLO.A, UNPUB; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; JONES EA, 1987, DEVELOPMENT, V101, P557; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KURIHARA K, 1981, DEV GROWTH DIFFER, V23, P361; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LOPO AC, 1988, BIOCHEMISTRY-US, V27, P351, DOI 10.1021/bi00401a053; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA O, 1970, P JPN ACAD, V46, P694, DOI 10.2183/pjab1945.46.694; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SAMBROOK J, 1990, MOL CLONING LABORATO; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; XU Z, 1990, CELL REGUL, V1, P1057, DOI 10.1091/mbc.1.13.1057	62	61	62	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					803	806		10.1126/science.8047887	http://dx.doi.org/10.1126/science.8047887			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047887				2022-12-28	WOS:A1994PA37200039
J	ZUKER, CS				ZUKER, CS			ON THE EVOLUTION OF EYES - WOULD YOU LIKE IT SIMPLE OR COMPOUND	SCIENCE			English	Editorial Material											ZUKER, CS (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DEPT BIOL,LA JOLLA,CA 92093, USA.							BARINAGA M, 1994, SCIENCE, V265, P265; CHEYETTE L, 1994, NEURON, V12, P977; GOLDSMITH TH, 1990, Q REV BIOL, V65, P281, DOI 10.1086/416840; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; Hill Robert E., 1992, Current Opinion in Cell Biology, V4, P967, DOI 10.1016/0955-0674(92)90126-W; LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245; Lawrence P., 1992, MAKING FLY GENETICS; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; OLIVER G, COMMUNICATION; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SALVINIPLAWEN LV, 1977, EVOLUTIONARY BIOL, V10, P207; Wolff T, 1993, DEV DROSOPHILA MELAN; ZIPURSKY L, 1994, ANN REV NEUROSCI, V17, P1	13	59	59	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					742	743		10.1126/science.8047881	http://dx.doi.org/10.1126/science.8047881			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047881				2022-12-28	WOS:A1994PA37200021
J	MAYET, J; SHAHI, M; FOALE, RA; POULTER, NR; SEVER, PS; THOM, SAM				MAYET, J; SHAHI, M; FOALE, RA; POULTER, NR; SEVER, PS; THOM, SAM			RACIAL-DIFFERENCES IN CARDIAC STRUCTURE AND FUNCTION IN ESSENTIAL-HYPERTENSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEFT-VENTRICULAR HYPERTROPHY; DIASTOLIC FUNCTION; BLOOD-PRESSURE; ECHOCARDIOGRAPHIC INDEXES; WHITE HYPERTENSIVES; HEART; BLACK; DOPPLER; VARIABLES; DISEASE	Objective-To assess racial differences in cardiac structure and function in patients presenting with previously untreated hypertension. Design-Untreated black patients with hypertension were compared with untreated white patients matched for age and sex. Both groups had similar body mass indices, blood pressures, and reported duration of hypertension. Setting-Cardiovascular risk factor clinic for outpatients. Subjects-36 men and 22 women with untreated essential hypertension. Main outcome measures-Variables of heart structure and function on cross sectional and Doppler echocardiography. Results-The black patients had a significantly greater interventricular septal thickness (mean 1.23 (95% confidence interval 1.14 to 1.33) v 1.09 (1.02 to 1.16) cm; P = 0 02) and posterior wall thickness (mean 1.14 (1.07 to 1.22) v 0.96 (0.88 to 1.03) cm; P - 0.001) than the white patients, although left ventricular internal diameter was not significantly different (mean 4.90 (4.68 to 5.12) v 4.82 (4.64 to 5.01) cm; P = 0.59). This resulted in a significantly greater left ventricular mass index (mean 151 (137 to 164) v 120 (107 to 133) g/m(2); P = 0.001) and relative wall thickness (mean 0.47 (0.43 to 0.51) v 0.40 (0.37 to 0.42) cm; P = 004) in the black patients. Comparison of Doppler measures of left ventricular diastolic function showed a significantly longer isovolumic relaxation time in black patients (mean 107 (98 to 116) v 92 (83 to 101) ms; P = 0 02) compared with white patients, although peak early to atrial filling ratios were similar in both groups (mean 1.14 (0.95 to 1.32) v 1.04 (0.94 to 1.15); P = 0.37). Conclusion-Among previously untreated hypertensive patients, black subjects compared with white subjects have significantly higher left ventricular mass index and relative wall thickness, as well as more impairment of left ventricular function during diastole.	ST MARYS HOSP, SCH MED, DEPT CARDIOL, LONDON W2 1NY, ENGLAND; UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND; ST MARYS HOSP, IMPERIAL COLL SCI TECHNOL & MED, SCH MED, PEART ROSE CLIN, LONDON W2 1NY, ENGLAND	Imperial College London; University of London; University College London; UCL Medical School; Imperial College London								[Anonymous], 1992, LANCET, V339, P28; BRUNNER HR, 1973, AM J MED, V55, P295, DOI 10.1016/0002-9343(73)90131-9; COLAN SD, 1985, J AM COLL CARDIOL, V6, P545, DOI 10.1016/S0735-1097(85)80111-X; COMSTOCK GW, 1957, AM J HYG, V65, P271, DOI 10.1093/oxfordjournals.aje.a119870; DEVEREUX RB, 1982, HYPERTENSION, V4, P524, DOI 10.1161/01.HYP.4.4.524; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; HARSHFIELD GA, 1989, HYPERTENSION, V14, P598, DOI 10.1161/01.HYP.14.6.598; HARSHFIELD GA, 1990, J HUM HYPERTENS, V4, P43; HINDERLITER AL, 1992, AM J CARDIOL, V69, P1196, DOI 10.1016/0002-9149(92)90935-R; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; LEE DK, 1992, JAMA-J AM MED ASSOC, V267, P3294, DOI 10.1001/jama.267.24.3294; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEWIS JF, 1992, BRIT HEART J, V68, P296; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MEADE TW, 1978, BRIT HEART J, V40, P789, DOI 10.1136/hrt.40.7.789; MENSAH G A, 1991, Journal of the American College of Cardiology, V17, p71A; MESSERLI FH, 1979, AM J MED, V67, P27, DOI 10.1016/0002-9343(79)90065-2; MURPHY MB, 1988, CIRCULATION, V48, pA2268; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; NISHIMURA RA, 1989, MAYO CLIN PROC, V64, P181, DOI 10.1016/S0025-6196(12)65673-0; OOI WL, 1989, HYPERTENSION, V14, P227, DOI 10.1161/01.HYP.14.3.227; PASIERSKI T, 1991, AM HEART J, V122, P1101, DOI 10.1016/0002-8703(91)90478-Z; PHILLIPS RA, 1989, J AM COLL CARDIOL, V14, P979, DOI 10.1016/0735-1097(89)90476-2; ROWLANDS DB, 1982, HYPERTENSION, V4, P817, DOI 10.1161/01.HYP.4.6.817; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Savage D D, 1979, J Natl Med Assoc, V71, P709; SHAHI M, 1990, LANCET, V336, P458, DOI 10.1016/0140-6736(90)92010-F; SHAHI M, 1989, CLIN SCI, V76, pP22; SHAPIRO LM, 1984, BRIT HEART J, V51, P637; SMITH SA, 1989, BRIT HEART J, V61, P344; SPIRITO P, 1988, BRIT HEART J, V59, P672; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0	35	67	68	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1011	1014		10.1136/bmj.308.6935.1011	http://dx.doi.org/10.1136/bmj.308.6935.1011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8068083	Green Published			2022-12-28	WOS:A1994NH08900019
J	THIBAULT, GE				THIBAULT, GE			DESPERATE APPLIANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							NECROTIZING FASCIITIS; INFECTIONS				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR W ROXBURY,1400 VFW PKWY,BOSTON,MA 02132, USA.							AITKEN DR, 1982, ARCH SURG-CHICAGO, V117, P561; BEATHARD GA, 1967, ARCH INTERN MED, V120, P63, DOI 10.1001/archinte.120.1.63; FEINGOLD DS, 1981, CURR CLIN TOP INFECT, V2, P259; FREEMAN HP, 1981, AM J SURG, V142, P377, DOI 10.1016/0002-9610(81)90353-6; Meleny FK, 1924, ARCH SURG-CHICAGO, V9, P317, DOI 10.1001/archsurg.1924.01120080083007; QUINTILIANI R, 1971, J BONE JOINT SURG AM, VA 53, P1391, DOI 10.2106/00004623-197153070-00017; REA WJ, 1970, ANN SURG, V172, P957, DOI 10.1097/00000658-197012000-00005; ROUSE TM, 1982, SURGERY, V92, P765; STAMENKOVIC I, 1984, NEW ENGL J MED, V310, P1689, DOI 10.1056/NEJM198406283102601; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; STRASBERG SM, 1968, AM J SURG, V115, P763, DOI 10.1016/0002-9610(68)90515-1	12	13	14	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					623	626		10.1056/NEJM199403033300908	http://dx.doi.org/10.1056/NEJM199403033300908			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8068070				2022-12-28	WOS:A1994MY57300008
J	KING, SB; LEMBO, NJ; WEINTRAUB, WS; KOSINSKI, AS; BARNHART, HX; KUTNER, NH; ALAZRAKI, NP; GUYTON, RA; ZHAO, XQ; ROUBIN, GS; CRAVER, JM; DOUGLAS, JS; JONES, EL; MORRIS, DC; DEPUEY, EG; BATTEY, LL; KRAWCZYNSKA, EG; KLEIN, JL; LIBERMAN, HA; MAULDIN, P; YEEPETERSON, J; FRERICHS, FA; MAYS, RR; MEAD, SI; CARLIN, SF; CASEY, M; MCFARLAND, K; MILLER, SJ; PEEBLES, BU; SCOTT, J; SUTOR, CE; KUTNER, MH; GRIFFIN, PJ; LYNN, MJ; SANDERS, AG; HALL, EC; JAMISON, P; MELLON, B; THOMAS, RG				KING, SB; LEMBO, NJ; WEINTRAUB, WS; KOSINSKI, AS; BARNHART, HX; KUTNER, NH; ALAZRAKI, NP; GUYTON, RA; ZHAO, XQ; ROUBIN, GS; CRAVER, JM; DOUGLAS, JS; JONES, EL; MORRIS, DC; DEPUEY, EG; BATTEY, LL; KRAWCZYNSKA, EG; KLEIN, JL; LIBERMAN, HA; MAULDIN, P; YEEPETERSON, J; FRERICHS, FA; MAYS, RR; MEAD, SI; CARLIN, SF; CASEY, M; MCFARLAND, K; MILLER, SJ; PEEBLES, BU; SCOTT, J; SUTOR, CE; KUTNER, MH; GRIFFIN, PJ; LYNN, MJ; SANDERS, AG; HALL, EC; JAMISON, P; MELLON, B; THOMAS, RG			A RANDOMIZED TRIAL COMPARING CORONARY ANGIOPLASTY WITH CORONARY-BYPASS SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY DISEASE; FOLLOW-UP; SURVIVAL	Background. The clinical benefit of percutaneous transluminal coronary angioplasty (PTCA) as compared with coronary-artery bypass grafting (CABG) for patients with multivessel coronary artery disease has not been established. To determine the outcomes of these treatments in patients referred for the first time for coronary revascularization, we conducted a three-year prospective, randomized trial comparing the two procedures. Methods. Revascularization was performed by accepted methods. Follow-up clinical information was collected every six months, and coronary arteriography and thallium stress scanning were performed at one and three years. The primary end point was a composite of death, Q-wave myocardial infarction, and a large ischemic defect identified on thallium scanning at three years. Secondary end points included clinical and angiographic status and the need for additional revascularization procedures. Data were analyzed according to the intention-to-treat principle. Results. Of the 5118 patients screened for the trial, 842 (16.5 percent) were eligible for enrollment, and 392 (7.7 percent) agreed to participate. A total of 194 patients were randomly assigned to the CABG group, and 198 to the PTCA group. The primary end point occurred in 27.3 percent of the CABG group and 28.8 percent of the PICA group (P = 0.81). Death occurred in 6.2 percent of the CABG group and 7.1 percent of the PTCA group (P = 0.73 by log-rank test). At three years, the proportions of patients in the CABG group who required repeated bypass surgery (1 percent) or angioplasty (13 percent) were significantly lower than the proportions in the PTCA group (22 and 41 percent, respectively; P<0.001). Angiographic studies at three years showed a greater degree of revascularization in the CABG group. Angina was more frequent in the PTCA group (20 percent) than in the CABG group (12 percent). Conclusions. We found that CABG and PTCA did not differ significantly with respect to the occurrence of the composite primary end point. Consequently, the selection of one procedure over the other should be guided by patients' preferences regarding the quality of life and the possible need for subsequent procedures.	EMORY UNIV, SCH MED, DIV CARDIOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DIV CARDIOTHORAC SURG, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DIV RADIOL, ATLANTA, GA USA; EMORY UNIV, SCH PUBL HLTH, DIV BIOSTAT, ATLANTA, GA 30322 USA; UNIV WASHINGTON, SCH MED, DIV CARDIOL, SEATTLE, WA USA; EMORY UNIV, BIOSTAT COORDINATING CTR, ATLANTA, GA USA	Emory University; Emory University; Emory University; Emory University; University of Washington; University of Washington Seattle; Emory University					NHLBI NIH HHS [R01 HL 33965] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033965] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAZRAKI NP, 1994, J NUCL MED, V35, P1237; [Anonymous], 1982, Lancet, V2, P1173; [Anonymous], 1991, CIRCULATION, V84, P1; BROWN BG, 1977, CIRCULATION, V55, P329, DOI 10.1161/01.CIR.55.2.329; BROWN BG, 1986, PROG CARDIOVASC DIS, V28, P403; COWLEY MJ, 1985, CIRCULATION, V72, P1314, DOI 10.1161/01.CIR.72.6.1314; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; DOUGLAS JS, 1990, HEART, P2131; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FISHER L, 1983, CIRCULATION, V68, P951; Fisher LD., 1997, BIOMETRICS, V53, P1182; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; JONES EL, 1980, ANN SURG, V192, P390, DOI 10.1097/00000658-198009000-00015; KILLIP T, 1985, CIRCULATION, V72, P102; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; MATA LA, 1985, J AM COLL CARDIOL, V6, P1239, DOI 10.1016/S0735-1097(85)80208-4; MYLER RK, 1987, CATHETER CARDIO DIAG, V13, P1, DOI 10.1002/ccd.1810130102; OKEEFE JH, 1990, J AM COLL CARDIOL, V16, P1097, DOI 10.1016/0735-1097(90)90538-Z; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Rubin DB., 1987, MULTIPLE IMPUTATION, DOI 10.1002/9780470316696; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; VANDORMAEL MG, 1987, J AM COLL CARDIOL, V10, P246, DOI 10.1016/S0735-1097(87)80003-7; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WEINTRAUB WS, 1993, AM J CARDIOL, V71, P511, DOI 10.1016/0002-9149(93)90504-6	29	606	630	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1044	1050		10.1056/NEJM199410203311602	http://dx.doi.org/10.1056/NEJM199410203311602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090163				2022-12-28	WOS:A1994PL56000002
J	BERWICK, DM				BERWICK, DM			11 WORTHY AIMS FOR CLINICAL LEADERSHIP OF HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY; LOW-BIRTH-WEIGHT; UNITED-STATES; MEDICAL-CARE; GEOGRAPHIC-VARIATION; CONTROLLED TRIAL; BREAST-CANCER; CAROTID ENDARTERECTOMY; EDUCATIONAL OUTREACH; CORONARY ANGIOGRAPHY	Clinicians ought to be playing a central role in making the changes in the health care system that will allow the system to offer better outcomes, greater ease of use, lower cost, and more social justice in health status. Instead, most of the proposed changes that are today called ''health care reform'' are actually changes in the surroundings of care rather than changes in the care itself. Clinicians have an opportunity to exercise leadership for the improvement of care, but they must first agree to address the aims of reform and to adopt an agenda of specific changes in their own work that are likely to meet the social needs driving the reform movement. Health services research offers a sound scientific basis for identifying promising improvement aims for clinician-led reform. Eleven plausible aims are these: (1) reducing inappropriate surgery, hospital admissions, and diagnostic tests; (2) reducing key underlying root causes of illness (especially smoking, handgun violence, preventable childhood injuries, and alcohol and cocaine abuse); (3) reducing cesarean section rates to pre-1980 levels;.(4) reducing the use of unwanted medical procedures; at the end of life; (5) simplifying pharmaceutical use, especially for antibiotics and medication of the elderly; (6) increasing active patient participation in therapeutic decision making; (7) decreasing waiting times in health care settings; (8) reducing inventory levels in health care organizations; (9) recording only useful information only once; (10) consolidating and reducing the total supply of high-technology medical and surgical care; and (1 1) reducing the racial gap in infant mortality and low birth weight. Health care professions and their professional organizations in concert should embrace these 11 aims, establish measurements of progress toward them, and commit to continuous and fundamental changes in their pursuit.			BERWICK, DM (corresponding author), INST HLTHCARE IMPROVEMENT,1 EXETER PLAZA,FLOOR 9,BOSTON,MA 02116, USA.							ADAMS MM, 1992, OBSTET GYNECOL, V80, P738; [Anonymous], 1989, GUIDE CLIN PREVENTIV; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; BERNSTEIN LR, 1989, MED CARE, V27, P654, DOI 10.1097/00005650-198906000-00008; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BOTTOMS SF, 1980, NEW ENGL J MED, V302, P559, DOI 10.1056/NEJM198003063021006; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; CHORBA TL, 1993, PEDIATRICS, V91, P897; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; CRAIN EF, 1991, PEDIATRICS, V88, P821; DEYO RA, 1991, NEW ENGL J MED, V325, P1039, DOI 10.1056/NEJM199110033251411; EINSTADTER D, 1993, MED CARE, V31, P711, DOI 10.1097/00005650-199308000-00004; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; FARBER BF, 1981, NEW ENGL J MED, V305, P200, DOI 10.1056/NEJM198107233050405; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FLAMM BL, 1990, OBSTET GYNECOL, V76, P750, DOI 10.1097/00006250-199011000-00004; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FRIEDMAN B, 1993, MED CARE, V31, P581, DOI 10.1097/00005650-199307000-00002; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GERMAN PS, 1989, J AGING HEALTH, V1, P5; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRINER PF, 1982, NEW ENGL J MED, V307, P1336, DOI 10.1056/NEJM198211183072109; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HIGGINS MW, 1993, JAMA-J AM MED ASSOC, V269, P2741, DOI 10.1001/jama.269.21.2741; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; KAHN KL, 1988, ANN INTERN MED, V109, P664, DOI 10.7326/0003-4819-109-8-664; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KEMPE A, 1992, NEW ENGL J MED, V327, P969, DOI 10.1056/NEJM199210013271401; KIMBERLIN CL, 1993, MED CARE, V31, P451, DOI 10.1097/00005650-199305000-00007; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LAFFEL GL, 1992, NEW ENGL J MED, V327, P1220, DOI 10.1056/NEJM199210223271707; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; LOPEZZENO JA, 1992, NEW ENGL J MED, V326, P450, DOI 10.1056/NEJM199202133260705; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HLTH SERV RES, V22, P158; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; REDELMEIER DA, 1993, NEW ENGL J MED, V328, P772, DOI 10.1056/NEJM199303183281107; ROCKENSCHAUB A, 1990, LANCET, V335, P977, DOI 10.1016/0140-6736(90)91044-B; ROESSNER J, 1993, QUAL CONNECTIONS, V2, P10; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SEIDMAN DS, 1990, OBSTET GYNECOL, V76, P1046; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOBEL DS, 1993, MENTAL MED UPDATE SP; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; SOUMERAI SB, 1993, JAMA-J AM MED ASSOC, V270, P961, DOI 10.1001/jama.270.8.961; THOMPSON RS, 1993, PEDIATRICS, V91, P902; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; WEGMAN ME, 1993, PEDIATRICS, V92, P743; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1988, JAMA-J AM MED ASSOC, V259, P3027, DOI 10.1001/jama.259.20.3027; WENNBERG JE, 1988, HEALTH AFFAIR, V7, P99, DOI 10.1377/hlthaff.7.1.99; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; Womack J.P., 1991, MACHINE CHANGED WORL; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WOOLHANDLER S, 1993, NEW ENGL J MED, V329, P400, DOI 10.1056/NEJM199308053290606; 1993, MMWR-MORBID MORTAL W, V42, P285; 1990, HLTH PEOPLE 2000 NAT; 1993, MMWR-MORBID MORTAL W, V42, P251; 1990, MMWR-MORBID MORTAL W, V39, P148; 1989, MMWR-MORBID MORTAL W, V38, P861; 1991, COMPUTER BASED PATIE; 1992, MMWR MORB MORTA SSS6, V41, P18; 1990, MMWR-MORBID MORTAL W, V39, P442	102	105	105	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					797	802		10.1001/jama.272.10.797	http://dx.doi.org/10.1001/jama.272.10.797			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078145				2022-12-28	WOS:A1994PF18800029
J	QIAN, YL; STURCHIO, NC; CHIARELLO, RP; LYMAN, PF; LEE, TL; BEDZYK, MJ				QIAN, YL; STURCHIO, NC; CHIARELLO, RP; LYMAN, PF; LEE, TL; BEDZYK, MJ			LATTICE LOCATION OF TRACE-ELEMENTS WITHIN MINERALS AND AT THEIR SURFACES WITH X-RAY STANDING WAVES	SCIENCE			English	Article							CALCITE; INTERFACE; SORPTION	The x-ray standing waves generated by dynamical Bragg diffraction were used to directly measure lattice locations of trace elements within and at the surface of a mineral single crystal. These high-precision measurements were made on natural Iceland spar calcite cleaved along the (<10(1)over bar 4>) plane and reacted with a dilute aqueous lead solution. Within the bulk crystal, naturally occurring trace manganese was found within (<10(1)over bar 4>) planes, consistent with its substitution for calcium. At the crystal surface, sorbed lead was found to be highly ordered and mostly within (<10(1)over bar 4>) planes. This demonstrates a powerful application of synchrotron radiation in the earth and environmental sciences.	ARGONNE NATL LAB,DIV MAT SCI,ARGONNE,IL 60439; NORTHWESTERN UNIV,DEPT MAT SCI & ENGN,EVANSTON,IL 60208; NORTHWESTERN UNIV,MAT RES CTR,EVANSTON,IL 60208	United States Department of Energy (DOE); Argonne National Laboratory; Northwestern University; Northwestern University			Bedzyk, Michael J/K-6903-2013; Bedzyk, Michael J/B-7503-2009	Sturchio, Neil/0000-0002-7581-9585	PHS HHS [IR01KD45295-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATTERMAN BW, 1969, PHYS REV LETT, V22, P703, DOI 10.1103/PhysRevLett.22.703; BATTERMAN BW, 1964, REV MOD PHYS, V36, P681, DOI 10.1103/RevModPhys.36.681; BATTERMAN BW, 1964, PHYS REV A, V133, P759; BEDZYK M, 1985, SURF SCI, V152, P10, DOI 10.1016/0039-6028(85)90119-0; BEDZYK MJ, 1990, SCIENCE, V248, P52, DOI 10.1126/science.2321026; CHIARELLO RP, 1993, GEOCHIM COSMOCHIM AC, V57, P4103, DOI 10.1016/0016-7037(93)90356-2; COWAN PL, 1980, PHYS REV LETT, V44, P1680, DOI 10.1103/PhysRevLett.44.1680; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; DAVIS JA, 1987, GEOCHIM COSMOCHIM AC, V51, P1477, DOI 10.1016/0016-7037(87)90330-9; GOLOVCHENKO JA, 1982, PHYS REV LETT, V49, P560, DOI 10.1103/PhysRevLett.49.560; GRATZ AJ, 1993, GEOCHIM COSMOCHIM AC, V57, P491, DOI 10.1016/0016-7037(93)90449-7; HAYES KF, 1987, SCIENCE, V238, P783, DOI 10.1126/science.238.4828.783; KRAUSE MO, 1979, J PHYS CHEM REF DATA, V8, P307, DOI 10.1063/1.555594; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; PINGITORE NE, 1986, GEOCHIM COSMOCHIM AC, V50, P2195, DOI 10.1016/0016-7037(86)90074-8; Reeder RJ, 1983, REV MINER GEOCHEM, V11, P1, DOI DOI 10.1515/9781501508134; ZACHARA JM, 1991, GEOCHIM COSMOCHIM AC, V55, P1549, DOI 10.1016/0016-7037(91)90127-Q; ZEGENHAGEN J, 1993, SURF SCI REP, V18, P199, DOI 10.1016/0167-5729(93)90025-K; [No title captured]	19	38	39	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1555	1557		10.1126/science.8079168	http://dx.doi.org/10.1126/science.8079168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079168				2022-12-28	WOS:A1994PF33600026
J	STUKENBERG, PT; TURNER, J; ODONNELL, M				STUKENBERG, PT; TURNER, J; ODONNELL, M			AN EXPLANATION FOR LAGGING-STRAND REPLICATION - POLYMERASE HOPPING AMONG DNA SLIDING CLAMPS	CELL			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; HOLOENZYME; COMPLEX; TEMPLATE; SUBUNIT; INVITRO; ORIGIN; SIZE	The replicase of E. coli, DNA polymerase III holoenzyme, is tightly fastened to DNA by its ring-shaped beta sliding clamp. However, despite being clamped to DNA, the polymerase must rapidly cycle on and off DNA to synthesize thousands of Okazaki fragments on the lagging strand. This study shows that DNA polymerase III holoenzyme cycles from one DNA to another by a novel mechanism of partial disassembly of its multisubunit structure and then reassembly. Upon completing a template, the polymerase disengages from its beta clamp, hops off DNA, and reassociates with another beta clamp at a new primed site. The original beta clamp is left on DNA and may be harnessed by other machineries to coordinate their action with chromosome replication.	CORNELL UNIV, COLL MED, HEARST RES FDN, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Howard Hughes Medical Institute	STUKENBERG, PT (corresponding author), CORNELL UNIV, COLL MED, DEPT MICROBIOL, NEW YORK, NY 10021 USA.			Stukenberg, Todd/0000-0002-6788-2111	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER CA, 1992, J BIOL CHEM, V267, P11431; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLORESROZAS H, 1994, IN PRESS P NATL ACAD; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HUBSCHER U, 1992, TRENDS BIOCHEM SCI, V17, P55, DOI 10.1016/0968-0004(92)90499-Y; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELMAN Z, 1994, IN PRESS METH ENZYMO; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MEYER TF, 1979, J BIOL CHEM, V254, P2642; MUNN MM, 1991, J BIOL CHEM, V266, P20034; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, THESIS CORNELL U MED; OREILLY DR, 1989, NATURE, V337, P606, DOI 10.1038/337606a0; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, UCLA SYM BI, V127, P153; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIAO H, 1993, J BIOL CHEM, V268, P11773; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	39	149	150	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					877	887		10.1016/S0092-8674(94)90662-9	http://dx.doi.org/10.1016/S0092-8674(94)90662-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087854				2022-12-28	WOS:A1994PG29600016
J	BRENNAN, TA				BRENNAN, TA			BUYING EDITORIALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONFLICTS-OF-INTEREST				BRENNAN, TA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.							CHREN MM, 1994, ARCH DERMATOL, V130, P432, DOI 10.1001/archderm.130.4.432; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; RELMAN AS, 1984, NEW ENGL J MED, V310, P1182, DOI 10.1056/NEJM198405033101809; RODWIN M, 1993, MED MONEY MORALS; RODWIN MA, 1989, NEW ENGL J MED, V321, P1405, DOI 10.1056/NEJM198911163212010; ROTHMAN KJ, 1993, JAMA-J AM MED ASSOC, V269, P2782, DOI 10.1001/jama.269.21.2782; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; 1990, CLIN RES, V38, P239; 1994, NEW ENGL J MED, V331, P140; 1990, POLICY CONFLICTS INT; 1993, LANCET, V342, P1498	15	35	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					673	675		10.1056/NEJM199409083311012	http://dx.doi.org/10.1056/NEJM199409083311012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052280				2022-12-28	WOS:A1994PE38200012
J	MEKALANOS, JJ; SADOFF, JC				MEKALANOS, JJ; SADOFF, JC			CHOLERA VACCINES - FIGHTING AN ANCIENT SCOURGE	SCIENCE			English	Editorial Material							VIBRIO-CHOLERAE; HUMANS; TOXIN		WALTER REED ARMY INST RES,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	MEKALANOS, JJ (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018045, R37AI018045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barua Dhiman, 1992, P1; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; Clemens John, 1994, P425; COSTER T, UNPUB; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; KAPER JB, 1994, INFECT IMMUN, V62, P1480, DOI 10.1128/IAI.62.4.1480-1483.1994; LEVINE M M, 1988, Lancet, V2, P467; LEVINE MM, 1988, INFECT IMMUN, V56, P161, DOI 10.1128/IAI.56.1.161-167.1988; LEVINE MM, 1984, INFECT IMMUN, V43, P515, DOI 10.1128/IAI.43.2.515-522.1984; Levine Myron M., 1992, P285; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Mekalanos John J., 1994, Current Opinion in Biotechnology, V5, P312, DOI 10.1016/0958-1669(94)90035-3; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; SHIMADA T, 1993, LANCET, V341, P1347; TACKET CO, 1993, J INFECT DIS, V168, P1536, DOI 10.1093/infdis/168.6.1536; TAYLOR DN, 1994, IN PRESS J INFECT DI; WALDOR MK, 1994, LANCET, V343, P1366, DOI 10.1016/S0140-6736(94)92504-6; WALDOR MK, 1994, J INFECT DIS, V172, P278; WANKE CA, 1987, INFECT IMMUN, V55, P1924, DOI 10.1128/IAI.55.8.1924-1926.1987	19	28	34	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1387	1389		10.1126/science.8073279	http://dx.doi.org/10.1126/science.8073279			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073279				2022-12-28	WOS:A1994PE73300031
J	BODENHEIMER, T; GRUMBACH, K				BODENHEIMER, T; GRUMBACH, K			PAYING FOR HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; INSURANCE		UNIV CALIF SAN FRANCISCO, DEPT FAMILY & COMMUNITY MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								Aaron H., 1991, SERIOUS UNSTABLE CON; ARROW KJ, 1963, AM ECON REV, V53, P941; BODENHEIMER T, 1992, J HEALTH POLIT POLIC, V17, P439, DOI 10.1215/03616878-17-3-439; BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; BUTLER SM, 1991, JAMA-J AM MED ASSOC, V265, P2541, DOI 10.1001/jama.265.19.2541; CANTOR JC, 1990, J HEALTH POLIT POLIC, V15, P755, DOI 10.1215/03616878-15-4-755; EVANS RG, 1984, STRAINED MERCY EC CA; FEIN R, 1986, MED CARE MED COSTS; Harris Richard, 1966, SACRED TRUST; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; Law Sylvia, 1974, BLUE CROSS WHAT WENT; Levit K R, 1992, Health Care Financ Rev, V14, P31; LEVIT KR, 1992, HLTH CARE FINANCING, V14, P1; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; Pechman J.A., 1985, WHO PAID TAXES 1966; Reinhardt U E, 1988, Health Manage Q, V10, P10; REINHARDT UE, 1993, HEALTH AFFAIR, V12, P172, DOI 10.1377/hlthaff.12.suppl_1.172; SHAPIRO RY, 1986, PUBLIC OPIN QUART, V50, P418, DOI 10.1086/268994; Starr P, 1982, SOCIAL TRANSFORMATIO; TODD JS, 1991, JAMA-J AM MED ASSOC, V265, P2503; 1993, HLTH US 1992; 1990, SOURCE BOOK HLTH INS	22	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					634	639		10.1001/jama.272.8.634	http://dx.doi.org/10.1001/jama.272.8.634			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057522				2022-12-28	WOS:A1994PC39800037
J	GEARING, AJH; BECKETT, P; CHRISTODOULOU, M; CHURCHILL, M; CLEMENTS, J; DAVIDSON, AH; DRUMMOND, AH; GALLOWAY, WA; GILBERT, R; GORDON, JL; LEBER, TM; MANGAN, M; MILLER, K; NAYEE, P; OWEN, K; PATEL, S; THOMAS, W; WELLS, G; WOOD, LM; WOOLLEY, K				GEARING, AJH; BECKETT, P; CHRISTODOULOU, M; CHURCHILL, M; CLEMENTS, J; DAVIDSON, AH; DRUMMOND, AH; GALLOWAY, WA; GILBERT, R; GORDON, JL; LEBER, TM; MANGAN, M; MILLER, K; NAYEE, P; OWEN, K; PATEL, S; THOMAS, W; WELLS, G; WOOD, LM; WOOLLEY, K			PROCESSING OF TUMOR-NECROSIS-FACTOR-ALPHA PRECURSOR BY METALLOPROTEINASES	NATURE			English	Article							COLLAGEN-INDUCED ARTHRITIS; TISSUE INHIBITOR; RABBIT BONE; CELLS; SECRETION; TIMP-2	TUMOUR necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory and immunomodulatory cytokine implicated in inflammatory conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and the cachexia associated with cancer or human immunodeficiency virus infection(1). TNF-alpha is initially expressed as a 233-amino-acid membrane-anchored precursor which is proteolytically processed to yield the mature, 157-amino-acid cytokine(2). The processing enzyme(s) which cleave TNF-alpha are unknown. Here we show that the release of mature TNF-alpha from leukocytes cultured in vitro is specifically prevented by synthetic hydroxamic acid-based metalloproteinase inhibitors, which also prevent the release of TNF-alpha into the circulation of endotoxin challenged rats. A recombinant, truncated TNF-alpha precursor is cleaved to biologically active, mature TNF-alpha by several matrix metalloproteinase enzymes. These results indicate that processing of the TNF-alpha precursor is dependent on at least one matrix metalloproteinase-like enzyme, inhibition of which represents a novel therapeutic mechanism for interfering with TNF-alpha production.	BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND									CARMICHAEL DF, 1989, AGENTS ACTIONS, V27, P378, DOI 10.1007/BF01972827; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DEZUBE BJ, 1993, CANCER IMMUNOL IMMUN, V36, P57, DOI 10.1007/BF01789132; DIMARTINO MJ, 1991, J CELL BIOCH SE, V19, P179; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ENDRES S, 1991, IMMUNOLOGY, V72, P56; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519; GEE NS, 1987, BIOCHEM J, V246, P97, DOI 10.1042/bj2460097; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MATTHEWS N, 1987, LYMPHOKINES INTERFER, P221; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WILSON BMG, 1991, J IMMUNOL METHODS, V139, P233, DOI 10.1016/0022-1759(91)90193-J	21	1100	1152	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					555	557		10.1038/370555a0	http://dx.doi.org/10.1038/370555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052310				2022-12-28	WOS:A1994PC53700054
J	SU, XD; TADDEI, N; STEFANI, M; RAMPONI, G; NORDLUND, P				SU, XD; TADDEI, N; STEFANI, M; RAMPONI, G; NORDLUND, P			THE CRYSTAL-STRUCTURE OF A LOW-MOLECULAR-WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE	NATURE			English	Article							CYTOSOLIC ACID-PHOSPHATASE; BOVINE HEART; CATALYTIC MECHANISM; GROWTH; REFINEMENT	PROTEIN tyrosine phosphorylation and dephosphorylation are central reactions for control of cellular division, differentiation and development(1). Here we describe the crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase (PTPase)(2), a cytosolic phosphatase present in many mammalian cells. The enzyme catalyses the dephosphorylation of phosphotyrosine-containing substrates(3-6), and overexpression of the protein in normal and transformed cells inhibits cell. proliferation(7,8). The structure of the low-molecular-weight PTPase reveals an alpha/beta protein containing a phosphate-binding loop motif at the amino end of helix alpha 1. This motif includes the essential active-site residues Cys 12 and Arg 18 and bears striking similarities to the active-site motif recently described in the structure of human PTP1B(9). The structure ofthe low-molecular-weight PTPase supports a reaction mechanism involving the conserved Cys 12 as an attacking nucleophile in an in-line associative mechanism. The structure also suggests a catalytic role for Asp 129 in the reaction cycle.	UNIV FLORENCE,DEPT BIOCHEM SCI,FLORENCE,ITALY	University of Florence	SU, XD (corresponding author), UNIV STOCKHOLM,DEPT MOLEC BIOL,STOCKHOLM,SWEDEN.			Taddei, Niccolo/0000-0003-2513-1018; STEFANI, MASSIMO/0000-0002-4490-1922				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERTI A, IN PRESS FEBS LETT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIRAGA A, 1991, ADV PROTEIN PHOSPHAT, V6, P251; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; SU XD, 1994, FEBS LETT, V343, P107, DOI 10.1016/0014-5793(94)80299-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006	23	202	206	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					575	578		10.1038/370575a0	http://dx.doi.org/10.1038/370575a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052313				2022-12-28	WOS:A1994PC53700060
J	SCHRADER, M; MULLER, KM; NAYERI, S; KAHLEN, JP; CARLBERG, C				SCHRADER, M; MULLER, KM; NAYERI, S; KAHLEN, JP; CARLBERG, C			VITAMIN-D-3 THYROID-HORMONE RECEPTOR HETERODIMER POLARITY DIRECTS LIGAND SENSITIVITY OF TRANSACTIVATION	NATURE			English	Article							RETINOIC ACID RECEPTORS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; GENE-EXPRESSION; DIRECT REPEATS; X-RECEPTOR; RXR; BINDING; RAR; IDENTIFICATION	The nuclear receptors for 1,25-dihydroxyvitamin D-3 (VD) and 3,5,3'-triiodothyronine (T-3), that is, VDRs and T(3)Rs respectively, control aspects of homeostasis, cell growth and differentiation(1-4). They activate transcription from response elements consisting of direct repeats, palindromes and inverted palindromes(5-8) of a variety of hexameric core-binding motifs. VDRs bind preferentially to direct repeats spaced by three nucleotides, whereas T(3)Rs bind to direct repeats spaced by four nucleotides(9). VDRs and T(3)Rs can function as homodimers(5,6,10) but heterodimerization with retinoid X(11-14) Or retinoic acid receptors(15,16) increases their affinity for DNA in vitro and resulting transcriptional activity in vivo. We recently observed the formation of VDR-T(3)R heterodimers(17). Here we show that the polarity of the binding of such heterodimers to the VD response element of the rat 9K (relative molecular mass 9,000) calbindin's gene promoter was 5'-T(3)R-VDR-3', whereas on the mouse 28K calbindin VD response element(19) this polarity was reversed to 5'-VDR-T(3)R-3'. We also show that the ligand for the downstream receptor controls the transcriptional activity of the heterodimeric complex. Thus, polarity seems to be an important regulatory property of heterodimeric nuclear receptor complexes.			SCHRADER, M (corresponding author), UNIV GENEVA,HOP CANTONAL,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND.		Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JWA, 1991, REV NUTR, V11, P189; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	125	126	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					382	386		10.1038/370382a0	http://dx.doi.org/10.1038/370382a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047145				2022-12-28	WOS:A1994PA30400059
J	MOLLER, H; KNUDSEN, LB; LYNGE, E				MOLLER, H; KNUDSEN, LB; LYNGE, E			RISK OF TESTICULAR CANCER AFTER VASECTOMY - COHORT STUDY OF OVER 73000 MEN	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES MEN; PROSTATE-CANCER; RETROSPECTIVE COHORT; RECORD LINKAGE; TESTIS CANCER; HOSPITALIZATION; ILLNESS; DISEASE; HEALTH	Objective-To confirm or refute reports that vasectomy may increase the risk of cancers of the testis and prostate. Design-Computerised record linkage study of cohort of men with vasectomy and comparison of cancer rates with those in the whole Danish population; manual check of all records of patients with testicular and prostate cancer diagnosed within the first year of follow up. Setting-Denmark 1977-89. Subjects-Cohort of 73 917 men identified in hospital discharge and pathology registers as having had a vasectomy for any reason during 1977-89. Main outcome measures-Observed incidences of testicular, prostate, and other cancers up to the end of 1989. Results-The overall pattern of cancer incidence in the study cohort was similar to that expected nationally. No increased incidence in testicular cancer was observed (70 cases; standardised morbidity ratio 1.01 (95% confidence interval 0.79 to 1.28)). The incidence during the first year of follow up was also close to that expected (nine cases; standardised morbidity ratio 0.80 (0.36 to 1.51)). The incidence of prostate cancer was not increased (165 cases; standardised morbidity ratio 0.98 (0.84 to 1.14)). Conclusions-The incidence of testicular cancer in men with vasectomy is no higher than in other men. Vasectomy does not cause testicular cancer and does not accelerate the growth or diagnosis of pre-existing testicular neoplasms. Data concerning a causal relation between vasectomy and prostate cancer were inconclusive.	DANISH CANC SOC,DK-2100 COPENHAGEN,DENMARK; DANMARKS STAT,DK-2100 COPENHAGEN,DENMARK	Danish Cancer Society				Moller, Henrik/0000-0001-8200-5929; Lynge, Elsebeth/0000-0003-4785-5236				Blom K, 1984, Ugeskr Laeger, V146, P616; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; FORD K, 1978, FAM PLANN PERSPECT, V10, P264, DOI 10.2307/2134378; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; GOLDACRE M, 1979, VASECTOMY IMMUNOLOGI, P567; GOLDACRE MJ, 1978, AM J EPIDEMIOL, V108, P176, DOI 10.1093/oxfordjournals.aje.a112609; HAYES RB, 1993, AM J EPIDEMIOL, V137, P263, DOI 10.1093/oxfordjournals.aje.a116673; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; JORGENSEN N, 1993, EUR J CANCER, V29A, P1062, DOI 10.1016/S0959-8049(05)80225-4; LYNGE E, 1990, Scandinavian Journal of Work Environment and Health, V16, P1; LYNGE E, 1933, EUR J CANCER, V29, P1064; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; MOLLER H, 1991, ACTA NEUROL SCAND, V84, P214, DOI 10.1111/j.1600-0404.1991.tb04941.x; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; PETITTI DB, 1983, J UROLOGY, V129, P760, DOI 10.1016/S0022-5347(17)52345-9; PETITTI DB, 1982, AM J PUBLIC HEALTH, V72, P476, DOI 10.2105/AJPH.72.5.476; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; Schuman L M, 1993, J Clin Epidemiol, V46, P697; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SIDNEY S, 1993, JAMA-J AM MED ASSOC, V270, P705, DOI 10.1001/jama.1993.03510060051018; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; SWERDLOW AJ, 1989, INT J CANCER, V43, P549, DOI 10.1002/ijc.2910430403; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; SZAREWSKI A, 1991, BRIT MED J, V302, P1224, DOI 10.1136/bmj.302.6787.1224; THORNHILL JA, 1988, EUR UROL, V14, P429; WALKER AM, 1981, JAMA-J AM MED ASSOC, V245, P2315, DOI 10.1001/jama.245.22.2315; WRIGHT N, 1977, Fertility and Contraception, V1, P41; 1988, IARC MONOGR EVAL CAR, V44	36	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					295	299		10.1136/bmj.309.6950.295	http://dx.doi.org/10.1136/bmj.309.6950.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086866	Green Published			2022-12-28	WOS:A1994PA37300016
J	BRUMMEL, TJ; TWOMBLY, V; MARQUES, G; WRANA, JL; NEWFELD, SJ; ATTISANO, L; MASSAGUE, J; OCONNOR, MB; GELBART, WM				BRUMMEL, TJ; TWOMBLY, V; MARQUES, G; WRANA, JL; NEWFELD, SJ; ATTISANO, L; MASSAGUE, J; OCONNOR, MB; GELBART, WM			CHARACTERIZATION AND RELATIONSHIP OF DPP RECEPTORS ENCODED BY THE SAXOPHONE AND THICK VEINS GENES IN DROSOPHILA	CELL			English	Article							GROWTH-FACTOR-BETA; PROTEIN-KINASE; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; CONSERVED FEATURES; GERM LAYERS; EXPRESSION; FAMILY; PATTERN; MELANOGASTER	The dpp/BMP family of TGF beta-related factors controls numerous events in pattern formation and morphogenesis. How these polypeptide signals are received and transduced by target cells is largely unknown. We combine molecular and genetic approaches to establish that the Drosophila saxophone (sax) gene encodes a dpp receptor. We compare the structural properties and expression patterns of sax with a second dpp receptor encoded by the thick veins (tkv) gene. While the sax gene is expressed ubiquitously, tkv is expressed in a highly localized and dynamic pattern during development. Some, but not all, of the tkv expression pattern parallels that of dpp. Ubiquitous expression of a tkv transgene rescues both tkv and sax loss-of function mutations. Thus, there is at least partial functional overlap of the sax and tkv receptors in vivo. We consider these observations in terms of possible ligand-receptor interactions during Drosophila development.	UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA; HARVARD UNIV, BIOL LABS, CAMBRIDGE, MA 02138 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	University of California System; University of California Irvine; Harvard University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	BRUMMEL, TJ (corresponding author), UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA.		O'Connor, Michael B/C-9977-2014; Wrana, Jeffrey/F-8857-2013	O'Connor, Michael B/0000-0002-3067-5506; Massague, Joan/0000-0001-9324-8408				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOENIG BB, 1994, IN PRESS MOL CELL BI; Maniatis T., 1982, MOL CLONING; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHUPBACH T, 1989, GENETICS, V121, P101; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TERRACOL R, 1994, IN PRESS GENETICS; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; Wieschaus E., 1986, P199; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	48	268	276	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					251	261		10.1016/0092-8674(94)90295-X	http://dx.doi.org/10.1016/0092-8674(94)90295-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044839				2022-12-28	WOS:A1994NZ24200009
J	LINGAM, S; JOESTER, J				LINGAM, S; JOESTER, J			LESSON OF THE WEEK - SPONTANEOUS FRACTURES IN CHILDREN AND ADOLESCENTS WITH CEREBRAL-PALSY	BRITISH MEDICAL JOURNAL			English	Article									MELDRETH MANOR SCH,MELDRETH SG8 6LG,HERTS,ENGLAND		LINGAM, S (corresponding author), ST ANNS HOSP,WARD M2,ST ANNS RD,LONDON N15 3TH,ENGLAND.							RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012	1	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					265	265		10.1136/bmj.309.6949.265	http://dx.doi.org/10.1136/bmj.309.6949.265			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069146	Green Published			2022-12-28	WOS:A1994NZ18000028
J	ADAMS, JE; SICARD, GA; ALLEN, BT; BRIDWELL, KH; LENKE, LG; DAVILAROMAN, VG; BODOR, GS; LADENSON, JH; JAFFE, AS				ADAMS, JE; SICARD, GA; ALLEN, BT; BRIDWELL, KH; LENKE, LG; DAVILAROMAN, VG; BODOR, GS; LADENSON, JH; JAFFE, AS			DIAGNOSIS OF PERIOPERATIVE MYOCARDIAL-INFARCTION WITH MEASUREMENT OF CARDIAC TROPONIN-I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREATINE-KINASE-MB; ABDOMINAL AORTIC-ANEURYSMS; SKELETAL-MUSCLES; DEVELOPMENTAL EXPRESSION; OPERATIVE TREATMENT; NONCARDIAC SURGERY; MARATHON RUNNERS; VASCULAR-SURGERY; SERUM; ISOENZYMES	Background. Perioperative myocardial infarction is the most common cause of morbidity and mortality in patients who have had noncardiac surgery, but its diagnosis can be difficult, The present study was designed to determine whether the measurement of serum levels of cardiac troponin I, a highly sensitive and specific marker for cardiac injury, would help establish the diagnosis of myocardial infarction. Methods. We obtained preoperative measurements of MB creatine kinase, total creatine kinase, and cardiac troponin I, in addition to base-line electrocardiograms and two-dimensional echocardiograms, in 96 patients undergoing vascular surgery and 12 undergoing spinal surgery. Blood samples were obtained every 6 hours for at least the first 36 hours after surgery, and electrocardiograms were obtained daily; a second echocardiogram was obtained approximately three days after surgery. The appearance of a new abnormality in segmental-wall motion on the postoperative echocardiogram (that is, an abnormality that had not been seen on the preoperative echocardiogram) was considered to be indicative of perioperative infarction. Results. Eight patients who underwent vascular surgery had new abnormalities in segmental-wall motion and received a diagnosis of perioperative infarction. All eight had elevations of cardiac troponin I, and six had elevations of MB creatine kinase. Of the 100 patients without perioperative infarction detected by echocardiography, 19 had elevations of MB creatine kinase, and 1 had a slight elevation of cardiac troponin I. Conclusions. The measurement of cardiac troponin I is a sensitive and specific method for the diagnosis of perioperative myocardial infarction. It avoids the high incidence of false diagnoses associated with the use of MB creatine kinase as a diagnostic marker.	WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,VASC SURG SECT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV ORTHOPED SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV LAB MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Bodor, Geza S./AAI-2930-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 17646] Funding Source: Medline; NIEHS NIH HHS [5-T32-ESO-7066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; ALLAF M, 1986, CLIN CHEM, V32, P291; APPLE FS, 1984, CLIN CHEM, V30, P413; AUSONI S, 1991, DEVELOPMENT, V112, P1041; BODOR GS, 1992, CLIN CHEM, V38, P2203; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; FORCE T, 1985, CIRCULATION, V72, P781, DOI 10.1161/01.CIR.72.4.781; HENRY WL, 1980, CIRCULATION, V62, P212, DOI 10.1161/01.CIR.62.2.212; HERTZER NR, 1984, J VASC SURG, V1, P13; HOLLIER LH, 1992, J VASC SURG, V15, P1046, DOI 10.1016/0741-5214(92)90462-H; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KESHGEGIAN AA, 1984, CLIN CHEM, V30, P575; LARUE C, 1993, CLIN CHEM, V39, P972; LENKE LG, IN PRESS J SPINAL DI; London MJ, 1988, ADV ANESTHESIA, V5, P53; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MARTIN AF, 1991, J MOL CELL CARDIOL, V23, P583, DOI 10.1016/0022-2828(91)90050-V; POTKIN RT, 1982, CIRCULATION, V66, P627, DOI 10.1161/01.CIR.66.3.627; Roberts SL, 1988, CARDIOVASCULAR DIS R, P33; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; SAGGIN L, 1990, DEVELOPMENT, V110, P547; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SICARD GA, 1989, SURG CLIN N AM, V69, P795; SNEDECOR GW, 1980, STATISTICAL METHODS, P121; SULLIVAN CA, 1990, J VASC SURG, V11, P799; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; TSUNG JS, 1986, CLIN CHEM, V32, P1568; TSUNG SH, 1981, AM J CLIN PATHOL, V75, P711, DOI 10.1093/ajcp/75.5.711; VAIDYA HC, 1986, CLIN CHEM, V32, P657; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WOLFSON D, 1991, AM HEART J, V122, P958, DOI 10.1016/0002-8703(91)90458-T; WUKICH DK, 1989, J TRAUMA, V29, P375, DOI 10.1097/00005373-198903000-00017	37	439	454	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					670	674		10.1056/NEJM199403103301003	http://dx.doi.org/10.1056/NEJM199403103301003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8054012	Bronze			2022-12-28	WOS:A1994MY57500003
J	BLOCH, AB; CAUTHEN, GM; ONORATO, IM; DANSBURY, KG; KELLY, GD; DRIVER, CR; SNIDER, DE				BLOCH, AB; CAUTHEN, GM; ONORATO, IM; DANSBURY, KG; KELLY, GD; DRIVER, CR; SNIDER, DE			NATIONWIDE SURVEY OF DRUG-RESISTANT TUBERCULOSIS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; OUTBREAK	Objective.-To determine antituberculosis drug resistance patterns, geographic distribution, demographic characteristics, and risk factors of reported tuberculosis (TB) patients in the United States. Design.-Survey of reported TB cases in the United States. For culture-positive cases reported to the Centers for Disease Control and Prevention, we asked health departments to provide drug susceptibility test results from initial Mycobacterium tuberculosis isolates. Study Population.-Culture-positive TB cases in the United States reported during the first quarter of 1991. Main Outcome Measures.-Individual TB case reports submitted to the Centers for Disease Control and Prevention and drug susceptibility test results. Result.-Resistance to one or more antituberculosis drugs was found in 14.2% of cases. Resistance to isoniazid and/or rifampin was found in 9.5% of cases whose isolates were tested against one or both drugs; such cases were found in 107 counties in 33 states. Resistance to both isoniazid and rifampin (multidrug-resistant [MDR] TB) was found in 3.5% of cases whose isolates were tested against both drugs; such cases were found in 35 counties in 13 states. New York City accounted for 61.4% of the nation's MDR TB cases. The 3-month population-based incidence rate of MDR TB in New York City was 52.4 times (95% confidence interval [CI], 35.5 to 78.3) that of the rest of the nation (9.559 vs 0.182 cases per million population). Compared with the rate in non-Hispanic whites in the rest of the nation (0.032 cases per million), the relative risk of MDR TB in New York City non-Hispanic whites was 39.0 (95% CI, 8.1 to 164.5), 299.3 (95% CI, 112.5 to 927.1) in Hispanics, 420.9 (95% CI, 121.0 to 1515.8) in Asian/Pacific islanders, and 701.0 (95% CI, 296.4 to 2018.1) in non-Hispanic blacks. Conclusions.-With nearly 10% of TB patients resistant to isoniazid and/or rifampin, greater use of four-drug regimens and directly observed therapy is indicated. Aggressive intervention to prevent the further spread of MDR TB is needed to find every TB patient and to provide optimal patient, management to ensure completion of chemotherapy.			BLOCH, AB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,INFORMAT SERV OFF,ATLANTA,GA 30333, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CORONADO VG, 1992, NOV WORLD C TUB BETH; DAVIDSON PT, 1987, AM REV RESPIR DIS, V136, P255, DOI 10.1164/ajrccm/136.2.255; Dean A. G., 1990, EPI INFO VERSION 5 W; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; IKEDA R, 1992, 32ND INT C ANT AG CH; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JEREB J, 1992, NOV WORLD C TUB BETH; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; KOPANOFF DE, 1988, AM J PUBLIC HEALTH, V78, P30, DOI 10.2105/AJPH.78.1.30; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767, DOI 10.1128/JCM.31.4.767-770.1993; Tuberculosis morbidity-United States, 1992, MMWR MORB MORTAL WKL, V42, P703; USSERY XT, 1992, 32ND INT C ANT AG CH; VALWAY SE, 1990, IN PRESS J INFECT DI; VALWAY SE, 1991, IN PRESS AM J EPIDEM; 1991, MMWR MORB MORTAL WKL, V40, P585; 1983, MMWR MORB MORTAL WKL, V32, P521; 1992, AM REV RESPIR DIS, V146, P1623; 1992, MMWR MORB MORTAL WKL, V41, P59; 1986, AM REV RESPIR DIS, V134, P855; 1992, MMWR MORB MORTAL WKL, V41, P507; 1993, OTAH574 US C OFF TEC; 1993, MMWR MORB MORTAL WKL, V42, P696; 1992, MMWR MORB MORTAL WKL, V41, P49; 1989, MMWR MORB MORTAL SS3, V38, P1; 1980, MMWR MORB MORTAL WKL, V29, P345; 1993, MMWR MORB MORTAL WKL, V42, P1	47	297	306	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					665	671		10.1001/jama.271.9.665	http://dx.doi.org/10.1001/jama.271.9.665			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8080502				2022-12-28	WOS:A1994MX57000026
J	MAYER, RJ; DAVIS, RB; SCHIFFER, CA; BERG, DT; POWELL, BL; SCHULMAN, P; OMURA, GA; MOORE, JO; MCINTYRE, OR; FREI, E				MAYER, RJ; DAVIS, RB; SCHIFFER, CA; BERG, DT; POWELL, BL; SCHULMAN, P; OMURA, GA; MOORE, JO; MCINTYRE, OR; FREI, E			INTENSIVE POSTREMISSION CHEMOTHERAPY IN ADULTS WITH ACUTE MYELOID-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOGENOUS LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; HIGH-DOSE CYTARABINE; BONE-MARROW TRANSPLANTATION; ACUTE NONLYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; BRITISH COOPERATIVE GROUP; ACUTE MYELOCYTIC-LEUKEMIA; TERM FOLLOW-UP; CONSOLIDATION THERAPY	Background. About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission therapy is administered. Uncontrolled trials have suggested that intensive postremission therapy may prolong these complete remissions. Methods. We treated 1088 adults with newly diagnosed AML with three days of daunorubicin and seven days of cytarabine and randomly assigned patients who had a complete remission to receive four courses of cytarabine at one of three doses: 100 mg per square meter of body-surface area per day for five days by continuous infusion, 400 mg per square meter per day for five days by continuous infusion, or 3 g per square meter in a 3-hour infusion every 12 hours (twice daily) on days 1, 3, and 5. All patients then received four courses of monthly maintenance treatment. Results. Of the 693 patients who had a complete remission, 596 were randomly assigned to receive postremission cytarabine. After a median follow-up of 52 months, the disease-free survival rates in the three treatment groups were significantly different (P = 0.003). Relative to the 100-mg group, the hazard ratios were 0.67 for the 3-g group (95 percent confidence interval, 0.53 to 0.86) and 0.75 for the 400-mg group (95 percent confidence interval, 0.60 to 0.94). The probability of remaining in continuous complete remission after four years for patients 60 years of age or younger was 24 percent in the 100-mg group, 29 percent in the 400-mg group, and 44 percent in the 3-g group (P = 0.002). in contrast, for patients older than 60, the probability of remaining disease-free after four years was 16 percent or less in each of the three postremission cytarabine groups. Conclusions. These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger. The results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA USA; UNIV MARYLAND, CTR CANC, BALTIMORE, MD 21201 USA; BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA; N SHORE UNIV HOSP, MANHASSET, NY USA; UNIV ALABAMA, BIRMINGHAM, AL USA; DUKE UNIV, MED CTR, DURHAM, NC USA; DARTMOUTH COLL, SCH MED, NORRIS COTTON CANC CTR, LEBANON, NH USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University System of Maryland; University of Maryland Baltimore; Wake Forest University; Wake Forest Baptist Medical Center; Northwell Health; North Shore University Hospital; University of Alabama System; University of Alabama Birmingham; Duke University; Dartmouth College; Norris Cotton Cancer Center	MAYER, RJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV MED ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [CA32291, CA31983, CA33601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA032291, U10CA033601, U10CA031983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER WJ, 1991, J CLIN ONCOL, V9, P679, DOI 10.1200/JCO.1991.9.4.679; BATTISTA R, 1991, HEMATOL ONCOL, V9, P43; BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460; BENNETT JM, 1991, LEUKEMIA RES, V15, P223, DOI 10.1016/0145-2126(91)90124-C; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERMAN E, 1992, NEW ENGL J MED, V326, P156, DOI 10.1056/NEJM199201163260303; BISHOP JF, 1992, PROG P AM SOC CLIN O, V11, P260; BLOOMFIELD CD, 1985, J CLIN ONCOL, V3, P1570, DOI 10.1200/JCO.1985.3.12.1570; BOLWELL BJ, 1988, LEUKEMIA, V2, P253; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; BUCHNER T, 1985, J CLIN ONCOL, V3, P1583; BUTTURINI A, 1989, BRIT J HAEMATOL, V72, P1, DOI 10.1111/j.1365-2141.1989.tb07642.x; CASSILETH PA, 1992, BLOOD, V79, P1924; CLIFT RA, 1990, BLOOD, V76, P1867; COX DR, 1972, J R STAT SOC B, V34, P187; DICK FR, 1982, CANCER, V49, P916, DOI 10.1002/1097-0142(19820301)49:5<916::AID-CNCR2820490515>3.0.CO;2-L; ELLISON RR, 1968, BLOOD, V32, P507, DOI 10.1182/blood.V32.4.507.507; Fleiss JL, 1981, STAT METHODS RATES P; GORIN NC, 1991, LEUKEMIA, V5, P896; HAROUSSEAU JL, 1991, J CLIN ONCOL, V9, P1432, DOI 10.1200/JCO.1991.9.8.1432; HURD DD, 1993, J CLIN ONCOL, V11, P1636, DOI 10.1200/JCO.1993.11.9.1636; JACOBS P, 1984, AM J HEMATOL, V16, P255, DOI 10.1002/ajh.2830160307; KANTARJIAN HM, 1986, CANCER, V58, P1603, DOI 10.1002/1097-0142(19861015)58:8<1603::AID-CNCR2820580804>3.0.CO;2-S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MAYER RJ, 1987, SEMIN ONCOL, V14, P25; MAYER RJ, 1982, CANCER TREAT REP, V66, P1455; MAYER RJ, 1987, SEMIN ONCOL, V14, P384; MAYER RJ, 1988, J CLIN ONCOL, V6, P1532, DOI 10.1200/JCO.1988.6.10.1532; MCCULLOCH EA, 1981, BLOOD, V58, P105; MOORE JO, 1992, BLOOD S, V80, pA291; PASSE S, 1982, CANCER, V50, P1462, DOI 10.1002/1097-0142(19821015)50:8<1462::AID-CNCR2820500804>3.0.CO;2-1; PETERSON BA, 1981, BLOOD, V57, P1144; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PREISLER H, 1987, BLOOD, V69, P1441; PREISLER HD, 1978, MED PEDIATR ONCOL, V4, P275, DOI 10.1002/mpo.2950040311; PREISLER HD, 1987, J CLIN ONCOL, V5, P722, DOI 10.1200/JCO.1987.5.5.722; RAI KR, 1981, BLOOD, V58, P1203; REES JKH, 1986, LANCET, V2, P1236; RUBIN EH, 1992, J CLIN ONCOL, V10, P948, DOI 10.1200/JCO.1992.10.6.948; SAUTER C, 1984, LANCET, V1, P379; SCHIFFER CA, 1990, UCLA SYM BI, V134, P313; SCHILLER G, 1992, BLOOD, V80, P2977; SCHILLER GJ, 1992, J CLIN ONCOL, V10, P41, DOI 10.1200/JCO.1992.10.1.41; SKIPPER HE, 1964, CANCER CHEMOTH REP, P3; STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P65, DOI 10.1016/S0889-8588(18)30258-2; SULTAN C, 1981, BRIT J HAEMATOL, V47, P545, DOI 10.1111/j.1365-2141.1981.tb02683.x; TRICOT G, 1987, BRIT J HAEMATOL, V66, P37, DOI 10.1111/j.1365-2141.1987.tb06887.x; VOGLER WR, 1984, BLOOD, V63, P1039; WEINSTEIN HJ, 1983, BLOOD, V62, P315; WEISS RB, 1993, JAMA-J AM MED ASSOC, V270, P459, DOI 10.1001/jama.270.4.459; WIECK J, 1992, PROG P AM SOC CLIN O, V1, P261; WOLFF SN, 1989, J CLIN ONCOL, V7, P1260, DOI 10.1200/JCO.1989.7.9.1260; WORSLEY AM, 1984, BRIT J HAEMATOL, V56, P361, DOI 10.1111/j.1365-2141.1984.tb03967.x; YOUNG JW, 1992, BLOOD, V79, P3380; 1984, LANCET, V1, P1389	56	1129	1158	2	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					896	903		10.1056/NEJM199410063311402	http://dx.doi.org/10.1056/NEJM199410063311402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078551				2022-12-28	WOS:A1994PJ41900002
J	KALLIO, MJT; KILPI, T; ANTTILA, M; PELTOLA, H				KALLIO, MJT; KILPI, T; ANTTILA, M; PELTOLA, H			THE EFFECT OF A RECENT PREVIOUS VISIT TO A PHYSICIAN ON OUTCOME AFTER CHILDHOOD BACTERIAL-MENINGITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; CEREBROSPINAL-FLUID; PNEUMOCOCCAL MENINGITIS; MENINGOCOCCAL DISEASE; DIAGNOSIS; SEQUELAE; CHILDREN; PROGNOSIS; DURATION; SYMPTOMS	Objective.-To assess the effect of a recent previous visit to a physician on the outcome of meningitis in children. Design.-Evaluation of data from children examined by a physician and sent home, either the previous day or 2 to 4 days before meningitis was diagnosed, and children whose meningitis was diagnosed at once. The patients were examined daily during hospitalization, neurologic examinations were repeated at 2 weeks and 3 and 6 months after discharge, and hearing was assessed 2 or more months after discharge. Setting.-Eighteen pediatric hospitals in Finland from 1984 through 1991. Population.-A total of 325 children aged 3 months to 15 years with bacterial meningitis. Main Outcome Measures.-Clinical and laboratory findings on admission, recovery during hospitalization, mortality, and neurologic abnormalities at 6 months of follow-up. Results.-In 74% of the patients, meningitis was diagnosed at once, 14% had visited a physician on the previous day, and 11% had seen a physician 2 to 4 days before diagnosis. The group seen 2 to 4 days earlier had a better level of consciousness, less frequent seizures, and more respiratory symptoms and otitis media than the other groups. The cerebrospinal fluid leukocyte count, white blood cell count, and erythrocyte sedimentation rate were highest and the cerebrospinal fluid glucose concentration was lowest in the children who had visited a physician 2 to 4 days earlier; although they also had lower cerebrospinal fluid protein and urine sodium and potassium levels. This group had the most rapid return to normal consciousness. There was no difference in the incidence of hearing impairment or neurologic sequelae. Even the mortality was virtually the same in the three groups: 4%, 4%, and 3% in the ''same day,'' ''previous day,'' and ''2 to 4 days earlier'' groups, respectively. Conclusions.-Children who had visited a physician the previous day or 2 to 4 days before meningitis was diagnosed did not exhibit an increased frequency of hearing impairment, other neurologic abnormalities, or overall adverse outcome compared with children whose meningitis was diagnosed at once.	UNIV HELSINKI, CHILDRENS HOSP, DIV INFECT DIS, SF-00290 HELSINKI, FINLAND	University of Helsinki								BAIRD DR, 1976, LANCET, V2, P1344; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; DAVIS SD, 1975, AM J DIS CHILD, V129, P802, DOI 10.1001/archpedi.1975.02120440028007; DODGE PR, 1984, NEW ENGL J MED, V311, P869, DOI 10.1056/NEJM198410043111401; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; FEIGIN RD, 1992, PEDIATR INFECT DIS J, V11, P698, DOI 10.1097/00006454-199209000-00003; Feigin RD, 1992, TXB PEDIAT INFECT DI, P401; FELDMAN WE, 1982, J PEDIATR-US, V100, P209, DOI 10.1016/S0022-3476(82)80636-7; FELDMAN WE, 1977, NEW ENGL J MED, V296, P433, DOI 10.1056/NEJM197702242960806; HERSON VC, 1977, PEDIATRICS, V59, P35; HODGES GR, 1975, AM J MED SCI, V270, P427, DOI 10.1097/00000441-197511000-00003; KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KLEIN JO, 1986, PEDIATRICS, V75, P959; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LAXER RM, 1977, AM J DIS CHILD, V131, P850, DOI 10.1001/archpedi.1977.02120210028004; PELTOLA H, 1993, LANCET, V342, P509, DOI 10.1016/0140-6736(93)91642-Y; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1989, LANCET, V1, P1281; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; RADETSKY M, 1992, PEDIATR INFECT DIS J, V11, P694, DOI 10.1097/00006454-199209000-00002; REILLY S, 1991, LANCET, V338, P1143, DOI 10.1016/0140-6736(91)91999-B; ROBERTSON WO, 1991, PEDIATRIC MANAGE OCT, P17; ROMER FK, 1977, LANCET, V2, P345; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SELL SHW, 1972, PEDIATRICS, V49, P206; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; TALAN DA, 1988, REV INFECT DIS, V10, P365; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; VALMARI P, 1985, ANN CLIN RES, V17, P310; VALMARI P, 1987, EUR J PEDIATR, V146, P515, DOI 10.1007/BF00441607; VIENNY H, 1984, PEDIATRICS, V73, P579; WILSON HD, 1975, AM J DIS CHILD, V129, P208, DOI 10.1001/archpedi.1975.02120390042009	35	25	25	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					787	791		10.1001/jama.272.10.787	http://dx.doi.org/10.1001/jama.272.10.787			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078143				2022-12-28	WOS:A1994PF18800027
J	EASON, JD; MCDONNELL, M; CLARK, G				EASON, JD; MCDONNELL, M; CLARK, G			LESSON OF THE WEEK - MALE RITUAL CIRCUMCISION RESULTING IN ACUTE-RENAL-FAILURE	BRITISH MEDICAL JOURNAL			English	Article									GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND; GUYS HOSP,OPTIMUM HLTH SERV,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								HOLDER T, 1993, PEDIATR SURG, P715; NIXON H, 1992, ESSENTIALS PAEDIATRI, P82; NIXON HH, 1978, SURGICAL CONDITIONS, P346; WELCH KJ, 1979, PEDIATR SURG, P1314; WILLIAMS N, 1993, BRIT J SURG, V80, P1231, DOI 10.1002/bjs.1800801005	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					660	661		10.1136/bmj.309.6955.660	http://dx.doi.org/10.1136/bmj.309.6955.660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086994	Green Published			2022-12-28	WOS:A1994PG02000036
J	BARGMANN, CI				BARGMANN, CI			MOLECULAR MECHANISMS OF MECHANOSENSATION	CELL			English	Review							MECHANOELECTRICAL TRANSDUCTION CHANNELS; VERTEBRATE HAIR-CELLS; CAENORHABDITIS-ELEGANS; NEURODEGENERATION; AMILORIDE; PROTEINS; BUNDLE		UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,GENET PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BARGMANN, CI (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143, USA.			Bargmann, Cornelia/0000-0002-8484-0618				ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BRAND JG, 1985, BRAIN RES, V334, P207, DOI 10.1016/0006-8993(85)90212-4; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; COREY DP, 1983, J NEUROSCI, V3, P962; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GILLESPIE PG, 1991, J CELL BIOL, V112, P625, DOI 10.1083/jcb.112.4.625; HACKNEY CM, 1992, P ROY SOC B-BIOL SCI, V248, P215, DOI 10.1098/rspb.1992.0064; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUDSPETH AJ, 1982, J NEUROSCI, V2, P1; JARAMILLO F, 1993, P NATL ACAD SCI USA, V90, P1330, DOI 10.1073/pnas.90.4.1330; JORGENSEN F, 1988, J PHYSIOL-LONDON, V403, P577, DOI 10.1113/jphysiol.1988.sp017265; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0	20	21	21	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					729	731						3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087840				2022-12-28	WOS:A1994PG29600002
J	IIRI, T; HERZMARK, P; NAKAMOTO, JM; VANDOP, C; BOURNE, HR				IIRI, T; HERZMARK, P; NAKAMOTO, JM; VANDOP, C; BOURNE, HR			RAPID GDP RELEASE FROM G(S-ALPHA) IN PATIENTS WITH GAIN AND LOSS OF ENDOCRINE FUNCTION	NATURE			English	Article							CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; GTP-BINDING; G-PROTEIN; SIGNAL TRANSDUCTION; PRECOCIOUS PUBERTY; PERTUSSIS TOXIN; RAS PROTEINS; RESOLUTION; HYDROLYSIS	LUTEINIZING hormone stimulates testicular Leydig cells to produce testosterone by binding to a receptor that activates the G protein G(s) and adenylyl cyclase. Testotoxicosis is a form of precocious puberty in which the Leydig cells secrete testosterone in the absence of luteinizing hormone, often due to constitutive activation of the luteinizing hormone receptor and (indirectly) G(s) (refs 1-4). Here we study two unrelated boys suffering from a paradoxical combination of testotoxicosis and pseudohypoparathyroidism type Ia (PHP-Ia)(5), a condition marked by resistance to hormones acting through cyclic AMP (parathyroid hormone and thyroid-stimulating hormone) as well as a 50% decrease in erythrocyte G(s) activity (the remaining 50% is due to the normal G(s) allele)(5,6). In both patients, a mutation in the gene encoding the G(s) alpha-subunit replaced alanine at position 366 with serine(5). We show that this alpha(s)-A366S mutation constitutively activates adenylyl cyclase in vitro, causing hormone-independent cAMP accumulation when expressed in cultured cells, and accounting for the testotoxicosis phenotype (as cAMP stimulates testosterone secretion). Although alpha(s)-A366S is quite stable at testis temperature, it is rapidly degraded at 37 degrees C, explaining the PHP-Ia phenotype caused by loss of G(s) activity. In vitro experiments indicate that accelerated release of GDP causes both the constitutive activity and the thermolability of alpha(s)-A366S.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; EGLI CA, 1985, J PEDIATR-US, V106, P33, DOI 10.1016/S0022-3476(85)80460-1; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IIRI T, 1992, J BIOL CHEM, V267, P1020; KATADA T, 1986, J BIOL CHEM, V261, P8182; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAKOMOTO JM, 1993, CLIN RES, V41, pA40; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REITER EO, 1984, NEW ENGL J MED, V311, P515, DOI 10.1056/NEJM198408233110807; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VANDOP C, 1989, SEMIN NEPHROL, V9, P168; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; ZORGNIOTTI AW, 1991, ADV EXP MED BIOL, V286, P1	28	195	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					164	168		10.1038/371164a0	http://dx.doi.org/10.1038/371164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072545				2022-12-28	WOS:A1994PF19100066
J	ELWYN, GJ; STOTT, NCH				ELWYN, GJ; STOTT, NCH			AVOIDABLE REFERRALS - ANALYSIS OF 170 CONSECUTIVE REFERRALS TO SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine appropriateness of referrals from primary care to secondary care. Design-Retrospective evaluation of appropriateness of referrals from a singlehanded general practice: evaluations carried out independently by referring doctor and by second general practitioner who worked in same area and had access to similar secondary care services. Subjects-168 referrals made between 1 October 1990 and 31 March 1991 and followed up for up to 12 months by matching with available information on outcome of episode of care. Main outcome measures-Appropriateness of referral and reasons for inappropriate referrals. Results-110 referrals were agreed to be appropriate and 58 were considered avoidable. The reason for 32 of the inappropriate referrals was lack of resources: 10 were due to lack of information (mainly failure of hospitals to pass on information to general practitioner), nine were due to a deficient primary health care team; five were due to insufficient use of home care nurses, three were due to absence of direct access to day hospital, and five were due to lack of access to general practitioner beds or other facilities. Most of the remaining 26 avoidable referrals were because available resources had not been fully used, because recognised management plans had not been followed, or because of lack of skills to perform certain procedures. Conclusions-Many theoretically avoidable referrals were due to managers' and politicians' decisions about allocation of resources, but same inappropriate referrals could be avoided by assessment of general practitioners' needs for further knowledge and skills.	UNIV WALES COLL MED,DEPT GEN PRACTICE,CARDIFF CF3 7PN,S GLAM,WALES	Cardiff University	ELWYN, GJ (corresponding author), LOUDOUN SQ HLTH CTR,CARDIFF CF1 5UZ,S GLAM,WALES.		Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; MCWHINNEY LR, 1989, TXB FAMILY MED, P45; MOORE AT, 1989, BRIT MED J, V298, P5400; PILL RM, 1993, HLTH SERVICES RESIDE, P20; STOTT N, 1994, BRIT J GEN PRACT, V44, P2; Stott NCH, 1983, PRIMARY HLTH CARE BR, P43; WILKIN D, 1992, HOSPITAL REFERRALS, P76; 1993, QUALITY HLTH CARE, V2, P117	8	37	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					576	578		10.1136/bmj.309.6954.576	http://dx.doi.org/10.1136/bmj.309.6954.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086946	Green Published			2022-12-28	WOS:A1994PF33000021
J	ROSENTHAL, N				ROSENTHAL, N			MOLECULAR MEDICINE - STALKING THE GENE - DNA LIBRARIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; WATSON J, 1992, RECOMBINANT DNA SHOR	2	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					599	600		10.1056/NEJM199409013310908	http://dx.doi.org/10.1056/NEJM199409013310908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047086				2022-12-28	WOS:A1994PD69900008
J	KATZ, SJ; HOFER, TP				KATZ, SJ; HOFER, TP			SOCIOECONOMIC DISPARITIES IN PREVENTIVE CARE PERSIST DESPITE UNIVERSAL COVERAGE - BREAST AND CERVICAL-CANCER SCREENING IN ONTARIO AND THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER WOMEN; MAMMOGRAPHY; TRENDS	Objective.-To compare the association of income and education with breast and cervical cancer screening in Ontario, Canada, and the United States. Design.-Survey using data from the Ontario Health Survey and the US National Health interview Survey. Participants.-A multistage random sample of women aged 18 years and older living in households in Ontario (N=23521) and the United States (N=23932) in 1990. Main Outcome Measure.-Persons were considered screened if they reported a Papanicolaou test within the previous 2 years, a clinical breast examination within the previous year, or a mammogram within the previous year. Results.-Papanicolaou test and clinical breast examination rates were similar between countries, but mammography rates were two to three times higher in the United States across all age groups. Compared with women with less than a high school degree, college graduates were more likely to receive screening (odds ratio [OR], 1.5; 95% confidence interval [Cl], 1.2 to 1.7) and there was no difference between countries. Across all procedures, women with higher incomes were more likely to receive screening. For Papanicolaou test and clinical breast examination, there was no difference between countries. Compared with the lowest income, the OR was 1.7 (95% Cl, 1.3 to 2.1) in Ontario and 1.9 (95% Cl, 1.6 to 2.2) in the United States for Papanicolaou test and 2.1 (95% Cl, 1.6 to 2.8) in Ontario and 2.1 (95% Cl, 1.8 to 2.6) in the United States for the clinical breast examination for women with income greater than $45600 (US dollars). For mammography screening, the association of income with use was greater in the United States: the OR was 1.8 (95% Cl, 1.3 to 2.6) in Ontario and 2.7 (95% Cl, 2.3 to 3.2) in the United States for women with income greater than $45600 (US dollars). Conclusions.-Despite the long-time presence of universal insurance coverage in Ontario, the disparities in the use of cancer screening procedures by the poor were similar to the United States. Universal coverage is not sufficient to overcome the large disparities in screenings across socioeconomic status demonstrated in both countries.	UNIV MICHIGAN,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; VET AFFAIRS MED CTR,ANN ARBOR,MI	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	KATZ, SJ (corresponding author), UNIV MICHIGAN,MED CTR,DIV GEN INTERNAL MED,3116 TAUBMAN CTR,ANN ARBOR,MI 48109, USA.		KATZ, STEVEN/ABH-8886-2020; Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787				ANDA RF, 1990, AM J PREV MED, V6, P123, DOI 10.1016/S0749-3797(18)31016-X; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CARNEY PA, 1993, ANN INTERN MED, V19, P129; Dutton D. B., 1989, PATHWAYS HLTH ROLE S, P29; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; GRADY KE, 1992, PREV MED, V21, P766, DOI 10.1016/0091-7435(92)90083-T; HARPER AP, 1993, CANCER, V72, P1478; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; Hofer T. P., 1994, Journal of General Internal Medicine, V9, P56; KATZ SJ, 1993, CLIN RES, V41, pA542; KATZ SJ, 1992, MED CARE, V30, P320, DOI 10.1097/00005650-199204000-00003; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; LURIE M, 1993, N ENGL JMED, V329, P478; NADWODNY R, 1990, MAY POP ASS AM C TOR; RUST K, 1985, J OFF STAT, V4, P381; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; 1990, JAMA-J AM MED ASSOC, V264, P54; 1992, 1991 1992 BRIT COL M; 1992, NATIONAL ACCOUNTS MA, V1, P157; 1991, PUBLIC USE DATA TA 1; 1993, NATIONAL STRATEGIC P; 1990, PUBLIC USE DATA TA 1; 1990, ONTARIO HLTH SURVEY; 1993, MMWR-MORBID MORTAL W, V42, P737	25	327	329	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					530	534		10.1001/jama.272.7.530	http://dx.doi.org/10.1001/jama.272.7.530			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB229	8046807				2022-12-28	WOS:A1994PB22900030
J	WOLFENDEN, R; RADZICKA, A				WOLFENDEN, R; RADZICKA, A			ON THE PROBABILITY OF FINDING A WATER MOLECULE IN A NONPOLAR CAVITY	SCIENCE			English	Article							MUTATIONS	Measurements of solubility and vapor pressure indicate that the cost of making a cavity in a nonpolar solvent that is large enough to accommodate a single water molecule is just balanced by the attraction between the water molecule and the walls of the cavity. As a result of this unexpected coincidence, the equilibrium constant for entry of an isolated water molecule from the vapor phase into cyclohexane is almost exactly unity at room temperature. Molecules smaller than water prefer the vapor phase, whereas molecules larger than water prefer cyclohexane. In equilibrium with liquid water, the tendency of single water molecules to enter small nonpolar cavities, such as may be present in mutant proteins, is expected to be vanishingly small.			WOLFENDEN, R (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018325, R37GM018325] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-18325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; CHRISTIAN SD, 1970, Q REV CHEM SOC, V24, P20, DOI 10.1039/qr9702400020; DORSEY NE, 1950, PROPERTIES ORDINARY; DOYLE D, UNPUB; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FINKELSTEIN A, 1987, WATER TRANSPORT LIPI, P94; Harkins WD, 1921, J AM CHEM SOC, V43, P35, DOI 10.1021/ja01434a006; PASCUALAHUIR JL, 1990, J COMPUT CHEM, V11, P1047, DOI 10.1002/jcc.540110907; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; UNGEMACH SR, 1974, J AM CHEM SOC, V96, P7898, DOI 10.1021/ja00833a010; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WADE RC, 1991, BIOPOLYMERS, V31, P919, DOI 10.1002/bip.360310802; WASHBURN EW, 1928, INT CRIT TABLES, V3, P210; WILHELM E, 1973, CHEM REV, V73, P1, DOI 10.1021/cr60281a001; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004	18	91	91	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					936	937		10.1126/science.8052849	http://dx.doi.org/10.1126/science.8052849			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052849				2022-12-28	WOS:A1994PB49900036
J	LEIZOROVICZ, A; SIMONNEAU, G; DECOUSUS, H; BOISSEL, JP				LEIZOROVICZ, A; SIMONNEAU, G; DECOUSUS, H; BOISSEL, JP			COMPARISON OF EFFICACY AND SAFETY OF LOW-MOLECULAR-WEIGHT HEPARINS AND UNFRACTIONATED HEPARIN IN INITIAL TREATMENT OF DEEP VENOUS THROMBOSIS - A METAANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTINUOUS INTRAVENOUS HEPARIN; PROXIMAL-VEIN THROMBOSIS; STANDARD HEPARIN; CLINICAL-TRIALS; MYOCARDIAL-INFARCTION; PULMONARY-EMBOLISM; METAANALYSIS; STREPTOKINASE; THERAPY; FRAGMIN	Objective-To compare the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis for the reduction of recurrent thromboembolic events, death, extension of thrombus, and haemorrhages. Design-Meta-analysis of results from 16 randomised controlled clinical studies. Subjects-2045 patients with established deep venous thrombosis. Intervention-Treatment with low molecular weight heparins or unfractionated heparin. Main outcome measures-Incidences of thromboembolic events (deep venous thrombosis or pulmonary embolism, orboth);major haemorrhages; total mortality; and extension of thrombus. Results-A significant reduction in the incidence of thrombus extension (common odds ratio 0.51, 95% confidence interval 0.32 to 0.83; P = 0.006) in favour of low molecular weight heparin was observed. Non-significant trends also in favour of the low molecular weight heparins were observed for the recurrence of thromboembolic events (0.66, 0.41 to 1.07; P = 0.09), major haemorrhages (0.65, 0.36 to 1.16; P = 0.15), and total mortality (0.72, 0.46 to 1.4; P = 0.16). Conclusions-Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in the treatment of venous thrombosis. These results, however, remain to be confirmed by using clinical outcomes in suitably powered clinical trials.	HOP ANTOINE BECLERE, SERV PNEUMOL, F-92140 CLAMART, FRANCE; HOP BELLEVUE, F-42023 ST ETIENNE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU de St Etienne	LEIZOROVICZ, A (corresponding author), SERV PHARMACOL CLIN, BP 3041, F-69394 LYON 03, FRANCE.		Simonneau, Gerald/ABE-6614-2020					ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; ARNESEN H, 1978, ACTA MED SCAND, V203, P457; BAKER SR, 1991, BRIT J SURG, V78, P864, DOI 10.1002/bjs.1800780729; BARA L, 1986, THROMB HAEMOSTASIS, V56, P418; BARRITT DW, 1960, LANCET, V1, P1309; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BOISSEL JP, 1992, EUR J CLIN PHARMACOL, V43, P235, DOI 10.1007/BF02333016; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, P254, DOI 10.1016/0197-2456(89)90067-6; BOISSEL JP, 1992, THROMB HAEMOSTASIS, V68, P752; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BRATT G, 1985, THROMB HAEMOSTASIS, V54, P813; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; BRESLOW NE, 1980, STATISTICAL METHODS; CARTER CJ, 1982, BLOOD, V59, P1239; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; FAIVRE R, 1988, PRESSE MED, V17, P197; FRYDMAN AM, 1988, J CLIN PHARMACOL, V28, P609, DOI 10.1002/j.1552-4604.1988.tb03184.x; GALLUS A, 1986, LANCET, V2, P1293; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HARENBERG J, 1990, HAEMOSTASIS, V20, P205; HAUCK WW, 1982, J AM STAT ASSOC, V77, P145, DOI 10.2307/2287781; HOLM HA, 1986, HAEMOSTASIS, V16, P30; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KAKKAR VV, 1985, THROMB HAEMOSTASIS, V54, P35; KEBER I, 1987, THROMB HAEMOSTASIS, V58, P91; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LINBLAD B, 1991, BRIT MED J, V302, P709; LINDMARKER P, 1993, THROMB HAEMOSTASIS, V69, P648; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; NOTARBARTOLO A, 1988, MED PRAXIS, V9, P1; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PRANDONI P, 1990, HAEMOSTASIS, V20, P220; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; TEDOLDI A, 1993, CLIN TRIAL META-ANAL, V28, P215; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZANGHI M, 1988, J INT MED RES, V16, P474, DOI 10.1177/030006058801600610; 1989, REV MED INTERNE, V10, P375	49	268	275	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 30	1994	309	6950					299	304		10.1136/bmj.309.6950.299	http://dx.doi.org/10.1136/bmj.309.6950.299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086867	Green Published			2022-12-28	WOS:A1994PA37300017
J	VANSTRAELEN, M; COTTRELL, D				VANSTRAELEN, M; COTTRELL, D			CHILD AND ADOLESCENT MENTAL-HEALTH-SERVICES - PURCHASERS KNOWLEDGE AND PLANS	BRITISH MEDICAL JOURNAL			English	Article								All purchasers in the North East Thames Regional Health Authority were contacted by telephone and questioned systematically about their purchasing plans for child and adolescent mental health. Purchasers' knowledge of the services they were purchasing was very limited. They had made little or no attempt to set quality standards or to monitor them. It is concluded that information about these services is so limited that purchasers would be unable to make informed decisions concerning changes in service patterns.	UNIV LONDON LONDON HOSP,COLL MED,DEPT PSYCHIAT,LONDON E1 2AD,ENGLAND	University of London; University College London			Cottrell, David J/A-1211-2013	Cottrell, David J/0000-0001-8674-0955				BERGER M, 1993, PROPOSED CORE DATA S; BLACK D, 1989, PSYCHIATRIC B, V13, P32; CAMPION PD, 1984, BRIT MED J, V288, P1426, DOI 10.1136/bmj.288.6428.1426; GARRALDA ME, 1986, J CHILD PSYCHOL PSYC, V27, P611, DOI 10.1111/j.1469-7610.1986.tb00186.x; GOODYER I, 1993, SEMINARS CHILD ADOLE, P276; KURTZ Z, 1992, HLTH MIND MENTAL HLT; Light D, 1993, Health Serv J, V103, P16; RUTTER M, 1970, ED HLTH BEHAVIOR; WEISELBERG M, 1993, SEMINARS CHILD ADOLE, P54	9	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					259	261		10.1136/bmj.309.6949.259	http://dx.doi.org/10.1136/bmj.309.6949.259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ180	8069145	Green Published			2022-12-28	WOS:A1994NZ18000025
J	BELSHE, RB; CLEMENTS, ML; KEEFER, MC; GRAHAM, BS; COREY, L; SPOSTO, R; WESCOTT, S; LAWRENCE, D; GORSE, GJ; KENNEDY, D; FREY, S; LAMBERT, J; SCHWARTZ, D; DOLIN, R; ROBERTS, N; MCELRATH, J; COOMBS, J; WRIGHT, P; KARZON, D; FAST, P; WALKER, MC; MESTECKY, J; JACKSON, S; STABLEIN, D; WOLFF, M				BELSHE, RB; CLEMENTS, ML; KEEFER, MC; GRAHAM, BS; COREY, L; SPOSTO, R; WESCOTT, S; LAWRENCE, D; GORSE, GJ; KENNEDY, D; FREY, S; LAMBERT, J; SCHWARTZ, D; DOLIN, R; ROBERTS, N; MCELRATH, J; COOMBS, J; WRIGHT, P; KARZON, D; FAST, P; WALKER, MC; MESTECKY, J; JACKSON, S; STABLEIN, D; WOLFF, M			INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; SERODIAGNOSIS; AIDS VACCINES; HIV SEROPOSITIVITY; PREJUDICE	GP160 RECOMBINANT VACCINIA; WESTERN-BLOT TESTS; NAIVE ADULTS; VIRUS; INFECTION; IMMUNOGENICITY; ANTIBODY; SAFETY	Objective: To evaluate the influence of a human immunodeficiency virus (HIV) vaccine given to uninfected volunteers on the interpretation of serodiagnostic HIV test results. Design: Retrospective cohort study. Setting: 5 AIDS Vaccine Evaluation Units funded by the National Institute of Allergy and Infectious Diseases. Participants: The first 266 healthy adult volunteers (aged 18 to 60 years) who did not have HIV infection and whose history suggested that they were at low risk for acquiring HIV infection. Measurements: HIV antibody was measured by enzyme-linked immunosorbent assay (ELISA) and Western blot test, the results of which were interpreted on the basis of four different published criteria. Results: At some time during the first 12 months of the vaccine studies, 68% of volunteers were positive for HIV antibodies by ELISA. Depending on criteria used to interpret Western blot test results, 0% to 44% of volunteers had positive results that might have caused them to be incorrectly labeled as HIV infected. Conclusions: Significant social risks to volunteers participating in HIV vaccine studies were identified. Persons interpreting HIV serodiagnostic test results must consider that an HIV vaccine can cause a positive result in persons who are not infected.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, BALTIMORE, MD 21205 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; VANDERBILT UNIV, SCH MED, MED CTR N, DEPT MED, NASHVILLE, TN 37232 USA; UNIV WASHINGTON, SCH MED, PACIFIC MED CTR AVEU, DEPT LAB MED, SEATTLE, WA 98144 USA; EMMES CORP, POTOMAC, MD 20854 USA; NIAID, DIV AIDS, BETHESDA, MD 20892 USA; UNIV ALABAMA, BIRMINGHAM, AL USA	Johns Hopkins University; University of Rochester; Vanderbilt University; University of Washington; University of Washington Seattle; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham	BELSHE, RB (corresponding author), ST LOUIS UNIV, SCH MED, DIV INFECT DIS, 3635 VISTA AVE, FDT-8N, ST LOUIS, MO 63110 USA.		Graham, Barney S./AAC-5898-2019; Corey, Lawrence/AAE-1796-2020	Graham, Barney S./0000-0001-8112-0853; Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005064, N01AI005061, N01AI005063] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-05064, N01-AI-05063, N01-AI-05061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELSHE RB, 1993, J INFECT DIS, V168, P1387, DOI 10.1093/infdis/168.6.1387; DAMATO JJ, 1991, LAB MED, V22, P107, DOI 10.1093/labmed/22.2.107; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; DOLIN R, 1992, 8TH INT C AIDS 3RD S; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; MIDTHUN K, 1990, J INFECT DIS, V162, P1379, DOI 10.1093/infdis/162.6.1379; POVOLOTSKY J, 1991, J INFECT DIS, V163, P247, DOI 10.1093/infdis/163.2.247; SCHINDZIELORZ AH, 1990, AM J TROP MED HYG, V42, P460, DOI 10.4269/ajtmh.1990.42.460; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; 1989, MMWR MORBID MORTAL W, V38, P1; 1988, PACKAGE INSERT BIOTE	13	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					584	+		10.7326/0003-4819-121-8-199410150-00005	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085690				2022-12-28	WOS:A1994PL48600005
J	ELEY, JW; HILL, HA; CHEN, VW; AUSTIN, DF; WESLEY, MN; MUSS, HB; GREENBERG, RS; COATES, RJ; CORREA, P; REDMOND, CK; HUNTER, CP; HERMAN, AA; KURMAN, R; BLACKLOW, R; SHAPIRO, S; EDWARDS, BK				ELEY, JW; HILL, HA; CHEN, VW; AUSTIN, DF; WESLEY, MN; MUSS, HB; GREENBERG, RS; COATES, RJ; CORREA, P; REDMOND, CK; HUNTER, CP; HERMAN, AA; KURMAN, R; BLACKLOW, R; SHAPIRO, S; EDWARDS, BK			RACIAL-DIFFERENCES IN SURVIVAL FROM BREAST-CANCER - RESULTS OF THE NATIONAL-CANCER-INSTITUTE BLACK/WHITE CANCER SURVIVAL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLACK-WHITE DIFFERENCES; SOCIOECONOMIC-STATUS; WOMEN; STAGE; RACE; EXPERIENCE; ESTROGEN; PROJECT; DELAY	Objective.-To examine the ability of recognized prognostic factors for breast cancer to account for the observed poorer survival in blacks compared with their white counterparts. Design and Participants.-Subjects included 1130 women (612 blacks and 518 whites) aged 20 to 79 years residing in metropolitan Atlanta, Ga, New Orleans, La, or San Francisco/Oakland, Calif, who were diagnosed with primary invasive breast cancer. Information on stage, tumor characteristics, treatment, comorbid conditions, and sociodemographic factors was obtained from personal interview, physician and hospital records, and a pathology review of biopsy and surgical specimens. Main Outcome Measure.-Multivariable survival models were used to estimate the hazard ratio (relative risk of mortality) for blacks compared with whites, adjusting for various combinations of potential explanatory factors. Results.-After controlling for geographic site and age, the risk of dying was 2.2 times (95% confidence interval [CI], 1.8 to 2.8) greater for blacks than whites. Adjustment for stage reduced the risk from 2.2 to 1.7; further adjustment for sociodemographic variables had no effect. Treatment was not a contributing factor once stage and tumor pathology were in the model. After adjusting for stage, treatment, comorbid illness, and pathologic and sociodemographic variables, blacks continued to demonstrate a slightly increased, but not statistically significant, risk of death (hazard ratio=1.3; 95% CI, 1.0 to 1.8). Results were similar for all-cause mortality and breast cancer-specific mortality. Conclusions.-Approximately 75% of the racial difference in survival was explained by the prognostic factors studied. Sociodemographic variables appeared to act largely through racial differences in stage at diagnosis, which may be amenable to change through improved access to and use of screening for black women.	LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,NEW ORLEANS,LA 70112; INFORMAT MANAGEMENT SERV INC,SILVER SPRING,MD; WAKE FOREST UNIV,CTR COMPREHENS CANC,WINSTON SALEM,NC; UNIV PITTSBURGH,DEPT BIOSTAT,PITTSBURGH,PA 15261; OFF RES WOMENS HLTH,BETHESDA,MD; NICHHD,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,DEPT OBSTET GYNECOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,DEPT PATHOL,BALTIMORE,MD; NE OHIO UNIV,COLL MED,ROOTSTOWN,OH 44272; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD; NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD	Louisiana State University System; Information Management Services, Inc.; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University; Johns Hopkins University; Northeast Ohio Medical University (NEOMED); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ELEY, JW (corresponding author), EMORY UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,ATLANTA,GA 30322, USA.				NCI NIH HHS [N01-CN-25501, N01-CN-45174, N01-CN-35043] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN045174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; COX DR, 1972, J R STAT SOC B, V34, P187; CROWE JP, 1986, SURGERY, V100, P599; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; FISHER ER, 1975, CANCER, V36, P1, DOI 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; GREGORIO DI, 1983, AM J PUBLIC HEALTH, V73, P590, DOI 10.2105/AJPH.73.5.590; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KIMMICK G, 1991, CANCER, V67, P2850, DOI 10.1002/1097-0142(19910601)67:11<2850::AID-CNCR2820671124>3.0.CO;2-S; KLEINBAUM DG, 1988, APPLIED REGRESSION A; MCWHORTER WP, 1987, AM J PUBLIC HEALTH, V77, P1515, DOI 10.2105/AJPH.77.12.1515; MILLER BA, 1992, CANCER STATISTICS RE; MOHLA S, 1982, CANCER-AM CANCER SOC, V50, P552, DOI 10.1002/1097-0142(19820801)50:3<552::AID-CNCR2820500328>3.0.CO;2-G; MUSS HB, 1992, CANCER-AM CANCER SOC, V70, P2460, DOI 10.1002/1097-0142(19921115)70:10<2460::AID-CNCR2820701012>3.0.CO;2-A; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; Oh B, 1983, MANUAL STAGING CANC, V2nd; OWNBY HE, 1985, J NATL CANCER I, V75, P55; PIERCE L, 1992, CANCER-AM CANCER SOC, V69, P2831, DOI 10.1002/1097-0142(19920601)69:11<2831::AID-CNCR2820691132>3.0.CO;2-J; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; 1986, FED REGISTER, V51, P5105; 1987, VITAL HLTH STAT 11, V230	26	465	466	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					947	954		10.1001/jama.272.12.947	http://dx.doi.org/10.1001/jama.272.12.947			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG737	8084062				2022-12-28	WOS:A1994PG73700022
J	MCGLYNN, EA; NAYLOR, CD; ANDERSON, GM; LEAPE, LL; PARK, RE; HILBORNE, LH; BERNSTEIN, SJ; GOLDMAN, BS; ARMSTRONG, PW; KEESEY, JW; MCDONALD, L; PINFOLD, SP; DAMBERG, C; SHERWOOD, MJ; BROOK, RH				MCGLYNN, EA; NAYLOR, CD; ANDERSON, GM; LEAPE, LL; PARK, RE; HILBORNE, LH; BERNSTEIN, SJ; GOLDMAN, BS; ARMSTRONG, PW; KEESEY, JW; MCDONALD, L; PINFOLD, SP; DAMBERG, C; SHERWOOD, MJ; BROOK, RH			COMPARISON OF THE APPROPRIATENESS OF CORONARY ANGIOGRAPHY AND CORONARY-ARTERY BYPASS GRAFT-SURGERY BETWEEN CANADA AND NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INAPPROPRIATE USE; UNITED-STATES; WOMEN; HEALTH; MORTALITY	Objective.-To compare the appropriateness of coronary angiography and coronary artery bypass graft (CABG) use between the United States and Canada. Design.-Retrospective randomized medical record review. Setting.-All hospitals performing coronary angiography and/or CABG surgery in two Canadian provinces (Ontario and British Columbia); in New York State, 15 randomly selected hospitals that provide coronary angiography and 15 randomly selected hospitals that provide CABG surgery. Patients.-All patients were randomly selected. For coronary angiography, 533 patients in Canada and 1333 patients in New York were selected; for CABG, 556 patients in Canada and 1336 patients in New York were selected. Main Outcome Measures.-Percentage of patients in each country who had coronary angiography or CABG for necessary, appropriate, uncertain, or inappropriate indications as rated by criteria developed separately in each country and the complications of those procedures. Results.-For coronary angiography, 9% of Canadian cases and 10% of New York cases were rated inappropriate using Canadian criteria compared with 5% and 4%, respectively, using US criteria. For CABG, 4% of Canadian cases and 6% of New York cases were rated inappropriate by Canadian criteria compared with 3% and 2%, respectively, using US criteria. A lower proportion of procedures were performed on persons aged 75 years or older in Canada than in New York for both coronary angiography (5% vs 11%; P<.001) and CABG (6% vs 14%; P<.001). Women were also represented in lower proportions among angiography cases in Canada than in New York (28% vs 35%; P=.023). Canadian patients with left main coronary disease waited significantly longer between angiography and CABG than did New York patients (P<.0001). Conclusions.-Rates of inappropriate use of cardiac procedures were low in Canada and New York, which suggests that the regionalization of cardiac procedures that characterizes both health care systems contributes to better clinical decision making. Differences in the use of cardiac procedures among the elderly in the two countries merits further comparative examination.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,TORONTO,ON,CANADA; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV MICHIGAN,SCH MED,ANN ARBOR,MI; UNIV MICHIGAN,SCH PUBL HLTH,ANN ARBOR,MI 48109; ST MICHAELS HOSP,TORONTO M5B 1W8,ON,CANADA; VALUE HLTH SCI INC,SANTA MONICA,CA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Harvard University; Harvard T.H. Chan School of Public Health; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	MCGLYNN, EA (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90407, USA.			Bernstein, Steven/0000-0003-3359-7168; Armstrong, Paul/0000-0002-0460-3445				ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BERNSTEIN SJ, 1992, RAND JRA03 PUBL; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; GARDNER TJ, 1985, ANN SURG, V201, P780, DOI 10.1097/00000658-198506000-00016; HILBORNE LH, 1991, PERCUTANEOUS TRANSLU; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LEAPE LL, 1991, CORONARY ARTERY BYPA; LEAPE LL, 1993, CORONARY ANGIOGRAPHY; LOOP FD, 1983, J AM COLL CARDIOL, V1, P393; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MARK DB, 1993, CIRCULATION, V88, P474; NAYLOR CD, 1993, CAN MED ASSOC J, V149, P955; NAYLOR CD, 1993, CORONARY ARTERY BYPA; PARSONNET V, 1989, CIRCULATION S1, V79, P13; ROTH CP, IN PRESS MED RECORD; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; WEINTRAUB WS, 1992, CIRCULATION, V86, P253; WEINTRAUB WS, 1992, CIRCULATION S1, V86, P1972; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; ZWANZIGER J, 1993, HEALTH AFFAIR, V12, P130, DOI 10.1377/hlthaff.12.2.130	26	99	99	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					934	940		10.1001/jama.272.12.934	http://dx.doi.org/10.1001/jama.272.12.934			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084060				2022-12-28	WOS:A1994PG73700020
J	TAKEMOTO, S; TERASAKI, PI; GJERTSON, DW; CECKA, JM				TAKEMOTO, S; TERASAKI, PI; GJERTSON, DW; CECKA, JM			EQUITABLE ALLOCATION OF HLA-COMPATIBLE KIDNEYS FOR LOCAL POOLS AND FOR MINORITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSPLANTATION; COSTS	Background. The methods used to allocate cadaveric kidneys in the United States have been criticized as being unfair to minorities because of an overemphasis on HLA matching. We evaluated a new HLA-matching method that might alleviate this problem. Methods. We used data from the United Network for Organ Sharing (UNOS) Kidney Transplant Registry to evaluate and project the outcome of cadaveric kidney transplantation. An HLA-matching method based on compatibility at 10 key amino acid residues of HLA-A and B molecules and a limited number of HLA-DR types was evaluated with use of the HLA types of the patients currently on the national waiting list and waiting lists in Los Angeles and Birmingham, Alabama. Results. With national kidney sharing, the projected 10-year rate of graft survival for transplants in which there were no HLA-A, B, or DR mismatches was 66 percent, as compared with 39 percent for transplants with more than two HLA-A, B, or DR mismatches. With local sharing, 43 percent of patients could be fully matched, and they had a projected 10-year graft-survival rate of 50 percent. When one HLA-DR mismatch was allowed, the projected 10-year graft survival was 46 percent, and 67 percent of patients waiting locally could receive such grafts. Even in Alabama, where 68 percent of the patients on the waiting list are black, 48 percent of waiting patients could obtain a matched kidney. Conclusions. Inserting two new HLA-matching categories into the UNOS point system for cadaveric kidney allocation would increase the number of patients for whom matches could be found in local pools.			TAKEMOTO, S (corresponding author), UNIV CALIF LOS ANGELES,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK002375] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01 DK 02375-34A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		EGGERS P, 1992, SEMIN NEPHROL, V12, P284; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; HALASZ NA, 1993, CLIN TRANSPLANT, V7, P357; MARUYA E, 1994, CLIN TRANSPLANTS 199, P511; MCDONALD JC, 1988, JAMA-J AM MED ASSOC, V259, P725, DOI 10.1001/jama.259.5.725; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; STARZL TE, 1993, CLIN TRANSPLANT, V7, P353; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TAKEMOTO S, 1993, CLIN TRANSPLANTS 199, P413; TERASAKI PI, 1993, CLIN TRANSPLANTS 199, P501; VANROOD JJ, 1994, CLIN TRANSPLANTS 199, P285	12	78	82	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					760	764		10.1056/NEJM199409223311202	http://dx.doi.org/10.1056/NEJM199409223311202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065403				2022-12-28	WOS:A1994PG30100002
J	GURNEY, AL; CARVERMOORE, K; DESAUVAGE, FJ; MOORE, MW				GURNEY, AL; CARVERMOORE, K; DESAUVAGE, FJ; MOORE, MW			THROMBOCYTOPENIA IN C-MPL-DEFICIENT MICE	SCIENCE			English	Article								Thrombopoietin (TPO) is a cytokine that is involved in the regulation of platelet production. The receptor for TPO is c-Mpl. To further investigate the role and specificity of this receptor in regulating megakaryocytopoiesis, c-mpl-deficient mice were generated by gene targeting. The c-mpl(-/-) mice had an 85 percent decrease in their number of platelets and megakaryocytes but had normal amounts of other hematopoietic cell types. These mice also had increased concentrations of circulating TPO. These results show that c-mpl specifically regulates megakaryocytopoiesis and thrombopoiesis through activation by its ligand TPO.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584				Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARVERMOORE K, UNPUB; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GURNEY AL, UNPUB; HOFFMAN R, 1981, NEW ENGL J MED, V305, P533, DOI 10.1056/NEJM198109033051001; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; METHIA N, 1993, BLOOD, V82, P1395; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; NAKEFF A, 1975, ACTA HAEMATOL-BASEL, V54, P340, DOI 10.1159/000208096; ODELL TT, 1961, P SOC EXP BIOL MED, V108, P428; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	16	542	554	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1445	1447		10.1126/science.8073287	http://dx.doi.org/10.1126/science.8073287			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073287				2022-12-28	WOS:A1994PE73300048
J	OLIVIERI, NF; NATHAN, DG; MACMILLAN, JH; WAYNE, AS; LIU, PP; MCGEE, A; MARTIN, M; KOREN, G; COHEN, AR				OLIVIERI, NF; NATHAN, DG; MACMILLAN, JH; WAYNE, AS; LIU, PP; MCGEE, A; MARTIN, M; KOREN, G; COHEN, AR			SURVIVAL IN MEDICALLY TREATED PATIENTS WITH HOMOZYGOUS BETA-THALASSEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SICKLE-CELL-ANEMIA; SUBCUTANEOUS DEFEROXAMINE; IRON STORES; CHELATION-THERAPY; CARDIAC DISEASE; OVERLOAD; FERRITIN	Background. The prognosis of patients with homozygous beta-thalassemia (thalassemia major) has been improved by transfusion and iron-chelation therapy. We analyzed outcome and prognostic factors among patients receiving transfusions and chelation therapy who had reached the age at which iron-induced cardiac disease, the most common cause of death, usually occurs. Methods. Using the duration of life without the need for either inotropic or antiarrhythmic drugs as a measure of survival without cardiac disease, we studied 97 patients born before 1976 who were treated with regular transfusions and chelation therapy. We used Cox proportional-hazards analysis to assess the effect of prognostic factors and life-table analysis to estimate freedom from cardiac disease over time. Results. Of the 97 patients, 59 (61 percent) had no cardiac disease; 36 (37 percent) had cardiac disease, and 18 of them had died. Univariate analysis demonstrated that factors affecting cardiac disease-free survival were age at the start of chelation therapy (P<0.001), the natural log of the serum ferritin concentration before chelation therapy began (P=0.01), the mean ferritin concentration (P<0.001), and the proportion of ferritin measurements exceeding 2500 ng per milliliter (P<0.001). With stepwise Cox modeling, only the proportion of ferritin measurements exceeding 2500 ng per milliliter affected cardiac disease-free survival (P<0.001). Patients in whom less than 33 percent of the serum ferritin values exceeded 2500 ng per milliliter had estimated rates of survival without cardiac disease of 100 percent after 10 years of chelation therapy and 91 percent after 15 years. Conclusions. The prognosis for survival without cardiac disease is excellent for patients with thalassemia major who receive regular transfusions and whose serum ferritin concentrations remain below 2500 ng per milliliter with chelation therapy.	UNIV TORONTO,TORONTO HOSP,TORONTO,ON,CANADA; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV HEMATOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	OLIVIERI, NF (corresponding author), UNIV TORONTO,HOSP SICK CHILDREN,DIV HAEMATOL ONCOL,HAEMOGLOBINOPATHY PROGRAM,555 UNIV AVE,TORONTO M5G 1X8,ON,CANADA.		Olivieri, Nancy/AAI-2250-2020		NCRR NIH HHS [2 M01 RR02172-12, M01 RR00240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240, M01RR002172] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADDISON GM, 1972, J CLIN PATHOL, V25, P326, DOI 10.1136/jcp.25.4.326; ALDOURI MA, 1990, ACTA HAEMATOL-BASEL, V84, P113; BRITTENHAM G, 1988, BLOOD S, V72, pA56; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; Cohen A, 1987, Hematol Oncol Clin North Am, V1, P521; DEVIRGILIIS S, 1988, J PEDIATR-US, V113, P661; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; ENGLE MA, 1964, CIRCULATION, V30, P698, DOI 10.1161/01.CIR.30.5.698; FOSBURG MT, 1990, BLOOD, V76, P435; HARTKAMP MJ, 1993, PEDIATR RADIOL, V23, P525, DOI 10.1007/BF02012139; KIRKPATRICK DV, 1991, SEMIN HEMATOL, V28, P240; LERNER N, 1990, AM J PEDIAT HEMATOL, V12, P56; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; OLIVIERI NF, 1992, AM J HEMATOL, V41, P61, DOI 10.1002/ajh.2830410112; OLIVIERI NF, 1990, ANN NY ACAD SCI, V612, P585; PORTER JB, 1989, BRIT J HAEMATOL, V73, P403, DOI 10.1111/j.1365-2141.1989.tb07761.x; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; SIMON TL, 1989, TRANSFUSION, V29, P221, DOI 10.1046/j.1537-2995.1989.29389162727.x; THOMAS ED, 1982, LANCET, V2, P227; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	25	711	729	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					574	578		10.1056/NEJM199409013310903	http://dx.doi.org/10.1056/NEJM199409013310903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047081				2022-12-28	WOS:A1994PD69900003
J	MITSUMOTO, H; IKEDA, K; KLINKOSZ, B; CEDARBAUM, JM; WONG, V; LINDSAY, RM				MITSUMOTO, H; IKEDA, K; KLINKOSZ, B; CEDARBAUM, JM; WONG, V; LINDSAY, RM			ARREST OF MOTOR-NEURON DISEASE IN WOBBLER MICE COTREATED WITH CNTF AND BDNF	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; RETROGRADE AXONAL-TRANSPORT; FACTOR PREVENTS; ADULT-RAT; NERVOUS-SYSTEM; SCIATIC-NERVE; CELL-DEATH; DEGENERATION; MOUSE; BRAIN	Ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF) each promote the survival and differentiation of developing motor neurons, but do so through distinct cellular signaling pathways. Administration of either factor alone has been shown to slow, but not to arrest, progression of motor neuron dysfunction in wobbler mice, an animal model of motor neuron disease. Because CNTF and BDNF are known to synergize in vitro and in ovo, the efficacy of CNTF and BDNF cotreatment was tested in the same animal model. Subcutaneous injection of the two factors on alternate days was found to arrest disease progression in wobbler mice for 1 month, as measured by several behavioral, physiological, and histological criteria.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Cleveland Clinic Foundation; Regeneron	MITSUMOTO, H (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROL,S-90,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Lindsay, Ronald/GQP-8001-2022					ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; EMFORS P, 1992, EUR J NEUROSCI, V4, P1140; EMFORS P, 1994, NATURE, V368, P147; FEFTI F, 1986, J NEUROSCI, V6, P2155; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HELGREN M, 1992, 22ND ANN M SOC NEUR; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; IKEDA K, 1993, MUSCLE NERVE, V16, P979; IKEDA K, UNPUB; IKEDA K, 1993, OCT ANN M AM NEUR AS; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1992, PROG GROWTH FACTOR R, V4, P93; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOZACHUK WE, 1987, J NEUROL SCI, V78, P253, DOI 10.1016/0022-510X(87)90039-6; LINDSAY RM, 1993, NEUROTROPHIC FACTORS, P257; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; MITSUMOTO H, 1990, MUSCLE NERVE, V13, P121, DOI 10.1002/mus.880130206; MITSUMOTO H, UNPUB; MITSUMOTO H, IN PRESS ANN NEUROL; MORSE JK, 1993, J NEUROSCI, V13, P4146; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1993, 23RD ANN M SOC NEUR; PAPAPETROPOULOS TA, 1972, J NEUROL NEUROSUR PS, V35, P60, DOI 10.1136/jnnp.35.1.60; POLLIN MM, 1990, J NEUROCYTOL, V19, P29, DOI 10.1007/BF01188437; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	49	385	400	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1107	1110		10.1126/science.8066451	http://dx.doi.org/10.1126/science.8066451			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066451				2022-12-28	WOS:A1994PC53900041
J	PROLLA, TA; PANG, QS; ALANI, E; KOLODNER, RD; LISKAY, RM				PROLLA, TA; PANG, QS; ALANI, E; KOLODNER, RD; LISKAY, RM			MLH1, PMS1, AND MSH2 INTERACTIONS DURING THE INITIATION OF DNA MISMATCH REPAIR IN YEAST	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENETIC INSTABILITY; PROTEIN; MUTATIONS; MUTL; ASSOCIATION; HOMOLOG	The discovery that mutations in DNA mismatch repair genes can cause hereditary nonpolyposis colorectal cancer has stimulated interest in understanding the mechanism of DNA mismatch repair in eukaryotes. In the yeast Saccharomyces cerevisiae, DNA mismatch repair requires the MSH2, MLH1, and PMS1 proteins. Experiments revealed that the yeast MLH1 and PMS1 proteins physically associate, possibly forming a heterodimer, and that MLH1 and PMS1 act in concert to bind a MSH2-heteroduplex complex containing a G-T mismatch. Thus, MSH2, MLH1, and PMS1 are likely to form a ternary complex during the initiation of eukaryotic DNA mismatch repair.	OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,PORTLAND,OR 97201; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Oregon Health & Science University; Yale University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NHGRI NIH HHS [HG00305/GM50006] Funding Source: Medline; NIGMS NIH HHS [GM 45413, GM 322741] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045413] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAITONEN LA, 1993, SCIENCE, V260, P812; ALANI E, 1994, GENETICS, V137, P19; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HAN HJ, 1993, CANCER RES, V53, P5087; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOATHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NICOLAIDES NC, IN PRESS NATURE; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; RISINGER JI, 1993, CANCER RES, V53, P5100; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SAUER RT, 1983, J MOL BIOL, V168, P699, DOI 10.1016/S0022-2836(83)80070-9; SHENA M, 1991, METHOD ENZYMOL, V194, P389; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	35	282	306	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1091	1093		10.1126/science.8066446	http://dx.doi.org/10.1126/science.8066446			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066446				2022-12-28	WOS:A1994PC53900035
J	PARTON, RF; VANKELECOM, IFJ; CASSELMAN, MJA; BEZOUKHANOVA, CP; UYTTERHOEVEN, JB; JACOBS, PA				PARTON, RF; VANKELECOM, IFJ; CASSELMAN, MJA; BEZOUKHANOVA, CP; UYTTERHOEVEN, JB; JACOBS, PA			AN EFFICIENT MIMIC OF CYTOCHROME-P-450 FROM A ZEOLITE ENCAGED IRON COMPLEX IN A POLYMER MEMBRANE	NATURE			English	Article							ALIPHATIC HYDROXYLATION; PORPHYRIN COMPLEXES; HYDROGEN-PEROXIDE; ALKANE OXIDATION; CATALYSTS; MANGANESE; MECHANISM; PYRIDINE	MANY attempts have been made to mimic the catalytic oxidative properties of the enzyme cytochrome P-450. For homogeneous systems' the mechanisms of oxidation can be readily determined but proper mimicry of the protein environment is difficult to achieve. Heterogeneous mimics have been designed that use organometallic complexes encapsulated in the supercages of zeolites(2,3), which enables control of selectivity and inhibition of auto-oxidation. But these systems do not show any mechanistic analogy with the enzymatic process, and the oxidation rates tend to be low. Here we report a composite catalytic system that achieves realistic mimicry of cytochrome P-450 as well as catalytic turnover rates that make the system industrially viable. Our catalyst incorporates iron phthalocyanine complexes encapsulated in crystals of zeolite Y, which are in turn embedded ina polydimethylsiloxane membrane. The polymer acts as a mimic of the phospholipid membrane in which cytochrome P-450 resides(4), acting as an interface between two immiscible phases and avoiding the need for solvents or phase-transfer agents. This system oxidizes alkanes at room temperature at rates comparable to those of the enzyme(5). The observation of a large kinetic isotope effect and the preferential oxidation of tertiary C-H bonds suggest close mechanistic similarities to the enzymatic process.			PARTON, RF (corresponding author), KATHOLIEKE UNIV LEUVEN, CENTRUM OPPERVLAKTECHEM KATALYSE, DEPT INTERFACE CHEM, B-3001 HEVERLEE, BELGIUM.		Vankelecom, Ivo/AAL-5006-2020; Nanozymes, Nanozymes/D-8197-2019					ARMOR JN, 1989, APPL CATAL, V102, P1; ASADA T, 1991, MEMBRANE SCI TECHNOL, V1, P439; BARTON DHR, 1991, TETRAHEDRON LETT, V32, P3811; BELL RP, 1974, CHEM SOC REV, V3, P513, DOI 10.1039/cs9740300513; BOWERS C, 1990, J CATAL, V122, P271, DOI 10.1016/0021-9517(90)90281-N; CAMBLOR MA, 1993, J ZEOLITES, V13, P82; CHE CM, 1993, J CHEM SOC DA, P1259; CORMA A, 1994, J CHEM SOC CHEM COMM, P147, DOI 10.1039/c39940000147; DEVOS DE, 1994, MACROMOL SYMP, V80, P157, DOI 10.1002/masy.19940800112; GROVES JT, 1990, J AM CHEM SOC, V112, P7796, DOI 10.1021/ja00177a050; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; HUYBRECHTS DRC, 1990, NATURE, V345, P240, DOI 10.1038/345240a0; ICHIKAWA M, 1991, STUD SURF SCI CATAL, V60, P335; Ingelman-Sundberg M, 1986, CYTOCHROME P450 STRU, P119; KHENKIN AM, 1989, NEW J CHEM, V13, P659; KNOPSGERRITS PP, 1994, NATURE, V369, P543, DOI 10.1038/369543a0; KWART H, 1982, ACCOUNTS CHEM RES, V15, P401, DOI 10.1021/ar00084a004; LEISING RA, 1993, J AM CHEM SOC, V115, P9524, DOI 10.1021/ja00074a017; Mansuy D., 1989, ACTIVATION FUNCTIONA, P195; MENAGE S, 1993, INORG CHEM, V32, P4766, DOI 10.1021/ic00074a019; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; NAKAMURA M, 1990, B CHEM SOC JPN, V63, P3334, DOI 10.1246/bcsj.63.3334; NAM W, 1989, NEW J CHEM, V13, P677; PARTON R, 1992, NATO ADV SCI I C-MAT, V352, P555; PARTON RF, 1991, STUD SURF SCI CATAL, V59, P395; PENNERHAHN JE, 1983, J BIOL CHEM, V258, P2761; SOROKIN A, 1993, J AM CHEM SOC, V115, P7293, DOI 10.1021/ja00069a031; SOROKIN AB, 1990, J CHEM SOC CHEM COMM, P45, DOI 10.1039/c39900000045; TANEV PT, 1994, NATURE, V368, P321, DOI 10.1038/368321a0; Tolman C. A., 1989, ACTIVATION FUNCTIONA, P303; Ullrich V, 1979, Top Curr Chem, V83, P67	32	255	258	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					541	544		10.1038/370541a0	http://dx.doi.org/10.1038/370541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	PC537	8052309				2022-12-28	WOS:A1994PC53700049
J	YU, RT; MCKEOWN, M; EVANS, RM; UMESONO, K				YU, RT; MCKEOWN, M; EVANS, RM; UMESONO, K			RELATIONSHIP BETWEEN DROSOPHILA GAP GENE TAILLESS AND A VERTEBRATE NUCLEAR RECEPTOR TLX	NATURE			English	Article							9-CIS RETINOIC ACID; EMBRYONIC TERMINI; DNA-BINDING; SUPERFAMILY; EXPRESSION; CLONING; REGION; BRAIN; SITES; CELL	We report here the identification of a unique vertebrate nuclear receptor, Tlx, which is expressed exclusively in the neuroepithelium of the embryonic brain. Sequence comparison reveals striking similarity to the product of the Drosophila terminal/gap gene tailless (tll)(1), which is expressed in the embryonic brain and is required for brain development in flies. In vitro DNA-binding assays demonstrated that Tlx and Tll proteins share a target gene specificity that, is unique among the nuclear receptor superfamily. Ectopic expression of Tlx in fly embryos caused a repression of segmentation comparable to that elicited by Tll. The similarities in structure, expression pattern, target gene specificity and phenotypes in transgenic flies suggest conservation of genetic programs upstream and downstream of this Tlx/Tll class of nuclear receptors during embryogenesis.	SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,GRAD PROGRAM MOLEC PATHOL,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Salk Institute; Salk Institute; University of California System; University of California San Diego			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; KAKIZUKA A, 1993, ESSENTIAL DEV BIOL P, P223; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; ORO AE, 1992, DEVELOPMENT, V115, P449; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUZ D, 1989, CHROMOSOMA, V98, P81; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418	28	161	173	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					375	379		10.1038/370375a0	http://dx.doi.org/10.1038/370375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047143				2022-12-28	WOS:A1994PA30400057
J	SHEIHAM, A				SHEIHAM, A			THE FUTURE OF PREVENTIVE DENTISTRY	BRITISH MEDICAL JOURNAL			English	Editorial Material											SHEIHAM, A (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.							EKANAYAKE LS, 1987, BRIT DENT J, V163, P265, DOI 10.1038/sj.bdj.4806269; FOCH CB, 1981, N1732RWJF RAND CORP; MOLLER IJ, 1987, PREVENTION NONCOMMUN, P79; NADANOVSKY P, 1993, THESIS U LONDON LOND; ROSE G, 1987, BRIT MED J, V294, P963, DOI 10.1136/bmj.294.6577.963; SHEIHAM A, 1977, LANCET, V2, P442; TODD JE, 1991, ADULT DENTAL HLTH; 1993, ED TRAINING PERSONNE; 1994, ORAL HLTH STRATEGY E; 1994, DENTAL CARIES CHILDR	10	10	10	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					214	215		10.1136/bmj.309.6949.214	http://dx.doi.org/10.1136/bmj.309.6949.214			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069132	Green Published			2022-12-28	WOS:A1994NZ18000002
J	VIOLI, F; FERRO, D; BASILI, S; DANGELO, A; MAZZOLA, G; QUINTARELLI, C; CORDOVA, C				VIOLI, F; FERRO, D; BASILI, S; DANGELO, A; MAZZOLA, G; QUINTARELLI, C; CORDOVA, C			RELATION BETWEEN LUPUS ANTICOAGULANT AND SPLANCHNIC VENOUS THROMBOSIS IN CIRRHOSIS OF THE LIVER	BRITISH MEDICAL JOURNAL			English	Article							ANTIPHOSPHOLIPID ANTIBODIES		UNIV ROMA LA SAPIENZA,IST TERAPIA MED,ROME,ITALY; IRCCS,HOSP SAN RAFFAELE,SERV COAGULAZ,MILAN,ITALY	Sapienza University Rome; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	VIOLI, F (corresponding author), POLICLIN UMBERTO 1,IST CLIN MED 1,I-00185 ROME,ITALY.		Violi, Francesco/K-1509-2016; ferro, domenico/AAT-5861-2020; Basili, Stefania/K-4024-2016; D'Angelo, Armando/K-2583-2018	Violi, Francesco/0000-0002-6610-7068; Basili, Stefania/0000-0002-6987-1926; D'Angelo, Armando/0000-0002-9857-4509				ALSEED A, 1991, THROMB HAEMOSTASIS, V65, P2028; ASHERSON RA, 1991, CLIN EXP RHEUMATOL, V9, P341; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; OKA K, 1979, THROMB HAEMOSTASIS, V42, P564; VIOLI F, 1990, THROMB HAEMOSTASIS, V63, P183	5	49	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					239	240		10.1136/bmj.309.6949.239	http://dx.doi.org/10.1136/bmj.309.6949.239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069141	Green Published			2022-12-28	WOS:A1994NZ18000017
J	GREENBERG, GR; FEAGAN, BG; MARTIN, F; SUTHERLAND, LR; THOMSON, ABR; WILLIAMS, CR; NILSSON, LG; PERSSON, T; BAIN, V; CHERRY, R; FEDORAK, R; LALOR, E; SHERBANIUK, R; YACYSHYN, B; KIERDEKIS, P; BAILEY, R; MEYER, D; FREEMAN, H; DAWS, P; HOLLAND, S; BUYTENDORP, M; WHITTAKER, S; CHANG, A; SUTHERLAND, L; HERSHFIELD, N; MACCANNELL, K; MEDDING, J; PRICE, L; SHAFFER, E; RACICOT, N; BASS, S; BRIDGES, R; BLUSTEIN, P; LAY, T; VANROSENDAAL, G; WATSON, M; WILLIAMS, CN; VANZANTEN, V; LEDDIN, D; FALKENHAM, J; TANTON, R; HUMAN, P; TURNBALL, G; SCHEP, G; WOOLNOUGH, J; DALLAIRE, C; ROSSEAU, B; BERNARD, F; DUBE, R; PARE, P; MORIN, A; LAFRANCE, D; LICHTER, J; POLESKI, M; CLELAND, D; DALY, D; WILD, G; FINENBINE, S; BELLIVEAU, P; DAUPHINEE, W; MISKIN, S; SUTHERLAND, H; BARBER, C; IRVINE, J; COLLINS, S; CROITORU, K; HUNT, R; SALINA, S; DONNELLY, M; BAKER, S; ALVI, A; ARCHAMBAULT, A; JOBIN, G; TROUVE, ML; GAGNON, M; GILLIES, R; CHAMPION, M; MACINTOSH, D; PATEL, D; SEKAR, A; THOMPSON, W; FITZGERALD, R; WOROBETZ, L; OSACHOFF, J; MCHATTIE, J; EDWARDS, J; STEINHART, H; SLATER, A; BAKER, J; JEEJEEBHOY, KN; MCDERMOTT, G; SAIBIL, F; COHEN, L; PEARAN, S; WOLMAN, SL; HABAL, F; STAFFORD, S; BARNETT, W; BONDY, D; MCDONALD, J; HOPKINS, MB; HOWARD, J; BELSHEIM, M; PONICH, T; WATSON, W; GILMORE, P; REYNOLDS, R; LLOYD, D; PROKOPIW, I; MOYER, L; VONWESTARP, C; SHUMAK, SL; REDDY, SSK; BELANGER, R; GEORGE, SR; SEIDEGARD, C; PERSSON, T				GREENBERG, GR; FEAGAN, BG; MARTIN, F; SUTHERLAND, LR; THOMSON, ABR; WILLIAMS, CR; NILSSON, LG; PERSSON, T; BAIN, V; CHERRY, R; FEDORAK, R; LALOR, E; SHERBANIUK, R; YACYSHYN, B; KIERDEKIS, P; BAILEY, R; MEYER, D; FREEMAN, H; DAWS, P; HOLLAND, S; BUYTENDORP, M; WHITTAKER, S; CHANG, A; SUTHERLAND, L; HERSHFIELD, N; MACCANNELL, K; MEDDING, J; PRICE, L; SHAFFER, E; RACICOT, N; BASS, S; BRIDGES, R; BLUSTEIN, P; LAY, T; VANROSENDAAL, G; WATSON, M; WILLIAMS, CN; VANZANTEN, V; LEDDIN, D; FALKENHAM, J; TANTON, R; HUMAN, P; TURNBALL, G; SCHEP, G; WOOLNOUGH, J; DALLAIRE, C; ROSSEAU, B; BERNARD, F; DUBE, R; PARE, P; MORIN, A; LAFRANCE, D; LICHTER, J; POLESKI, M; CLELAND, D; DALY, D; WILD, G; FINENBINE, S; BELLIVEAU, P; DAUPHINEE, W; MISKIN, S; SUTHERLAND, H; BARBER, C; IRVINE, J; COLLINS, S; CROITORU, K; HUNT, R; SALINA, S; DONNELLY, M; BAKER, S; ALVI, A; ARCHAMBAULT, A; JOBIN, G; TROUVE, ML; GAGNON, M; GILLIES, R; CHAMPION, M; MACINTOSH, D; PATEL, D; SEKAR, A; THOMPSON, W; FITZGERALD, R; WOROBETZ, L; OSACHOFF, J; MCHATTIE, J; EDWARDS, J; STEINHART, H; SLATER, A; BAKER, J; JEEJEEBHOY, KN; MCDERMOTT, G; SAIBIL, F; COHEN, L; PEARAN, S; WOLMAN, SL; HABAL, F; STAFFORD, S; BARNETT, W; BONDY, D; MCDONALD, J; HOPKINS, MB; HOWARD, J; BELSHEIM, M; PONICH, T; WATSON, W; GILMORE, P; REYNOLDS, R; LLOYD, D; PROKOPIW, I; MOYER, L; VONWESTARP, C; SHUMAK, SL; REDDY, SSK; BELANGER, R; GEORGE, SR; SEIDEGARD, C; PERSSON, T			ORAL BUDESONIDE FOR ACTIVE CROHNS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; DRUG-TREATMENT; TRIAL; THERAPY	Background. Corticosteroids are the most efficacious drugs for inducing remission in active Crohn's disease, but their benefits are frequently offset by serious side effects. Budesonide is a corticosteroid with high topical antiinflammatory activity but low systemic activity because of extensive hepatic metabolism. We investigated the efficacy and safety of an oral controlled-ileal-release preparation of budesonide in patients with active Crohn's disease involving the ileum or ileum and proximal colon. Methods. In a double-blind, multicenter trial, 258 patients were randomly assigned to receive placebo or one of three doses of budesonide - 3, 9, or 15 mg daily. The primary outcome measure was clinical remission, as defined by a score of 150 or less on the Crohn's disease activity index. Results. After eight weeks of treatment, remission occurred in 51 percent of the patients in the group receiving 9 mg of budesonide (95 percent confidence interval, 39 to 63 percent), 43 percent of those receiving 15 mg (95 percent confidence interval, 31 to 55 percent), and 33 percent of those receiving 3 mg (95 percent confidence interval, 21 to 44 percent), as compared with 20 percent of those receiving placebo (P < 0.001, P = 0.009, and P = 0.13, respectively). Improvements in the quality of life, as measured by the patients' responses to the inflammatory bower disease questionnaire, parallelled these remission rates. Location of disease, prior surgical resection, and previous use of corticosteroids did not affect the outcome. A total of 119 patients (46 percent) were withdrawn from the study before the trial ended, 96 because of insufficient therapeutic effects, 13 because of adverse reactions, and 10 because of noncompliance. Budesonide caused a dose-related reduction in basal and corticotropin-stimulated plasma cortisol concentrations but was not associated with clinically important corticosteroid-related symptoms or other toxic effects. Conclusions. In an eight-week trial, an oral controlled-release preparation of budesonide at an optimal daily dose of 9 mg was well tolerated and effective against active Crohn's disease of the ileum and proximal colon.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,PQ,CANADA; UNIV CALGARY,DEPT MED,CALGARY,AB,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON,AB,CANADA; DALHOUSIE UNIV,DEPT MED,HALIFAX,NS,CANADA; ASTRO DRACO AB,DEPT CLIN RES & DEV,LUND,SWEDEN; ASTRO DRACO AB,DEPT BIOSTAT & DATA PROC,LUND,SWEDEN; UNIV ALBERTA HOSP,EDMONTON,AB,CANADA; ROYAL ALEXANDRA HOSP,EDMONTON,AB,CANADA; UNIV BRITISH COLUMBIA HOSP,VANCOUVER,BC,CANADA; VICTORIA GEN HOSP,HALIFAX,NS,CANADA; ST PAULS HOSP,VANCOUVER,BC,CANADA; FOOTHILLS PROV GEN HOSP,CALGARY,AB,CANADA; CALGARY GEN HOSP,CALGARY,AB,CANADA; HALIFAX INFIRM,HALIFAX,NS,CANADA; CAMP HILL HOSP,HALIFAX,NS,CANADA; UNIV LAVAL,QUEBEC CITY,PQ,CANADA; HOP ST FRANCOIS ASSISE,QUEBEC CITY,PQ,CANADA; HOP HOTEL DIEU,QUEBEC CITY,PQ,CANADA; MCGILL UNIV,JEWISH GEN HOSP,MONTREAL,PQ,CANADA; MONTREAL GEN HOSP,MONTREAL,PQ,CANADA; ROYAL VICTORIA HOSP,MONTREAL,PQ,CANADA; MCMASTER UNIV,HLTH SCI CTR,HAMILTON,ON,CANADA; UNIV MANITOBA,WINNIPEG,MB,CANADA; ST BONIFACE GEN HOSP,WINNIPEG,MB,CANADA; UNIV MONTREAL,HOP MAISON NEUVE ROSEMONT,MONTREAL,PQ,CANADA; HOP ST LUC,MONTREAL,PQ,CANADA; CARLETON UNIV,OTTAWA CIVIC HOSP,OTTAWA,ON,CANADA; UNIV SASKATCHEWAN,ROYAL UNIV HOSP,SASKATOON,SK,CANADA; PASQUA HOSP,REGINA,SK,CANADA; UNIV TORONTO,MT SINAI HOSP,TORONTO M5G 1X5,ON,CANADA; ST MICHAELS HOSP,TORONTO,ON,CANADA; SUNNYBROOK MED CTR,TORONTO,ON,CANADA; TORONTO GEN HOSP,TORONTO,ON,CANADA; WOMENS COLL HOSP,TORONTO,ON,CANADA; UNIV WESTERN ONTARIO HOSP,LONDON,ON,CANADA; ST JOSEPHS HOSP,HAMILTON,ON,CANADA; UNIV BRITISH COLUMBIA,VICTORIA GEN HOSP,VICTORIA,BC,CANADA; HALIFAX INFIRM,HALIFAX,NS,CANADA; ASTRA PHARMA CANADA,TORONTO,ON,CANADA	University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario); Universite de Montreal; University of Calgary; University of Alberta; Dalhousie University; University of Alberta; Royal Alexandra Hospital; University of British Columbia; Dalhousie University; University of Victoria; St. Paul's Hospital; University of Saskatchewan; University of Calgary; University of Calgary; Dalhousie University; Laval University; Laval University; McGill University; McGill University; McGill University; Royal Victoria Hospital; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; Universite de Montreal; Universite de Montreal; Carleton University; University of Ottawa; Ottawa Hospital Research Institute; University of Saskatchewan; University of Saskatchewan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Womens College Hospital; Western University (University of Western Ontario); McGill University; McMaster University; University of British Columbia; University of Victoria			Feagan, Brian/G-3292-2011; George, Susan/W-7494-2019; George, Susan R/P-9669-2018; Feagan, Brian G/M-4283-2015; Greenberg, Gordon/C-4620-2015					BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Brattsand R, 1990, CAN J GASTROENTEROL, V4, P407; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BROGDEN RN, 1992, DRUGS, V44, P1012, DOI 10.1007/BF03259142; BROGDEN RN, 1993, DRUGS, V45, P130, DOI 10.1007/BF03259101; CHRISTY NP, 1992, NEW ENGL J MED, V326, P266, DOI 10.1056/NEJM199201233260410; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; EDSBACKER S, 1993, GASTROENTEROLOGY, V104, pA695; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; KOTZ S, 1988, ENCY STATISTICAL SCI, V9; LINDGREN BW, 1976, STATISTICAL THEORY; LOFBERG R, 1991, Gastroenterology, V100, pA226; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; ODONOGHUE DP, 1978, LANCET, V2, P955, DOI 10.1016/S0140-6736(78)92524-2; PORRO G B, 1992, Gastroenterology, V102, pA595; RIJK MCM, 1991, ANN INTERN MED, V114, P445, DOI 10.7326/0003-4819-114-6-445; RUTGEERTS P, 1994, NEW ENGL J MED, V331, P842, DOI 10.1056/NEJM199409293311304; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SUTHERLAND L, 1991, GUT, V32, P1071, DOI 10.1136/gut.32.9.1071; THOMSON ABR, 1993, CAN J GASTROENTEROL, V9, P142; WOLMAN S L, 1991, Gastroenterology, V100, pA263; 1991, SCAND J GASTROENTERO, V26, P1225	26	473	486	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					836	841		10.1056/NEJM199409293311303	http://dx.doi.org/10.1056/NEJM199409293311303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078529				2022-12-28	WOS:A1994PH53000003
J	HOU, JZ; SCHINDLER, U; HENZEL, WJ; HO, TC; BRASSEUR, M; MCKNIGHT, SL				HOU, JZ; SCHINDLER, U; HENZEL, WJ; HO, TC; BRASSEUR, M; MCKNIGHT, SL			AN INTERLEUKIN-4-INDUCED TRANSCRIPTION FACTOR - IL-4 STAT	SCIENCE			English	Article							RECEPTOR GAMMA-CHAIN; B-CELLS; TYROSINE PHOSPHORYLATION; FUNCTIONAL COMPONENT; LYMPHOCYTES-B; FC-EPSILON; EXPRESSION; PROTEINS; SEQUENCE; LINE	Interleukin-4 (IL-4) is an immunomodulatory cytokine secreted by activated T lymphocytes, basophils, and mast cells. It plays an important role in modulating the balance of T helper (Th) cell subsets, favoring expansion of the Th2 lineage relative to Th1. Imbalance of these T lymphocyte subsets has been implicated in immunological diseases including allergy, inflammation, and autoimmune disease. IL-4 may mediate its biological effects, at least in part, by activating a tyrosine-phosphorylated DNA binding protein. This protein has now been purified and its encoding gene cloned. Examination of the primary amino acid sequence of this protein indicates that it is a member of the signal transducers and activators of transcription (Stat) family of DNA binding proteins, hereby designated IL-4 Stat. Study of the inhibitory activities of phosphotyrosine-containing peptides derived from the intracellular domain of the IL-4 receptor provided evidence for direct coupling of receptor and transcription factor during the IL-4 Stat activation cycle. Such observations indicate that IL-4 Stat has the same functional domain for both receptor coupling and dimerization.	TULARIK INC, San Francisco, CA 94080 USA; GENENTECH INC, San Francisco, CA 94080 USA	Roche Holding; Genentech				Henzel, William/0000-0003-2940-3797				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HUDAK SA, 1987, P NATL ACAD SCI USA, V84, P4606, DOI 10.1073/pnas.84.13.4606; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matthews B., COMMUNICATION; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; POLLA BS, 1986, P NATL ACAD SCI USA, V83, P4878, DOI 10.1073/pnas.83.13.4878; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHREIBER R, COMMUNICATION; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WONG SC, 1993, TECHNIQUES PROTEIN C, V4, P371; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YUAN X, 1992, P NATL ACAD SCI USA, V89, P7840; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	761	786	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1701	1706		10.1126/science.8085155	http://dx.doi.org/10.1126/science.8085155			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085155				2022-12-28	WOS:A1994PG28400029
J	MANOLIS, AS; WANG, PJ; ESTES, NAM				MANOLIS, AS; WANG, PJ; ESTES, NAM			RADIOFREQUENCY CATHETER ABLATION FOR CARDIAC TACHYARRHYTHMIAS	ANNALS OF INTERNAL MEDICINE			English	Review							PARKINSON-WHITE SYNDROME; ACCESSORY ATRIOVENTRICULAR PATHWAYS; NODAL REENTRANT TACHYCARDIA; JUNCTIONAL RECIPROCATING TACHYCARDIA; LOCAL ELECTROGRAM CHARACTERISTICS; ENDOCARDIAL MAPPING TECHNIQUES; ECTOPIC ATRIAL TACHYCARDIA; TERM FOLLOW-UP; VENTRICULAR-TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA	Purpose: To review the radiofrequency ablation method, describe the technique, and discuss the indications, results, and limitations of its use in patients with cardiac tachyarrhythmias. Data Sources: Peer-reviewed reports in the literature by clinical investigators who use radiofrequency catheter ablation as identified by a MEDLINE search and our own experience with this intervention in 214 patients with cardiac tachyarrhythmias. Study Selection: All articles reporting results of radiofrequency ablation for cardiac tachyarrhythmias and articles describing the ablation technique or comparing it with direct-current or surgical methods. Results of Data Synthesis: Percutaneous catheter ablation of cardiac arrhythmias using high-voltage, direct current was limited by a high complication rate and a need for general anesthesia. This method was recently replaced by a new safe and efficacious technique using low-voltage, high-frequency (radiofrequency) alternating current. Nonsurgical cure of many supraventricular arrhythmias is now feasible with radiofrequency ablation, especially in patients with accessory pathways or atrioventricular nodal reentrant tachycardia. For these arrhythmias, success rates are greater than 90%. The indications for ablation include preexcitation syndromes, atrioventricular nodal reentrant tachycardia, and other selected atrial and ventricular tachyarrhythmias refractory to antiarrhythmic drug therapy. The efficacy and safety profile of this technique has made it feasible for children as well as adults. Conclusions: Percutaneous radiofrequency catheter ablation has evolved as a safe and effective method for managing and curing the two most common forms of supraventricular tachycardia: those associated with preexcitation syndromes and atrioventricular nodal reentrant tachycardia. Further studies are needed to determine the efficacy of this method or to evaluate alternative transcatheter techniques in patients with atrial tachycardias and, more importantly, in the large population of patients with ischemic ventricular tachycardia.			MANOLIS, AS (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DIV CARDIOL,BOX 868, 750 WASHINGTON ST, BOSTON, MA 02111 USA.		Manolis, Antonis/F-5003-2014	Manolis, Antonis/0000-0002-0336-4745				AIZAWA Y, 1993, AM HEART J, V125, P1269, DOI 10.1016/0002-8703(93)90994-K; AKHTAR M, 1993, CIRCULATION, V88, P282, DOI 10.1161/01.CIR.88.1.282; BASHIR Y, 1993, BRIT HEART J, V69, P315; Bashir Y, 1993, J AM COLL CARDIOL, V22, P550, DOI 10.1016/0735-1097(93)90063-7; BORGGREFE M, 1992, PACE, V15, P616, DOI 10.1111/j.1540-8159.1992.tb05151.x; CALKINS H, 1993, AM J CARDIOL, V71, P1104, DOI 10.1016/0002-9149(93)90581-V; CALKINS H, 1992, CIRCULATION, V85, P565, DOI 10.1161/01.CIR.85.2.565; CALKINS H, 1992, CIRCULATION, V85, P1337, DOI 10.1161/01.CIR.85.4.1337; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CALKINS H, 1993, AM J CARDIOL, V71, P827, DOI 10.1016/0002-9149(93)90832-W; CASE CL, 1992, J AM COLL CARDIOL, V20, P1405, DOI 10.1016/0735-1097(92)90255-L; CHANG RJ, 1993, AM HEART J, V125, P1276, DOI 10.1016/0002-8703(93)90995-L; CHEN SA, 1993, CIRCULATION, V88, P578, DOI 10.1161/01.CIR.88.2.578; CHEN SA, 1993, AM HEART J, V125, P1, DOI 10.1016/0002-8703(93)90050-J; CHEN SA, 1992, AM J CARDIOL, V70, P321; CHEN SA, 1993, AM HEART J, V125, P381, DOI 10.1016/0002-8703(93)90016-3; CHIEN WW, 1992, CIRCULATION, V85, P1329, DOI 10.1161/01.CIR.85.4.1329; COHEN TJ, 1991, J AM COLL CARDIOL, V18, P1767, DOI 10.1016/0735-1097(91)90519-F; COSIO FG, 1993, AM J CARDIOL, V71, P705, DOI 10.1016/0002-9149(93)91014-9; COX JL, 1990, J THORAC CARDIOV SUR, V99, P440; CRITELLI G, 1984, J AM COLL CARDIOL, V4, P601, DOI 10.1016/S0735-1097(84)80108-4; CRUZ FES, 1990, J AM COLL CARDIOL, V16, P739, DOI 10.1016/0735-1097(90)90368-Y; DEBUITLEIR M, 1991, AM J CARDIOL, V68, P1656, DOI 10.1016/0002-9149(91)90325-F; DESAI JM, 1991, PACE, V14, P1179, DOI 10.1111/j.1540-8159.1991.tb02849.x; EHLERT FA, 1992, AM J CARDIOL, V69, P1092, DOI 10.1016/0002-9149(92)90872-V; EVANS GT, 1988, PACE, V11, P1621, DOI 10.1111/j.1540-8159.1988.tb06284.x; FELD GK, 1992, CIRCULATION, V86, P1233, DOI 10.1161/01.CIR.86.4.1233; FITZPATRICK AP, 1994, J AM COLL CARDIOL, V23, P107, DOI 10.1016/0735-1097(94)90508-8; GADHOKE A, 1992, CIRCULATION, V86, P191; GOLDBERGER J, 1993, AM J CARDIOL, V72, P787, DOI 10.1016/0002-9149(93)91063-N; GONSKA BD, 1991, EUR HEART J, V12, P1257, DOI 10.1093/eurheartj/12.12.1257; GUIRAUDON GM, 1986, ANN THORAC SURG, V42, P651, DOI 10.1016/S0003-4975(10)64600-0; HAINES DE, 1990, CIRCULATION, V82, P1034, DOI 10.1161/01.CIR.82.3.1034; HAINES DE, 1991, CIRCULATION S2, V84, P710; HAISSAGUERRE M, 1992, CIRCULATION, V86, P1464, DOI 10.1161/01.CIR.86.5.1464; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; HEINZ G, 1992, AM J CARDIOL, V69, P489, DOI 10.1016/0002-9149(92)90991-7; HOGENHUIS W, 1993, CIRCULATION, V88, P437; HUANG SKS, 1991, J AM COLL CARDIOL, V18, P1091, DOI 10.1016/0735-1097(91)90772-2; HUANG SKS, 1991, PACE, V14, P28, DOI 10.1111/j.1540-8159.1991.tb04044.x; JACKMAN WM, 1989, PACE, V12, P204, DOI 10.1111/j.1540-8159.1989.tb02648.x; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; KALBFLEISCH SJ, 1993, J AM COLL CARDIOL, V21, P567, DOI 10.1016/0735-1097(93)90086-G; KALBFLEISCH SJ, 1993, AM J CARDIOL, V72, P1406, DOI 10.1016/0002-9149(93)90188-I; KALBFLEISCH SJ, 1992, J AM COLL CARDIOL, V19, P1583, DOI 10.1016/0735-1097(92)90621-S; KAY GN, 1993, J CARDIOVASC ELECTR, V4, P371, DOI 10.1111/j.1540-8167.1993.tb01277.x; KAY GN, 1993, J AM COLL CARDIOL, V21, P901, DOI 10.1016/0735-1097(93)90345-2; KAY GN, 1992, CIRCULATION, V85, P1675, DOI 10.1161/01.CIR.85.5.1675; KEIM S, 1992, J AM COLL CARDIOL, V19, P1005, DOI 10.1016/0735-1097(92)90285-U; KEIM S, 1992, CIRCULATION, V86, P919, DOI 10.1161/01.CIR.86.3.919; KLEIN LS, 1992, CIRCULATION, V85, P1666, DOI 10.1161/01.CIR.85.5.1666; KLITZNER TS, 1993, AM J DIS CHILD, V147, P769, DOI 10.1001/archpedi.1993.02160310071021; KOCOVIC DZ, 1993, CIRCULATION, V88, P1671, DOI 10.1161/01.CIR.88.4.1671; KUCH KH, 1991, J AM COLL CARDIOL, V17, pA108; KUCK KH, 1991, LANCET, V337, P1557, DOI 10.1016/0140-6736(91)93258-B; LANGBERG JJ, 1992, J AM COLL CARDIOL, V19, P1588, DOI 10.1016/0735-1097(92)90622-T; LANGBERG JJ, 1993, J AM COLL CARDIOL, V22, P1100, DOI 10.1016/0735-1097(93)90422-W; LANGBERG JJ, 1993, CIRCULATION, V87, P1551, DOI 10.1161/01.CIR.87.5.1551; LANGBERG JJ, 1992, AM J CARDIOL, V69, P503, DOI 10.1016/0002-9149(92)90994-A; LANGBERG JJ, 1992, CIRCULATION, V86, P1469, DOI 10.1161/01.CIR.86.5.1469; LANGBERG JJ, 1993, CIRCULATION, V88, P245, DOI 10.1161/01.CIR.88.1.245; LAVERGNE T, 1989, PACE, V12, P177, DOI 10.1111/j.1540-8159.1989.tb02645.x; LEATHER RA, 1991, AM J CARDIOL, V68, P1651, DOI 10.1016/0002-9149(91)90324-E; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; LEITCH JW, 1992, AM J CARDIOL, V70, P830, DOI 10.1016/0002-9149(92)90575-J; LESH MD, 1992, J AM COLL CARDIOL, V19, P1303, DOI 10.1016/0735-1097(92)90338-N; Lesh MD, 1993, J AM COLL CARDIOL, V22, P542, DOI 10.1016/0735-1097(93)90062-6; LI HG, 1993, J AM COLL CARDIOL, V22, P1849, DOI 10.1016/0735-1097(93)90768-V; LINDSAY BD, 1992, AM J CARDIOL, V70, P218, DOI 10.1016/0002-9149(92)91278-C; MAN KC, 1993, AM J CARDIOL, V72, P1323, DOI 10.1016/0002-9149(93)90308-Y; MANOLIS AS, 1989, AM J CARDIOL, V63, P746, DOI 10.1016/0002-9149(89)90265-8; MANOLIS AS, 1989, AM J CARDIOL, V64, P194, DOI 10.1016/0002-9149(89)90456-6; MANOLIS AS, 1992, EUR HEART J, V13, P1489, DOI 10.1093/oxfordjournals.eurheartj.a060091; MANOLIS AS, 1987, ARCH INTERN MED, V147, P1706, DOI 10.1001/archinte.147.10.1706; MANOLIS AS, 1993, CHEST, V104, pS79; MANOLIS AS, 1992, HELL J CARDIOL, V33, P122; MANOLIS AS, 1993, CHEST, V104, pS84; Mclean AJ., 1929, ARCH SURG-CHICAGO, V18, P1863, DOI [10.1001/archsurg.1929.01140130965064, DOI 10.1001/ARCHSURG.1929.01140130965064]; MORADY F, 1993, J AM COLL CARDIOL, V21, P102, DOI 10.1016/0735-1097(93)90723-E; MORADY F, 1993, CIRCULATION, V87, P363, DOI 10.1161/01.CIR.87.2.363; MOULTON K, 1993, PACE, V16, P760, DOI 10.1111/j.1540-8159.1993.tb01656.x; NAKAGAWA H, 1993, CIRCULATION, V88, P2607, DOI 10.1161/01.CIR.88.6.2607; NATALE A, 1992, AM J CARDIOL, V70, P114, DOI 10.1016/0002-9149(92)91403-Q; OLGIN JE, 1993, J AM COLL CARDIOL, V21, P557, DOI 10.1016/0735-1097(93)90084-E; ROSS DL, 1985, J AM COLL CARDIOL, V6, P1383, DOI 10.1016/S0735-1097(85)80229-1; SAUL JP, 1993, J AM COLL CARDIOL, V21, P571, DOI 10.1016/0735-1097(93)90087-H; SCHEINMAN MM, 1987, AM HEART J, V114, P1291, DOI 10.1016/0002-8703(87)90218-3; SCHEINMAN MM, 1992, PACE, V15, P715, DOI 10.1111/j.1540-8159.1992.tb06835.x; SCHEINMAN MM, 1992, PACE, V15, P2228, DOI 10.1111/j.1540-8159.1992.tb04163.x; SCHEINMAN MM, 1991, CIRCULATION, V83, P2146, DOI 10.1161/01.CIR.83.6.2146; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SCHLUTER M, 1992, J AM COLL CARDIOL, V19, P663, DOI 10.1016/S0735-1097(10)80289-X; SCHLUTER M, 1991, CIRCULATION, V84, P1644, DOI 10.1161/01.CIR.84.4.1644; SILKA MJ, 1992, PACE, V15, P1000, DOI 10.1111/j.1540-8159.1992.tb03093.x; SOUZA O, 1992, PACE, V15, P1454, DOI 10.1111/j.1540-8159.1992.tb02918.x; STEVENSON WG, 1993, CIRCULATION, V88, P1647, DOI 10.1161/01.CIR.88.4.1647; SWARTZ JF, 1993, CIRCULATION, V87, P487, DOI 10.1161/01.CIR.87.2.487; TICHO BS, 1992, AM J CARDIOL, V70, P1559, DOI 10.1016/0002-9149(92)90457-A; TOUBOUL P, 1992, J CARDIOVASC ELECTR, V3, P641, DOI 10.1111/j.1540-8167.1992.tb01942.x; TRACY CM, 1993, J AM COLL CARDIOL, V21, P910, DOI 10.1016/0735-1097(93)90346-3; TROHMAN RG, 1992, AM J CARDIOL, V70, P1438, DOI 10.1016/0002-9149(92)90296-B; VANHARE GF, 1991, J AM COLL CARDIOL, V17, P1613, DOI 10.1016/0735-1097(91)90656-T; Vatz J B, 1992, JAMA, V268, P2091, DOI 10.1001/jama.268.15.2091; WALSH EP, 1992, CIRCULATION, V86, P1138, DOI 10.1161/01.CIR.86.4.1138; WARIN JF, 1988, CIRCULATION, V78, P800, DOI 10.1161/01.CIR.78.4.800; WATHEN M, 1992, AM J CARDIOL, V70, P886, DOI 10.1016/0002-9149(92)90732-E; WILBER DJ, 1993, CIRCULATION, V87, P126, DOI 10.1161/01.CIR.87.1.126; WOOD MA, 1992, AM J CARDIOL, V70, P200, DOI 10.1016/0002-9149(92)91275-9; WU DL, 1992, J AM COLL CARDIOL, V20, P884, DOI 10.1016/0735-1097(92)90189-T; WU DL, 1993, J AM COLL CARDIOL, V21, P1612, DOI 10.1016/0735-1097(93)90376-C; XU C, 1992, J AM COLL CARDIOL, V20, P656, DOI 10.1016/0735-1097(92)90021-E; YEUNGLAIWAH JA, 1991, J AM COLL CARDIOL, V18, P1753, DOI 10.1016/0735-1097(91)90516-C	114	45	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					452	461		10.7326/0003-4819-121-6-199409150-00010	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053620				2022-12-28	WOS:A1994PF33700010
J	SCOGNAMIGLIO, R; RAHIMTOOLA, SH; FASOLI, G; NISTRI, S; DALLAVOLTA, S				SCOGNAMIGLIO, R; RAHIMTOOLA, SH; FASOLI, G; NISTRI, S; DALLAVOLTA, S			NIFEDIPINE IN ASYMPTOMATIC PATIENTS WITH SEVERE AORTIC REGURGITATION AND NORMAL LEFT-VENTRICULAR FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM VASODILATOR THERAPY; VALVE-REPLACEMENT; CARDIAC-PERFORMANCE; INSUFFICIENCY; VOLUME; SURVIVAL; ECHOCARDIOGRAPHY; HYPERTROPHY; DYSFUNCTION; PROGRESSION	Background. Vasodilator therapy with nifedipine reduces left ventricular volume and mass and increases the ejection fraction in asymptomatic patients with severe aortic regurgitation. Methods. To assess whether vasodilator therapy reduces or delays the need for valve replacement, we randomly assigned 143 asymptomatic patients with isolated, severe aortic regurgitation and normal left ventricular systolic function to receive either nifedipine (20 mg twice dally, 69 patients) or digoxin (0.25 mg daily, 74 patients). Results. By actuarial analysis, we determined that after six years a mean (+/-SD) of 34+/-6 percent of the patients in the digoxin group had undergone valve replacement, as compared with only 15+/-3 percent of those in the nifedipine group (P<0.001). in the digoxin group, valve replacement (in a total of 20 patients) was performed because of left ventricular dysfunction (ejection fraction <50 percent) in 75 percent, left ventricular dysfunction plus symptoms in 10 percent, and symptoms alone in 15 percent. In the nifedipine group, all six patients who underwent valve replacement did so because of the development of left ventricular dysfunction. In addition, ail the patients in both groups who underwent aortic-valve replacement had an increase of 15 percent or more in the left ventricular end-diastolic volume index. After aortic-valve replacement, 12 of the 16 patients (75 percent) in the digoxin group and all six patients in the nifedipine group who had had an abnormal left ventricular ejection fraction before surgery had a normal ejection fraction. Conclusions, Long-term vasodilator therapy with nifedipine reduces or delays the need for aortic-valve replacement in asymptomatic patients with severe aortic regurgitation and normal left ventricular systolic function.	UNIV PADUA, SCH MED,DEPT INTERNAL MED,DIV CARDIOL, I-35100 PADUA, ITALY; UNIV SO CALIF, LOS ANGELES CTY MED CTR,DIV CARDIOL, LOS ANGELES, CA 90033 USA	University of Padua; University of Southern California			Nistri, Stefano/K-7056-2016	Nistri, Stefano/0000-0003-1511-3449				BONOW RO, 1983, CIRCULATION, V68, P509, DOI 10.1161/01.CIR.68.3.509; BONOW RO, 1988, CIRCULATION, V78, P1108, DOI 10.1161/01.CIR.78.5.1108; BONOW RO, 1985, CIRCULATION, V72, P1244, DOI 10.1161/01.CIR.72.6.1244; BONOW RO, 1987, J AM COLL CARDIOL, V10, P713, DOI 10.1016/S0735-1097(87)80217-6; BRAUNWALD E, 1984, HEART DISEASE TXB CA, V2, P1114; CLARK DG, 1980, CIRCULATION, V61, P411, DOI 10.1161/01.CIR.61.2.411; CRAWFORD MH, 1989, INT J CARDIOL, V23, P385, DOI 10.1016/0167-5273(89)90199-X; FIORETTI P, 1982, AM J CARDIOL, V49, P1728, DOI 10.1016/0002-9149(82)90252-1; GAASCH WH, 1978, CIRCULATION, V58, P825, DOI 10.1161/01.CIR.58.5.825; GAULT JH, 1970, CIRCULATION, V42, P773, DOI 10.1161/01.CIR.42.5.773; GREENBERG B, 1988, CIRCULATION, V78, P92, DOI 10.1161/01.CIR.78.1.92; GREENBERG BH, 1980, ANN INTERN MED, V93, P440, DOI 10.7326/0003-4819-93-3-440; GREENBERG BH, 1980, CIRCULATION, V62, P49, DOI 10.1161/01.CIR.62.1.49; GREENBERG BH, 1981, CIRCULATION, V63, P263, DOI 10.1161/01.CIR.63.2.263; GREVES J, 1981, AM HEART J, V101, P300, DOI 10.1016/0002-8703(81)90194-0; HELAK JW, 1981, CIRCULATION, V63, P1398, DOI 10.1161/01.CIR.63.6.1398; HENRY WL, 1980, CIRCULATION, V61, P484, DOI 10.1161/01.CIR.61.3.484; KARAIAN CH, 1985, CHEST, V88, P553, DOI 10.1378/chest.88.4.553; PANTELY G, 1978, J THORAC CARDIOV SUR, V75, P383; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; RAHIMTOOLA SH, 1980, J THORAC CARDIOV SUR, V79, P163; RAHIMTOOLA SH, 1990, J AM COLL CARDIOL, V16, P430, DOI 10.1016/0735-1097(90)90597-I; RAHIMTOOLA SH, 1992, CLIN CARDIOL, V15, pI22; RAHIMTOOLA SH, 1989, J AM COLL CARDIOL, V14, P1, DOI 10.1016/0735-1097(89)90047-8; RAHIMTOOLA SH, 1990, INTERNAL MED, P150; ROSS J, 1985, J AM COLL CARDIOL, V5, P811, DOI 10.1016/S0735-1097(85)80418-6; ROSS J, 1974, CIRC RES, V35, P64; SCOGNAMIGLIO R, 1990, J AM COLL CARDIOL, V16, P424, DOI 10.1016/0735-1097(90)90596-H; SCOGNAMIGLIO R, 1986, CLIN CARDIOL, V9, P151, DOI 10.1002/clc.4960090404; SIEMIENCZUK D, 1989, ANN INTERN MED, V110, P587, DOI 10.7326/0003-4819-110-8-587; STARLING MR, 1991, J AM COLL CARDIOL, V17, P887, DOI 10.1016/0735-1097(91)90870-F; WYATT HL, 1980, CIRCULATION, V61, P1119, DOI 10.1161/01.CIR.61.6.1119	32	191	196	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					689	694		10.1056/NEJM199409153311101	http://dx.doi.org/10.1056/NEJM199409153311101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058074				2022-12-28	WOS:A1994PF33200001
J	TOUBIA, N				TOUBIA, N			FEMALE CIRCUMCISION AS A PUBLIC-HEALTH ISSUE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY; RES ACT & INFORMAT NETWORK BODILY INTEGR WOMEN,NEW YORK,NY	Columbia University								[Anonymous], 1985, PROHIBITION FEMALE C; Baasher T, 1979, WHO EMRO TECHNICAL P, V2, P71; BAKER CA, 1993, FEMALE CIRCUMCISION; Dorkeno E., 1992, FEMALE GENITAL MUTIL; KARIM M, 1965, FEMALE CIRCUMCISION; KLEIN HL, 1991, J OBSTET GYNECOL NEO, V20, P102; Remondino P. C., 1891, HIST CIRCUMCISION EA; SINGHATEH SK, 1989, FEMALE CIRCUMCISION, P77; SULLIVAN D, JUN WORLD C HUM RIGH; TABA AH, 1979, WHO EMRO TECHNICAL P, V2, P43; Toubia N., 1993, FEMALE GENITAL MUTIL; Verzin J, 1975, TROPICAL DOCTOR, V5, P163; Walker A., 1992, POSSESSING SECRET JO; Walker Alice, 1993, WARRIOR MARKS FEMALE; WARSAME A, 1989, FEMALE CIRCUMCISION, P88; WARSAME M, 1989, FEMALE CIRCUMCISION, P94; 1993, DPI139439399 UN PUBL; 1993, FEMALE CIRCUMCISION; 1992, MUTILATION GIRLS GEN; 1992, INT J GYNECOL OBSTET, V37, P149; 1993, FEMALE CIRCUMCISION, V26, P8; 1993, 46TH WORLD HLTH ASS	22	194	196	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					712	716		10.1056/NEJM199409153311106	http://dx.doi.org/10.1056/NEJM199409153311106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058079	Bronze			2022-12-28	WOS:A1994PF33200006
J	GARROW, JS				GARROW, JS			CONTROVERSIES IN MANAGEMENT - SHOULD OBESITY BE TREATED - TREATMENT IS NECESSARY	BRITISH MEDICAL JOURNAL			English	Article											GARROW, JS (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,RANK DEPT HUMAN NUTR,LONDON EC1M 6BQ,ENGLAND.							BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; Bush A., 1988, Journal of Human Nutrition and Dietetics, V1, P429, DOI 10.1111/j.1365-277X.1988.tb00216.x; GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H; Garrow J.S., 1988, OBESITY RELATED DISE; GARROW JS, 1989, LANCET, V1, P1429; GARROW JS, 1993, HUMAN NUTR DIETETICS, P465; White A, 1993, HLTH SURVEY ENGLAND	7	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					654	655		10.1136/bmj.309.6955.654	http://dx.doi.org/10.1136/bmj.309.6955.654			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086991	Green Published			2022-12-28	WOS:A1994PG02000033
J	WOOLEY, SC; GARNER, DM				WOOLEY, SC; GARNER, DM			CONTROVERSIES IN MANAGEMENT - SHOULD OBESITY BE TREATED - DIETARY TREATMENTS FOR OBESITY ARE INEFFECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BECK INST COGNIT THERAPY & RES, BALA CYNWOOD, PA 19001 USA		WOOLEY, SC (corresponding author), UNIV CINCINNATI, COLL MED, CINCINNATI, OH 45267 USA.							ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; BROWNELL KD, 1991, BEHAV THER, V22, P153, DOI 10.1016/S0005-7894(05)80174-1; Ernsberger Paul, 1987, J OBESITY WEIGHT REG, V6, P58; GARNER DM, 1991, CLIN PSYCHOL REV, V6, P58; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; Keesey R.E., 1993, OBESITY THEORY THERA, P77; Meyer JM, 1993, OBESITY THEORY THERA, P137; RAVITCH MM, 1979, ANN SURG, V190, P382, DOI 10.1097/00000658-197909000-00014; Ravussin E, 1993, OBESITY THEORY THERA, P97; Rothblum E. D, 1994, FEMINIST PERSPECTIVE, P53; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; Wadden T., 1993, OBESITY THEORY THERA, V2, P163; Wadden T, 1993, OBESITY THEORY THERA, P197; 1992, NATIONAL I HLTH TECH	14	35	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 10	1994	309	6955					655	656						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086992				2022-12-28	WOS:A1994PG02000034
J	STILLMAN, B				STILLMAN, B			SMART MACHINES AT THE DNA-REPLICATION FORK	CELL			English	Review							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; STRAND SYNTHESIS; PRIMER-TEMPLATE; LEADING-STRAND; COMPLEX; BETA; CLAMP; DELTA				STILLMAN, B (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Stillman, Bruce/0000-0002-9453-4091				CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER K, 1994, IN PRESS J BIOL CHEM, V269; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1991, J BIOL CHEM, V266, P594; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NETHANEL T, 1988, J VIROL, V6, P2867; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1994, CELL, V78; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	19	249	255	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					725	728		10.1016/S0092-8674(94)90362-X	http://dx.doi.org/10.1016/S0092-8674(94)90362-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087839				2022-12-28	WOS:A1994PG29600001
J	HANNAFORD, PC; KAY, CR; FERRY, S				HANNAFORD, PC; KAY, CR; FERRY, S			AGISM AS EXPLANATION FOR SEXISM IN PROVISION OF THROMBOLYSIS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY; DISEASE; WOMEN				HANNAFORD, PC (corresponding author), ROYAL COLL GEN PRACTITIONERS,MANCHESTER RES UNIT,MANCHESTER M22 4DB,LANCS,ENGLAND.		Hannaford, Philip C/B-7867-2012					AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402	5	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					573	573		10.1136/bmj.309.6954.573	http://dx.doi.org/10.1136/bmj.309.6954.573			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086943	Green Published			2022-12-28	WOS:A1994PF33000017
J	GLASS, RI; GENTSCH, J; SMITH, JC				GLASS, RI; GENTSCH, J; SMITH, JC			ROTAVIRUS VACCINES - SUCCESS BY REASSORTMENT	SCIENCE			English	Editorial Material							YOUNG-CHILDREN; PROTECTION; INFECTION				GLASS, RI (corresponding author), CTR DIS CONTROL & PREVENT,VIRAL GASTROENTERITIS SECT,ATLANTA,GA 30333, USA.							BERNSTEIN DI, 1991, J INFECT DIS, V164, P277, DOI 10.1093/infdis/164.2.277; BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; BISHOP RF, 1973, LANCET, V2, P1281, DOI 10.1016/s0140-6736(73)92867-5; CRAWFORD SE, IN PRESS J VIROL; DENNEHY PH, 1984, PEDIATR RES, V35, P1052; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; GLASS RI, 1990, PROSPECTS PUBLIC HLT, P102; GORZIGLIA M, 1990, P NATL ACAD SCI USA, V87, P7155, DOI 10.1073/pnas.87.18.7155; HARDY DB, 1987, REV INFECT DIS, V9, P461; Kapikian AZ, 1990, VIROLOGY, P1353; KAPIKIAN AZ, 1994, VIRAL INFECTIONS GAS, P409; MATTION NM, 1994, VIRAL INFECTIONS GAS, P169; OFFIT P, IN PRESS VIROLOGY; OFFIT PA, 1994, ADV VIRUS RES, V44, P161, DOI 10.1016/S0065-3527(08)60329-2; REDMOND MJ, 1993, VACCINE, V11, P273, DOI 10.1016/0264-410X(93)90029-W; SACK D, 1992, 32ND INT C ANT AG CH; TREANER JJ, 1994, 34TH INT C ANT AG CH; VESIKARI T, 1993, VACCINE, V11, P255, DOI 10.1016/0264-410X(93)90026-T; VESIKARI T, 1994, VIRAL INFECTIONS GAS, P419; WARD RL, 1994, J INFECT DIS, V169, P900, DOI 10.1093/infdis/169.4.900; WYATT RG, 1980, SCIENCE, V207, P189, DOI 10.1126/science.6243190; 1993, 1993 WORLD BANK WORL	24	76	86	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1389	1391		10.1126/science.8073280	http://dx.doi.org/10.1126/science.8073280			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073280				2022-12-28	WOS:A1994PE73300032
J	BARBOSA, J; STEFFES, MW; SUTHERLAND, DER; CONNETT, JE; RAO, KV; MAUER, SM				BARBOSA, J; STEFFES, MW; SUTHERLAND, DER; CONNETT, JE; RAO, KV; MAUER, SM			EFFECT OF GLYCEMIC CONTROL ON EARLY DIABETIC RENAL LESIONS - A 5-YEAR RANDOMIZED CONTROLLED CLINICAL-TRIAL OF INSULIN-DEPENDENT DIABETIC KIDNEY-TRANSPLANT RECIPIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISLET TRANSPLANTATION; GLOMERULAR-LESIONS; LONG-TERM; NEPHROPATHY; COMPLICATIONS; RATS; PROGRESSION; RETINOPATHY; SURFACE	Objective.-To determine whether optimized glycemic control in type I diabetic recipients of renal allografts will prevent or delay diabetic renal lesions in the allograft. Design.-Prospective, controlled, and randomized trial of glycemic control in an inception cohort of type I diabetic renal allograft recipients. The experimental group underwent maximized glycemic control, and the standard group was treated in the same way as other patients in the transplant clinic. Patients underwent baseline (before transplant) and 5-year posttransplant allograft biopsies. Setting.-University of Minnesota Hospital and Clinic and the Clinical Research Center and Hennepin County Medical Center, Minneapolis. Patients.-Type I diabetics with terminal diabetic renal failure undergoing renal transplantation. Forty-eight patients randomized to maximized or standard control completed the trial. Intervention.-Subcutaneous insulin given several times a day or continuously (maximized group) and once or twice each day (standard group) was used throughout the trial. A significant difference for hemoglobin A(1) level was maintained (mean+/-SD: standard, 0.117+/-0.013; maximized, 0.096+/-0.016; P<.001). Main Outcome.-The primary end point of this trial was the difference between the groups in renal glomerular mesangial expansion as determined by electron microscopy. Results.-There was a more than twofold increase in the volume fraction of mesangial matrix per glomerulus in the standard group (mean+/-SD, 0.043+/-0.034) compared with the maximized group (0.019+/-0.038; P=.024). The threefold increase in arteriolar hyalinosis, the greater widening of the glomerular basement membrane, and increase of Volume fraction of the total mesangium in the patients who received standard treatment all approached significance (P=.10 or less). The incidence of severe hypoglycemic episodes was greater in the maximized group (1.7 per patient per year) than in the standard treatment group (<0.1 per patient per year; P<.001). Conclusions.-This trial indicates a causal relationship between hyperglycemia and an important lesion of diabetic nephropathy mesangial matrix expansion, in renal allografts transplanted into diabetic recipients. In addition, the results with other lesions central to the development of diabetic nephropathy support the major conclusion.	UNIV MINNESOTA HOSP, SCH MED, DEPT MED, DIV ENDOCRINOL & METAB, MINNEAPOLIS, MN USA; UNIV MINNESOTA HOSP, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN USA; UNIV MINNESOTA HOSP, SCH MED, DEPT SURG, MINNEAPOLIS, MN USA; UNIV MINNESOTA HOSP, SCH MED, DEPT PEDIAT, MINNEAPOLIS, MN USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN USA; UNIV MINNESOTA, HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities				Barbosa, Jose/0000-0002-0982-2049	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM020742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK013083] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM43605, AM20742] Funding Source: Medline; NIDDK NIH HHS [2P01DK13083] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BARBOSA J, 1983, ARCH INTERN MED, V143, P1118, DOI 10.1001/archinte.143.6.1118; BARBOSA J, 1983, DIABETES CARE, V6, P62, DOI 10.2337/diacare.6.1.62; BARBOSA J, 1980, DIABETES CARE, V3, P155, DOI 10.2337/diacare.3.1.155; CHAVERS BM, 1989, NEW ENGL J MED, V320, P966, DOI 10.1056/NEJM198904133201503; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DCCT Res Grp, 1988, NEW ENGL J MED, V318, P246; DECKERT T, 1983, DIABETIC NEPHROPATHY, V2, P6; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FELDTRASMUSSEN B, 1986, NEW ENGL J MED, V314, P665, DOI 10.1056/NEJM198603133141101; FIORETTO P, 1992, Journal of the American Society of Nephrology, V3, P332; Fisher R. A., 1950, STATISTICAL METHODS; Fisher RA., 1948, AM STAT, V2, P30, DOI DOI 10.2307/2681650; Fryd D S, 1987, Clin Transpl, P167; HABIB R, 1993, KIDNEY INT, V44, pS104; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; HARRIS RD, 1991, KIDNEY INT, V40, P107, DOI 10.1038/ki.1991.187; HUNG J, 1984, DIABETES METAB, V10, P48; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; Kimmelstiel P, 1936, AM J PATHOL, V12, P83; MAUER SM, 1989, DIABETES, V38, P516, DOI 10.2337/diabetes.38.4.516; MAUER SM, 1975, DIABETES, V24, P280; MAUER SM, 1976, NEW ENGL J MED, V295, P916, DOI 10.1056/NEJM197610212951703; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MAUER SM, 1976, DIABETES, V25, P709, DOI 10.2337/diabetes.25.8.709; MAUER SM, 1989, KIDNEY INT, V35, P48, DOI 10.1038/ki.1989.7; Miller R.G., 1981, SIMULTANEOUS STAT IN, Ved 2nd, DOI DOI 10.1007/s11263-015-0816-y; OSTERBY R, 1988, DIABETOLOGIA, V31, P265; Osterby R, 1975, ACTA MED SCAND     S, V574, P1; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; RENNKE HG, 1986, KIDNEY INT, V291, P389; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; STEFFES MW, 1983, LAB INVEST, V49, P82; WEST KM, 1982, DIABETOLOGIA, V22, P412, DOI 10.1007/BF00282582; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396	39	110	112	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					600	606		10.1001/jama.272.8.600	http://dx.doi.org/10.1001/jama.272.8.600			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057515				2022-12-28	WOS:A1994PC39800029
J	GELLERT, GA				GELLERT, GA			PREPARING FOR EMERGING INFECTIONS	NATURE			English	Editorial Material											GELLERT, GA (corresponding author), PROJECT HOPE,CTR HLTH SCI EDUC,MILLWOOD,VA 22646, USA.							DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; KILBOURNE ED, 1990, JAMA-J AM MED ASSOC, V264, P68, DOI 10.1001/jama.264.1.68; Lederberg J., 1992, EMERGING INFECTIONS; 1993, MMWR-MORBID MORTAL W, V4, P441; 1994, MMWR-MORBID MORTAL W, V43, P45	6	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					409	410		10.1038/370409a0	http://dx.doi.org/10.1038/370409a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047155	Green Published, Bronze			2022-12-28	WOS:A1994PB40700022
J	NELSON, S; TOTH, L; SHETH, B; SUR, M				NELSON, S; TOTH, L; SHETH, B; SUR, M			ORIENTATION SELECTIVITY OF CORTICAL-NEURONS DURING INTRACELLULAR BLOCKADE OF INHIBITION	SCIENCE			English	Article							CAT VISUAL-CORTEX; RAT HIPPOCAMPAL SLICES; SYNAPTIC POTENTIALS; STRIATE CORTEX; SIMPLE CELLS; MECHANISMS; RESPONSES; EXCITATION; RECORDINGS; RECEPTOR	Neurons in the primary visual cortex of the cat are selectively activated by stimuli with particular orientations. This selectivity can be disrupted by the application of antagonists of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) to a local region of the cortex. In order to determine whether inhibitory inputs are necessary for a single cortical neuron to show orientation selectivity, GABA receptors were blocked intracellularly during whole cell recording. Although the membrane potential, spontaneous activity, subfield antagonism, and directional selectivity of neurons were altered after they were perfused internally with the blocking solution, 18 out of 18 neurons remained selective for stimulus orientation. These results indicate that excitatory inputs are sufficient to generate orientation selectivity.			NELSON, S (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.			Nelson, Sacha/0000-0002-0108-8599	NATIONAL EYE INSTITUTE [U01EY006363, U10EY006363] Funding Source: NIH RePORTER; NEI NIH HHS [EY07023, EY06363] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKAIKE N, 1985, EXPERIENTIA, V41, P70; AKAIKE N, 1989, J NEUROPHYSIOL, V62, P1388, DOI 10.1152/jn.1989.62.6.1388; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; BORGGRAHAM LJ, 1992, THESIS MIT; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CREUTZFELDT OD, 1974, EXP BRAIN RES, V21, P251; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; FERSTER D, 1986, J NEUROSCI, V6, P1284; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KOKUBUN S, 1991, PFLUG ARCH EUR J PHY, V418, P204, DOI 10.1007/BF00370515; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; METHERATE R, 1993, J NEUROSCI, V13, P5312, DOI 10.1523/JNEUROSCI.13-12-05312.1993; NELSON SB, 1991, J NEUROSCI, V11, P369; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; SHIRASAKI T, 1992, J PHYSIOL-LONDON, V449, P551, DOI 10.1113/jphysiol.1992.sp019101; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1979, J PHYSIOL-LONDON, V289, P33, DOI 10.1113/jphysiol.1979.sp012723; SILLITO AM, 1977, J PHYSIOL-LONDON, V271, P699, DOI 10.1113/jphysiol.1977.sp012021; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; Somers D., 1993, Society for Neuroscience Abstracts, V19, P628; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VOLGUSHEV M, 1993, VISUAL NEUROSCI, V10, P1151, DOI 10.1017/S0952523800010257; WHITE EL, 1989, CORTICAL CIRCUITS, P69; XING P, 1991, NEUROREPORT, V2, P485; YAKUSHIJI T, 1987, NEUROSCIENCE, V22, P1123, DOI 10.1016/0306-4522(87)92987-3	32	207	210	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					774	777		10.1126/science.8047882	http://dx.doi.org/10.1126/science.8047882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047882				2022-12-28	WOS:A1994PA37200031
J	FABRE, E; BOELENS, WC; WIMMER, C; MATTAJ, IW; HURT, EC				FABRE, E; BOELENS, WC; WIMMER, C; MATTAJ, IW; HURT, EC			NUP145P IS REQUIRED FOR NUCLEAR EXPORT OF MESSENGER-RNA AND BINDS HOMOPOLYMERIC RNA IN-VITRO VIA A NOVEL CONSERVED MOTIF	CELL			English	Article							XENOPUS-LAEVIS OOCYTES; PORE MEMBRANE DOMAIN; COLD-SHOCK PROTEIN; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN-PARTICLES; NUCLEOCYTOPLASMIC TRANSPORT; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE	An essential yeast protein, Nup145p, is identified via its genetic interaction with the nucleoporin Nsp1p. Nup145p contains GLFG repeats and localizes to nuclear pores. Depletion of Nup145p in vivo leads rapidly to nuclear retention of polyadenylated RNAs and more slowly to cytoplasmic accumulation of a nuclear reporter protein. A stretch of 140 amino acids within Nup145p is conserved in two other yeast nucleoporins, Nup116p and Nup100p, and in an uncharacterized C. elegans protein. Genetic experiments in yeast reveal that the three copies of the motif carry out an essential, redundant function. Fragments of Nup145p and Nup116p including this motif bind specifically to homopolymeric RNAs in vitro. Nup145p, Nup116p, and Nup100p thus represent a novel class of nucleoporins involved in nucleocytoplasmic transport.			FABRE, E (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Boelens, Wilbert/D-8877-2012; Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255; FABRE, Emmanuelle/0000-0002-0009-4604; Mattaj, Iain/0000-0002-5537-8284				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ANDREAZZOLI M, 1993, NUCLEIC ACIDS RES, V21, P4218, DOI 10.1093/nar/21.18.4218; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bossie MA, 1992, CURR OPIN GENET DEV, V2, P768, DOI 10.1016/S0959-437X(05)80137-6; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, CHROMOSOMA, V97, P193, DOI 10.1007/BF00292960; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GOLDFARB DS, 1992, CELL, V70, P185, DOI 10.1016/0092-8674(92)90094-S; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITOH H, 1983, J BACTERIOL, V153, P163; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5466; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	87	123	129	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					275	289		10.1016/0092-8674(94)90297-6	http://dx.doi.org/10.1016/0092-8674(94)90297-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044840				2022-12-28	WOS:A1994NZ24200011
J	WALKER, NPC; TALANIAN, RV; BRADY, KD; DANG, LC; BUMP, NJ; FERENZ, CR; FRANKLIN, S; GHAYUR, T; HACKETT, MC; HAMMILL, LD; HERZOG, L; HUGUNIN, M; HOUY, W; MANKOVICH, JA; MCGUINESS, L; ORLEWICZ, E; PASKIND, M; PRATT, CA; REIS, P; SUMMANI, A; TERRANOVA, M; WELCH, JP; XIONG, L; MOLLER, A; TRACEY, DE; KAMEN, R; WONG, WW				WALKER, NPC; TALANIAN, RV; BRADY, KD; DANG, LC; BUMP, NJ; FERENZ, CR; FRANKLIN, S; GHAYUR, T; HACKETT, MC; HAMMILL, LD; HERZOG, L; HUGUNIN, M; HOUY, W; MANKOVICH, JA; MCGUINESS, L; ORLEWICZ, E; PASKIND, M; PRATT, CA; REIS, P; SUMMANI, A; TERRANOVA, M; WELCH, JP; XIONG, L; MOLLER, A; TRACEY, DE; KAMEN, R; WONG, WW			CRYSTAL-STRUCTURE OF THE CYSTEINE PROTEASE INTERLEUKIN-1-BETA-CONVERTING ENZYME - A (P20/P10)(2) HOMODIMER	CELL			English	Article							IL-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; CELL-DEATH; 3-DIMENSIONAL STRUCTURE; TRIACYLGLYCEROL LIPASE; INTERLEUKIN 1-BETA; MOLECULAR-CLONING; TRIAD FORMS; RESOLUTION; FIBROBLASTS	Interleukin-1 beta-converting enzyme (ICE) proteolytically cleaves pro-IL-1 beta to its mature, active form. The crystal structure at 2.5 Angstrom resolution of a recombinant human ICE-tetrapeptide chloromethylketone complex reveals that the holoenzyme is a homodimer of catalytic domains, each of which contains a p20 and a p10 subunit. The spatial separation of the C-terminus of p20 and the N-terminus of pin in each domain suggests two alternative pathways of assembly and activation in vivo. ICE is homologous to the C. elegans cell death gene product, CED-3, and these may represent a novel class of cytoplasmic cysteine proteases that are important in programmed cell death (apoptosis). Conservation among members of the ICE/CED-3 family of the amino acids that form the active site region of ICE supports the hypothesis that they share functional similarities.	BASF BIORES CORP, WORCESTER, MA 01605 USA	BASF	WALKER, NPC (corresponding author), BASF AG, MAIN LAB, D-67056 LUDWIGSHAFEN, GERMANY.		Somani, ally-khan/AAA-9656-2020	Somani, Ally-Khan/0000-0003-2166-4896				BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P11; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; DRENTH J, 1972, EUR J BIOCHEM, V26, P177, DOI 10.1111/j.1432-1033.1972.tb01754.x; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NETT MA, 1992, J IMMUNOL, V149, P3254; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; POWERS JC, 1977, CHEM BIOCH AMINO ACI, V4, P65; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STERNBERG MJE, 1977, J MOL BIOL, V110, P269, DOI 10.1016/S0022-2836(77)80072-7; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	60	518	556	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					343	352		10.1016/0092-8674(94)90303-4	http://dx.doi.org/10.1016/0092-8674(94)90303-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044845				2022-12-28	WOS:A1994NZ24200017
J	AICKIN, R; HILL, D; KEMP, A				AICKIN, R; HILL, D; KEMP, A			MEASLES IMMUNIZATION IN CHILDREN WITH ALLERGY TO EGG	BRITISH MEDICAL JOURNAL			English	Article							RUBELLA VACCINE; MUMPS; IMMUNIZATION; HYPERSENSITIVITY; PROTEIN; IGE	Objective-To examine the occurrence of adverse reactions to measles vaccine given as a single dose to children with egg allergy, and to determine if the administration of single dose to children with a positive result in an intradermal skin prick test with the vaccine is associated with adverse reactions, Design-Review of results of immunisation and prospective study of 96 consecutively presenting children given intradermal skin testing with the vaccine. Setting-Children's allergy centre. Subjects-410 children sensitive to egg referred to the allergy unit for advice about measles immunisation. Main outcome measures-Nature and severity of reactions associated with the administration of measles vaccine. Results-All children had a positive result in a skin prick test with egg white, and five had a positive result in a skin prick test with vaccine. Of 96 consecutive children, 46 had a positive result in an intradermal test with vaccine. After immunisation with a full dose (0.5 ml) of vaccine adverse reactions were associated with a mild reaction in four children, none of whom required treatment. Only one of the 46 children with a positive result in an intradermal vaccine skin test had a reaction associated with vaccine administration. None of the children with a positive result in a skin prick test with measles vaccine reacted to the vaccine. The rate of minor reactions to the vaccine not requiring treatment was 0.98% (95% confidence interval 0.27% to 2.48%) and serious reactions requiring treatment was 0% (0% to 0.9%). Conclusion-Chiidren with IgE mediated allergic reactions to egg protein should be investigated and managed by practitioners with special knowledge in this subject. Measles immunisation should be performed in a setting where any adverse reactions can be dealt with appropriately. Skin tests and measles vaccine and desensitisation are not necessary.	ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne								BECK SA, 1991, PEDIATRICS, V88, P913; BRUNO G, 1990, LANCET, V335, P739, DOI 10.1016/0140-6736(90)90863-Z; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KAMIN PB, 1963, JAMA-J AM MED ASSOC, V185, P647, DOI 10.1001/jama.1963.03060080043012; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KEMP A, 1990, AM J DIS CHILD, V144, P33, DOI 10.1001/archpedi.1990.02150250039027; LAVI S, 1990, JAMA-J AM MED ASSOC, V263, P269, DOI 10.1001/jama.263.2.269; MCEWEN J, 1983, MED J AUSTRALIA, V2, P503, DOI 10.5694/j.1326-5377.1983.tb122619.x; PUVYADA L, 1993, PEDIATRICS, V91, P835; STIEHM ER, 1990, AM J DIS CHILD, V144, P32, DOI 10.1001/archpedi.1990.02150250034026; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANASPEREN PP, 1981, MED J AUSTRALIA, V2, P330; 1989, PRODUCT INFORMATION; 1991, REPORT COMMITTEE INF	17	52	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					223	225		10.1136/bmj.309.6949.223	http://dx.doi.org/10.1136/bmj.309.6949.223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069138	Green Published			2022-12-28	WOS:A1994NZ18000013
J	MACLENNAN, ICM; DRAYSON, M; DUNN, J				MACLENNAN, ICM; DRAYSON, M; DUNN, J			MULTIPLE-MYELOMA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BONE-MARROW TRANSPLANTATION; CONVENTIONAL INDUCTION CHEMOTHERAPY; REQUIRING PROLONGED OBSERVATION; COMBINATION CHEMOTHERAPY; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY; MAINTENANCE TREATMENT; AGGRESSIVE MYELOMA; MELPHALAN; PREDNISONE	Multiple myeloma occurs in over 2000 new patients in England and Wales each year. It presents most frequently as bone pain and patients tend to become dehydrated and may develop renal failure. No available treatment is curative, but about two thirds of patients achieve a stable response with low dose combination chemotherapy. Combination chemotherapy including doxorubicin and carmustine with the alkylating agents cyclophosphamide and melphalan achieve a higher stable response rate than conventional treatment with melphalan and prednisone without additional haematological toxicity. These responses are associated with loss of bone pain and patients remain symptom free for months without further treatment. Relapse occurs on average in a little under two years and, though second responses are frequently obtained, the disease eventually becomes refractory. This paper looks at who should be treated and the benefits that may be expected from the treatments available.	UNIV BIRMINGHAM, SCH MED, CANC RES CAMPAIGN, TRIALS UNIT, BIRMINGHAM, W MIDLANDS, ENGLAND	University of Birmingham	MACLENNAN, ICM (corresponding author), UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.			Drayson, Mark/0000-0002-1528-7564; Dunn, Janet/0000-0001-7313-4446				ALBERTS DS, 1976, LANCET, V1, P926; ALEXANIAN R, 1968, BLOOD, V31, P1; ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ANDERSON KC, 1991, BLOOD, V77, P712; ATTAL M, 1991, BONE MARROW TRANSPL, V8, P125; ATTAL M, 1992, BLOOD, V79, P1130, DOI 10.1182/blood.V79.5.1130.bloodjournal7951130; BALDINI L, 1991, CANCER-AM CANCER SOC, V68, P62, DOI 10.1002/1097-0142(19910701)68:1<62::AID-CNCR2820680112>3.0.CO;2-6; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BELCH A, 1988, BRIT J CANCER, V57, P94, DOI 10.1038/bjc.1988.17; BENSINGER WI, 1992, J CLIN ONCOL, V10, P1492, DOI 10.1200/JCO.1992.10.9.1492; BERGSAGEL DE, 1988, HEMATOL ONCOL, V6, P159, DOI 10.1002/hon.2900060216; BLADE J, 1993, J CLIN ONCOL, V11, P1165, DOI 10.1200/JCO.1993.11.6.1165; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; BOCCADORO M, 1984, BRIT J HAEMATOL, V58, P689, DOI 10.1111/j.1365-2141.1984.tb06116.x; COOPER EH, 1984, J CLIN PATHOL, V37, P852, DOI 10.1136/jcp.37.8.852; CUZICK J, 1985, BRIT J CANCER, V52, P1, DOI 10.1038/bjc.1985.140; DURIE BGM, 1986, J CLIN ONCOL, V4, P1227, DOI 10.1200/JCO.1986.4.8.1227; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; FRIEDENBERG WR, 1991, AM J HEMATOL, V36, P171, DOI 10.1002/ajh.2830360303; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; GREIPP PR, 1983, BLOOD, V62, P166; HJORTH M, 1990, BRIT J HAEMATOL, V74, P185, DOI 10.1111/j.1365-2141.1990.tb02564.x; HOOGSTRATEN B, 1967, BLOOD-J HEMATOL, V30, P74, DOI 10.1182/blood.V30.1.74.74; JAGANNATH S, 1992, BLOOD, V80, P1666; Joshua D., 1991, HEMATOL REV, V5, P59; KELLY KA, 1988, HEMATOL ONCOL, V6, P131, DOI 10.1002/hon.2900060213; KYLE RA, 1980, NEW ENGL J MED, V302, P1347, DOI 10.1056/NEJM198006123022405; LUDWIG H, 1991, EUR J CANCER, V27, pS40, DOI 10.1016/0277-5379(91)90570-4; MACLENNAN ICM, 1985, BRIT J CANCER, V52, P153, DOI 10.1038/bjc.1985.171; MACLENNAN ICM, 1988, HEMATOL ONCOL, V6, P145, DOI 10.1002/hon.2900060215; MACLENNAN ICM, 1992, LANCET, V339, P200, DOI 10.1016/0140-6736(92)90004-M; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MANSI J, 1992, J CLIN ONCOL, V10, P1569, DOI 10.1200/JCO.1992.10.10.1569; NORFOLK DR, 1989, HEMATOL ONCOL, V7, P61, DOI 10.1002/hon.2900070107; PALMER M, 1989, BRIT J CANCER, V59, P110, DOI 10.1038/bjc.1989.22; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; REECE DE, 1993, BONE MARROW TRANSPL, V11, P139; SAVAGE DG, 1982, ANN INTERN MED, V96, P47, DOI 10.7326/0003-4819-96-1-47; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; TURA S, 1992, HEMATOL ONCOL CLIN N, V6, P425, DOI 10.1016/S0889-8588(18)30354-X; WESTIN J, 1991, EUR J CANCER, V27, pS45, DOI 10.1016/0277-5379(91)90571-T; 1992, MORTALITY STATISTICS, P18; 1984, BRIT MED J, V228, P1411; 1980, BRIT J CANCER, V42, P831; 1975, ARCH INTERN MED, V135, P147	47	39	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1033	1036		10.1136/bmj.308.6935.1033	http://dx.doi.org/10.1136/bmj.308.6935.1033			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8068084	Green Published			2022-12-28	WOS:A1994NH08900029
J	BEAL, AL; CERRA, FB				BEAL, AL; CERRA, FB			MULTIPLE ORGAN FAILURE SYNDROME IN THE 1990S - SYSTEMIC INFLAMMATORY RESPONSE AND ORGAN DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RESPIRATORY-DISTRESS SYNDROME; SURGICAL INTENSIVE-CARE; CRITICALLY ILL PATIENTS; TUMOR NECROSIS FACTOR; ACUTE-PHASE RESPONSE; OXYGEN DELIVERY; SEPTIC SHOCK; DOUBLE-BLIND; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT	Objective.-This review of the systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) provides an overview of a common but complex problem found in critically ill patients. It emphasizes definitions, common clinical patterns, metabolic responses, and pathophysiological changes. A brief discussion of treatment concepts is also included. Data Sources.-Data for this review were gathered from peer-reviewed journals, review articles by experts in SIRS/MODS, and selections from reference volumes written on SIRS/MODS. Study Selection.-Reference selections were chosen on the basis of quality of research. Peer-reviewed journals were given primary consideration. Those review articles cited were felt to be essential to any discussion of SIRS/MODS. Data Extraction.-Where possible, randomized, controlled, prospective studies were reviewed and conclusions used in this overview of SIRS/MODS. Conclusion.-Our ability to care for critically ill patients has led to a new problem, SIRS and eventually MODS, which may become progressive organ failure and death. Unfortunately, these conditions are extremely frequent and carry high mortality rates. Increased oxygen consumption demands highlight the physiological response. The typical metabolic responses are characterized by hyperglycemia and accelerated protein catabolism. Unrecognized perfusion deficits, an uncontrolled septic focus, a persistent source of inflammation, or injured tissue is commonly present with SIRS/MODS and should be corrected. Restoration of oxygen transport and metabolic support are also important components of treatment. The cause of SIRS/MODS is complex and not fully understood, but multiple mediators and stimulated macrophages likely are important components and areas where treatment may well be focused.	UNIV MINNESOTA,SCH MED,DEPT SURG,406 HARVARD ST SE,BOX 42,MINNEAPOLIS,MN 55455; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital								AIKAWA N, 1987, BURNS, V13, P103, DOI 10.1016/0305-4179(87)90097-0; ALEXANDER JW, 1986, ANN SURG, V204, P1, DOI 10.1097/00000658-198607000-00001; ALLARDYCE DB, 1987, AM J SURG, V154, P295, DOI 10.1016/0002-9610(89)90614-4; ANDERSON BO, 1991, SURG GYNECOL OBSTET, V172, P415; ARCHIE JP, 1981, ANN SURG, V193, P296, DOI 10.1097/00000658-198103000-00008; ASHBAUGH DG, 1967, LANCET, V2, P319; ASTIZ ME, 1987, CRIT CARE MED, V15, P26, DOI 10.1097/00003246-198701000-00005; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BERG RD, 1988, ARCH SURG-CHICAGO, V123, P1359; BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BERSTEN A, 1989, CRIT CARE CLIN, V5, P233; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BILLIAR TR, 1988, SURGERY, V104, P343; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1991, HOSP PRACT, V26, P101; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; BORDER JR, 1976, SURG CLIN N AM, V56, P1147; BUMASCHNY E, 1988, ARCH SURG-CHICAGO, V123, P722; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; CERRA F, 1987, ANN SURG, V205, P282, DOI 10.1097/00000658-198703000-00011; Cerra F B, 1989, Prog Clin Biol Res, V308, P563; CERRA FB, 1987, SURGERY, V101, P1; CERRA FB, 1979, J TRAUMA, V19, P621, DOI 10.1097/00005373-197908000-00010; CERRA FB, 1984, ANN SURG, V199, P286, DOI 10.1097/00000658-198403000-00007; CERRA FB, 1990, CRIT CARE MED, V18, pS154; CERRA FB, 1990, J TRAUMA, V30, pS169; CERRA FB, 1988, SURGERY, V104, P727; CERRA FB, 1983, CRIT CARE MED, V11, P775, DOI 10.1097/00003246-198310000-00003; CERRA FB, 1990, ARCH SURG-CHICAGO, V125, P519; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CERRA FB, 1979, ANN SURG, V190, P577, DOI 10.1097/00000658-197911000-00004; CERRA FB, 1991, NUTRITION, V7, P193; CERRA FB, 1992, ARCH SURG-CHICAGO, V127, P163; CERRA FB, 1989, NEW HORIZONS MULTIPL; CIPOLLE MD, 1993, CRIT CARE CLIN, V9, P261, DOI 10.1016/S0749-0704(18)30196-9; CLOWES GHA, 1976, SURG CLIN N AM, V56, P1169; COOK JA, 1989, NEW HORIZONS MULTIPL, P101; DAHN MS, 1987, SURGERY, V101, P69; DALY JM, 1992, SURGERY, V112, P56; DANEK SJ, 1980, AM REV RESPIR DIS, V122, P387; DEITCH EA, 1987, ANN SURG, V205, P681, DOI 10.1097/00000658-198706000-00010; DEUTSCHMAN CS, 1987, ARCH SURG-CHICAGO, V122, P21; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DINARELLO CA, 1991, BLOOD, V77, P1627; DONG YL, 1992, BURNS, V18, P283, DOI 10.1016/0305-4179(92)90148-N; DORINSKY PM, 1989, CHEST, V96, P885, DOI 10.1378/chest.96.4.885; EISEMAN B, 1977, SURG GYNECOL OBSTET, V144, P323; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; EYER SD, 1987, WORLD J SURG, V11, P241, DOI 10.1007/BF01656408; FAIST E, 1983, J TRAUMA, V23, P775, DOI 10.1097/00005373-198309000-00002; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; FRASER I, 1984, JPEN-PARENTER ENTER, V8, P381, DOI 10.1177/0148607184008004381; FRY DE, 1980, ARCH SURG-CHICAGO, V115, P136; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GORIS FJA, 1987, PROG CLIN BIOL RES, V236, P3; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GORIS RJA, 1982, J TRAUMA, V22, P141, DOI 10.1097/00005373-198202000-00011; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GUTIERREZ G, 1989, CRIT CARE CLIN, V5, P271; HAMAWY KJ, 1985, JPEN-PARENTER ENTER, V9, P559, DOI 10.1177/0148607185009005559; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; HANKELN KB, 1991, CRIT CARE MED, V19, P642, DOI 10.1097/00003246-199105000-00010; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HENAO FJ, 1991, J TRAUMA, V31, P74, DOI 10.1097/00005373-199101000-00014; HERTZ M, 1989, NEW HORIZONS MULTIPL, P217; HUNT C E, 1981, Progress in Lipid Research, V20, P199, DOI 10.1016/0163-7827(81)90037-0; KELLER GA, 1985, ANN SURG, V201, P87, DOI 10.1097/00000658-198501000-00013; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KINSELLA JE, 1990, CRIT CARE MED, V18, pS94; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KORIMAN K, 1985, AM REV RESPIR DIS, V132, P109; KRUSE JA, 1990, CHEST, V98, P959, DOI 10.1378/chest.98.4.959; LAMY M, 1989, NEW HORIZONS MULTIPL, P193; MACLEAN LD, 1967, ANN SURG, V166, P543, DOI 10.1097/00000658-196710000-00004; MADOFF RD, 1985, ARCH SURG-CHICAGO, V120, P698; MAIER RV, 1984, J SURG RES, V36, P362, DOI 10.1016/0022-4804(84)90112-4; MANSHIP L, 1984, AM SURGEON, V50, P94; MARSHALL JC, 1988, ARCH SURG-CHICAGO, V123, P309; MARSHALL WG, 1983, J TRAUMA, V23, P102, DOI 10.1097/00005373-198302000-00005; MCFADDEN DW, 1991, PANCREAS, V6, pS37, DOI 10.1097/00006676-199101001-00007; MEAKINS JL, 1990, J TRAUMA, V30, pS165; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; NORTON LW, 1985, AM J SURG, V149, P347, DOI 10.1016/S0002-9610(85)80105-7; NUYTINCK JKS, 1986, ARCH SURG-CHICAGO, V121, P886; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; PALMER RMJ, 1993, ARCH SURG-CHICAGO, V128, P396; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1988, AM REV RESPIR DIS, V138, P724, DOI 10.1164/ajrccm/138.3.724; PINE RW, 1983, ARCH SURG-CHICAGO, V118, P243; POLK HC, 1977, SURGERY, V81, P310; RAFFIN T A, 1989, American Review of Respiratory Disease, V140, pS28; REVHAUG A, 1988, ARCH SURG-CHICAGO, V123, P162; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; SCHUMACKER PT, 1989, CRIT CARE CLIN, V5, P255; SHOEMAKER WC, 1983, AM J SURG, V146, P43, DOI 10.1016/0002-9610(83)90257-X; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIEGEL JH, 1979, SURGERY, V86, P163; SIEGEL JH, 1980, J TRAUMA, V20, P558, DOI 10.1097/00005373-198007000-00005; TILNEY NL, 1973, ANN SURG, V178, P117, DOI 10.1097/00000658-197308000-00001; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; TUCHSCHMIDT J, 1991, CRIT CARE MED, V19, P664, DOI 10.1097/00003246-199105000-00013; VALLANCE P, 1989, LANCET, V2, P997; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANSAENE HF, 1992, CRIT CARE MED, V20, P691, DOI 10.1097/00003246-199205000-00024; VERMEIJ CG, 1991, CHEST, V99, P1438, DOI 10.1378/chest.99.6.1438; VINCENT JL, 1990, AM REV RESPIR DIS, V142, P2, DOI 10.1164/ajrccm/142.1.2; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WILES JB, 1980, CRIT CARE MED, V8, P55, DOI 10.1097/00003246-198002000-00001; WYSOCKI M, 1992, CHEST, V102, P221, DOI 10.1378/chest.102.1.221; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; Zimmermann T, 1989, Prog Clin Biol Res, V308, P291	124	443	486	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					226	233		10.1001/jama.271.3.226	http://dx.doi.org/10.1001/jama.271.3.226			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8080494				2022-12-28	WOS:A1994MQ64500038
J	MCCLELLAN, M; MCNEIL, BJ; NEWHOUSE, JP				MCCLELLAN, M; MCNEIL, BJ; NEWHOUSE, JP			DOES MORE INTENSIVE TREATMENT OF ACUTE MYOCARDIAL-INFARCTION IN THE ELDERLY REDUCE MORTALITY - ANALYSIS USING INSTRUMENTAL VARIABLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BYPASS GRAFT-SURGERY; IMMEDIATE ANGIOPLASTY; HEALTH-CARE; MANAGEMENT; OUTCOMES; TRIALS; RATES; QUALITY; VOLUME	Objective.-To determine the effect of more intensive treatments on mortality in elderly patients with acute myocardial infarction (AMI). Design.-Analysis of incremental treatment effects using differential distances as instrumental variables to account for unobserved case-mix variation (selection bias) in observational Medicare claims data (1987 through 1991). Main Outcome Measures.-Survival to 4 years after AMI. Results.-Patients who receive different treatments differ in observable and unobservable health characteristics, biasing estimates of treatment effects based on standard methods of adjusting for observable differences. Patients' differential distances to alternative types of hospitals are strong independent predictors of how intensively an AMI patient will be treated and appear uncorrelated with health status. Thus, differential distances approximately randomize patients to different likelihoods of receiving intensive treatments. Comparisons of patient groups that differ only in differential distances show that the impact on mortality at 1 to 4 years after AMI of the incremental (''marginal'') use of invasive procedures in Medicare patients was at most 5 percentage points; this gain was achieved during the first day of hospitalization and therefore appears attributable to treatments other than the procedures. Admission to a hospital treating a high volume of AMI patients was associated with an effect on mortality at 4 years of less than 1 percentage point, again arising on day 1. Patients living in rural areas experienced acute mortality that was an additional 0.6 percentage-point higher, after controlling for less access to intensive treatments. Conclusions.-For elderly patients with AMI, the aspects of treatment most affecting long-term survival relate to care within the first 24 hours of admission. The survival benefits from greater use of catheterization and revascularization procedures appear minimal in marginal patients.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University	MCCLELLAN, M (corresponding author), NATL BUR ECON RES,1050 MASSACHUSETTS AVE,CAMBRIDGE,MA 02138, USA.		Newhouse, Joseph/AGJ-5632-2022		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS007638, R01HS006341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000186] Funding Source: NIH RePORTER; AHRQ HHS [R03-HS07638-01, R0I-HS06341] Funding Source: Medline; NIA NIH HHS [T32-AG00186-03] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BLUMBERG MS, 1987, HEALTH SERV RES, V21, P715; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; CHAMBERLAIN G, 1987, J ECONOMETRICS, V34, P305, DOI 10.1016/0304-4076(87)90015-7; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRADY ML, 1992, AHCPR920056 AG HLTH; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; IMBENS A, 1994, ECONOMETRICA, V62, P467; MCCLELLAN MB, 1994, MARGINAL BENEFITS ME; MCCLELLAN MB, 1994, EFFECTS HOSPITAL TEC; NEWEY WK, 1985, ECONOMETRICA, V53, P1047, DOI 10.2307/1911011; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RJ Bowden, 1984, INSTRUMENTAL VARIABL; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Wagner D P, 1986, Health Aff (Millwood), V5, P148, DOI 10.1377/hlthaff.5.2.148; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YUSUF S, 1990, CIRCULATION, V82, P117; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1992, C PROFILING WASHINGT	34	627	630	4	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					859	866		10.1001/jama.272.11.859	http://dx.doi.org/10.1001/jama.272.11.859			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	8078163				2022-12-28	WOS:A1994PG18200024
J	RAGSDALE, DS; MCPHEE, JC; SCHEUER, T; CATTERALL, WA				RAGSDALE, DS; MCPHEE, JC; SCHEUER, T; CATTERALL, WA			MOLECULAR DETERMINANTS OF STATE-DEPENDENT BLOCK OF NA+ CHANNELS BY LOCAL-ANESTHETICS	SCIENCE			English	Article							SQUID GIANT-AXONS; SOMATIC-CELL LINE; SODIUM-CHANNELS; RAT-BRAIN; MYELINATED NERVE; POTASSIUM CHANNELS; SLOW INACTIVATION; GATING PROPERTIES; IONIC CURRENTS; ALPHA-SUBUNIT	Sodium ion (Na+) channels, which initiate the action potential in electrically excitable cells, are the molecular targets of local anesthetic drugs. Site-directed mutations in transmembrane segment S6 of domain IV of the Na+ channel alpha subunit from rat brain selectively modified drug binding to resting or to open and inactivated channels when expressed in Xenopus oocytes. Mutation F1764A, near the middle of this segment, decreased the affinity of open and inactivated channels to 1 percent of the wild-type value, resulting in almost complete abolition of both the use-dependence and voltage-dependence of drug block, whereas mutation N1769A increased the affinity of the resting channel 15-fold. Mutation I1760A created an access pathway for drug molecules to reach the receptor site from the extracellular side. The results define the location of the local anesthetic receptor site in the pore of the Na+ channel and identify molecular determinants of the state-dependent binding of local anesthetics.			RAGSDALE, DS (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NHLBI NIH HHS [P01-HL44948] Funding Source: Medline; NINDS NIH HHS [R01-NS15751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN WJ, 1969, J GEN PHYSIOL, V54, P589, DOI 10.1085/jgp.54.5.589; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BEAN BP, 1983, J GEN PHYSIOL, V81, P613, DOI 10.1085/jgp.81.5.613; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOKESCH PM, 1986, J PHARMACOL EXP THER, V237, P773; BRISMAR T, 1977, J PHYSIOL-LONDON, V270, P283, DOI 10.1113/jphysiol.1977.sp011952; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CAHALAN MD, 1979, BIOPHYS J, V27, P39, DOI 10.1016/S0006-3495(79)85201-7; CAHALAN MD, 1978, BIOPHYS J, V23, P285, DOI 10.1016/S0006-3495(78)85449-6; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; CHANDLER WK, 1970, J PHYSIOL-LONDON, V211, P707, DOI 10.1113/jphysiol.1970.sp009300; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; COURTNEY KR, 1975, J PHARMACOL EXP THER, V195, P225; COURTNEY KR, 1988, J MOL CELL CARDIOL, V20, P465; FOX JM, 1976, BIOCHIM BIOPHYS ACTA, V426, P232, DOI 10.1016/0005-2736(76)90334-5; FRAZIER DT, 1970, J PHARMACOL EXP THER, V171, P45; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; MCPHEE JC, IN PRESS P NATL ACAD; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; QUANDT FN, 1987, J PHYSIOL-LONDON, V392, P563, DOI 10.1113/jphysiol.1987.sp016797; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUDY B, 1978, J PHYSIOL-LONDON, V283, P1; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHELDON RS, 1991, MOL PHARMACOL, V39, P609; STARMER CF, 1990, AM J PHYSIOL, V259, pH626, DOI 10.1152/ajpheart.1990.259.2.H626; STARMER CF, 1986, BIOPHYS J, V49, P913, DOI 10.1016/S0006-3495(86)83719-5; STARMER CF, 1986, AM J PHYSIOL, V251, pH848, DOI 10.1152/ajpheart.1986.251.4.H848; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P9203; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; YEH JZ, 1985, BIOPHYS J, V47, P685, DOI 10.1016/S0006-3495(85)83965-5; ZAMPONI GW, 1993, BIOPHYS J, V65, P2335, DOI 10.1016/S0006-3495(93)81292-X	47	680	688	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1724	1728		10.1126/science.8085162	http://dx.doi.org/10.1126/science.8085162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085162				2022-12-28	WOS:A1994PG28400036
J	RUBENSTEIN, LZ; JOSEPHSON, KR; ROBBINS, AS				RUBENSTEIN, LZ; JOSEPHSON, KR; ROBBINS, AS			FALLS IN THE NURSING-HOME	ANNALS OF INTERNAL MEDICINE			English	Article							TERM-CARE FACILITY; ELDERLY PEOPLE; POSTURAL HYPOTENSION; RECURRENT FALLS; RISK-FACTORS; POPULATION; RESIDENTS; RESTRAINTS; INJURIES; PATIENT	Objective: To review the epidemiology and causes of falls and fall-related injuries in nursing homes and to provide clinicians with a structured framework to evaluate and treat nursing home residents at risk for falls. Data Sources: All large-scale published studies documenting incidence, causes, risk factors, and preventive strategies for falls in nursing homes were reviewed. Results: The mean incidence of falls in nursing homes is 1.5 falls per bed per year (range, 0.2 to 3.6 falls). The most common precipitating causes include gait and balance disorders, weakness, dizziness, environmental hazards, confusion, visual impairment, and postural hypotension. The most important underlying risk factors for falls and injuries include some of these same items and others, such as lower-extremity weakness, gait and balance instability, poor vision, cognitive and functional impairment, and sedating and psychoactive medications. Many strategies for the prevention of falls have been tried, with mixed success. The most successful consider the multifactorial causes of falls and include interventions to improve strength and functional status, reduce environmental hazards, and allow staff to identify and monitor high-risk residents. Strategies that reduce mobility through use of restraints have been shown to be more harmful than beneficial and should be avoided. Conclusions: A focused history and physical examination after a fall can usually determine both the immediate underlying causes of the fall and contributing risk factors. In addition, regular evaluations in the nursing home can help identify patients at high risk who can then be targeted for specific treatment and prevention strategies.			RUBENSTEIN, LZ (corresponding author), VET AFFAIRS MED CTR, CTR GERIATR RES EDUC & CLIN, 16111 PLUMMER ST, SEPULVEDA, CA 91343 USA.			Rubenstein, Laurence/0000-0001-5910-0266				AISEN PS, 1992, INT J GERIATR PSYCH, V7, P709, DOI 10.1002/gps.930071004; ASHLEY M J, 1977, Age and Ageing, V6, P211, DOI 10.1093/ageing/6.4.211; Baker S P, 1985, Clin Geriatr Med, V1, P501; BERRY G, 1981, J AM GERIATR SOC, V29, P322, DOI 10.1111/j.1532-5415.1981.tb01273.x; Berryman E, 1989, Geriatr Nurs, V10, P199, DOI 10.1016/S0197-4572(89)80203-4; BLAKE C, 1986, PUBLIC HEALTH, V100, P385, DOI 10.1016/S0033-3506(86)80101-9; Brocklehurst J C, 1978, Age Ageing, V7, P2; Cacha C A, 1979, J Am Health Care Assoc, V5, P29; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; CLARK ANG, 1968, GERONTOL CLIN, V10, P257, DOI 10.1159/000245191; CONNELL BR, 1993, GERONTOLOGIST, V33, P58; DUBER NP, 1988, HOSP COMMUNITY PSYCH, V39, P79; EVANS LK, 1991, ADV LONG TERM CARE, P81; EXTONSMITH AN, 1977, CARE ELDERLY M CHALL, P41; Feist R R, 1978, J Gerontol Nurs, V4, P15; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FROEHLING DA, 1994, JAMA-J AM MED ASSOC, V271, P385, DOI 10.1001/jama.271.5.385; GOSTYNSKI M, 1991, SOZ PRAVENTIV MED, V36, P341, DOI 10.1007/BF01368742; GRANEK E, 1987, J AM GERIATR SOC, V35, P503, DOI 10.1111/j.1532-5415.1987.tb01395.x; Gross Y T, 1990, J Gerontol Nurs, V16, P20; GRYFE C I, 1977, Age and Ageing, V6, P201, DOI 10.1093/ageing/6.4.201; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; HING EE, 1989, VITAL HLTH STATIS 13, V97; HOGUE CC, 1982, J AM GERIATR SOC, V30, P183, DOI 10.1111/j.1532-5415.1982.tb01302.x; HOGUE CC, 1982, J AM GERIATR SOC, V30, P276, DOI 10.1111/j.1532-5415.1982.tb07102.x; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518, DOI 10.1001/archinte.150.7.1518; KAPP MB, 1992, J LEGAL MED, V13, P1, DOI 10.1080/01947649209510872; KERMAN M, 1990, MT SINAI J MED, V57, P343; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LIPSITZ LA, 1985, Q J MED, V55, P45; LIPSITZ LA, 1986, J AM GERIATR SOC, V34, P267, DOI 10.1111/j.1532-5415.1986.tb04222.x; LIPSITZ LA, 1991, J GERONTOL, V46, pM114, DOI 10.1093/geronj/46.4.M114; Louis M, 1983, J Gerontol Nurs, V9, P143; LOUIS M, 1983, J GERONTOL NURS, V9, P156; LUCHT U, 1971, ACTA SOCIO-MED SCAND, V3, P105; MADER SL, 1987, JAMA-J AM MED ASSOC, V258, P1511, DOI 10.1001/jama.258.11.1511; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; MILLER MB, 1979, CURRENT ISSUES CLIN, P97; MORFITT JM, 1983, PUBLIC HEALTH, V97, P115, DOI 10.1016/S0033-3506(83)80008-0; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MURRAY MP, 1980, PHYS THER, V60, P412, DOI 10.1093/ptj/60.4.412; MYERS AH, 1991, AM J EPIDEMIOL, V133, P1179, DOI 10.1093/oxfordjournals.aje.a115830; NEUFELD RR, 1991, GERONTOLOGIST, V31, P120, DOI 10.1093/geront/31.1.120; NORRE ME, 1988, J AM GERIATR SOC, V36, P425; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; PABLO RY, 1977, CAN J PUBLIC HEALTH, V68, P237; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; Rhymes J, 1988, Clin Geriatr Med, V4, P613; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; ROBBINS AS, 1984, J AM GERIATR SOC, V32, P769, DOI 10.1111/j.1532-5415.1984.tb04178.x; ROBBINS S, 1992, J AM GERIATR SOC, V40, P1089, DOI 10.1111/j.1532-5415.1992.tb01795.x; ROSADO JA, 1989, J AM GERIATR SOC, V37, P430, DOI 10.1111/j.1532-5415.1989.tb02639.x; RUBENSTEIN LZ, 1988, J AM GERIATR SOC, V36, P266, DOI 10.1111/j.1532-5415.1988.tb01811.x; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SCHMID NA, 1990, MIL MED, V155, P202, DOI 10.1093/milmed/155.5.202; SCHNELLE JF, 1992, GERONTOLOGIST, V32, P767, DOI 10.1093/geront/32.6.767; SHELDON JH, 1960, BRIT MED J, V2, P1685, DOI 10.1136/bmj.2.5214.1685; STEWART RB, 1992, J AM GERIATR SOC, V40, P1217, DOI 10.1111/j.1532-5415.1992.tb03645.x; SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441; Svensson M L, 1991, Aging (Milano), V3, P181; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1992, ANN INTERN MED, V116, P369, DOI 10.7326/0003-4819-116-5-369; TINETTI ME, 1987, J AM GERIATR SOC, V35, P644, DOI 10.1111/j.1532-5415.1987.tb04341.x; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; TRUEBLOOD P R, 1991, Comprehensive Therapy, V17, P20; WELLS BG, 1985, DRUG INTEL CLIN PHAR, V19, P142; WERNER P, 1994, J AM GERIATR SOC, V42, P321, DOI 10.1111/j.1532-5415.1994.tb01759.x; WHIPPLE RH, 1987, J AM GERIATR SOC, V35, P13, DOI 10.1111/j.1532-5415.1987.tb01313.x; Widder B, 1985, Geriatr Nurs, V6, P287, DOI 10.1016/S0197-4572(85)80068-9; WOLFSON L, 1990, J GERONTOL, V45, pM12, DOI 10.1093/geronj/45.1.M12	71	489	501	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					442	451		10.7326/0003-4819-121-6-199409150-00009	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053619				2022-12-28	WOS:A1994PF33700009
J	GURWITZ, JH; AVORN, J; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H				GURWITZ, JH; AVORN, J; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H			INITIATION OF ANTIHYPERTENSIVE TREATMENT DURING NONSTEROIDAL ANTIINFLAMMATORY DRUG-THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIINFLAMMATORY DRUGS; BLOOD-PRESSURE; ELDERLY PERSONS; ESSENTIAL-HYPERTENSION; PEPTIC-ULCER; RISK; KNEE; OSTEOARTHRITIS; PROSTAGLANDINS; METAANALYSIS	Objective.-To determine whether there is an increased risk for the initiation of antihypertensive therapy in older persons prescribed nonaspirin, nonsteroidal antiinflammatory drugs (NSAIDs). Design.-Case-control study. Setting.-New Jersey Medicaid program. Patients.-Medicaid enrollees aged 65 years and older. The 9411 case patients were newly started on an antihypertensive medication between November 1981 and February 1990. A similar number of controls were randomly selected among other enrollees. Main Outcome Measures.-We used logistic regression to determine the odds ratio for the initiation of antihypertensive therapy in patients using NSAIDs relative to nonusers, after adjusting for age, sex, race, nursing home residence, number of prescriptions filled, intensity of physician utilization, and days hospitalized. Results.-The adjusted odds ratio for the initiation of antihypertensive therapy for recent NSAID users compared with nonusers was 1.66 (95% confidence interval, 1.54 to 1.80). The odds ratio increased with increasing daily NSAID dose: the adjusted odds ratio for users of low average daily doses relative to nonusers was 1.55 (95% Cl, 1.38 to 1.74), that for medium-dose users was 1.64 (95% Cl, 1.44 to 1.87), and that for high-dose users was 1.82 (95% Cl, 1.62 to 2.05). Conclusions.-Use of NSAIDs may increase the risk for initiation of antihypertensive therapy in older persons. Given the high prevalence of NSAID use by elderly persons, this association may have important public health implications for the management of hypertension in the older population.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BROCKTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE ON AGING [K08AG000642, K08AG000510, P30AG008812, P60AG008812] Funding Source: NIH RePORTER; NIA NIH HHS [KO8 AG000642, AG-08812, KO8 AG00510] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Applegate W B, 1992, Clin Geriatr Med, V8, P103; BEERS MH, 1990, J AM GERIATR SOC, V38, P1183, DOI 10.1111/j.1532-5415.1990.tb01496.x; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CHRISCHILLES EA, 1993, J GERONTOL, V48, pM91, DOI 10.1093/geronj/48.3.M91; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; COHEN RA, 1993, VITAL HLTH STAT 3, V29; Cox DR., 1970, ANAL BINARY DATA; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; JOHNSON AG, 1993, BRIT J CLIN PHARMACO, V35, P455, DOI 10.1111/j.1365-2125.1993.tb04169.x; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P160; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; MACKENZIE T, 1984, NEPHRON, V38, P178, DOI 10.1159/000183304; MECONI M, 1987, J AM GERIATR SOC, V35, P239; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; RADACK K, 1987, J GEN INTERN MED, V2, P108, DOI 10.1007/BF02596307; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P84; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STAMLER J, 1991, HYPERTENSION, V18, P95, DOI 10.1161/01.HYP.18.3_Suppl.I95; STOFF JS, 1986, AM J MED, V80, P56, DOI 10.1016/0002-9343(86)90932-0; TAN SY, 1978, PROSTAG OTH LIPID M, V15, P139, DOI 10.1016/S0090-6980(78)80012-4; TRIMARCO B, 1985, AM J CARDIOL, V55, P116, DOI 10.1016/0002-9149(85)90311-X; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1985, SAS USERS GUIDE STAT; 1994, PHYSICIANS DESK REFE; 1992, STAT B METROPOLITAN, V73, P24; 1985, PHYSICIANS DESK REFE; 1985, 3204 US DEP HLTH HUM; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1981, MED LETT DRUGS THER, V23, P1; 1982, MED LETT DRUGS THER, V24, P63	39	158	161	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					781	786		10.1001/jama.272.10.781	http://dx.doi.org/10.1001/jama.272.10.781			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078142				2022-12-28	WOS:A1994PF18800026
J	ROCK, KL; GRAMM, C; ROTHSTEIN, L; CLARK, K; STEIN, R; DICK, L; HWANG, D; GOLDBERG, AL				ROCK, KL; GRAMM, C; ROTHSTEIN, L; CLARK, K; STEIN, R; DICK, L; HWANG, D; GOLDBERG, AL			INHIBITORS OF THE PROTEASOME BLOCK THE DEGRADATION OF MOST CELL-PROTEINS AND THE GENERATION OF PEPTIDES PRESENTED ON MHC CLASS-I MOLECULES	CELL			English	Article							ATP-DEPENDENT PROTEOLYSIS; ANTIGEN PRESENTATION; LYMPHOCYTE-T; HEAVY-CHAINS; COMPLEX; PATHWAY; GENE; DETERMINANTS; EXPRESSION; ANTIBODIES	Reagents that inhibit the ubiquitin-proteasome proteolytic pathway in cells have not been available. Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degradation of protein and ubiquitinated protein substrates by 26S particles. Unlike inhibitors of lysosomal proteolysis, these compounds inhibit the degradation of not only abnormal and short-lived polypeptides but also long-lived proteins in intact cells. We used these agents to test the importance of the proteasome in antigen presentation. When ovalbumin is introduced into the cytosol of lymphoblasts, these inhibitors block the presentation on MHC class I molecules of an ovalbumin-derived peptide by preventing its proteolytic generation. By preventing peptide production from cell proteins, these inhibitors block the assembly of class I molecules. Therefore, the proteasome catalyzes the degradation of the vast majority of cell proteins and generates most peptides presented on MHC class I molecules.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA; MYOGEN INC, CAMBRIDGE, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	ROCK, KL (corresponding author), DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA.		Dick, Lawrence/ABA-8831-2021; Eckhardt, Erik/G-1567-2010	Dick, Larry/0000-0002-6880-0405	NIAID NIH HHS [AI20248] Funding Source: Medline; NIGMS NIH HHS [GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020248, R37AI020248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; CHOMEZ P, 1992, IMMUNOGENETICS, V35, P241, DOI 10.1007/BF00166829; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; FETTEN JV, 1991, J IMMUNOL, V147, P2697; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZATO K, 1981, J IMMUNOL, V126, P317; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1983, J EXP MED, V157, P1618, DOI 10.1084/jem.157.5.1618; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; TAMURA T, 1991, FEBS LETT, V292, P154, DOI 10.1016/0014-5793(91)80856-X; TAWA NE, 1992, AM J PHYSIOL, V263, pE326, DOI 10.1152/ajpendo.1992.263.2.E326; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014	45	2169	2229	1	112	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					761	771		10.1016/S0092-8674(94)90462-6	http://dx.doi.org/10.1016/S0092-8674(94)90462-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087844				2022-12-28	WOS:A1994PG29600006
J	DEYOE, EA; FELLEMAN, DJ; VANESSEN, DC; MCCLENDON, E				DEYOE, EA; FELLEMAN, DJ; VANESSEN, DC; MCCLENDON, E			MULTIPLE PROCESSING STREAMS IN OCCIPITOTEMPORAL VISUAL-CORTEX	NATURE			English	Article							MACAQUE MONKEY; AREA V2; ASSOCIATION CORTEX; STRIATE CORTEX; CONNECTIONS; SEGREGATION; ORGANIZATION; COLOR; ANATOMY; FORM	THE earliest stages of cortical visual processing in areas V1 and V2 of the macaque monkey contain internal subdivisions ('blobs' and 'interblobs' in layer 4B in V1; thin, thick and interstripes in V2) that are selectively interconnected and contain neurons with distinctive visual response properties(1-10). Here ae use anatomical pathway tracing to demonstrate that higher visual areas, V4 and the ventral posterior inferotemporal cortex, each contain anatomical subdivisions that have distinct input and output projections. These findings, in conjunction with others(11-15), suggest that modularity and multistream processing within individual cortical areas are widespread features of neocortical organization.	UNIV TEXAS,SCH MED,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77030; CALTECH,DIV BIOL 21676,PASADENA,CA 91125	University of Texas System; California Institute of Technology	DEYOE, EA (corresponding author), MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DEYOE E A, 1988, Investigative Ophthalmology and Visual Science, V29, P115; DEYOE EA, 1985, NATURE, V317, P58, DOI 10.1038/317058a0; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; DEYOE EA, 1990, VISUAL NEUROSCI, V5, P67, DOI 10.1017/S0952523800000080; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; GOLDMANRAKIC PS, 1982, SCIENCE, V216, P755, DOI 10.1126/science.6177037; GROSSBERG S, 1987, PERCEPT PSYCHOPHYS, V41, P87, DOI 10.3758/BF03204874; HUBEL DH, 1987, J NEUROSCI, V7, P3378; KRUBITZER LA, 1989, BRAIN RES, V478, P161, DOI 10.1016/0006-8993(89)91490-X; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P309; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; Maunsell J H, 1992, Curr Opin Neurobiol, V2, P506, DOI 10.1016/0959-4388(92)90188-Q; MAUNSELL JHR, 1987, A REV NEUROSCI, V10, P353; SHIPP S, 1989, EUR J NEUROSCI, V1, P333, DOI 10.1111/j.1460-9568.1989.tb00799.x; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; TANAKA M, 1990, ANAT EMBRYOL, V181, P19; TOOTELL RBH, 1989, J NEUROSCI, V9, P2620; TSO DY, 1988, J NEUROSCI, V8, P1712; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204; VANESSEN DC, 1982, J NEUROSCI, V2, P265; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; VANESSEN DC, 1994, COGNITIVE NEUROSCIEN, P383; ZEKI S, 1989, EUR J NEUROSCI, V1, P494, DOI 10.1111/j.1460-9568.1989.tb00356.x	30	138	138	2	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					151	154		10.1038/371151a0	http://dx.doi.org/10.1038/371151a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072543				2022-12-28	WOS:A1994PF19100062
J	COHEN, JJ; TODD, JS				COHEN, JJ; TODD, JS			ASSOCIATION-OF-AMERICAN-MEDICAL-COLLEGES AND AMERICAN-MEDICAL-ASSOCIATION JOINT STATEMENT ON PHYSICIAN WORKFORCE PLANNING AND GRADUATE MEDICAL-EDUCATION REFORM POLICIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,OFF EXECUT VICE PRESIDENT,CHICAGO,IL 60610	American Medical Association	COHEN, JJ (corresponding author), ASSOC AMER MED COLL,OFF PRESIDENT,WASHINGTON,DC 20036, USA.								0	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					712	712		10.1001/jama.272.9.712	http://dx.doi.org/10.1001/jama.272.9.712			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064988				2022-12-28	WOS:A1994PE32700017
J	GANEM, JL; KRAKOWER, JK; BERAN, RL				GANEM, JL; KRAKOWER, JK; BERAN, RL			REVIEW OF US MEDICAL-SCHOOL FINANCES, 1992-1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									ASSOC AMER MED COLL,DIV MED STUDENT & RESIDENT EDUC,WASHINGTON,DC 20036	Association of American Medical Colleges	GANEM, JL (corresponding author), ASSOC AMER MED COLL,OPERAT STUDIES SECT,2450 N ST NW,WASHINGTON,DC 20037, USA.								0	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					705	711						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064987				2022-12-28	WOS:A1994PE32700016
J	KATZ, SL; GELLIN, BG				KATZ, SL; GELLIN, BG			MEASLES-VACCINE - DO WE NEED NEW VACCINES OR NEW PROGRAMS	SCIENCE			English	Editorial Material							MORTALITY; TITER		JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205	Johns Hopkins University	KATZ, SL (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710, USA.							CUTTS FT, 1994, B WORLD HEALTH ORGAN, V72, P227; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; Markowitz LE, 1994, VACCINES, P229; PABST HF, 1988, PEDIATR INFECT DIS J, V1, P963; ROTA JS, 1992, VIROLOGY, V188, P135, DOI 10.1016/0042-6822(92)90742-8; WHITTLE HC, 1988, LANCET, V1, P963; 1992, EPI NEWSL        JUN, V14, P2; 1994, B WORLD HEALTH ORGAN, V72, P199	9	21	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1391	1392		10.1126/science.8073281	http://dx.doi.org/10.1126/science.8073281			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073281				2022-12-28	WOS:A1994PE73300033
J	PAULING, L				PAULING, L			MY FIRST 5 YEARS IN SCIENCE	NATURE			English	Editorial Material																		Pauling L., 1939, NATURE CHEM BOND	1	2	2	2	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					10	10		10.1038/371010a0	http://dx.doi.org/10.1038/371010a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072515	Bronze			2022-12-28	WOS:A1994PE38100018
J	NGUYEN, PV; ABEL, T; KANDEL, ER				NGUYEN, PV; ABEL, T; KANDEL, ER			REQUIREMENT OF A CRITICAL PERIOD OF TRANSCRIPTION FOR INDUCTION OF A LATE-PHASE OF LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; NMDA RECEPTOR ACTIVATION; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; MESSENGER-RNA; DENTATE GYRUS	Repeated high-frequency trains of stimuli induce long-term potentiation (LTP) in the CA1 region that persists for up to 8 hours in hippocampal slices and for days in intact animals. This long time course has made LTP an attractive model for certain forms of long-term memory in the mammalian brain. A hallmark of long-term memory in the intact animal is a requirement for transcription, and thus whether the late phase of LTP (L-LTP) requires transcription was investigated here. With the use of different inhibitors, it was found in rat hippocampal slices that the induction of L-LTP [produced either by tetanic stimulation or by application of the cyclic adenosine monophosphate (cAMP) analog Sp-cAMPS (Sp-cyclic adenosine 3',5'-monophosphorothioate)] was selectively prevented when transcription was blocked immediately after tetanization or during application of cAMP. As with behavioral memory, this requirement for transcription had a critical time window, Thus, the late phase of LTP in the CA1 region requires transcription during a critical period, perhaps because cAMP-inducible genes must be expressed during this period.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	NGUYEN, PV (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168 ST, NEW YORK, NY 10032 USA.		Abel, Ted/AAX-2825-2021	Abel, Ted/0000-0003-2423-4592; Nguyen, Peter/0000-0002-1419-5975	NIGMS NIH HHS [GM32099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM WC, 1991, MOL NEUROBIOL, V5, P297, DOI 10.1007/BF02935553; AGRANOFF B, 1970, CHEM MOOD MOTIVATION; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CASTELLUCCI VF, 1988, NEURON, V1, P321, DOI 10.1016/0896-6273(88)90080-3; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DOUGLAS RM, 1975, BRAIN RES, V86, P205, DOI 10.1016/0006-8993(75)90697-6; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Frey Uwe, 1993, Society for Neuroscience Abstracts, V19, P912; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; Huang Y Y, 1994, Learn Mem, V1, P74; HURWITZ J, 1962, P NATL ACAD SCI USA, V48, P1222, DOI 10.1073/pnas.48.7.1222; JEFFERY KJ, 1990, MOL BRAIN RES, V8, P267, DOI 10.1016/0169-328X(90)90039-G; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MATTHIES H, 1989, PROG NEUROBIOL, V32, P277, DOI 10.1016/0301-0082(89)90024-5; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; REICH E, 1961, SCIENCE, V134, P556, DOI 10.1126/science.134.3478.556; REICH E, 1962, P NATL ACAD SCI USA, V48, P1238, DOI 10.1073/pnas.48.7.1238; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Sobell H M, 1973, Prog Nucleic Acid Res Mol Biol, V13, P153, DOI 10.1016/S0079-6603(08)60103-8; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; TAMM I, 1978, ADV VIRUS RES, V22, P188; TEYLER TJ, 1984, BRAIN RES REV, V7, P15, DOI 10.1016/0165-0173(84)90027-4; WORLEY PF, 1993, J NEUROSCI, V13, P4776	45	689	704	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1104	1107		10.1126/science.8066450	http://dx.doi.org/10.1126/science.8066450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066450				2022-12-28	WOS:A1994PC53900040
J	GOODMAN, CS				GOODMAN, CS			THE LIKENESS OF BEING - PHYLOGENETICALLY CONSERVED MOLECULAR MECHANISMS OF GROWTH CONE GUIDANCE	CELL			English	Review							PIONEER AXON MIGRATIONS; CENTRAL-NERVOUS-SYSTEM; C-ELEGANS; GUIDES CELL; DROSOPHILA; PROTEIN; IMMUNOGLOBULIN; INHIBITION; COLLAPSE; NEURITES				GOODMAN, CS (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.							BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V2, P61; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KAPFHAMMER JP, 1986, J NEUROSCI, V6, P2527; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUMSDEN A, 1983, NATURE, V306, P766; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PLACZEK M, 1990, DEVELOPMENT, V110, P19; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J	27	101	101	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					353	356		10.1016/0092-8674(94)90413-8	http://dx.doi.org/10.1016/0092-8674(94)90413-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062381				2022-12-28	WOS:A1994PC40500001
J	MANSOUR, SJ; MATTEN, WT; HERMANN, AS; CANDIA, JM; RONG, S; FUKASAWA, K; VANDEWOUDE, GF; AHN, NG				MANSOUR, SJ; MATTEN, WT; HERMANN, AS; CANDIA, JM; RONG, S; FUKASAWA, K; VANDEWOUDE, GF; AHN, NG			TRANSFORMATION OF MAMMALIAN-CELLS BY CONSTITUTIVELY ACTIVE MAP KINASE KINASE	SCIENCE			English	Article							PROTEIN S6 KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; PHOSPHORYLATION; MOS; ACTIVATION; CASCADE; INVITRO; RAS	Mitogen-activated protein (MAP) kinase kinase (MAPKK) activates MAP kinase in a signal transduction pathway that mediates cellular responses to growth and differentiation factors. Oncogenes such as ras, src, raf, and mos have been proposed to transform cells by prolonging the activated state of MAPKK and of components downstream in the signaling pathway. To test this hypothesis, constitutively active MAPKK mutants were designed that had basal activities up to 400 times greater than that of the unphosphorylated wild-type kinase. Expression of these mutants in mammalian cells activated AP-1-regulated transcription. The cells formed transformed foci, grew efficiently in soft agar, and were highly tumorigenic in nude mice. These findings indicate that constitutive activation of MAPKK is sufficient to promote cell transformation.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM48521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKASAWA K, IN PRESS CELL GROWTH; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, IN PRESS J BIOCH; MARIAS R, 1993, CELL, V73, P381; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RESING KA, UNPUB; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	51	1298	1333	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					966	970		10.1126/science.8052857	http://dx.doi.org/10.1126/science.8052857			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052857				2022-12-28	WOS:A1994PB49900047
J	GALCHEVAGARGOVA, Z; DERIJARD, B; WU, IH; DAVIS, RJ				GALCHEVAGARGOVA, Z; DERIJARD, B; WU, IH; DAVIS, RJ			AN OSMOSENSING SIGNAL-TRANSDUCTION PATHWAY IN MAMMALIAN-CELLS	SCIENCE			English	Article							C-JUN ACTIVITY; ACTIVATION DOMAIN; PHOSPHORYLATION; OSMOREGULATION; KINASE; SERINE-63; YEAST	The osmotic balance between the cytoplasmic and extracellular compartments of cells is critical for the control of cell volume. A mammalian protein kinase, Jnk, which is a distant relative of the mitogen-activated protein kinase group, was activated by phosphorylation on threonine and tyrosine in osmotically shocked cells. The activation of Jnk may be relevant to the biological response to osmotic shock because the expression of human Jnk in the yeast Saccharomyces cerevisiae rescued a defect in growth on hyper-osmolar media. These data indicate that related protein kinases may mediate osmosensing signal transduction in yeast and mammalian cells.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DALLASTA V, 1994, J BIOL CHEM, V269, P10485; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINKENZELLER G, 1994, FEBS LETT, V340, P163, DOI 10.1016/0014-5793(94)80129-0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAMAMURA M, 1992, BRAIN RES, V572, P42, DOI 10.1016/0006-8993(92)90448-I; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JILL LE, 1987, AM J PHYSIOL, V252, pF1; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PAREDES A, 1992, AM J PHYSIOL, V263, pC1282, DOI 10.1152/ajpcell.1992.263.6.C1282; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TILLY BC, 1993, J BIOL CHEM, V268, P19919; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	22	538	556	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					806	808		10.1126/science.8047888	http://dx.doi.org/10.1126/science.8047888			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047888				2022-12-28	WOS:A1994PA37200040
J	CAMILLERI, M; THOMPSON, WG; FLESHMAN, JW; PEMBERTON, JH				CAMILLERI, M; THOMPSON, WG; FLESHMAN, JW; PEMBERTON, JH			CLINICAL MANAGEMENT OF INTRACTABLE CONSTIPATION	ANNALS OF INTERNAL MEDICINE			English	Article							SEVERE IDIOPATHIC CONSTIPATION; PELVIC FLOOR DISORDERS; PUBORECTALIS MUSCLE; OUTLET OBSTRUCTION; DIETARY FIBER; ANAL ENDOSONOGRAPHY; COLONIC MOTILITY; SMALL-BOWEL; TRANSIT; DEFECATION	Purpose: To review current management of intractable constipation. Data Sources: Original articles and reviews published in the English-language literature between 1965 and 1993 identified by MEDLINE search. Verbal feedback from attendees after presentation of the document as a clinical symposium at the 14th International Symposium on Gastrointestinal Motility in September 1993. Study Selection: Key words included constipation, epidemiology, colonic inertia, pseudo-obstruction, pelvic floor dysfunction, and results of therapeutic interventions, particularly the effects of biofeedback training and subtotal colectomy. Results: In most patients, constipation is usually due to lack of dietary fiber and responds to simple measures to correct these factors, often without consulting a physician. In some, probably fewer than 10% of patients who consult their physicians, structural diseases of the colon and rectum, systemic disease, or medications that slow gut transit should be excluded, and regular exercise, dietary fiber, and an osmotic laxative prescribed. In a series of 277 highly selected patients from a tertiary referral center who had intractable constipation, only 29% had a definable abnormality; identification of abnormal transit facilitates selection of patients for further investigations identifying colonic inertia or pelvic floor dysfunction. Conclusion: An algorithmic approach can carefully select patients with intractable constipation for behavioral modification and biofeedback; the long-term outcome is excellent, with at least 75% success in several series. In a minority of patients with slow transit constipation unresponsive to medical treatment, subtotal colectomy with ileorectostomy is indicated and effective.	OTTAWA CIVIC HOSP, OTTAWA K1Y 4E9, ON, CANADA; MAYO CLIN & MAYO FDN, COLON & RECTAL SURG SECT, ROCHESTER, MN 55905 USA; WASHINGTON UNIV, ST LOUIS, MO USA; UNIV OTTAWA, OTTAWA, ON, CANADA	University of Ottawa; Ottawa Hospital Research Institute; Mayo Clinic; Washington University (WUSTL); University of Ottawa	CAMILLERI, M (corresponding author), MAYO CLIN & MAYO FDN, MAYO MED SCH, GASTROENTEROL RES UNIT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ANDORSKY RI, 1990, AM J GASTROENTEROL, V85, P261; [Anonymous], 1992, GASTROENTEROL INT; ASHRAF W, 1994, GASTROENTEROLOGY, V106, pA461; BANNISTER JJ, 1987, GUT, V28, P1246, DOI 10.1136/gut.28.10.1246; BARNES PRH, 1985, BRIT J SURG, V72, P475, DOI 10.1002/bjs.1800720623; BARTOLO DC, 1988, PERSPECT COLON RECTA, V1, P1; BARTRAM CI, 1992, ANN GASTROENT HEPATO, V28, P185; BAZZOCCHI G, 1990, GASTROENTEROLOGY, V98, P686, DOI 10.1016/0016-5085(90)90289-D; BLACKSTONE MO, 1991, LARGE INTESTINE PHYS, P253; BUENO L, 1980, GUT, V21, P480, DOI 10.1136/gut.21.6.480; BURKITT DP, 1972, LANCET, V1, P1408; CAMILLERI M, 1992, GASTROENTEROLOGY, V103, P36, DOI 10.1016/0016-5085(92)91092-I; CAMPBELL AJ, 1993, J EPIDEMIOL COMMUN H, V47, P23, DOI 10.1136/jech.47.1.23; CONNELL AM, 1965, BMJ-BRIT MED J, V2, P1095, DOI 10.1136/bmj.2.5470.1095; CUMMINGS JH, 1984, POSTGRAD MED J, V60, P811, DOI 10.1136/pgmj.60.709.811; DILORENZO C, 1993, GUT, V34, P803, DOI 10.1136/gut.34.6.803; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; ENCK P, 1993, DIGEST DIS SCI, V38, P1953, DOI 10.1007/BF01297069; FELTBERSMA RJF, 1992, DIS COLON RECTUM, V35, P944, DOI 10.1007/BF02253496; FLESHMAN JW, 1989, NETH J SURG, V41, P145; FLESHMAN JW, 1992, DIS COLON RECTUM, V35, P1019, DOI 10.1007/BF02252990; GOEEL R, 1990, RADIOLOGY, V174, P121; GOEI R, 1989, RADIOLOGY, V173, P137, DOI 10.1148/radiology.173.1.2780999; HALLAN RI, 1988, LANCET, V2, P714; HEATON KW, 1992, GUT, V33, P818, DOI 10.1136/gut.33.6.818; HERDMANN J, 1991, AM J PHYSIOL, V260, pG720, DOI 10.1152/ajpgi.1991.260.5.G720; HINTON JM, 1969, GUT, V10, P842, DOI 10.1136/gut.10.10.842; JOHANSON JF, 1989, J CLIN GASTROENTEROL, V11, P525, DOI 10.1097/00004836-198910000-00008; JOHANSON JF, 1990, GASTROENTEROLOGY, V98, P380, DOI 10.1016/0016-5085(90)90828-O; JUHASZ ES, 1993, GASTROENTEROLOGY, V104, pA530; KAMM MA, 1991, INT J COLORECTAL DIS, V6, P49, DOI 10.1007/BF00703962; KAMM MA, 1988, BRIT J SURG, V75, P661, DOI 10.1002/bjs.1800750713; KRONBORG O, 1975, DIS COLON RECTUM, V18, P674, DOI 10.1007/BF02604275; KUIJPERS HC, 1985, DIS COLON RECTUM, V28, P669, DOI 10.1007/BF02553449; KUIJPERS HC, 1990, ANN MED, V22, P405, DOI 10.3109/07853899009147279; LEON SH, 1987, DIGEST DIS SCI, V32, P1249, DOI 10.1007/BF01296374; LOENINGBAUCKE VA, 1987, DIGEST DIS SCI, V32, P1104, DOI 10.1007/BF01300196; LUBOWSKI DZ, 1988, INT J COLORECTAL DIS, V3, P158, DOI 10.1007/BF01648359; MACDONALD L, 1986, FAM PRACT, V3, P80, DOI 10.1093/fampra/3.2.80; MARTELLI H, 1978, GASTROENTEROLOGY, V75, P623; Murtagh J, 1990, Aust Fam Physician, V19, P1693; NARDUCCI F, 1987, GUT, V28, P17, DOI 10.1136/gut.28.1.17; PARKS TG, 1992, WORLD J SURG, V16, P804, DOI 10.1007/BF02066974; PEMBERTON JH, 1990, J GASTROEN HEPATOL, V5, P127, DOI 10.1111/j.1440-1746.1990.tb01786.x; PEMBERTON JH, 1991, ANN SURG, V214, P403, DOI 10.1097/00000658-199110000-00005; PEZIM M, 1987, DIGEST DIS SCI, V32, P924; PEZIM ME, 1993, DIS COLON RECTUM, V36, P484, DOI 10.1007/BF02050015; PRESTON DM, 1984, BRIT J SURG, V71, P547, DOI 10.1002/bjs.1800710726; PRESTON DM, 1985, DIGEST DIS SCI, V30, P413, DOI 10.1007/BF01318172; PROANO M, 1990, AM J PHYSIOL, V258, pG856, DOI 10.1152/ajpgi.1990.258.6.G856; PROHERT CS, IN PRESS GUT; SANDLER RS, 1987, DIGEST DIS SCI, V32, P841, DOI 10.1007/BF01296706; SELVAGGI F, 1990, DIS COLON RECTUM, V33, P698, DOI 10.1007/BF02150748; SHORVON PJ, 1989, GUT, V30, P1737, DOI 10.1136/gut.30.12.1737; SOFFER E, 1993, GASTROENTEROLOGY, V104, pA585; STABILE G, 1991, GUT, V32, P1538, DOI 10.1136/gut.32.12.1538; STEADMAN CJ, 1991, GASTROENTEROLOGY, V101, P373, DOI 10.1016/0016-5085(91)90014-C; STIVLAND T, 1991, GASTROENTEROLOGY, V101, P107, DOI 10.1016/0016-5085(91)90466-X; SWASH M, 1985, J ROY SOC MED, V78, P906, DOI 10.1177/014107688507801105; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P781, DOI 10.1016/0016-5085(93)90896-K; THOENI RF, 1983, RADIOLOGY, V146, P603, DOI 10.1148/radiology.146.3.6600844; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; TUCKER DM, 1981, GASTROENTEROLOGY, V81, P879; VASSALLO M, 1992, GASTROENTEROLOGY, V102, P102, DOI 10.1016/0016-5085(92)91789-7; VONDEROHE M, 1994, IN PRESS NEUROGASTRO; VONDEROHE MR, 1993, NEW ENGL J MED, V329, P1073, DOI 10.1056/NEJM199310073291503; VONDEROHE MR, 1992, MAYO CLIN PROC, V67, P1169, DOI 10.1016/S0025-6196(12)61147-1; VONDEROHE MR, 1994, IN PRESS AM J GASTRO; WALLACE WC, 1969, DIS COLON RECTUM, V12, P196; WASSERMAN I F, 1964, Dis Colon Rectum, V7, P87, DOI 10.1007/BF02616902; WEXNER SD, 1992, DIS COLON RECTUM, V35, P145, DOI 10.1007/BF02050669; WOMACK NR, 1986, BRIT J SURG, V73, P404, DOI 10.1002/bjs.1800730531; YOSHIOKA K, 1987, BRIT J SURG, V74, P373, DOI 10.1002/bjs.1800740516	73	95	97	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					520	528		10.7326/0003-4819-121-7-199410010-00008	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067650				2022-12-28	WOS:A1994PJ10200008
J	NICHOL, KL; MARGOLIS, KL; WUORENMA, J; VONSTERNBERG, T				NICHOL, KL; MARGOLIS, KL; WUORENMA, J; VONSTERNBERG, T			THE EFFICACY AND COST-EFFECTIVENESS OF VACCINATION AGAINST INFLUENZA AMONG ELDERLY PERSONS LIVING IN THE COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE RESPIRATORY-DISEASE; UNITED-STATES; NURSING-HOME; A H3N2; EPIDEMICS; MORTALITY; PNEUMONIA; IMPACT; IMMUNIZATION; ASSOCIATION	Background. Despite recommendations for annual vaccination against influenza, more than half of elderly Americans do not receive this vaccine. In a serial cohort study, we assessed the efficacy and cost effectiveness of influenza vaccine administered to older persons living in the community. Methods. Using administrative data bases, we studied men and women over 64 years of age who were enrolled in a large health maintenance organization in the Minneapolis-St. Paul area. We examined the rate of vaccination and the occurrence of influenza and its complications in each of three seasons: 1990-1991, 1991-1992, and 1992-1993. Outcomes were adjusted for age, sex, diagnoses indicating a high risk, use of medications, and previous use of health care services. Results. Each cohort included more than 25,000 persons 65 years of age or older. Immunization rates ranged from 45 percent to 58 percent. Although the vaccine recipients had more coexisting illnesses at base line than those who did not receive the vaccine, during each influenza season vaccination was associated with a reduction in the rate of hospitalization for pneumonia and influenza (by 48 to 57 percent, P less than or equal to 0.002) and for all acute and chronic respiratory conditions (by 27 to 39 percent, P less than or equal to 0.01). Vaccination was also associated with a 37 percent reduction (P = 0.04) in the rate of hospitalization for congestive heart failure during the 1991-1992 season, when influenza A was epidemic. The costs of hospitalization for all types of illness studied were lower in the vaccinated group during 1991-1992 (range of reduction, 47 to 66 percent; P<0.005) and for acute and chronic respiratory conditions and congestive heart failure in 1990-1991 (reductions of 37 percent and 43 percent, respectively; P less than or equal to 0.05). Direct savings per year averaged $117 per person vaccinated (range, $21 to $235), with cumulative savings of nearly $5 million. Vaccination was also associated with reductions of 39 to 54 percent in mortality from all causes during the three influenza seasons (P<0.001). Conclusions. For elderly citizens living in the community, vaccination against influenza is associated with reductions in the rate of hospitalization and in deaths from influenza and its complications, as compared with the rates in unvaccinated elderly persons, and vaccination produces direct dollar savings.	HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; GRP HLTH INC, MINNEAPOLIS, MN USA	Hennepin County Medical Center	NICHOL, KL (corresponding author), VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, 1 VET DR, MINNEAPOLIS, MN 55417 USA.			Margolis, Karen/0000-0003-1862-7402				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; ARDEN NH, 1988, ARCH INTERN MED, V148, P865, DOI 10.1001/archinte.148.4.865; BARKER W, 1993, OPTIONS CONTROL INFL, V2, P143; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P511, DOI 10.1164/arrd.1982.125.5.511; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; Fedson D S, 1992, Clin Geriatr Med, V8, P183; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEDSON DS, 1992, ANN INTERN MED, V116, P550, DOI 10.7326/0003-4819-116-7-550; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HELLIWELL BE, 1988, CAN J PUBLIC HEALTH, V79, P175; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P1; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; MARGOLIS KL, 1992, J AM GERIATR SOC, V40, P1021, DOI 10.1111/j.1532-5415.1992.tb04480.x; MAUCHER JM, 1990, AGE, V13, P81, DOI 10.1007/BF02432385; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY J, 1993, EXCERPTA MED, V2, P53; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PAUL WS, 1988, J INFECT DIS, V157, P633, DOI 10.1093/infdis/157.4.633; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; RUSSELL LB, 1992, HEALTH AFFAIR, V11, P162, DOI 10.1377/hlthaff.11.2.162; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P285; SCHOENBA.SC, 1969, B WORLD HEALTH ORGAN, V41, P531; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STRIKAS R, 1993, EXCERPTA MED, P153; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; WILLIAMS WW, 1988, ANN INTERN MED, V109, P348, DOI 10.7326/0003-4819-109-4-348_2; 1989, GUIDE CLIN PREVENTIV, P363; 1990, MMWR-MORBID MORTAL W, V39, P165; 1990, DIS CONTROL NEWSL, V19, P33; 1979, CAN MED ASS J, V121, P1193; 1993, MMWR-MORBID MORTAL W, V42, P385; 1990, MMWR-MORBID MORTAL W, V39, P204; 1993, MMWR-MORBID MORTAL W, V42, P601; 1994, GUIDE ADULT IMMUNIZA, P21; 1993, MMWR-MORBID MORTAL W, V42, P768; 1993, DIS CONTROL NEWSL, V21, P37; 1981, COST EFFECTIVENESS I; 1992, DIS CONTROL NEWSL, V20, P33; 1990, MMWR-MORBID MORTAL W, V39, P159	46	769	792	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					778	784		10.1056/NEJM199409223311206	http://dx.doi.org/10.1056/NEJM199409223311206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065407				2022-12-28	WOS:A1994PG30100006
J	RODEN, DM				RODEN, DM			DRUG-THERAPY - RISKS AND BENEFITS OF ANTIARRHYTHMIC THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; ARRHYTHMIA SUPPRESSION TRIAL; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; DEFIBRILLATION ENERGY-REQUIREMENTS; LEFT-VENTRICULAR FUNCTION; ATRIAL-FIBRILLATION; SINUS RHYTHM; DOUBLE-BLIND; SUDDEN-DEATH; IMPLANTABLE DEFIBRILLATORS				RODEN, DM (corresponding author), VANDERBILT UNIV, DIV CLIN PHARMACOL, 532C MED RES BLDG, NASHVILLE, TN 37232 USA.		Roden, Dan/ABD-5412-2021					AKIYAMA T, 1991, AM J CARDIOL, V68, P1551, DOI 10.1016/0002-9149(91)90308-8; ANDERSON JL, 1983, AM J CARDIOL, V51, P1196, DOI 10.1016/0002-9149(83)90368-5; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1993, Am J Cardiol, V72, P280; ANTMAN EM, 1992, CIRCULATION, V86, P764, DOI 10.1161/01.CIR.86.3.764; BHANDARI AK, 1992, AM HEART J, V124, P381, DOI 10.1016/0002-8703(92)90601-Q; BODEN WE, 1992, AM J CARDIOL, V69, P681, DOI 10.1016/0002-9149(92)90164-T; Boissel J P, 1981, Eur Heart J, V2, P49; BOURKE JP, 1991, J AM COLL CARDIOL, V18, P780, DOI 10.1016/0735-1097(91)90802-G; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; CAIRNS JA, 1991, CIRCULATION, V84, P933, DOI 10.1161/01.CIR.84.2.933; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CALKINS H, 1991, CIRCULATION, V84, P2376, DOI 10.1161/01.CIR.84.6.2376; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P959, DOI 10.1016/0002-9149(92)90801-5; COPLEN SE, 1991, CIRCULATION, V83, P714; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DELUNA AB, 1990, EUR HEART J SUPPL, V11, P338; DENNISS AR, 1986, CIRCULATION, V74, P731, DOI 10.1161/01.CIR.74.4.731; DORIAN P, 1986, J AM COLL CARDIOL, V8, P327, DOI 10.1016/S0735-1097(86)80047-X; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ECHT DS, 1989, CIRCULATION, V79, P1106, DOI 10.1161/01.CIR.79.5.1106; EPSTEIN AE, 1991, J AM COLL CARDIOL, V18, P14, DOI 10.1016/S0735-1097(10)80210-4; EPSTEIN AE, 1991, J AM COLL CARDIOL, V18, P888; EPSTEIN AE, 1993, PACE, V16, P1773, DOI 10.1111/j.1540-8159.1993.tb01808.x; FAIN ES, 1986, CIRCULATION, V73, P1334, DOI 10.1161/01.CIR.73.6.1334; FALIK R, 1987, AM J MED, V82, P1102, DOI 10.1016/0002-9343(87)90211-7; FELD GK, 1990, AM J CARDIOL, V66, P378, DOI 10.1016/0002-9149(90)90856-V; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FRIEDMAN LM, 1986, J AM COLL CARDIOL, V7, P1, DOI 10.1016/S0735-1097(86)80250-9; GREENBERG ML, 1987, J AM COLL CARDIOL, V9, P1148, DOI 10.1016/S0735-1097(87)80320-0; GREENE HL, 1992, J AM COLL CARDIOL, V19, P894, DOI 10.1016/0735-1097(92)90267-Q; HALLSTROM AP, 1991, CONTROL CLIN TRIALS, V12, P486, DOI 10.1016/0197-2456(91)90009-B; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HARTEL G, 1970, BRIT HEART J, V32, P57; HENTHORN RW, 1991, CIRCULATION, V83, P119, DOI 10.1161/01.CIR.83.1.119; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HJALMARSON A, 1981, LANCET, V2, P823; HOHNLOSER SH, 1992, PACE, V15, P2211, DOI 10.1111/j.1540-8159.1992.tb03049.x; Impact Research Group, 1984, J AM COLL CARDIOL, V4, P1148; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; KIM SG, 1992, CIRCULATION, V85, P1304, DOI 10.1161/01.CIR.85.4.1304; KOSTER RW, 1976, AM J CARDIOL, V38, P519, DOI 10.1016/0002-9149(76)90471-9; LAZZARA R, 1989, ANN INTERN MED, V111, P549, DOI 10.7326/0003-4819-111-7-549; LEHMANN MH, 1991, AM J CARDIOL, V67, P1421, DOI 10.1016/0002-9149(91)90474-Y; LIE KI, 1974, NEW ENGL J MED, V291, P1324, DOI 10.1056/NEJM197412192912504; LLOYD EA, 1984, S AFR MED J, V65, P367; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MARCUS FI, 1990, AM J CARDIOL, V66, P366, DOI 10.1016/0002-9149(90)90851-Q; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; MATTIONI TA, 1989, ANN INTERN MED, V111, P574, DOI 10.7326/0003-4819-111-7-574; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NATTEL S, 1985, CIRCULATION, V72, P898, DOI 10.1161/01.CIR.72.4.898; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; OETGEN WJ, 1983, AM J CARDIOL, V52, P746, DOI 10.1016/0002-9149(83)90409-5; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PFISTERER M, 1992, AM J CARDIOL, V69, P1399, DOI 10.1016/0002-9149(92)90889-7; PRITCHETT ELC, 1991, AM J CARDIOL, V67, P976, DOI 10.1016/0002-9149(91)90170-P; RADFORD MD, 1968, BRIT HEART J, V30, P91; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; Roden DM, 1991, CARDIAC PACING ELECT, V3rd, P265; SAKSENA S, 1992, CIRCULATION, V85, P2316, DOI 10.1161/01.CIR.85.6.2316; SAKSENA S, 1992, CIRCULATION, V86, P1347; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; SODERMARK T, 1975, BRIT HEART J, V37, P486; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; STEINBECK G, 1993, NEW ENGL J MED, V328, P71; STEWART R A, 1989, European Heart Journal, V10, P229; VLAY SC, 1985, AM HEART J, V110, P904, DOI 10.1016/0002-8703(85)90485-5; WARD DE, 1993, NEW ENGL J MED, V329, P498, DOI 10.1056/NEJM199308123290710; WASPE LE, 1985, J AM COLL CARDIOL, V5, P1292, DOI 10.1016/S0735-1097(85)80339-9; WETHERBEE DG, 1952, AM HEART J, V43, P89, DOI 10.1016/0002-8703(52)90028-8; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WOOSLEY RL, 1979, CIRCULATION, V60, P819, DOI 10.1161/01.CIR.60.4.819; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; 1991, NEW ENGL J MED, V327, P227; 1984, POSTGRAD MED J, V60, P98	86	94	99	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					785	791						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065408				2022-12-28	WOS:A1994PG30100007
J	DOYLE, MP				DOYLE, MP			COOKING WITH SALMONELLA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DOYLE, MP (corresponding author), UNIV GEORGIA,CTR FOOD SAFETY & QUAL ENHANCEMENT,GRIFFIN,GA, USA.							COTTERILL JO, 1973, POULTRY SCI, V52, P568; HUMPHREY TJ, 1990, EPIDEMIOL INFECT, V104, P237, DOI 10.1017/S0950268800059409; RODIGUE DC, 1990, EPIDEMIOL INFECT, V105, P21; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					895	895						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078170				2022-12-28	WOS:A1994PG18200032
J	SALEMSCHATZ, S; MOORE, G; RUCKER, M; PEARSON, SD				SALEMSCHATZ, S; MOORE, G; RUCKER, M; PEARSON, SD			THE CASE FOR CASE-MIX ADJUSTMENT IN PRACTICE PROFILING - WHEN GOOD APPLES LOOK BAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Objective.-To assess the influence of patient characteristics on practice profiling. Using the example of specialty referrals by primary care physicians, we evaluated the impact of adjusting for patient characteristics (age/sex vs case mix) on the estimation of practice variation, the identification of outlier practices, and the evaluation of potential predictors of variation. Design and Setting.-We applied several measurement strategies to a retrospective cohort of patients (N=37 830) within 52 physician practices in a large staff-model health maintenance organization during a 1-year period. Outcome Measures.-We calculated unadjusted referral rates and adjusted standardized referral ratios for each physician. Using these, we determined coefficients of variation and statistical ''outlier status.'' Results.-Adjustment for patient characteristics decreased the observed variation in referral profiles, with a decrease of more than 50% in the coefficient of variation. Three quarters of the physicians identified as statistical outliers with use of an age/sex-adjusted measure were no longer identified as such with use of a case-mix-adjusted measure. Several key predictors of unadjusted referral rate (including physician age, practice tenure, site of practice, and extent of laboratory test ordering) dropped out of regression models when the outcome variable was adjusted for patient characteristics. Conclusion.-Failure to adjust for case mix in physician practice profiles may lead to overestimates of variation and misidentification of outliers. To the extent that unadjusted practice profiles are used for decisions about education, sanctions, or employment, physicians may be subject to inequitable decisions and actions. Misinformation about the causes and extent of practice variation may also lead to misdirection of scarce resources for quality improvement efforts.			SALEMSCHATZ, S (corresponding author), HARVARD COMMUNITY HLTH PLAN,CLIN QUAL MANAGEMENT,10 BROOKLINE PL W,2ND FLOOR,BROOKLINE,MA 02146, USA.							ARMSTRONG D, 1988, J ROY COLL GEN PRACT, V38, P494; BRESLOW N, 1985, BIOSTATISTICS STATIS; CAMPBELL DM, 1984, SOC SCI MED, V18, P365, DOI 10.1016/0277-9536(84)90054-6; Fleiss JL, 1981, STAT METHODS RATES P; LASKER RD, 1992, INQUIRY-J HEALTH CAR, V29, P287; LEWIS PAW, 1989, SIMULATION METHODOLO, P120; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; PINEAULT R, 1977, MED CARE, V15, P51, DOI 10.1097/00005650-197701000-00004; SOBOL J, 1988, J COMMUNITY HLTH, V13, P171; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006	12	125	125	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					871	874		10.1001/jama.272.11.871	http://dx.doi.org/10.1001/jama.272.11.871			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	8078165				2022-12-28	WOS:A1994PG18200026
J	FREED, E; SYMONS, M; MACDONALD, SG; MCCORMICK, F; RUGGIERI, R				FREED, E; SYMONS, M; MACDONALD, SG; MCCORMICK, F; RUGGIERI, R			BINDING OF 14-3-3-PROTEINS TO THE PROTEIN-KINASE RAF AND EFFECTS ON ITS ACTIVATION	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; GROWTH-FACTOR; GENE-PRODUCT; IN-VITRO; IDENTIFICATION; P21(RAS); FAMILY; CELLS; TRANSFORMATION	To identify proteins that may participate in the activation of the protein kinase Raf, proteins that interact with Raf were selected in a two-hybrid screen. Two members of the 14-3-3 protein family were isolated that interacted with both the amino terminal regulatory regions of Raf and the kinase domain of Raf, but did not compete with the guanine nucleotide-binding protein Ras for binding to Raf. 14-3-3 proteins associated with Raf in mammalian cells and accompanied Raf to the membrane in the presence of activated Ras. in yeast cells expressing Raf and MEK, mammalian 14-3-3 beta or 14-3-3 zeta activated Raf to a similar extent as did expression of Ras. Therefore, 14-3-3 proteins may participate in or be required for the regulation of Raf function. These findings suggest a role for 14-3-3 proteins in Raf-mediated signal transduction.			FREED, E (corresponding author), ONYX PHARMACEUT,RICHMOND,CA 94806, USA.							AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BRASELMANN S, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREED EO, UNPUB; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; ICHIMURA T, 1991, J NEUROCHEM, V56, P1449, DOI 10.1111/j.1471-4159.1991.tb11446.x; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACDONALD SG, UNPUB; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; Ruggieri R., UNPUB; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SYMONS MCR, UNPUB; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANAELST L, COMMUNICATION; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YASHAR B, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	54	384	398	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1713	1716		10.1126/science.8085158	http://dx.doi.org/10.1126/science.8085158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085158				2022-12-28	WOS:A1994PG28400032
J	LAINE, L; PETERSON, WL				LAINE, L; PETERSON, WL			MEDICAL PROGRESS - BLEEDING PEPTIC-ULCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							UPPER GASTROINTESTINAL HEMORRHAGE; ANTI-INFLAMMATORY DRUGS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LASER PHOTO-COAGULATION; ENDOSCOPIC INJECTION THERAPY; HEAT PROBE THERMOCOAGULATION; PROSPECTIVE RANDOMIZED TRIAL; NONBLEEDING VISIBLE VESSEL; PLACEBO-CONTROLLED TRIAL; PURE ALCOHOL INJECTION		VET AFFAIRS MED CTR, MED SERV, DALLAS, TX 75216 USA; UNIV SO CALIF, SCH MED, DEPT MED, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, LOS ANGELES CTY MED CTR, LOS ANGELES, CA 90033 USA; UNIV TEXAS, SW MED SCH, DALLAS, TX USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Southern California; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALLAN R, 1976, Q J MED, V45, P533; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; AVGERINOS A, 1989, Gastroenterology, V96, pA18; BALANZO J, 1988, ENDOSCOPY, V20, P289, DOI 10.1055/s-2007-1013023; BALANZO J, 1990, ENDOSCOPY, V22, P157, DOI 10.1055/s-2007-1012828; BECKLY DE, 1986, GUT, V27, P96, DOI 10.1136/gut.27.1.96; BENDAHAN J, 1992, AM J GASTROENTEROL, V87, P733; BIGARD MA, 1988, GASTROENTEROLOGY, V94, pA34; BLOOM BS, 1989, ARCH INTERN MED, V149, P1019, DOI 10.1001/archinte.149.5.1019; BOOKSTEIN JJ, 1974, RADIOLOGY, V113, P277, DOI 10.1148/113.2.277; BRANICKI FJ, 1990, WORLD J SURG, V14, P262, DOI 10.1007/BF01664889; BREARLEY S, 1985, ENDOSCOPY, V17, P173, DOI 10.1055/s-2007-1018493; BREARLEY S, 1987, ENDOSCOPY, V19, P160, DOI 10.1055/s-2007-1018269; BRULLET E, 1991, ENDOSCOPY, V23, P73, DOI 10.1055/s-2007-1010616; BRYANT LR, 1972, AM J SURG, V124, P570, DOI 10.1016/0002-9610(72)90090-6; BUSET M, 1988, GASTROINTEST ENDOSC, V34, P173; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CARSTENSEN HE, 1980, SCAND J GASTROENTERO, V15, P103, DOI 10.3109/00365528009181439; CHANGCHIEN CS, 1988, DIGEST DIS SCI, V33, P400, DOI 10.1007/BF01536021; CHIOZZINI G, 1989, Gastroenterology, V96, pA86; CHOUDARI CP, 1992, GUT, V33, P1159, DOI 10.1136/gut.33.9.1159; CHOUDARI CP, 1993, GASTROENTEROLOGY, V104, pA54; CHRISTIANSEN J, 1989, GASTROENTEROLOGY, V97, P568, DOI 10.1016/0016-5085(89)90626-4; CHUNG S C S, 1990, Gastroenterology, V98, pA31; CHUNG SCS, 1990, GASTROINTEST ENDOSC, V36, P194; CHUNG SCS, 1988, BRIT MED J, V296, P1631, DOI 10.1136/bmj.296.6637.1631; CHUNG SCS, 1991, GASTROENTEROLOGY, V100, P33, DOI 10.1016/0016-5085(91)90579-A; CHUNG SCS, 1992, GASTROINTEST ENDOSC, V38, P231; COCHRAN TA, 1993, GASTROENTEROL CLIN N, V22, P751; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; CONN HO, 1981, NEW ENGL J MED, V304, P967, DOI 10.1056/NEJM198104163041610; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; COTTON PB, 1981, ENDOSCOPIC CONTROL G, P103; CUTLER A, 1993, GASTROENTEROLOGY, V104, pA61; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; Daniel WA, 1939, J AMER MED ASSOC, V113, P2232; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; EMMANUEL A, 1985, GASTROINTEST ENDOSC, V31, P52, DOI 10.1016/S0016-5107(85)71976-1; Enquist I F, 1965, Ann Surg, V162, P550, DOI 10.1097/00000658-196510000-00002; FOSTER JH, 1963, SURG GYNECOL OBSTET, V117, P257; FREEMAN ML, 1993, GASTROINTEST ENDOSC, V39, P359, DOI 10.1016/S0016-5107(93)70106-6; FREITAS D, 1985, AM J GASTROENTEROL, V80, P853; FULLARTON GM, 1990, ENDOSCOPY, V22, P68, DOI 10.1055/s-2007-1012795; FULLARTON GM, 1989, BRIT J SURG, V76, P541, DOI 10.1002/bjs.1800760606; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GILBERT DA, 1981, GASTROINTEST ENDOSC, V27, P94; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P939, DOI 10.3109/00365529309098288; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUSTAVSSON S, 1988, GASTROENTEROLOGY, V94, P688, DOI 10.1016/0016-5085(88)90240-5; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; HALL WH, 1972, GASTROENTEROLOGY, V62, P1120; HENRY DA, 1989, BMJ-BRIT MED J, V298, P1142, DOI 10.1136/bmj.298.6681.1142; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOSKING S W, 1992, Gastroenterology, V102, pA85; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HOVOET J, 1991, GUT, V32, P730; HUI W M, 1992, Gastroenterology, V102, pA85; HUI W M, 1991, Gastroenterology, V100, pA87; HUI WM, 1991, GASTROINTEST ENDOSC, V37, P299, DOI 10.1016/S0016-5107(91)70719-0; JENSEN D M, 1992, Gastroenterology, V102, pA90; JENSEN D M, 1991, Gastroenterology, V100, pA92; JENSEN DM, 1982, GASTROINTEST ENDOSC, V28, P151; JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; JENSEN DM, 1990, GASTROINTEST ENDOSC, V36, pS42; JENSEN DM, 1988, GASTROENTEROLOGY, V95, P1569, DOI 10.1016/S0016-5085(88)80079-9; JENSEN DM, 1988, GASTROENTEROLOGY S, V94, pA208; JENSEN DM, 1993, GASTROINTEST ENDOSC, V39, P279; JOHNSTON JH, 1987, GASTROENTEROLOGY, V92, P1101, DOI 10.1016/S0016-5085(87)91065-1; Kim Jong G., 1994, American Journal of Gastroenterology, V89, P203; KOHLER B, 1991, SCAND J GASTROENTERO, V26, P471, DOI 10.3109/00365529108998568; KOVACS T O G, 1991, Gastroenterology, V100, pA101; KREJS GJ, 1987, NEW ENGL J MED, V316, P1618, DOI 10.1056/NEJM198706253162602; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; LABENZ J, 1994, DIGESTION, V55, P19, DOI 10.1159/000201117; LAINE L, 1992, AM J GASTROENTEROL, V87, P1398; LAINE L, 1990, GASTROENTEROLOGY, V99, P1303, DOI 10.1016/0016-5085(90)91154-X; LAINE L, 1992, GASTROENTEROLOGY, V102, P314, DOI 10.1016/0016-5085(92)91816-M; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LAINE L, 1990, GASTROINTEST ENDOSC, V36, pS38; LANG EK, 1992, RADIOLOGY, V182, P703, DOI 10.1148/radiology.182.3.1535883; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LAURITSEN K, 1985, BRIT MED J, V291, P1093, DOI 10.1136/bmj.291.6502.1093; LEE M, 1994, ANN INTERN MED, V120, P184, DOI 10.7326/0003-4819-120-3-199402010-00002; LIEBERMAN DA, 1984, GASTROENTEROLOGY, V86, P876; LIN H J, 1992, Gastroenterology, V102, pA113; LIN HJ, 1990, GUT, V31, P753, DOI 10.1136/gut.31.7.753; LIN HJ, 1988, AM J GASTROENTEROL, V83, P283; LIN HJ, 1993, GASTROINTEST ENDOSC, V39, P15, DOI 10.1016/S0016-5107(93)70003-6; LIN HJ, 1990, GASTROINTEST ENDOSC, V36, P241, DOI 10.1016/S0016-5107(90)71015-2; LOEB DS, 1992, GASTROENTEROLOGY, V102, P1899, DOI 10.1016/0016-5085(92)90311-L; LOIZOU LA, 1991, GUT, V32, P1100, DOI 10.1136/gut.32.10.1100; MACLEOD IA, 1983, BRIT MED J, V286, P345, DOI 10.1136/bmj.286.6362.345; MAGNUSSON I, 1985, GUT, V26, P221, DOI 10.1136/gut.26.3.221; MAKELA J, 1992, HEPATO-GASTROENTEROL, V39, P144; MATOLO NM, 1979, AM J SURG, V138, P840, DOI 10.1016/0002-9610(79)90308-8; MATTHEWSON K, 1990, GASTROENTEROLOGY, V98, P1239, DOI 10.1016/0016-5085(90)90339-3; MEULENGRACHT E, 1947, ARCH INTERN MED, V80, P697, DOI 10.1001/archinte.1947.00220180002001; MICHALETZ PA, 1990, GASTROINTEST ENDOSC, V36, P190; MORETO M, 1987, ENDOSCOPY, V19, P54, DOI 10.1055/s-2007-1018234; MORETO M, 1992, GUT, V33, P456, DOI 10.1136/gut.33.4.456; MORRIS DL, 1984, BRIT MED J, V288, P1277, DOI 10.1136/bmj.288.6426.1277; MURRAY WR, 1988, SCAND J GASTROENTERO, V23, P183, DOI 10.3109/00365528809103965; MURRAY WR, 1986, GUT, V27, P1387, DOI 10.1136/gut.27.11.1387; NORTHFIELD TC, 1971, BMJ-BRIT MED J, V1, P26, DOI 10.1136/bmj.1.5739.26; OBRIEN JD, 1986, LANCET, V1, P464; OXNER RBG, 1992, LANCET, V339, P966, DOI 10.1016/0140-6736(92)91537-I; PANES J, 1987, LANCET, V2, P1292; PANES J, 1991, GASTROINTEST ENDOSC, V37, P611, DOI 10.1016/S0016-5107(91)70865-1; PAPP JP, 1982, SURG CLIN N AM, V62, P797; PASCU O, 1989, ENDOSCOPY, V21, P53, DOI 10.1055/s-2007-1012899; PATCHETT SE, 1989, GUT, V30, P1704, DOI 10.1136/gut.30.12.1704; PETERSON W, 1992, MANAGEMENT GASTROINT, V1, P5; PETERSON WL, 1990, GASTROENTEROLOGY, V98, P1725, DOI 10.1016/0016-5085(90)91131-O; PETERSON WL, 1981, NEW ENGL J MED, V304, P925, DOI 10.1056/NEJM198104163041601; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; PONSKY JL, 1980, J SURG RES, V28, P204, DOI 10.1016/0022-4804(80)90115-8; RAJGOPAL C, 1991, GUT, V32, P727, DOI 10.1136/gut.32.7.727; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; REUTER SR, 1975, AM J ROENTGENOL, V125, P119, DOI 10.2214/ajr.125.1.119; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; RUTGEERTS P, 1993, GUT, V34, P348, DOI 10.1136/gut.34.3.348; RUTGEERTS P, 1989, GASTROENTEROLOGY, V97, P610, DOI 10.1016/0016-5085(89)90632-X; RUTGEERTS P, 1989, LANCET, V1, P1164; RUTGEERTS P, 1987, GASTROINTEST ENDOSC, V33, P199, DOI 10.1016/S0016-5107(87)71558-2; RUTGEERTS P, 1992, GASTROINTEST ENDOSC, V38, P241; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; SCHEIMAN J M, 1992, Gastroenterology, V102, pA160; Schiff L, 1942, AM J MED SCI, V203, P409, DOI 10.1097/00000441-194203000-00016; SCHILLER KF, 1970, BRIT MED J, V2, P7, DOI 10.1136/bmj.2.5700.7; SHERMAN LM, 1979, ANN SURG, V189, P298, DOI 10.1097/00000658-197903000-00007; SHORROCK C J, 1992, Gastroenterology, V102, pA165; SILVERSTEIN FE, 1981, GASTROINTEST ENDOSC, V27, P80, DOI 10.1016/S0016-5107(81)73156-0; SOMERVILLE K, 1986, LANCET, V1, P462; SOMERVILLE KW, 1985, LANCET, V1, P130; SWAIN CP, 1993, GASTROENTEROLOGY, V104, pA202; SWAIN CP, 1986, LANCET, V1, P1113; SWAIN CP, 1981, LANCET, V2, P1313; SWAIN CP, 1986, GASTROENTEROLOGY, V90, P595, DOI 10.1016/0016-5085(86)91113-3; VALLON AG, 1981, GUT, V22, P228, DOI 10.1136/gut.22.3.228; WALT RP, 1992, LANCET, V340, P1058, DOI 10.1016/0140-6736(92)93078-2; WARA P, 1985, SCAND J GASTROENTERO, V20, P72, DOI 10.3109/00365528509089635; WARA P, 1985, GASTROENTEROLOGY, V88, P1209, DOI 10.1016/S0016-5085(85)80081-0; WARING JP, 1991, GASTROINTEST ENDOSC, V37, P295; ZUCKERMAN G, 1984, AM J MED, V76, P361, DOI 10.1016/0002-9343(84)90652-1	151	516	539	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					717	727		10.1056/NEJM199409153311107	http://dx.doi.org/10.1056/NEJM199409153311107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058080				2022-12-28	WOS:A1994PF33200007
J	TREIER, M; STASZEWSKI, LM; BOHMANN, D				TREIER, M; STASZEWSKI, LM; BOHMANN, D			UBIQUITIN-DEPENDENT C-JUN DEGRADATION IN-VIVO IS MEDIATED BY THE DELTA-DOMAIN	CELL			English	Article							METAL CHELATE ADSORBENT; CELL-SPECIFIC INHIBITOR; SHORT-LIVED PROTEIN; TRANSCRIPTIONAL ACTIVATION; FOS PROTEIN; V-JUN; ONCOGENE; AP-1; TRANSFORMATION; SEQUENCES	The role of the ubiquitin-dependent proteolysis system in c-Jun breakdown was investigated. Using in vitro experiments and a novel in vivo assay that utilizes molecularly-tagged ubiquitin and c-Jun proteins, it was shown that c-Jun, but not its transforming counterpart, retroviral v-Jun, can be efficiently multiubiquitinated. Consistently, v-Jun has a longer half-life than c-Jun. Mutagenesis experiments indicate that the reason for the escape of v-Jun from multiubiquitination and its resulting stabilization is the deletion of the delta domain, a stretch of 27 amino acids that is present in c-Jun but not in v-Jun. c-Jun sequences containing the delta domain, when transferred to the bacterial beta-galactosidase protein, function as a cis-acting ubiquitination and degradation signal. The correlation between transforming ability and the escape from ubiquitin-dependent degradation described here suggests a novel route to oncogenesis.			TREIER, M (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY.		Treier, Mathias/AAD-6388-2021					ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHN SL, 1990, ONCOGENE, V5, P1821; Curran T, 1988, ONCOGENE HDB, P307; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5	45	848	872	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					787	798		10.1016/S0092-8674(94)90502-9	http://dx.doi.org/10.1016/S0092-8674(94)90502-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087846				2022-12-28	WOS:A1994PG29600008
J	LEHMING, N; THANOS, D; BRICKMAN, JM; MA, J; MANIATIS, T; PTASHNE, M				LEHMING, N; THANOS, D; BRICKMAN, JM; MA, J; MANIATIS, T; PTASHNE, M			AN HMG-LIKE PROTEIN THAT CAN SWITCH A TRANSCRIPTIONAL ACTIVATOR TO A REPRESSOR	NATURE			English	Article							BETA-INTERFERON GENE; DORSOVENTRAL PATTERN; DORSAL MORPHOGEN; DROSOPHILA; ENHANCER; SILENCER; CONVERSION; PROMOTERS; ELEMENTS; CACTUS	ONE protein can activate some genes and repress others in the same cell(1). The Drosophila protein Dorsal(2) (which, like the human protein NF-kappa B-3, is a member of the Rel family of transcriptional activators) activates the twist gene and represses the zen gene in the ventral region of early embryos(4,5). Here we describe a Drosophila HMG1 protein, called DSP1 (dorsal switch protein), that converts Dorsal and NF-kappa B from transcriptional activators to repressors. This effect requires a sequence termed a negative regulatory element (NRE), found adjacent to Dorsal-binding sites in the zen promoter and adjacent to the NF-kappa B-binding site in the human interferon-beta (IFN-beta) enhancer(6-8). Previous studies have shown that another type of HMG protein, HMG I(Y), can stimulate NF-kappa B activity(9). Thus, the HMG-like proteins DSP1 and HMG I(Y) can determine whether a specific regulator functions as an activator or a repressor of transcription.			LEHMING, N (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019; Ma, Jun/GLT-4809-2022	Ma, Jun/0000-0002-1609-3294; Brickman, Joshua/0000-0003-1580-7491				BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KAMENS J, 1991, NEW BIOL, V3, P1005; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KING CY, 1993, P NATL ACAD SCI USA, V90, P1190; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PTASHNE M, 1992, GENETIC SWITCH GENE; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P	31	205	211	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					175	179		10.1038/371175a0	http://dx.doi.org/10.1038/371175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072548				2022-12-28	WOS:A1994PF19100069
J	LILFORD, R; JONES, AM; BISHOP, DT; THORNTON, J; MUELLER, R				LILFORD, R; JONES, AM; BISHOP, DT; THORNTON, J; MUELLER, R			CASE-CONTROL STUDY OF WHETHER SUBFERTILITY IN MEN IS FAMILIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALE-INFERTILITY; DISORDERS	Objective-To test the hypothesis that subfertility in men is familial and to examine the distribution of subfertility within families for consistency with a genetic cause. Design-Case-control study and segregation analysis. Setting-Two teaching hospitals in Leeds. Subjects-Cases (probands) were men with an abnormal sperm count who attended a subfertility clinic and whose partners had no major factor contravening fertility. Controls were fathers of two or more childen recruited through vasectomy clinics or a maternity department. Main outcome measures-The incidence of involuntary childlessness among brothers with partners and among sisters and second and third degree male relatives. When possible clinical and laboratory details were obtained from involuntarily childless brothers. Results-Seventeen of the 148 (11.5%) brothers of probands but none of the 169 brothers of controls had sought medical advice for childlessness (P < 0.0005). Four probands had more than one involuntarily childless brother. There were six further brothers whose childlessness was thought to be involuntary bringing the total prevalence of subfertility among brothers of probands to 16%. Segregation analysis was consistent with an autosomal recessive mode of inheritance accounting for 60% of subfertility in men. Seventeen of the 346 (4.9%) uncles of probands and 10 of 420 (2.8%) uncles of controls were reported to be involuntarily childless (P = 0.09), but there was no difference in childlessness among sisters. In three families sperm counts from ''affected'' brothers confirmed the diagnosis and showed considerable similarities within but not between families. Conclusion-Subfertility in men has a familial component, and the observations are consistent with an autosomal recessive mode of inheritance in over half the cases. Several different genes are probably involved.			LILFORD, R (corresponding author), UNIV LEEDS, DEPT CLIN MED, INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, W YORKSHIRE, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876; Bishop, Tim/0000-0002-8752-8785	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AFZELIUS BA, 1975, J CELL BIOL, V66, P225, DOI 10.1083/jcb.66.2.225; [Anonymous], [No title captured]; Cavalli-Sforza L.L., 1971, GENETICS HUMAN POPUL; CHUBB C, 1989, J ANDROL, V10, P77; CZYGLIK F, 1986, FERTIL STERIL, V45, P255; DEBRAEKELEER M, 1991, HUM REPROD, V6, P245, DOI 10.1093/oxfordjournals.humrep.a137315; EIBEN B, 1987, ANDROLOGIA, V19, P684; JOHNSON G, 1987, BRIT MED J, V294, P804, DOI 10.1136/bmj.294.6575.804; MATSUDA T, 1991, INT J FERTIL, V36, P178; Maule J. P, 1962, SEMEN ANIMALS ARTIFI; MILLER D, 1994, HUM REPROD, V9, P864, DOI 10.1093/oxfordjournals.humrep.a138607; NAVARRETE C, 1986, ANN GENET-PARIS, V29, P98; PEARSON PL, 1970, CYTOGENETICS, V9, P460, DOI 10.1159/000130115; PINSKY L, 1987, ADV HUM GENET, V16, P299; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; VOGT P, 1992, HUM GENET, V89, P491; Watson PF., 1990, MARSHALLS PHYSL REPR; 1987, LABORATORY MANUAL EX	19	136	139	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	1994	309	6954					570	573		10.1136/bmj.309.6954.570	http://dx.doi.org/10.1136/bmj.309.6954.570			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086942	Green Published			2022-12-28	WOS:A1994PF33000016
J	BULLOUGH, PA; HUGHSON, FM; SKEHEL, JJ; WILEY, DC				BULLOUGH, PA; HUGHSON, FM; SKEHEL, JJ; WILEY, DC			STRUCTURE OF INFLUENZA HEMAGGLUTININ AT THE PH OF MEMBRANE-FUSION	NATURE			English	Article							VIRUS HEMAGGLUTININ; CONFORMATIONAL CHANGE; PROTEIN MODELS; ACTIVATION; ACID; GLYCOPROTEIN; ANTIBODIES; HEMOLYSIS; MECHANISM; RESOLUTION	Low pH induces a conformational change in the influenza virus haemagglutinin, which then mediates fusion of the viral and host cell membranes. The three-dimensional structure of a fragment of the haemagglutinin in this conformation reveals a major refolding of the secondary and tertiary structure of the molecule. The apolar fusion peptide moves at least 100 Angstrom to one tip of the molecule. At the other end a helical segment unfolds, a subdomain relocates reversing the chain direction, and part of the structure becomes disordered.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Harvard University; Harvard University; Howard Hughes Medical Institute; MRC National Institute for Medical Research				Bullough, Per/0000-0001-8147-1127				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BULLOUGH PA, 1994, J MOL BIOL, V236, P1262, DOI 10.1016/0022-2836(94)90027-2; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; DANIELS RS, 1985, ORIGIN PANDEMIC INFL, P8; DANIELS RS, 1985, ORIGIN PANDEMIC INFL, P1; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GOLDSMITH EJ, 1994, STRUCTURE, V2, P241, DOI 10.1016/S0969-2126(00)00025-3; GRAVES PN, 1983, VIROLOGY, V126, P106, DOI 10.1016/0042-6822(83)90465-8; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; Leslie A.G.W., 1992, CCP4 ESF EACMB NEWSL; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; METCALF P, 1987, NATURE, V325, P84, DOI 10.1038/325084a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WARD CW, 1980, AUST J BIOL SCI, V33, P441; WEBSTER RG, 1983, VIROLOGY, V126, P587, DOI 10.1016/S0042-6822(83)80015-4; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YEWDELL JW, 1983, J VIROL, V48, P239, DOI 10.1128/JVI.48.1.239-248.1983; 1979, SERC4 DAR LAB COLL C	50	1358	1423	2	181	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					37	43		10.1038/371037a0	http://dx.doi.org/10.1038/371037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072525				2022-12-28	WOS:A1994PE38100042
J	ROTHE, M; WONG, SC; HENZEL, WJ; GOEDDEL, DV				ROTHE, M; WONG, SC; HENZEL, WJ; GOEDDEL, DV			A NOVEL FAMILY OF PUTATIVE SIGNAL TRANSDUCERS ASSOCIATED WITH THE CYTOPLASMIC DOMAIN OF THE 75 KDA TUMOR-NECROSIS-FACTOR RECEPTOR	CELL			English	Article							NF-KAPPA-B; TNF RECEPTOR; MOLECULAR-CLONING; ZINC-FINGER; PROTEIN; ACTIVATION; EXPRESSION; GENE; STIMULATION; MEDIATOR	Mutational analysis identified a C-terminal region of 78 amine acids within the cytoplasmic domain of the human 75 kDa tumor necrosis factor receptor (TNF-R2) that is required for signal transduction. This region was subsequently shown to mediate the interaction of cytoplasmic factors with TNF-R2. Two of these factors were isolated and molecularly cloned using biochemical purification and the yeast two-hybrid system. TNF receptor-associated factor 1 (TRAF1) and TRAF2 are the first two members of a novel protein family containing a never C-terminal homology region, the TRAP domain. In addition, TRAF2 contains an N-terminal RING finger motif. TRAF1 and TRAF2 can form homo- and heterotypic dimers. Our analysis indicates that TRAF1 and TRAF2 are associated with the cytoplasmic domain of TNF-R2 in a heterodimeric complex in which TRAF2 contacts the receptor directly. TRAF1 interacts with TNF-RP indirectly through heterodimer formation with TRAF2.	GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA	Roche Holding; Genentech	ROTHE, M (corresponding author), GENENTECH INC, DEPT MOLEC BIOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BERG JM, 1990, J BIOL CHEM, V265, P6513; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GEHR G, 1992, J IMMUNOL, V149, P911; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; ITOH N, 1993, J BIOL CHEM, V268, P10932; JACOBSEN FW, 1994, IN PRESS P NATL ACAD; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	45	915	987	2	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					681	692		10.1016/0092-8674(94)90532-0	http://dx.doi.org/10.1016/0092-8674(94)90532-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069916				2022-12-28	WOS:A1994PD69300016
J	SUNG, P				SUNG, P			CATALYSIS OF ATP-DEPENDENT HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE BY YEAST RAD51 PROTEIN	SCIENCE			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE; RECOMBINATION; HELICASE; ENCODES; CLONING; REPAIR; MOUSE	The RAD51 gene of Saccharomyces cerevisiae is required for genetic recombination and DNA double-strand break repair. Here it is demonstrated that RAD51 protein pairs circular viral single-stranded DNA from phi X 174 or M13 with its respective homologous linear double-stranded form. The product of synapsis between these DNA partners is further processed by RAD51 to yield nicked circular duplex DNA, which indicates that RAD51 can catalyze strand exchange. The pairing and strand exchange reaction requires adenosine triphosphate, a result consistent with the presence of a DNA-dependent adenosine triphosphatase activity in RAD51 protein. Thus, RAD51 is a eukaryotic recombination protein that can catalyze the strand exchange reaction.			SUNG, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555, USA.							ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KLECKNER N, 1991, COLD SH Q B, V56, P729; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG PH, UNPUB; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	20	734	758	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1241	1243		10.1126/science.8066464	http://dx.doi.org/10.1126/science.8066464			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066464				2022-12-28	WOS:A1994PD42200040
J	IPPOLITO, G; DECARLI, G; PURO, V; PETROSILLO, N; ARICI, C; BERTUCCI, R; BIANCIARDI, L; BONAZZI, L; CESTRONE, A; DAGLIO, M; DESPERATI, W; FRANCESCONI, M; MIGLIORI, M; MONTI, A; PERNA, MC; PIETROBON, F; JAGGER, J				IPPOLITO, G; DECARLI, G; PURO, V; PETROSILLO, N; ARICI, C; BERTUCCI, R; BIANCIARDI, L; BONAZZI, L; CESTRONE, A; DAGLIO, M; DESPERATI, W; FRANCESCONI, M; MIGLIORI, M; MONTI, A; PERNA, MC; PIETROBON, F; JAGGER, J			DEVICE-SPECIFIC RISK OF NEEDLESTICK INJURY IN ITALIAN HEALTH-CARE WORKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HAZARDS	Objectives.-To identify the types of medical devices causing needlestick injuries among Italian health care workers, to document the device-specific injury rates and time trends for different hollow-bore needles, and to compare injury rates from these devices with those reported in the United States. Design.-Longitudinal survey. Settings.-Twelve Italian acute care public hospitals. Methods.-Data were obtained from a multihospital surveillance database on the number of total injuries reported in each device category. Hospitals provided the corresponding number of devices used annually for each needle type. Main Outcome Measure.-Number of needlestick injuries by type of hollow-bore needle per 100 000 devices used per year. Results.-A total of 2524 injuries from hollow-bore needles were reported. Disposable syringes/hypodermic needles accounted for 59.3% of injuries, followed by winged steel needles (33.1%), intravenous catheter stylets (5.4%), and vacuum-tube phlebotomy needles (2.2%). Intravenous catheter stylets had the highest needlestick injury rate (15.7/100 000 devices used), and disposable syringes had the lowest needlestick injury rate (3.8/100 000). In contrast to the other devices, the injury rate from winged steel needles increased from 6.2 per 100 000 in 1990 to 13.9 per 100 000 in 1992. Conclusions.-The device-specific needlestick injury rates in Italy are similar to those reported in the United States, suggesting similar exposure experience in two countries. However, in contrast to the United States, needleless intravenous access is standard practice in Italy and thus eliminates one potential risk to Italian health workers. Implementation of safer equipment, such as shielded or retracting needles, and continuing training programs are needed to further reduce the hazards that health care workers face.	LAZZARO SPALLANZANI HOSP INFECT DIS, ITALIAN STUDY GRP OCCUPAT RISK HIV INFECT, ROME, ITALY; OSPED RIUNITI BERGAMO, BERGAMO, ITALY; OSPED AMEDEO SAVOIA, TURIN, ITALY; POLICLIN LA SCOTTE, SIENA, ITALY; OSPED MAGGIORE CA PIZZARDI, BOLOGNA, ITALY; ARCISPEDALE S MARIA NUOVA, REGGIO EMILIA, ITALY; OSPED CIVILE, PADUA, ITALY; POLICLIN SAN MATTEO, PAVIA, ITALY; OSPED CIVILE, ALESSANDRIA, ITALY; OSPED S SEBASTIANO, FRASCATI, ITALY; ARCISPEDALE ST ANNA, FERRARA, ITALY; POLICLIN S ORSOLA MALPIGHI, BOLOGNA, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED CAFONCELLO, TREVISO, ITALY; UNIV VIRGINIA, DEPT NEUROSURG, CHARLOTTESVILLE, VA USA	Ospedali Riuniti di Bergamo; AUSL di Bologna; IRCCS Arcispedale S. Maria Nuova; IRCCS Fondazione San Matteo; University of Ferrara; Arcispedale Sant'Anna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Milan; Luigi Sacco Hospital; ULSS 2 Marca TV; Ospedale Ca' Foncello Treviso; University of Virginia			De Carli, Gabriella/B-9258-2013; Ippolito, Giuseppe/J-7207-2017; Petrosillo, Nicola/AAZ-2095-2021	De Carli, Gabriella/0000-0002-3972-8301; puro, vincenzo/0000-0003-0291-4490; Ippolito, Giuseppe/0000-0002-1076-2979; petrosillo, nicola/0000-0002-2585-7567				BENSON JS, 1992, FDA SAFETY ALERT NEE, V4; Dean A. G., 1990, EPI INFO VERSION 5 W; EAKIN J M, 1990, AIDS (London), V4, pS257; Fleiss JL, 1981, STAT METHODS RATES P; IPPOLITO G, 1994, J ACQ IMMUN DEF SYND, V7, P208; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JAGGER J, 1990, AM J INFECT CONTROL, V18, P227, DOI 10.1016/0196-6553(90)90163-M; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JAGGER J, 1991, INFECT CONT HOSP EP, V12, P211, DOI 10.2307/30146993; MOORE RM, 1990, AM J INFECT CONTROL, V18, P316, DOI 10.1016/0196-6553(90)90231-G; USA Council of State and Territorial Epidemiologists, 1987, Morbidity and Mortality Weekly Report, V36, P1; YASSI A, 1991, AM J INFECT CONTROL, V19, P129, DOI 10.1016/0196-6553(91)90018-8; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1988, MMWR-MORBID MORTAL W, V37, P377; 1989, LINEEGUIDA COMPORTAM; 1988, MMWR-MORBID MORTAL W, V37, P387	16	60	60	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					607	610		10.1001/jama.272.8.607	http://dx.doi.org/10.1001/jama.272.8.607			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057516				2022-12-28	WOS:A1994PC39800030
J	SASSONECORSI, P				SASSONECORSI, P			RHYTHMIC TRANSCRIPTION AND AUTOREGULATORY LOOPS - WINDING UP THE BIOLOGICAL CLOCK	CELL			English	Review							MESSENGER-RNA LEVELS; PROTO-ONCOGENE FOS; CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; LIGHT; CREM; PERIOD; NEUROSPORA; REPRESSOR				SASSONECORSI, P (corresponding author), FAC MED STRASBOURG,CNRS,INSERM,U184,GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.							Arechiga H, 1993, Curr Opin Neurobiol, V3, P1005, DOI 10.1016/0959-4388(93)90174-W; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MITTAG M, 1994, P NATL ACAD SCI USA, V91, P5257, DOI 10.1073/pnas.91.12.5257; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; TAKAHASHI J, 1991, CURR OPIN NEUROSCI, V1, P21; TAKAHASHI JS, 1993, NATURE, V365, P299, DOI 10.1038/365299a0; TAKAHASHI JS, 1993, ANNU REV PHYSIOL, V55, P729, DOI 10.1146/annurev.physiol.55.1.729; TAKEUCHI J, 1993, NEURON, V11, P825, DOI 10.1016/0896-6273(93)90112-5; TAMARKIN L, 1985, SCIENCE, V227, P714, DOI 10.1126/science.3881822; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A	31	68	69	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					361	364		10.1016/0092-8674(94)90415-4	http://dx.doi.org/10.1016/0092-8674(94)90415-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062383				2022-12-28	WOS:A1994PC40500003
J	KWON, H; IMBALZANO, AN; KHAVARI, PA; KINGSTON, RE; GREEN, MR				KWON, H; IMBALZANO, AN; KHAVARI, PA; KINGSTON, RE; GREEN, MR			NUCLEOSOME DISRUPTION AND ENHANCEMENT OF ACTIVATOR BINDING BY A HUMAN SW1/SNF COMPLEX	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; YEAST; GAL4; DNA; SNF2/SWI2; PROTEINS; INVITRO; FAMILY; CHROMATIN; DOMAINS	CHROMATIN structure can affect the transcriptional activity of eukaryotic structural genes by blocking access of sequence-specific activator proteins (activators) to their promoter-binding sites(1). For example, the DNA-binding domain of the yeast GAL4 protein interacts very poorly with nucleosome cores compared with naked DNA(2) (and see below), and binding of other activators is even more strongly inhibited(2,3). The way in which activators bind to nucleosomal DNA is therefore a critical aspect of transcriptional activation. Genetic studies have suggested that the multi-component SWI/SNF complex of Saccharomyces cerevisiae facilitates transcription by altering the structure of the chromatin(4,5). Here we identify and partially purify a human homologue of the yeast SWI/SNF complex (hSWI/SNF complex). We show that a partially purified hSWI/SNF complex mediates the ATP-dependent disruption of a nucleosome, thereby enabling the activators, GAL4-VP16 and GAL4-AH, to bind within a nucleosome core. We conclude that the hSWI/SNF complex acts directly to reorganize chromatin structure so as to facilitate binding of transcription factors.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; STANFORD UNIV,CTR MOILEC & GENET MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Stanford University								CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	24	647	655	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					477	481		10.1038/370477a0	http://dx.doi.org/10.1038/370477a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047169				2022-12-28	WOS:A1994PB40700061
J	DIFFLEY, JFX; COCKER, JH; DOWELL, SJ; ROWLEY, A				DIFFLEY, JFX; COCKER, JH; DOWELL, SJ; ROWLEY, A			2 STEPS IN THE ASSEMBLY OF COMPLEXES AT YEAST REPLICATION ORIGINS IN-VIVO	CELL			English	Article							CEREVISIAE CELL-CYCLE; DNA-BINDING FACTORS; SACCHAROMYCES-CEREVISIAE; RECOGNITION COMPLEX; TRANSCRIPTIONAL REPRESSION; SUBCELLULAR-LOCALIZATION; CHROMATIN ORGANIZATION; MULTIPROTEIN COMPLEX; CHROMOSOMAL ORIGIN; LICENSING FACTOR	The integration of chromosomal DNA replication into the eukaryotic cell cycle might involve temporal regulation of interactions between cellular factors and replication origins. We show here that yeast replication origins exist in two chromatin states during the cell cycle. In the postreplicative state, genomic footprints closely resemble those produced in vitro by the purified ORC and ABF1 proteins, indicating that the binding of these proteins to replication origins is not sufficient to drive the initiation of DNA replication. The prereplicative state is characterized by an additional region of protection overlapping the ORC footprint. This prereplicative complex appears near the end of mitosis and persists through G1. After entry into S phase, origins return to the postreplicative state. Similarities in temporal regulation of the prereplicative state and the Xenopus licensing factor suggest that mechanisms limiting DNA replication to once per cell cycle may be conserved among eukaryotes.			DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.			Diffley, John/0000-0001-5184-7680; Dowell, Simon/0000-0001-6499-7573				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1992, MOL BIOL SACCHAROMYC, P25; DORSMAN JC, 1990, NUCLEIC ACIDS RES, V18, P2769, DOI 10.1093/nar/18.9.2769; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; ESTES HG, 1992, P NATL ACAD SCI USA, V89, P11156, DOI 10.1073/pnas.89.23.11156; FAGRELIUS TJ, 1984, J MOL BIOL, V173, P1, DOI 10.1016/0022-2836(84)90400-5; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; RIVIN CJ, 1980, J CELL BIOL, V85, P96, DOI 10.1083/jcb.85.1.96; SRIENC F, 1985, MOL CELL BIOL, V5, P1676, DOI 10.1128/MCB.5.7.1676; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VEIT BE, 1985, MOL CELL BIOL, V5, P2190, DOI 10.1128/MCB.5.9.2190; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5; [No title captured]	62	479	487	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					303	316		10.1016/0092-8674(94)90299-2	http://dx.doi.org/10.1016/0092-8674(94)90299-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044842				2022-12-28	WOS:A1994NZ24200013
J	GUNNELL, D; FRANKEL, S				GUNNELL, D; FRANKEL, S			PREVENTION OF SUICIDE - ASPIRATIONS AND EVIDENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TREATMENT-OF-DEPRESSION; LONG-TERM LITHIUM; GENERAL-PRACTITIONERS; EDUCATIONAL-PROGRAM; AFFECTIVE-DISORDERS; NEWSPAPER REPORTS; CONTROLLED TRIAL; FOLLOW-UP; BEHAVIOR; RATES	The Health of the Nation white paper set a target for 15% reduction in overall suicide rates by the year 2000. If the targets are to be achieved interventions must be identified which are of proved effectiveness. This paper examines the evidence on the available interventions and points of access to the population at risk. No single intervention has been shown in a well, conducted randomised controlled trial to reduce suicide. The greatest potential seems to arise From limiting the availability of methods. In particular it is likely that the introduction of the catalytic convertor will lead to reduced lethality of car exhausts and reductions in suicide using this method. General practitioner education programmes, the effectiveness of lithium and maintenance antidepressants, and limits on the quantity of medicines available over the counter or on prescription should all be evaluated. Particular high risk groups include people recently discharged from psychiatric hospitals and those with a history of parasuicide. Many social processes affect suicide rates and these rather than specific interventions may help or hinder the ability to realise the Health of the Nation targets. Well conducted trials are essential to distinguish complex social processes from the effects of specific interventions for suicide prevention. This review of the available evidence offers little support for the aspiration that the posited targets can be achieved on the basis of current knowledge and current policy.			GUNNELL, D (corresponding author), UNIV BRISTOL, DEPT EPIDEMIOL & PUBL HLTH MED, HLTH CARE EVALUAT UNIT, BRISTOL BS8 2PR, ENGLAND.		Gunnell, David/ABE-6653-2020; anand, amit/A-7222-2009	Gunnell, David/0000-0002-0829-6470; 				Adelstein A, 1976, POPULATION TRENDS, V6, P7; ALLEBECK P, 1990, ACTA PSYCHIAT SCAND, V81, P565, DOI 10.1111/j.1600-0447.1990.tb05500.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; APTER A, 1993, ARCH GEN PSYCHIAT, V50, P138; ARORA RC, 1989, AM J PSYCHIAT, V146, P730; ASBERG M, 1988, CURRENT ISSUES SUICI, P221; ASHTON JR, 1981, PSYCHOL MED, V11, P735, DOI 10.1017/S0033291700041234; BABIGIAN HM, 1969, AM J PSYCHIAT, V126, P470, DOI 10.1176/ajp.126.4.470; BAGLEY C, 1968, SOC SCI MED, V2, P1, DOI 10.1016/0037-7856(68)90097-8; BANCROFT J, 1977, PSYCHOL MED, V7, P289, DOI 10.1017/S0033291700029391; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BARRACLOUGH B, 1977, BRIT J PSYCHIAT, V131, P528, DOI 10.1192/bjp.131.5.528; BARRACLOUGH BM, 1970, LANCET, V2, P868; BERGLUND M, 1984, ARCH GEN PSYCHIAT, V41, P888; BILLINGS JH, 1976, DISS ABSTR INT 1, V36, P6369; Black D.W., 1989, ANN CLIN PSYCHIATRY, V1, P165, DOI [10.3109/10401238909149975, DOI 10.3109/10401238909149975]; BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; BRIDGES K, 1987, PRESENTATION DEPRESS, P9; BROWN GL, 1986, SUICIDE LIFE-THREAT, V16, P223; BUCKLEY NA, 1994, LANCET, V343, P159, DOI 10.1016/S0140-6736(94)90940-7; BUGLASS D, 1977, PARASUICIDE, P158; BUSUTTIL A, 1993, LANCET, V342, P744, DOI 10.1016/0140-6736(93)91737-7; CANTOR CH, 1989, BRIT J PSYCHIAT, V155, P829, DOI 10.1192/bjp.155.6.829; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CATFORD JC, 1991, BRIT MED J, V302, P980, DOI 10.1136/bmj.302.6783.980; Charlton J., 1992, Population Trends, P10; Charlton J., 1993, POPULATION TRENDS, V71, P34; CHOWDHURY N, 1973, SOC PSYCHIATR, V8, P67, DOI 10.1007/BF00589238; Clarke R. V., 1989, SUICIDE CLOSING EXIT; CLARKE RV, 1987, J EPIDEMIOL COMMUN H, V41, P114, DOI 10.1136/jech.41.2.114; COPPEN A, 1971, LANCET, V2, P275; COPPEN A, 1990, LANCET, V335, P1347, DOI 10.1016/0140-6736(90)91232-Y; COX JF, 1988, INT J LAW PSYCHIAT, V11, P391, DOI 10.1016/0160-2527(88)90009-X; CROME P, 1993, ACTA PSYCHIAT SCAND, V87, P33, DOI 10.1111/j.1600-0447.1993.tb05371.x; Dashef S S, 1984, J Am Coll Health, V33, P118; DEW MA, 1987, J CONSULT CLIN PSYCH, V55, P239, DOI 10.1037/0022-006X.55.2.239; DEYKIN EY, 1986, J ADOLESCENT HEALTH, V7, P88, DOI 10.1016/S0197-0070(86)80002-X; DIEKSTRA RFW, 1993, ACTA PSYCHIAT SCAND, V87, P9, DOI 10.1111/j.1600-0447.1993.tb05368.x; DONNELL I, 1992, ACTA PSYCHIAT SCAND, V86, P60; DOOLEY E, 1990, BRIT J PSYCHIAT, V156, P40, DOI 10.1192/bjp.156.1.40; Durkheim E., 1952, SUICIDE; Ettlinger R, 1975, Acta Psychiatr Scand Suppl, V260, P1; ETZERSDORFER E, 1992, NEW ENGL J MED, V327, P502; FARMER R, 1991, INT J EPIDEMIOL, V20, P707, DOI 10.1093/ije/20.3.707; FARMER RDT, 1988, BRIT J PSYCHIAT, V153, P16, DOI 10.1192/bjp.153.1.16; FARMER RDT, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb03044.x; FOX R, 1975, R SOC HLTH J, V95, P19; FREELING P, 1985, BMJ-BRIT MED J, V290, P1880, DOI 10.1136/bmj.290.6485.1880; GARNIER R, 1993, BRIT MED J, V306, P718, DOI 10.1136/bmj.306.6879.718; GIBBONS JS, 1978, BRIT J PSYCHIAT, V133, P111, DOI 10.1192/bjp.133.2.111; GLATT KM, 1987, SUICIDE LIFE-THREAT, V17, P299; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GOLDSTEIN RB, 1991, ARCH GEN PSYCHIAT, V48, P418; GUNNELL D, 1994, PREVENTION SUICIDE, P114; HAWTON K, 1992, BMJ-BRIT MED J, V304, P1000, DOI 10.1136/bmj.304.6833.1000; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; HAWTON K, 1993, BRIT J PSYCHIAT, V162, P422, DOI 10.1192/bjp.162.3.422a; HAWTON K, 1987, PSYCHOL MED, V17, P751, DOI 10.1017/S0033291700025988; HERBERT M, 1989, ADOLESCENT SUICIDE R, P89; HICKS BB, 1991, DISS ABSTR INT A, V52, P812; HOLDING TA, 1974, BRIT J PSYCHIAT, V124, P470, DOI 10.1192/bjp.124.5.470; JAMES IP, 1967, BRIT J ADDICT, V62, P391; JENNINGS C, 1978, PSYCHOL MED, V8, P413, DOI 10.1017/S0033291700016081; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KIMBERLEY MD, 1991, CAN MED ASSOC J, V145, P1211; KRAGHSORENSEN P, 1993, ACTA PSYCHIAT SCAND, V87, P57, DOI 10.1111/j.1600-0447.1993.tb05376.x; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; KRIEGER G, 1978, J CLIN PSYCHIAT, V39, P649; LESTER D, 1990, ACTA PSYCHIAT SCAND, V81, P146, DOI 10.1111/j.1600-0447.1990.tb06468.x; LESTER D, 1989, PERCEPT MOTOR SKILL, V68, P273, DOI 10.2466/pms.1989.68.1.273; LESTER D, 1992, SOC PSYCH PSYCH EPID, V27, P75, DOI 10.1007/BF00788509; LESTER D, 1990, UNDERSTANDNG PREVENT; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; Litman R E, 1976, Evaluation, V3, P36; LOW AA, 1981, PSYCHOL MED, V11, P359, DOI 10.1017/S003329170005217X; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; MARZUK PM, 1993, NEW ENGL J MED, V329, P1508, DOI 10.1056/NEJM199311113292022; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MARZUK PM, 1992, ARCH GEN PSYCHIAT, V49, P451; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MILLER HL, 1984, AM PUBLIC HLTH, V74, P430; MOENS GFG, 1988, ACTA PSYCHIAT SCAND, V77, P320, DOI 10.1111/j.1600-0447.1988.tb05128.x; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; MONTGOMERY SA, 1982, J AFFECT DISORDERS, V4, P291, DOI 10.1016/0165-0327(82)90026-X; MORGAN HG, 1993, BRIT J PSYCHIAT, V163, P111, DOI 10.1192/bjp.163.1.111; MORGAN HG, 1992, BRIT J PSYCHIAT, V160, P149, DOI 10.1192/bjp.160.2.149; MORGAN HG, 1991, BRIT J PSYCHIAT, V158, P368, DOI 10.1192/bjp.158.3.368; MORGAN HG, 1994, BRIT J PSYCHIAT, V164, P126, DOI 10.1192/bjp.164.1.126; MORGAN HG, 1993, PSYCHIATRIC B, V17, P135; MORRO JA, 1976, SUICIDE LIFE-THREAT, V6, P223; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; Mulder A M, 1989, Crisis, V10, P36; MULLEROERLINGHAUSEN B, 1992, ACTA PSYCHIAT SCAND, V86, P218, DOI 10.1111/j.1600-0447.1992.tb03255.x; MURPHY GE, 1975, ANN INTERN MED, V82, P301, DOI 10.7326/0003-4819-82-3-301; NORDENTOFT M, 1993, BRIT MED J, V306, P1637, DOI 10.1136/bmj.306.6893.1637; O'Carroll P W, 1988, MMWR Suppl, V37, P1; OLIVER RG, 1973, INT J EPIDEMIOL, V2, P91, DOI 10.1093/ije/2.1.91; OSTROFF RB, 1987, NEW ENGL J MED, V316, P876; OVENSTON.IM, 1974, BRIT J PSYCHIAT, V124, P336, DOI 10.1192/bjp.124.4.336; PAYKEL ES, 1974, BRIT J PSYCHIAT, V124, P460, DOI 10.1192/bjp.124.5.460; PHILLIPS DP, 1986, NEW ENGL J MED, V315, P685, DOI 10.1056/NEJM198609113151106; PLATT S, 1987, BRIT MED J, V294, P954, DOI 10.1136/bmj.294.6577.954; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; RALEIGH VS, 1992, BRIT J PSYCHIAT, V161, P365, DOI 10.1192/bjp.161.3.365; Raleigh VS, 1992, HLTH TRENDS, V24, P91; RAMSAY RF, 1987, CAN J CRIMINOL, V29, P295; RICH CL, 1990, AM J PSYCHIAT, V147, P342; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; RIHMER Z, 1990, J AFFECT DISORDERS, V20, P87, DOI 10.1016/0165-0327(90)90121-N; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSS TE, 1991, AM J PUBLIC HEALTH, V81, P1677, DOI 10.2105/AJPH.81.12.1677-a; ROUILLON F, 1989, Encephale, V15, P527; ROY A, 1989, ARCH GEN PSYCHIAT, V46, P609; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; RUTZ W, 1990, ACTA PSYCHIAT SCAND, V82, P399, DOI 10.1111/j.1600-0447.1990.tb03068.x; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V79, P19, DOI 10.1111/j.1600-0447.1989.tb09229.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P457, DOI 10.1111/j.1600-0447.1992.tb03212.x; SALKOVSKIS PM, 1990, BRIT J PSYCHIAT, V157, P871, DOI 10.1192/bjp.157.6.871; SCHMIDTKE A, 1988, PSYCHOL MED, V18, P665, DOI 10.1017/S0033291700008345; SCHOU M, 1988, BRIT J PSYCHIAT, V153, P324, DOI 10.1192/bjp.153.3.324; SCHWARTZ AJ, 1988, AM J COLL HLTH, V37, P53; SEAGER CP, 1965, BRIT J PSYCHIAT, V111, P919, DOI 10.1192/bjp.111.479.919; SHAFFER D, 1988, J AM ACAD CHILD PSY, V27, P675, DOI 10.1097/00004583-198811000-00001; SHERMAN L G, 1989, Psychiatric Quarterly (New York), V60, P119, DOI 10.1007/BF01064939; SMIALEK JE, 1978, JAMA-J AM MED ASSOC, V240, P2563, DOI 10.1001/jama.240.23.2563; SOUZA FGM, 1991, BRIT J PSYCHIAT, V158, P666, DOI 10.1192/bjp.158.5.666; SURTEES SJ, 1982, BMJ-BRIT MED J, V284, P321, DOI 10.1136/bmj.284.6312.321; TODD CJ, 1992, J PSYCHOPHARMACOL, V6, P318, DOI 10.1177/0269881192006002061; TURNER RJ, 1979, PSYCHOL MED, V9, P487, DOI 10.1017/S0033291700032037; VASSILAS CA, 1993, BRIT MED J, V307, P300, DOI 10.1136/bmj.307.6899.300; VIELAND V, 1991, J AM ACAD CHILD PSY, V30, P811, DOI 10.1016/S0890-8567(10)80021-8; WAGG AS, 1993, LANCET, V342, P1295, DOI 10.1016/0140-6736(93)92383-5; WHITAKER LC, 1990, J COLL STUDENT PSYCH, V4, P211; Whitlock F., 1986, SUICIDE, V4, P151; 1993, TREATMENT DEPRESSION, P1; 1981, SUICIDE DILIBERATE S; 1992, HLTH NATION STRATEGY; 1993, PRODUCERS GUIDELINES, P83; 1993, KEY AREA HDB MENTAL; 1990, SUICIDE PREVENTION C	142	301	309	2	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 7	1994	308	6938					1227	1233		10.1136/bmj.308.6938.1227	http://dx.doi.org/10.1136/bmj.308.6938.1227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8080520	Green Published			2022-12-28	WOS:A1994NK95600029
J	WERTZ, DC; FANOS, JH; REILLY, PR				WERTZ, DC; FANOS, JH; REILLY, PR			GENETIC TESTING FOR CHILDREN AND ADOLESCENTS - WHO DECIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUNTINGTON DISEASE; ILLNESS; CONSENT; PARTICIPATION; PHYSICIANS; DECISIONS; ATTITUDES; CANCER; ISSUES; ADULTS	In the future there is likely to be a large array of DNA-based tests to diagnose single-gene disorders and to identify predispositions to genetically influenced disorders. This article focuses on ethical, legal, and psychological implications of testing healthy children and adolescents for such disorders. Testing may offer medical or psychological benefits but may harm parent-child bonds or the child's self-concept. Clinicians may encounter situations where they must weigh the child's or adolescent's wishes against wishes of parents. We examine the legal history and current status of miners as health care consumers; psychosocial research on their maturity to make choices; impact of testing on intrafamilial relationships; views of national commissions on appropriate ages of assent and full informed consent; ethical and legal requirements for competence in children and adolescents; and disclosure of genetic information. We propose guidelines for predictive genetic testing and counseling of children and discuss risks and benefits of testing.	CALIF PACIFIC MED CTR, SAN FRANCISCO, CA USA	California Pacific Medical Center	WERTZ, DC (corresponding author), EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, DIV SOCIAL SCI ETH & LAW, 200 TRAPELO RD, WALTHAM, MA 02254 USA.				NHGRI NIH HHS [R01-HG00639-02, R01-HG00540-02] Funding Source: Medline; NICHD NIH HHS [N01-HD-1-3136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD013136] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000540, R01HG000639] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AMBUEL B, 1992, LAW HUMAN BEHAV, V16, P129, DOI 10.1007/BF01044794; ANDREWS LB, 1987, MED GENETICS LEGAL F, P115; Aries 27Philippe, 1965, CENTURIES CHILDHOOD; BAUER IL, 1952, J PEDIATR-US, V40, P796, DOI 10.1016/S0022-3476(52)80083-6; BEAUCHAMP TL, 1984, MED ETHICS MORAL RES; BEAUCHAMP TL, 1979, PRINCIPLES BIOMEDICA, P50; BENNETT R, 1976, VA LAW REV, V62, P285, DOI 10.2307/1072299; BIBACE R, 1980, PEDIATRICS, V66, P912; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BLOCH M, 1989, AM J MED GENET, V32, P217, DOI 10.1002/ajmg.1320320215; BLOCH M, 1990, AM J HUM GENET, V46, P1; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; Brock DW, 1989, CHILDREN HLTH CARE M, P181; Broyde Channah Sageev, 1987, Natl Jew Law Rev, V2, P123; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P215; CAPRON AM, 1982, WHO SPEAKS CHILD PRO, P57; CHAPMAN MA, 1990, AM J HUM GENET, V47, P1; Childress J., 1982, WHO SHOULD DECIDE PA; Clow C L, 1977, Prog Clin Biol Res, V18, P381; CLOW CL, 1977, PEDIATRICS, V59, P86; CRAUFURD D, 1990, LANCET, V335, P1406, DOI 10.1016/0140-6736(90)91289-M; Dunn J., 1985, SISTERS BROTHERS; EISER C, 1983, CHILD CARE HLTH DEV, V9, P233, DOI 10.1111/j.1365-2214.1983.tb00320.x; ENGELHARDT HT, 1982, CONT ISSUES BIOETHIC, P132; Ewald Linda Sorenson, 1982, St Louis Univ Law J, V25, P689; FANOS JH, 1992, PEDIATR PULM, P228; FANOS JH, 1987, DEV CONSEQUENCES ADU; FANOS JH, 1993, AM J HUM GENET S, V53; Feigenbaum Matthew S, 1992, De Paul Law Rev, V41, P841; FLETCHER JC, 1989, PRINCIPLES PRACTICE, P309; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; Freedman Stephen D, 1980, Cap Univ Law Rev, V10, P309; FRIEDENBERG EA, 1965, COMING AGE AM GROWTH; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GABOW PA, 1989, AM J KIDNEY DIS, V13, P85; GANS JE, 1993, POLICY COMPENDIUM CO; GAYLIN W, 1982, HASTINGS CENT REP, V12, P33, DOI 10.2307/3561805; Gilligan C., 1982, DIFFERENT VOICE; Green A. H., 1985, POST TRAUMATIC STRES, P133; GREEN M, 1964, PEDIATRICS, V34, P58; GRISSO T, 1981, JUVENILES WAIVER RIG; GRISSO T, 1983, PROFESSIONAL PSYCHOL, V9, P412; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; HOLDER A, 1989, CHILDREN HLTH CARE M, P161; Holder A R, 1988, Law Med Health Care, V16, P219; HOLDER AR, 1977, LEGAL ISSUES PEDIATR; Katz J., 1984, SILENT WORLD DOCTOR; Katz J., 1972, EXPT HUMAN BEINGS; KESSLER S, 1988, AM J MED GENET, V31, P617, DOI 10.1002/ajmg.1320310316; Kett Joseph F., 1977, RITES PASSAGE ADOLES; KISTER MC, 1980, CHILD DEV, V51, P839, DOI 10.1111/j.1467-8624.1980.tb02621.x; Kohlberg L., 1976, MORAL DEV BEHAV THEO, P31; KOOCHER G P, 1986, Cancer, V58, P468, DOI 10.1002/1097-0142(19860715)58:2+<468::AID-CNCR2820581310>3.0.CO;2-Q; KORSCH BM, 1961, J MED ASS GA, V50, P519; LEIKIN SL, 1982, MAKING HLTH CARE DEC, V3, P175; Lewis C. E., 1983, CHILDRENS COMPETENCE, P75; LEWIS CC, 1980, AM J ORTHOPSYCHIAT, V50, P446, DOI 10.1111/j.1939-0025.1980.tb03304.x; LEWIS CE, 1978, AM J PUBLIC HEALTH, V68, P1079, DOI 10.2105/AJPH.68.11.1079; LOCICERO A, 1976, CHILDRENS RIGHTS MEN, P13; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Macklin R, 1982, WHO SPEAKS CHILD PRO, P265; MADDUX JE, 1986, AM PSYCHOL, V41, P25, DOI 10.1037/0003-066X.41.1.25; MEAD M, 1971, COMING AGE SAMOA; MELTON GB, 1983, CHILDRENS COMPETENCE, P1; MELTON GB, 1982, RIGHTS CHILDREN LEGA, P161; MILLSTEIN SG, 1981, PEDIATRICS, V68, P834; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; Nicholson RH, 1986, MED RES CHILDREN ETH; Nickerson B., 1991, J ADOLESCENT RES, V6, P70, DOI DOI 10.1177/074355489161006; PAGE A, 1992, AM J HUM GENET S, V51; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PERRIN EC, 1981, PEDIATRICS, V67, P841; PETERSEN GM, 1993, HUM GENET, V91, P307; Piaget J., 1965, MORAL JUDGEMENT CHIL; Piaget J., 1969, PSYCHOL CHILD; Platt Anthony M., 2009, CHILD SAVERS INVENTI; REILLY P, 1991, SURGICAL SOLUTION; Ruddick W., 1989, CHILDREN HLTH CARE M, P221; SCHERER DG, 1988, LAW HUMAN BEHAV, V12, P123, DOI 10.1007/BF01073121; SHARPE NF, 1993, AM J MED GENET, V46, P250, DOI 10.1002/ajmg.1320460232; SHERIDAN MS, 1975, SOC WORK, V20, P40; Sherwin S., 1992, NO LONGER PATIENT FE; SPONETTA JJ, 1981, LIVING CHILDHOOD CAN, P5; SUSMAN EJ, 1992, J PEDIATR-US, V121, P547, DOI 10.1016/S0022-3476(05)81142-4; SUSMAN EJ, 1987, J DEV BEHAV PEDIATR, V8, P266; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243; Wadlington Walter, 1973, Osgoode Hall Law J, V11, P115; WADLINGTON WJ, 1983, CHILDRENS COMPETENCE, P57; WAISBREN SE, 1991, AM J PUBLIC HEALTH, V81, P299, DOI 10.2105/AJPH.81.3.299; Weithorn L. A., 1983, CHILDRENS COMPETENCE, P235; WEITHORN LA, 1982, CHILD DEV, V53, P1589, DOI 10.2307/1130087; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34; Wertz Dorothy C, 1993, J Womens Health, V2, P173, DOI 10.1089/jwh.1993.2.173; Wexler N S, 1985, Prog Med Genet, V6, P277; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; Zelizer V., 1985, PRICING PRICELESS CH; 1993, ASSESSING GENETIC RI; 1977, DHEW OS770004 PUBL, V1, P1213; 1993, GPO0887809 NAT COMM; FED REGISTER, V48, P9818; 1982, MAKING HLTH CARE DEC, V1, P60; 1993, GENETIC TESTING CHIL; 1987, GUIDELINES RES INVOL	103	216	216	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					875	881		10.1001/jama.272.11.875	http://dx.doi.org/10.1001/jama.272.11.875			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078166				2022-12-28	WOS:A1994PG18200027
J	TOLEDANO, MB; KULLIK, I; TRINH, F; BAIRD, PT; SCHNEIDER, TD; STORZ, G				TOLEDANO, MB; KULLIK, I; TRINH, F; BAIRD, PT; SCHNEIDER, TD; STORZ, G			REDOX-DEPENDENT SHIFT OF OXYR-DNA CONTACTS ALONG AN EXTENDED DNA-BINDING SITE - A MECHANISM FOR DIFFERENTIAL PROMOTER SELECTION	CELL			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATOR; POSITIVE REGULATOR; OXIDATIVE STRESS; INDUCIBLE GENES; NOD BOX; PROTEIN; RECOGNITION; EXPRESSION; ACTIVATOR	The redox-sensitive OxyR protein activates the transcription of antioxidant defense genes in response to oxidative stress and represses its own expression under both oxidizing and reducing conditions. Previous studies showed that OxyR-binding sites are unusually long with limited sequence similarity. Here, we report that oxidized OxyR recognizes a motif comprised of four ATAGnt elements spaced at 10 bp intervals and contacts these elements in four adjacent major grooves on one face of the DNA helix. In contrast, reduced OxyR contacts two pairs of adjacent major grooves separated by one helical turn. The two modes of binding are essential for OxyR to function as both an activator and a repressor in vivo. We propose that specific DNA recognition by an OxyR tetramer is achieved with four contacts of intermediate affinity allowing OxyR to reposition its DNA contacts and target alternate sets of promoters as the cellular redox state is altered.	NCI,MATH BIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TOLEDANO, MB (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Storz, Gisela/0000-0001-6698-1241; Schneider, Thomas/0000-0002-9841-1531				ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; BOLKER M, 1989, EMBO J, V8, P2403, DOI 10.1002/j.1460-2075.1989.tb08370.x; CHANG M, 1990, NUCLEIC ACIDS RES, V18, P979, DOI 10.1093/nar/18.4.979; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FISHER RF, 1993, J MOL BIOL, V233, P336, DOI 10.1006/jmbi.1993.1515; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; Miller J.H., 1972, EXPT MOL GENETICS; PAPP PP, 1993, J MOL BIOL, V233, P219, DOI 10.1006/jmbi.1993.1501; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RICHET E, 1991, CELL, V66, P1185, DOI 10.1016/0092-8674(91)90041-V; ROTHMEL RK, 1991, J BACTERIOL, V173, P4717, DOI 10.1128/jb.173.15.4717-4724.1991; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STORZ G, 1994, METHOD ENZYMOL, V234, P217; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAO K, 1991, J BIOCHEM-TOKYO, V109, P262; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P2038; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6	26	323	335	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					897	909		10.1016/S0092-8674(94)90702-1	http://dx.doi.org/10.1016/S0092-8674(94)90702-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087856				2022-12-28	WOS:A1994PG29600018
J	GILLINGSMITH, C; TOOZSHOBSON, P; POTTS, DJ; TOUQUET, R; BEARD, RW				GILLINGSMITH, C; TOOZSHOBSON, P; POTTS, DJ; TOUQUET, R; BEARD, RW			MANAGEMENT OF BLEEDING IN EARLY-PREGNANCY IN ACCIDENT AND EMERGENCY DEPARTMENTS	BRITISH MEDICAL JOURNAL			English	Article									ST MARKS HOSP,DEPT ACCID & EMERGENCY,LONDON W2 1NY,ENGLAND	Imperial College London				Toozs-Hobson, Philip/0000-0002-1859-9934				CHAMBERLAIN G, 1991, BRIT MED J, V302, P1141, DOI 10.1136/bmj.302.6785.1141; GILLINGSMITH C, 1988, ARCH EMERG MED, V5, P133; HUGGON AM, 1993, ARCH EMERG MED, V10, P306; TOUQUET R, 1994, MED NEGLIGENCE; 1991, PRESCRIBERS J, V31, P137	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					574	575						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086945				2022-12-28	WOS:A1994PF33000019
J	SPRENT, J; TOUGH, DF				SPRENT, J; TOUGH, DF			LYMPHOCYTE LIFE-SPAN AND MEMORY	SCIENCE			English	Review							T-CELL MEMORY; RECENT THYMIC EMIGRANTS; RECEPTOR TRANSGENIC MICE; HEAT-STABLE ANTIGEN(HI); ADULT MURINE THYMUS; PERIPHERAL B-CELLS; IMMUNOLOGICAL MEMORY; CLONAL ELIMINATION; SYNGENEIC HOSTS; IMMUNE-RESPONSE	Differentiation of immature T and B cells in the primary lymphoid organs gives rise to a pool of long-lived lymphocytes that recirculate through the secondary lymphoid tissues. On the basis of their surface markers, T and B cells comprise a mixture of naive and memory cells with differing life-spans. Immunization (and vaccination) causes naive lymphocytes to proliferate and differentiate into effector cells and memory cells. Whether the survival of memory cells is innate or requires persistent contact with residual antigen is controversial. Resolving this issue may be crucial for designing optimal vaccines.			SPRENT, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA025803, R01CA038355, R37CA038355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021487] Funding Source: NIH RePORTER; NCI NIH HHS [CA25803, CA38355] Funding Source: Medline; NIAID NIH HHS [AI21487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUS DB, 1991, J EXP MED, V173, P1039, DOI 10.1084/jem.173.5.1039; Ahmed R, 1992, Semin Immunol, V4, P105; AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; ARTHUR RP, 1986, J EXP MED, V163, P774, DOI 10.1084/jem.163.4.774; BASTEN A, 1973, CELL IMMUNOL, V7, P404; Bell E B, 1992, Semin Immunol, V4, P43; BELL EB, 1987, J IMMUNOL, V139, P1379; Beverley P C, 1992, Semin Immunol, V4, P35; BUDD RC, 1987, J IMMUNOL, V138, P3120; CELADA F, 1971, PROG ALLERGY, V15, P223; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; COLLE JH, 1990, CRIT REV IMMUNOL, V10, P259; COOPER MD, 1976, COLD SPRING HARB SYM, V41, P139; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DEENEN GJ, 1993, INT IMMUNOL, V5, P735, DOI 10.1093/intimm/5.7.735; DEENEN GJ, 1993, EUR J IMMUNOL, V23, P12, DOI 10.1002/eji.1830230104; Doherty P C, 1993, Trends Microbiol, V1, P207, DOI 10.1016/0966-842X(93)90133-C; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ERNST DN, 1993, J IMMUNOL, V151, P575; EVERETT NB, 1964, ANN NY ACAD SCI, V113, P887, DOI 10.1111/j.1749-6632.1964.tb40710.x; FELDBUSH TL, 1973, CELL IMMUNOL, V8, P435, DOI 10.1016/0008-8749(73)90134-2; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; FORSTER I, 1991, EUR J IMMUNOL, V21, P1779, DOI 10.1002/eji.1830210732; FOWELL D, 1991, IMMUNOL REV, V123, P37, DOI 10.1111/j.1600-065X.1991.tb00605.x; FREITAS AA, 1993, IMMUNOL TODAY, V14, P25, DOI 10.1016/0167-5699(93)90320-K; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOWANS JL, 1966, J EXP MED, V124, P1017, DOI 10.1084/jem.124.5.1017; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HEEG K, 1993, INT IMMUNOL, V5, P929, DOI 10.1093/intimm/5.8.929; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HOSSEINZADEH H, 1993, J IMMUNOL, V150, P1670; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KELLY KA, 1990, INT IMMUNOL, V2, P419, DOI 10.1093/intimm/2.5.419; KELLY KA, 1993, INT IMMUNOL, V5, P331, DOI 10.1093/intimm/5.4.331; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Linton P J, 1992, Semin Immunol, V4, P3; LUCAS B, 1994, J IMMUNOL, V153, P53; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MICHIE SA, 1989, THYMUS, V13, P141; Miller J F, 1969, Transplant Rev, V1, P3; MILLER JFA, 1967, PHYSIOL REV, V47, P437, DOI 10.1152/physrev.1967.47.3.437; MITCHISON NA, 1968, IMMUNOLOGY, V15, P509; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOTYKA B, 1991, EUR J IMMUNOL, V21, P1951, DOI 10.1002/eji.1830210825; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; NOSSAL GJV, 1989, FUNDAMENTAL IMMUNOLO, P571; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; OSMOND DG, 1993, IMMUNOL TODAY, V14, P34, DOI 10.1016/0167-5699(93)90322-C; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; REYNOLDS JD, 1986, J IMMUNOL, V136, P2005; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROMBALL CG, 1993, J EXP MED, V178, P1637, DOI 10.1084/jem.178.5.1637; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SCOLLAY R, 1982, ADV EXP MED BIOL, V149, P269; SCOLLAY R, 1985, RECOGNITION REGULATI, P3; SCOTT DE, 1993, J IMMUNOL, V150, P664; Shortman K, 1990, Semin Immunol, V2, P3; SHORTMAN K, 1987, J IMMUNOL, V138, P342; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1976, CELL IMMUNOL, V21, P314, DOI 10.1016/0008-8749(76)90059-9; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRENT J, 1973, CELL IMMUNOL, V7, P10, DOI 10.1016/0008-8749(73)90180-9; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; SPRENT J, 1977, LYMPHOCYTE STRUCTURE, P43; Sprent Jonathan, 1993, P75; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STROBER S, 1975, TRANSPLANT REV, V24, P84; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SURH CD, 1993, J EXP MED, V177, P379, DOI 10.1084/jem.177.2.379; Swain S L, 1992, Semin Immunol, V4, P59; TABI Z, 1988, CELL IMMUNOL, V113, P268, DOI 10.1016/0008-8749(88)90026-3; TOUGH D, UNPUB; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; UNUTMAZ D, IN PRESS J EXP MED; VERNACHIO J, 1989, J IMMUNOL, V142, P48; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1993, IMMUNOL REV, V131, P169, DOI 10.1111/j.1600-065X.1993.tb01535.x; WEILL JC, 1992, CURR OPIN IMMUNOL, V4, P177, DOI 10.1016/0952-7915(92)90009-4; YANG CP, 1992, EUR J IMMUNOL, V22, P2261, DOI 10.1002/eji.1830220913; YIN XM, 1992, INT IMMUNOL, V4, P691, DOI 10.1093/intimm/4.6.691; YOFFEY JM, 1958, ANN NY ACAD SCI, V73, P47, DOI 10.1111/j.1749-6632.1959.tb40792.x	115	362	373	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1395	1400		10.1126/science.8073282	http://dx.doi.org/10.1126/science.8073282			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073282				2022-12-28	WOS:A1994PE73300035
J	STENDAHL, O; KRAUSE, KH; KRISCHER, J; JERSTROM, P; THELER, JM; CLARK, RA; CARPENTIER, JL; LEW, DP				STENDAHL, O; KRAUSE, KH; KRISCHER, J; JERSTROM, P; THELER, JM; CLARK, RA; CARPENTIER, JL; LEW, DP			REDISTRIBUTION OF INTRACELLULAR CA2+ STORES DURING PHAGOCYTOSIS IN HUMAN NEUTROPHILS	SCIENCE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; FREE CALCIUM; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; HL-60 CELLS; CA-2+ PUMP; PROTEIN; CALRETICULIN; ACTIVATION; GRADIENTS	Subcellular gradients of cytosolic free Ca2+ concentration, [Ca2+](i), are thought to be critical for the localization of functional responses within a cell. A potential but previously unexplored mechanism for the generation of gradients of [Ca2+](i) is the accumulation of Ca2+ stores at the site of Ca2+ action. The distribution of the Ca2+ store markers Ca2+-dependent adenosine triphosphatase and calreticulin was investigated in resting and phagocytosing human neutrophils. Both proteins showed an evenly distributed fine granular pattern in nonphagocytosing cells, but became markedly concentrated in the filamentous actin-rich cytoplasmic area around the ingested particle during phagocytosis. This redistribution began at early stages of phagocytosis and did not depend on an increase in [Ca2+](i). Thus, accumulation of Ca2+ stores in a restricted area of the cell may contribute to the generation of localized increases in [Ca2+](i).	HOP CANTONAL UNIV GENEVA, DIV INFECT DIS, CH-1211 GENEVA 14, SWITZERLAND; CTR MED UNIV GENEVA, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND; VET ADM MED CTR, DEPT MED, IOWA CITY, IA 52242 USA; UNIV IOWA, IOWA CITY, IA 52242 USA	University of Geneva; University of Geneva; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	STENDAHL, O (corresponding author), LINKOPING UNIV, DEPT MED MICROBIOL, S-58185 LINKOPING, SWEDEN.		Krischer, Jeffrey P/I-5004-2012; Clark, Robert/Q-6764-2019; Krause, Karl-Heinz/E-8030-2011	Clark, Robert/0000-0002-4892-3619; Krause, Karl-Heinz/0000-0002-9033-6768				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BENGTSSON T, 1993, EUR J CELL BIOL, V62, P49; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARK RD, UNPUB; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GILL DL, 1989, NATURE, V342, P16, DOI 10.1038/342016a0; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; KRAUSE KH, 1991, FEBS LETT, V285, P225, DOI 10.1016/0014-5793(91)80806-E; KRAUSE KH, UNPUB; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MARKS PW, 1990, CELL CALCIUM, V11, P18, DOI 10.1016/0143-4160(90)90069-7; MATTSON MP, 1990, DEV BRAIN RES, V52, P201, DOI 10.1016/0165-3806(90)90236-R; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MURATA T, 1987, INFECT IMMUN, V55, P1784, DOI 10.1128/IAI.55.8.1784-1791.1987; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SAWYER W, 1992, J LEUKOCYTE BIOL, V51, P437; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; THELER JM, 1991, J RECEPTOR RES, V11, P627, DOI 10.3109/10799899109066431; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; YELAMARTY RV, 1990, J CLIN INVEST, V85, P1799, DOI 10.1172/JCI114638	42	131	131	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1439	1441		10.1126/science.8073285	http://dx.doi.org/10.1126/science.8073285			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073285				2022-12-28	WOS:A1994PE73300046
J	KEENE, WE; MCANULTY, JM; HOESLY, FC; WILLIAMS, LP; HEDBERG, K; OXMAN, GL; BARRETT, TJ; PFALLER, MA; FLEMING, DW				KEENE, WE; MCANULTY, JM; HOESLY, FC; WILLIAMS, LP; HEDBERG, K; OXMAN, GL; BARRETT, TJ; PFALLER, MA; FLEMING, DW			A SWIMMING-ASSOCIATED OUTBREAK OF HEMORRHAGIC COLITIS CAUSED BY ESCHERICHIA-COLI O157-H7 AND SHIGELLA-SONNEI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; WATERBORNE OUTBREAK; GEL-ELECTROPHORESIS; NURSING-HOME; TOXIN-II; O157-H7; INFECTIONS; DIARRHEA; TRANSMISSION; CONSUMPTION	Background. In the summer of 1991, simultaneous outbreaks of bloody diarrhea and hemolytic-uremic syndrome caused by Escherichia coli O157:H7 and of bloody diarrhea caused by Shigella sonnei were traced to a lakeside park near Portland, Oregon. Methods. We identified cases primarily from routine surveillance reports. In case-control studies, the activities of persons with park-associated E. coli O157:H7 or S. sonnei infections were compared independently with those of three sets of controls. We also evaluated environmental conditions at the park and subtyped the bacterial isolates. Results. We identified 21 persons with park-associated E. coli O157:H7 infections (all of them children; median age, six years) and 38 persons with S. sonnei infections (most of them children). These 59 people had visited the park over a 24-day period. Their illnesses were not associated with food or beverage consumption. All the case patients reported swimming, however, and in case-control studies swimming was strongly associated with both types of infection (P = 0.015 or less). The case patients were more likely than the controls to report having swallowed lake water, and they had spent more time in the lake. Numbers of enterococci indicative of substantial fecal contamination (geometric mean, > 50 per deciliter) were detected in the swimming area during some but not all of the outbreak period. Park-associated E. coli O157:H7 isolates were identical by pulsed-field gel electrophoresis and were distinguishable from other isolates in the Portland area. Conclusions. Lake water that was fecally contaminated by bathers was the most likely vehicle for the transmission of both the E. coli O157:H7 and the S. sonnei infections. The unusually prolonged outbreak suggests both the survival of these enteric organisms in lake water and a low infectious dose.	CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, ENTER DIS BRANCH, ATLANTA, GA 30341 USA; MULTNOMAH CTY HLTH DEPT, PORTLAND, OR USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Oregon Health & Science University	KEENE, WE (corresponding author), OREGON HLTH DIV, CTR DIS PREVENT & EPIDEMIOL, 800 NE OREGON ST, SUITE 772, PORTLAND, OR 97232 USA.							[Anonymous], 1992, STANDARD METHODS EXA; Balows A, 1991, MANUAL CLIN MICROBIO; BARON RC, 1982, AM J EPIDEMIOL, V115, P163, DOI 10.1093/oxfordjournals.aje.a113287; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BLOSTEIN J, 1991, PUBLIC HEALTH REP, V106, P317; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; BRENNIMAN GR, 1981, AM J PUBLIC HEALTH, V71, P283, DOI 10.2105/AJPH.71.3.283; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; DUFOUR AP, 1984, EPA600184004 REP; Duncan L., 1987, Canada Diseases Weekly Report, V13, P5; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GOERING RV, 1990, J CLIN MICROBIOL, V28, P1088; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HARTSTEIN AI, 1990, INFECT CONT HOSP EP, V11, P531; KEENE WE, 1993, 33 INT C ANT AG CHEM, P354; MAKINTUBEE S, 1987, AM J PUBLIC HEALTH, V77, P166, DOI 10.2105/AJPH.77.2.166; MCGOWAN KL, 1989, LANCET, V1, P967; Mitscherlich E., 1984, MICROBIAL SURVIVAL E; MORGAN D, 1993, EPIDEMIOL INFECT, V111, P181, DOI 10.1017/S0950268800056880; NEWLAND JW, 1988, J CLIN MICROBIOL, V26, P1292, DOI 10.1128/JCM.26.7.1292-1297.1988; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROSENBERG ML, 1976, JAMA-J AM MED ASSOC, V236, P1849, DOI 10.1001/jama.236.16.1849; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SORVILLO FJ, 1988, AM J TROP MED HYG, V38, P613, DOI 10.4269/ajtmh.1988.38.613; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; Zar JH., 1999, BIOSTAT ANAL; 1981, EPI80922 CTR DIS CON; 1982, MMWR-MORBID MORTAL W, V30, P633; 1986, EPA440584002 REP; 1986, CAN MED ASSOC J, V134, P50; 1982, MMWR-MORBID MORTAL W, V30, P623; 1993, MMWR-MORBID MORTAL W, V42, P85; 1969, MMWR-MORBID MORTAL W, V18, P403	43	240	243	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					579	584		10.1056/NEJM199409013310904	http://dx.doi.org/10.1056/NEJM199409013310904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047082				2022-12-28	WOS:A1994PD69900004
J	FRY, DW; KRAKER, AJ; MCMICHAEL, A; AMBROSO, LA; NELSON, JM; LEOPOLD, WR; CONNERS, RW; BRIDGES, AJ				FRY, DW; KRAKER, AJ; MCMICHAEL, A; AMBROSO, LA; NELSON, JM; LEOPOLD, WR; CONNERS, RW; BRIDGES, AJ			A SPECIFIC INHIBITOR OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; BREAST-CANCER; TGF-ALPHA; OVEREXPRESSION; ACTIVATION; ONCOGENE	A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant. The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concentrations. PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation. PD 153035 demonstrates an increase in potency over that of other tyrosine kinase inhibitors of four to five orders of magnitude for inhibition of isolated EGF receptor tyrosine kinase and three to four orders of magnitude for inhibition of cellular phosphorylation.			FRY, DW (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BRUNTON VG, 1993, CANCER CHEMOTH PHARM, V32, P1, DOI 10.1007/BF00685870; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; FRY D, UNPUB; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; GILL GN, 1987, METHOD ENZYMOL, V146, P82; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GRUAN E, 1989, INT J CELL CLONING, V7, P242; HENDLER FJ, 1989, CANCER CEL, V7, P347; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; MACIAS A, 1987, ANTICANCER RES, V7, P459; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1986, CANCER RES, V46, P5592; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUKAIDA H, 1991, CANCER, V68, P142, DOI 10.1002/1097-0142(19910701)68:1<142::AID-CNCR2820680126>3.0.CO;2-X; NAKAMURA M, 1990, CANCER, V65, P1980; NEAL DE, 1985, LANCET, V1, P366; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODECK U, 1987, CANCER RES, V47, P3692; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TRAXLER PM, 1991, J MED CHEM, V34, P2328, DOI 10.1021/jm00112a003; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513	29	781	848	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1093	1095		10.1126/science.8066447	http://dx.doi.org/10.1126/science.8066447			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066447				2022-12-28	WOS:A1994PC53900036
J	SYLVESTRE, DL; RAVETCH, JV				SYLVESTRE, DL; RAVETCH, JV			FC-RECEPTORS INITIATE THE ARTHUS REACTION - REDEFINING THE INFLAMMATORY CASCADE	SCIENCE			English	Article							MAST-CELLS; RESPONSES	Antibody-antigen complexes initiate the inflammatory response and are central to the pathogenesis of tissue injury. The classical model for this immunopathological cascade, the Arthus reaction, was reinvestigated with a murine strain deficient in Fe receptor expression. Despite normal inflammatory responses to other stimuli, the inflammatory response to immune complexes was markedly attenuated. These results suggest that immune complex-triggered inflammation is initiated by cell bound Fe receptors and is then amplified by cellular mediators and activated complement. These results redefine the inflammatory cascade and may offer other approaches for the study and treatment of immunological injury.			SYLVESTRE, DL (corresponding author), SLOAN KETTERING INST,DEWITT WALLACE RES LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001067, R37AI034662, R01AI034662] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01067, AI34662] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arthus M, 1903, CR SOC BIOL, V55, P817; BENACERRAF B, 1950, J IMMUNOL, V64, P1; BENACERRAF BARUJ, 1959, AMER JOUR PATHOL, V35, P75; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cannon PR, 1941, J IMMUNOL, V40, P127; COCHRANE CG, 1970, J IMMUNOL, V105, P55; COCHRANE CG, 1958, J EXP MED, V108, P591, DOI 10.1084/jem.108.5.591; COCHRANE CG, 1959, J EXP MED, V110, P481, DOI 10.1084/jem.110.3.481; COCHRANE CG, 1974, INFLAMMATORY PROCESS, V3, pCH3; Culbertson JT, 1935, J IMMUNOL, V29, P29; DEWAAL RMW, 1988, J IMMUNOL METHODS, V108, P213, DOI 10.1016/0022-1759(88)90422-X; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; FISCHEL EE, 1947, J IMMUNOL, V55, P337; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; HMPHREY JH, 1955, BR J EXP PATHOL, V36, P283; HUMPHREY JH, 1955, BRIT J EXP PATHOL, V36, P268; ISSEKUTZ AC, 1988, METHOD ENZYMOL, V162, P301; OVARY Z, 1982, INT ARCH ALLER A IMM, V69, P385, DOI 10.1159/000233205; PERLMUTTER DH, 1986, ANNU REV IMMUNOL, V4, P231, DOI 10.1146/annurev.iy.04.040186.001311; POBER JS, 1993, J IMMUNOL, V150, P5114; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, IN PRESS CELL; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; STETSON CA, 1951, J EXP MED, V94, P349; SYLVESTRE DL, UNPUB; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WARD PA, 1964, FED PROC, V23, P509; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	30	265	306	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1095	1098		10.1126/science.8066448	http://dx.doi.org/10.1126/science.8066448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066448				2022-12-28	WOS:A1994PC53900037
J	KLERMAN, JA; GOLDMAN, DP				KLERMAN, JA; GOLDMAN, DP			JOB LOSS DUE TO HEALTH-INSURANCE MANDATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM-WAGE; EMPLOYMENT	The proposed Health Security Act provides universal health insurance by extending the current employer-based health insurance financing system. It requires employers to pay approximately 80% of the health insurance premium for each of their workers. Experience with other legislation requiring employers to provide benefits to their employees indicates that most of the cost of a mandated benefit is shifted to employees in the form of lower wages. However, for workers without health insurance and with earnings close to the minimum wage, minimum-wage legislation prohibits employers from lowering wages in response to a health insurance mandate. These employers can be expected to respond by cutting employment. Recent evidence from employer reactions to increases in the minimum wage suggests that approximately 100000 jobs would be lost due to the Health Security Act's employer mandate.			KLERMAN, JA (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90407, USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396	AHRQ HHS [1R03HS08219-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BRITTAIN JA, 1971, AM ECON REV, V61, P110; BROWN C, 1982, J ECON LIT, V20, P487; CARD D, 1992, IND LABOR RELAT REV, V46, P38, DOI 10.2307/2524737; CARD D, 1992, IND LABOR RELAT REV, V46, P22, DOI 10.2307/2524736; Gruber J., 1990, INCIDENCE MANDATED E; GRUBER J, 1992, EFFICIENCY GROUP SPE; HAMERMESH DS, 1979, SOUTHERN ECON J, V45, P1208, DOI 10.2307/1056965; HAN B, 1992, 930007 AG HLTH CAR P; JUHN CH, 1992, Q J ECON, V107, P79, DOI 10.2307/2118324; KATZ LF, 1992, IND LABOR RELAT REV, V46, P6, DOI 10.2307/2524735; KLERMAN J, 1992, HLTH BENEFITS WORKFO; LEVITT K, 1992, HLTH CARE FINANCING, V4, P31; SMITH RE, 1992, IND LABOR RELAT REV, V46, P82, DOI 10.2307/2524739; STIGLER G, 1976, AM ECON REV, V36, P358; SUMMERS LH, 1989, AM ECON REV, V79, P177; TAYLOR H, 1993, INQUIRY-J HEALTH CAR, V30, P228; VROMAN W, 1974, PUBLIC FINANC, V24, P184; 1994, ANAL ADM HLTH PROPOS; 1993, STATISTICAL ABSTRACT; 1993, P16184 US BUR CENS C	20	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					552	556		10.1001/jama.272.7.552	http://dx.doi.org/10.1001/jama.272.7.552			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB229	8046811				2022-12-28	WOS:A1994PB22900034
J	ASHFORD, MLJ; BOND, CT; BLAIR, TA; ADELMAN, JP				ASHFORD, MLJ; BOND, CT; BLAIR, TA; ADELMAN, JP			RETRACTED: CLONING AND FUNCTIONAL EXPRESSION OF A RAT-HEART K-ATP CHANNEL (RETRACTED ARTICLE. SEE VOL 378, PG 792, 1995)	NATURE			English	Article; Retracted Publication							POTASSIUM CHANNELS; VENTRICULAR MYOCYTES; MEMBRANE PATCHES; GUINEA-PIG; CELL; PINACIDIL	POTASSIUM channels that are ATP-sensitive (K-ATP) couple membrane potential to the metabolic status of the cell. K-ATP channels are inhibited by intracellular ATP and are stimulated by intracellular nucleotide diphosphates(1). K-ATP channel are important regulators of secretory processes and muscle contraction, and are targets for therapeutic treatment of type II diabetes by the inhibitory sulphonylureas(2) and for hypertension by activators such as pinacidil(3). In cardiac tissue, K-ATP channels are central regulators of post-ischaemic cardioprotection(4,5). Electrophysiological and pharmacological characteristics vary among K-ATP channels recorded from diverse tissues suggesting extensive molecular heterogeneity(1) A complementary DNA encoding a K-ATP channel was isolated from rat heart using the polymerase chain reaction. We report here that the expressed channels possess all of the essential features of native cardiac K-ATP channels, including sensitivity to intracellular nucleotides. In addition the cloned channels are activated by the potassium channel opener, pinacidil, but are not inhibited by the sulphonylurea, glibenclamide.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; UNIV CAMBRIDGE, DEPT PHARMACOL, CAMBRIDGE CB2 1QJ, ENGLAND	Oregon Health & Science University; University of Cambridge				Ashford, Michael/0000-0002-0861-7676				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BOND CT, IN PRESS RECEPT CHAN; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; Dempster J., 1993, COMPUTER ANAL ELECTR; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; ESCANDE D, 1992, TRENDS PHARMACOL SCI, V13, P269, DOI 10.1016/0165-6147(92)90083-I; FAN Z, 1990, J PHYSIOL-LONDON, V430, P273, DOI 10.1113/jphysiol.1990.sp018291; FINDLAY I, 1992, J PHARMACOL EXP THER, V261, P540; FINDLAY I, 1988, BIOCHIM BIOPHYS ACTA, V943, P297, DOI 10.1016/0005-2736(88)90561-5; FRIEDEL HA, 1990, DRUGS, V39, P929, DOI 10.2165/00003495-199039060-00008; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOPALAKRISHNAN M, 1993, DRUG DEVELOP RES, V28, P95, DOI 10.1002/ddr.430280202; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LEE K, 1994, BRIT J PHARMACOL, V111, P632, DOI 10.1111/j.1476-5381.1994.tb14783.x; LYNCH JJ, 1992, FASEB J, V6, P2952, DOI 10.1096/fasebj.6.11.1386585; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; TUNG RT, 1991, J PHYSIOL-LONDON, V437, P239, DOI 10.1113/jphysiol.1991.sp018593; ZILBERTER Y, 1988, PFLUG ARCH EUR J PHY, V411, P584, DOI 10.1007/BF00582382	25	190	194	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					456	459		10.1038/370456a0	http://dx.doi.org/10.1038/370456a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047164				2022-12-28	WOS:A1994PB40700055
J	MAHAJANMIKLOS, S; COOLEY, L				MAHAJANMIKLOS, S; COOLEY, L			THE VILLIN-LIKE PROTEIN ENCODED BY THE DROSOPHILA QUAIL GENE IS REQUIRED FOR ACTIN BUNDLE ASSEMBLY DURING OOGENESIS	CELL			English	Article							BRUSH-BORDER CYTOSKELETON; SEVERING PROTEINS; BICAUDAL-D; GELSOLIN; MELANOGASTER; SEQUENCE; DOMAINS; ORGANIZATION; MORPHOLOGY; RESIDUES	Mutations in the Drosophila quail gene result in female sterility due to the disruption of cytoplasmic transport from the nurse cells into the oocyte late in oogenesis. Nurse cells from quail mutant egg chambers fail to assemble cytoplasmic actin filament bundles correctly. We have cloned the quail gene and found that it encodes a protein with homology to the vertebrate actin-regulating protein villin. Unlike vertebrate villin, which is restricted to specialized absorptive epithelial cells, the villin-like protein encoded by quail is germline specific in adult flies. Antibodies directed against the quail protein show a striking colocalization with filamentous actin in the nurse cells and the oocyte. Our results demonstrate that the villin-like product of quail is required for the formation of cytoplasmic actin filament bundles in nurse cells, possibly by regulating both the polymerization and organization of actin filaments as demonstrated for vertebrate villin in vitro.			MAHAJANMIKLOS, S (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.				NIGMS NIH HHS [GM43301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BONFANTI P, 1992, EUR J CELL BIOL, V57, P298; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DIMITRIADIS VK, 1984, CAN J ZOOL, V62, P659, DOI 10.1139/z84-097; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; GUTZEIT HO, 1986, J CELL SCI, V80, P159; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINTZELMAN MB, 1992, CURR TOP DEV BIOL, V26, P93, DOI 10.1016/S0070-2153(08)60442-1; HEINTZELMAN MB, 1993, J MOL BIOL, V230, P709, DOI 10.1006/jmbi.1993.1191; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFMANN A, 1993, FEBS LETT, V328, P71, DOI 10.1016/0014-5793(93)80968-Z; King R. C., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; PATERSON J, 1991, GENETICS, V129, P1073; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; RANA AP, 1993, P NATL ACAD SCI USA, V90, P6651, DOI 10.1073/pnas.90.14.6651; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; Spradling Allan C., 1993, P1; STELLA MC, 1994, J CELL BIOL, V125, P607, DOI 10.1083/jcb.125.3.607; STEWARD R, 1986, GENETICS, V113, P665; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; TOWER J, 1993, GENETICS, V133, P3347; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WRIGHT TRF, 1976, GENETICS, V84, P267; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	54	120	121	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					291	301		10.1016/0092-8674(94)90298-4	http://dx.doi.org/10.1016/0092-8674(94)90298-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044841				2022-12-28	WOS:A1994NZ24200012
J	WOOD, WC; BUDMAN, DR; KORZUN, AH; COOPER, MR; YOUNGER, J; HART, RD; MOORE, A; ELLERTON, JA; NORTON, L; FERREE, CR; BALLOW, AC; FREI, E; HENDERSON, IC				WOOD, WC; BUDMAN, DR; KORZUN, AH; COOPER, MR; YOUNGER, J; HART, RD; MOORE, A; ELLERTON, JA; NORTON, L; FERREE, CR; BALLOW, AC; FREI, E; HENDERSON, IC			DOSE AND DOSE INTENSITY OF ADJUVANT CHEMOTHERAPY FOR STAGE-II, NODE-POSITIVE BREAST-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER	Background. Adjuvant chemotherapy is widely used for breast cancer and is known to extend survival. Some clinicians seek a greater survival benefit by increasing the intensity of the dose, whereas others lower it to diminish toxicity. Methods. The Cancer and Leukemia Group B (CALGB) conducted a randomized trial of different levels of doses and dose intensity (dose per unit of time) of adjuvant chemotherapy in 1572 women with node-positive, stage II breast cancer who were assigned to three treatment groups. One group received 400 mg of cyclophosphamide per square meter of body-surface area and 40 mg of doxorubicin per square meter once every 28 days and 400 mg of fluorouracil per square meter twice every 28 days, for six cycles. Another group received 50 percent higher doses of the three drugs (600 mg, 60 mg, and 600 mg, respectively) but for only four cycles, so that the total dose was identical in these two groups but the dose intensity was higher in the second. The third group of women received half the total dose used in the other two groups and at half the dose intensity used in the second group. Results. After a median of 3.4 years of follow-up, the women treated with a high or moderate dose intensity had significantly longer disease-free survival (P<0.001) and overall survival (P = 0.004) than those treated with a low dose intensity, in three-way log-rank comparisons. However, the difference in survival between the two groups treated with a moderate or high dose intensity was not significant. These results are consistent with either a dose-response effect or a threshold level of the dose or dose intensity. Conclusions. The doses of chemotherapy used to treat breast cancer, especially early breast cancer, should not be reduced if the maximal benefit is to be achieved.	N SHORE UNIV HOSP,MANHASSET,NY; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; ST LUKES HOSP,MILWAUKEE,WI; NEW YORK HOSP,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,NEW YORK,NY 10021; S NEVADA CANC RES FDN,LAS VEGAS,NV; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; FRONTIER SCI TECHNOL & RES FDN,AMHERST,MA; DANA FARBER CANC INST,BOSTON,MA; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA	Northwell Health; North Shore University Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Massachusetts General Hospital; NewYork-Presbyterian Hospital; Cornell University; Memorial Sloan Kettering Cancer Center; Frontier Science Foundation; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco	WOOD, WC (corresponding author), EMORY UNIV,SCH MED,WINSHIP CANC CTR,DEPT SURG,1364 CLIFTON RD NE,ATLANTA,GA 30322, USA.				NATIONAL CANCER INSTITUTE [U10CA035421, U10CA033601, U10CA035279, U10CA012449] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35279, U10 CA035421, U10 CA033601, CA-33601, CA-12449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELOFF MD, 1981, P AM ASSOC CANC RES, V22, P440; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BUDMAN DR, 1990, CANCER INVEST, V8, P571, DOI 10.3109/07357909009018922; BUZDAR AU, 1979, JAMA-J AM MED ASSOC, V242, P1509, DOI 10.1001/jama.242.14.1509; CANELLOS GP, 1988, J CLIN ONCOL, V6, P1363, DOI 10.1200/JCO.1988.6.9.1363; Cochran W.G, 1957, STAT METHODS, V6th ed; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1987, ADJUVANT THERAPY CAN, P283; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORZUN A, 1988, P AN M AM SOC CLIN, V7, P12; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; 1983, MANUAL STAGING CANCE, P127; 1988, NEW ENGL J MED, V319, P1681; 1985, CANCER RES, V45, P4454	19	572	579	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1253	1259		10.1056/NEJM199405053301801	http://dx.doi.org/10.1056/NEJM199405053301801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8080512				2022-12-28	WOS:A1994NJ51200001
J	TOBIN, MJ				TOBIN, MJ			CURRENT CONCEPTS - MECHANICAL VENTILATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							END-EXPIRATORY PRESSURE; ACUTE RESPIRATORY-FAILURE; POSITIVE AIRWAY PRESSURE; QUANTITATIVE CULTURE TECHNIQUES; OBSTRUCTIVE PULMONARY-DISEASE; PROTECTED SPECIMEN BRUSH; INSPIRATORY WORK; FLOW OBSTRUCTION; PRONE POSITION; AUTO-PEEP		VET AFFAIRS EDWARD HINES JR HOSP,HINES,IL	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	TOBIN, MJ (corresponding author), LOYOLA UNIV,STRITCH SCH MED,DIV PULM & CRIT CARE MED,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.							ALBERT RK, 1985, CHEST, V87, P2, DOI 10.1378/chest.87.1.2; [Anonymous], 1992, Respir Care, V37, P1000; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; CONNORS AF, 1981, AM REV RESPIR DIS, V124, P537; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DUNCAN AW, 1986, ANAESTH INTENS CARE, V14, P236, DOI 10.1177/0310057X8601400304; ELLIOTT M, 1994, PRINCIPLES PRACTICE, P427; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FIELD S, 1982, AM REV RESPIR DIS, V126, P9; GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GIBNEY RTN, 1982, CHEST, V82, P692, DOI 10.1378/chest.82.6.692; GUREVITCH MJ, 1989, CRIT CARE MED, V17, P354, DOI 10.1097/00003246-198904000-00011; HANSENFLASCHEN J, 1993, AM REV RESPIR DIS, V147, P234, DOI 10.1164/ajrccm/147.1.234; HEFFNER JE, 1990, CRIT CARE CLIN, V6, P533; HERNANDEZ LA, 1990, J APPL PHYSIOL, V69, P2057, DOI 10.1152/jappl.1990.69.6.2057; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; HUBMAYR RD, 1990, CRIT CARE MED, V18, P103, DOI 10.1097/00003246-199001000-00022; IBSEN B, 1954, P ROY SOC MED, V47, P72, DOI 10.1177/003591575404700120; JUBRAN A, 1993, AM REV RESPIR DIS, V147, pA875; KAEM, 1990, CRIT CARE CLIN, V6, P551; KATZ JA, 1985, ANESTHESIOLOGY, V63, P598, DOI 10.1097/00000542-198512000-00008; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LANGER M, 1988, CHEST, V94, P103, DOI 10.1378/chest.94.1.103; MACINTYRE NR, 1986, CHEST, V89, P677, DOI 10.1378/chest.89.5.677; MALO J, 1984, J APPL PHYSIOL, V57, P1002, DOI 10.1152/jappl.1984.57.4.1002; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; MATHRU M, 1982, CRIT CARE MED, V10, P423, DOI 10.1097/00003246-198207000-00001; MUSCEDERE J G, 1992, American Review of Respiratory Disease, V145, pA454; NISHIMURA M, 1990, CHEST, V97, P600, DOI 10.1378/chest.97.3.600; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PIERSON DJ, 1990, CRIT CARE CLIN, V6, P711; PINSKY MR, 1990, CRIT CARE CLIN, V6, P663; ROSSI A, 1985, AM REV RESPIR DIS, V131, P672; SASSOON CSH, 1990, CRIT CARE CLIN, V6, P605; SASSOON CSH, 1992, AM REV RESPIR DIS, V145, P1219, DOI 10.1164/ajrccm/145.5.1219; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SMITH TC, 1988, J APPL PHYSIOL, V65, P1488, DOI 10.1152/jappl.1988.65.4.1488; TOBIN M J, 1991, Respiratory Care, V36, P395; TOBIN MJ, 1986, AM REV RESPIR DIS, V134, P1111; TOBIN MJ, 1989, CHEST, V96, P449, DOI 10.1378/chest.96.3.449; TOBIN MJ, 1988, AM REV RESPIR DIS, V138, P1625, DOI 10.1164/ajrccm/138.6.1625; Tobin MJ, 1994, PRINCIPLES PRACTICE, P1177; TOCINO IM, 1985, AM J ROENTGENOL, V144, P901, DOI 10.2214/ajr.144.5.901; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TUXEN DV, 1992, AM REV RESPIR DIS, V146, P1136, DOI 10.1164/ajrccm/146.5_Pt_1.1136; TUXEN DV, 1994, PRINCIPLES PRACTICE, P371; ULYATT DB, 1991, CRIT CARE MED, V19, P985, DOI 10.1097/00003246-199107000-00029; WARD ME, 1988, ANESTHESIOLOGY, V69, P29, DOI 10.1097/00000542-198807000-00005; WIENER CM, 1990, J APPL PHYSIOL, V68, P1386, DOI 10.1152/jappl.1990.68.4.1386; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	58	176	184	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1056	1061		10.1056/NEJM199404143301507	http://dx.doi.org/10.1056/NEJM199404143301507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8080509				2022-12-28	WOS:A1994NF02200007
J	SMITH, EP; BOYD, J; FRANK, GR; TAKAHASHI, H; COHEN, RM; SPECKER, B; WILLIAMS, TC; LUBAHN, DB; KORACH, KS				SMITH, EP; BOYD, J; FRANK, GR; TAKAHASHI, H; COHEN, RM; SPECKER, B; WILLIAMS, TC; LUBAHN, DB; KORACH, KS			ESTROGEN RESISTANCE CAUSED BY A MUTATION IN THE ESTROGEN-RECEPTOR GENE IN A MAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN INSENSITIVITY; AROMATASE DEFICIENCY; MEN; OSTEOPOROSIS; HYPOGONADISM; CONSEQUENCES; PUBERTY; FEMALE; MICE	Background and Methods. Mutations in the estrogen-receptor gene have been thought to be lethal. A 28-year-old man whose estrogen resistance was caused by a disruptive mutation in the estrogen-receptor gene underwent studies of pituitary-gonadal function and bone density and received transdermal estrogen for six months. Estrogen-receptor DNA, extracted from lymphocytes, was evaluated by analysis of single-strand-conformation polymorphisms and by direct sequencing. Results. The patient was tall (204 cm [80.3 in.]) and had incomplete epiphyseal closure, with a history of continued linear growth into adulthood despite otherwise normal pubertal development. He was normally masculinized and had bilateral axillary acanthosis nigricans. Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal. Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased. Glucose tolerance was impaired, and hyperinsulinemia was present. The bone mineral density of the lumbar spine was 0.745 g per square centimeter, 3.1 SD below the mean for age-matched normal women; there was biochemical evidence of increased bone turnover. The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration. Conformation analysis of his estrogen-receptor gene revealed a variant banding pattern in exon 2. Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon. The patient's parents were heterozygous carriers of this mutation, and pedigree analysis revealed consanguinity. Conclusions. Disruption of the estrogen receptor in humans need not be lethal. Estrogen is important for bone maturation and mineralization in men as well as women.	UNIV CINCINNATI, CHILDRENS HOSP, COLL MED, MED CTR, DIV NEONATOL, CINCINNATI, OH USA; UNIV CINCINNATI, COLL MED, DEPT INTERNAL MED, DIV ENDOCRINOL, CINCINNATI, OH USA; UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC USA; NIEHS, RECEPTOR BIOL SECT, RES TRIANGLE PK, NC USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	SMITH, EP (corresponding author), UNIV CINCINNATI, CHILDRENS HOSP,COLL MED,MED CTR,DEPT PEDIAT, DIV ENDOCRINOL, 3333 BURNETT AVE, CINCINNATI, OH 45229 USA.			Specker, Bonny/0000-0003-4759-9957; Korach, Kenneth/0000-0002-7765-418X; Boyd, Jeff/0000-0002-3517-7637	NCRR NIH HHS [MO1 RR 08084] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARBIERI RL, 1983, AM J OBSTET GYNECOL, V147, P90, DOI 10.1016/0002-9378(83)90091-1; BHATNAGAR AS, 1992, J STEROID BIOCHEM, V41, P437, DOI 10.1016/0960-0760(92)90369-T; BOYD J, 1991, MOL CARCINOGEN, V4, P189, DOI 10.1002/mc.2940040305; BROOKS MH, 1978, NEW ENGL J MED, V298, P996, DOI 10.1056/NEJM197805042981804; BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; CARLSTROM K, 1989, PROSTATE, V14, P177, DOI 10.1002/pros.2990140210; CHROUSOS GP, 1993, ANN INTERN MED, V119, P1113, DOI 10.7326/0003-4819-119-11-199312010-00009; CONTE FA, 1994, J CLIN ENDOCR METAB, V78, P1287, DOI 10.1210/jc.78.6.1287; DEQUEKER J, 1985, ACTA ENDOCRINOL-COP, V110, P45; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; FORESTA C, 1984, HORM RES, V19, P18, DOI 10.1159/000179855; George F.W., 1988, P3; Greulich WW., 1959, CALIF MED, V91, P53; HANSON DA, 1992, J BONE MINER RES, V7, P1251; ITO Y, 1993, P NATL ACAD SCI USA, V90, P11673, DOI 10.1073/pnas.90.24.11673; KAPLAN SL, 1990, J CLIN ENDOCR METAB, V71, P785, DOI 10.1210/jcem-71-4-785; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; LEITER EH, 1987, METABOLISM, V36, P863, DOI 10.1016/0026-0495(87)90095-3; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MACDONALD PC, 1979, J CLIN ENDOCR METAB, V49, P905, DOI 10.1210/jcem-49-6-905; MCDERMOTT MT, 1993, AM J MED, V94, P424, DOI 10.1016/0002-9343(93)90155-I; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; PROCHAZKA M, 1986, DIABETES, V35, P725, DOI 10.2337/diabetes.35.6.725; SEIBEL MJ, 1992, TRENDS ENDOCRIN MET, V3, P263, DOI 10.1016/1043-2760(92)90129-O; SHARP SC, 1993, DIABETES REV, V1, P318; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SWARTZ CM, 1988, NEW ENGL J MED, V318, P996; VALENTA LJ, 1992, J NATL MED ASSOC, V84, P241; ZACHMANN M, 1986, J PEDIATR-US, V108, P694, DOI 10.1016/S0022-3476(86)81043-5	31	1832	1893	1	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1056	1061		10.1056/NEJM199410203311604	http://dx.doi.org/10.1056/NEJM199410203311604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090165				2022-12-28	WOS:A1994PL56000004
J	FRIES, JF; SINGH, G; MORFELD, D; HUBERT, HB; LANE, NE; BROWN, BW				FRIES, JF; SINGH, G; MORFELD, D; HUBERT, HB; LANE, NE; BROWN, BW			RUNNING AND THE DEVELOPMENT OF DISABILITY WITH AGE	ANNALS OF INTERNAL MEDICINE			English	Article						RUNNING; AGING; EXERCISE; DISABLED; PHYSICAL FITNESS	WEIGHT-BEARING EXERCISE; PHYSICAL-ACTIVITY; OSTEO-ARTHRITIS; BONE-DENSITY; HEALTH OUTCOMES; OSTEOARTHRITIS; KNEE; ASSOCIATION; DIMENSIONS; MORTALITY	Objective: To determine, by longitudinal study, whether regular vigorous running activity is associated with accelerated, unchanged, or postponed development of disability with increasing age. Study Design: 8-year prospective, longitudinal study with yearly assessments. Participants: 451 members of a runners' club and 330 community controls who were initially 50 to 72 years old (also characterized as ''ever-runners'' [n = 534] and ''never-runners'' [n = 247], respectively). Measurements: The dependent variable was disability as assessed by the Health Assessment Questionnaire and separately validated in these participant cohorts. Covariates included age, sex, body mass index, comorbid conditions, education level, smoking history, alcohol intake, mean blood pressure, initial disability level, family history of arthritis, and radiologic evidence of osteoarthritis of the knee in a subsample. Results: Initially, the runners were leaner, reported joint symptoms less frequently, took fewer medications, had fewer medical problems, and had fewer instances of and less severity of disability, suggesting either that the average previous 12 years of running had improved health or that self-selection bias was present. After 8 years of longitudinal study, the differences in initial disability levels (0.026 compared with 0.079; P < 0.001) had steadily increased to 0.071 for runners compared with 0.242 for controls (P < 0.001). The difference was consistent for men and women. The rate of development of disability was several times lower in the runners' club members than in community controls; this difference persisted after adjusting for age, sex, body mass, baseline disability, smoking history, history of arthritis, or other comorbid conditions (slopes of progression of disability for the years 1984 to 1992, after adjusting for covariates: men in the runners' club, 0.004 [SE, 0.002]; community controls, 0.012 [SE, 0.002]; women in the runners' club, 0.009 [SE, 0.005]; community controls, 0.027 [SE, 0.004]; P < 0.002 for both sets of comparisons). In addition to differences in disability, there were significant differences in mortality between the runners' club members (1.49%) and community controls (7.09%) (P < 0.001). These differences remained significant after adjusting for age, sex, body mass, comorbid conditions, education level, smoking history, alcohol intake, and mean blood pressure (P < 0.002, conditional risk ratio for community controls compared with the runners, 4.27; 95% CI, 1.78 to 10.26). Conclusions: Older persons who engage in vigorous running and other aerobic activities have lower mortality and slower development of disability than do members of the general population. This association is probably related to increased aerobic activity, strength, fitness, and increased organ reserve rather than to an effect of postponed osteoarthritis development.	STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA	Stanford University			Fries, James F/F-6271-2011		NIAMS NIH HHS [AR20610-16] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020610] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN JH, 1984, AM J PUBLIC HEALTH, V74, P159, DOI 10.2105/AJPH.74.2.159; BRUCE RA, 1984, MED SCI SPORT EXER, V16, P8; CURFMAN GD, 1993, NEW ENGL J MED, V328, P574, DOI 10.1056/NEJM199302253280810; Dill D B, 1967, J Sports Med Phys Fitness, V7, P4; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1982, J RHEUMATOL, V9, P789; GLYN JH, 1966, BMJ-BRIT MED J, V2, P739, DOI 10.1136/bmj.2.5516.739; HANNAN MT, 1993, J RHEUMATOL, V20, P704; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1552; LANE NE, 1986, JAMA-J AM MED ASSOC, V255, P1147; LANE NE, 1987, AM J MED, V82, P772, DOI 10.1016/0002-9343(87)90014-3; LANE NE, 1989, J RHEUMATOL, V16, P637; LANE NE, 1990, AM J MED, V88, P452, DOI 10.1016/0002-9343(90)90422-A; LANE NE, 1993, J RHEUMATOL, V20, P461; LARSON EB, 1986, ANN INTERN MED, V105, P783, DOI 10.7326/0003-4819-105-5-783; LUBECK DP, 1985, MED CARE, V23, P266, DOI 10.1097/00005650-198503000-00008; MCALINDON TE, 1993, ANN RHEUM DIS, V52, P258, DOI 10.1136/ard.52.4.258; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; MICHEL BA, 1992, INT ORTHOP, V16, P87; MICHEL BA, 1991, ANN MED, V23, P397, DOI 10.3109/07853899109148081; MICHEL BA, 1992, CLIN RHEUMATOL, V11, P235, DOI 10.1007/BF02207964; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PANUSH RS, 1986, JAMA-J AM MED ASSOC, V255, P1152, DOI 10.1001/jama.255.9.1152; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; RADIN EL, 1972, LANCET, V1, P519; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; REIMANN I, 1973, ACTA ORTHOP SCAND, V44, P496, DOI 10.3109/17453677308989085; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; STEWART AL, 1993, GERONTOLOGIST, V33, P782, DOI 10.1093/geront/33.6.782	30	107	108	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					502	509		10.7326/0003-4819-121-7-199410010-00005	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067647				2022-12-28	WOS:A1994PJ10200005
J	KUUSISTO, J; KOIVISTO, K; KERVINEN, K; MYKKANEN, L; HELKALA, EL; VANHANEN, M; HANNINEN, T; PYORALA, K; KESANIEMI, YA; RIEKKINEN, P; LAAKSO, M				KUUSISTO, J; KOIVISTO, K; KERVINEN, K; MYKKANEN, L; HELKALA, EL; VANHANEN, M; HANNINEN, T; PYORALA, K; KESANIEMI, YA; RIEKKINEN, P; LAAKSO, M			ASSOCIATION OF APOLIPOPROTEIN-E PHENOTYPES WITH LATE-ONSET ALZHEIMERS-DISEASE - POPULATION-BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; E POLYMORPHISM; DEMENTIA; LINKAGE; ALLELE; EPSILON-4; MEMORY	Objective-To determine the association between the e4 allele of apolipoprotein E and Alzheimer's disease in a randomly selected population sample. Design-Cross sectional population based study. Subjects-980 people aged 69 to 78 (349 men, 631 women). Setting-Population of Kuopio, eastern Finland. Main outcome measures-Presence of e4 allele and diagnosis of Alzheimer's disease by detailed neurological and neurophysiological evaluation. Results-46 (4.7%) subjects were classified as having probable or possible Alzheimer's disease. The frequency of the apolipoprotein E e4 allele was 0.359 in patients with Alzheimer's disease and 0.165 in subjects without dementia (P<0.0001). The prevalence of Alzheimer's disease was 2.9% in subjects with no e4 alleles, 7.6% in subjects with one e4 allele, and 21.4% in subjects with two e4 alleles of apolipoprotein E. Conclusions-Allele e4 of apolipoprotein is associated with Alzheimer's disease in a dose-response fashion in a randomly selected elderly population.	KUOPIO UNIV HOSP,DEPT MED,KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT NEUROL,KUOPIO,FINLAND; OULU UNIV HOSP,DEPT INTERNAL MED,OULU,FINLAND; UNIV OULU,BIOCTR,OULU,FINLAND	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Oulu; University of Oulu								BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EHNHOLM C, 1986, J LIPID RES, V27, P227; Elston RC, 1987, ESSENTIALS BIOSTATIS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GERDES LU, 1992, GENET EPIDEMIOL, V9, P155, DOI 10.1002/gepi.1370090302; GROBER E, 1988, NEUROLOGY, V38, P90; HACHINSKI VC, 1974, LANCET, V2, P207; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KAY DWK, 1991, REV CLIN GERONTOLOGY, V1, P55; KERVINEN K, 1994, ATHEROSCLEROSIS, V105, P89, DOI 10.1016/0021-9150(94)90011-6; Koivisto K, 1992, J Geriatr Psychiatry Neurol, V5, P162; LAAKSO M, 1991, BMJ-BRIT MED J, V303, P1159, DOI 10.1136/bmj.303.6811.1159; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; PAYNE MN, 1992, LANCET, V340, P1350, DOI 10.1016/0140-6736(92)92532-K; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P8098; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; UKKOLA O, 1993, ATHEROSCLEROSIS, V101, P9, DOI 10.1016/0021-9150(93)90096-D; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WARRINGTON EK, 1966, BRAIN, V89, P53, DOI 10.1093/brain/89.1.53; 1987, DIAGNOSTIC STATISTIC	35	182	184	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					636	638		10.1136/bmj.309.6955.636	http://dx.doi.org/10.1136/bmj.309.6955.636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086986	Green Published			2022-12-28	WOS:A1994PG02000019
J	HERRIOT, R; GRAY, ES				HERRIOT, R; GRAY, ES			OWLS EYE CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											HERRIOT, R (corresponding author), ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZD,SCOTLAND.								0	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					649	649						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052274				2022-12-28	WOS:A1994PE38200005
J	SURRIDGE, C				SURRIDGE, C			SHORTING OUT THE CELLULAR BATTERY	NATURE			English	Article							COLICIN-A	A low-resolution structure of the bacterial toxin collicin Ia provides a model for its lethal membrane association and an explanation for the anomalous behaviour of its C-terminal peptide fragment.						Surridge, Christopher/0000-0003-4264-5176				GHOSH P, 1994, NAT STRUCT BIOL, V1, P597, DOI 10.1038/nsb0994-597; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; SANSOM MSP, 1994, NAT STRUCT BIOL, V1, P563, DOI 10.1038/nsb0994-563; STEIN PE, 1994, NAT STRUCT BIOL, V1, P591, DOI 10.1038/nsb0994-591; WORMALD MR, 1990, EUR J BIOCHEM, V191, P155, DOI 10.1111/j.1432-1033.1990.tb19105.x	5	1	1	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					84	84		10.1038/371084a0	http://dx.doi.org/10.1038/371084a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072534	Bronze			2022-12-28	WOS:A1994PE38100058
J	RING, BZ; ROBERTS, JW				RING, BZ; ROBERTS, JW			FUNCTION OF A NONTRANSCRIBED DNA STRAND SITE IN TRANSCRIPTION ELONGATION	CELL			English	Article							COLI RNA-POLYMERASE; PHAGE-LAMBDA; PAUSE SITE; Q-PROTEIN; TERMINATION; RHO; REGION; ANTITERMINATION; SEQUENCE; PROMOTER	A prolonged pause in transcription elongation at positions +16 and +17 of the phage lambda late gene operon has an important role in the modification of RNA polymerase by the lambda gene Q transcription antiterminator. Mutations included in the transcription bubble of the paused transcription complex, particularly at +2 and +6, abolish pausing and the ability of Q protein to modify RNA polymerase. By transcribing heteroduplex templates made in vitro, we show that the sites identified by these mutations act through the nontranscribed strand of DNA. This result suggests unexpected regulatory functions of the nontranscribed DNA strand in transcription.			RING, BZ (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021941, R01GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN M, 1994, IN PRESS HARVEY LECT; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; Dahlberg JE, 1973, VIRUS RES, P533; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GILBERT W, 1974, COLD SPRING HARB SYM, V38, P845; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1990, THESIS CORNELL U ITH; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; Sambrook J, 1989, MOL CLONING LABORATO; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T	25	58	58	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					317	324		10.1016/0092-8674(94)90300-X	http://dx.doi.org/10.1016/0092-8674(94)90300-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044843				2022-12-28	WOS:A1994NZ24200014
J	GRUNSTEIN, RR; HO, KKY; SULLIVAN, CE				GRUNSTEIN, RR; HO, KKY; SULLIVAN, CE			EFFECT OF OCTREOTIDE, A SOMATOSTATIN ANALOG, ON SLEEP-APNEA IN PATIENTS WITH ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Article						ACROMEGALY; SLEEP APNEA SYNDROMES; OCTREOTIDE; SOMATOTROPIN; INSULIN-LIKE GROWTH FACTOR	VENTILATORY RESPONSE; SMS-201-995; REVERSAL; HUMANS	Objective: To determine the effects of octreotide, a somatostatin analog, on the severity of sleep apnea and on growth hormone levels in patients with acromegaly. Design: Open-label, prospective study. Setting: Tertiary referral hospital. Patients: 19 patients with active acromegaly. Intervention: Octreotide in a 6-month, stepwise incremental dosage. Measurements: Sleep studies and indices of hormonal activity (levels of insulin-like growth factor 1 [IGF-1] and growth hormone). Results: A 50% decrease occurred in the respiratory disturbance index (baseline compared with 6 months, 39 events/h compared with 19 events/h; P = 0.0002), and a 40% decrease occurred in total apnea time (27.6% of total sleep time compared with 15.1%; P = 0.001). Indices of oxygen desaturation, sleep quality, and subjective sleepiness improved after 6 months of octreotide. A parallel decrease was noted in mean levels of growth hormone (40.0 mu g/L compared with 9.1 mu g/L; P = 0.003) and IGF-1 (107 nmol/L compared with 47 nmol/L; P = 0.0001). However, no correlation was noted between the decrease in the total amount of sleep time spent in apnea and the decrease in growth hormone levels (rho = -0.35; P > 0.2). The residual respiratory disturbance index after 6 months of treatment was similar in patients who improved, regardless of whether or not biochemical remission (IGF-I < 35 nmol/L) occurred. Conclusions: Improvement in indices of sleep apnea severity occurs in association with octreotide treatment in patients with sleep apnea and acromegaly. However, sleep apnea may either persist despite normalization of growth hormone levels or may improve markedly even if there is only partial biochemical remission.	ST VINCENTS HOSP, GARVAN INST MED RES, SYDNEY, NSW 2010, AUSTRALIA; UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney			Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011	Ho, Ken/0000-0002-2508-9588; 				ASTROM C, 1991, NEUROENDOCRINOLOGY, V53, P328, DOI 10.1159/000125737; BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; CADIEUX RJ, 1982, J CLIN ENDOCR METAB, V55, P18, DOI 10.1210/jcem-55-1-18; CHANSON P, 1986, LANCET, V1, P1270; CHAPMAN KR, 1988, J APPL PHYSIOL, V64, P1000, DOI 10.1152/jappl.1988.64.3.1000; CHAPPEL W, 1896, J LARYNGOL OTOL, V10, P142; CHEN ZB, 1990, J APPL PHYSIOL, V69, P2233, DOI 10.1152/jappl.1990.69.6.2233; CHERNIACK NS, 1984, J CLIN INVEST, V73, P1501, DOI 10.1172/JCI111355; DANGUIR J, 1989, NEUROSCI LETT, V98, P154, DOI 10.1016/0304-3940(89)90502-8; ESNAULT S, 1989, Neurophysiologie Clinique, V19, P367, DOI 10.1016/S0987-7053(89)80089-9; FILUK RB, 1988, J APPL PHYSIOL, V65, P1050, DOI 10.1152/jappl.1988.65.3.1050; GLEESON K, 1989, J APPL PHYSIOL, V67, P1630, DOI 10.1152/jappl.1989.67.4.1630; GRUNSTEIN RR, 1991, ANN INTERN MED, V115, P527, DOI 10.7326/0003-4819-115-7-527; HART TB, 1985, ARCH INTERN MED, V145, P865, DOI 10.1001/archinte.145.5.865; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; ISSA FG, 1986, CHEST, V90, P165, DOI 10.1378/chest.90.2.165; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; KALIA M, 1984, BRAIN RES, V296, P339, DOI 10.1016/0006-8993(84)90070-2; LAMBERTS SWJ, 1992, ENDOCRIN METAB CLIN, V21, P737, DOI 10.1016/S0889-8529(18)30211-1; LAROCHE C, 1976, ANN MED INTERNE, V127, P381; LONGOBARDO GS, 1989, ANN BIOMED ENG, V17, P377, DOI 10.1007/BF02368057; MAIN G, 1988, POSTGRAD MED J, V64, P945, DOI 10.1136/pgmj.64.758.945; MAXWELL DL, 1986, J APPL PHYSIOL, V60, P997, DOI 10.1152/jappl.1986.60.3.997; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; MEYER TJ, 1993, CHEST, V103, P756, DOI 10.1378/chest.103.3.756; MEZON BJ, 1980, AM J MED, V69, P615, DOI 10.1016/0002-9343(80)90477-5; PEKKARINEN T, 1987, CLIN ENDOCRINOL, V27, P649, DOI 10.1111/j.1365-2265.1987.tb02947.x; PERKS WH, 1980, BRIT MED J, V280, P894, DOI 10.1136/bmj.280.6218.894; ROSENSTOCK J, 1982, J ROY SOC MED, V75, P209; ROXBURGH F, 1896, BRIT MED J, V2, P63; SULLIVAN CE, 1984, SLEEP BREATHING; SULLIVAN CE, 1989, PRINCIPLES PRACTICE; SVANBORG E, 1993, CHEST, V104, P340, DOI 10.1378/chest.104.2.340; YAMAMOTO Y, 1988, ACTA PHYSIOL SCAND, V134, P529, DOI 10.1111/j.1365-201X.1988.tb10631.x; Younes M., 1989, CURR PULMONOL, V10, P265; ZIEMER DC, 1988, AM J MED SCI, V295, P49, DOI 10.1097/00000441-198801000-00010	37	107	109	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					478	483		10.7326/0003-4819-121-7-199410010-00002	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067645				2022-12-28	WOS:A1994PJ10200002
J	SHERERTZ, RJ; STREED, SA				SHERERTZ, RJ; STREED, SA			MEDICAL DEVICES - SIGNIFICANT RISK VS NONSIGNIFICANT RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									N CAROLINA BAPTIST HOSP,DEPT INFECT CONTROL,WINSTON SALEM,NC	Wake Forest University; Wake Forest Baptist Medical Center	SHERERTZ, RJ (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,INFECT DIS SECT,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.							KESSLER DA, 1987, NEW ENGL J MED, V317, P357, DOI 10.1056/NEJM198708063170606; YIN L, 1986, OTOLARYNG CLIN N AM, V19, P423; 1984, IRBS MED DEVICES; 1986, IDE861 OFF DEV EV CT; 1992, US DHHS FDA924159 PU, P32	5	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					955	956		10.1001/jama.272.12.955	http://dx.doi.org/10.1001/jama.272.12.955			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084063				2022-12-28	WOS:A1994PG73700023
J	HOOK, EW; SPITTERS, C; REICHART, CA; NEUMANN, TM; QUINN, TC				HOOK, EW; SPITTERS, C; REICHART, CA; NEUMANN, TM; QUINN, TC			USE OF CELL-CULTURE AND A RAPID DIAGNOSTIC ASSAY FOR CHLAMYDIA-TRACHOMATIS SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; POLYMERASE CHAIN-REACTION; TESTPACK CHLAMYDIA; INFECTION; WOMEN; CLINICS; SPECIMENS; TESTS; MEN	Objective.-To compare a rapid, office-based test with standard cell culture for screening of women for Chlamydia trachomatis infections. Design and Settings.-An 8-month prospective crossover trial used alternating screening protocols in two Baltimore (Md) sexually transmitted disease clinics from January 2 through August 14, 1991. Participants.-Consecutive women attending the two clinics who had no indication for administration of antichlamydial antibiotic therapy (eg, history of recent sexual contact with a partner with a sexually transmitted disease, mucopurulent cervicitis, pelvic inflammatory disease, known gonorrhea, or previously diagnosed Chlamydia infections). Interventions.-Chlamydia screening was offered according to one of two protocols. Use of the two screening protocols was alternated between clinics each month. In the ''rapid test clinic,'' eligible women were screened with both a 30-minute enzyme immunoassay test and tissue culture. Patients screened with the rapid test were asked to remain in the clinic until their rapid assay results were available so that, if positive, the patients could be treated. In the ''routine screening clinic,'' eligible women were screened for Chlamydia by cell culture. Women identified as being infected with Chlamydia by screening culture were later confidentially notified of their test results by health department disease intervention specialists and referred for therapy. Main Outcome Measures.-Performance of screening tests for bringing infected patients to therapy; time intervals between initial clinic visits and therapy; and pelvic inflammatory disease occurring between initial visits and therapy. Results.-Chlamydia cultures were positive in 100 (6.6%) of 1526 women screened with the solid-phase immunoassay, 47 of which were detected and treated on the basis of rapid test results. In contrast, 93 (74%) of 126 women with positive screening cultures returned to the clinic and received therapy. The median interval between testing and therapy for women with positive screening cultures was 14 days, and three (3.2%) developed pelvic inflammatory disease in the interval between testing and return for therapy. Conclusions.-Neither cell culture nor a rapid diagnostic test performed well for ensuring therapy of women with Chlamydia infections. The sensitivity of the rapid diagnostic test was low, and nearly one fourth of the women with positive screening cultures did not return for therapy. Evaluation of screening for Chlamydia should consider the utility of strategies for bringing patients to treatment, as well as the more usual measures of test performance, such as sensitivity, specificity, and predictive values.	BALTIMORE CITY DEPT HLTH,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT PREVENT MED,BALTIMORE,MD; NIAID,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HOOK, EW (corresponding author), UNIV ALABAMA,DEPT MED,229 THT,1900 UNIV BLVD,BIRMINGHAM,AL 35294, USA.				PHS HHS [R30/CCR302723] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRUNHAM RC, 1984, NEW ENGL J MED, V311, P1, DOI 10.1056/NEJM198407053110101; COLEMAN P, 1989, J CLIN MICROBIOL, V27, P2811, DOI 10.1128/JCM.27.12.2811-2814.1989; GANN PH, 1990, J CLIN MICROBIOL, V28, P1580, DOI 10.1128/JCM.28.7.1580-1585.1990; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HOOK EW, 1992, AM J EPIDEMIOL, V136, P662, DOI 10.1093/oxfordjournals.aje.a116546; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; KLUYTMANS JAJW, 1993, J CLIN MICROBIOL, V31, P3204, DOI 10.1128/JCM.31.12.3204-3210.1993; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; MERCER L, 1990, J REPROD MED, V35, P1141; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; RAHM VA, 1986, EUR J SEX TRANSM DIS, V3, P91; REICHART CA, 1990, SEX TRANSM DIS, V17, P147, DOI 10.1097/00007435-199007000-00007; REICHART CA, 1992, 1992 INT C ANT AG CH; REITMEIJER CAM, 1991, SEX TRANSM DIS, V18, P28; SCHACHTER J, 1992, SEX TRANSM DIS, V19, P243, DOI 10.1097/00007435-199209000-00001; SCHAFER M, 1993, JAMA, V270, P2065; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; 1993, MMWR-MORBID MORTAL W, V42, P21; 1993, MMWR-MORBID MORTAL W, V42, P47; 1993, MMWR-MORBID MORTAL W, V42, P1	21	63	64	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					867	870		10.1001/jama.272.11.867	http://dx.doi.org/10.1001/jama.272.11.867			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078164				2022-12-28	WOS:A1994PG18200025
J	CACERES, JF; STAMM, S; HELFMAN, DM; KRAINER, AR				CACERES, JF; STAMM, S; HELFMAN, DM; KRAINER, AR			REGULATION OF ALTERNATIVE SPLICING IN-VIVO BY OVEREXPRESSION OF ANTAGONISTIC SPLICING FACTORS	SCIENCE			English	Article							PRE-MESSENGER-RNA; PREMESSENGER RNA; NONMUSCLE CELLS; SITE SELECTION; SR PROTEINS; GENE; INVITRO; EXPRESSION; EXON; CIS	The opposing effects of SF2/ASF and heterogeneous nuclear ribonucleoprotein (hnRNP) A1 influence alternative splicing in vitro. SF2/ASF or hnRNP A1 complementary DNAs were transiently overexpressed in HeLa cells, and the effect on alternative splicing of several cotransfected reporter genes was measured. Increased expression of SF2/ASF activated proximal 5' splice sites, promoted inclusion of a neuron-specific exon, and prevented abnormal exon skipping. Increased expression of hnRNP A1 activated distal 5' splice sites. Therefore, variations in the intracellular levels of antagonistic splicing factors influence different modes of alternative splicing in vivo and may be a natural mechanism for tissue-specific or developmental regulation of gene expression.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Helfman, David M./C-2058-2011; Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169; Krainer, Adrian/0000-0001-9024-9501				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; CACERES JF, UNPUB; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GE H, 1991, CELL, V66, P372; GILMAN M, 1988, CURRENT PROTOCOLS MO, V1; GUO W, 1993, NUCLEIC ACIDS RES, V21, P4762, DOI 10.1093/nar/21.20.4762; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HANAMURA A, UUNPUB; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	36	556	561	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1706	1709		10.1126/science.8085156	http://dx.doi.org/10.1126/science.8085156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085156				2022-12-28	WOS:A1994PG28400030
J	HATA, Y; STRYKER, MP				HATA, Y; STRYKER, MP			CONTROL OF THALAMOCORTICAL AFFERENT REARRANGEMENT BY POSTSYNAPTIC ACTIVITY IN DEVELOPING VISUAL-CORTEX	SCIENCE			English	Article							OCULAR DOMINANCE COLUMNS; PLASTICITY; BLOCKADE; SITES	The formation of specific connections in the developing central nervous system is thought to result from mechanisms that increase the strengths of synapses at which pre- and postsynaptic activity are correlated and decrease it otherwise. In the visual cortex, initially widespread inputs normally sort out into eye-specific patches during early life. If only one eye can see during this period, its patches are much larger than normal, and patches from the occluded eye become much smaller. Anatomical experiments here show that closed-eye inputs expand within a region of cortex that is silenced, establishing that inhibition of common target cells gives less active inputs a competitive advantage.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,CTR INTEGRAT NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [EY02874, R01 EY002874] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002874, R01EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONINI A, 1993, J NEUROSCI, V13, P3549; BOWERY NG, 1982, TRENDS PHARMACOL SCI, V3, P400, DOI 10.1016/0165-6147(82)91205-6; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; NEEDLER MC, 1984, BRAIN RES, V308, P347, DOI 10.1016/0006-8993(84)91076-X; OLAVARRIA J, 1985, J NEUROSCI METH, V15, P191, DOI 10.1016/0165-0270(85)90098-6; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003	13	108	109	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1732	1735		10.1126/science.8085163	http://dx.doi.org/10.1126/science.8085163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085163				2022-12-28	WOS:A1994PG28400038
J	SIK, A; YLINEN, A; PENTTONEN, M; BUZSAKI, G				SIK, A; YLINEN, A; PENTTONEN, M; BUZSAKI, G			INHIBITORY CA1-CA3-HILAR REGION FEEDBACK IN THE HIPPOCAMPUS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; RAT HIPPOCAMPUS; DENTATE GYRUS; CA1 REGION; PYRAMIDAL NEURONS; CELLS; ORGANIZATION; INTERNEURONS; MESSENGER	The organization of the hippocampus is generally thought of as a series of cell groups that form a unidirectionally excited chain, regulated by localized inhibitory circuits. With the use of in vivo intracellular labeling, histochemical, and extracellular tracing methods, a longitudinally widespread, inhibitory feedback in rat brain from the CA1 area to the CA3 and hilar regions was observed. This long-range, cross-regional inhibition may allow precise synchronization of population activity by timing the occurrence of action potentials in the principal cells and may contribute to the coordinated induction of synaptic plasticity in distributed networks.	RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,NEWARK,NJ 07102	Rutgers State University Newark; Rutgers State University New Brunswick			Penttonen, Markku/B-8348-2013	Penttonen, Markku/0000-0002-1033-7286; Buzsaki, Gyorgy/0000-0002-3100-4800				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BULLOCK TH, 1990, NEUROSCIENCE, V38, P609, DOI 10.1016/0306-4522(90)90055-9; BUZSAKI G, 1987, BRAIN RES, V400, P334, DOI 10.1016/0006-8993(87)90632-9; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Buzsaki G, 1991, Hippocampus, V1, P163, DOI 10.1002/hipo.450010205; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; DASILVA FHL, 1990, PHYSIOL REV, V70, P453, DOI 10.1152/physrev.1990.70.2.453; Douglas RJ, 1990, NEURAL COMPUT, V2, P283, DOI 10.1162/neco.1990.2.3.283; ENGEL J, 1990, NEUROLOGY, V40, P1670, DOI 10.1212/WNL.40.11.1670; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HOLSHEIMER J, 1989, EXP BRAIN RES, V77, P69, DOI 10.1007/BF00250568; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; KAWAGUCHI Y, 1987, BRAIN RES, V416, P369, DOI 10.1016/0006-8993(87)90921-8; KUNKEL DD, 1988, SYNAPSE, V2, P382, DOI 10.1002/syn.890020405; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LI XG, 1992, EXP BRAIN RES, V90, P519; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SIK A, 1993, EUR J NEUROSCI, V5, P1719, DOI 10.1111/j.1460-9568.1993.tb00239.x; SLOVITER RS, 1987, J COMP NEUROL, V256, P42, DOI 10.1002/cne.902560105; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TAMAMAKI N, 1990, J COMP NEUROL, V291, P509, DOI 10.1002/cne.902910403; TAMAMAKI N, 1991, J COMP NEUROL, V303, P435, DOI 10.1002/cne.903030309; TAMAMAKI N, 1988, BRAIN RES, V452, P255, DOI 10.1016/0006-8993(88)90030-3; VALTSCHANOFF JG, 1993, J COMP NEUROL, V331, P111, DOI 10.1002/cne.903310107; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; YLINEN A, IN PRESS J NEUROSCI; YOUNG HM, 1992, HISTOCHEMISTRY, V97, P375, DOI 10.1007/BF00270041; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	42	165	166	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1722	1724		10.1126/science.8085161	http://dx.doi.org/10.1126/science.8085161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085161				2022-12-28	WOS:A1994PG28400035
J	PALOMBELLA, VJ; RANDO, OJ; GOLDBERG, AL; MANIATIS, T				PALOMBELLA, VJ; RANDO, OJ; GOLDBERG, AL; MANIATIS, T			THE UBIQUITIN-PROTEASOME PATHWAY IS REQUIRED FOR PROCESSING THE NF-KAPPA-B1 PRECURSOR PROTEIN AND THE ACTIVATION OF NF-KAPPA-B	CELL			English	Article							DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; P50 PRECURSOR; ANTIGEN PRESENTATION; 65-KD SUBUNIT; REL ONCOGENE; COMPLEX; GENE; P105; INHIBITOR	We demonstrate an essential role for the proteasome complex in two proteolytic processes required for activation of the transcription factor NF-kappa B. The p105 precursor of the p50 subunit of NF-kappa B is processed in vitro by an ATP-dependent process that requires proteasomes and ubiquitin conjugation. The C-terminal region of p105 is rapidly degraded, leaving the N-terminal p50 domain. p105 processing can be blocked in intact cells with inhibitors of the proteasome or in yeast with proteasome mutants. These inhibitors also block the activation of NF-kappa B and the rapid degradation of I kappa B alpha induced by tumor necrosis factor alpha. Thus, the ubiquitin-proteasome pathway functions not only in the complete degradation of polypeptides, but also in the regulated processing of precursors into active proteins.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	PALOMBELLA, VJ (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.			Rando, Oliver/0000-0003-1516-9397	NIAID NIH HHS [AI20642] Funding Source: Medline; NIGMS NIH HHS [GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; COLLINS T, 1993, LAB INVEST, V68, P499; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARLOW E, 1988, ANTIBODIES LABORATOR; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1987, J BIOL CHEM, V262, P8303; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEUMANN M, 1992, ONCOGENE, V7, P2095; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TANAKA K, 1992, NEW BIOL, V4, P173; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	71	1917	2025	0	74	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					773	785		10.1016/S0092-8674(94)90482-0	http://dx.doi.org/10.1016/S0092-8674(94)90482-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087845				2022-12-28	WOS:A1994PG29600007
J	EGGERT, RW; PARKINSON, MD				EGGERT, RW; PARKINSON, MD			PREVENTIVE MEDICINE AND HEALTH SYSTEM REFORM - IMPROVING PHYSICIAN EDUCATION, TRAINING, AND PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ENVIRONMENTAL MEDICINE; PRIMARY-CARE; RECOMMENDATIONS; ASSOCIATION; CURRICULUM; SERVICES; TEACHERS; MODEL		UNIV N CAROLINA, DEPT SOCIAL MED, CHAPEL HILL, NC USA; HLTH RESOURCES & SERV ADM, BUR HLTH PROFESS, DIV ASSOCIATED DENT & PUBL HLTH PROFESS, ROCKVILLE, MD USA	University of North Carolina; University of North Carolina Chapel Hill; United States Health Resources & Service Administration (HRSA)								ALTEKRUSE J, 1991, ACAD MED, V66, P312, DOI 10.1097/00001888-199106000-00002; [Anonymous], 1988, FUTURE PUBLIC HLTH; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BABBOTT D, 1988, JAMA-J AM MED ASSOC, V259, P1970, DOI 10.1001/jama.259.13.1970; BLUMENTHAL DS, 1993, AM J PREV MED, V9, P122, DOI 10.1016/S0749-3797(18)30752-9; BOYER MH, 1992, ACAD MED, V67, P363, DOI 10.1097/00001888-199206000-00003; CASTORINA JS, 1990, ANN INTERN MED, V113, P983, DOI 10.7326/0003-4819-113-12-983; COLLINS TR, 1991, ACAD MED, V66, P317, DOI 10.1097/00001888-199106000-00003; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; DAVIS K, 1990, AM J PREV MED S, V6, P3; DIAL TH, 1987, J MED EDUC, V62, P955; FRANK E, 1991, AM J PREV MED, V7, P128, DOI 10.1016/S0749-3797(18)30952-8; GELLERT GA, 1991, AM J PREV MED, V7, P183, DOI 10.1016/S0749-3797(18)30937-1; GOTTLIEB LK, 1992, J GEN INTERN MED, V7, P630, DOI 10.1007/BF02599203; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HAVAS S, 1993, PUBLIC HEALTH REP, V108, P333; HERSEY J, 1992, PRACTICING PREVENTIV; Kralewski J, 1994, Physician Exec, V20, P3; LANE DS, 1986, AM J PREV MED, V2, P216; LEAF A, 1993, JAMA-J AM MED ASSOC, V269, P616, DOI 10.1001/jama.269.5.616; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; LEWIS CE, 1970, ARCH ENVIRON HEALTH, V21, P99, DOI 10.1080/00039896.1970.10667200; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MULLER S, 1984, J MED EDUC, V59, P1; PARKINSON MD, 1991, J FAM PRACTICE, V33, P529; RABIN DL, 1993, AM J PREV MED, V9, P124, DOI 10.1016/S0749-3797(18)30753-0; ROSENSTOCK L, 1991, NEW ENGL J MED, V325, P924, DOI 10.1056/NEJM199109263251305; ROSENTHAL MP, 1994, JAMA-J AM MED ASSOC, V271, P914, DOI 10.1001/jama.271.12.914; ROWLEY BD, 1991, JAMA-J AM MED ASSOC, V266, P933, DOI 10.1001/jama.266.7.933; SALIVE ME, 1991, AM J PREV MED, V7, P445, DOI 10.1016/S0749-3797(18)30885-7; SALIVE ME, 1992, AM J PREV MED, V8, P257, DOI 10.1016/S0749-3797(18)30814-6; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SHUGARS DA, 1991, HEALTHY AM PRACTITIO; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; TEICHMAN RF, 1990, J OCCUP ENVIRON MED, V32, P124; WHEAT JR, 1991, EVAL HEALTH PROF, V14, P304, DOI 10.1177/016327879101400304; WILLIAMS SJ, 1988, AM J PREV MED, V4, P231, DOI 10.1016/S0749-3797(18)31178-4; 1992, JAMA-J AM MED ASSOC, V268, P1092; [No title captured]; 1992, EXECUTIVE SUMMARY; 1980, REPORT GRADUATE MED, V2; 1993, PREVENTIVE SERVICES; 1991, DIRECTORY PREVENTIVE; 1994, RECOMMENDATIONS IMPR; 1992, 3RD US DEP HLTH HUM; 1993, 1993 94 AAMC CURRICU; 1983, BOOKLET INFORMATION; 1988, 1ST US DEP HLTH HUM; 1994, ACADEMIC MED HLTH CA; 1991, ADDRESSING PHYSICIAN; 1994, INVENTORY KNOWLEDGE; 1992, GOOD HLTH HIAA PREVE; 1993, HLTH CARE REFORM PUB; 1993, ANAL PREVENTIVE MED	55	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					688	693		10.1001/jama.272.9.688	http://dx.doi.org/10.1001/jama.272.9.688			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064984				2022-12-28	WOS:A1994PE32700013
J	NIGHTINGALE, SL				NIGHTINGALE, SL			BROCHURES ON SEAFOOD SAFETY FOR PEOPLE WITH CERTAIN DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					582	582		10.1001/jama.272.8.582	http://dx.doi.org/10.1001/jama.272.8.582			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057499				2022-12-28	WOS:A1994PC39800004
J	BARTZOKAS, CA; JOHNSON, R; JANE, M; MARTIN, MV; PEARCE, PK; SAW, Y				BARTZOKAS, CA; JOHNSON, R; JANE, M; MARTIN, MV; PEARCE, PK; SAW, Y			RELATION BETWEEN MOUTH AND HEMATOGENOUS INFECTION IN TOTAL JOINT REPLACEMENTS	BRITISH MEDICAL JOURNAL			English	Article							TOTAL HIP-REPLACEMENT; PROPHYLACTIC ANTIBIOTICS; HEMATOGENOUS INFECTION; ARTHROPLASTY	Objective-To investigate the source of infections associated with orthopaedic prostheses. Design-Analysis of four infections of prosthetic joints with case records; minimum inhibitory and minimum bactericidal concentrations and sodium dodecylsulphate polyacrylamide gel electrophoresis of the cell wall polypeptides of the Streptococcus sanguis isolates from the mouth and infected prostheses; examination of the patients' mouths for periodontal disease and caries. Subjects-Four adults (three men) aged 58-83. Results-For each patient the strain of S sanguis isolated from the mouth was indistinguishable from that isolated from the prosthesis. Ah patients had severe periodontal disease and caries. Conclusions-The mouth was probably the source of bacterial infection in the prosthetic joints of these patients; the route of infection was possibly haematogenous. Incipient oral infection should be treated before joint replacement, and oral health should be maintained indefinitely.	WIRRAL HOSP NHS TRUST,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND; LIVERPOOL DENT HOSP,LIVERPOOL L3 5PS,MERSEYSIDE,ENGLAND	University of Liverpool								AHLBERG A, 1978, CLIN ORTHOP RELAT R, V137, P69; ARTZ TD, 1975, J BONE JOINT SURG AM, V57, P1024; BEIGHTON D, 1991, J MED MICROBIOL, V35, P367, DOI 10.1099/00222615-35-6-367; Brand R A, 1975, J Iowa Med Soc, V65, P388; CARLSSON AS, 1977, ACTA ORTHOP SCAND, V48, P405, DOI 10.3109/17453677708992017; CREUSS RL, 1975, CLIN ORTHOPAEDICS, V106, P99; DOWNES EM, 1977, J BONE JOINT SURG BR, V59, P42, DOI 10.1302/0301-620X.59B1.845227; Jacobson J J, 1988, J Dent Educ, V52, P599; KLENERMAN L, 1984, J BONE JOINT SURG BR, V66, P645, DOI 10.1302/0301-620X.66B5.6389556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTIMER GL, 1979, JAMA-J AM MED ASSOC, V242, P2213, DOI 10.1001/jama.242.20.2213; LINDQVIST C, 1985, ACTA ORTHOP SCAND, V56, P506, DOI 10.3109/17453678508993046; MULLIGAN R, 1980, J AM DENT ASSOC, V101, P44, DOI 10.14219/jada.archive.1980.0334; REEVES DS, 1978, LABORATORY METHODS A; RUBIN R, 1976, ORAL SURG ORAL MED O, V41, P18, DOI 10.1016/0030-4220(76)90247-4; RUSSELL RRB, 1976, MICROBIOS LETT, V2, P55; SCHURMAN DJ, 1976, WESTERN J MED, V125, P226; STINCHFIELD FE, 1980, J BONE JOINT SURG AM, V62, P1345, DOI 10.2106/00004623-198062080-00015; WILSON PD, 1975, SURG CLIN N AM, V55, P1431	19	73	74	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					506	508		10.1136/bmj.309.6953.506	http://dx.doi.org/10.1136/bmj.309.6953.506			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086903	Green Published			2022-12-28	WOS:A1994PD30800016
J	GREENFIELD, SM; HARVEY, RS; THOMPSON, RPH				GREENFIELD, SM; HARVEY, RS; THOMPSON, RPH			RHABDOMYOLYSIS AFTER TREATMENT WITH INTERFERON-ALFA	BRITISH MEDICAL JOURNAL			English	Letter											GREENFIELD, SM (corresponding author), ST THOMAS HOSP,RAYNE INST,GASTROINTESTINAL LAB,LONDON SE1 7EH,ENGLAND.							IINIO S, 1993, GUT, V34, pS114; 1993, DRUG THER B, V31, P61	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					512	512		10.1136/bmj.309.6953.512a	http://dx.doi.org/10.1136/bmj.309.6953.512a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086910	Green Published			2022-12-28	WOS:A1994PD30800022
J	WARK, NC				WARK, NC			30 YEARS LATER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					497	498						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046787				2022-12-28	WOS:A1994PB22900001
J	SERAFINI, T; KENNEDY, TE; GALKO, MJ; MIRZAYAN, C; JESSELL, TM; TESSIERLAVIGNE, M				SERAFINI, T; KENNEDY, TE; GALKO, MJ; MIRZAYAN, C; JESSELL, TM; TESSIERLAVIGNE, M			THE NETRINS DEFINE A FAMILY OF AXON OUTGROWTH-PROMOTING PROTEINS HOMOLOGOUS TO C-ELEGANS UNC-6	CELL			English	Article							MEMBRANE ANCHOR ATTACHMENT; CENTRAL-NERVOUS-SYSTEM; RAT SPINAL-CORD; FLOOR PLATE; CELL-DIFFERENTIATION; CHICK-EMBRYO; LAMININ; GUIDANCE; GROWTH; SIGNAL	In vertebrates, commissural axons pioneer a circumferential pathway to the floor plate at the ventral midline of the embryonic spinal cord. Floor plate cells secrete a diffusible factor that promotes the outgrowth of commissural axons in vitro. We have purified from embryonic chick brain two proteins, netrin-1 and netrin-2, that each possess commissural axon outgrowth-promoting activity, and we have also identified a distinct activity, that potentiates their effects. Cloning of cDNAs encoding the two netrins shows that they are homologous to UNC-6, a laminin-related protein required for the circumferential migration of cells and axons in C. elegans. This homology suggests that growth cones in the vertebrate spinal cord and the nematode are responsive to similar molecular cues.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & BIOPHYS, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Columbia University; Howard Hughes Medical Institute	SERAFINI, T (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA.			Galko, Michael/0000-0002-3759-2017	NINDS NIH HHS [NS07067] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; CJAL SRY, 1909, HISTOLOGIE SYSTEME N, V1, P1952; DAVIES AM, 1987, DEVELOPMENT, V101, P185; DIAMOND J, 1992, J NEUROSCI, V12, P1467; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EBENDAL T, 1989, NERVE GROWTH FACTORS, P81; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GOODMAN C, 1993, CELL S, V10, P65; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOLLEY JA, 1982, J COMP NEUROL, V205, P371, DOI 10.1002/cne.902050406; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JESSELL TM, 1992, HARVEY LECT, V86, P87; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEVIMONTALCINI R, 1972, STRUCTURE FUNCTION N, V5, P1; MCKENNA MP, 1988, DEV BIOL, V130, P232, DOI 10.1016/0012-1606(88)90429-0; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NURCOMBE V, 1992, PHARMACOL THERAPEUT, V56, P247, DOI 10.1016/0163-7258(92)90019-V; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Weber A., 1938, Bio-Morphosis Basel, V1, P30; WENTWORTH LE, 1984, J COMP NEUROL, V222, P96, DOI 10.1002/cne.902220109; YAGINUMA H, 1991, J NEUROSCI, V11, P2598; YAGINUMA H, 1990, DEVELOPMENT, V108, P705; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; 1992, SEQUENCE ANAL SOFTWA	58	1112	1155	0	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	1994	78	3					409	424		10.1016/0092-8674(94)90420-0	http://dx.doi.org/10.1016/0092-8674(94)90420-0			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062384				2022-12-28	WOS:A1994PC40500008
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING FOR COLORECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article							FECAL OCCULT BLOOD; SIGMOIDOSCOPY; MORTALITY; HEMOCCULT; TESTS	In the United Kingdom there are almost 31000 new cases of colorectal cancer each year and nearly 20000 deaths. It is the second most common cause of all deaths from cancer in the United Kingdom. The efficacy of screening with faecal occult blood tests to detect and treat tumours at an early stage, and thereby to reduce mortality, is currently being assessed in several randomised controlled trials. In general, faecal occult blood tests have a low sensitivity and only moderate levels of uptake among the population invited for screening. Until the studies in Denmark, Sweden, and Nottingham report their findings, there is no case for providing such screening routinely to an asymptomatic population. Detecting and removing premalignant adenomas by flexible sigmoidoscopy could be more effective than detecting early localised, asymptomatic cancers in reducing deaths from colorectal cancer. It is estimated that screening people at about the age of 60 by a single flexible sigmoidoscopy examination with appropriate colonoscopic surveillance could prevent 5500 cases of colorectal cancer and 3500 deaths in the United Kingdom each year. A randomised controlled trial to confirm these observations should be seen as a priority.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; AUSTOKER J, 1994, BRIT MED J, V308, P1610, DOI 10.1136/bmj.308.6944.1610; BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BOX V, 1984, PUBLIC HEALTH, V98, P16, DOI 10.1016/S0033-3506(84)80055-4; CHAMBERLAIN J, 1990, BRIT J CANCER, V62, P1, DOI 10.1038/bjc.1990.216; CUZICK J, 1993, COMMUNICATION; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; Farrands P A, 1984, Community Med, V6, P12; Hardcastle J, 1991, Eur J Cancer Prev, V1 Suppl 2, P21, DOI 10.1097/00008469-199110002-00004; HARDCASTLE JD, 1989, LANCET, V1, P1160; HOBBS FDR, 1992, BRIT MED J, V304, P483, DOI 10.1136/bmj.304.6825.483; HUNTER W, 1991, FAM PRACT, V8, P367, DOI 10.1093/fampra/8.4.367; KINSELLA AR, 1993, COLORECTAL CANCER SC; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; LEVIN B, 1992, NEW ENGL J MED, V326, P700, DOI 10.1056/NEJM199203053261009; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANT D, 1992, BRIT J GEN PRACT, V42, P18; MANT D, 1990, BRIT J GEN PRACT, V40, P423; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; PONDER B, 1994, GENETIC TESTING CANC; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, LANCET, V341, P728, DOI 10.1016/0140-6736(93)90493-Z; Silman A, 1984, Community Med, V6, P8; THOMAS W, 1991, CANCER SCREENING, P106; Verne J, 1993, Eur J Cancer Prev, V2, P301, DOI 10.1097/00008469-199307000-00003; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1993, CANCER LARGE BOWEL	32	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					382	386		10.1136/bmj.309.6951.382	http://dx.doi.org/10.1136/bmj.309.6951.382			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081142	Green Published			2022-12-28	WOS:A1994PB31600025
J	GREENHALGH, R				GREENHALGH, R			ORGANIZATION OF VASCULAR SURGICAL SERVICES - EVOLUTION OR REVOLUTION - COMMENTARY - THE OBITUARY OF GENERAL-SURGERY	BRITISH MEDICAL JOURNAL			English	Note											GREENHALGH, R (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.							DRAKE SG, 1987, EUR J VASCULAR SURG, V1, P217; 1993, VASCULAR SURGERY SER	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					388	388		10.1136/bmj.309.6951.388	http://dx.doi.org/10.1136/bmj.309.6951.388			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081144	Green Published			2022-12-28	WOS:A1994PB31600027
J	NUDLER, E; GOLDFARB, A; KASHLEV, M				NUDLER, E; GOLDFARB, A; KASHLEV, M			DISCONTINUOUS MECHANISM OF TRANSCRIPTION ELONGATION	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CLEAVAGE; DNA	During transcription elongation, three flexibly connected parts of RNA polymerase of Escherichia coli advance along the template so that the front-end domain is followed by the catalytic site which in turn is followed by the RNA product binding site. The advancing enzyme was found to maintain the same conformation throughout extended segments of the transcribed region. However, when the polymerase traveled across certain DNA sites that seemed to briefly anchor the front-end domain, cyclic shifting of the three parts, accompanied by buildup and relief of internal strain, was observed. Thus, elongation proceeded in alternating laps of monotonous and inchworm-like movement with the flexible RNA polymerase configuration being subject to direct sequence control.	PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016					Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1994, HARVEY LECTURES 88, P1; GU WG, 1993, J BIOL CHEM, V268, P25604; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LUSE DS, COMMUNICATION; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, UNPUB; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; YAGER TD, 1987, CELLULAR MOL BIOL, P1241	14	141	141	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					793	796		10.1126/science.8047884	http://dx.doi.org/10.1126/science.8047884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047884				2022-12-28	WOS:A1994PA37200036
J	KRAMER, J; RAJCZY, K; HEGYI, L; FULOP, T; MOHACSI, A; MEZEI, Z; KELTAI, M; BLASKO, G; FERENCZY, E; ANHTUAN, N; FUST, G				KRAMER, J; RAJCZY, K; HEGYI, L; FULOP, T; MOHACSI, A; MEZEI, Z; KELTAI, M; BLASKO, G; FERENCZY, E; ANHTUAN, N; FUST, G			C4B(ASTERISK)Q0 ALLOTYPE AS RISK FACTOR FOR MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-COMPLEMENT; 4TH COMPONENT		SEMMELWEIS UNIV MED,SCH MED,INST GERONTOL,BUDAPEST,HUNGARY; SZENT IMRE HOSP,BUDAPEST,HUNGARY; DEBRECEN UNIV MED,SCH MED,DEPT MED 1,H-4012 DEBRECEN,HUNGARY; SZENT ISTVAN HOSP,BUDAPEST,HUNGARY; HUNGARIAN INST CARDIOL,BUDAPEST,HUNGARY	Semmelweis University; University of Debrecen	KRAMER, J (corresponding author), NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL,DEPT IMMUNOPATHOL,POB 44,H-1502 BUDAPEST,HUNGARY.							AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; GERSH BJ, 1987, CARDIOLOGY FUNDAMENT, P1116; KRAMER J, 1991, HUM GENET, V86, P595; SIM E, 1986, BIOCHEM J, V239, P763, DOI 10.1042/bj2390763	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					313	314		10.1136/bmj.309.6950.313	http://dx.doi.org/10.1136/bmj.309.6950.313			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086869	Green Published			2022-12-28	WOS:A1994PA37300020
J	LEVY, A; LIGHTMAN, SL				LEVY, A; LIGHTMAN, SL			FORTNIGHTLY REVIEW - DIAGNOSIS AND MANAGEMENT OF PITUITARY-TUMORS	BRITISH MEDICAL JOURNAL			English	Article							RADIATION				LEVY, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,ENGLAND.			Lightman, Stafford/0000-0002-8546-9646				BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220; JAFFE CA, 1992, ENDOCRIN METAB CLIN, V21, P713, DOI 10.1016/S0889-8529(18)30210-X; JONES KL, 1990, PEDIATR CLIN N AM, V37, P1313; LAMBERTS SWJ, 1993, FRONT NEUROENDOCRIN, V14, P27, DOI 10.1006/frne.1993.1002; LEVY A, 1993, CLIN ENDOCRINOL, V38, P559, DOI 10.1111/j.1365-2265.1993.tb02136.x; LITTLEY MD, 1990, BAILLIERE CLIN ENDOC, V4, P147, DOI 10.1016/S0950-351X(05)80321-0; LOSA M, 1989, J NEUROSURG, V70, P561, DOI 10.3171/jns.1989.70.4.0561; LUDECKE DK, 1991, PATHOL RES PRACT, V187, P608; MOLITCH ME, 1989, ANNU REV MED, V40, P225; MOUNTCASTLE RB, 1989, AM J MED SCI, V298, P109, DOI 10.1097/00000441-198908000-00007; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; SNYDER PJ, 1993, ENDOCRIN METAB CLIN, V22, P163, DOI 10.1016/S0889-8529(18)30185-3; TRAN LM, 1991, AM J CLIN ONCOL-CANC, V14, P25, DOI 10.1097/00000421-199102000-00005; WEBSTER J, 1992, CLIN ENDOCRINOL, V37, P534, DOI 10.1111/j.1365-2265.1992.tb01485.x; Wilson C B, 1990, Neurosurg Clin N Am, V1, P139	15	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1087	1091		10.1136/bmj.308.6936.1087	http://dx.doi.org/10.1136/bmj.308.6936.1087			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8080517	Green Published			2022-12-28	WOS:A1994NH48900030
J	HAMM, CW; REIMERS, J; ISCHINGER, T; RUPPRECHT, HJ; BERGER, J; BLEIFELD, W; ENGELSTEIN, E; SCHUCHERT, A; CORTES, A; FRANKE, C; KUCK, KH; TERRES, W; MEINERTZ, T; KALMAR, P; KREBBER, H; DARUP, J; DIETZ, U; MEYER, J; ERBEL, R; OELERT, H; TRAUTMANN, S; IVERSEN, S; DELIUS, W; RIESS, G; ANTONI, D; HACKER, R; MEUDT, M; VOELKER, W; KARSCH, K; SEIPEL, L; SCHANZENBACHER, P; KOCHSIEK, K; UEBIS, R; SIGMUND, M; HANRATH, P; SCHMITT, H; NEUHAUS, KL; SUPPLIETH, M; LUNSTEDT, G; WENDEROTH, U				HAMM, CW; REIMERS, J; ISCHINGER, T; RUPPRECHT, HJ; BERGER, J; BLEIFELD, W; ENGELSTEIN, E; SCHUCHERT, A; CORTES, A; FRANKE, C; KUCK, KH; TERRES, W; MEINERTZ, T; KALMAR, P; KREBBER, H; DARUP, J; DIETZ, U; MEYER, J; ERBEL, R; OELERT, H; TRAUTMANN, S; IVERSEN, S; DELIUS, W; RIESS, G; ANTONI, D; HACKER, R; MEUDT, M; VOELKER, W; KARSCH, K; SEIPEL, L; SCHANZENBACHER, P; KOCHSIEK, K; UEBIS, R; SIGMUND, M; HANRATH, P; SCHMITT, H; NEUHAUS, KL; SUPPLIETH, M; LUNSTEDT, G; WENDEROTH, U			A RANDOMIZED STUDY OF CORONARY ANGIOPLASTY COMPARED WITH BYPASS-SURGERY IN PATIENTS WITH SYMPTOMATIC MULTIVESSEL CORONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANGIOGRAPHIC FOLLOW-UP; ARTERY DISEASE; COMPLETE REVASCULARIZATION; CASS REGISTRY; CLASSIFICATION; RESTENOSIS; OPERATION; SURVIVAL; 2-VESSEL; SERIES	Background. The standard treatment for patients with symptomatic multivessel coronary artery disease is coronary-artery bypass grafting (CABG). Percutaneous transluminal coronary angioplasty (PTCA) is widely used as an alternative approach to revascularization, but a systematic comparison of the two procedures is needed. We compared the outcomes in patients one year after complete revascularization with CABG or PTCA. Methods. A total of 8981 patients with multivessel coronary disease were screened at eight clinical sites, and 359 patients were randomly assigned to undergo CABG (177 patients) or PTCA (182 patients). Enrollment required that complete revascularization of at least two major vessels supplying different myocardial regions be deemed clinically necessary and technically feasible. Results. Among the patients in the CABG group, an average (+/-SD) of 2.2+/-0.6 vessels were grafted, and among those in the PTCA group, 1.9+/-0.5 vessels were dilated. After CABG, hospitalization was longer (median, 19 days, as compared with 5 for PTCA), and Q-wave myocardial infarction in relation to the procedure was more frequent (8.1 percent, as compared with 2.3 percent after PTCA; P = 0.022), whereas in-hospital mortality did not differ significantly between the two groups (2.5 percent in the CABG group and 1.1 percent in the PTCA group). At discharge 93 percent of the patients in the CABG group were free of angina, as compared with 82 percent of those in the PTCA group (P = 0.005). During the first year of follow-up, further interventions were necessary in 44 percent of the patients in the PTCA group (repeated PTCA in 23 percent, CABG in 18 percent, and both in 3 percent) but in only 6 percent of the patients in the CABG group (repeated CABG in 1 percent and PTCA in 5 percent; P<0.001). Seventy-four percent of the patients in the CABG group and 71 percent of those in the PTCA group were free of angina one year after treatment. Exercise capacity improved similarly in both groups. However, 22 percent of the CABG group, as compared with only 12 percent of the PTCA group, did not require antianginal medication (P = 0.041). Conclusions. In selected patients with multivessel coronary disease, PTCA and CABG as initial treatments resulted in equivalent improvement in angina after one year. However, in order to achieve similar clinical outcomes, the patients treated with PTCA were more likely to require further interventions and antianginal drugs, whereas the patients treated with CABG were more likely to sustain an acute myocardial infarction at the time of the procedure.	UNIV HAMBURG, HOSP EPPENDORF, INST MATH & COMP SCI MED, D-20246 HAMBURG, GERMANY; KLINIKUM BOGENHAUSEN, DIV CARDIOL, MUNICH, GERMANY; UNIV MAINZ, MED CLIN 2, MAINZ, GERMANY; UNIV TUBINGEN, TUBINGEN, GERMANY	University of Hamburg; Munchen Klinik; Johannes Gutenberg University of Mainz; Eberhard Karls University of Tubingen	HAMM, CW (corresponding author), UNIV HAMBURG, HOSP EPPENDORF, MED CLIN, DEPT CARDIOL, MARTINISTR 52, D-20246 HAMBURG, GERMANY.		Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; ARMITAGE P, 1987, STATISTICAL METHODS; BELL MR, 1992, CIRCULATION, V86, P446, DOI 10.1161/01.CIR.86.2.446; BELL MR, 1990, J AM COLL CARDIOL, V16, P553, DOI 10.1016/0735-1097(90)90342-M; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COWLEY MJ, 1993, J AM COLL CARDIOL, V22, P1289, DOI 10.1016/0735-1097(93)90532-6; DELIGONUL U, 1988, J AM COLL CARDIOL, V11, P1173, DOI 10.1016/0735-1097(88)90278-1; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FAXON DP, 1992, AM HEART J, V123, P854, DOI 10.1016/0002-8703(92)90687-Q; FISHER L, 1983, CIRCULATION, V68, P951; GLEICHMANN U, 1987, Z KARDIOL, V76, P319; GRONDIN CM, 1984, CIRCULATION, V70, P208; HAMPTON JR, 1993, LANCET, V341, P573; HOCHBERG MS, 1989, J THORAC CARDIOV SUR, V97, P496; JONES EL, 1983, AM J CARDIOL, V51, P7, DOI 10.1016/S0002-9149(83)80003-4; KING SB, 1990, CIRCULATION, V82, P508; KING SB, 1991, CIRCULATION, V84, P2574, DOI 10.1161/01.CIR.84.6.2574; MOCK MB, 1985, NEW ENGL J MED, V312, P916, DOI 10.1056/NEJM198504043121410; MYERS WO, 1985, ANN THORAC SURG, V40, P245, DOI 10.1016/S0003-4975(10)60037-9; MYLER RK, 1987, CATHETER CARDIO DIAG, V13, P1, DOI 10.1002/ccd.1810130102; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; OKEEFE JH, 1990, J AM COLL CARDIOL, V16, P1097, DOI 10.1016/0735-1097(90)90538-Z; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; RYAN TJ, 1990, CIRCULATION, V81, P2041; RYAN TJ, 1993, J AM COLL CARDIOL, V22, P2033, DOI 10.1016/0735-1097(93)90794-2; SEGGEWISS H, 1993, Z KARDIOL, V82, P504; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; VACEK JL, 1992, AM J CARDIOL, V69, P592, DOI 10.1016/0002-9149(92)90147-Q; VANDORMAEL MG, 1987, J AM COLL CARDIOL, V10, P246, DOI 10.1016/S0735-1097(87)80003-7; VANDORMAEL MG, 1985, J AM COLL CARDIOL, V6, P983, DOI 10.1016/S0735-1097(85)80298-9; WARNER MF, 1992, AM HEART J, V124, P1169, DOI 10.1016/0002-8703(92)90396-D; WEINTRAUB WS, 1993, AM J CARDIOL, V71, P511, DOI 10.1016/0002-9149(93)90504-6; 1991, CIRCULATION S5, V84, P1; 1990, LANCET, V335, P1315	39	450	463	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1037	1043		10.1056/NEJM199410203311601	http://dx.doi.org/10.1056/NEJM199410203311601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090162				2022-12-28	WOS:A1994PL56000001
J	DERKSEN, J; NAGESSER, SK; MEINDERS, AE; HAAK, HR; VANDEVELDE, CJH				DERKSEN, J; NAGESSER, SK; MEINDERS, AE; HAAK, HR; VANDEVELDE, CJH			IDENTIFICATION OF VIRILIZING ADRENAL-TUMORS IN HIRSUTE WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADRENOCORTICAL TUMORS; ADENOMA; TESTOSTERONE; VIRILIZATION; ADULT	Background. Hirsutism in women is usually caused by benign adrenal or ovarian disorders, but it can also be caused by adrenal carcinoma. The most effective way to identify such carcinomas is not known. Methods. We measured serum and urinary steroids before and after the administration of 3 mg of dexamethasone per day for five days in 14 hirsute women with histologically proved adrenal tumors (12 adrenal carcinomas and 2 adrenal adenomas) and in 73 women with hirsutism of non-neoplastic origin. Results. All the women with adrenal tumors had elevated basal serum concentrations of testosterone or dehydroepiandrosterone sulfate, as compared with 36 of the 73 women with non-neoplastic hirsutism (sensitivity, 100 percent; 95 percent confidence interval, 77 to 100; specificity, 50 percent; 95 percent confidence interval, 38 to 62). After the administration of dexamethasone, serum dehydroepiandrosterone sulfate concentrations and urinary 17-ketosteroid excretion decreased to values similar to those in normal women in all the women with non-neoplastic hirsutism, but in none of the 12 with adrenal tumors who were tested. All the women who did not have adrenal tumors had serum cortisol concentrations below 3.3 mu g per deciliter (90 nmol per liter) after dexamethasone administration, whereas in all 12 patients tested who had tumors the values were higher. The suppression of serum dehydroepiandrosterone sulfate and cortisol and urinary 17-ketosteroid excretion excluded the likelihood of adrenal tumors with a sensitivity of 100 percent (95 percent confidence interval, 74 to 100) and a specificity of 100 percent (95 percent confidence interval, 89 to 100). Conclusions. Among women with hirsutism, an adrenal tumor is unlikely it the patient has normal basal serum concentrations of testosterone and dehydroepiandrosterone sulfate. In women in whom these concentrations are elevated, a tumor is unlikely if the serum concentration of dehydroepiandrosterone sulfate and urinary 17-ketosteroid excretion are in the normal basal range and the serum cortisol concentration is less than 3.3 mu g per deciliter after the administration of dexamethasone.	LEIDEN UNIV HOSP, DEPT ENDOCRINOL & METAB, LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT SURG, LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	DERKSEN, J (corresponding author), UNIV LEIDEN HOSP, DEPT GEN INTERNAL MED, BLDG 1, CL-R41, POB 9600, 2300 RC LEIDEN, NETHERLANDS.							ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; ANDERSON DC, 1978, CLIN ENDOCRINOL, V9, P1, DOI 10.1111/j.1365-2265.1978.tb03567.x; BERTAGNA C, 1981, AM J MED, V71, P855, DOI 10.1016/0002-9343(81)90384-3; CHECK JH, 1978, OBSTET GYNECOL, V51, pS46; CLOUSTON WM, 1989, CLIN ENDOCRINOL, V31, P467, DOI 10.1111/j.1365-2265.1989.tb01270.x; DELGAUDIO A, 1993, CANCER, V72, P1997; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; GABRILOVE JL, 1981, ENDOCR REV, V2, P462, DOI 10.1210/edrv-2-4-462; GARDNER MJ, 1990, STATISTICS CONFIDENC, P28; GREENBLATT RB, 1963, HIRSUTE FEMALE, P109; KAMILARIS TC, 1987, JAMA-J AM MED ASSOC, V258, P2558, DOI 10.1001/jama.258.18.2558; KENDALL JW, 1968, NEW ENGL J MED, V279, P532, DOI 10.1056/NEJM196809052791007; KIRK JMW, 1990, J CLIN ENDOCR METAB, V70, P1280, DOI 10.1210/jcem-70-5-1280; MAHESH VB, 1968, AM J OBSTET GYNECOL, V100, P1043, DOI 10.1016/S0002-9378(15)33402-5; MAROULIS GB, 1981, FERTIL STERIL, V36, P273; OLEARY TJ, 1986, J PEDIATR-US, V109, P840, DOI 10.1016/S0022-3476(86)80707-7; SAMAAN NA, 1975, OBSTET GYNECOL, V46, P104, DOI 10.1097/00006250-197507000-00022; TAYLOR L, 1986, FERTIL STERIL, V46, P1005; TURPIN G, 1986, REV MED INTERNE, V7, P371, DOI 10.1016/S0248-8663(86)80126-6; VANDEKAMP JJP, 1984, EUR J PEDIATR, V142, P140, DOI 10.1007/BF00445598; VANSETERS AP, 1991, ACTA ENDOCRINOL-COP, V124, P526, DOI 10.1530/acta.0.1240526; VANSETERS AP, 1981, CLIN ENDOCRINOL, V14, P325; VILLEE DB, 1967, J CLIN ENDOCR METAB, V27, P1112, DOI 10.1210/jcem-27-8-1112; VONSLOOTEN H, 1985, CANCER, V55, P766; YUEN BH, 1983, AM J OBSTET GYNECOL, V145, P164, DOI 10.1016/0002-9378(83)90484-2	25	107	114	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					968	973		10.1056/NEJM199410133311502	http://dx.doi.org/10.1056/NEJM199410133311502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	8084355				2022-12-28	WOS:A1994PK50400002
J	MARTENSEN, RL				MARTENSEN, RL			MEDICINE AND THE CARE OF PUBLIC BODIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	MARTENSEN, RL (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,641 HUNTINGTON AVE,BOSTON,MA 02115, USA.							DULAURENS, 1787, MOYENS RENDRE HOPITA; FOUCAULT M, 1973, BIRTH CLINIC; Miller Genevieve, 1957, ADOPTION INOCULATION; Starr P, 1982, SOCIAL TRANSFORMATIO	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					927	927						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084059				2022-12-28	WOS:A1994PG73700018
J	BARST, RJ; RUBIN, LJ; MCGOON, MD; CALDWELL, EJ; LONG, WA; LEVY, PS				BARST, RJ; RUBIN, LJ; MCGOON, MD; CALDWELL, EJ; LONG, WA; LEVY, PS			SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION, PULMONARY; EPOPROSTENOL; HEMODYNAMICS; LUNG TRANSPLANTATION; HEART-LUNG TRANSPLANTATION	HEART-LUNG TRANSPLANTATION; HYDRALAZINE THERAPY; NIFEDIPINE; DIAZOXIDE; EPOPROSTENOL; REGISTRY	Objective: To evaluate,the effects of long-term intravenous infusion of prostacyclin on exercise capacity, hemodynamics, and survival in patients with primary pulmonary hypertension. Design: Open, multicenter, uncontrolled trial. Setting: Four referral centers. Patients: 18 patients with primary pulmonary hypertension: 1 New York Heart Association (NYHA) class II patient, 13 NYHA class III patients, and 4 NYHA class IV patients. Interventions: Continuous intravenous prostacyclin administered by portable infusion pumps. All patients were treated with anticoagulant agents. Measurements and Main Results: With the 6-minute walk used to evaluate exercise capacity, patients could walk on average more than 100 meters farther after prostacyclin therapy was initiated (distance at 6 months, 370 +/- 119 meters compared with 264 +/- 160 meters at baseline; P < 0.001; distance at 18 months, 408 +/- 138 meters; P = 0.02 compared with baseline). Hemodynamics were improved at 6 months: The cardiac index increased 18% (95% CI, 0.1% to 36.7%; P = 0.02), and mean pulmonary artery pressure and total pulmonary resistance decreased 9% (CI, 1.4% to 15.7%; P = 0.03) and 26% (CI, 6.1% to 46.3%; P = 0.02), respectively, compared with baseline. The improvements in cardiac index and total pulmonary resistance were maintained at 12 months (27% increase [CI, 1.3% to 51.9%; P = 0.05] and 32% decrease [CI, 9.7% to 53.6%; P = 0.02] compared with baseline, respectively). Survival was improved in NYHA class III and IV patients who received continuous prostacyclin (n = 17; follow-up, 37 to 69 months) when compared with historical controls who received standard therapy (National Institutes of Health Primary Pulmonary Hypertension Registry, n = 31, P = 0.045). Kaplan-Meier estimates of 1-, 2-, and 3-year survival rates for the patients treated with prostacyclin were 86.9%, 72.4%, and 63.3%, respectively, compared with 77.4%, 51.6%, and 40.6% for the historical control group (hazard ratio, 2.9 [CI, 1.0 to 8.0; P = 0.045]). Serious complications attributable to the drug and delivery system included two deaths and seven episodes of nonfatal sepsis in three patients. Conclusions: Continuous intravenous prostacyclin resulted in sustained clinical and hemodynamic improvement and probably in improved survival in patients with severe primary pulmonary hypertension. Despite potentially serious complications, long-term prostacyclin may be especially helpful in seriously ill patients awaiting transplantation.	UNIV MARYLAND, MED SYST, BALTIMORE, MD 21201 USA; MAYO CLIN & MAYO FDN, DIV CARDIOVASC, ROCHESTER, MN 55905 USA; MAINE MED CTR, PORTLAND, ME 04102 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA	University System of Maryland; University of Maryland Baltimore; Mayo Clinic; Maine Medical Center; Burroughs Wellcome Fund; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	BARST, RJ (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, DIV PEDIAT CARDIOL, 3959 BROADWAY, NEW YORK, NY 10032 USA.		Austin, Eric Douglas/A-6070-2013	Austin, Eric Douglas/0000-0002-1709-9022				AROMATORIO GJ, 1985, CHEST, V87, P265, DOI 10.1378/chest.87.2.265; BARST RJ, 1986, CHEST, V89, P497, DOI 10.1378/chest.89.4.497; BERKENBOOM G, 1982, BRIT HEART J, V47, P511; CAMERINI F, 1980, BRIT HEART J, V44, P352; CHAN NS, 1987, BRIT HEART J, V57, P207; DALONZO GE, 1986, AM REV RESPIR DIS, V133, P380; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DANIEL WW, 1987, BIOSTATISTICS F ANAL; DEHOYOS AL, 1992, J THORAC CARDIOV SUR, V103, P295; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GLANVILLE AR, 1987, CHEST, V91, P675, DOI 10.1378/chest.91.5.675; HAYDOCK DA, 1992, J THORAC CARDIOV SUR, V103, P329; HONEY M, 1980, THORAX, V35, P269, DOI 10.1136/thx.35.4.269; HUGHES JD, 1986, MEDICINE, V65, P56, DOI 10.1097/00005792-198601000-00004; JONES DK, 1987, BRIT HEART J, V57, P270; LEE ET, 1980, STATISTICAL MMODELS; LUPIHERRERA E, 1982, CIRCULATION, V65, P645, DOI 10.1161/01.CIR.65.4.645; MCCARTHY PM, 1992, CLEV CLIN J MED, V59, P307, DOI 10.3949/ccjm.59.3.307; MORGAN JM, 1991, CHEST, V99, P551, DOI 10.1378/chest.99.3.551; OLIVARI MT, 1984, CHEST, V86, P14, DOI 10.1378/chest.86.1.14; PACKER M, 1982, NEW ENGL J MED, V306, P1326, DOI 10.1056/NEJM198206033062203; PACKER M, 1989, CHEST, V95, P1173, DOI 10.1378/chest.95.6.1173; PASQUE MK, 1991, CIRCULATION, V84, P2275, DOI 10.1161/01.CIR.84.6.2275; Pocock SJ., 2013, CLIN TRIALS PRACTICA; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; RICH S, 1988, PROG CARDIOVASC DIS, V31, P205, DOI 10.1016/0033-0620(88)90016-3; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RUBIN LJ, 1983, ANN INTERN MED, V99, P433, DOI 10.7326/0003-4819-99-4-433; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUBIN LJ, 1980, NEW ENGL J MED, V302, P69, DOI 10.1056/NEJM198001103020201; RUBIN LJ, 1982, CIRCULATION, V66, P334, DOI 10.1161/01.CIR.66.2.334; RUSKIN JN, 1979, ANN INTERN MED, V90, P772, DOI 10.7326/0003-4819-90-5-772; WANG SWS, 1978, BRIT HEART J, V40, P572; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WOOD BA, 1982, CHEST, V82, P793, DOI 10.1378/chest.82.6.793; 1993, UNOS ORGAN PROCUREME, V9	39	417	428	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					409	415		10.7326/0003-4819-121-6-199409150-00003	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053614				2022-12-28	WOS:A1994PF33700003
J	CHAUDHARY, AK; NOKUBO, M; REDDY, GR; YEOLA, SN; MORROW, JD; BLAIR, IA; MARNETT, LJ				CHAUDHARY, AK; NOKUBO, M; REDDY, GR; YEOLA, SN; MORROW, JD; BLAIR, IA; MARNETT, LJ			DETECTION OF ENDOGENOUS MALONDIALDEHYDE-DEOXYGUANOSINE ADDUCTS IN HUMAN LIVER	SCIENCE			English	Article							LIPID-PEROXIDATION; DNA-ADDUCTS; CANCER; MALONALDEHYDE; DERIVATIVES; NUCLEOSIDES; HOMOLOG; ACID	Endogenous DNA adducts may contribute to the etiology of human genetic disease and cancer. One potential source of endogenous DNA adducts is lipid peroxidation, which generates mutagenic carbonyl compounds such as malondialdehyde. A sensitive mass spectrometric method permitted detection and quantitation of the major malondialdehyde-DNA adduct, a pyrimidopurinone derived from deoxyguanosine. DNA from disease-free human liver was found to contain 5400 adducts per cell, a frequency comparable to that of adducts formed by exogenous carcinogens.	VANDERBILT UNIV,SCH MED,AB HANCOCK JR MEM LAB CANC RES,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University			Blair, Ian A/B-3320-2010		NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, R01GM042056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BENAMIRA M, IN PRESS CARCINOGENE; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chaudhary A, UNPUB; DIX TA, 1983, SCIENCE, V221, P77, DOI 10.1126/science.6304879; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLOYD RA, IN PRESS 1ST P OXYG; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Kagan V. E, 1988, LIPID PEROXIDATION B; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MARNETT LJ, 1986, J AM CHEM SOC, V108, P1348, DOI 10.1021/ja00266a065; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; MILLER EC, 1966, PHARMACOL REV, V18, P805; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187; NOKUBO M, UNPUB; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; RANDERATH K, 1993, MUTAT RES, V295, P11, DOI 10.1016/0921-8734(93)90007-P; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; Singer B., 1983, MOL BIOL MUTAGENS CA; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; 1984, CHEM CARCINOGENS	31	408	414	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1580	1582		10.1126/science.8079172	http://dx.doi.org/10.1126/science.8079172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079172				2022-12-28	WOS:A1994PF33600035
J	XU, B; SELSING, E				XU, B; SELSING, E			ANALYSIS OF SEQUENCE TRANSFERS RESEMBLING GENE CONVERSION IN A MOUSE ANTIBODY TRANSGENE	SCIENCE			English	Article							HEAVY-CHAIN TRANSGENE; RECOMBINATION; MUTATION; SEGMENT	The role of gene conversion in murine immunoglobulin gene diversification is unclear. An antibody gene construct designed to provide the homologous donor and acceptor sequences required for conversion mechanisms was produced and used to generate transgenic mice. When these transgenic mice were immunized, DNA sequence transfers between tandem transgene VDJ regions were detectable and resembled gene conversion events. There is a strong link between these conversion-like sequence transfers and transgene somatic hypermutation, suggesting that both processes might occur at the same stage of B cell differentiation.			XU, B (corresponding author), TUFTS UNIV,SCH MED,SACKLER SCH GRAD BIOMED SCI,DEPT PATHOL,136 HARRISON AVE,BOSTON,MA 02111, USA.							CHIEN NC, 1988, J EXP MED, V167, P954, DOI 10.1084/jem.167.3.954; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; KRAWINKEL U, 1986, NUCLEIC ACIDS RES, V14, P3871, DOI 10.1093/nar/14.9.3871; KRAWINKEL U, 1983, P NATL ACAD SCI-BIOL, V80, P4997, DOI 10.1073/pnas.80.16.4997; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROTHSTEIN TL, 1983, MOL IMMUNOL, V20, P161, DOI 10.1016/0161-5890(83)90127-X; SOHN J, 1993, J EXP MED, V177, P493, DOI 10.1084/jem.177.2.493; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; WYSOCKI LJ, 1990, J EXP MED, V172, P315, DOI 10.1084/jem.172.1.315	12	43	44	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1590	1593		10.1126/science.8079173	http://dx.doi.org/10.1126/science.8079173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079173				2022-12-28	WOS:A1994PF33600039
J	SOUTTER, WP				SOUTTER, WP			IMMEDIATE REFERRAL TO COLPOSCOPY IS SAFER	BRITISH MEDICAL JOURNAL			English	Article							CERVICAL SMEAR				SOUTTER, WP (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							BOLGER BS, 1988, BRIT J OBSTET GYNAEC, V95, P1117, DOI 10.1111/j.1471-0528.1988.tb06788.x; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; MITCHELL H, 1990, BRIT MED J, V300, P1622, DOI 10.1136/bmj.300.6740.1622; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; SOUTTER WP, 1994, BMJ-BRIT MED J, V308, P1421, DOI 10.1136/bmj.308.6941.1421; SOUTTER WP, 1992, REPORT WORKSHOP MILD; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440; 1987, REPORT INTERCOLLEGIA; 1986, BRIT MED J, V293, P659	13	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					591	592		10.1136/bmj.309.6954.591	http://dx.doi.org/10.1136/bmj.309.6954.591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086951	Green Published			2022-12-28	WOS:A1994PF33000028
J	PUROHIT, P; STERN, S				PUROHIT, P; STERN, S			INTERACTIONS OF A SMALL RNA WITH ANTIBIOTIC AND RNA LIGANDS OF THE 30S SUBUNIT	NATURE			English	Article							16S RIBOSOMAL-RNA; I INTRON RNA; CHEMICAL PROBES; P-SITE; BINDING; NUCLEOTIDES; INHIBITION	IT is now generally accepted that 16S and 23S ribosomal RNA play important roles in the decoding and peptidyl transferase activities of ribosomes(1,2). Despite their complex structures and numerous associated proteins it is possible that small domains of these rRNAs can fold and function autonomously, particularly those that appear devoid of protein interactions(3). One candidate for such a domain is the decoding region, located near the 3' end of 16S rRNA (Fig. 1a, b). Consistent with this hypothesis, aminoglycoside antibiotics that interact with the decoding region in 30S subunits interact with other RNAs in the absence of proteins(4-7). In addition, certain activities of self-splicing introns, at least superficially, resemble translational decoding(8,9). We report here that an oligoribonucleotide analogue of the decoding region interacts with both antibiotic and RNA ligands of the 30S subunit in a manner that correlates with normal subunit function. The activities of the decoding region analogue suggest that the intimidating structural complexity of the ribosome can be, to some degree, circumvented.			PUROHIT, P (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA.							DAVIS PW, 1993, NUCLEIC ACIDS RES, V21, P537, DOI 10.1093/nar/21.3.537; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; GUTELL RR, 1993, TRANSLATIONAL APPARATUS, P477; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME, P73; NOLTER HF, 1991, NATURE, V353, P302; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; SCHROEDER R, 1993, SCIENCE, V260, P1443, DOI 10.1126/science.8502988; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; VONAHSEN U, 1993, SCIENCE, V260, P1500, DOI 10.1126/science.8502993; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B	26	260	278	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					659	662		10.1038/370659a0	http://dx.doi.org/10.1038/370659a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065453				2022-12-28	WOS:A1994PD31000053
J	ETTER, A; BERNARD, V; KENZELMANN, M; TOBLER, H; MULLER, F				ETTER, A; BERNARD, V; KENZELMANN, M; TOBLER, H; MULLER, F			RIBOSOMAL HETEROGENEITY FROM CHROMATIN DIMINUTION IN ASCARIS-LUMBRICOIDES	SCIENCE			English	Article							PROTEIN GENES; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; TURNER SYNDROME; RNA; S19; ORGANIZATION; EXPRESSION; GENOME; YEAST	The genome of Ascaris lumbricoides encodes both germline- and soma-specific proteins homologous to the eukaryotic small ribosomal protein (Rp) S19. The two Ascaris homologs differ by 24 amino acid substitutions and are both components of the small ribosomal subunits. In oocytes, the germline RpS19 homolog (RpS19G) predominates. During chromatin diminution, however, the gene is eliminated from all presomatic cells, and RpS19G is replaced by the product of the somatic gene (RpS19S). Chromatin diminution in A. lumbricoides causes a change in the protein composition of ribosomes during development and represents an alternative means of gene regulation.	UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg								AEBY P, 1986, EMBO J, V5, P3353, DOI 10.1002/j.1460-2075.1986.tb04650.x; BAUMGARTNER S, 1993, NUCLEIC ACIDS RES, V21, P3897, DOI 10.1093/nar/21.16.3897; BRADSHAW RE, 1991, GENE, V108, P157, DOI 10.1016/0378-1119(91)90502-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONOVAN DM, 1990, MOL CELL BIOL, V10, P6097, DOI 10.1128/MCB.10.11.6097; ETTER A, 1991, P NATL ACAD SCI USA, V88, P1593, DOI 10.1073/pnas.88.5.1593; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GODAY C, 1993, PARASITOL TODAY, V9, P319, DOI 10.1016/0169-4758(93)90229-9; GORENSTEIN C, 1976, P NATL ACAD SCI USA, V73, P1547, DOI 10.1073/pnas.73.5.1547; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARLOW E, 1988, ANTIBODIES LABORATOR; KIMURA J, 1987, FEBS LETT, V224, P65, DOI 10.1016/0014-5793(87)80423-4; KONDOH N, 1992, CANCER RES, V52, P791; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MOLENAAR CMT, 1984, NUCLEIC ACIDS RES, V12, P7345, DOI 10.1093/nar/12.19.7345; MORITZ KB, 1976, NATURE, V259, P55, DOI 10.1038/259055a0; MULLER F, 1982, NUCLEIC ACIDS RES, V10, P7493, DOI 10.1093/nar/10.23.7493; MULLER F, 1991, CELL, V67, P815, DOI 10.1016/0092-8674(91)90076-B; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; Poinar GO., 1983, NATURAL HIST NEMATOD; RAMAGOPAL S, 1993, TRANSLATIONAL APPARATUS, P713; Sambrook J, 1989, MOL CLONING LABORATO; Spedding G, 1990, RIBOSOMES PROTEIN SY, P9; SPICHER A, 1994, DEV BIOL, V164, P72, DOI 10.1006/dbio.1994.1181; STORTKUHL KF, 1994, CELL TISSUE RES, V275, P27, DOI 10.1007/BF00305373; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1990, BIOCHIMIE, V72, P299, DOI 10.1016/0300-9084(90)90088-X; TOBLER H, 1992, TRENDS GENET, V8, P427, DOI 10.1016/0168-9525(92)90326-Y; TOBLER H, 1986, RESULTS PROBLEMS CEL, V13; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414	33	45	47	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					954	956		10.1126/science.8052853	http://dx.doi.org/10.1126/science.8052853			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052853				2022-12-28	WOS:A1994PB49900043
J	OROURKE, B; RAMZA, BM; MARBAN, E				OROURKE, B; RAMZA, BM; MARBAN, E			OSCILLATIONS OF MEMBRANE CURRENT AND EXCITABILITY DRIVEN BY METABOLIC OSCILLATIONS IN HEART-CELLS	SCIENCE			English	Article							PURINE NUCLEOTIDE CYCLE; SENSITIVE K+ CHANNELS; CALCIUM CHANNELS; GLYCOLYTIC OSCILLATIONS; POTENTIAL OSCILLATIONS; INTRACELLULAR CALCIUM; MUSCLE EXTRACTS; ATP; MYOCYTES; MODULATION	Periodic changes in membrane ionic current linked to intrinsic oscillations of energy metabolism were identified in guinea pig cardiomyocytes. Metabolic stress initiated cyclical activation of adenosine triphosphate-sensitive potassium current and concomitant suppression of depolarization-evoked intracellular calcium transients. The oscillations in membrane current and excitation-contraction coupling were linked to oscillations in the oxidation state of pyridine nucleotides but were not driven by pacemaker currents or alterations in the concentration of cytosolic calcium. Interventions that altered the rate of glucose metabolism modulated the oscillations, suggesting that the rhythms originated at the level of glycolysis. The energy-driven oscillations in potassium currents produced cyclical changes in the cardiac action potential and thus may contribute to the genesis of arrhythmias during metabolic compromise.	JOHNS HOPKINS UNIV, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036957] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 36957] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES V, 1990, J BIOL CHEM, V265, P21441; AON MA, 1991, J CELL SCI, V99, P325; BACKX PH, 1991, AM J HYPERTENS, V4, pS416, DOI 10.1093/ajh/4.7.416S; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; BOITEUX A, 1975, P NATL ACAD SCI USA, V72, P3829, DOI 10.1073/pnas.72.10.3829; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHANCE B, 1964, BIOCHEMISTRY-US, V52, P337; CHEN V, 1985, BIOCHIM BIOPHYS ACTA, V846, P398, DOI 10.1016/0167-4889(85)90012-6; COLLATZ KG, 1990, COMP BIOCHEM PHYS B, V96, P771, DOI 10.1016/0305-0491(90)90229-M; CONNOR JA, 1979, J EXP BIOL, V81, P153; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; FRENKEL R, 1966, ARCH BIOCHEM BIOPHYS, V115, P112, DOI 10.1016/S0003-9861(66)81046-9; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; GOLDBETER A, 1980, MATH MODELS MOL CELL, P260; GOLDMAN YE, 1982, NATURE, V300, P701, DOI 10.1038/300701a0; GOOCH VD, 1974, BIOCHIM BIOPHYS ACTA, V346, P245, DOI 10.1016/0304-4173(74)90002-0; GWILT M, 1993, EUR J PHARMACOL, V236, P107, DOI 10.1016/0014-2999(93)90232-7; HESS B, 1983, H-S Z PHYSIOL CHEM, V364, P1; Hess B, 1979, Ann N Y Acad Sci, V316, P203, DOI 10.1111/j.1749-6632.1979.tb29470.x; KEUNG EC, 1991, J CLIN INVEST, V88, P1772, DOI 10.1172/JCI115497; KORT AA, 1985, J PHYSIOL-LONDON, V367, P291, DOI 10.1113/jphysiol.1985.sp015825; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MARKUS M, 1984, FEBS LETT, V172, P235, DOI 10.1016/0014-5793(84)81132-1; MEECH RW, 1979, J EXP BIOL, V81, P93; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; OROURKE B, 1992, SCIENCE, V257, P245, DOI 10.1126/science.1321495; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; Stryer L, 1981, BIOCHEMISTRY; TORNHEIM K, 1974, J BIOL CHEM, V249, P3241; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TSIEN RW, 1979, J EXP BIOL, V81, P205; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; WEISS JN, 1992, J PHYSIOL-LONDON, V447, P649, DOI 10.1113/jphysiol.1992.sp019022; Wit A. L., 1993, VENTRICULAR ARRHYTHM	38	212	222	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					962	966		10.1126/science.8052856	http://dx.doi.org/10.1126/science.8052856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052856				2022-12-28	WOS:A1994PB49900046
J	ZHANG, J; DAWSON, VL; DAWSON, TM; SNYDER, SH				ZHANG, J; DAWSON, VL; DAWSON, TM; SNYDER, SH			NITRIC-OXIDE ACTIVATION OF POLY(ADP-RIBOSE) SYNTHETASE IN NEUROTOXICITY	SCIENCE			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ADP-RIBOSYLATION; RIBONUCLEOTIDE REDUCTASE; GLUTAMATE NEUROTOXICITY; DNA DAMAGE; CELLS; INHIBITION; POLYMERASE; CALCIUM; NICOTINAMIDE	Poly(adenosine 5'-diphosphoribose) synthetase (PARS) is a nuclear enzyme which, when activated by DNA strand breaks, adds up to 100 adenosine 5'-diphosphoribose (ADP-ribose) units to nuclear proteins such as histones and PARS itself. This activation can lead to cell death through depletion of beta-nicotinamide adenine dinucleotide (the source of ADP-ribose) and adenosine triphosphate. Nitric oxide (NO) stimulated ADP-ribosylation of PARS in rat brain. Benzamide and other derivatives, which inhibit PARS, blocked N-methyl-D-aspartate- and NO-mediated neurotoxicity with relative potencies paralleling their ability to inhibit PARS. Thus, NO appeared to elicit neurotoxicity by activating PARS.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-271-90-7408, DA-00266, DA-00074] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DAWSON TM, IN PRESS J NEUROSCI; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MCNERNEY R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P185, DOI 10.1016/0167-4781(89)90099-7; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Molina Y Vedia Luis, 1992, Journal of Biological Chemistry, V267, P24929; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; RALEY KM, 1990, NEUROSCI LETT, V110, P118, DOI 10.1016/0304-3940(90)90798-E; RANDALL RD, 1992, J NEUROSCI, V12, P1882; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; UEMATSU D, 1989, BRAIN RES, V482, P129, DOI 10.1016/0006-8993(89)90549-0; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	34	1035	1084	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					687	689		10.1126/science.8080500	http://dx.doi.org/10.1126/science.8080500			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8080500				2022-12-28	WOS:A1994MU96400051
J	PERAZELLA, MA; MAGALDI, J				PERAZELLA, MA; MAGALDI, J			RETINOPATHY IN LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PERAZELLA, MA (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					922	922						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078553				2022-12-28	WOS:A1994PJ41900006
J	KOGAN, MD; PAPPAS, G; YU, SM; KOTELCHUCK, M				KOGAN, MD; PAPPAS, G; YU, SM; KOTELCHUCK, M			OVER-THE-COUNTER MEDICATION USE AMONG US PRESCHOOL-AGE CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-MEDICATION; COMMON COLD	Objective.-To estimate the prevalence of recent over-the-counter (OTC) medication use in a national sample of preschool-age children. Design.-Follow-up survey of a nationally representative sample of 3-year-old children in the US population by telephone or personal interview. Participants.-A total of 8145 children whose mothers were interviewed for the 1991 Longitudinal Follow-up to the National Maternal and Infant Health Survey. Main Outcome Measures.-Report of any OTC medications given in the past 30 days and the type of medications that the child received. Results.-During the past 30 days, 53.7% of all 3-year-old children in the United States were given some OTC medications. Among OTC medication users, the most common medications reported were Tylenol (66.7%) and cough or cold medicine (66.7%). Most respondents reported that recent child illness episodes (70%) were treated with OTC medications. After adjustment for recent child illness, women who were white (odds ratio [OR], 1.32; 95% confidence interval [Cl], 1.13 to 1.55), were more educated (OR, 1.58; 95% CI, 1.24 to 2.00), and had higher incomes (OR, 1.75; 95% Cl, 1.33 to 2.30) were more likely to have given their child OTC medications. Women without health insurance were also more likely to have given OTC medications (OR, 1.27; 95% Cl, 1.04 to 1.55). Provider visits, but not telephone calls, were associated with a reduction in OTC medication usage. Conclusions.-Over-the-counter medications are an important component of health care for treating illness in US preschool-age children. The high prevalence of use has occurred despite the dearth of scientific proof for the effectiveness of certain classes of OTC medications and the risks associated with improper use.	US HLTH RESOURCES & SERV ADM, BUR MATERNAL & CHILD HLTH, ROCKVILLE, MD USA; UNIV N CAROLINA, DEPT MATERNAL & CHILD HLTH, CHAPEL HILL, NC USA	United States Health Resources & Service Administration (HRSA); University of North Carolina; University of North Carolina Chapel Hill	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, ROOM 840, HYATTSVILLE, MD 20782 USA.							BLAKE KD, 1993, LANCET, V341, P640, DOI 10.1016/0140-6736(93)90410-I; BONADIO WA, 1993, CLIN PEDIATR, V32, P343, DOI 10.1177/000992289303200604; BUSH PJ, 1976, MED CARE, V14, P1014; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; CONN VS, 1991, J ADV NURS, V16, P1190, DOI 10.1111/j.1365-2648.1991.tb01528.x; CRAIG RS, 1992, J DRUG EDUC, V22, P303, DOI 10.2190/2NHN-NUY7-Q88U-CDJH; DRWALKLEIN LA, 1992, CLIN PHARMACY, V11, P1005; DUKES GE, 1990, AM J MED, V88, pS24, DOI 10.1016/0002-9343(90)90272-F; Dunnell Karen, 1972, MED TAKERS PRESCRIBE; FRIEDMAN A D, 1990, Pediatric Emergency Care, V6, P6, DOI 10.1097/00006565-199003000-00003; GINSBURG CM, 1973, AM J DIS CHILD, V125, P241, DOI 10.1001/archpedi.1973.04160020065012; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; JEFFERYS M, 1960, Br J Prev Soc Med, V14, P64; JOHNSON RE, 1983, MED CARE, V21, P225, DOI 10.1097/00005650-198302000-00009; KNAPP DA, 1972, AM J HOSP PHARM, V29, P1004, DOI 10.1093/ajhp/29.12.1004; KOVAR MG, 1985, PUBLIC HEALTH REP, V100, P470; LITOVITZ T, 1992, PEDIATRICS, V89, P999; Lowenstein S R, 1987, Adv Intern Med, V32, P207; Maheady D C, 1989, J Pediatr Health Care, V3, P246; MAIMAN LA, 1986, SOC SCI MED, V22, P41, DOI 10.1016/0277-9536(86)90307-2; MAIMAN LA, 1982, PUBLIC HEALTH REP, V97, P140; PICKERING LK, 1991, J PEDIATR-US, V118, pS118, DOI 10.1016/S0022-3476(05)81439-8; Rosenthal I., 1988, DRUG TOPICS, V132, P62; RUMACK BH, 1974, PEDIATRICS, V53, P495; SAKCHAINANONT B, 1990, Journal of the Medical Association of Thailand, V73, P96; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SCHACHTEL BP, 1993, CLIN PHARMACOL THER, V53, P593, DOI 10.1038/clpt.1993.75; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; 1993, LONGITUDINAL FOLLOW; 1993, SURVEY DATA ANAL VER; 1993, PHYSICIANS DESK REFE	32	164	170	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1025	1030		10.1001/jama.272.13.1025	http://dx.doi.org/10.1001/jama.272.13.1025			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089884				2022-12-28	WOS:A1994PH77500027
J	ALS, H; LAWHON, G; DUFFY, FH; MCANULTY, GB; GIBESGROSSMAN, R; BLICKMAN, JG				ALS, H; LAWHON, G; DUFFY, FH; MCANULTY, GB; GIBESGROSSMAN, R; BLICKMAN, JG			INDIVIDUALIZED DEVELOPMENTAL CARE FOR THE VERY-LOW-BIRTH-WEIGHT PRETERM INFANT - MEDICAL AND NEUROFUNCTIONAL EFFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRONCHOPULMONARY DYSPLASIA; INTRAVENTRICULAR HEMORRHAGE; PREMATURE-INFANTS; GESTATIONAL-AGE; RETINOPATHY; OUTCOMES; EQUALITY	Objective.-To investigate the effectiveness of individualized developmental care in reducing medical and neurodevelopmental sequelae for very low-birthweight infants. Design.-Randomized controlled trial. Setting.-Newborn intensive care unit. Patients.-Thirty-eight singleton preterm infants, free of known congenital abnormalities, weighing less than 1250 g, born before 30 weeks' gestation, mechanically ventilated within 3 hours of delivery and for more than 24 hours in the first 48 hours, randomly assigned to a control or an experimental group. Intervention.-Caregiving by nurses specifically trained in individualized developmental care; observation and documentation of the infants' behavior within 12 hours of admission, and subsequently every 10th day; developmental care recommendations and ongoing clinical support for the nurses and parents based on regular observation of the infant by developmental specialists; and the availability of special caregiving accessories. Main Outcome Measures.-Medical outcome, including average daily weight gain; number of days the infant required mechanical ventilation, oxygen, gavage tube feeding, and hospitalization; severity of retinopathy of prematurity, bronchopulmonary dysplasia, pneumothorax, and intraventricular hemorrhage; pediatric complications; age at discharge; and hospital charges. Neurodevelopmental outcome, including Assessment of Preterm Infants' Behavior scale and quantified electroencephalography (2 weeks after due date); and Bayley Scales of Infant Development and Kangaroo Box Paradigm (9 months after due date). Results.-The infants in the experimental group had a significantly shorter duration of mechanical ventilation and supplemental oxygen support; earlier oral feeding; reduced incidence of intraventricular hemorrhage, pneumothorax, and severe bronchopulmonary dysplasia; improved daily weight gain; shorter hospital stays; younger ages at hospital discharge; and reduced hospital charges compared with the infants in the control group. At 2 weeks after their due dates, these infants also showed improved autonomic regulation, motor system functioning, self-regulatory abilities, and visual evoked potential measures; and at 9 months, they had improved Bayley Mental and Psychomotor Developmental Index scores, as well as Kangaroo Box Paradigm scores. Conclusion.-Very low-birth-weight preterm infants may benefit from individualized developmental care in the neonatal intensive care unit in terms of medical and neurodevelopmental outcome.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT NURSING,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								ALS H, 1986, PEDIATRICS, V78, P1123; Als H., 1990, INFANT BEHAV DEV, V13, P159; Als H., 1992, ADV APPLIED DEV PSYC, V6, P341; ALS H, 1987, APIB FEATURES SUMMAR; Als H, 1984, MANUAL NATURALISTIC; Als H., 1989, STABILITY CONTINUITY, P3; ALS H, 1986, MANUAL SCORING SYSTE; Als H., 2006, NEWBORN INDIVIDUALIZ; Als H, 1982, THEORY RES BEHAVIORA, P65; APGAR V, 1953, ANESTH ANALG CLEVE, V32, P260, DOI DOI 10.1213/00000539-195301000-00041; BALLARD JL, 1977, PEDIATR RES, V11, P374, DOI 10.1203/00006450-197704000-00030; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BECKER PT, 1991, NURS RES, V40, P150; Brown M. B., 1979, J AM STAT ASSOC, V69, P364, DOI [DOI 10.2307/2285659, DOI 10.1080/01621459.1974.10482955]; BROWN MB, 1974, TECHNOMETRICS, V16, P129, DOI 10.2307/1267501; COHEN J, 1969, STATISTICAL POWER AN; COOLEY WW, 1971, MULTIVARIATE DATA AN; DUFFY FH, 1990, CHILD DEV, V61, P1271, DOI 10.2307/1130893; DUNCAN OD, 1966, AM J SOCIOL, V72, P1, DOI 10.1086/224256; GARNER A, 1984, PEDIATRICS, V74, P127; GLASS P, 1985, NEW ENGL J MED, V313, P401, DOI 10.1056/NEJM198508153130701; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; KUBAN K, 1984, PEDIATRICS, V74, P358; LITTMAN B, 1974, MANUAL OBSTETRIC COM; LITTMAN B, 1974, MANUAL PEDIATRIC COM; MCCORMICK MC, 1992, ADV APPL DEV PSYCHOL, V6, P37; MERRITT TA, 1988, AM J DIS CHILD, V142, P1333, DOI 10.1001/archpedi.1988.02150120087047; NORTHWAY WH, 1979, J PEDIATR-US, V95, P815, DOI 10.1016/S0022-3476(79)80441-2; Paneth N, 1991, REPROD PERINATAL EPI, P371; PARAD R B, 1990, Current Opinion in Pediatrics, V2, P459, DOI 10.1097/00008480-199006000-00004; PERLMAN JM, 1989, PEDIATRICS, V84, P215; VOLPE JJ, 1983, PEDIATRICS, V72, P589; VOLPE JJ, 1989, ANN NEUROL, V25, P3, DOI 10.1002/ana.410250103; WARE J, 1990, PEDIATRICS, V85, P1103; WRIGHT S, 1960, BIOMETRICS, V16, P189, DOI 10.2307/2527551	35	427	438	3	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					853	858		10.1001/jama.272.11.853	http://dx.doi.org/10.1001/jama.272.11.853			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	8078162				2022-12-28	WOS:A1994PG18200023
J	RODGERS, KR; SPIRO, TG				RODGERS, KR; SPIRO, TG			NANOSECOND DYNAMICS OF THE R-]T TRANSITION IN HEMOGLOBIN - ULTRAVIOLET RAMAN STUDIES	SCIENCE			English	Article							SPIN COBALT PORPHYRINS; MOLECULAR STEREOCHEMISTRY; COOPERATIVITY; BINDING; OXYGEN; IRON; SPECTROSCOPY; RESOLUTION; PHOTOLYSIS; MODEL	Pulse-probe transient Raman spectroscopy, with probe excitation at 230 nanometers, reveals changes in signals arising from tyrosine and tryptophan residues of the hemoglobin molecule as it moves from the relaxed (R) to the tense (T) state after photodeligation. Signals associated with intersubunit contacts in the T state develop in about 10 microseconds but are preceded by quite different signals, which reach maximum amplitude in about 50 nanoseconds. These signals involve the interior tryptophan residues that bridge the A and E helices by means of H bonds between the indole rings and serine or threonine side chains. Alterations of the H bond strengths, as a result of interhelix motions, can account for the signals. A model is proposed here in which loss of the ligand from the heme binding pocket is concerted with inward motion of the adjacent E helix; this motion, along with a complementary motion of the proximal F helix, transmits the energy associated with heme deligation to the subunit interfaces, leading to the T state rearrangement.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; N DAKOTA STATE UNIV,DEPT CHEM,FARGO,ND 58105	Princeton University; North Dakota State University Fargo					NIGMS NIH HHS [GM 25158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; DWYER PN, 1974, J AM CHEM SOC, V96, P4815, DOI 10.1021/ja00822a018; FERMI G, 1977, J MOL BIOL, V114, P421, DOI 10.1016/0022-2836(77)90259-5; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; GELLIN BR, 1983, J MOL BIOL, V171, P489; HARADA I, 1988, ADV INFRARED RAMAN S, V13, pCH3; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOPFIELD JJ, 1971, J MOL BIOL, V61, P425, DOI 10.1016/0022-2836(71)90391-3; IKEDASAITO M, 1977, J BIOL CHEM, V252, P8639; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; LITTLE RG, 1974, J AM CHEM SOC, V96, P4452, DOI 10.1021/ja00821a018; LUISI B, 1989, J MOL BIOL, V206, P723, DOI 10.1016/0022-2836(89)90579-2; MARTIN JL, 1983, P NATL ACAD SCI-BIOL, V80, P173, DOI 10.1073/pnas.80.1.173; MIURA T, 1989, J RAMAN SPECTROSC, V20, P667, DOI 10.1002/jrs.1250201007; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; RAVA RP, 1985, J PHYS CHEM-US, V89, P1856, DOI 10.1021/j100256a007; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; SAWICKI CA, 1979, J BIOL CHEM, V254, P4058; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHEIDT WR, 1974, J AM CHEM SOC, V96, P90, DOI 10.1021/ja00808a014; SCOTT TW, 1983, FEBS LETT, V158, P68, DOI 10.1016/0014-5793(83)80678-4; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303	30	85	85	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1697	1699		10.1126/science.8085153	http://dx.doi.org/10.1126/science.8085153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085153				2022-12-28	WOS:A1994PG28400027
J	MCCOMBS, RJ; MARCADIS, DE; ELLIS, J; WEINBERG, RB				MCCOMBS, RJ; MARCADIS, DE; ELLIS, J; WEINBERG, RB			ATTENUATED HYPERCHOLESTEROLEMIC RESPONSE TO A HIGH-CHOLESTEROL DIET IN SUBJECTS HETEROZYGOUS FOR THE APOLIPOPROTEIN A-IV-2 ALLELE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEINS; A-IV POLYMORPHISM; ESTER TRANSFER PROTEIN; SERUM-CHOLESTEROL; PLASMA-LIPOPROTEINS; E PHENOTYPE; C-III; GENE; ABSORPTION; FREQUENCY	Background. Previous studies have suggested that the variant apolipoprotein (ape) allele apo A-IV-2 may influence the response of the plasma cholesterol concentration to dietary cholesterol. Methods. We measured plasma lipids and lipoproteins in 11 subjects who were heterozygous for the apo A-IV-2 allele (ape A-IV-1/2 heterozygotes) and a control group of 12 subjects who were homozygous for the common apo A-IV allele (ape A-IV-III homozygotes) in an outpatient dietary-modification study. (Approximately one in seven persons in the United States is a heterozygote.) The subjects consumed a low-cholesterol diet (about 200 mg [0.5 mmol] of cholesterol per day) during a two-week run-in period; daily cholesterol intake was then increased to approximately 1100 mg (2.8 mmol) by the addition of four egg yolks per day. Results. The fat intake and the ratio of polyunsaturated to saturated fat were similar in the two groups throughout the study. After three weeks of egg intake, the mean plasma total cholesterol increased by 22 mg per deciliter (0.57 mmol per liter) in the ape A-IV-1/1 group, but by only 6 mg per deciliter (0.15 mmol per liter) in the apo A-IV-1/2 group (P = 0.05). The mean plasma low-density lipoprotein cholesterol increased by 19 mg per deciliter (0.49 mmol per liter) in the apo A-IV-1/1 group, but by only 1 mg per deciliter (0.03 mmol per liter) in the ape A-IV-1/2 group (P = 0.03). There were no changes in the plasma triglyceride or high-density lipoprotein cholesterol concentrations in either group. Conclusions. The apo A-IV-2 allele attenuates the hypercholesterolemic response to the short-term ingestion of a very-high-cholesterol diet and may partially account for the heterogeneous response to dietary cholesterol. However, cholesterol intake in this study was more than twice that of the general population; whether the apo A-IV-2 allele alters responsiveness at lower levels of cholesterol intake remains to be determined.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,GASTROENTEROL SECT,WINSTON SALEM,NC 27257	Wake Forest University; Wake Forest Baptist Medical Center					NCRR NIH HHS [M01-RR07122] Funding Source: Medline; NHLBI NIH HHS [R01 HL030897-23, HL30897, R01 HL030897] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030897, R01HL030897] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFELBAUM TF, 1987, AM J PHYSIOL, V252, pG662, DOI 10.1152/ajpgi.1987.252.5.G662; APPLEBAUMBOWDEN D, 1984, AM J CLIN NUTR, V39, P360, DOI 10.1093/ajcn/39.3.360; Barter Philip, 1993, Current Opinion in Lipidology, V4, P210, DOI 10.1097/00041433-199306000-00006; BEYNEN AC, 1987, ADV LIPID RES, V22, P115; BISGAIER CL, 1985, J LIPID RES, V26, P11; BOERWINKLE E, 1991, AM J HUM GENET, V49, P1145; BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; DEKNIJFF P, 1988, J LIPID RES, V29, P1621; DORY L, 1985, J LIPID RES, V26, P519; DREON DM, 1992, MONOGR HUM GENET, V14, P325; EICHNER JE, 1989, GENET EPIDEMIOL, V6, P493, DOI 10.1002/gepi.1370060404; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GLATZ JFC, 1993, ANN NY ACAD SCI, V676, P163; GOFF DC, 1993, AM J EPIDEMIOL, V137, P171, DOI 10.1093/oxfordjournals.aje.a116657; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; GYLLING H, 1992, J LIPID RES, V33, P1361; HANIS CL, 1991, HUM GENET, V86, P323; HIXSON JE, 1993, J BIOL CHEM, V268, P15667; KAPRIO J, 1991, ARTERIOSCLER THROMB, V11, P1330, DOI 10.1161/01.ATV.11.5.1330; KATAN MB, 1987, AM J EPIDEMIOL, V125, P387, DOI 10.1093/oxfordjournals.aje.a114545; KEM F, 1991, NEW ENGL J MED, V324, P896; KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107; KEYS A, 1965, METABOLIS, V14, P759, DOI 10.1016/0026-0495(65)90002-8; LEHTIMAKI T, 1992, ANN MED, V24, P61, DOI 10.3109/07853899209164146; LOHSE P, 1990, J BIOL CHEM, V265, P10061; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MARTIN LJ, 1993, J LIPID RES, V34, P437; MATA P, 1992, CIRCULATION, V86, P405; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; MENZEL HJ, 1990, HUM GENET, V84, P344; MENZEL HJ, 1988, HUM GENET, V79, P368; MIETTINEN TA, 1989, AM J CLIN NUTR, V49, P629, DOI 10.1093/ajcn/49.4.629; MISTRY P, 1981, J CLIN INVEST, V67, P493, DOI 10.1172/JCI110058; NESTEL PJ, 1976, METABOLISM, V25, P1591, DOI 10.1016/0026-0495(76)90112-8; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; RYE KA, 1992, J LIPID RES, V33, P215; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEINBERG RB, 1983, J LIPID RES, V24, P52; WEINBERG RB, 1985, J LIPID RES, V26, P26	44	96	96	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					706	710		10.1056/NEJM199409153311104	http://dx.doi.org/10.1056/NEJM199409153311104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058077				2022-12-28	WOS:A1994PF33200004
J	WINFREE, AT				WINFREE, AT			PERSISTENT TANGLED VORTEX RINGS IN GENERIC EXCITABLE MEDIA	NATURE			English	Article							SPIRAL WAVES; ORGANIZING CENTERS; CELLULAR AUTOMATON; CHEMICAL WAVES; MODEL; EXCITATION; EQUATIONS; MECHANISM; DYNAMICS	EXCITABLE media are exemplified by a range of living systems(1-8), such as mammalian heart muscle(6) and its cells(1) and Xenopus eggs(2,3). They also occur in non-living systems such as the autocatalytic Belousov-Zhabatinsky reactiong(9-14). In most of these systems, activity patterns, such as concentration waves, typically radiate as spiral waves from a vortex of excitation created by some nonuniform stimulus. In three-dimensional systems, the vortex is commonly a line, and these vortex lines can form linked and knotted rings which contract into compact, particle-like bundles(9-30). In most previous work these stable 'organizing centres' have been found to be symmetrical and can be classified topologically. Here I show through numerical studies of a generic excitable medium that the more general configuration of vortex lines is a turbulent tangle, which is robust against changes in the parameters of the system or perturbations to it. In view of their stability, I suggest that these turbulent tangles should be observable in any of the many known excitable media.			WINFREE, AT (corresponding author), UNIV ARIZONA, DEPT ECOL & EVOLUT BIOL, TUCSON, AZ 85721 USA.							ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BRAUNE M, 1993, CHEM PHYS LETT, V204, P257, DOI 10.1016/0009-2614(93)90005-L; CHEN PS, 1988, CIRC RES, V62, P1191, DOI 10.1161/01.RES.62.6.1191; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; COURTEMANCHE M, 1990, PHYSICA D, V41, P173, DOI 10.1016/0167-2789(90)90120-E; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; FRAZIER DW, 1989, J CLIN INVEST, V83, P1039, DOI 10.1172/JCI113945; GERHARDT M, 1991, PHYSICA D, V50, P189, DOI 10.1016/0167-2789(91)90175-9; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; HENZE C, 1990, CAN J PHYS, V68, P683, DOI 10.1139/p90-100; HENZE C, 1993, THESIS U ARIZONA; Henze C, 1991, INT J BIFURCAT CHAOS, V1, P891, DOI 10.1142/S0218127491000658; JAHNKE W, 1988, NATURE, V336, P662, DOI 10.1038/336662a0; Jahnke W, 1991, INT J BIFURCAT CHAOS, V1, P445, DOI 10.1142/S0218127491000348; KEENER JP, 1988, PHYSICA D, V31, P269, DOI 10.1016/0167-2789(88)90080-2; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LIPP P, 1993, BIOPHYS J, V65, P2272, DOI 10.1016/S0006-3495(93)81316-X; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; Nagy-Ungvarai Z, 1993, CHAOS, V3, P15, DOI 10.1063/1.165973; Nandapurkar P. J., 1987, SIMULATION WAVE PROC; PANFILOV AV, 1984, DOKL AKAD NAUK SSSR+, V274, P1500; PERTSOV A, 1993, PHYSICA D, V63, P233, DOI 10.1016/0167-2789(93)90157-V; PERTSOV AM, 1990, NATURE, V345, P419, DOI 10.1038/345419a0; STEINBOCK O, 1993, P NATL ACAD SCI USA, V90, P7332, DOI 10.1073/pnas.90.15.7332; Tyson JJ, 1991, INT J BIFURCAT CHAOS, V1, P723, DOI 10.1142/S0218127491000543; Winfree A. T, 1988, BIOMATHEMATICS RELAT, P697; Winfree A. T., 1985, OSCILLATIONS TRAVELL, P441; Winfree Arthur T., 1991, Chaos, V1, P303, DOI 10.1063/1.165844; WINFREE AT, 1974, SCI AM, V230, P82, DOI 10.1038/scientificamerican0674-82; WINFREE AT, 1993, SFI SCI C L, V5, P207; WINFREE AT, 1984, NATURE, V311, P611, DOI 10.1038/311611a0; WINFREE AT, 1991, PHYSICA D, V49, P125, DOI 10.1016/0167-2789(91)90202-K; WINFREE AT, 1990, SIAM REV, V32, P1, DOI 10.1137/1032001; WINFREE AT, 1984, PHYSICA D, V13, P221, DOI 10.1016/0167-2789(84)90279-3; WINFREE AT, 1978, THEORETICAL CHEM, V4, P1; Winfree AT, 1987, TIME BREAKS; WINFREE AT, 1994, CHEM WAVES PATTERNS, pCH1	38	57	57	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					233	236		10.1038/371233a0	http://dx.doi.org/10.1038/371233a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078583				2022-12-28	WOS:A1994PG29000047
J	VALE, RD				VALE, RD			GETTING A GRIP ON MYOSIN	CELL			English	Review							RNA-POLYMERASE; MUSCLE; MOTOR		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	VALE, RD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HOWARD J, 1994, NATURE, V368, P98, DOI 10.1038/368098a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MADDOX J, 1994, NATURE, V368, P287, DOI 10.1038/368287a0; MALIK F, 1994, P NATL ACAD SCI USA, V91, P4584, DOI 10.1073/pnas.91.10.4584; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	23	23	23	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					733	737		10.1016/S0092-8674(94)90402-2	http://dx.doi.org/10.1016/S0092-8674(94)90402-2			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087841				2022-12-28	WOS:A1994PG29600003
J	BLOWER, SM; MCLEAN, AR				BLOWER, SM; MCLEAN, AR			PROPHYLACTIC VACCINES, RISK BEHAVIOR-CHANGE, AND THE PROBABILITY OF ERADICATING HIV IN SAN-FRANCISCO	SCIENCE			English	Article							EFFICACY	Theory is linked with data to assess the probability of eradicating human immunodeficiency virus (HIV) in San Francisco through the use of prophylactic vaccines. The necessary vaccine efficacy levels and population coverage levels for eradication are quantified. The likely impact of risk behavior changes on vaccination campaigns is assessed. The results show it is unlikely that vaccines will be able to eradicate HIV in San Francisco unless they are combined with considerable reductions in risk behaviors. Furthermore, if risk behavior increases as the result of a vaccination campaign, then vaccination could result in a perverse outcome by increasing the severity of the epidemic.	UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford	BLOWER, SM (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, DEPT EPIDEMIOL, BERKELEY, CA 94720 USA.				NIAID NIH HHS [AI33831] Funding Source: Medline; NIDA NIH HHS [1R29DA08153] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA008153] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON R M, 1991; HALLORAN ME, 1992, AM J EPIDEMIOL, V136, P328, DOI 10.1093/oxfordjournals.aje.a116498; LONGINI IM, 1993, STAT MED, V12, P249, DOI 10.1002/sim.4780120309; MACDONALD G, 1952, Trop Dis Bull, V49, P813; MCLEAN AR, 1993, P ROY SOC B-BIOL SCI, V253, P9, DOI 10.1098/rspb.1993.0075; OSMOND DH, IN PRESS AM J PUBLIC; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87	7	189	190	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1451	1454		10.1126/science.8073289	http://dx.doi.org/10.1126/science.8073289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073289				2022-12-28	WOS:A1994PE73300050
J	LANGECARTER, CA; JOHNSON, GL				LANGECARTER, CA; JOHNSON, GL			RAS-DEPENDENT GROWTH-FACTOR REGULATION OF MEK KINASE IN PC12 CELLS	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; THREONINE KINASE; INHIBITION; TYROSINE; INSULIN; ERKS; CAMP	Mitogen-activated protein kinases (MAPKs) are rapidly activated in response to stimulation of diverse receptor types. MAPKs are positively regulated by phosphorylation on threonine and tyrosine by MAP kinase or extracellular signal-regulated kinase (ERK) kinases (MEKs). MEK kinase (MEKK) is part of a family of serine-threonine protein kinases that phosphorylate and activate MEKs independently of Raf. MEKK was rapidly and persistently activated in response to stimulation of resting PC12 cells with epidermal growth factor (EGF). Nerve growth factor (NGF) and 12-O-tetradecanoylphorbol-13-acetate (TPA) also activated MEKK, although to a lesser degree than did EGF. Activation of MEKK and B-Raf in response to EGF was inhibited by expression of dominant negative N(17)Ras. Expression of oncogenic Ras resulted in activation of MEKK. Stimulation of synthesis of cyclic adenosine 3',5'-monophosphate abolished activation of MEKK and B-Raf by EGF, NGF, and TPA. Thus, Ras simultaneously controls the activation of members of the Raf and MEKK families of protein kinases.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	LANGECARTER, CA (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.			Lange, Carol/0000-0003-2751-3976	NCI NIH HHS [CA58157] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank J. H., UNPUB; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER C, UNPUB; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; VAILLANCOURT RR, 1992, MOL CELL BIOL, V12, P3733; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1031; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	33	325	330	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1458	1461		10.1126/science.8073291	http://dx.doi.org/10.1126/science.8073291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073291				2022-12-28	WOS:A1994PE73300052
J	MADURA, K; VARSHAVSKY, A				MADURA, K; VARSHAVSKY, A			DEGRADATION OF G-ALPHA BY THE N-END RULE PATHWAY	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; G-PROTEINS; YEAST; UBIQUITIN; SUBUNIT; SIGNAL; MYRISTOYLATION; RECOGNITION; CONJUGATION	The N-end rule relates the in vivo half-life of a protein to the identity of its amino-terminal residue. Overexpression of targeting components of the N-end rule pathway in Saccharomyces cerevisiae inhibited the growth of haploid but not diploid cells. This ploidy-dependent toxicity was shown to result from enhanced degradation of Gpa1, the alpha subunit (G alpha) of a heterotrimeric guanine nucleotide-binding protein (G protein) that regulates cell differentiation in response to mating pheromones. Sst2, a protein whose absence renders cells hypersensitive to pheromone, was essential for degradation of G alpha but not other N-end rule substrates, suggesting the involvement of an indirect, or trans-, targeting mechanism. G alpha degradation by the N-end rule pathway adds another regulatory dimension to the multitude of signaling functions mediated by G proteins.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DOHMEN J, UNPUB; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HONERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KURJAN J, 1993, ANNU REV GENET, V27, P147; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MADURA K, 1993, J BIOL CHEM, V268, P12046; MADURA K, UNPUB; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Reed SI, 1991, CURR OPIN GENET DEV, V1, P391, DOI 10.1016/S0959-437X(05)80305-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; UTHRIE C, 1991, GUIDE YEAST GENETICS; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	45	134	134	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1454	1458		10.1126/science.8073290	http://dx.doi.org/10.1126/science.8073290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073290				2022-12-28	WOS:A1994PE73300051
J	COPPES, MJ; HABER, DA; GRUNDY, PE				COPPES, MJ; HABER, DA; GRUNDY, PE			GENETIC EVENTS IN THE DEVELOPMENT OF WILMS-TUMOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WIEDEMANN-BECKWITH SYNDROME; DENYS-DRASH SYNDROME; FACTOR-II GENE; FAMILIAL PREDISPOSITION; MENTAL-RETARDATION; KIDNEY DEVELOPMENT; DISTINCT REGIONS; SUPPRESSOR GENE; POINT MUTATIONS; WT1 GENE		TOM BAKER CANC CLIN,DEPT ONCOL,CALGARY,AB,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA; CROSS CANC INST,DEPT PEDIAT,EDMONTON,AB,CANADA; UNIV ALBERTA,FAC MED,EDMONTON,AB,CANADA	Tom Baker Cancer Clinic; University of Calgary; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Alberta; University of Alberta	COPPES, MJ (corresponding author), ALBERTA CHILDRENS PROV GEN HOSP,PEDIAT ONCOL PROGRAM,1820 RICHMOND RD SW,CALGARY T2T 5C7,AB,CANADA.							ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BECKWITH JB, 1993, MED PEDIATR ONCOL, V21, P158, DOI 10.1002/mpo.2950210303; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COPPES MJ, 1989, J CLIN ONCOL, V7, P310, DOI 10.1200/JCO.1989.7.3.310; COPPES MJ, 1993, CANCER RES, V53, P2712; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; GRUNDY P, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91937-P; GRUNDY PE, 1994, CANCER RES, V54, P2331; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HALL JG, 1990, AM J HUM GENET, V46, P857; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JADRESIC L, 1990, J PEDIATR-US, V117, P717, DOI 10.1016/S0022-3476(05)83327-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MALKIN D, 1994, CANCER RES, V54, P2077; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MAW MA, 1992, CANCER RES, V52, P3094; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PING AJ, 1989, AM J HUM GENET, V44, P720; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TURLEAU C, 1981, HUM GENET, V57, P300, DOI 10.1007/BF00278949; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807; 1991, J CLIN ONCOL, V9, P877	58	92	93	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					586	590						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047084				2022-12-28	WOS:A1994PD69900006
J	MATTHEWS, S; BARLOW, P; BOYD, J; BARTON, G; RUSSELL, R; MILLS, H; CUNNINGHAM, M; MEYERS, N; BURNS, N; CLARK, N; KINGSMAN, S; KINGSMAN, A; CAMPBELL, I				MATTHEWS, S; BARLOW, P; BOYD, J; BARTON, G; RUSSELL, R; MILLS, H; CUNNINGHAM, M; MEYERS, N; BURNS, N; CLARK, N; KINGSMAN, S; KINGSMAN, A; CAMPBELL, I			STRUCTURAL SIMILARITY BETWEEN THE P17 MATRIX PROTEIN OF HIV-1 AND INTERFERON-GAMMA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; 3-DIMENSIONAL STRUCTURE; TERMINAL REGION; ASSIGNMENT; C-13; INTERLEUKIN-1-BETA; SPECTROSCOPY; RESONANCE; BACKBONE; SPECTRA	THE human immunodeficiency virus (HIV) matrix protein, p17, Forms the outer shell of the core of the virus, lining the inner surface of the viral membrane(1-4). The protein has several key functions. It orchestrates viral assembly via targeting signals that direct the gag precursor polyprotein, p55, to the host cell membrane(1,5-7) and it interacts with the transmembrane protein, gp41, to retain the env-encoded proteins in the virus(8). In addition, p17 contains a nuclear localization signal that directs the preintegration complex to the nucleus of infected cells(9). This permits the virus to infect productively non-dividing cells, a distinguishing feature of HIV and other lentiviruses. We have determined the solution structure of p17 by nuclear magnetic resonance (NMR) with a root-mean square deviation for the backbone of the well-defined regions of 0.9 Angstrom. It consists of four helices connected by short loops and an irregular, mixed beta-sheet which provides a positively charged surface for interaction with the inner layer of the membrane. The helical topology is unusual; the Brookhaven protein database contains only one similar structure, that of the immune modulator interferon-gamma.	UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND	University of Oxford; University of Oxford; University of Oxford			Barlow, Paul N/G-2853-2011; Barton, Geoffrey/N-1037-2019; Russell, Rob/AAH-9145-2019; Barton, Geoffrey J/C-6267-2011; Russell, Robert/GWU-6389-2022	Barton, Geoffrey/0000-0002-9014-5355; Russell, Rob/0000-0002-1905-4717; Russell, Robert/0000-0002-7213-1398; Matthews, Steve/0000-0003-0676-0927				ARNOLD E, 1991, ADV VIRUS RES, V39, P1; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Brunger A. T., 1993, XPLOR MANUAL VER 3 1; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GEIDERBLOM HR, 1989, ARCH VIROL, V106, P1; GONZALEZ SA, 1993, VIROLOGY, V194, P548, DOI 10.1006/viro.1993.1293; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MATTHEWS SJ, 1993, BIOCHEMISTRY-US, V32, P657, DOI 10.1021/bi00053a034; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; NIIGES M, 1988, PROTEIN ENG, V2, P27; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	28	125	128	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					666	668		10.1038/370666a0	http://dx.doi.org/10.1038/370666a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065455				2022-12-28	WOS:A1994PD31000055
J	SCHIFF, SJ; JERGER, K; DUONG, DH; CHANG, T; SPANO, ML; DITTO, WL				SCHIFF, SJ; JERGER, K; DUONG, DH; CHANG, T; SPANO, ML; DITTO, WL			CONTROLLING CHAOS IN THE BRAIN	NATURE			English	Article							RAT HIPPOCAMPAL SLICE; INTERICTAL SPIKING; POTASSIUM; SEIZURES; SYSTEM	In a spontaneously bursting neuronal network in vitro, chaos can be demonstrated by the presence of unstable fixed-point behaviour. Chaos control techniques can increase the periodicity of such neuronal population bursting behaviour. Periodic pacing is also effective in entraining such systems, although in a qualitatively different fashion. Using a strategy of anticontrol such systems can be made less periodic. These techniques may be applicable to in vivo epileptic foci.	GEORGE WASHINGTON UNIV, SCH MED, WASHINGTON, DC 20010 USA; USN, CTR SURFACE WARFARE, WHITE OAK LAB, SILVER SPRING, MD 20903 USA; GEORGIA INST TECHNOL, SCH PHYS, ATLANTA, GA 30332 USA	George Washington University; United States Department of Defense; United States Navy; University System of Georgia; Georgia Institute of Technology	SCHIFF, SJ (corresponding author), CHILDRENS NATL MED CTR, DEPT NEUROSURG, WASHINGTON, DC 20010 USA.		Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; Chang, Taeun/0000-0002-1797-8449				AUERBACH D, 1992, PHYS REV LETT, V69, P3479, DOI 10.1103/PhysRevLett.69.3479; CHANG T, 1994, BIOPHYS J, V67, P671, DOI 10.1016/S0006-3495(94)80526-0; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; DURAND D, 1986, BRAIN RES, V382, P139, DOI 10.1016/0006-8993(86)90121-6; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; GOTMAN J, 1991, CAN J NEUROL SCI, V18, P573, DOI 10.1017/S031716710003273X; HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953; JEFFERYS JGR, 1981, J PHYSIOL-LONDON, V319, P143, DOI 10.1113/jphysiol.1981.sp013897; KATZ A, 1991, ELECTROEN CLIN NEURO, V79, P153, DOI 10.1016/0013-4694(91)90054-8; KAYYALI H, 1991, EXP NEUROL, V113, P249, DOI 10.1016/0014-4886(91)90181-B; KORN SJ, 1987, J NEUROPHYSIOL, V57, P325, DOI 10.1152/jn.1987.57.1.325; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; Ott E., 1993, CHAOS DYNAMICAL SYST; Pedley TA, 1990, CURRENT PRACTICE CLI, P107; PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0; ROLLINS RW, 1993, PHYS REV E, V47, pR780, DOI 10.1103/PhysRevE.47.R780; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; RUTECKI PA, 1985, J NEUROPHYSIOL, V54, P1363, DOI 10.1152/jn.1985.54.5.1363; SCHIFF SJ, 1994, BIOPHYS J, V67, P684, DOI 10.1016/S0006-3495(94)80527-2; SHINBROT T, 1993, NATURE, V363, P411, DOI 10.1038/363411a0; Traub R.D., 1991, NEURONAL NETWORKS HI; TRAUB RD, 1990, J NEUROPHYSIOL, V64, P1009, DOI 10.1152/jn.1990.64.3.1009; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259	23	718	751	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					615	620		10.1038/370615a0	http://dx.doi.org/10.1038/370615a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065447				2022-12-28	WOS:A1994PD31000040
J	PAHOR, M; GURALNIK, JM; SALIVE, ME; CHRISCHILLES, EA; BROWN, SL; WALLACE, RB				PAHOR, M; GURALNIK, JM; SALIVE, ME; CHRISCHILLES, EA; BROWN, SL; WALLACE, RB			PHYSICAL-ACTIVITY AND RISK OF SEVERE GASTROINTESTINAL HEMORRHAGE IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-INFLAMMATORY DRUGS; CORONARY HEART-DISEASE; COMMUNITY-BASED SAMPLE; BLEEDING PEPTIC-ULCER; DIVERTICULAR-DISEASE; EXERCISE; MEN; MORTALITY; ADULTS; FICSIT	Objective.-To assess whether regular physical activity is associated with a decreased risk of severe gastrointestinal hemorrhage (GIH) in older persons. Design.-Cohort study with 3 years of follow-up. Setting.-Three communities of the Established Populations for Epidemiologic Studies of the Elderly. Participants.-A total of 8205 persons aged 68 years or older, yielding 22 277 person-years of follow-up. Measurements.-The occurrence of severe GIH was defined as either a hospital discharge diagnosis of gastrointestinal bleeding associated with blood transfusion or death during the hospital stay or a nonhospital death with mention of GIH on the death certificate. Physical activity was measured by self-reported frequency of walking, gardening, or doing vigorous physical activity. Those participants doing the activity three times per week or more were compared with the remaining participants. Adjusted relative risks (RRs) of GIH were controlled for age, gender, body mass index, blood pressure, chronic conditions, number of hospital admissions in the past year, and number and types of drugs taken. Results.-Severe GIH occurred in 241 participants (rate, 10.8 per 1000 person-years). After adjusting for potential confounding variables, the RRs and 95% confidence intervals (Cls) for severe GIH associated with walking, gardening, and vigorous physical activity were 0.6 (0.4 to 0.8), 0.8 (0.5 to 1.1), and 0.7 (0.4 to 1.2), respectively. The RR associated with a summary variable for the three activities was 0.7 (95% Cl, 0.5 to 0.9). These results were consistent after stratifying on health status and disability or by excluding those who were not mobile, ie, not able to walk half a mile or climb a flight of stairs. Conclusions.-Regular physical activity is associated with a decreased risk for severe GIH in older persons.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD; UNIV IOWA,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Iowa	PAHOR, M (corresponding author), UNIV CATTOLICA SACRO CUORE,DEPT GERONTOL,LGO F VITO 1,I-00168 ROME,ITALY.							ADES PA, 1993, CIRCULATION, V88, P572, DOI 10.1161/01.CIR.88.2.572; AHREN C, 1973, ACTA PHYSIOL SCAND, V88, P541, DOI 10.1111/j.1748-1716.1973.tb05483.x; ALMY TP, 1980, NEW ENGL J MED, V302, P324, DOI 10.1056/NEJM198002073020605; [Anonymous], 1988, INT CLASSIFICATION D; BIATARONE MA, 1993, J AM GERIATR SOC, V41, P333; BLAIR SN, 1993, CIRCULATION, V88, P1402, DOI 10.1161/01.CIR.88.3.1402; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BORTZ WM, 1982, JAMA-J AM MED ASSOC, V248, P1203, DOI 10.1001/jama.248.10.1203; BORTZ WM, 1989, J AM GERIATR SOC, V37, P1092, DOI 10.1111/j.1532-5415.1989.tb06926.x; BRANICKI FJ, 1992, J GASTROEN HEPATOL, V7, P184, DOI 10.1111/j.1440-1746.1992.tb00959.x; BRESALIER RS, 1991, J CLIN GASTROENTEROL, V13, pS35; BROUNS F, 1993, SPORTS MED, V15, P242, DOI 10.2165/00007256-199315040-00003; Buchner D M, 1992, Clin Geriatr Med, V8, P1; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; BUCHNER DM, 1992, ANNU REV PUBL HEALTH, V13, P469, DOI 10.1146/annurev.publhealth.13.1.469; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P321, DOI 10.1111/j.1532-5415.1993.tb06711.x; CAMPBELL AJ, 1993, J EPIDEMIOL COMMUN H, V47, P23, DOI 10.1136/jech.47.1.23; CARSON JL, 1991, AM J MED, V91, P223, DOI 10.1016/0002-9343(91)90119-I; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CHESKIN LJ, 1990, GASTROENTEROL CLIN N, V19, P391; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DONAHUE RP, 1988, AM J PUBLIC HEALTH, V78, P683, DOI 10.2105/AJPH.78.6.683; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, pS8; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; HUDDY SPJ, 1991, BRIT J SURG, V78, P293, DOI 10.1002/bjs.1800780309; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; KOHL HW, 1988, SPORTS MED, V6, P222, DOI 10.2165/00007256-198806040-00004; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MCINTOSH JH, 1988, AM J EPIDEMIOL, V128, P761, DOI 10.1093/oxfordjournals.aje.a115029; PAHOR M, 1994, J AM GERIATR SOC, V42, P1; Reinus J F, 1991, Clin Geriatr Med, V7, P301; REINUS JF, 1990, GASTROENTEROL CLIN N, V19, P293; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; SAUVE JS, 1993, INT ANESTHESIOL CLIN, V31, P169, DOI 10.1097/00004311-199331020-00011; SCHOENBERG MH, 1984, ACTA CHIR SCAND, V150, P301; SHEPHARD RJ, 1993, SPORTS MED, V15, P258, DOI 10.2165/00007256-199315040-00004; SILEN W, 1987, CLIN INVEST MED, V10, P270; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; SOMERVILLE K, 1986, LANCET, V1, P462; WOLF SL, 1993, J AM GERIATR SOC, V41, P329, DOI 10.1111/j.1532-5415.1993.tb06713.x; YOUNG DR, 1993, AM J EPIDEMIOL, V138, P205, DOI 10.1093/oxfordjournals.aje.a116849; 1977, JAMA-J AM MED ASSOC, V237, P2385; 1991, VITAL STATISTICS US; 1984, VITAL STATISTICS US; 1991, VITAL HLTH STATISTIC	54	34	35	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					595	599		10.1001/jama.272.8.595	http://dx.doi.org/10.1001/jama.272.8.595			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PC398	8057514				2022-12-28	WOS:A1994PC39800028
J	RIMMINGTON, MR; VINE, SJ; CHUI, KC; WALKER, SM				RIMMINGTON, MR; VINE, SJ; CHUI, KC; WALKER, SM			CONVULSIONS AFTER CLOMIPHENE CITRATE	BRITISH MEDICAL JOURNAL			English	Letter											RIMMINGTON, MR (corresponding author), UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES.							BIDER D, 1991, HUM REPROD, V6, P1441; CHOW KK, 1984, BRIT J OBSTET GYNAEC, V91, P1051, DOI 10.1111/j.1471-0528.1984.tb03688.x; HERZOG AG, 1988, NEUROLOGY, V38, P432, DOI 10.1212/WNL.38.3.432; MCKENNA KM, 1988, BAILLIERE CLIN OB GY, V2, P545, DOI 10.1016/S0950-3552(88)80043-9; SOTREL G, 1976, J REPROD MED, V16, P78	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					512	512		10.1136/bmj.309.6953.512c	http://dx.doi.org/10.1136/bmj.309.6953.512c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086907	Green Published			2022-12-28	WOS:A1994PD30800024
J	KOPP, E; GHOSH, S				KOPP, E; GHOSH, S			INHIBITION OF NF-KAPPA-B BY SODIUM-SALICYLATE AND ASPIRIN	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TUMOR NECROSIS FACTOR; EXPRESSION; BINDING; CELLS; GENE; RESISTANCE; INDUCTION; DRUGS; HSP70	The transcription factor nuclear factor-kappa B (NF-kappa B) is critical for the inducible expression of multiple cellular and viral genes involved in inflammation and infection including interleukin-1 (IL-1), IL-6, and adhesion molecules. The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B, which further explains the mechanism of action of these drugs. This inhibition prevented the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B was retained in the cytosol. Sodium salicylate and aspirin also inhibited NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 33443-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V14; BEGG AA, 1993, GENE DEV, V7, P2064; BROOKS PM, 1986, CLIN PHARM ANTIINFLA, P32; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FAMAEY JP, 1992, THERAPEUTIC APPLICAT; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; MACILWAIN C, 1993, NATURE, V364, P369; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; PALMOSKI MJ, 1984, ARTHRITIS RHEUM, V27, P398, DOI 10.1002/art.1780270406; PALMOSKI MJ, 1985, ARTHRITIS RHEUM, V28, P237, DOI 10.1002/art.1780280226; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; Rainsford K.D., 1984, ASPIRIN SALICYLATES; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; VANE JR, 1990, STROKE S, V4, P12; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84	27	1534	1605	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					956	959		10.1126/science.8052854	http://dx.doi.org/10.1126/science.8052854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052854				2022-12-28	WOS:A1994PB49900044
J	ABDELILAH, S; SOLNICAKREZEL, L; STAINIER, DYR; DRIEVER, W				ABDELILAH, S; SOLNICAKREZEL, L; STAINIER, DYR; DRIEVER, W			IMPLICATIONS FOR DORSOVENTRAL AXIS DETERMINATION FROM THE ZEBRAFISH MUTATION JANUS	NATURE			English	Article							OCCURRING DIBLASTODERMIC EGGS; XENOPUS-LAEVIS; CELL LINEAGE; FATE MAP; CLEAVAGE; EMBRYOS; EXPRESSION; ORGANIZER; PATTERN; GENES	THE mechanisms underlying the formation of dorsoventral polarity in the zebrafish Danio rerio are unknown. Here we describe the zebrafish recessive maternal-effect mutation janus(m55). The mutant phenotype is a division of the blastoderm along the first cleavage plane into two detached half-sized blastoderms. Partial-axis bifurcation occurs in a subset of mutants. Analysis of goosecoid expression in the mutant embryos indicates that only one organizer region is present in each embryo. Furthermore, the position of this organizer region is random with respect to the first cleavage plant bisecting the two blastoderms. Finally, cell tracing in wild-type embryos demonstrates that there is no strict correlation of the dorsoventral axis with early cleavage planes in zebrafish. These findings support the notion that the establishment of the dorsoventral axis and the first cleavage planes are determined by separate mechanisms in the zebrafish embryo.	HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Harvard Medical School	ABDELILAH, S (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,13TH ST,BLDG 149,BOSTON,MA 02129, USA.			Stainier, Didier/0000-0002-0382-0026; Driever, Wolfgang/0000-0002-9551-9141				BLACK SD, 1988, DEV BIOL, V128, P65, DOI 10.1016/0012-1606(88)90267-9; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CARROLL CR, 1973, DEV BIOL, V32, P155, DOI 10.1016/0012-1606(73)90227-3; CARTER CA, 1993, J MORPHOL, V215, P301, DOI 10.1002/jmor.1052150309; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DANILCHIK MV, 1988, DEV BIOL, V128, P58, DOI 10.1016/0012-1606(88)90266-7; DROIN A, 1984, ROUX ARCH DEV BIOL, V193, P86, DOI 10.1007/BF00848635; GERHART J, 1981, NATURE, V292, P511, DOI 10.1038/292511a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GEVERS P, 1992, ROUX ARCH DEV BIOL, V201, P275, DOI 10.1007/BF00592108; HELDE KA, 1994, SCIENCE, V265, P517, DOI 10.1126/science.8036493; IKENISHI K, 1988, DEV BIOL, V125, P458, DOI 10.1016/0012-1606(88)90227-8; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1985, DEV BIOL, V108, P78, DOI 10.1016/0012-1606(85)90010-7; KUBOTA HY, 1991, DEV BIOL, V144, P145, DOI 10.1016/0012-1606(91)90486-M; LAALE HW, 1984, CAN J ZOOL, V62, P386, DOI 10.1139/z84-060; MALACINSKI GM, 1974, SCIENCE, V184, P1142, DOI 10.1126/science.184.4142.1142; Oppenheimer JM, 1936, J EXP ZOOL, V73, P405, DOI 10.1002/jez.1400730304; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; SCHIRONE RC, 1968, J EXP ZOOL, V169, P43, DOI 10.1002/jez.1401690106; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STREHLOW D, 1993, NATURE, V361, P451, DOI 10.1038/361451a0; Westerfield M, 1993, ZEBRAFISH BOOK	24	43	46	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					468	471		10.1038/370468a0	http://dx.doi.org/10.1038/370468a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047167				2022-12-28	WOS:A1994PB40700058
J	ROUND, A; MARSHALL, AJ				ROUND, A; MARSHALL, AJ			SURVEY OF GENERAL-PRACTITIONERS PREHOSPITAL MANAGEMENT OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article									DERRIFORD HOSP,PLYMOUTH PL6 5QT,DEVON,ENGLAND	Derriford Hospital	ROUND, A (corresponding author), PLYMOUTH & TORBAY HLTH AUTHOR,PLYMOUTH PL6 5QZ,DEVON,ENGLAND.							BOUTEN MJM, 1991, EUR HEART J, V12, P39; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; WAINE C, 1993, BRIT HEART J, V70, P218; 1992, BRIT MED J, V305, P588; 1989, BRIT MED J, V299, P555	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					375	376		10.1136/bmj.309.6951.375	http://dx.doi.org/10.1136/bmj.309.6951.375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081137	Green Published			2022-12-28	WOS:A1994PB31600019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			RECOMMENDATION TO IMMEDIATELY WITHDRAWN PATIENTS FROM TREATMENT WITH FELBAMATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					995	995		10.1001/jama.272.13.995	http://dx.doi.org/10.1001/jama.272.13.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089899				2022-12-28	WOS:A1994PH77500007
J	MCNERNEY, WJ; LOHR, KN; GROSSMAN, JH				MCNERNEY, WJ; LOHR, KN; GROSSMAN, JH			STATE ROLES IN HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									INST MED,DIV HLTH CARE SERV,WASHINGTON,DC; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts Medical Center	MCNERNEY, WJ (corresponding author), NORTHWESTERN UNIV,JL KELLOGG GRAD SCH MANAGEMENT,EVANSTON,IL, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					913	913						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084049				2022-12-28	WOS:A1994PG73700005
J	SIMPSONBROSE, M; TREISMAN, J; DESPLAN, C				SIMPSONBROSE, M; TREISMAN, J; DESPLAN, C			SYNERGY BETWEEN THE HUNCHBACK AND BICOID MORPHOGENS IS REQUIRED FOR ANTERIOR PATTERNING IN DROSOPHILA	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; HEAD DEVELOPMENT; BODY PATTERN; GAP GENE; GRADIENT MORPHOGEN; EMPTY SPIRACLES; EMBRYO; PROTEIN; EXPRESSION; KRUPPEL	Anterior patterning of the Drosophila embryo is specified by the localized expression of the gap genes, which is controlled by the gradient of the maternal morphogen bicoid (bcd). Another maternal component, hunch back (hb), can substitute for bcd in the thorax and abdomen. Here we show that hb is required for bcd to execute all of its functions. Removal of both maternal and zygotic hb produces embryos with disrupted polarity that fail to express all known bcd target genes correctly. Proper expression of hb and the head gap genes requires synergistic activation by hb and bcd. We propose that it is the combined activity of bcd and hb, and not bcd alone, that forms the morphogenetic gradient that specifies polarity along the embryonic axis and patterns the embryo. bcd may be a newly acquired Drosophila gene, which is gradually replacing some of the functions performed by maternal hb in other species.			SIMPSONBROSE, M (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Treisman, Jessica/0000-0002-7453-107X; Desplan, Claude/0000-0002-6914-1413				COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; KRESZBERG M, 1994, IN PRESS P NATL ACAD; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LUKOWITZ W, 1994, MECH DEVELOP, V45, P105, DOI 10.1016/0925-4773(94)90024-8; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; SCHRODER R, 1993, ROUX ARCH DEV BIOL, V203, P34, DOI 10.1007/BF00539888; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SOMMER R, 1991, DEVELOPMENT, V113, P419; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	46	202	205	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					855	865		10.1016/S0092-8674(94)90622-X	http://dx.doi.org/10.1016/S0092-8674(94)90622-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087852				2022-12-28	WOS:A1994PG29600014
J	HIATT, H; GOLDMAN, L				HIATT, H; GOLDMAN, L			MAKING MEDICINE MORE SCIENTIFIC	NATURE			English	Editorial Material									HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University	HIATT, H (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.								0	27	27	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					100	100		10.1038/371100a0	http://dx.doi.org/10.1038/371100a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072536	Bronze			2022-12-28	WOS:A1994PF19100028
J	MAGIAKOU, MA; MASTORAKOS, G; OLDFIELD, EH; GOMEZ, MT; DOPPMAN, JL; CUTLER, GB; NIEMAN, LK; CHROUSOS, GP				MAGIAKOU, MA; MASTORAKOS, G; OLDFIELD, EH; GOMEZ, MT; DOPPMAN, JL; CUTLER, GB; NIEMAN, LK; CHROUSOS, GP			CUSHINGS-SYNDROME IN CHILDREN AND ADOLESCENTS - PRESENTATION, DIAGNOSIS, AND THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; STIMULATION TEST; FREE CORTISOL; DISEASE; CHILDHOOD; MICROADENOMAS	Background and Methods. Cushing's syndrome is rare in children and adolescents. We analyzed the clinical presentation, diagnostic evaluation, and treatment of 59 patients with Cushing's syndrome between the ages of 4 and 20 years who were admitted to the National Institutes of Health during the period from 1982 to 1992. The cause of hypercortisolism was identified by low- and high-dose dexamethasone suppression tests, the ovine corticotropin-releasing hormone (CRH) stimulation test, imaging studies, and bilateral sampling of the inferior petrosal sinuses combined with administration of CRH. Results. Fifty patients had Cushing's disease, six had primary adrenal disease, and three had ectopic corticotropin secretion. The initial signs were excessive weight gain in 90 percent of the patients and growth retardation in 83 percent. Most patients (81 percent) had normal bone age at the time of diagnosis. Forty-seven percent had hypertension, whereas only 19 percent had mental or behavioral problems. The high-dose dexamethasone suppression test and the CRH stimulation test identified 68 and 80 percent, respectively, of the patients with Cushing's disease. Magnetic resonance imaging of the pituitary indicated the presence of tumor in 52 percent of the patients with pituitary adenomas. The maximal central-to-peripheral ratio of plasma corticotropin during sampling of the interior petrosal sinuses was greater than or equal to 2.5 in all the patients with Cushing's disease and <2.5 in those with ectopic corticotropin secretion. Remission of hypercortisolism was achieved in 48 of the 49 patients who underwent transsphenoidal surgery for Cushing's disease, in all 6 of the patients who underwent adrenalectomy for primary adrenal disease, and in the 2 patients in whom the ectopic source of corticotropin could be identified. Conclusions. Weight gain and growth retardation are common clinical characteristics of Cushing's syndrome in children and adolescents. Diagnostic evaluation of such patients with CRH stimulation alone and combined with inferior petrosal sinus sampling and imaging studies is accurate, and therapy is usually successful.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892; NIH,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA	MAGIAKOU, MA (corresponding author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N262,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; DANON M, 1975, J PEDIATR-US, V87, P917, DOI 10.1016/S0022-3476(75)80905-X; DOPPMAN JL, 1984, RADIOLOGY, V150, P99, DOI 10.1148/radiology.150.1.6316418; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; FRANKS RC, 1973, J CLIN ENDOCR METAB, V36, P702, DOI 10.1210/jcem-36-4-702; FRIEDMAN RB, 1989, J NEUROSURG, V71, P520, DOI 10.3171/jns.1989.71.4.0520; GOMEZ MT, 1991, J PEDIATR-US, V118, P256, DOI 10.1016/S0022-3476(05)80496-2; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; JOB JC, 1981, PEDIATRIC ENDOCRINOL, P275; JONES KL, 1990, PEDIATR CLIN N AM, V37, P1313; KAO M, 1975, CLIN CHEM, V21, P1644; KAPLAN SA, 1979, PEDIATR CLIN N AM, V26, P65; KORTHSCHUTZ S, 1984, ADRENAL DISEASES CHI, V13, P185; KRIEGER DT, 1982, CUSHINGS SYNDROME; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCARTHUR RG, 1972, MAYO CLIN PROC, V47, P318; MUGURUZA MTG, 1989, J PEDIATR-US, V115, P270, DOI 10.1016/S0022-3476(89)80081-2; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NEW MI, 1989, CLIN PEDIATRIC ENDOC, P181; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; NIEMAN LK, 1989, J CLIN ENDOCR METAB, V69, P165, DOI 10.1210/jcem-69-1-165; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1992, NEW ENGL J MED, V326, P1172; ORTH DN, 1978, METHOD HORM RADIOIMM, P245; SILBER RH, 1954, J BIOL CHEM, V210, P923; STREETEN DHP, 1975, PEDIATRICS, V56, P797; STRICKLAND AL, 1972, AM J DIS CHILD, V123, P207, DOI 10.1001/archpedi.1972.02110090077007; STYNE DM, 1984, NEW ENGL J MED, V310, P889, DOI 10.1056/NEJM198404053101405; THOMAS CG, 1984, ANN SURG, V199, P538, DOI 10.1097/00000658-198405000-00008; TYRRELL JB, 1978, NEW ENGL J MED, V298, P753, DOI 10.1056/NEJM197804062981401	33	292	300	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					629	636		10.1056/NEJM199409083311002	http://dx.doi.org/10.1056/NEJM199409083311002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052272				2022-12-28	WOS:A1994PE38200002
J	MAYALL, FG; BLEWITT, RW; STAFF, WG				MAYALL, FG; BLEWITT, RW; STAFF, WG			LESSON OF THE WEEK - CYSTITIS AND URETERAL OBSTRUCTION IN PATIENTS TAKING TIAPROFENIC ACID	BRITISH MEDICAL JOURNAL			English	Article							EOSINOPHILIC CYSTITIS		ROYAL LANCASTER INFIRM,LANCASTER,ENGLAND		MAYALL, FG (corresponding author), WITHINGTON HOSP,DEPT HISTOPATHOL,MANCHESTER M20 8LE,LANCS,ENGLAND.							AHMED M, 1991, BRIT MED J, V303, P1376, DOI 10.1136/bmj.303.6814.1376; HELLSTROM HR, 1979, AM J CLIN PATHOL, V72, P777; HUNNER GL, 1914, T S SURG GYNECOL, V27, P247; MARSHALL FF, 1974, J UROLOGY, V112, P335, DOI 10.1016/S0022-5347(17)59723-2; SMITH BH, 1972, ARCH PATHOL, V93, P76	5	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					599	600		10.1136/bmj.309.6954.599	http://dx.doi.org/10.1136/bmj.309.6954.599			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086954	Green Published			2022-12-28	WOS:A1994PF33000033
J	KREJCHI, MT; ATKINS, EDT; WADDON, AJ; FOURNIER, MJ; MASON, TL; TIRRELL, DA				KREJCHI, MT; ATKINS, EDT; WADDON, AJ; FOURNIER, MJ; MASON, TL; TIRRELL, DA			CHEMICAL SEQUENCE CONTROL OF BETA-SHEET ASSEMBLY IN MACROMOLECULAR CRYSTALS OF PERIODIC POLYPEPTIDES	SCIENCE			English	Article							SOLID-STATE; CONFORMATION; CHAIN; MORPHOLOGY; EXPRESSION; GENES	A family of uniform periodic polypeptides has been prepared by bacterial expression of the corresponding artificial genes, with the objective of exploring the potential for control of supramolecular organization in genetically engineered protein-based polymeric materials. The repeating units of the polypeptides consist of oligomeric alanylglycine sequences interspersed with glutamic acid residues inserted at intervals of 8 to 14 amino acids. Crystallization of such materials from formic acid produces beta-sheet structures in the solid state, as shown by vibrational spectroscopy, nuclear magnetic resonance spectroscopy, and wide-angle x-ray diffraction. The diffraction results, together with observations from electron microscopy, are consistent with the formation of needle-shaped lamellar crystals whose thickness is controlled by the periodicity of the primary sequence. These results can be used to control solid-state structure in macromolecular materials.	UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; UNIV BRISTOL,HH WILLS PHYS LAB,BRISTOL BS8 1TL,AVON,ENGLAND; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Bristol; University of Massachusetts System; University of Massachusetts Amherst								ATKINS EDT, 1992, MACROMOLECULES, V25, P917, DOI 10.1021/ma00028a063; ATKINS EDT, 1972, J POLYM SCI POL LETT, V10, P863, DOI 10.1002/pol.1972.130101108; BASSETT DC, 1981, MORPHOLOGY POLYM; BROWN L, 1956, T FARADAY SOC, V52, P537, DOI 10.1039/tf9565200537; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DREYFUS P, 1970, J POLYM SCI POL LETT, V8, P253, DOI 10.1002/pol.1970.110080407; DREYFUSS P, 1970, J MACROMOL SCI PHYS, VB  4, P811, DOI 10.1080/00222347008217125; FERRARI FA, 1836, Patent No. 927258; FISCHER EW, 1957, Z NATURFORSCH PT A, V12, P753, DOI 10.1515/zna-1957-0912; Fraser R.D.B., 1973, CONFORMATION FIBROUS; FRASER RDB, 1965, J MOL BIOL, V11, P706, DOI 10.1016/S0022-2836(65)80028-6; Fritsch E., 1989, MOL CLONING LABORATO, P3; FRUSHOUR BG, 1976, J MACROMOL SCI R M C, VC 15, P29; FRUSHOUR BG, 1975, BIOPOLYMERS, V14, P2115, DOI 10.1002/bip.1975.360141011; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; HIRICHSEN G, 1973, MAKROMOL CHEM, V166, P291; ISHIDA M, 1990, MACROMOLECULES, V23, P88, DOI 10.1021/ma00203a017; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KEITH HD, 1969, BIOPOLYMERS, V7, P775, DOI 10.1002/bip.1969.360070512; KELLER A, 1959, J POLYM SCI, V36, P361, DOI 10.1002/pol.1959.1203613032; KELLER A, 1957, PHILOS MAG, V2, P1171, DOI 10.1080/14786435708242746; KREJCHI MT, UNPUB; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LUCAS F, 1960, J MOL BIOL, V2, P339, DOI 10.1016/S0022-2836(60)80045-9; MAGILL JH, 1981, POLYMER, V22, P43, DOI 10.1016/0032-3861(81)90075-6; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P345; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042; MOORE WH, 1976, BIOPOLYMERS, V15, P2483; NEMETHY G, 1972, MACROMOLECULES, V5, P755, DOI 10.1021/ma60030a017; PARKHE AD, 1993, MACROMOLECULES, V26, P6691, DOI 10.1021/ma00076a067; SAITO H, 1984, MACROMOLECULES, V17, P1405, DOI 10.1021/ma00137a018; SAKAOKU K, 1973, J POLYM SCI POL PHYS, V11, P31, DOI 10.1002/pol.1973.180110104; SMITH BJ, 1988, METHODS MOL BIOL NEW, P70; Staudinger H, 1920, BER DTSCH CHEM GES, V53, P1073, DOI 10.1002/cber.19200530627; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TILL PH, 1957, J POLYM SCI, V24, P301, DOI 10.1002/pol.1957.1202410616; Tirrell DA, 1991, CURR OPIN STRUC BIOL, V1, P638, DOI 10.1016/S0959-440X(05)80089-2; VONK CG, 1982, SMALL ANGLE XRAY SCA, P443; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	240	246	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1427	1432		10.1126/science.8073284	http://dx.doi.org/10.1126/science.8073284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073284				2022-12-28	WOS:A1994PE73300043
J	DOWELL, SJ; ROMANOWSKI, P; DIFFLEY, JFX				DOWELL, SJ; ROMANOWSKI, P; DIFFLEY, JFX			INTERACTION OF DBF4, THE CDC7 PROTEIN-KINASE REGULATORY SUBUNIT, WITH YEAST REPLICATION ORIGINS IN-VIVO	SCIENCE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; RECOGNITION COMPLEX; S-PHASE; TRANSCRIPTION; GENE; SEQUENCE; SYSTEM; ACTIVATION; MUTATIONS	DNA replication in the budding yeast Saccharomyces cerevisiae initiates from origins of specific DNA sequences during S phase. A screen based on two- and one-hybrid approaches demonstrates that the product of the DBF4 gene interacts with yeast replication origins in vivo. The Dbf4 protein interacts with and positively regulates the activity of the Cdc7 protein kinase, which is required for entry into S phase in the yeast mitotic cell cycle. The analysis described here suggests a model in which one function of Dbf4 may be to recruit the Cdc7 protein kinase to initiation complexes.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; UNIV GDANSK SCH MED, DEPT BIOL & GENET, PL-80211 GDANSK, POLAND	Fahrenheit Universities; Medical University Gdansk				Dowell, Simon/0000-0001-6499-7573; Diffley, John/0000-0001-5184-7680				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SD, COMMUNICATION; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DOWELL SJ, UNPUB; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JAZWINSKI SM, 1988, P NATL ACAD SCI USA, V85, P2101, DOI 10.1073/pnas.85.7.2101; JOHNSTON LH, 1991, COLD SH Q B, V56, P169; JOHNSTON LH, 1982, MOL GEN GENET, V186, P439, DOI 10.1007/BF00729466; KITADA K, 1992, GENETICS, V131, P21; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405	33	176	182	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	1994	265	5176					1243	1246		10.1126/science.8066465	http://dx.doi.org/10.1126/science.8066465			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066465				2022-12-28	WOS:A1994PD42200041
J	MUHUA, L; KARPOVA, TS; COOPER, JA				MUHUA, L; KARPOVA, TS; COOPER, JA			A YEAST ACTIN-RELATED PROTEIN HOMOLOGOUS TO THAT IN VERTEBRATE DYNACTIN COMPLEX IS IMPORTANT FOR SPINDLE ORIENTATION AND NUCLEAR MIGRATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CAPPING PROTEIN; CYTOPLASMIC DYNEIN; CAENORHABDITIS-ELEGANS; VESICLE MOTILITY; SHUTTLE VECTORS; NULL MUTATIONS; GENE; CYTOSKELETON; DISRUPTION	Spindle orientation controls nuclear migration and segregation during mitosis. In yeast, defects in dynein and astral microtubules lead to abnormal spindle orientation and nuclear migration. Dynactin complex is necessary for dynein-mediated vesicle motility in vitro. The major polypeptide of dynactin complex is an actin-related protein in the family Arp1. We have identified in S. cerevisiae a novel actin-related gene, ACTS, in the Arp1 family. An act5 null mutant has defects in spindle orientation and nuclear migration, as does overexpression of Act5p. The phenotype of a double mutant lacking dynein and Act5p is similar to that of single mutants. Therefore, dynactin complex is in the same pathway as dynein and may be necessary for the action of dynein in vivo.			MUHUA, L (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA.		Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571; Karpova, Tatiana/0000-0001-6025-2128	NIGMS NIH HHS [GM47337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1993, MOL BIOL CELL, V4, P459, DOI 10.1091/mbc.4.5.459; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FRYBERG C, 1994, J MOL BIOL, V241, P498; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HARATA M, 1994, IN PRESS P NATL ACAD; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; IIDA K, 1993, GENE, V124, P115; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KARLSSON R, 1991, MOL CELL BIOL, V11, P213, DOI 10.1128/MCB.11.1.213; KARPOVA TS, 1993, GENETICS, V135, P693; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIU HP, 1992, GENETICS, V132, P665; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; NEFSKY B, 1992, EUR J BIOCHEM, V206, P949, DOI 10.1111/j.1432-1033.1992.tb17005.x; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; PLAMANN M, 1994, IN PRESS J CELL BIOL; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; READ EB, 1992, MOL BIOL CELL, V3, P429, DOI 10.1091/mbc.3.4.429; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SIKORSKI RS, 1989, GENETICS, V122, P19; WADDLE JA, 1993, MOL BIOL CELL, V4, P907, DOI 10.1091/mbc.4.9.907; WADDLE JA, 1994, IN PRESS DEVELOPMENT, V120; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	51	199	200	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					669	679		10.1016/0092-8674(94)90531-2	http://dx.doi.org/10.1016/0092-8674(94)90531-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069915				2022-12-28	WOS:A1994PD69300015
J	UHLIN, U; EKLUND, H				UHLIN, U; EKLUND, H			STRUCTURE OF RIBONUCLEOTIDE REDUCTASE PROTEIN R1	NATURE			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; BARREL ENZYMES; INHIBITION; REFINEMENT; MUTANT; SITE; R2	Ribonucleotide reductase is the only enzyme that catalyses de novo formation of deoxyribonucleotides and is thus a key enzyme in DNA synthesis. The radical-based reaction involves five cysteines. Two redox-active cysteines are located at adjacent antiparallel strands in a new type of ten-stranded alpha/beta-barrel, and two others at the carboxyl end in a flexible arm. The fifth cysteine, in a loop in the centre of the barrel, is positioned to initiate the radical reaction.			UHLIN, U (corresponding author), SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOLEC BIOL, BOX 590, S-75124 UPPSALA, SWEDEN.							ABERG A, 1989, J BIOL CHEM, V264, P12249; ABERG A, 1993, THESIS U STOCKHOLM; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BOOKER S, 1993, BIOCHEM SOC T, V21, P727, DOI 10.1042/bst0210727; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ERIKSSON S, 1986, J BIOL CHEM, V261, P1878; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; KNIGHT S, 1989, THESIS SWEDISH U AGR; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Nyborg J., 1977, ROTATION METHOD CRYS, P139; OTWINOWSKI Z, 1991, DENZO MANUAL; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PRONGAY AJ, 1990, J BIOL CHEM, V265, P18968; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TUGGLE CK, 1990, J BACTERIOL, V172, P1711, DOI 10.1128/jb.172.4.1711-1718.1990; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	47	505	515	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					533	539		10.1038/370533a0	http://dx.doi.org/10.1038/370533a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052308				2022-12-28	WOS:A1994PC53700047
J	LIU, JP; SIM, ATR; ROBINSON, PJ				LIU, JP; SIM, ATR; ROBINSON, PJ			CALCINEURIN INHIBITION OF DYNAMIN-I GTPASE ACTIVITY COUPLED TO NERVE-TERMINAL DEPOLARIZATION	SCIENCE			English	Article							PROTEIN-PHOSPHORYLATION; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; SYNAPTOSOMES; ENDOCYTOSIS; CALCIUM; DEPHOSPHORYLATION; MICROTUBULES; PHOSPHATASES; SHIBIRE	Dynamin I is a nerve terminal phosphoprotein with intrinsic guanosine triphosphatase (GTPase) activity that is required for endocytosis. Upon depolarization and synaptic vesicle recycling, dynamin I undergoes a rapid dephosphorylation. Dynamin I was found to be a specific high-affinity substrate for calcineurin in vitro. At low concentrations, calcineurin dephosphorylated dynamin I that had been phosphorylated by protein kinase C. The dephosphorylation inhibited dynamin I GTPase activity in vitro and after depolarization of nerve terminals. The effect in nerve terminals was prevented by the calcineurin inhibitor cyclosporin A. This suggests that in nerve terminals, calcineurin serves as a Ca2+-sensitive switch for depolarization-evoked synaptic vesicle recycling.	UNIV NEWCASTLE,NEUROSCI GRP,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle	LIU, JP (corresponding author), JOHN HUNTER HOSP,ENDOCRINE UNIT,LOCKED BAG 1,HUNTER REG MAIL CTR,NEWCASTLE,NSW 2310,AUSTRALIA.		Liu, Jun-Ping/AAA-5521-2020; Robinson, Phillip J/G-4008-2011	Liu, Jun-Ping/0000-0001-7442-2116; Robinson, Phillip J/0000-0002-7878-0313				CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KING MM, 1984, J BIOL CHEM, V259, P8080; KRUEGER BK, 1977, J BIOL CHEM, V252, P2764; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, IN PRESS J BIOL CHEM; LIU Y, 1989, J BIOL CHEM, V264, P12800; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIM ATR, 1991, NEUROSCI LETT, V126, P203, DOI 10.1016/0304-3940(91)90554-7; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TYAN TA, 1993, NEURON, V11, P713; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	25	189	192	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					970	973		10.1126/science.8052858	http://dx.doi.org/10.1126/science.8052858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052858				2022-12-28	WOS:A1994PB49900048
J	OHNO, T; GORDON, D; SAN, H; POMPILI, VJ; IMPERIALE, MJ; NABEL, GJ; NABEL, EG				OHNO, T; GORDON, D; SAN, H; POMPILI, VJ; IMPERIALE, MJ; NABEL, GJ; NABEL, EG			GENE-THERAPY FOR VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION AFTER ARTERIAL INJURY	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; TRANSLUMINAL CORONARY ANGIOPLASTY; ENDOTHELIAL-CELLS; BALLOON ANGIOPLASTY; INTIMAL HYPERPLASIA; EXPRESSION INVIVO; RETROVIRAL VECTOR; ADENOVIRAL VECTOR; CONTROLLED TRIAL; MODEL	Accumulation of vascular smooth muscle cells as a consequence of arterial injury is a major feature of vascular proliferative disorders. Molecular approaches to the inhibition of smooth muscle cell proliferation in these settings could potentially limit intimal expansion. This problem was approached by introducing adenoviral vectors encoding the herpesvirus thymidine kinase (tk) into porcine arteries that had been injured by a balloon on a catheter. These smooth muscle cells were shown to be infectable with adenoviral vectors, and introduction of the tk gene rendered them sensitive to the nucleoside analog ganciclovir. When this vector was introduced into porcine arteries immediately after a balloon injury, intimal hyperplasia decreased after a course of ganciclovir treatment. No major local or systemic toxicities were observed. These data suggest that transient expression of an enzyme that catalyzes the formation of a cytotoxic drug locally may limit smooth muscle cell proliferation in response to balloon injury.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	OHNO, T (corresponding author), UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL143507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI033355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43507] Funding Source: Medline; NIAID NIH HHS [AI33355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALCON R, 1992, CIRCULATION, V86, P100; BARR E, 1994, GENE THER, V1, P51; BAUMGARTNER HR, 1976, THROMB HAEMOSTASIS, V35, P124, DOI 10.1055/s-0038-1647919; BLOCK PC, 1981, NEW ENGL J MED, V305, P382, DOI 10.1056/NEJM198108133050706; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; BREAKEFIELD XO, 1991, NEW BIOL, V3, P203; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FAXON DP, 1992, CIRCULATION, V86, P53; FIELD AK, 1983, P NATL ACAD SCI-BIOL, V80, P4139, DOI 10.1073/pnas.80.13.4139; FRENCH J. E., 1965, ANN N Y ACAD SCI, V127, P780, DOI 10.1111/j.1749-6632.1965.tb49444.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GINSBURG D, 1992, BLOOD, V79, P2507; GONCHOROFF NJ, 1986, J IMMUNOL METHODS, V93, P97, DOI 10.1016/0022-1759(86)90438-2; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; ISIK FF, 1992, AM J PATHOL, V141, P1139; KNUDTSON ML, 1990, J AM COLL CARDIOL, V15, P691, DOI 10.1016/0735-1097(90)90648-9; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; MOOLTEN FL, 1990, HUM GENE THER, V1, P125, DOI 10.1089/hum.1990.1.2-125; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; OHNO T, UNPUB; OKEEFE JH, 1992, J AM COLL CARDIOL, V19, P1597, DOI 10.1016/0735-1097(92)90624-V; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; PLAUTZ G, 1991, NEW BIOL, V3, P709; POMPILI VJ, UNPUB; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PRESCOTT MF, 1991, AM J PATHOL, V139, P139; REITMAN JS, 1982, ATHEROSCLEROSIS, V43, P119, DOI 10.1016/0021-9150(82)90104-6; REKHTER MD, 1993, AM J PATHOL, V143, P1634; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; SCHWARTZ RS, 1994, ARTERIOSCLER THROMB, V14, P395, DOI 10.1161/01.ATV.14.3.395; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V19, P267, DOI 10.1016/0735-1097(92)90476-4; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1992, CIRCULATION, V86, P100; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIMS FH, 1989, PATHOLOGY, V21, P115, DOI 10.3109/00313028909059547; SMITH KO, 1982, ANTIMICROB AGENTS CH, V22, P55, DOI 10.1128/AAC.22.1.55; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; WEINER BH, 1986, NEW ENGL J MED, V315, P841, DOI 10.1056/NEJM198610023151401; WEINER BH, 1985, CIRCULATION, V72, P1081, DOI 10.1161/01.CIR.72.5.1081; Winer BJ, 1971, STATISTICAL PRINCIPL, P261; WISSLER RW, 1968, ANN NY ACAD SCI, V149, P907	68	424	467	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					781	784		10.1126/science.8047883	http://dx.doi.org/10.1126/science.8047883			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047883				2022-12-28	WOS:A1994PA37200033
J	RHOADS, JE				RHOADS, JE			MEMOIR OF A SURGICAL NUTRITIONIST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RHOADS, JE (corresponding author), UNIV PENN, SCH MED, DEPT SURG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.							WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WILMORE DW, 1968, J AMER MED ASSOC, V203, P860, DOI 10.1001/jama.203.10.860	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					963	966						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084065				2022-12-28	WOS:A1994PG73700025
J	HOHLFELD, P; DAFFOS, F; COSTA, JM; THULLIEZ, P; FORESTIER, F; VIDAUD, M				HOHLFELD, P; DAFFOS, F; COSTA, JM; THULLIEZ, P; FORESTIER, F; VIDAUD, M			PRENATAL-DIAGNOSIS OF CONGENITAL TOXOPLASMOSIS WITH A POLYMERASE-CHAIN-REACTION TEST ON AMNIOTIC-FLUID	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL TOXOPLASMOSIS; TISSUE-CULTURE; FOLLOW-UP; GONDII; PREGNANCY; AMPLIFICATION; AMNIOCENTESIS; SAMPLES; PCR; INFECTIONS	Background. Congenital infection with Toxoplasma gondii can produce serious sequelae. However, there is little consensus about screening during pregnancy, and the tests used to establish a prenatal diagnosis of toxoplasmosis are complex and slow. We evaluated a simpler approach that is based on a polymerase-chain-reaction (PCR) test. Methods. Prenatal diagnostic tests, including ultrasonography, amniocentesis, and fetal-blood sampling, were performed in 2632 women with T. gondii infection acquired during pregnancy. In 339 consecutive women, a competitive PCR test for T, gondii was performed on amniotic fluid, and its results were compared with those of conventional diagnostic tests. The PCR test targets the B1 gene of T. gondii, uses an internal control, and can be completed in a day. Positive tests were confirmed by serologic testing of newborns or by autopsy in terminated pregnancies. Results. Overall, the risk of fetal infection was 7.4 percent, but it increased sharply with gestational age. Congenital infection was demonstrated in 34 of 339 fetuses by conventional methods, and the PCR test was positive in ail 34. In three other fetuses, only the PCR test gave positive results, and follow-up testing confirmed the presence of congenital toxoplasmosis. The PCR test gave one false negative result but no false positive results. The PCR test performed better than conventional parasitologic methods (sensitivity, 97.4 percent vs. 89.5 percent; negative predictive value, 99.7 percent vs. 98.7 percent). Conclusions. For the prenatal diagnosis of congenital T. gondii infection, an approach based on a PCR test performed on amniotic fluid is rapid, safe, and accurate.	INST PUERICULTURE, SERV MED & BIOL FOETALES, F-75014 PARIS, FRANCE; INST PUERICULTURE, TOXOPLASMOSE LAB, F-75014 PARIS, FRANCE				Vidaud, Michel/O-7346-2017					Aspock H., 1986, Mitteilungen der Osterreichischen Gesellschaft fur Tropenmedizin und Parasitologie, V8, P105; BRETAGNE S, 1993, J INFECT DIS, V168, P1585, DOI 10.1093/infdis/168.6.1585; CAZENAVE J, 1992, PRENATAL DIAG, V12, P119, DOI 10.1002/pd.1970120207; COUVREUR J, 1991, ARCH FR PEDIATR, V48, P397; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DALTON ME, 1993, NEW ENGL J MED, V328, P114; DEROUIN F, 1988, EUR J CLIN MICROBIOL, V7, P423, DOI 10.1007/BF01962355; DEROUIN F, 1987, J CLIN MICROBIOL, V25, P1597, DOI 10.1128/JCM.25.9.1597-1600.1987; DESMONTS G, 1985, LANCET, V1, P500; DESMONTS G, 1990, LANCET, V336, P1017, DOI 10.1016/0140-6736(90)92485-Z; DESMONTS G, 1990, PRESSE MED, V19, P1445; DUPOUYCAMET J, 1992, ANN BIOL CLIN-PARIS, V50, P315; ENDERS G, 1988, INFEKTIONEN IMPFUNGE, P143; Flamm H, 1981, Padiatr Grenzgeb, V20, P27; FORESTIER F, 1988, AM J OBSTET GYNECOL, V158, P1184, DOI 10.1016/0002-9378(88)90251-7; FOULON W, 1988, OBSTET GYNECOL, V72, P363; FRIESE K, 1991, GEBURTSH FRAUENHEILK, V51, P890, DOI 10.1055/s-2008-1026231; GARCIA AGP, 1968, ARCH DIS CHILD, V43, P705, DOI 10.1136/adc.43.232.705; GHIDINI A, 1993, AM J OBSTET GYNECOL, V168, P1339, DOI 10.1016/S0002-9378(11)90761-3; GROVER CM, 1990, J CLIN MICROBIOL, V28, P2297, DOI 10.1128/JCM.28.10.2297-2301.1990; GUAY JM, 1993, J CLIN MICROBIOL, V31, P203, DOI 10.1128/JCM.31.2.203-207.1993; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HALLIDAY JL, 1992, LANCET, V340, P1236; HALLIDAY JL, 1992, LANCET, V340, P886, DOI 10.1016/0140-6736(92)93293-V; HOHLFELD P, 1989, J PEDIATR-US, V115, P765, DOI 10.1016/S0022-3476(89)80660-2; HOHLFELD P, 1991, ULTRASOUND OBST GYN, V1, P241, DOI 10.1046/j.1469-0705.1991.01040241.x; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; JOYNSON DHM, 1988, LANCET, V2, P795; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; MITCHELL CD, 1990, PEDIATR INFECT DIS J, V9, P512, DOI 10.1097/00006454-199007000-00012; PROMPELER HJ, 1989, GEBURTSH FRAUENHEILK, V49, P642, DOI 10.1055/s-2008-1026670; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; SAVVA D, 1990, J MED MICROBIOL, V32, P25, DOI 10.1099/00222615-32-1-25; SIBLEY LD, 1992, NATURE, V359, P82, DOI 10.1038/359082a0; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; TABOR A, 1986, LANCET, V1, P1287; THALHAMMER O, 1979, WIEN KLIN WOCHENSCHR, V91, P20; THULLIEZ P, 1992, SCAND J INFECT DIS, P18; VANDEVEN E, 1991, J CLIN MICROBIOL, V29, P2120, DOI 10.1128/JCM.29.10.2120-2124.1991	43	289	308	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					695	699		10.1056/NEJM199409153311102	http://dx.doi.org/10.1056/NEJM199409153311102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058075				2022-12-28	WOS:A1994PF33200002
J	BAIER, H; BONHOEFFER, F				BAIER, H; BONHOEFFER, F			ATTRACTIVE AXON GUIDANCE MOLECULES	SCIENCE			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; NEURITE GROWTH; TARGETS; PROTEIN				BAIER, H (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,POB 2109,D-72011 TUBINGEN,GERMANY.							BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; CAJAL SRY, 1892, CELLULE, V9, P119; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HEDGECOCK EM, 1990, NEURON, V2, P61; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LEMMON V, 1992, J NEUROSCI, V12, P818; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MITCHELL KA, UNPUB; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PLACZEK M, 1990, DEVELOPMENT, V110, P19; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0	17	43	44	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1541	1542		10.1126/science.8079167	http://dx.doi.org/10.1126/science.8079167			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079167				2022-12-28	WOS:A1994PF33600022
J	RESTREPO, BI; BARBOUR, AG				RESTREPO, BI; BARBOUR, AG			ANTIGEN DIVERSITY IN THE BACTERIUM B-HERMSII THROUGH SOMATIC MUTATIONS IN REARRANGED VMP GENES	CELL			English	Article							RELAPSING FEVER BORRELIA; LINEAR PLASMIDS; POINT MUTATIONS; DNA; CHICKEN; BURGDORFERI; EXPRESSION; AGENT; RECOMBINATION; TRYPANOSOME	B. hermsii counters host immunity with multiphasic antigenic variation. Th is is conferred by interplasmidic and intraplasmidic rearrangements of vmp genes. In several independent events, activation of a silent vmp gene through intraplasmidic deletions but not interplasmidic recombinations was followed by the appearance at its 5' end of multiple mutations that were not present in the silent gene. The prevalence of mutant alleles in postswitch populations increased during infections. Differences between the silent and expressed genes were at the same nucleotides at which vmp pseudogenes differed, suggesting these were templates for postswitch gene conversions. The mechanism of this bacterium to generate diversity, namely, intramolecular deletions followed by mutations in the rearranged gene, mirrors the strategy used by vertebrate hosts to eliminate it.	UNIV TEXAS, HLTH SCI CTR, DEPT MED, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	RESTREPO, BI (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA.		Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248; Restrepo, Blanca I/0000-0002-3743-9098	NIAID NIH HHS [AI24424] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024424, R37AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; Barbour A G, 1993, Trends Microbiol, V1, P236, DOI 10.1016/0966-842X(93)90139-I; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1991, INFECT IMMUN, V59, P390, DOI 10.1128/IAI.59.1.390-397.1991; BARBOUR AG, 1988, J CLIN MICROBIOL, V26, P475, DOI 10.1128/JCM.26.3.475-478.1988; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BARBOUR AG, 1985, GENOME REARRANGEMENT, P123; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; BURMAN N, 1990, MOL MICROBIOL, V4, P1715, DOI 10.1111/j.1365-2958.1990.tb00549.x; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; CADAVID D, 1993, J INFECT DIS, V168, P143, DOI 10.1093/infdis/168.1.143; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HUGHES CAN, 1990, J BACTERIOL, V172, P6602, DOI 10.1128/jb.172.11.6602-6604.1990; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; KITTEN T, 1992, GENETICS, V132, P311; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; MCCORMACK WT, 1990, GENE DEV, V4, P548, DOI 10.1101/gad.4.4.548; MEIER JT, 1985, CELL, V41, P403, DOI 10.1016/S0092-8674(85)80013-1; MOLTER G, 1987, IMMUNOL REV, V96, P1; PARVARI R, 1987, EMBO J, V6, P97, DOI 10.1002/j.1460-2075.1987.tb04724.x; PIASTERK RH, 1985, NATURE, V318, P257; RADDING CM, 1982, COLD SPRING HARB SYM, V47, P821, DOI 10.1101/SQB.1983.047.01.094; RESTREPO BI, 1992, MOL MICROBIOL, V6, P3299, DOI 10.1111/j.1365-2958.1992.tb02198.x; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; Sambrook J, 1989, MOL CLONING LABORATO; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; Swanson J., 1989, MOBILE DNA, P743; VANDERPLOEG LHT, 1992, TRENDS GENET, V8, P452, DOI 10.1016/0168-9525(92)90179-8; WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0	42	66	76	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					867	876		10.1016/S0092-8674(94)90642-4	http://dx.doi.org/10.1016/S0092-8674(94)90642-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087853				2022-12-28	WOS:A1994PG29600015
J	DENG, TL; KARIN, M				DENG, TL; KARIN, M			C-FOS TRANSCRIPTIONAL ACTIVITY STIMULATED BY H-RAS-ACTIVATED PROTEIN-KINASE DISTINCT FROM JNK AND ERK	NATURE			English	Article							CELL-PROLIFERATION; TYROSINE KINASES; JUN ACTIVITY; MAP KINASES; PHOSPHORYLATION; DOMAIN; RECEPTOR; COMPLEX; EXPRESSION; ONCOGENES	RAS proteins exert their mitogenic and oncogenic effects through activation of downstream protein kinases(1). An important question is how Ras-generated signals reach the nucleus to activate downstream target genes. AP-1, a heterodimeric complex of Jun and Fos proteins, which activates mitogen-inducible genes(2), is a major nuclear target of Ras(3). Ras can stimulate AP-1 activity by inducing c-fos transcription(2,3), a process which is probably mediated by the ERK1 and -2 mitogen-activated protein (MAP) kinases(4), which phosphorylate the transcription factor Elk-1/TCF5,6. Besides inducing transcription from fos and jun genes, mitogens and Ras proteins enhance AP-1 activity through phosphorylation of c-Jun(7,8). Phosphorylation of the c-Jun activation domain leads to c-jun induction through an autoregulatory loop(2). Ras- and ultraviolet-responsive protein kinases that phosphorylate c-Jun on serine residues at positions 63 and 73 and stimulate its transcriptional activity have been identified(9). These proline-directed kinases, termed JNKs, are novel MAP kinases(10). It is not clear, however, whether c-Jun is the only recipient and JNK the only transducer of the Ras signal to AP-1 proteins, A short sequence surrounding the major JNK phosphorylation site of c-Jun is conserved in c-Fos and is part of its activation domain(11), suggesting that c-Fos may be similarly regulated. Here we show that Ras does indeed augment the transcriptional activity of c-Fos through phosphorylation at Thr 232, the homologue of Ser 73 of c-Jun. However, this is mediated by a novel Ras- and mitogen-responsive proline-directed protein kinase that is different from JNKs and ERKs. Therefore, at least three types of proline-directed kinases(4) transmit Ras- and mitogen-generated signals to the transcriptional machinery.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								ALVAREZ E, 1991, J BIOL CHEM, V266, P15297; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P312; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Landon, 1977, Methods Enzymol, V47, P145; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	41	322	328	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	1994	371	6493					171	175		10.1038/371171a0	http://dx.doi.org/10.1038/371171a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072547				2022-12-28	WOS:A1994PF19100068
J	JONAS, HS; ETZEL, SI; BARZANSKY, B				JONAS, HS; ETZEL, SI; BARZANSKY, B			EDUCATIONAL-PROGRAMS IN US MEDICAL-SCHOOLS, 1993-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DEPT DATA SYST,CHICAGO,IL 60610	American Medical Association	JONAS, HS (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							BARKUN H, 1994, ASS CAN MED COLL FOR, V27, P6; BARKUN H, 1994, ASS CAN MED COLL FOR, V27, P1; COHEN JJ, 1994, JAMA-J AM MED ASSOC, V272, P712, DOI 10.1001/jama.272.9.712; WHITCOMB ME, 1993, POTENTIAL IMPACT HLT; 1993, FUNCTIONS STRUCTURE	5	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					694	701						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064985				2022-12-28	WOS:A1994PE32700014
J	LLOYD, EL				LLOYD, EL			ABC OF SPORTS MEDICINE - TEMPERATURE AND PERFORMANCE .2. HEAT	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	LLOYD, EL (corresponding author), PRINCESS MARGARET ROSE ORTHOPAED HOSP,EDINBURGH EH10 7ED,MIDLOTHIAN,SCOTLAND.							1994, BRIT MED J, V309, P531	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					587	589		10.1136/bmj.309.6954.587	http://dx.doi.org/10.1136/bmj.309.6954.587			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086949	Green Published			2022-12-28	WOS:A1994PF33000025
J	HARBURY, PB; KIM, PS; ALBER, T				HARBURY, PB; KIM, PS; ALBER, T			CRYSTAL-STRUCTURE OF AN ISOLEUCINE-ZIPPER TRIMER	NATURE			English	Article							ALPHA-FIBROUS PROTEINS; HELICAL COILED COILS; GCN4 LEUCINE-ZIPPER; AMINO-ACID SEQUENCE; HEMAGGLUTININ; REFINEMENT; GLYCOPROTEIN; SPECIFICITY; NUCLEOTIDE; RESOLUTION	SUBUNIT oligomerization in many proteins is mediated by short coiled-coil motifs(1,2). These motifs share a characteristic seven-amino-acid repeat containing hydrophobic residues at the first (a) and fourth (d) positions. Despite this common pattern, different sequences form two-, three- and four-stranded helical ropes. We have investigated the basis for oligomer choice by characterizing variants(3) of the GCN4 lencine-zipper dimerization domain that adopt trimeric or tetrameric structures in response to mutations at the a and d positions. We now report the high-resolution X-ray crystal structure of an isoleucine-containing mutant that folds into a parallel three-stranded, alpha-helical coiled coil. In contrast to the dimer and tetramer structures(3,4), the interior packing of the trimer can accommodate beta-branched residues in the most preferred rotamer at both hydrophobic positions. Compatibility of the shape of the core amino acids with the distinct packing spaces in the two-, three- and four-stranded conformations appears to determine the oligomerization state of the GCN4 leucine-zipper variants.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California Berkeley	HARBURY, PB (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; COELINGH KLV, 1988, VIROLOGY, V162, P137, DOI 10.1016/0042-6822(88)90402-3; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUNCAN R, 1990, VIROLOGY, V174, P399, DOI 10.1016/0042-6822(90)90093-7; ELANGO N, 1986, J VIROL, V57, P481, DOI 10.1128/JVI.57.2.481-489.1986; GARBER AT, 1989, EMBO J, V8, P1727, DOI 10.1002/j.1460-2075.1989.tb03565.x; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARBURY PH, 1994, THESIS HARVARD U; HU JC, 1992, PROGR NUCLEIC ACIDS, P82; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	31	421	462	3	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					80	83		10.1038/371080a0	http://dx.doi.org/10.1038/371080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072533				2022-12-28	WOS:A1994PE38100056
J	SYMONDS, H; KRALL, L; REMINGTON, L; SAENZROBLES, M; LOWE, S; JACKS, T; VANDYKE, T				SYMONDS, H; KRALL, L; REMINGTON, L; SAENZROBLES, M; LOWE, S; JACKS, T; VANDYKE, T			P53-DEPENDENT APOPTOSIS SUPPRESSES TUMOR-GROWTH AND PROGRESSION IN-VIVO	CELL			English	Article							WILD-TYPE P53; VIRUS-40 T-ANTIGEN; TRANSGENIC MICE; GENE AMPLIFICATION; CHOROID-PLEXUS; TUMORIGENESIS; MUTANT; CELLS; EXPRESSION; MUTATIONS	To determine the contribution of p53 loss to tumor progression, we have induced abnormal proliferation in the brain choroid plexus epithelium of transgenic mice using a SV40 T antigen fragment that perturbs pRB family function but does not affect p53 function. Tumors induced by this mutant develop slowly compared with those induced by wild-type T antigen. Suppressed tumor growth is directly attributable to p53 function, since rapid tumor development occurs when the T antigen fragment is expressed in p53-null mice. In p53-heterozygous mice, stochastic loss of the wildtype p53 allele results in the focal emergence of aggressive tumor nodules characteristic of tumor progression. In each case, aggressive tumor development in the absence of p53 function corresponds to a decrease in the level of apoptosis. These results provide in vivo evidence that p53-dependent apoptosis, occurring in response to oncogenic events, is a critical regulator of tumorigenesis.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15213	Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SYMONDS, H (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA046283] Funding Source: NIH RePORTER; NCI NIH HHS [CA46283] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, ONCOGENE, V6, P1699; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CHEN JD, 1991, MOL CELL BIOL, V11, P5968, DOI 10.1128/MCB.11.12.5968; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ICHIKAWA A, 1992, BLOOD, V79, P2701; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHULTZE B, 1981, CELL TISSUE KINET, V14, P309, DOI 10.1111/j.1365-2184.1981.tb00535.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	32	879	891	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					703	711		10.1016/0092-8674(94)90534-7	http://dx.doi.org/10.1016/0092-8674(94)90534-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069917				2022-12-28	WOS:A1994PD69300018
J	CHANG, PC; COHEN, SN				CHANG, PC; COHEN, SN			BIDIRECTIONAL REPLICATION FROM AN INTERNAL ORIGIN IN A LINEAR STREPTOMYCES PLASMID	SCIENCE			English	Article							DNA FRAGMENTS	Commonly, linear replicons that have protein covalently attached to 5' DNA termini replicate by protein-primed, strand-displacing, continuous synthesis of full-length strands. The synthesis of DNA in pSLA2, a 17-kilobase linear plasmid of Streptomyces rochei containing 5' terminal protein, occurs bidirectionally from an internally located replication origin. The replication intermediates are linear duplex molecules that have recessed (similar to 280 nucleotides) 5' ends rather than full-length single strands. The 3' over-hangs may serve as templates for the non-displacing synthesis of the lagging strand terminus primed by the covalently attached 5' DNA binding protein.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University								BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; HARDING NE, 1980, VIROLOGY, V104, P323, DOI 10.1016/0042-6822(80)90337-2; HINNEBUSCH J, 1993, MOL MICROBIOL, V10, P917, DOI 10.1111/j.1365-2958.1993.tb00963.x; HIROCHIKA H, 1982, PLASMID, V7, P59, DOI 10.1016/0147-619X(82)90027-0; HIROCHIKA H, 1984, EMBO J, V3, P761, DOI 10.1002/j.1460-2075.1984.tb01881.x; Hopwood D.A., 1985, GENETIC MANIPULATION; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KINASHI H, 1987, NATURE, V328, P454, DOI 10.1038/328454a0; LECHNER RL, 1977, CELL, V12, P1007, DOI 10.1016/0092-8674(77)90165-9; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; MEINHARDT F, 1990, CURR GENET, V17, P89, DOI 10.1007/BF00312851; SAKAGUCHI K, 1990, MICROBIOL REV, V54, P66, DOI 10.1128/MMBR.54.1.66-74.1990; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J, 1989, MOL CLONING LABORATO; SHIFFMAN D, 1992, P NATL ACAD SCI USA, V89, P6129, DOI 10.1073/pnas.89.13.6129; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGIMOTO K, 1968, P NATL ACAD SCI USA, V60, P1356, DOI 10.1073/pnas.60.4.1356; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WU XN, 1993, J BACTERIOL, V175, P37, DOI 10.1128/JB.175.1.37-52.1993	21	87	95	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					952	954		10.1126/science.8052852	http://dx.doi.org/10.1126/science.8052852			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052852				2022-12-28	WOS:A1994PB49900042
J	GRAINGER, DJ; KEMP, PR; LIU, AC; LAWN, RM; METCALFE, JC				GRAINGER, DJ; KEMP, PR; LIU, AC; LAWN, RM; METCALFE, JC			ACTIVATION OF TRANSFORMING GROWTH-FACTOR-BETA IS INHIBITED IN TRANSGENIC APOLIPOPROTEIN(A) MICE	NATURE			English	Article							SMOOTH-MUSCLE CELLS; EXPRESSING HUMAN APOLIPOPROTEIN(A); LIPOPROTEIN(A); PROLIFERATION; OSTEOPONTIN; CULTURE; INVITRO	A HIGH concentration of serum lipoprotein(a) is a risk factor for atherosclerosis(1-3). Lipoprotein(a) consists of low-density lipoprotein with the additional protein component, apolipoprotein(a), a homologue of plasminogen(4). Lipoprotein(a) and apolipoprotein(a) enhance proliferation of human vascular smooth muscle cells (hVSMCs) in culture by inhibiting activation of plasminogen to plasmin, thus blocking the proteolytic activation of transforming growth factor-beta (TGF-beta)(5), an autocrine inhibitor of hVSMC proliferation(5,6). The hypothesis that this pathway is a key step in atherogenesis(5) is tested on transgenic mice expressing the human apolipoprotein(a) gene. We show here that the activation of TGF-beta is inhibited in the aortic wall and serum of mice expressing apolipoprotein(a), as a consequence of apolipoprotein(a) inhibition of plasminogen activation. These effects are closely correlated with VSMC activation.	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305	Stanford University	GRAINGER, DJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.			Kemp, Paul/0000-0001-8975-7293	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CHIESA G, 1992, J BIOL CHEM, V267, P24369; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; KIRSCHENLOHR HL, 1993, AM J PHYSIOL, V265, pC571, DOI 10.1152/ajpcell.1993.265.2.C571; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RINDERKNECHT H, 1960, EXPERIENTIA, V16, P430, DOI 10.1007/BF02178856; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631	21	337	352	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					460	462		10.1038/370460a0	http://dx.doi.org/10.1038/370460a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047165				2022-12-28	WOS:A1994PB40700056
J	EADS, JC; SCAPIN, G; XU, YM; GRUBMEYER, C; SACCHETTINI, JC				EADS, JC; SCAPIN, G; XU, YM; GRUBMEYER, C; SACCHETTINI, JC			THE CRYSTAL-STRUCTURE OF HUMAN HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE WITH BOUND GMP	CELL			English	Article							LESCH-NYHAN; NUCLEOSIDE HYDROLASE; TRANSITION-STATE; DEFICIENCY; PATIENT; EXPRESSION; STABILITY; PURINE; GENE	The crystal structure of HGPRTase with bound GMP has been determined and refined to 2.5 Angstrom resolution, The enzyme has a core alpha/beta structure resembling the nucleotide-binding fold of dehydrogenases, and a second lobe composed of residues from the amino and carboxy termini. The GMP molecule binds in an anti conformation in a solvent-exposed cleft of the enzyme. Lys-165, which forms a hydrogen bond to O6 of GMP, appears to be critical for determining the specificity for guanine and hypoxanthine over adenine. The location of active site residues also provides evidence for a possible mechanism for general base-assisted HGPRTase catalysis. A rationalization of the effects on stability and activity of naturally occurring single amino acid mutations of HGPRTase is presented, including a discussion of several mutations at the active site that lead to Lesch-Nyhan syndrome.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; FELS INST CANC RES, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	EADS, JC (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048623] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA12227] Funding Source: Medline; NIGMS NIH HHS [GM48623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1983, J BIOL CHEM, V258, P6450; ARNOLD WJ, 1971, J BIOL CHEM, V246, P7398; BLABER M, 1994, J MOL BIOL, V235, P600, DOI 10.1006/jmbi.1994.1016; BOUWENSROMBOUTS AGM, 1993, HUM GENET, V91, P451, DOI 10.1007/BF00217770; BRENNAND J, 1983, J BIOL CHEM, V258, P9593; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; DAVIDSON BL, 1988, GENE, V68, P85, DOI 10.1016/0378-1119(88)90601-4; DAVIDSON BL, 1989, J BIOL CHEM, V264, P520; DAVIDSON BL, 1988, GENE, V63, P331, DOI 10.1016/0378-1119(88)90536-7; DOVEY HF, 1984, MOL BIOCHEM PARASIT, V11, P157, DOI 10.1016/0166-6851(84)90062-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUJIMORI S, 1991, ADV EXP MED BIOL, V309, P101; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GIACOMELLO A, 1978, J BIOL CHEM, V253, P6038; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GORDON RB, 1991, ADV EXP MED BIOL, V309, P95; Gutteridge W, 1977, BIOCH PARASITIC PROT, P69, DOI 10.1007/978-1-349-15809-6_6; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOWARD AJ, 1986, GUIDE DATA REDUCTION; JOHNSON GG, 1979, SCIENCE, V203, P174, DOI 10.1126/science.569362; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1263; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MAIN P, 1993, SQUASH SUITE PROGRAM; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; NICHOLLS A, 1993, GRASP; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P72; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STOUT JT, 1989, METABOLIC BASIS INHE, P1007; STRAUSS M, 1978, EUR J BIOCHEM, V90, P89, DOI 10.1111/j.1432-1033.1978.tb12578.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VELLIEUX FMD, 1993, DEMON PROGRAM SUITE; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WILSON JM, 1983, NEW ENGL J MED, V309, P900; WILSON JM, 1982, J BIOL CHEM, V257, P978; WILSON JM, 1986, J CLIN INVEST, V77, P188, DOI 10.1172/JCI112275; YAMADA Y, 1991, ADV EXP MED BIOL, V309, P121	47	211	214	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					325	334		10.1016/0092-8674(94)90301-8	http://dx.doi.org/10.1016/0092-8674(94)90301-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044844				2022-12-28	WOS:A1994NZ24200015
J	LEY, C; LE, C; OLSHEN, EM; REINGOLD, AL				LEY, C; LE, C; OLSHEN, EM; REINGOLD, AL			THE USE OF SEROLOGIC TESTS FOR LYME-DISEASE IN A PREPAID HEALTH PLAN IN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; TICK BITES; ANTIBODY; LABORATORIES; POPULATION	Objective.-To determine the reason(s) why serologic tests for Lyme disease are performed, who initiates the test requests, and how the test results are used in a clinical setting. Design.-Retrospective cohort. Setting.-Prepaid health plan in northern California. Patients.-Consecutive sample of 117 patients for whom at least one serologic test for Lyme disease was performed during a 3-month period. Main Outcome Measures.-Reason for ordering and result of the serologic test, differential diagnoses, and treatment. Results.-One of 117 patients had antibodies to Borrelia burgdorferi. Fifty-six percent of test requests were initiated by the physician and 35% by the patient. Of 66 tests ordered by the physician, 20% were performed because of suspected early Lyme disease, 6% as follow-up of a tick bite, 2% to confirm a prior history of Lyme disease, 14% as a workup for arthritis, and 60% as one of a battery of laboratory tests for vague symptoms. Of 41 tests initiated by the patient, 51% were performed because of a history of a tick bite. The reasons for ordering 10 tests were undetermined. Conclusion.-Only 19% of all serologic tests for Lyme disease were performed because the physician suspected Lyme disease in the patient. Particularly in light of the low probability of contracting Lyme disease in California, it appears that this serologic test is being overused. Indiscriminate testing increases health care costs and does not appear to affect treatment decisions. Education is needed regarding the limitations of this serologic test.	KAISER PERMANENTE MED GRP,SANTA ROSA,CA	Kaiser Permanente; Permanente Medical Groups	LEY, C (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,EPIDEMIOL PROGRAM,140 WARREN HALL,BERKELEY,CA 94720, USA.				PHS HHS [U50/CCU906612-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; LANE RS, 1990, J CLIN MICROBIOL, V28, P1774, DOI 10.1128/JCM.28.8.1774-1779.1990; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; 1991, WIS EPIDEMIOL B, V13; 1990, MMWR MORB MORTAL WKL, V39, P19; 1991, CALIFORNIA MORRB	27	31	31	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					460	463		10.1001/jama.271.6.460	http://dx.doi.org/10.1001/jama.271.6.460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8080498				2022-12-28	WOS:A1994MU49100034
J	SCHICK, BP				SCHICK, BP			CLINICAL IMPLICATIONS OF BASIC RESEARCH - HOPE FOR TREATMENT OF THROMBOCYTOPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MPL				SCHICK, BP (corresponding author), THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107, USA.							DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; GEWIRTZ AM, 1994, HEMOSTASIS THROMBOSI, P353; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; METHIA N, 1993, BLOOD, V82, P1395; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	8	12	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					875	876		10.1056/NEJM199409293311312	http://dx.doi.org/10.1056/NEJM199409293311312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078536				2022-12-28	WOS:A1994PH53000012
J	ZHOU, JS; HOFFMAN, BM				ZHOU, JS; HOFFMAN, BM			STERN-VOLMER IN REVERSE - 2/1 STOICHIOMETRY OF THE CYTOCHROME-C CYTOCHROME-C PEROXIDASE ELECTRON-TRANSFER COMPLEX	SCIENCE			English	Article							METALLOPROTEIN COMPLEX; IONIC-STRENGTH; BINDING; RECOGNITION; PLASTOCYANIN; EQUILIBRIUM; ASSOCIATION; MOLECULES; DIFFUSION	A reverse protocol for measurements of molecular binding and reactivity by excited-state quenching has been developed in which the quencher, held at a fixed concentration, is titrated by a photoexcitable probe molecule whose decay is monitored. The binding stoichiometries, affinities, and reactivities of the electron-transfer complexes between cytochrome c (Cc) and cytochrome c peroxidase (CcP) were determined over a wide range of ionic strengths (4.5 to 118 millimolar) by the study of photoinduced electron-transfer quenching of the triplet excited state of zinc-substituted Cc (ZnCc) by Fe(3+)CcP. The 2:1 stoichiometry seen for the binding of Cc to CcP at low ionic strength persists at the physiologically relevant ionic strengths and likely has functional significance. Analysis of the stoichiometric binding and rate constants confirms that one surface domain of CcP binds Cc with a high affinity but with poor electron-transfer quenching of triplet-state ZnCc, whereas a second binds weakly but with a high rate of electron-transfer quenching.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013531, R37HL013531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13531] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; CLARKE MJ, 1991, STRUCT BONDING BERLI, V75, P1; CONKLIN KT, 1986, INORG CHEM, V25, P4804, DOI 10.1021/ic00247a003; EISEN HN, 1971, METHODS IMMUNOLOGY I, V3, P395; ERMAN JE, 1980, J BIOL CHEM, V255, P6224; GUPTA RK, 1973, BIOCHIM BIOPHYS ACTA, V292, P502, DOI 10.1016/0005-2728(73)90056-X; HAZZARD JT, 1988, BIOCHEM BIOPH RES CO, V151, P429, DOI 10.1016/0006-291X(88)90611-0; KANG CH, 1977, J BIOL CHEM, V252, P919; Klotz I.M, 1986, INTRO BIOMOLECULAR E; KLOTZ IM, 1979, ARCH BIOCHEM BIOPHYS, V193, P314, DOI 10.1016/0003-9861(79)90036-5; KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354; LAURENCE DJR, 1952, BIOCHEM J, V51, P168, DOI 10.1042/bj0510168; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1465, DOI 10.1021/bi00704a023; MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/ja00062a035; MCLENDON G, 1991, STRUCT BOND, V75, P159; MOCHAN E, 1970, BIOCHIM BIOPHYS ACTA, V216, P80, DOI 10.1016/0005-2728(70)90161-1; MOCHAN E, 1971, BIOCHEM J, V121, P69, DOI 10.1042/bj1210069; MOORE GR, 1980, J INORG BIOCHEM, V12, P1, DOI 10.1016/S0162-0134(00)80039-2; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; SIGEL H, 1992, MET IONS BIOL SYST, V27, P1; STEMP EDA, 1993, BIOCHEMISTRY-US, V32, P10848, DOI 10.1021/bi00091a041; Stern O, 1919, PHYS Z, V20, P183; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; VELICK SF, 1961, LIGHT LIFE, P108; WALLIN SA, 1991, J AM CHEM SOC, V113, P1842, DOI 10.1021/ja00005a065; WEBER G, 1965, PROTEINS, V3, P445; YI Q, 1994, J AM CHEM SOC, V116, P1981, DOI 10.1021/ja00084a043; YONETANI T, 1966, J BIOL CHEM, V241, P700; ZHANG QP, 1990, J PHYS CHEM-US, V94, P8628, DOI 10.1021/j100387a003; ZHOU JS, 1993, J AM CHEM SOC, V115, P10796, DOI 10.1021/ja00076a042; ZHOU JS, 1992, J AM CHEM SOC, V114, P3562, DOI 10.1021/ja00035a065; ZHOU JS, 1993, J AM CHEM SOC, V115, P11008, DOI 10.1021/ja00076a076	35	91	91	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1693	1696		10.1126/science.8085152	http://dx.doi.org/10.1126/science.8085152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085152				2022-12-28	WOS:A1994PG28400026
J	AIELLO, LC				AIELLO, LC			THUMBS UP FOR OUR EARLY ANCESTORS	SCIENCE			English	Editorial Material							HAND; SWARTKRANS; MEMBER-1				AIELLO, LC (corresponding author), UNIV LONDON UNIV COLL,DEPT ANTHROPOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.							BOESCH C, 1994, J HUM EVOL, V26, P325, DOI 10.1006/jhev.1994.1020; Brain C.K., 1993, SWARTKRANS CAVES CHR; Gibson K. R., 1993, TOOLS LANGUAGE COGNI; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; MARZKE MW, 1986, J HUM EVOL, V15, P439, DOI 10.1016/S0047-2484(86)80027-6; MARZKE MW, 1983, J HUM EVOL, V12, P197, DOI 10.1016/S0047-2484(83)80025-6; SCHRENK F, 1994, NATURE, V365, P833; SUSMAN RL, 1994, SCIENCE, V265, P1570, DOI 10.1126/science.8079169; SUSMAN RL, 1988, SCIENCE, V240, P781, DOI 10.1126/science.3129783; TRINKAUS E, 1990, AM J PHYS ANTHROPOL, V83, P419, DOI 10.1002/ajpa.1330830403	11	1	1	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1540	1541		10.1126/science.8079166	http://dx.doi.org/10.1126/science.8079166			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PF336	8079166				2022-12-28	WOS:A1994PF33600021
J	SCOTT, EW; SIMON, MC; ANASTASI, J; SINGH, H				SCOTT, EW; SIMON, MC; ANASTASI, J; SINGH, H			REQUIREMENT OF TRANSCRIPTION FACTOR PU.1 IN THE DEVELOPMENT OF MULTIPLE HEMATOPOIETIC LINEAGES	SCIENCE			English	Article							MURINE FETAL LIVER; BONE-MARROW; REGULATES EXPRESSION; PUTATIVE ONCOGENE; LYMPHOCYTES-B; ETS ONCOGENE; CHAIN GENE; STEM-CELLS; PRO-B; STAGE	The transcription factor PU.1 is a hematopoietic-specific member of the ets family. Mice carrying a mutation in the PU.1 locus were generated by gene targeting. Homozygous mutant embryos died at a late gestational stage. Mutant embryos produced normal numbers of megakaryocytes and erythroid progenitors, but some showed an impairment of erythroblast maturation. An invariant consequence of the mutation was a multilineage defect in the generation of progenitors for B and T lymphocytes, monocytes, and granulocytes. Thus, the developmental programs of lymphoid and myeloid lineages require a common genetic function likely acting at the level of a multipotential progenitor.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago			Simon, Celeste/AAG-3941-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008933] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI08933] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1988, MOL REPROD DEV; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; Coligan J.E., 1993, CURRENT PROTOCOLS IM; COLLINS MD, 1989, AM J PHYSIOL, V257, pR542, DOI 10.1152/ajpregu.1989.257.3.R542; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LENNON GG, 1990, J IMMUNOL, V144, P1983; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1992, MOL CELL BIOL, V12, P518, DOI 10.1128/MCB.12.2.518; PALACIOS R, 1993, BLOOD, V81, P1222; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; SCOTT EW, UNPUB; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; TRINCHIERI G, 1990, NEOPLASTIC HEMATOPAT; Williams WJ., 1990, HEMATOLOGY HEMATOLOGY, V4th; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	40	1260	1275	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 9	1994	265	5178					1573	1577		10.1126/science.8079170	http://dx.doi.org/10.1126/science.8079170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079170				2022-12-28	WOS:A1994PF33600033
J	BUSH, AI; PETTINGELL, WH; MULTHAUP, G; PARADIS, MD; VONSATTEL, JP; GUSELLA, JF; BEYREUTHER, K; MASTERS, CL; TANZI, RE				BUSH, AI; PETTINGELL, WH; MULTHAUP, G; PARADIS, MD; VONSATTEL, JP; GUSELLA, JF; BEYREUTHER, K; MASTERS, CL; TANZI, RE			RAPID INDUCTION OF ALZHEIMER A-BETA AMYLOID FORMATION BY ZINC	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; CEREBRAL-HEMORRHAGE; DOWNS-SYNDROME; DISEASE; MUTATION; PEPTIDE; BRAIN; AGGREGATION; DEMENTIA; HIPPOCAMPUS	A beta(1-40), a major component of Alzheimer's disease cerebral amyloid, is present in the cerebrospinal fluid and remains relatively soluble at high concentrations (less than or equal to 3.7 mM). Thus, physiological factors which induce A beta amyloid formation could provide clues to the pathogenesis of the disease. It has been shown that human A beta specifically and saturably binds zinc. Here, concentrations of zinc above 300 nM rapidly destabilized human A beta(1-40) solutions, inducing tinctorial amyloid formation. However, rat A beta(1-40) binds zinc less avidly and is immune to these effects, perhaps explaining the scarcity with which these animals form cerebral A beta amyloid. These data suggest a role for cerebral zinc metabolism in the neuropathogenesis of Alzheimer's disease.	MASSACHUSETTS GEN HOSP, GENET & AGING LAB, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02114 USA; UNIV HEIDELBERG, ZENTRUM MOLEK BIOL HEIDELBERG, HEIDELBERG, GERMANY; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02114 USA; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA; MENTAL HLTH RES INST VICTORIA, PARKVILLE, VIC, AUSTRALIA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; University of Melbourne			Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069; Paradis, Marc d./0000-0003-2387-3157	NIA NIH HHS [R01 AG11899-01] Funding Source: Medline; NINDS NIH HHS [R01 NS30428-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011899] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BURNET FM, 1981, LANCET, V1, P186; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1992, THESIS U MELBOURNE; BUSH AW, UNPUB; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CONSTANTINIDIS J, 1990, Encephale, V16, P231; CORRIGAN FM, 1993, BIOMETALS, V6, P149; DAVIES IJT, 1968, J CLIN PATHOL, V21, P359, DOI 10.1136/jcp.21.3.359; FRANCESCHI C, 1988, J MENT DEFIC RES, V32, P169; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, COMMUNICATION; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P	39	1375	1415	1	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1464	1467		10.1126/science.8073293	http://dx.doi.org/10.1126/science.8073293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073293				2022-12-28	WOS:A1994PE73300054
J	COOMBS, J				COOMBS, J			QUALITY STANDARDS AND THE JOB MARKET	NATURE			English	Article								Adoption of quality standards, increased legislation and the need to prove due diligence are generating a growing market for personnel with skills in quality control, quality assurance and regulatory matters. This assessment comes from a company offering recruitment services in the field.			COOMBS, J (corresponding author), CPL SCI LTD,NEWBURY,BERKS,ENGLAND.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					673	674		10.1038/370673a0	http://dx.doi.org/10.1038/370673a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PD310	8065456				2022-12-28	WOS:A1994PD31000056
J	MCAFEE, RE				MCAFEE, RE			THE ROAD LESS TRAVELED - A CONVERSATION WITH MY SON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MCAFEE, RE (corresponding author), AMER MED ASSOC,515 N STATE ST,CHICAGO,IL 60610, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					627	629		10.1001/jama.272.8.627	http://dx.doi.org/10.1001/jama.272.8.627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057519				2022-12-28	WOS:A1994PC39800034
J	MEIGHAN, S				MEIGHAN, S			AN OMISSION RECTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					586	586		10.1001/jama.272.8.586	http://dx.doi.org/10.1001/jama.272.8.586			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057502				2022-12-28	WOS:A1994PC39800008
J	PANTALEO, G; DEMAREST, JF; SOUDEYNS, H; GRAZIOSI, C; DENIS, F; ADELSBERGER, JW; BORROW, P; SAAG, MS; SHAW, GM; SEKALY, RP; FAUCI, AS				PANTALEO, G; DEMAREST, JF; SOUDEYNS, H; GRAZIOSI, C; DENIS, F; ADELSBERGER, JW; BORROW, P; SAAG, MS; SHAW, GM; SEKALY, RP; FAUCI, AS			MAJOR EXPANSION OF CD8+ T-CELLS WITH A PREDOMINANT V-BETA USAGE DURING THE PRIMARY IMMUNE-RESPONSE TO HIV	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VARIABLE REGION GENES; CD8+ LYMPHOCYTES-T; VACCINIA VIRUS; EXPRESSION VECTOR; INFECTION; CHAIN; RECOGNITION; SEQUENCES; DIVERSITY	A SIGNIFICANT proportion (up to 70%) of individuals experience an acute clinical syndrome of varying severity associated with primary infection with the human immunodeficiency virus (HIV)(1-4). We report here studies on six individuals who showed an acute HIV syndrome which generally resolved within four weeks, concomitant with a dramatic downregulation of viraemia(2-5). To characterize the T-cell-mediated primary immune response to HIV, we used combined semiquantitative polymerase chain reaction assay and cytofluorometry to analyse the T-cell antigen receptor repertoire in sequential peripheral blood mononuclear cells from the patients. We found major oligoclonal expansions in a restricted set of variable-domain beta-chain (V beta) families. Cells expressing the expanded V beta s predominantly expressed the CD8 T-cell differentiation antigen and mediated HIV-specific cytotoxicity. Major oligoclonal expansions of these CD8(+) T lymphocytes may represent an important component of the primary immune response to viral infections and may help to clarify both the immunopathogenic and the protective mechanisms of HIV infection.	INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, PQ, CANADA; PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, LA JOLLA, CA 92037 USA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, PQ, CANADA; MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL H3A 2B4, PQ, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute; Universite de Montreal; McGill University	PANTALEO, G (corresponding author), NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA.		Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019	Borrow, Persephone/0000-0002-3877-9780				BORROW P, IN PRESS J VIROL; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FERRADINI L, 1991, EUR J IMMUNOL, V21, P935, DOI 10.1002/eji.1830210412; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REBAI N, 1994, P NATL ACAD SCI USA, V91, P1529, DOI 10.1073/pnas.91.4.1529; SMITH TJ, 1993, BLOOD, V81, P1521; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514	26	566	584	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					463	467		10.1038/370463a0	http://dx.doi.org/10.1038/370463a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047166	Bronze			2022-12-28	WOS:A1994PB40700057
J	ROSKIES, AL; OLEARY, DDM				ROSKIES, AL; OLEARY, DDM			CONTROL OF TOPOGRAPHIC RETINAL AXON BRANCHING BY INHIBITORY MEMBRANE-BOUND MOLECULES	SCIENCE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; POSITION-SPECIFIC PROPERTIES; TECTAL CELL-MEMBRANES; RETINOTECTAL PROJECTION; VISUAL-SYSTEM; XENOPUS TADPOLES; NEURITE GROWTH; MAP FORMATION; INVITRO; GUIDANCE	Retinotopic map development in nonmammalian vertebrates appears to be controlled by molecules that guide or restrict retinal axons to correct locations in their targets. However, the retinotopic map in the superior colliculus (SC) of the rat is developed instead by a topographic bias in collateral branching and arborization. Temporal retinal axons extending across alternating membranes from the topographically correct rostral SC or the incorrect caudal SC of embryonic rats preferentially branch on rostral membranes. Branching preference is due to an inhibitory phosphatidylinositol-linked molecule in the caudal SC. Thus, position-encoding membrane-bound molecules may establish retinotopic maps in mammals by regulating axon branching, not by directing axon growth.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute					NEI NIH HHS [NEI RO1 EY07025] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007025] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; COLELLO RJ, IN PRESS J NEUROSCI; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CORNEL E, 1992, NEURON, V9, P1001, DOI 10.1016/0896-6273(92)90061-H; COX EC, 1990, NEURON, V2, P31; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; Fraser S E, 1992, Curr Opin Neurobiol, V2, P83, DOI 10.1016/0959-4388(92)90167-J; FUJISAWA H, 1984, DEV GROWTH DIFFER, V26, P545; FUJISAWA H, 1987, J COMP NEUROL, V260, P127, DOI 10.1002/cne.902600110; GIERER A, 1987, DEVELOPMENT, V101, P479; GODEMENT P, 1989, DEVELOPMENT, V106, P313; GODEMENT P, 1987, DEVELOPMENT, V101, P697; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATSUI K A, 1989, Society for Neuroscience Abstracts, V15, P1212; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; OLEARY DDM, 1992, SEMIN NEUROSCI, V4, P365; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; OROURKE NA, 1986, DEV BIOL, V114, P265, DOI 10.1016/0012-1606(86)90191-0; Roskies A. L., 1992, Society for Neuroscience Abstracts, V18, P222; SAKAGUCHI DS, 1985, J NEUROSCI, V5, P3228; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1993, CELL NEURON S, V72, P77; SIMON DK, 1992, J NEUROSCI, V12, P1212; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SIMON DK, 1992, NEURON, V9, P1; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J NEUROSCI, V8, P4513; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; THANOS S, 1984, J COMP NEUROL, V224, P407, DOI 10.1002/cne.902240308; TUTTLE R, 1991, J NEUROSCI METH, V39, P193, DOI 10.1016/0165-0270(91)90085-E; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VIELMETTER J, 1989, NEURON, V2, P1331, DOI 10.1016/0896-6273(89)90071-8; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909	50	116	116	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					799	803		10.1126/science.8047886	http://dx.doi.org/10.1126/science.8047886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047886				2022-12-28	WOS:A1994PA37200038
J	DUGUID, JKM; BROMILOW, I				DUGUID, JKM; BROMILOW, I			VALUE OF KLEIHAUER TESTING AFTER ADMINISTRATION OF ANTI-D-IMMUNOGLOBULIN	BRITISH MEDICAL JOURNAL			English	Article											DUGUID, JKM (corresponding author), NATL BLOOD TRANSFUS SERV MERSEY & N WALES,LIVERPOOL L7 8TW,MERSEYSIDE,ENGLAND.							LEE D, 1993, BRIT MED J, V307, P1145, DOI 10.1136/bmj.307.6912.1145-d; POLESKY HF, 1981, AM J CLIN PATHOL, V76, P525; 1991, PRESCRIBERS J, V31, P137; 1992, NOTE GUIDANCE CORE S	4	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					240	240		10.1136/bmj.309.6949.240	http://dx.doi.org/10.1136/bmj.309.6949.240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069142	Green Published			2022-12-28	WOS:A1994NZ18000018
J	BLATTER, EE; ROSS, W; TANG, H; GOURSE, RL; EBRIGHT, RH				BLATTER, EE; ROSS, W; TANG, H; GOURSE, RL; EBRIGHT, RH			DOMAIN ORGANIZATION OF RNA-POLYMERASE ALPHA-SUBUNIT - C-TERMINAL-85 AMINO-ACIDS CONSTITUTE A DOMAIN CAPABLE OF DIMERIZATION AND DNA-BINDING	CELL			English	Article							ESCHERICHIA-COLI; TRANSCRIPTION ACTIVATION; CAMP-CRP; PROMOTERS; PROTEINS; PURIFICATION; REGION	Using limited proteolysis, we show that the Escherichia coli RNA polymerase alpha subunit consists of an N-terminal domain comprised of amino acids 8-241, a C-terminal domain comprised of amino acids 249-329, and an unstructured and/or flexible interdomain linker. We have carried out a detailed structural and functional analysis of an 85 amino acid proteolytic fragment corresponding to the C-terminal domain (alpha CTD-2). Our results establish that alpha CTD-2 has a defined secondary structure (similar to 40% alpha helix, similar to 0% beta sheet). Our results further establish that alpha CTD-2 is a dimer and that alpha CTD-2 exhibits sequence-specific DNA binding activity. Our results suggest a model for the mechanism of involvement of alpha in transcription activation by promoter upstream elements and upstream-binding activator proteins.	RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Rutgers State University New Brunswick; University of Wisconsin System; University of Wisconsin Madison	BLATTER, EE (corresponding author), RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037048, R01GM041376, R01GM037048, R01GM051527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51527, GM37048, GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTEN BM, 1976, BIOCHEM BIOPH RES CO, V72, P411, DOI 10.1016/S0006-291X(76)80058-7; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burgess RR, 1976, RNA POLYMERASE, P69; BURGNER R L, 1991, P3; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; Hermanson G. T., 1992, IMMOBILIZED AFFINITY; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; Ishihama A, 1981, Adv Biophys, V14, P1; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JANIN J, 1985, METHOD ENZYMOL, V115, P420; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; NEWLANDS JT, 1992, NUCLEIC ACIDS RES, V20, P719, DOI 10.1093/nar/20.4.719; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; RYU S, 1994, IN PRESS P NATL ACAD; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SELUTCHENKO OA, 1985, BIOORG KHIM+, V11, P480; SHEER D, 1990, ANAL BIOCHEM, V187, P76, DOI 10.1016/0003-2697(90)90419-A; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONHIPPEL PH, 1992, TRANSCRIPTIONAL REGU, P179; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; ZHOU Y, 1994, IN PRESS J MOL BIOL; ZHOU Y, 1994, IN PRESS EMBO J; ZILLIG W, 1976, RNA POLYMERASE, P101; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	44	203	204	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					889	896		10.1016/S0092-8674(94)90682-3	http://dx.doi.org/10.1016/S0092-8674(94)90682-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087855				2022-12-28	WOS:A1994PG29600017
J	CHESS, A; SIMON, I; CEDAR, H; AXEL, R				CHESS, A; SIMON, I; CEDAR, H; AXEL, R			ALLELIC INACTIVATION REGULATES OLFACTORY RECEPTOR GENE-EXPRESSION	CELL			English	Article							BETA-GLOBIN GENE; ODORANT RECEPTORS; MULTIGENE FAMILY; REPLICATION TIME; X-CHROMOSOME; MOUSE; LOCUS; REGION; FLUORESCENCE; EPITHELIUM	We suggest a model in which a hierarchy of controls is exerted on the family of odorant receptor genes to assure that a sensory neuron expresses a single receptor from a family of 1000 genes. We propose that a cis-regulatory element directs the stochastic expression of only one gene from a large array of linked receptor genes. Moreover, only one allelic array encoding multiple receptor genes is active in an individual neuron. We demonstrate that in a neuron expressing a given receptor, expression derives exclusively from one allele. In addition, we observe that alleles encoding the odorant receptors are replicated asynchronously, a phenomenon consistently associated with allelic inactivation. This model, involving inactivation of one allelic array and cis control of the active array, provides a mechanism such that individual neurons express one or a small number of receptors.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL	Columbia University; Columbia University; Howard Hughes Medical Institute; Hebrew University of Jerusalem	CHESS, A (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.			Axel, Richard/0000-0002-3141-4076; Simon, Itamar/0000-0002-8517-1903	NIDCD NIH HHS [DC00082] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000082] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1992, COLD SPRING HARB SYM, V57, P505, DOI 10.1101/SQB.1992.057.01.056; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EMERSON BM, 1985, CELL, V41, P21, DOI 10.1016/0092-8674(85)90057-1; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; KELSEY G, 1992, GENOMICS, V14, P275, DOI 10.1016/S0888-7543(05)80217-4; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LEE JE, 1993, MOL REPROD DEV, V35, P362; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; MANAITIS T, 1982, MOL CLONING LABORATO; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, COLD SPRING HARB SYM, V57, P501, DOI 10.1101/SQB.1992.057.01.055; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; TAKAGI N, 1973, EXP CELL RES, V78, P127, DOI 10.1016/0014-4827(73)90046-3; TAKAGI N, 1962, CHROMOSOMA, V85, P275; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERPLOEG LHT, 1992, TRENDS GENET, V8, P452, DOI 10.1016/0168-9525(92)90179-8; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONBOEHMER H, 1992, BONE MARROW TRANSPL, V1, P46; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; [No title captured]	37	848	859	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					823	834		10.1016/S0092-8674(94)90562-2	http://dx.doi.org/10.1016/S0092-8674(94)90562-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087849				2022-12-28	WOS:A1994PG29600011
J	ZHANG, JZ; DAVLETOV, BA; SUDHOF, TC; ANDERSON, RGW				ZHANG, JZ; DAVLETOV, BA; SUDHOF, TC; ANDERSON, RGW			SYNAPTOTAGMIN-I IS A HIGH-AFFINITY RECEPTOR FOR CLATHRIN-AP-2 - IMPLICATIONS FOR MEMBRANE RECYCLING	CELL			English	Article							COATED VESICLES; NEUROTRANSMITTER RELEASE; INVITRO BINDING; GOLGI MEMBRANES; PROTEIN; EXOCYTOSIS; DOMAIN; FUSION; PITS; DROSOPHILA	In nerve terminals, Ca2+-stimulated synaptic vesicle exocytosis is rapidly followed by endocytosis. Synaptic vesicle endocytosis requires clathrin-coated pits similar to receptor-mediated endocytosis in fibroblasts. Binding of clathrin AP-2 (adaptor complex) to an unidentified high affinity membrane receptor appears to be necessary for coated pit assembly in fibroblasts. We now show that synaptic vesicles have a high affinity AP-2 site (K-D, similar to 1 x 10(-10) M) similar to the one observed in fibroblasts. Using a combination of competition and direct binding assays, we demonstrate that synaptotagmin I, an intrinsic membrane protein of synaptic vesicles, has all of the properties of the AP-2 receptor and that AP-2 binds to the second C-2 domain in the molecule. Thus, synaptotagmin I may be a multifunctional protein with a function in endocytosis in addition to the previously proposed role in exocytosis.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZHANG, JZ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.		Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FISHER GW, 1983, DEV BIOL, V99, P456, DOI 10.1016/0012-1606(83)90295-6; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PERIN MS, 1994, J BIOL CHEM, V269, P8576; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PFEFFER SR, 1983, J CELL BIOL, V97, P40, DOI 10.1083/jcb.97.1.40; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	47	436	443	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					751	760		10.1016/S0092-8674(94)90442-1	http://dx.doi.org/10.1016/S0092-8674(94)90442-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087843				2022-12-28	WOS:A1994PG29600005
J	WEINSTEIN, DC; ALTABA, ARI; CHEN, WS; HOODLESS, P; PREZIOSO, VR; JESSELL, TM; DARNELL, JE				WEINSTEIN, DC; ALTABA, ARI; CHEN, WS; HOODLESS, P; PREZIOSO, VR; JESSELL, TM; DARNELL, JE			THE WINGED-HELIX TRANSCRIPTION FACTOR HNF-3-BETA IS REQUIRED FOR NOTOCHORD DEVELOPMENT IN THE MOUSE EMBRYO	CELL			English	Article							CELL-SPECIFIC EXPRESSION; HOMEOBOX GENE XHOX3; FLOOR PLATE; FORK-HEAD; XENOPUS-LAEVIS; MESODERM FORMATION; NEURAL EXPRESSION; PATTERN-FORMATION; NERVOUS-SYSTEM; MUTANT EMBRYOS	HNF-3 beta, a transcription factor of the winged-helix family, is expressed in embryonic and adult endoderm and also in midline cells of the node, notochord, and floor plate in mouse embryos. To define the function of HNF-3 beta a targeted mutation in the HNF 3P locus was generated by homologous recombination in embryonic stem cells. Mice lacking HNF-3 beta die by embryonic day (6) 10-11. Mutant embryos examined from E6.5 to E9.5 do not form a distinct node and lack a notochord. In addition, mutant embryos show marked defects in the organization of somites and neural tube that may result from the absence of the notochord. The neural tube of mutant embryos exhibits overt anteroposterior polarity but lacks a floor plate and motor neurons. Endodermal cells are present but fail to form a gut tube in mutant embryos. These studies indicate that HNF-3 beta has an essential role in the development of axial mesoderm in mouse embryos.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	WEINSTEIN, DC (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021, USA.			Ruiz i Altaba, Ariel/0000-0003-2292-3933; Weinstein, Daniel/0000-0001-7832-9285; Hoodless, Pamela/0000-0003-1371-0725	NATIONAL CANCER INSTITUTE [R01CA016006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16006] Funding Source: Medline; NIGMS NIH HHS [GM 07982-09] Funding Source: Medline; NINDS NIH HHS [NS 30532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTABA ARI, 1990, DEVELOPMENT, V108, P595; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1993, DEVELOPMENT, V119, P1301; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DIXON JE, 1989, DEVELOPMENT, V106, P749; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; Gruneberg, 1963, PATHOLOGY DEVELPMENT; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JESSELL TM, 1992, HARVEY LECT, V86, P67; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KISPERT A, 1994, DEV BIOL, V161, P179, DOI 10.1006/dbio.1994.1019; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KORZH V, 1993, DEVELOPMENT, V118, P417; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PAPALOPULU N, 1993, DEVELOPMENT, V117, P961; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Spemann H., 1938, EMBRYONIC DEV INDUCT; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THEILER K, 1959, AM J ANAT, V104, P319, DOI 10.1002/aja.1001040302; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	82	687	705	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					575	588		10.1016/0092-8674(94)90523-1	http://dx.doi.org/10.1016/0092-8674(94)90523-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069910				2022-12-28	WOS:A1994PD69300007
J	CHELALA, C				CHELALA, C			LETTER FROM HAITI - FIGHTING FOR SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article								The political crisis in Haiti has had a severe impact on the health of the population. Mortality among Haitians is 13 per 1000, much higher than the Latin American rate of seven per 1000, and the incidence of ADDS, tuberculosis, and malnourishment is increasing among children. Although food and medicine are exempt, United Nations sanctions have had a negative impact on most of the population. In particular the embargo on fuel has limited most people's access to health care. The difficulties of distributing aid and health care without softening the embargo on fuel are immense, and the health of Haitians is not likely to improve until the political crisis is resolved.										BERNIER M, 1992, THESIS U MONTREAL; 1993, RELANCE POLITIQUE SA; 1993, HLTH SITUATION ANAL	3	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					525	526		10.1136/bmj.309.6953.525	http://dx.doi.org/10.1136/bmj.309.6953.525			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086913	Green Published			2022-12-28	WOS:A1994PD30800029
J	FUCHS, S; KAMINSKI, N; BREZIS, M				FUCHS, S; KAMINSKI, N; BREZIS, M			METABOLIC ABNORMALITY INDUCED STREPTOMYCIN	BRITISH MEDICAL JOURNAL			English	Letter											FUCHS, S (corresponding author), HADASSAH UNIV HOSP,DEPT MED,IL-91240 JERUSALEM,ISRAEL.		Brezis, Mayer/A-1041-2010					BENISHAY D, 1972, ISRAEL J MED SCI, V8, P1835; HARRINGTON JT, 1982, ACID BASE, P287; LIEBER IH, 1984, CANCER, V54, P808, DOI 10.1002/1097-0142(19840901)54:5<808::AID-CNCR2820540507>3.0.CO;2-Y; PEREZFONTAN M, 1988, AM J KIDNEY DIS, V11, P298, DOI 10.1016/S0272-6386(88)80134-3; STEINER RW, 1986, AM J KIDNEY DIS, V7, P245, DOI 10.1016/S0272-6386(86)80012-9	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					512	512		10.1136/bmj.309.6953.512	http://dx.doi.org/10.1136/bmj.309.6953.512			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086909	Green Published			2022-12-28	WOS:A1994PD30800021
J	RAWAL, J; SHAH, A; STIRK, F; MEHTAR, S				RAWAL, J; SHAH, A; STIRK, F; MEHTAR, S			WATER BIRTH AND INFECTION IN BABIES	BRITISH MEDICAL JOURNAL			English	Article									N MIDDLESEX HOSP,DEPT PAEDIAT,LONDON N18 1QX,ENGLAND; N MIDDLESEX HOSP,DEPT OBSTET & GYNAECOL,LONDON N18 1QX,ENGLAND									BALAKAS J, 1990, WATER BIRTH; GEORGE R, 1990, NURS TIMES, V86, P14; LOOMES SA, 1990, NURS TIMES, V86, P14; Robb E J, 1991, Nurs Times, V87, P14; ZIMMERMANN R, 1993, J PERINAT MED, V21, P5	5	39	43	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					511	511		10.1136/bmj.309.6953.511	http://dx.doi.org/10.1136/bmj.309.6953.511			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086906	Green Published			2022-12-28	WOS:A1994PD30800020
J	REDGMENT, CJ; ALSHAWAF, T; GRUDZINSKAS, JG; CRAFT, IL				REDGMENT, CJ; ALSHAWAF, T; GRUDZINSKAS, JG; CRAFT, IL			GAMETE INTRAFALLOPIAN TRANSFER IN OLDER WOMEN - EFFECT OF LIMITING NUMBER OF GAMETES TRANSFERRED	BRITISH MEDICAL JOURNAL			English	Article									LONDON GYNAECOL & FERTIL CTR,LONDON W1N 1AF,ENGLAND; ROYAL LONDON HOSP,ACAD DEPT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital								CRAFT I, 1988, LANCET, V1, P1094; CRAFT I, 1993, LANCET, V341, P697, DOI 10.1016/0140-6736(93)90467-U; NELSON JR, 1993, FERTIL STERIL, V60, P116; SAUER MV, 1992, LANCET, V286, P1275; 1993, ANN REPORT, P19	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					510	511		10.1136/bmj.309.6953.510	http://dx.doi.org/10.1136/bmj.309.6953.510			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086905	Green Published			2022-12-28	WOS:A1994PD30800019
J	HAFNER, MS; SUDMAN, PD; VILLABLANCA, FX; SPRADLING, TA; DEMASTES, JW; NADLER, SA				HAFNER, MS; SUDMAN, PD; VILLABLANCA, FX; SPRADLING, TA; DEMASTES, JW; NADLER, SA			DISPARATE RATES OF MOLECULAR EVOLUTION IN COSPECIATING HOSTS AND PARASITES	SCIENCE			English	Article							POCKET GOPHERS RODENTIA; GENETIC DIFFERENTIATION; PHYLOGENETIC TREES; BASE SUBSTITUTIONS; MITOCHONDRIAL-DNA; TRICHODECTIDAE; MALLOPHAGA; GEOMYIDAE; GENOME; GEOMYDOECUS	DNA sequences for the gene encoding mitochondrial cytochrome oxidase I in a group of rodents (pocket gophers) and their ectoparasites (chewing lice) provide evidence for cospeciation and reveal different rates of molecular evolution in the hosts and their parasites. The overall rate of nucleotide substitution (both silent and replacement changes) is approximately three times higher in lice, and the rate of synonymous substitution (based on analysis of fourfold degenerate sites) is approximately an order of magnitude greater in lice. The difference in synonymous substitution rate between lice and gophers correlates with a difference of similar magnitude in generation times.	LOUISIANA STATE UNIV, DEPT ZOOL & PHYSIOL, BATON ROUGE, LA 70803 USA; NO ILLINOIS UNIV, DEPT BIOL SCI, DE KALB, IL 60115 USA	Louisiana State University System; Louisiana State University; Northern Illinois University	HAFNER, MS (corresponding author), LOUISIANA STATE UNIV, MUSEUM NAT SCI, BATON ROUGE, LA 70803 USA.		Hypsa, Vaclav/G-9847-2014					ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN GG, 1982, P NATL ACAD SCI-BIOL, V79, P3246, DOI 10.1073/pnas.79.10.3246; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DEMASTES JW, 1993, J MAMMAL, V74, P521, DOI 10.2307/1382271; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FUKAMIKOBAYASHI K, 1991, J MOL EVOL, V32, P79, DOI 10.1007/BF02099932; HAFNER MS, 1991, J MAMMAL, V72, P1, DOI 10.2307/1381975; HAFNER MS, 1982, Z ZOOL SYST EVOL, V20, P118; HAFNER MS, 1988, NATURE, V332, P258, DOI 10.1038/332258a0; HAFNER MS, 1990, SYST ZOOL, V39, P192, DOI 10.2307/2992181; HELLENTHAL RA, 1984, J KANSAS ENTOMOL SOC, V57, P231; HILLIS DM, 1992, J HERED, V83, P189, DOI 10.1093/oxfordjournals.jhered.a111190; HILLIS DM, 1993, METHOD ENZYMOL, V224, P456, DOI 10.1016/0076-6879(93)24035-S; HONEYCUTT RL, 1982, J MAMMAL, V63, P208, DOI 10.2307/1380629; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kimura M., 1983, NEUTRAL THEORY MOL E; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KONDO R, 1993, J MOL EVOL, V36, P517, DOI 10.1007/BF00556356; Liu H, 1992, MOL PHYLOGENET EVOL, V1, P41, DOI 10.1016/1055-7903(92)90034-E; MANTEL N, 1967, CANCER RES, V27, P209; MARSHALL AG, 1981, ECOLOGY ECTOPARASITI; MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087, DOI 10.1073/pnas.90.9.4087; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; NADLER SA, 1989, ANN ENTOMOL SOC AM, V82, P109, DOI 10.1093/aesa/82.1.109; NADLER SA, 1990, EVOLUTION, V44, P942, DOI [10.2307/2409557, 10.1111/j.1558-5646.1990.tb03816.x]; NADLER SA, 1993, INT J PARASITOL, V23, P191, DOI 10.1016/0020-7519(93)90141-K; Nelson G., 1981, SYSTEMATICS BIOGEORA; PAGE RDM, 1994, SYST BIOL, V43, P58, DOI 10.2307/2413581; PAGE RDM, 1993, INT J PARASITOL, V23, P499, DOI 10.1016/0020-7519(93)90039-2; PAGE RDM, 1990, SYST ZOOL, V39, P205, DOI 10.2307/2992182; PRICE RD, 1971, J MED ENTOMOL, V8, P228, DOI 10.1093/jmedent/8.3.228; Russell, 1968, U KANS PUBL MUS NAT, V16, P473; RUST RW, 1974, OECOLOGIA, V15, P287, DOI 10.1007/BF00345184; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sokal Robert R., 1969, BIOMETRY; Sudman PD, 1992, MOL PHYLOGENET EVOL, V1, P17, DOI 10.1016/1055-7903(92)90031-B; Swofford David L., 1990, P411; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; [No title captured]	41	381	391	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1087	1090		10.1126/science.8066445	http://dx.doi.org/10.1126/science.8066445			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066445	Green Submitted			2022-12-28	WOS:A1994PC53900034
J	XU, D; EMOTO, N; GIAID, A; SLAUGHTER, C; KAW, S; DEWIT, D; YANAGISAWA, M				XU, D; EMOTO, N; GIAID, A; SLAUGHTER, C; KAW, S; DEWIT, D; YANAGISAWA, M			ECE-1 - A MEMBRANE-BOUND METALLOPROTEASE THAT CATALYZES THE PROTEOLYTIC ACTIVATION OF BIG ENDOTHELIN-1	CELL			English	Article							RECEPTOR ANTAGONIST; CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; MESSENGER-RNA; EXPRESSION; CELLS; SEQUENCE; SUBTYPE; PROTEIN	Endothelin-1 (ET-1), a 21-residue vasoactive peptide, is produced in vascular endothelial cells from the 38-residue inactive intermediate big endothelin-1 via a specific cleavage at Trp-21-Val-22. The protease that catalyzes the conversion, endothelin-converting enzyme (ECE), constitutes a potential regulatory site for the production of the active peptide. We report the identification of ECE-1, a novel membrane-bound neutral metalloprotease that is expressed abundantly in endothelial cells in vivo and is structurally related to neutral endopeptidase 24.11 and Kell blood group protein. When transfected into cultured cells that normally secrete only big ET-1, the ECE-1 cDNA conferred the ability to secrete mature ET-1. In transfected cells, ECE-1 processes endogenously synthesized big ET-1 as well as exogenously supplied big ET-1, which interacts with ECE-1 on the cell surface. ECE-1 may provide a target for pharmacological intervention to alter ET-1 production.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL H3G 1A4,PQ,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	XU, D (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Emoto, Noriaki/0000-0001-6673-2616				AHN K, 1992, P NATL ACAD SCI USA, V89, P8606, DOI 10.1073/pnas.89.18.8606; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; BLOOM ITM, 1993, SURGERY, V114, P480; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GELLAI M, 1994, J CLIN INVEST, V93, P900, DOI 10.1172/JCI117046; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GROVER GJ, 1993, CARDIOVASC RES, V27, P1613, DOI 10.1093/cvr/27.9.1613; IMAI T, 1992, BIOCHEM BIOPH RES CO, V182, P1115, DOI 10.1016/0006-291X(92)91847-J; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITOH S, 1993, BIOCHEM BIOPH RES CO, V195, P969, DOI 10.1006/bbrc.1993.2139; KIVLIGHN SD, 1993, KIDNEY INT, V45, P131; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; NAKAJIMA K, 1989, J CARDIOVASC PHARM, V13, pS8, DOI 10.1097/00005344-198900135-00004; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; NISHIKORI K, 1991, NEUROCHEM INT, V18, P535, DOI 10.1016/0197-0186(91)90152-4; OHLSTEIN EH, 1994, IN PRESS P NATL ACAD; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; OPGENORTH TJ, 1992, FASEB J, V6, P2653, DOI 10.1096/fasebj.6.9.1612289; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROSOLOWSKY LJ, 1994, AM J PHYSIOL-ENDOC M, V266, P107; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SEIDAH NG, 1993, ANN NY ACAD SCI, V680, P135, DOI 10.1111/j.1749-6632.1993.tb19680.x; SOGABE K, 1993, J PHARMACOL EXP THER, V264, P1040; STEIN PD, 1994, J MED CHEM, V37, P329, DOI 10.1021/jm00029a001; SUZUKI N, 1990, J IMMUNOL METHODS, V127, P165, DOI 10.1016/0022-1759(90)90065-4; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21395; TSURUMI Y, 1994, J ANTIBIOT, V47, P667; TURNER AJ, 1993, BIOCHEM SOC T, V21, P697, DOI 10.1042/bst0210697; UJIIE K, 1992, J CLIN INVEST, V90, P1043, DOI 10.1172/JCI115918; Vane J R, 1992, J Physiol Pharmacol, V43, P195; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; WAXMAN L, 1993, ARCH BIOCHEM BIOPHYS, V308, P240; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	48	807	821	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					473	485		10.1016/0092-8674(94)90425-1	http://dx.doi.org/10.1016/0092-8674(94)90425-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062389				2022-12-28	WOS:A1994PC40500013
J	WIEDMANN, B; SAKAI, H; DAVIS, TA; WIEDMANN, M				WIEDMANN, B; SAKAI, H; DAVIS, TA; WIEDMANN, M			A PROTEIN COMPLEX REQUIRED FOR SIGNAL-SEQUENCE-SPECIFIC SORTING AND TRANSLOCATION	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; LARGE RIBOSOMAL-SUBUNIT; RECOGNITION PARTICLE; NASCENT PREPROLACTIN; ESCHERICHIA-COLI; CROSS-LINKING; POLYPEPTIDE-CHAINS; RECEPTOR; TRANSCRIPTION; CELL	We have purified a nascent-polypeptide-associated complex (NAC) which prevents short ribosome-associated nascent polypeptides from inappropriate interactions with proteins in the cytosol. NAC binds nascent-polypeptide domains emerging from ribosomes unless a signal peptide is fully exposed. Depletion of cytosolic proteins (including NAC) from ribosomes carrying nascent polypeptides allows the signal recognition particle (SRP) to crosslink to polypeptides irrespective of whether or not they contain signal peptides. In the absence of cytosol, proteins lacking signal peptides can be mistranslocated into the endoplasmic reticulum in vitro, albeit with low efficiency. Readdition of NAC restores the specificity of SRP and fidelity of translocation.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center								BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; KANNO M, 1992, GENE, V117, P219, DOI 10.1016/0378-1119(92)90732-5; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	30	331	349	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					434	440		10.1038/370434a0	http://dx.doi.org/10.1038/370434a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047162				2022-12-28	WOS:A1994PB40700048
J	BURDEN, AD; VESTEY, JP; SIREL, JM; AITCHISON, TC; HUNTER, JAA; MACKIE, RM				BURDEN, AD; VESTEY, JP; SIREL, JM; AITCHISON, TC; HUNTER, JAA; MACKIE, RM			MULTIPLE PRIMARY MELANOMA - RISK-FACTORS AND PROGNOSTIC IMPLICATIONS	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA		UNIV EDINBURGH,ROYAL INFIRM,DEPT DERMATOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QW,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Glasgow	BURDEN, AD (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT DERMATOL,GLASGOW G11 6NT,SCOTLAND.							GUPTA BK, 1991, CANCER-AM CANCER SOC, V67, P1984, DOI 10.1002/1097-0142(19910401)67:7<1984::AID-CNCR2820670727>3.0.CO;2-H; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; Scheibner A, 1982, Australas J Dermatol, V23, P1, DOI 10.1111/j.1440-0960.1982.tb00230.x; SLINGLUFF CL, 1993, SURGERY, V113, P330	5	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					375	375						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081136				2022-12-28	WOS:A1994PB31600018
J	ROBERTSON, JR; RONALD, PJM; RAAB, GM; ROSS, AJ; PARPIA, T				ROBERTSON, JR; RONALD, PJM; RAAB, GM; ROSS, AJ; PARPIA, T			DEATHS, HIV-INFECTION, ABSTINENCE, AND OTHER OUTCOMES IN A COHORT OF INJECTING DRUG-USERS FOLLOWED UP FOR 10 YEARS	BRITISH MEDICAL JOURNAL			English	Article							RISK-TAKING BEHAVIOR; HEROIN-ADDICTION; RECOVERY	Objective-To trace, follow up, and interview a group of patients known to be injecting drug users in order to establish current drug taking and other features related to drug use over 10 gears. Design-Descriptive follow up study of a cohort of injecting drug users established between 1982 and 1985. Setting-General practice based patient population study initially, with later tracing of subjects throughout the United Kingdom through NHS Central Registries and current general practitioners. Subjects-203 injecting drug users recruited up to December 1985. Main outcome measures-Survival, cause of death, abstinence, or continued drug use; HIV status; and demographic variables. Results-Of the 203 injecting drug users recruited into the study, over half were known to be HIV positive and 42 died of various causes (increasingly AIDS). From the start of follow up in 1990, 163 (91%) of the 180 survivors were traced, of whom 116 (71%) were interviewed. Dramatic changes had occurred in drug taking, with a move away from injecting towards oral drug use. A few patients, however, continued to inject. 90 (78%) of those interviewed had been in prison, of whom 37 (41%) had injected drugs while in prison. Conclusions-The pattern of deaths had changed from being largely due to overdose in the early 1980s to predominantly AIDS related in later years, The reduction in deaths due to overdose may have been connected with but was not always causally related to a new approach by legal, social, and medical services. Drug use continues in a modified form in a large proportion of patients followed up. As a group, drug users require long term support for a multiplicity of problems.	CTR HIV RES,MRC BIOSTAT INITIAT AIDS & HIV RES SCOTLAND,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND		ROBERTSON, JR (corresponding author), MUIRHOUSE MED GRP,EDINBURGH DRUG ADDICT STUDY,EDINBURGH EH4 4PL,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1988, AIDS DRUG MISUSE 1; BATH GE, 1993, LANCET, V342, P1368, DOI 10.1016/0140-6736(93)92279-3; BEWLEY TH, 1968, BRIT MED J, V1, P725, DOI 10.1136/bmj.1.5594.725; BUCKNALL ABV, 1986, J ROY COLL GEN PRACT, V36, P120; CHAPPLE PAL, 1972, BRIT J ADDICT, V67, P33; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; NEWMAN RG, 1988, NEW ENGL J MED, V318, P386; ROBERTSON JR, 1988, BRIT J ADDICT, V83, P387; ROBINS LN, 1993, ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x; RONALD PJM, 1993, BRIT MED J, V307, P1184, DOI 10.1136/bmj.307.6913.1184; RONALD PJM, 1992, BRIT J ADDICT, V87, P115; SELWYN PA, 1993, ANN INTERN MED, V119, P1044, DOI 10.7326/0003-4819-119-10-199311150-00013; SKIDMORE CA, 1989, BRIT J ADDICT, V84, P695; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; STIMSON GV, 1978, BRIT MED J, V1, P1190, DOI 10.1136/bmj.1.6121.1190; VALLAINT GE, 1973, ARCH GEN PSYCHIAT, V29, P237; WALDORF D, 1979, J DRUG ISSUES, V9, P281, DOI 10.1177/002204267900900212; 1989, AIDS DRUGS MISUSE 2; 1985, MISUSE DRUGS SPECIAL; 1988, LANCET, V2, P1039; 1984, GUIDELINES GOOD CLIN; 1993, AIDS DRUGS MISUSE UP; 1992, GUIDELINES GOOD CLIN	24	46	46	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					369	372		10.1136/bmj.309.6951.369	http://dx.doi.org/10.1136/bmj.309.6951.369			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB316	8081134	Green Published			2022-12-28	WOS:A1994PB31600016
J	STRAIN, EC; MUMFORD, GK; SILVERMAN, K; GRIFFITHS, RR				STRAIN, EC; MUMFORD, GK; SILVERMAN, K; GRIFFITHS, RR			CAFFEINE DEPENDENCE SYNDROME - EVIDENCE FROM CASE-HISTORIES AND EXPERIMENTAL EVALUATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAJOR DEPRESSION; PHYSICAL-DEPENDENCE; NORMAL VOLUNTEERS; DISCRIMINATION; HUMANS; WITHDRAWAL; CESSATION; NICOTINE; SMOKING	Objective.-The extent to which daily caffeine use is associated with a substance dependence syndrome similar to that associated with other psychoactive drugs is unknown. The purpose of this study was to assess volunteers who reported problems with their use of caffeine for evidence suggesting a diagnosis of caffeine dependence based on the generic criteria for substance dependence from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Design.-Case-series evaluations. Setting.-An academic research center. Participants.-Self-identified adults who believed they were psychologically or physically dependent on caffeine. Main Outcome Measure.-Diagnoses made by a psychiatrist using a structured clinical interview that included a section on caffeine dependence based on generic criteria for DSM-IV substance dependence. Secondary Outcome Measure.-Double-blind caffeine-withdrawal evaluation. Results.-Ninety-nine subjects were screened for the study, and 16 were identified as having a diagnosis of caffeine dependence. Median daily caffeine intake was 357 mg, and 19% of subjects consumed less than the national (US) daily average of caffeine. Criteria used for making diagnoses (and rates of their prevalence) were as follows: withdrawal (94%), use continued despite knowledge of a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by caffeine use (94%), persistent desire or unsuccessful efforts to cut down or control use (81%), and tolerance (75%). Eleven subjects underwent the double-blind caffeine-withdrawal evaluation portion of the study, and nine (82%) of the 11 showed objective evidence of caffeine withdrawal, including eight of 11 with functional impairment. Conclusions.-These results, together with other experimental evidence, suggest that caffeine exhibits the features of a typical psychoactive substance of dependence. It is valuable to recognize caffeine dependence as a clinical syndrome, since some people feel compelled to continue caffeine use despite desires and recommendations to the contrary.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University			/ABG-5735-2021	Silverman, Kenneth/0000-0003-2724-1413	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003890, K20DA000166] Funding Source: NIH RePORTER; NIDA NIH HHS [K20 DA 00166, R01 DA 03890] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1971, EITS MANUAL PROFILE; Barone JJ, 1984, CAFFEINE PERSPECTIVE, P59, DOI 10.1007/978-3-642-69823-1_4; Beck A.T., 1987, BECK DEPRESSION INVE; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BRESLAU N, 1993, ARCH GEN PSYCHIAT, V50, P31; CHAIT LD, 1992, BEHAV PHARMACOL, V3, P219; EVANS SM, 1991, BEHAV PHARMACOL, V2, P345; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; GRAHAM DM, 1978, NUTR REV, V36, P97, DOI 10.1111/j.1753-4887.1978.tb03717.x; Graham H N, 1984, Prog Clin Biol Res, V158, P29; GREDEN JF, 1992, SUBSTANCE ABUSE COMP, P357; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V255, P1123; GRIFFITHS RR, 1988, PSYCHOPHARMACOLOGY, V94, P437, DOI 10.1007/BF00212836; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V252, P970; GRIFFITHS RR, 1988, J PHARMACOL EXP THER, V246, P21; GRIFFITHS RR, PSYCHOPHARMACOLOGY 4; HUGHES JR, 1992, AM J PSYCHIAT, V149, P33; Hughes JR, 1993, NIDA RES MONOGR, V132, P194; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; JAMES JE, 1991, CAFFEINE HLTH; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KOZLOWSKI LT, 1993, J SUBST ABUSE TREAT, V10, P171, DOI 10.1016/0740-5472(93)90042-Z; SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601; SILVERMAN K, 1992, J EXP ANAL BEHAV, V57, P91, DOI 10.1901/jeab.1992.57-91; Spitzer R., 1985, STRUCTURED CLIN INTE; Yesair D W, 1984, Prog Clin Biol Res, V158, P215; 1987, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC	30	124	128	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1043	1048		10.1001/jama.272.13.1043	http://dx.doi.org/10.1001/jama.272.13.1043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089887				2022-12-28	WOS:A1994PH77500030
J	BRENT, GA				BRENT, GA			THE MOLECULAR-BASIS OF THYROID-HORMONE ACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MESSENGER-RIBONUCLEIC-ACID; PITUITARY-TUMOR CELLS; GENE-EXPRESSION; GENERALIZED RESISTANCE; BINDING-CAPACITY; RESPONSE ELEMENT; RECEPTOR GENE; GROWTH; RAT; TRIIODOTHYRONINE		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	BRENT, GA (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV THYROID,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043714, R01DK044128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43714, DK-44128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MJ, 1992, ENDOCR REV, V13, P207, DOI 10.1210/er.13.2.207; BIANCO AC, 1992, ENDOCRINOLOGY, V130, P2625, DOI 10.1210/en.130.5.2625; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CHATTERJEE VKK, 1992, CANCER SURV, V14, P147; CHERNAUSEK SD, 1989, J PEDIATR-US, V114, P968, DOI 10.1016/S0022-3476(89)80439-1; CHILDS GV, 1992, ENDOCRINOLOGY, V131, P310; CHILDS GV, 1991, ENDOCRINOLOGY, V129, P2767, DOI 10.1210/endo-129-5-2767; CHIN WW, 1993, RECENT PROG HORM RES, V48, P393; CHOMCZYNSKI P, 1993, J CLIN ENDOCR METAB, V77, P281, DOI 10.1210/jc.77.1.281; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HAUSER P, 1993, NEW ENGL J MED, V328, P997, DOI 10.1056/NEJM199304083281403; HAYASHI Y, 1993, J CLIN ENDOCR METAB, V76, P64, DOI 10.1210/jc.76.1.64; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HOOGWERF BJ, 1984, AM J MED, V76, P963, DOI 10.1016/0002-9343(84)90842-8; ISAACS RE, 1987, MOL ENDOCRINOL, V1, P569, DOI 10.1210/mend-1-8-569; ISMAILBEIGI F, 1992, SEMIN NEPHROL, V12, P44; JAMESON JL, 1992, J CLIN ENDOCR METAB, V74, P708, DOI 10.1210/jc.74.4.708; KATZ D, 1993, J BIOL CHEM, V268, P20904; KLEIN I, 1992, J CLIN INVEST, V89, P68, DOI 10.1172/JCI115587; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LADENSON PW, 1992, P NATL ACAD SCI USA, V89, P5251, DOI 10.1073/pnas.89.12.5251; LADENSON PW, 1992, P NATL ACAD SCI USA, V89, P8856; Larsen PR, 1992, WILLIAMS TXB ENDOCRI, P357; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; MACKERROW SD, 1992, ANN INTERN MED, V117, P1014, DOI 10.7326/0003-4819-117-12-1014; MIELL JP, 1993, J CLIN ENDOCR METAB, V76, P950, DOI 10.1210/jc.76.4.950; MIXSON AJ, 1993, J CLIN INVEST, V91, P2296, DOI 10.1172/JCI116458; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; NORMAN MF, 1989, J CLIN INVEST, V83, P306, DOI 10.1172/JCI113874; NOVITZKY D, 1989, J THORAC CARDIOV SUR, V98, P972; OJAMAA K, 1993, ANN THORAC SURG, V56, pS61, DOI 10.1016/0003-4975(93)90556-W; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; OPPENHEIMER JH, 1991, J CLIN INVEST, V87, P125, DOI 10.1172/JCI114961; PACKARD CJ, 1993, J CLIN ENDOCR METAB, V76, P1209, DOI 10.1210/jc.76.5.1209; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; RIVKEES SA, 1988, NEW ENGL J MED, V318, P599, DOI 10.1056/NEJM198803103181003; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; TAGAMI T, 1993, ENDOCRINOLOGY, V132, P275, DOI 10.1210/en.132.1.275; VALCAVI R, 1992, J ENDOCRINOL INVEST, V15, P313, DOI 10.1007/BF03348744; WILLIAMS GR, 1989, LANCET, V2, P1477; WISEMAN SA, 1993, J CLIN ENDOCR METAB, V77, P108, DOI 10.1210/jc.77.1.108; WOEBER KA, 1992, NEW ENGL J MED, V327, P94; YEN PM, 1992, J BIOL CHEM, V267, P3565; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	61	325	350	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					847	853						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078532				2022-12-28	WOS:A1994PH53000006
J	TINETTI, ME; BAKER, DI; MCAVAY, G; CLAUS, EB; GARRETT, P; GOTTSCHALK, M; KOCH, ML; TRAINOR, K; HORWITZ, RI				TINETTI, ME; BAKER, DI; MCAVAY, G; CLAUS, EB; GARRETT, P; GOTTSCHALK, M; KOCH, ML; TRAINOR, K; HORWITZ, RI			A MULTIFACTORIAL INTERVENTION TO REDUCE THE RISK OF FALLING AMONG ELDERLY PEOPLE LIVING IN THE COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SLEEP DISORDERS; OLDER PERSONS; HEALTH-STATUS; PREVENTION; POPULATION; GERIATRICS; ADULTS; FICSIT; HOME	Background. Since falling is associated with serious morbidity among elderly people, we investigated whether the risk of falling could be reduced by modifying known risk factors. Methods. We studied 301 men and women living in the community who were at least 70 years of age and who had at least one of the following risk factors for falling: postural hypotension; use of sedatives; use of at least four prescription medications; and impairment in arm or leg strength or range of motion, balance, ability to move safely from bed to chair or to the bathtub or toilet (transfer skills), or gait. These subjects were given either a combination of adjustment in their medications, behavioral instructions, and exercise programs aimed at modifying their risk factors (intervention group, 153 subjects) or usual health care plus social visits (control group, 148 subjects). Results. During one year of follow-up, 35 percent of the intervention group fell, as compared with 47 percent of the control group (P = 0.04). The adjusted incidence-rate ratio for falling in the intervention group as compared with the control group was 0.69 (95 percent confidence interval, 0.52 to 0.90). Among the subjects who had a particular risk factor at base line, a smaller percentage of those in the intervention group than of those in the control group still had the risk factor at the time of reassessment, as follows: at least four prescription medications, 63 percent versus 86 percent, P = 0.009; balance impairment, 21 percent versus 46 percent, P = 0.001;impairment in toilet-transfer skills, 49 percent versus 65 percent, P = 0.05; and gait impairment, 45 percent versus 62 percent, P = 0.07. Conclusions. The multiple-risk-factor intervention strategy resulted in a significant reduction in the risk of falling among elderly persons in the community. In addition, the proportion of persons who had the targeted risk factors for falling was reduced in the intervention group, as compared with the control group. Thus, risk-factor modification may partially explain the reduction in the risk of falling.	YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH NURSING, NEW HAVEN, CT 06536 USA; YALE NEW HAVEN MED CTR, DEPT REHABIL SERV, NEW HAVEN, CT 06504 USA; QUINNIPIAC COLL, DEPT PHYS THERAPY, HAMDEN, CT 06518 USA	Yale University; Yale University; Yale University; Yale University; Quinnipiac University					NATIONAL INSTITUTE ON AGING [U01AG009087] Funding Source: NIH RePORTER; NIA NIH HHS [UO1 AG09087] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BAKER RJ, 1979, GLIM SYSTEM; BERG RL, 1990, 2 50 YEARS PROMOTING, P263; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; COVINGTON DL, 1993, J AM GERIATR SOC, V41, P847, DOI 10.1111/j.1532-5415.1993.tb06182.x; DUNN JE, 1992, AM J PUBLIC HEALTH, V82, P395, DOI 10.2105/AJPH.82.3.395; Edgington E. S., 1980, RANDOMIZATION TESTS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOTTLIEB GL, 1990, AM J MED, V88, pS29, DOI 10.1016/0002-9343(90)90283-J; HOPPENFELD S, 1976, PHYSICAL EXAMINATION; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; Hosmer DW, 1989, APPL LOGISTIC REGRES, P238; KIEL DP, 1991, MED CARE, V29, P221; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOCH M, 1994, PHYS THER, V74, P286, DOI 10.1093/ptj/74.4.286; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LIPSITZ LA, 1989, NEW ENGL J MED, V321, P952; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MERRIAM SB, 1989, GERONTOLOGIST, V29, P761, DOI 10.1093/geront/29.6.761; NEUFELD RR, 1991, GERONTOLOGIST, V31, P120, DOI 10.1093/geront/31.1.120; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PRINZ PN, 1990, NEW ENGL J MED, V323, P520; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SATTIN RW, 1992, ANNU REV PUBL HEALTH, V13, P489, DOI 10.1146/annurev.pu.13.050192.002421; SPIELMAN AJ, 1987, SLEEP, V10, P45; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1993, J AM GERIATR SOC, V41, P315, DOI 10.1111/j.1532-5415.1993.tb06710.x; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WOLFKLEIN GP, 1988, ARCH PHYS MED REHAB, V69, P689; WOLINSKY FD, 1992, MED CARE, V30, P587, DOI 10.1097/00005650-199207000-00002; 1990, DHHS PHS9150213 PUBL; [No title captured]; 1988, SAS STAT USERS GUIDE	44	1414	1444	2	167	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					821	827		10.1056/NEJM199409293311301	http://dx.doi.org/10.1056/NEJM199409293311301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078528				2022-12-28	WOS:A1994PH53000001
J	SINGH, N; STEMPEL, K				SINGH, N; STEMPEL, K			BRAIN HERNIATION IN TOXOPLASMOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SINGH, N (corresponding author), VET AFFAIRS MED CTR,PITTSBURGH,PA 15240, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					711	711						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058078				2022-12-28	WOS:A1994PF33200005
J	TSAI, FY; KELLER, G; KUO, FC; WEISS, M; CHEN, JZ; ROSENBLATT, M; ALT, FW; ORKIN, SH				TSAI, FY; KELLER, G; KUO, FC; WEISS, M; CHEN, JZ; ROSENBLATT, M; ALT, FW; ORKIN, SH			AN EARLY HEMATOPOIETIC DEFECT IN MICE LACKING THE TRANSCRIPTION FACTOR GATA-2	NATURE			English	Article							EMBRYONIC STEM-CELLS; ERYTHROID-DIFFERENTIATION; TARGETED MUTATION; DEVELOPING MOUSE; DNA-BINDING; YOLK-SAC; ES CELLS; EXPRESSION; GENE; HEMATOPOIESIS	Blood cell development relies on the expansion and maintenance of haematopoietic stem and progenitor cells in the embryo. By gene targeting in mouse embryonic stem cells, we demonstrate that the transcription factor GATA-2 plays a critical role in haematopoiesis, particularly of an adult type. We propose that GATA-2 regulates genes controlling growth factor responsiveness or the proliferative capacity of early haematopoietic cells.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR BLOOD RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; National Jewish Health			Weiss, Mitchell J/W-9814-2018	Weiss, Mitchell J/0000-0003-2460-3036; Keller, Gordon/0000-0001-9309-9297				BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GEISSLER EN, 1981, GENETICS, V97, P337; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER G, 1993, MOL CELL BIOL, V13, P472; KELLEY C, IN PRESS DEV BIOL; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEONARD M, 1993, BLOOD, V82, P1071; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUSSELL ES, 1968, GENETICS, V58, P259; RUSSELL ES, 1979, ADV GENET, V20, P358; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VISVADER J, 1993, BLOOD, V82, P1493; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	39	1158	1185	4	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					221	226		10.1038/371221a0	http://dx.doi.org/10.1038/371221a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078582				2022-12-28	WOS:A1994PG29000043
J	SMITH, T				SMITH, T			WAITING-TIMES - MONITORING THE TOTAL POSTREFERRAL WAIT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine whether the period spent on the true inpatient waiting list is a valid indication of the total time that patients have to wait for an operation; and to assess the feasibility of monitoring the total ''postreferral waiting time'' by using existing computerised information systems. Setting-Three randomly selected Scottish hospitals. Subjects-Waiting list patients admitted to hospital for operations during June to August 1993 in six major specialties, separate attention being focused on cataract operations and hip and knee replacements. Main outcome measure-The total time that patients have to wait for an operation after the initial general practitioner referral-the postreferral waiting time-compared with that spent at the final stage of the process on the true inpatient waiting list. Results-In the specialties investigated roughly half (58 days; 53%) of the average postreferral wait of 110 days was spent on the true inpatient waiting list, one third (35 days; 32%) being spent on the outpatient waiting list and one sixth (17 days; 15%) waiting between waiting lists. Only: a quarter of cataract patients (73/292) were treated within three months of general practitioner referral compared with over three quarters (228/292) within three months of being placed on the inpatient waiting list. Nevertheless, within a year over 99% of patients (290) had been treated whichever date was taken as the starting point. Conclusions-Monitoring postreferral waiting times would provide a much more accurate picture for purchasers and patients of waiting times for treatment than is obtained by focusing exclusively on the true inpatient waiting list and facilitate fairer comparisons between NHS trusts in national league tables. Stringent national and local monitoring is essential to ensure (a) that future reductions in the time waiting on true inpatient waiting lists are not gained at the expense of longer periods waiting to be placed on the lists, and (b) that no increases occur in the number of patients placed instead on deferred waiting lists or exempted from the normal maximum waiting time guarantees.	TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND									GERMAN K, 1993, BRIT MED J, V306, P429, DOI 10.1136/bmj.306.6875.429; Smith Trevor, 1993, Health Bulletin (Edinburgh), V51, P299; 1993, NHS PATIENT TREATMEN; 1994, HOSPITAL WAITING LIS; 1991, DEFINITIONS CODES NH; 1991, PATIENTS CHARTER CHA	6	23	23	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					593	596		10.1136/bmj.309.6954.593	http://dx.doi.org/10.1136/bmj.309.6954.593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086952	Green Published			2022-12-28	WOS:A1994PF33000031
J	ANG, SL; ROSSANT, J				ANG, SL; ROSSANT, J			HNF-3-BETA IS ESSENTIAL FOR NODE AND NOTOCHORD FORMATION IN MOUSE DEVELOPMENT	CELL			English	Article							DEVELOPING NERVOUS-SYSTEM; EMBRYONIC STEM-CELLS; GERM LAYER FORMATION; GENE FORK-HEAD; FLOOR PLATE; CHICK-EMBRYO; NEURAL INDUCTION; XENOPUS-LAEVIS; FROG EMBRYOS; PATTERN-FORMATION	HNF-3 beta, a member of the HNF-3/fork head family of transcription factors, is expressed in the node, notochord, floor plate, and gut in mouse embryos. A null mutation of this gene leads to embryonic lethality. The primary defect of HNF-3 beta(-/-) embryos is an absence of organized node and notochord formation, which leads to secondary defects in dorsal-ventral patterning of the neural tube. In contrast, patterning along the anterior-posterior axis was surprisingly little affected. Although HNF-3 beta is required for node and notochord formation, some organizer activity persists in the absence of these structures. HNF-3 beta is not required for the development of definitive endoderm cells, but foregut morphogenesis is severely affected in HNF-3 beta(-/-)embryos.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1993, DEVELOPMENT, V119, P1301; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BEDDINGTON RSP, 1989, DEVELOPMENT, V116, P357; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DIAS MS, 1990, ANAT REC, V229, P437; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JONES EA, 1989, DEVELOPMENT, V107, P785; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAI E, 1990, GENE DEV, V4, P1426; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHOENWOLF GC, 1992, DEV DYNAM, V193, P235, DOI 10.1002/aja.1001930304; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SELLECK MAJ, 1992, DEVELOPMENT, V114, P403; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STOREY KG, 1992, DEVELOPMENT, V114, P729; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; Waddington CH, 1933, J EXP BIOL, V10, P38; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WURST W, 1993, GENE TARGETING PRACT, P31; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	68	857	877	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					561	574		10.1016/0092-8674(94)90522-3	http://dx.doi.org/10.1016/0092-8674(94)90522-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069909				2022-12-28	WOS:A1994PD69300006
J	DERRY, JMJ; OCHS, HD; FRANCKE, U				DERRY, JMJ; OCHS, HD; FRANCKE, U			ISOLATION OF A NOVEL GENE MUTATED IN WISKOTT-ALDRICH SYNDROME	CELL			English	Article							HUMAN X-CHROMOSOME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; TRANSCRIPTION FACTOR; FUNCTIONAL DISSECTION; CELL LINEAGES; EXPRESSION; REGION; IDENTIFICATION; SEQUENCES; PROTEIN	Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency characterized by eczema, thrombocytopenia, and recurrent infections. Linkage studies have placed the gene at Xp11.22-p11.23. We have isolated from this interval a novel gene, WASP, which is expressed in lymphocytes, spleen, and thymus. The gene is not expressed in two unrelated WAS patients, one of whom has a single base deletion that produces a frame shift and premature termination of translation. Two additional patients have been identified with point mutations that change the same arginine residue to either a histidine or a leucine. WASP encodes a 501 amino acid proline-rich protein that is likely to be a key regulator of lymphocyte and platelet function.	STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT PEDIAT, STANFORD, CA 94305 USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA	Stanford University; Stanford University; University of Washington; University of Washington Seattle	DERRY, JMJ (corresponding author), STANFORD UNIV, MED CTR, BECKMAN CTR MOLEC & GENET MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.							Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; BASILE GD, 1989, LANCET, V2, P1319; BROCHSTEIN JA, 1991, J PEDIATR-US, V119, P907, DOI 10.1016/S0022-3476(05)83041-0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Creighton T. E., 1984, PROTEINS, P242; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DONNER M, 1988, BLOOD, V72, P1849; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEARON ER, 1988, BLOOD, V72, P1735; GEALY WJ, 1980, LANCET, V1, P63; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Goodship J., 1991, J PEDIATR, V119, P907; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GREER WL, 1989, GENOMICS, V4, P60, DOI 10.1016/0888-7543(89)90315-7; GREER WL, 1989, BIOCHEM CELL BIOL, V67, P503, DOI 10.1139/o89-081; GREER WL, 1990, GENOMICS, V6, P568, DOI 10.1016/0888-7543(90)90489-H; GREER WL, 1992, HUM GENET, V88, P453, DOI 10.1007/BF00215681; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KWAN S-P, 1988, Genomics, V3, P39, DOI 10.1016/0888-7543(88)90156-5; KWAN SP, 1991, GENOMICS, V10, P29, DOI 10.1016/0888-7543(91)90480-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAJERUS PW, 1987, MOL BASIS BLOOD DISE, P689; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; Nizetle D., 1991, BLOOD, V77, P2677; NOTARANGELO LD, 1991, HUM GENET, V88, P237; OCHS HD, 1980, BLOOD, V55, P243; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; PEACOCKE M, 1987, P NATL ACAD SCI USA, V84, P3430, DOI 10.1073/pnas.84.10.3430; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; RAMBALDI I, 1994, NUCLEIC ACIDS RES, V22, P376, DOI 10.1093/nar/22.3.376; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1987, BLOOD, V70, P104; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHLESSINGER D, 1993, CYTOGENET CELL GENET, V64, P147, DOI 10.1159/000133572; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; STANDEN GR, 1986, Q J MED, V59, P401; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	56	738	772	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					635	644		10.1016/0092-8674(94)90528-2	http://dx.doi.org/10.1016/0092-8674(94)90528-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069912				2022-12-28	WOS:A1994PD69300012
J	MOSCICKI, RA; SANMARTIN, JE; QUINTERO, CH; RAUCH, SD; NADOL, JB; BLOCH, KJ				MOSCICKI, RA; SANMARTIN, JE; QUINTERO, CH; RAUCH, SD; NADOL, JB; BLOCH, KJ			SERUM ANTIBODY TO INNER-EAR PROTEINS IN PATIENTS WITH PROGRESSIVE HEARING-LOSS - CORRELATION WITH DISEASE-ACTIVITY AND RESPONSE TO CORTICOSTEROID TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOANTIBODIES; TESTS	Objective.-To test whether detection of serum antibody to a 68-kd inner ear protein distinguishes among different causes of sensorineural hearing loss, and identifies patients with active disease and those likely to respond to corticosteroid therapy. Design.-Serum samples were tested by Western blot using bovine inner ear extract as antigen, and results were correlated with patient information obtained by chart review. Setting.-Referral center. Subjects of Study.-Serum samples were obtained from patients with idiopathic, progressive, bilateral sensorineural hearing loss (IPBSNHL) (n=72) otosclerosis (n=11), Cogan's syndrome (n=8), patients with positive tests for antinuclear antibodies (n=10), and normal controls (n=53). Main Outcome Measure.-Detection of serum antibody to a 68-kd inner eat protein. Results.-Serum from 42 of 72 patients with IPBSNHL reacted with a 68-kd protein constituent of inner ear extract. This reactivity was not detected in serum from 11 of 11 patients with otosclerosis, or in eight of eight with Cogan's syndrome. It was found in serum from one of 10 patients with a positive test for antinuclear antibody and in one of 53 normal controls. Antibody to the 68-kd protein was detected in serum from 89% of patients with actively progressing IPBSNHL and none of the 25 patients with inactive disease (P<.001). Patients who were antibody-positive responded to steroid treatment more frequently than did those who were antibody-negative (P<.001). Conclusions.-These results indicate that the presence of circulating antibody to a 68-kd constituent of bovine inner ear extract serves as a marker for IPBSNHL and that its presence correlates with disease activity and responsiveness to corticosteroid treatment.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT OTOL & LARYNGOL,BOSTON,MA 02115; MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA; MASSACHUSETTS GEN HOSP,ALLERGY UNIT,GEN MED SERV,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts General Hospital	MOSCICKI, RA (corresponding author), MASSACHUSETTS GEN HOSP,CLIN IMMUNOL UNIT,32 FRUIT ST,BULLFINCH 422,BOSTON,MA 02114, USA.				NIDCD NIH HHS [DC00824] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000824] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ARNOLD W, 1987, ACTA OTO-LARYNGOL, V103, P373; ARNOLD W, 1985, ACTA OTO-LARYNGOL, V99, P437, DOI 10.3109/00016488509108935; BARNETTE WN, 1981, ANAL BIOCHEM, V112, P195; HARRIS JP, 1990, LARYNGOSCOPE, V100, P516; HUGHES GB, 1986, LARYNGOSCOPE, V96, P502, DOI 10.1288/00005537-198605000-00006; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; HUGHES GB, 1991, ADV OTO-RHINO-LARYNG, V46, P82; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCABE BF, 1984, AM J OTOL, V5, P447; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; RAFFIN MJM, 1980, J SPEECH HEAR RES, V23, P5, DOI 10.1044/jshr.2301.05; RAUCH SD, 1992, ANN OTO RHINOL LARYN, V101, P688; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; YAMANOBE S, 1993, LARYNGOSCOPE, V103, P319, DOI 10.1288/00005537-199303000-00013; YAMANOBE S, 1993, ANN OTO RHINOL LARYN, V102, P22, DOI 10.1177/000348949310200105; Zar JH., 1999, BIOSTAT ANAL	18	158	163	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					611	616		10.1001/jama.272.8.611	http://dx.doi.org/10.1001/jama.272.8.611			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057517				2022-12-28	WOS:A1994PC39800031
J	MICHAELS, JA; GALLAND, RB; MORRIS, PJ				MICHAELS, JA; GALLAND, RB; MORRIS, PJ			ORGANIZATION OF VASCULAR SURGICAL SERVICES - EVOLUTION OR REVOLUTION	BRITISH MEDICAL JOURNAL			English	Article								The trend towards subspecialisation in hospital services is likely to lead to the development of vascular surgery as a separate specialty. If vascular surgery is to emerge as a high quality service then vascular emergencies-a substantial component of the workload-should be dealt with by surgeons with adequate training, and all patients should have equal access to the service. A specialist vascular surgical unit would have to be large enough to make efficient use of other services that it needs, such as radiology, and so may require the amalgamation of smaller health district units. Because of the differing local degrees of subspecialisation, national or regional strategies for vascular surgery must be developed.	ROYAL BERKSHIRE HOSP,READING RG1 5AN,BERKS,ENGLAND	Royal Berkshire Hospital	MICHAELS, JA (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.							BEARD JD, 1993, BRIT J SURG, V80, P185, DOI 10.1002/bjs.1800800216; CLASON AE, 1989, BRIT J SURG, V76, P592, DOI 10.1002/bjs.1800760621; Darke S G, 1987, Eur J Vasc Surg, V1, P217, DOI 10.1016/S0950-821X(87)80070-1; JOHNSON CE, 1990, INT STUD PHILOS, V22, P37, DOI 10.5840/intstudphil199022175; MICHAELS JA, 1991, BRIT J SURG, V78, P1271, DOI 10.1002/bjs.1800781040; MICHAELS JA, 1994, BRIT J SURG, V81, P377, DOI 10.1002/bjs.1800810318; OUNEL K, 1990, J VASC SURGERY, V11, P493; RUCKLEY CV, 1988, BRIT MED J, V297, P577	8	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					387	388		10.1136/bmj.309.6951.387	http://dx.doi.org/10.1136/bmj.309.6951.387			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081143	Green Published			2022-12-28	WOS:A1994PB31600026
J	OETTGEN, HC; MARTIN, TR; WYNSHAWBORIS, A; DENG, CX; DRAZEN, JM; LEDER, P				OETTGEN, HC; MARTIN, TR; WYNSHAWBORIS, A; DENG, CX; DRAZEN, JM; LEDER, P			ACTIVE ANAPHYLAXIS IN IGE-DEFICIENT MICE	NATURE			English	Article							PERTUSSIGEN PERTUSSIS TOXIN; IMMUNOGLOBULIN HEAVY-CHAIN; MAST-CELLS; CUTANEOUS ANAPHYLAXIS; HISTAMINE-RELEASE; MOUSE; LYMPHOCYTES; LETHALITY; MUTATION; ANTIGEN	The IgE-triggered release of mast cell mediators in response to antigen is thought to be the primary event in immediate hypersensitivity reactions such as systemic anaphylaxis(1). Although mast cells and basophils can be activated in vitro by non-IgE stimuli(2-5), it is not known whether these triggers lead to physiological changes in vivo. To investigate this possibility, we generated mice with a homozygous null mutation of the CE gene. Such mice make no IgE, but produce other immunoglobulin isotypes normally. We report that despite the IgE deficiency, sensitized mutant mice become anaphylactic on antigen challenge and display tachycardia and pulmonary function changes similar to those seen in wildtype animals. These responses are accompanied by vascular leak, sharply elevated plasma histamine and rapid death. IgE-independent anaphylaxis does not depend on complement activation, but, as indicated in studies using genetically immunodeficient RAG-2(-) and SCID mice, does require a functional immune system. Such results clearly demonstrate that non-IgE pathways for hypersensitivity reactions exist in mice.	CHILDRENS HOSP,DEPT PEDIAT,INA SUE PERLMUTTER LAB,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital	OETTGEN, HC (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.		deng, chuxia/N-6713-2016; Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890				ARIMURA A, 1990, IMMUNOL INVEST, V19, P227, DOI 10.3109/08820139009041837; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLAUSEN C R, 1970, Journal of Immunology, V104, P312; DAERON M, 1982, CELL IMMUNOL, V70, P27, DOI 10.1016/0008-8749(82)90130-7; DOMBROWICZ D, 1993, CELL, V75, P979; FOX PC, 1982, J IMMUNOL, V129, P314; HOOK WA, 1975, J IMMUNOL, V114, P1185; INAGAKI N, 1992, JPN J PHARMACOL, V59, P201, DOI 10.1254/jjp.59.201; KATZ HR, 1992, J IMMUNOL, V148, P868; KLERX JPAM, 1983, J IMMUNOL METHODS, V63, P215, DOI 10.1016/0022-1759(83)90425-8; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIN TR, 1993, J IMMUNOL, V151, P367; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; MUNOZ JJ, 1987, INFECT IMMUN, V55, P1004, DOI 10.1128/IAI.55.4.1004-1008.1987; NUSSENZWEIG RS, 1964, J EXP MED, V120, P315, DOI 10.1084/jem.120.2.315; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; Rothman P, 1989, Semin Immunol, V1, P65; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SHIMIZU A, 1981, NATURE, V289, P149, DOI 10.1038/289149a0; SILVERS WS, 1992, ANN ALLERGY, V68, P58; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUN SJ, 1992, J LAB CLIN MED, V120, P589; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBERG CW, 1991, J IMMUNOL METHODS, V136, P287, DOI 10.1016/0022-1759(91)90015-8; VAZ E M, 1970, International Archives of Allergy and Applied Immunology, V39, P459	30	337	348	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					367	370		10.1038/370367a0	http://dx.doi.org/10.1038/370367a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047141				2022-12-28	WOS:A1994PA30400054
J	STEMMER, WPC				STEMMER, WPC			RAPID EVOLUTION OF A PROTEIN IN-VITRO BY DNA SHUFFLING	NATURE			English	Article							SEARCHING SEQUENCE SPACE; SPECTRUM BETA-LACTAMASES; MOLECULAR EVOLUTION; ENSEMBLE MUTAGENESIS	DNA shuffling is a method for in vitro homologous recombination of pools of selected mutant genes by random fragmentation and polymerase chain reaction (PCR) reassembly(1). Computer simulations called genetic algorithms(2-4) have demonstrated the importance of iterative homologous recombination for sequence evolution. Oligonucleotide cassette mutagenesis(5-11) and error-prone PCR are not combinatorial and thus are limited in searching sequence space(1,14). We have tested mutagenic DNA shuffling for molecular evolution(14-18) in a beta-lactamase model system(9,19). Three cycles of shuffling and two cycles of backcrossing with wild-type DNA, to eliminate non-essential mutations, were each followed by selection on increasing concentrations of the antibiotic cefotaxime. We report here that selected mutants had a minimum inhibitory concentration of 640 mu g ml(-1), a 32,000-fold increase and 64-fold greater than any published TEM-1 derived enzyme. Cassette mutagenesis and error-prone PCR resulted in only a 16-fold increase(9).			STEMMER, WPC (corresponding author), AFFYMAX RES INST,4001 MIRANDA AVE,PALO ALTO,CA 94304, USA.		Wood, David W/B-2992-2012					AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; ARKIN AP, 1992, P NATL ACAD SCI USA, V89, P7811, DOI 10.1073/pnas.89.16.7811; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; DELAGRAVE S, 1993, BIO-TECHNOL, V11, P1548, DOI 10.1038/nbt1293-1548; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; HOLLAND JH, 1992, SCI AM, V267, P66, DOI 10.1038/scientificamerican0792-66; HOLLAND JH, 1992, ADAPTATION NATURAL A; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kauffman S. A., 1993, ORIGINS ORDER; KAUFFMAN SA, 1992, J THEOR BIOL, V157, P1, DOI 10.1016/S0022-5193(05)80753-2; Leung DW, 1989, TECHNIQUE, V1, P11; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; STEMMER WPC, IN PRESS P NATN ACAD; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WATSON N, 1988, GENE, V70, P399, DOI 10.1016/0378-1119(88)90212-0; [No title captured]	22	1457	2415	18	358	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					389	391		10.1038/370389a0	http://dx.doi.org/10.1038/370389a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047147				2022-12-28	WOS:A1994PA30400061
J	LUCAS, A; MORLEY, R				LUCAS, A; MORLEY, R			DOES EARLY NUTRITION IN INFANTS BORN BEFORE TERM PROGRAM LATER BLOOD-PRESSURE	BRITISH MEDICAL JOURNAL			English	Article							PRETERM INFANTS; CARDIOVASCULAR-DISEASE; ADULT LIFE; EARLY DIET; GROWTH; CHILDHOOD; INUTERO	Objectives-To test whether nutrition early in infants' development programmes later blood pressure and whether the reported relation between low birth weight and later high blood pressure is due to poor nutrition or growth before full term. Design-Prospective randomisation of preterm infants to early diets differing greatly in nutrient content in four parallel multicentre trials, with blinded follow up 7.5-8 years later. Setting-Neonatal units at Cambridge, Ipswich, King's Lynn, Norwich, and Sheffield. Subjects-758 children weighing under 1850 g at birth. Main outcome measure-Blood pressure at age of 7.5-8 years. Results-There were major differences in nutrient intake from randomised diets (preterm formula v standard formula and preterm formula v donor breast milk; in each case with or without mother's. milk), but follow up showed no differences in later blood pressure. Individual subjects showed large variation in protein and energy intakes and in growth performance, including degrees of growth failure seldom seen in utero, but these factors were also unrelated to later blood pressure. Conclusion-Extremes of nutritional intake and growth performance in preterm infants do not programme later blood pressure at 7.5-8 years of age. These findings do not support the hypothesis that high blood pressure has early nutritional origins. We suggest that the long term rise in blood pressure reported in individuals who had low birthweight (at full term) is not, as previously speculated, due to poor fetal nutrition or growth as such.			LUCAS, A (corresponding author), MRC,DUNN NUTR UNIT,DOWNHAMS LANE,CAMBRIDGE CB4 1XJ,ENGLAND.							BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1992, FETAL INFANT ORIGINS, P175; GAIRDNER D, 1971, ARCH DIS CHILD, V46, P783, DOI 10.1136/adc.46.250.783; HAHN P, 1989, ATHEROSCLEROSIS PEDI, P155; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEWIS DS, 1988, ARTERIOSCLEROSIS, V8, P274, DOI 10.1161/01.ATV.8.3.274; LUCAS A, 1989, ARCH DIS CHILD, V64, P1570, DOI 10.1136/adc.64.11.1570; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1991, CIBA F SYMP, V156, P38; LUCAS A, 1988, ARCH DIS CHILD, V63, P656, DOI 10.1136/adc.63.6.656; LUCAS A, 1986, EARLY HUM DEV, V13, P313, DOI 10.1016/0378-3782(86)90066-6; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; LUCAS A, 1992, TXB NEONATOLOGY, P279; MCCANCE RA, 1962, LANCET, V2, P621; MORLEY R, 1994, ARCH DIS CHILD, V70, P536, DOI 10.1136/adc.70.6.536; ROBERTS SB, 1985, EARLY HUM DEV, V12, P301, DOI 10.1016/0378-3782(85)90152-5; Spalding D.A., 1873, MACMILLANS MAGAZINE, V27, P282; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411; 1980, SOCIAL TRENDS, V10	24	73	75	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					304	308		10.1136/bmj.309.6950.304	http://dx.doi.org/10.1136/bmj.309.6950.304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086868	Green Published			2022-12-28	WOS:A1994PA37300018
J	SENIOR, PA; BHOPAL, R				SENIOR, PA; BHOPAL, R			ETHNICITY AS A VARIABLE IN EPIDEMIOLOGIC RESEARCH	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; HEALTH RESEARCH; BLOOD-PRESSURE; INDIAN DESCENT; ASIAN PATIENTS; SOUTH ASIANS; MINORITIES; LONDON; BIRMINGHAM	Ethnicity is used increasingly as a key variable to describe health data, and ethnic monitoring in the NHS will further stimulate this trend. We identify four fundamental problems with ethnicity in this type of research: the difficulties of measurement, the heterogeneity of the populations being studied, lack of clarity about the research purpose of the research, and ethnocentricity affecting the interpretation and use of data. Ethnicity needs to be used carefully to be a useful tool for health research. We make nine recommendations for future practice, one of which is that ethnicity and race should be recognised and treated as distinct concepts.	MED SCH NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK			Senior, Peter A/E-3031-2013; Senior, Peter/O-4934-2019	Senior, Peter A/0000-0003-1033-8673; Senior, Peter/0000-0003-1033-8673				AHMAD WIU, 1989, LANCET, V1, P148; Allen R.E., 1990, CONCISE OXFORD DICT; ALPER JS, 1992, BRIT MED J, V305, P666, DOI 10.1136/bmj.305.6855.666; [Anonymous], 1989, CHURCHILLS ILLUSTRAT; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BARKER RM, 1990, J EPIDEMIOL COMMUN H, V44, P125, DOI 10.1136/jech.44.2.125; BECKLES GLA, 1986, LANCET, V1, P1298; BEEVERS DG, 1981, POSTGRAD MED J, V57, P763, DOI 10.1136/pgmj.57.674.763; Bhopal R S, 1988, Health Educ J, V47, P137, DOI 10.1177/001789698804700411; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; BHOPAL RS, 1992, POLITICS RACE HLTH, P51; BHOPAL RS, IN PRESS ASSESSING H; BHOPAL RS, 1988, EQUITY PREREQUISITE; BOND J, 1986, SOCIOLOGY HLTH CARE; Coleman D. A., 1985, POPULATION TRENDS, V40, P4; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; CRUICKSHANK JK, 1989, ETHNIC FACTORS HLTH, P3; DEGIOVANNI JV, 1983, POSTGRAD MED J, V59, P627, DOI 10.1136/pgmj.59.696.627; DONALDSON LJ, 1983, BRIT MED J, V286, P949, DOI 10.1136/bmj.286.6369.949; DONOVAN JL, 1984, SOC SCI MED, V19, P663, DOI 10.1016/0277-9536(84)90237-5; ECOB R, 1991, J EPIDEMIOL COMMUN H, V45, P93, DOI 10.1136/jech.45.2.93; HAZUDA HP, 1988, AM J EPIDEMIOL, V128, P1289, DOI 10.1093/oxfordjournals.aje.a115082; HEATH I, 1991, BRIT J GEN PRACT, V41, P310; HILL AV, 1989, ETNIC FACTORS HLTH D, P25; JACKSON SHD, 1981, POSTGRAD MED J, V57, P777, DOI 10.1136/pgmj.57.674.777; JOHNSON MRD, 1984, J ROY COLL PHYS LOND, V18, P228; KHAW KT, 1983, POSTGRAD MED J, V59, P630, DOI 10.1136/pgmj.59.696.630; Last J., 1988, DICT EPIDEMIOLOGY; MADHOK R, 1992, J PUBLIC HEALTH MED, V14, P271; Marmot M. G., 1989, ETHNIC FACTORS HLTH, P12; Marmot MG, 1984, IMMIGRANT MORTALITY; Mausner J, 1985, EPIDEMIOLOGY INTRO T; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1982, LANCET, V2, P200; NICOLL A, 1986, J EPIDEMIOL COMMUN H, V40, P364, DOI 10.1136/jech.40.4.364; POTTER JF, 1984, J ROY COLL PHYS LOND, V18, P231; QURESHI B, 1990, HLTH CARE ASIANS, P117; RAMAIYA KL, 1991, BRIT MED J, V303, P271, DOI 10.1136/bmj.303.6797.271; SENIOR PA, 1992, THESIS U NEWCASTLE; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P104; TERRY PB, 1981, POSTGRAD MED J, V57, P790, DOI 10.1136/pgmj.57.674.790; WEBSTER J, 1989, ETHNIC FACTORS HLTH, P7; 1992, 1992 U LOND LOND SCH, P31; 1990, WORKING PATIENTS FRA, P57	49	362	366	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					327	330		10.1136/bmj.309.6950.327	http://dx.doi.org/10.1136/bmj.309.6950.327			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA373	8086873	Green Published			2022-12-28	WOS:A1994PA37300026
J	ROSENTHAL, N				ROSENTHAL, N			MOLECULAR MEDICINE - REGULATION OF GENE-EXPRESSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365					0	25	25	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					931	933		10.1056/NEJM199410063311408	http://dx.doi.org/10.1056/NEJM199410063311408			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078555				2022-12-28	WOS:A1994PJ41900008
J	GARG, A; GRUNDY, SM				GARG, A; GRUNDY, SM			CHOLESTYRAMINE THERAPY FOR DYSLIPIDEMIA IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A SHORT-TERM, DOUBLE-BLIND, CROSSOVER TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						CHOLESTYRAMINE; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; HYPERCHOLESTEROLEMIA; BLOOD GLUCOSE; LIPOPROTEINS, LDL CHOLESTEROL	HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY; HYPERCHOLESTEROLEMIA; TRIGLYCERIDE; CHOLESTEROL; COLESTIPOL; METABOLISM	Objective: To assess clinical efficacy and tolerability of cholestyramine therapy in patients with dyslipidemia and non-insulin-dependent diabetes mellitus (NIDDM). Design: A randomized, double-blind, crossover study of cholestyramine (8 g twice daily) compared with placebo for a period of 6 weeks each. Setting: Metabolic Unit and the Lipid and Diabetes Clinics at the Department of Veterans Affairs Medical Center, Dallas, Texas. Patients: 21 patients with NIDDM that was well controlled using either glyburide or insulin therapy and with low-density lipoprotein (LDL) cholesterol levels more than 3.36 mmol/L (130 mg/dL) and fasting plasma triglyceride levels less than 3.4 mmol/L (300 mg/dL). Measurements: During the last week of each period, for 5 consecutive days fasting plasma lipids and lipoproteins were measured, and plasma glucose levels were determined at 3, 7, and 11 a.m. and at 4 and 8 p.m. Daily urinary glucose excretion was measured for 3 days and glycosylated hemoglobin concentrations were determined on days 28 and 38 of the study periods. Results: In this short-term study, when compared with placebo, cholestyramine reduced total cholesterol by 18% (95% CI, 14% to 22%) and LDL cholesterol by 28% (CI, 21% to 35%). Although cholestyramine therapy increased plasma triglyceride levels by 13.5% (CI, 1% to 26%), very-low density lipoprotein cholesterol and high-density lipoprotein cholesterol levels remained unchanged. Cholestyramine therapy improved glycemic control; mean plasma glucose values were lower by 13% (CI, 5% to 21%), a median reduction in urinary glucose excretion of 0.22 g/d was observed (P < 0.001), and a tendency to lower glycosylated hemoglobin concentration was noted. The doses of glyburide and insulin did not change during the study, and body weight remained stable. Constipation was the main side effect, and two patients dropped out of the study because of cholestyramine intolerance. Conclusions: In carefully selected male patients with NIDDM and high LDL cholesterol and normal triglyceride levels, cholestyramine therapy effectively reduces LDL levels and also may improve glycemic control. The long-term efficacy of cholestyramine therapy in patients with NIDDM needs further evaluation.			GARG, A (corresponding author), UNIV TEXAS, SW MED CTR, CTR HUMAN NUTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							ABATE N, 1993, CLIN RES, V41, pA299; ANGELIN B, 1990, J INTERN MED, V227, P201, DOI 10.1111/j.1365-2796.1990.tb00143.x; [Anonymous], 1992, Arch Intern Med, V152, P1399; ASSMANN G, 1988, AM HEART J, V116, P1713, DOI 10.1016/0002-8703(88)90220-7; BANDISODE MS, 1975, CURR THER RES CLIN E, V18, P276; BERGEN SS, 1959, P SOC EXP BIOL MED, V102, P676, DOI 10.3181/00379727-102-25358; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CROUSE JR, 1987, AM J MED, V83, P243, DOI 10.1016/0002-9343(87)90692-9; DUNTSCH G, 1981, FORTSCHR MED, V99, P73; Fielding C J, 1986, Adv Exp Med Biol, V201, P205; FIELDING CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2512, DOI 10.1073/pnas.81.8.2512; GABOR J, 1980, CLIN CHEM, V26, P1261; GARG A, 1988, NEW ENGL J MED, V318, P81, DOI 10.1056/NEJM198801143180204; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hanefeld M, 1985, Monogr Atheroscler, V13, P98; Harris JA., 1919, BIOMETRIC STUDY BASA; HARRIS M, 1979, DIABETES, V28, P1039; HASHIM SA, 1961, P SOC EXP BIOL MED, V106, P173; HASHIM SA, 1965, J AMER MED ASSOC, V192, P289, DOI 10.1001/jama.1965.03080170017004; JONES RJ, 1970, J LAB CLIN MED, V75, P953; LANE JT, 1991, J LAB CLIN MED, V118, P120; LEVY RI, 1973, ANN INTERN MED, V79, P51, DOI 10.7326/0003-4819-79-1-51; NETER J, 1985, APPLIED LINEAR STATI, P1021; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; STEIN E, 1990, ARCH INTERN MED, V150, P341, DOI 10.1001/archinte.150.2.341; STERN MP, 1989, JAMA-J AM MED ASSOC, V262, P360, DOI 10.1001/jama.262.3.360; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; Wilson P W, 1985, Monogr Atheroscler, V13, P1; WITZTUM JL, 1979, METABOLISM, V28, P221, DOI 10.1016/0026-0495(79)90067-2; WITZTUM JL, 1976, J LAB CLIN MED, V88, P1008; YOUNG SG, 1989, J LIPID RES, V30, P225; 1982, MANUAL LABORATORY OP; 1988, JAMA-J AM MED ASSOC, V260, P359; 1987, DAIBETES CARE, V10, P126	34	138	146	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1994	121	6					416	422		10.7326/0003-4819-121-6-199409150-00004	http://dx.doi.org/10.7326/0003-4819-121-6-199409150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF337	8053615				2022-12-28	WOS:A1994PF33700004
J	CONE, RW; HOBSON, AC; BROWN, Z; ASHLEY, R; BERRY, S; WINTER, C; COREY, L				CONE, RW; HOBSON, AC; BROWN, Z; ASHLEY, R; BERRY, S; WINTER, C; COREY, L			FREQUENT DETECTION OF GENITAL HERPES-SIMPLEX VIRUS-DNA BY POLYMERASE CHAIN-REACTION AMONG PREGNANT-WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; DELIVERY; LESIONS; TYPE-1; ENCEPHALITIS; SEQUENCE; CULTURES	Objective.-To investigate the prevalence and level of genital herpes simplex virus (HSV) among women at delivery. Design, Patients, and Setting.-A prospective analysis of HSV by culture and by polymerase chain reaction (PCR) of genital specimens and by HSV serologic studies in 100 asymptomatic women in labor; prospective analysis of HSV by PCR among 50 seronegative nonpregnant women at a student health center; and retrospective analysis of genital specimens for HSV by PCR from 17 HSV culture-positive women with uninfected neonates and from two HSV culture-negative women with HSV-infected neonates. All pregnant women were at a university hospital. Main Outcome Measures.-Presence of HSV by culture and levels of HSV by quantitative, type-specific PCR in cervical and vulvar specimens; HSV serologic testing by Western blot. Results.-All of the 100 asymptomatic women in labor who were studied prospectively were HSV culture negative. In nine HSV was recovered by PCR. Herpes simplex virus was recovered by PCR in one of the 50 seronegative nonpregnant women; she soon became seropositive. All 17 culture-positive women had HSV recovered by PCR. High levels of HSV DNA were obtained by PCR from the two culture-negative women with infected neonates. Among those from whom HSV was recovered by PCR, HSV DNA levels were 250 times higher from culture-positive samples than from culture-negative samples (11 571 genome equivalents vs 46 genome equivalents; P<.001). Conclusions.-The frequency of infant exposure to HSV DNA-containing secretions from HSV-seropositive mothers is about eight times higher than previously reported using HSV culture methods. High maternal levels of HSV DNA may be associated with an increased frequency of transmission of HSV to the infant.	UNIV WASHINGTON,DEPT LAB MED,DIV VIROL,SEATTLE,WA 98144; UNIV WASHINGTON,DEPT OBSTET & GYNECOL,SEATTLE,WA; UNIV WASHINGTON,DEPT INFECT DIS,SEATTLE,WA; UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI 30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BZIK DJ, 1986, VIROLOGY, V155, P322, DOI 10.1016/0042-6822(86)90196-0; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; CONE RW, 1992, J CLIN MICROBIOL, V30, P3185, DOI 10.1128/JCM.30.12.3185-3189.1992; CONE RW, 1993, J CLIN MICROBIOL, V31, P1774, DOI 10.1128/JCM.31.7.1774-1776.1993; COREY L, 1988, LANCET, V1, P1; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LASKY LA, 1984, DNA-J MOLEC CELL BIO, V3, P23, DOI 10.1089/dna.1.1984.3.23; MALM G, 1991, ACTA PAEDIATR SCAND, V80, P226, DOI 10.1111/j.1651-2227.1991.tb11838.x; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; NAHMIAS AJ, 1982, J INFECT DIS, V145, P829, DOI 10.1093/infdis/145.6.829; PROBER CG, 1992, CLIN INFECT DIS, V15, P1031, DOI 10.1093/clind/15.6.1031; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; RANDOLPH AG, 1993, JAMA-J AM MED ASSOC, V270, P77, DOI 10.1001/jama.270.1.77; STAGNO S, 1985, NEW ENGL J MED, V313, P1327, DOI 10.1056/NEJM198511213132105; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109	20	97	99	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					792	796		10.1001/jama.272.10.792	http://dx.doi.org/10.1001/jama.272.10.792			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078144				2022-12-28	WOS:A1994PF18800028
J	HILLIS, WS; MCINTYRE, PD; MACLEAN, J; GOODWIN, JF; MCKENNA, WJ				HILLIS, WS; MCINTYRE, PD; MACLEAN, J; GOODWIN, JF; MCKENNA, WJ			ABC OF SPORTS MEDICINE - SUDDEN-DEATH IN SPORT	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND	Imperial College London; St Georges University London	HILLIS, WS (corresponding author), UNIV GLASGOW,WESTERN INFIRM,GARDINER INST,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.		McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460					0	14	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					657	660		10.1136/bmj.309.6955.657	http://dx.doi.org/10.1136/bmj.309.6955.657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086993	Green Published			2022-12-28	WOS:A1994PG02000035
J	LAIDLAW, DAH; BLOOM, PA; HUGHES, AO; SPARROW, JM; MARMION, VJ				LAIDLAW, DAH; BLOOM, PA; HUGHES, AO; SPARROW, JM; MARMION, VJ			THE SIGHT TEST FEE - EFFECT ON OPHTHALMOLOGY REFERRALS AND RATE OF GLAUCOMA DETECTION	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To assess changes, if any, in the numbers of referrals and outcome of glaucoma referrals to the hospital eye service since the introduction of the sight test fee on 1 April 1989. Design-Review of referral records and clinical notes. Setting-Referrals to the Bristol Eye Hospital. Subjects-51 919 patients referred to the Bristol Eye Hospital between 1984 and 1992. 9438 case notes of patients referred between 1987 and 1991 were examined in detail. Main outcome measures-Numbers of referrals; rate of adult true positive glaucoma referrals. Results-Referrals to the Bristol Eye Hospital were between 13.7% and 19.0% fewer than expected after the introduction of the sight test fee. True positive glaucoma referrals were reduced by the same proportion. Conclusions-The numbers of patients being identified as requiring treatment or follow up for potentially blinding glaucoma have declined by nearly one fifth since the introduction of the sight test fee. An increased prevalence of preventable blindness may result.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND; UNIV BRISTOL,DEPT OPHTHALMOL,BRISTOL BS1 2LX,ENGLAND	University of Bristol; University of Bristol	LAIDLAW, DAH (corresponding author), BRISTOL EYE HOSP,BRISTOL BS1 2LX,ENGLAND.							Brittain G P, 1988, Health Trends, V20, P43; GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; HALL C, 1989, INDEPENDENT     1230, P3; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; HITCHINGS RA, 1993, BR J OPHTHALMOL, V77, P236; Hoskins HD, 1989, BECKER SHAFFERS DIAG; JAY JL, 1993, BRIT J OPHTHALMOL, V77, P176, DOI 10.1136/bjo.77.3.176; ROSENTHAL AR, 1990, BRIT MED J, V300, P695, DOI 10.1136/bmj.300.6726.695; SORSBY A, 1966, 114 PUBL HLTH MED SU; TUCK MW, 1991, BRIT MED J, V302, P998, DOI 10.1136/bmj.302.6783.998; 1991, INFORMATION ORG INDI; 1989, OFFICE POPULATION VS, V16; 1992, OPTICS GLANCE	15	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					634	636		10.1136/bmj.309.6955.634	http://dx.doi.org/10.1136/bmj.309.6955.634			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086985	Green Published			2022-12-28	WOS:A1994PG02000018
J	FAGAN, R; FLINT, KJ; JONES, N				FAGAN, R; FLINT, KJ; JONES, N			PHOSPHORYLATION OF E2F-1 MODULATES ITS INTERACTION WITH THE RETINOBLASTOMA GENE-PRODUCT AND THE ADENOVIRAL E4 19-KDA PROTEIN	CELL			English	Article							TRANSCRIPTION FACTOR; CELL-CYCLE; RB PROTEIN; TRANS-ACTIVATION; BINDING PROTEIN; E1A PROTEINS; T-ANTIGEN; EXPRESSION; IDENTIFICATION; ELEMENT	The transcription factor E2F is regulated through its cyclical interaction with a spectrum of cellular proteins. One such protein is the product of the retinoblastoma gene (Rb); association of E2F with Rb inhibits its transactivation potential. However, in adenovirus-infected cells, E2F is complexed to the 19 kDa product of the adenovirus E4 gene. We have studied the interaction of E2F-1 with the Rb and adenovirus E4 proteins and show that phosphorylation of E2F-1 on serine residues 332 and 337 prevented its interaction with Rb but was a prerequisite for interaction with E4. These residues were phosphorylated in vivo and by p34(cdc2) kinase in vitro. Upon stimulation of serum-starved cells, phosphorylation was induced in the late G1 phase of the cell cycle. These observations suggest that phosphorylation of E2F-1 is important in the regulation of its activity during the cell cycle and during infection of cells tay adenovirus.			FAGAN, R (corresponding author), IMPERIAL CANC RES FUND, GENE REGULAT LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.							AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLINT KJ, 1991, ONCOGENE, V6, P2019; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; SADROWSKI J, 1989, NUCLEIC ACIDS RES, V17, P7539; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	53	131	136	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					799	811		10.1016/S0092-8674(94)90522-3	http://dx.doi.org/10.1016/S0092-8674(94)90522-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087847				2022-12-28	WOS:A1994PG29600009
J	CORR, L				CORR, L			FORTNIGHTLY REVIEW - NEW METHODS OF MAKING BLOCKED CORONARY-ARTERIES PATENT AGAIN	BRITISH MEDICAL JOURNAL			English	Review							ROTATIONAL ABLATION; BALLOON ANGIOPLASTY; LASER ANGIOPLASTY; RESTENOSIS; DISEASE	The use of percutaneous transluminal coronary angioplasty is limited by procedural complications and the serious drawback of restenosis, but some new techniques have been developed in an attempt to lower the complication rate for difficult lesions and reduce the rate of restenosis. These include devices to physically remove atheromatous plaque, such as the Simpson Coronary AtheroCath and the transluminal extraction catheter, as well as devices to ablate the plaque in situ, including the Rotablator and the excimer laser catheter. Although each device may have advantages in certain types of lesion, few data on their use have been reported in properly controlled randomised trials. The data available so far do not suggest that these devices will be safer than balloon angioplasty or that they will reduce restenosis. However, using metallic stents to support coronary arteries after balloon angioplasty seems to reduce acute complications and to lower the rate of restenosis, and the use of stents is likely to increase.			CORR, L (corresponding author), BROOK GEN HOSP,REG CARDIAC UNIT,LONDON SE18 4LW,ENGLAND.							BUCHBINDER M, 1992, J AM COLL CARDIOL, V19, P333; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DIETHRICHEB EV, 1991, J AM COLL CARDIOL, V18, P43; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; GIBB MD, 1992, CORONARY ARTERY DIS, V3, P908; HAUDE M, 1993, Z KARDIOL, V82, P77; HUBNER PJB, 1993, BRIT HEART J, V70, P201; KARSCH KR, 1990, CIRCULATION, V81, P1849, DOI 10.1161/01.CIR.81.6.1849; LAU KW, 1992, AM HEART J, V123, P497, DOI 10.1016/0002-8703(92)90666-J; LITVACK F, 1990, AM J CARDIOL, V66, P1027, DOI 10.1016/0002-9149(90)90499-Q; LITVACK F, 1992, CORONARY ARTERY DIS, V3, P533, DOI 10.1097/00019501-199206000-00012; LITVACK F, 1992, CIRCULATION S, V19, P795; MEHTA S, 1992, CORONARY ARTERY DIS, V3, P887; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; ROSENBLUM J, 1991, AM HEART J, V122, P1766, DOI 10.1016/0002-8703(91)90297-U; SERRUYS PW, 1993, AM HEART J, V126, P1243, DOI 10.1016/0002-8703(93)90689-7; SPEARS JR, 1990, J AM COLL CARDIOL, V16, P293, DOI 10.1016/0735-1097(90)90576-B; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; 1993, LANCET, V341, P573	19	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					579	583		10.1136/bmj.309.6954.579	http://dx.doi.org/10.1136/bmj.309.6954.579			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086947	Green Published			2022-12-28	WOS:A1994PF33000022
J	BLOOM, BR				BLOOM, BR			THE UNITED-STATES NEEDS A NATIONAL VACCINE AUTHORITY	SCIENCE			English	Editorial Material											BLOOM, BR (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461, USA.							[Anonymous], 1993, WORLD DEV REPORT INV; RABINOVICH NR, 1994, SCIENCE, V265, P1401, DOI 10.1126/science.7521064; 1994, DEV NATIONAL CHILDHO; 1993, CHILDRENS VACCINE IN; 1994, COMMERCIAL PERSPECTI; 1993, ASSESSMENT FEASIBILI; 1992, MMWR-MORBID MORTAL W, V41, P104; 1992, ACCESS CHILDHOOD IMM; 1986, VACCINE SUPPLY INNOV; 1990, HLTH RES ESSENTIAL L; 1994, ADULT IMMUNIZATION; 1994, EMERGING INFECTIONS; 1994, STATE LOCAL IMPEDIME; 1994, DISEASE PREVENTION V; 1993, JAMA-J AM MED ASSOC, V269, P1817; 1990, STATE WORLDS CHILDRE; 1993, STATE WORLDS CHILDRE; 1991, JAMA-J AM MED ASSOC, V226, P1547	18	13	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1378	1380		10.1126/science.8073275	http://dx.doi.org/10.1126/science.8073275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073275				2022-12-28	WOS:A1994PE73300027
J	CALKINS, DJ; SCHEIN, SJ; TSUKAMOTO, Y; STERLING, P				CALKINS, DJ; SCHEIN, SJ; TSUKAMOTO, Y; STERLING, P			M-CONE AND L-CONE IN MACAQUE FOVEA CONNECT TO MIDGET GANGLION-CELLS BY DIFFERENT NUMBERS OF EXCITATORY SYNAPSES	NATURE			English	Article							BIPOLAR CELLS; ELECTRON-MICROSCOPY; MONKEY RETINA; CAT RETINA	VISUAL acuity depends on the fine-grained neural image set by the foveal cone mosaic(1-3). To preserve this spatial detail, cones transmit through non-divergent pathways: cone-->midget bipolar cell-->midget ganglion cell. Adequate gain must be established along each pathway; crosstalk and sources of variation between pathways must be minimized. These requirements raise fundamental questions regarding the synaptic connections: (1) how many synapses from bipolar to ganglion cell transmit a cone signal and with what degree of crosstalk between adjacent pathways; (2) how accurately these connections are reproduced across the mosaic; and (3) whether the midget circuits for middle (M) and long (L) wavelength sensitive cones are the same. We report here that the midget ganglion cell collects without crosstalk either 28 +/- 14 or 47 +/- 3 midget bipolar synapses. Two cone types are defined by this difference; being about equal in number and distributing randomly in small clusters of like type, they are probably M and L.	UNIV CALIF LOS ANGELES,DEPT PSYCHOL,LOS ANGELES,CA 90024; HYOGO MED UNIV,DEPT ANAT,NISHINOMIYA,HYOGO 663,JAPAN	University of California System; University of California Los Angeles; Hyogo College of Medicine; University of Hyogo	CALKINS, DJ (corresponding author), UNIV PENN,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.			Calkins, David/0000-0002-8475-9959				ANHELT P, 1990, J COMP NEUROL, V293, P39; BOYCOTT BB, 1969, PHILOS T ROY SOC B, V255, P109, DOI 10.1098/rstb.1969.0004; COHEN E, 1992, EUR J NEUROSCI, V4, P506, DOI 10.1111/j.1460-9568.1992.tb00901.x; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DACEY DM, 1992, P NATL ACAD SCI USA, V89, P9666, DOI 10.1073/pnas.89.20.9666; DEVALOIS RL, 1974, VISION RES, V14, P75, DOI 10.1016/0042-6989(74)90118-7; DOWLING JE, 1966, PROC R SOC SER B-BIO, V166, P80, DOI 10.1098/rspb.1966.0086; GIACOMELLI F, 1971, J HISTOCHEM CYTOCHEM, V19, P426, DOI 10.1177/19.7.426; KLUG K, 1992, SOC NEUR ABSTR; KLUG K, 1993, ARVO ABSTR; KOLB H, 1970, PHILOS T R SOC B, V258, P261, DOI 10.1098/rstb.1970.0036; KOLB H, 1991, J COMP NEUROL, V303, P617, DOI 10.1002/cne.903030408; KOUYAMA N, 1992, J NEUROSCI, V12, P1233; MARIANI AP, 1984, NATURE, V308, P184, DOI 10.1038/308184a0; MCGUIRE BA, 1984, J NEUROSCI, V4, P2920; MENDENHALL W, 1990, MATH STATISTICS APPL, P708; MERIGAN WH, 1990, VISION RES, V30, P985, DOI 10.1016/0042-6989(90)90107-V; MOLLON JD, 1992, NATURE, V360, P677, DOI 10.1038/360677a0; NELSON R, 1978, J NEUROPHYSIOL, V41, P472, DOI 10.1152/jn.1978.41.2.472; Polyak S. L., 1941, RETINA-J RET VIT DIS; SMITH RG, 1987, J NEUROSCI METH, V21, P55, DOI 10.1016/0165-0270(87)90102-6; TSUKAMOTO Y, 1992, VISION RES, V32, P1809, DOI 10.1016/0042-6989(92)90042-H; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WILLIAMS DR, 1986, TRENDS NEUROSCI, V9, P193, DOI 10.1016/0166-2236(86)90058-5	24	153	153	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					70	72		10.1038/371070a0	http://dx.doi.org/10.1038/371070a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072528				2022-12-28	WOS:A1994PE38100053
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			INVASIVE INTERVENTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DESCENDING CORONARY-ARTERY; ACUTE CARDIAC ISCHEMIA; PREDICTIVE INSTRUMENT; CARE-UNIT; MYOCARDIAL-INFARCTION; NUCLEAR CARDIOLOGY; MEDICAL PROGRESS; FOLLOW-UP; MULTICENTER; ANGIOPLASTY		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOX 302,750 WASHINGTON ST,BOSTON,MA 02111, USA.							ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; [Anonymous], 1982, JUDGMENT UNCERTAINTY; BRAUNWALD E, 1994, AHCPR940602 DEP HLTH; BROWN KA, 1991, CIRCULATION, V83, P363, DOI 10.1161/01.CIR.83.2.363; DEZWAAN C, 1989, AM HEART J, V117, P657, DOI 10.1016/0002-8703(89)90742-4; FRIERSON JH, 1992, J AM COLL CARDIOL, V19, P745, DOI 10.1016/0735-1097(92)90512-L; GASPOZ JM, 1991, AM J CARDIOL, V68, P145, DOI 10.1016/0002-9149(91)90734-3; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GREEN LA, 1993, MED DECIS MAKING, V13, P387; Hill M, 1989, QRC Advis, V6, P1; JAYES RL, 1992, J CLIN EPIDEMIOL, V45, P621, DOI 10.1016/0895-4356(92)90134-9; KARCZ A, 1990, ANN EMERG MED, V19, P865, DOI 10.1016/S0196-0644(05)81559-8; KRAMER JR, 1989, AM HEART J, V118, P1144, DOI 10.1016/0002-8703(89)90002-1; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCNUTT RA, 1993, MED DECIS MAK, V13, P393; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PASTERNAK RC, 1994, HARRISONS PRINCIPLES, V1, P1066; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1992, MED CARE, V30, P188; SOBEL BE, 1992, CECIL TXB MED, P304; VANLIERDE J, 1991, AM HEART J, V122, P1542, DOI 10.1016/0002-8703(91)90269-N; ZARET BL, 1993, NEW ENGL J MED, V329, P855, DOI 10.1056/NEJM199309163291208; ZARET BL, 1993, NEW ENGL J MED, V329, P775, DOI 10.1056/NEJM199309093291107; 1991, J AM COLL CARDIOL, V17, P543; 1993, J AM COLL CARDIOL, V22, P2033	30	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					601	605		10.1056/NEJM199409013310909	http://dx.doi.org/10.1056/NEJM199409013310909			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047087				2022-12-28	WOS:A1994PD69900009
J	MATSUSHIMA, GK; TANIIKE, M; GLIMCHER, LH; GRUSBY, MJ; FRELINGER, JA; SUZUKI, K; TING, JPY				MATSUSHIMA, GK; TANIIKE, M; GLIMCHER, LH; GRUSBY, MJ; FRELINGER, JA; SUZUKI, K; TING, JPY			ABSENCE OF MHC CLASS-II MOLECULES REDUCES CNS DEMYELINATION, MICROGLIAL/MACROPHAGE INFILTRATION, AND TWITCHING IN MURINE GLOBOID-CELL LEUKODYSTROPHY	CELL			English	Article							COMPLEX CLASS-II; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; T-CELLS; HLA-DR; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; IA ANTIGENS; HUMAN-BRAIN	Globoid cell leukodystrophy (GLD) is a severe genetic demyelinating disorder with an increased number of la (immune response antigen) positive brain microglial macrophages. To assess the role of aberrant la expression in the central nervous system (CNS), twitcher mice, which represent the murine model for GLD, were mated with la(-) transgenic mice. Compared with the la(+) controls, la(-) twitcher mice showed a profound reduction in the severity of demyelinating lesions correlated with significantly fewer microglia/macrophages. Most importantly, la(-) twitcher mice showed significantly reduced twitching compared with la(+) twitcher mice. In contrast with experimental allergic encephalomyelitis (EAE), there was no significant amount of inflammatory T cell infiltrates, implying that T eels may not play a predominant role in this disease. These findings may have broad therapeutic implications for Alzheimer's disease, Parkinson's disease, and Huntington's disease, which display enhanced la expression in the CNS without obvious T cell infiltrates.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, BRAIN & DEV RES CTR, CHAPEL HILL, NC 27599 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	MATSUSHIMA, GK (corresponding author), UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA.		Frelinger, Jeffrey A/F-2448-2014	Frelinger, Jeffrey A/0000-0002-2503-6267	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020288, R37AI021569, R37AI020288, R01AI021569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024453] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20288, AI 21569] Funding Source: Medline; NINDS NIH HHS [NS 24453] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; BALUYUT AR, 1993, CELL IMMUNOL, V147, P353, DOI 10.1006/cimm.1993.1075; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BISHOP GA, 1989, P NATL ACAD SCI USA, V86, P5933, DOI 10.1073/pnas.86.15.5933; BISHOP GA, 1986, P NATL ACAD SCI USA, V83, P7410, DOI 10.1073/pnas.83.19.7410; BROWN T, 1993, CURRENT PROTOCOLS MO; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHAO CC, 1993, J IMMUNOL, V151, P1473; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; COHEN IH, 1990, GENETIC MAPS LOCUS M; COLTON CA, 1992, J NEUROIMMUNOL, V40, P89, DOI 10.1016/0165-5728(92)90216-8; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DUCHEN LW, 1980, BRAIN, V103, P695, DOI 10.1093/brain/103.3.695; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; FRELINGER JA, 1975, SCIENCE, V188, P268, DOI 10.1126/science.1118728; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HARTON JA, 1993, J IMMUNOL, V151, P5282; HAUSER SL, 1983, J NEUROIMMUNOL, V5, P197, DOI 10.1016/0165-5728(83)90010-3; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HIGASHI Y, 1992, J NEUROPATH EXP NEUR, V51, P47, DOI 10.1097/00005072-199201000-00007; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; JUHLER M, 1984, BRAIN RES, V302, P347, DOI 10.1016/0006-8993(84)90249-X; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; KOBAYASHI T, 1982, BIOCHEM MED METAB B, V27, P8, DOI 10.1016/0006-2944(82)90003-5; KONDO A, 1987, BRAIN RES, V425, P186, DOI 10.1016/0006-8993(87)90499-9; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANG AE, 1991, NEUROLOGY CLIN PRACT, P320; LI H, 1993, NEUROPATH APPL NEURO, V19, P214, DOI 10.1111/j.1365-2990.1993.tb00431.x; LOUGHLIN AJ, 1993, IMMUNOLOGY, V79, P125; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MATSUSHIMA GK, 1992, MOL CELL BIOL, V12, P5610, DOI 10.1128/MCB.12.12.5610; MATTIACE LA, 1990, AM J PATHOL, V136, P1101; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NABAVI N, 1989, J IMMUNOL, V142, P1444; ODUM N, 1991, EUR J IMMUNOL, V21, P123, DOI 10.1002/eji.1830210119; OHNO M, 1993, BRAIN RES, V625, P186, DOI 10.1016/0006-8993(93)91058-Z; OHNO M, 1993, BRAIN RES, V602, P268, DOI 10.1016/0006-8993(93)90692-G; OHNO M, 1992, DEV BRAIN RES, V67, P37, DOI 10.1016/0165-3806(92)90023-P; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; POSER CM, 1980, ARCH NEUROL-CHICAGO, V37, P471, DOI 10.1001/archneur.1980.00500570019001; SEARS ES, 1978, ARCH NEUROL-CHICAGO, V35, P426, DOI 10.1001/archneur.1978.00500310028006; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; SHEEHAN DC, 1980, THEORY PRACTICE HIST, P263; SPERTINI F, 1992, J IMMUNOL, V149, P65; STEINMAN L, 1991, ADV IMMUNOL, V49, P357; Steinman L, 1988, Adv Neurol, V47, P255; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STOLL G, 1989, J NEUROSCI, V9, P2327; STYREN SD, 1990, EXP NEUROL, V110, P93, DOI 10.1016/0014-4886(90)90054-V; SUZUKI K, 1983, AM J PATHOL, V111, P394; SUZUKI K, 1989, METABOLIC BASIS INHE, P1699; SUZUKI K, IN PRESS MICR RES TE; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; TAKAHASHI H, 1984, ACTA NEUROPATHOL, V62, P298, DOI 10.1007/BF00687612; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; TING JPY, 1983, IMMUNOGENETICS, V17, P295, DOI 10.1007/BF00364413; TING JPY, 1981, P NATL ACAD SCI-BIOL, V78, P3170, DOI 10.1073/pnas.78.5.3170; TOIMOTO H, 1993, AM J PATHOL, V143, P579; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; TREDE NS, 1991, J IMMUNOL, V146, P2310; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	73	100	104	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					645	656		10.1016/0092-8674(94)90529-0	http://dx.doi.org/10.1016/0092-8674(94)90529-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069913				2022-12-28	WOS:A1994PD69300013
J	CANTWELL, MF; SNIDER, DE; CAUTHEN, GM; ONORATO, IM				CANTWELL, MF; SNIDER, DE; CAUTHEN, GM; ONORATO, IM			EPIDEMIOLOGY OF TUBERCULOSIS IN THE UNITED-STATES, 1985 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RACIAL-DIFFERENCES; SUSCEPTIBILITY; DISEASE; RISK	Objective.-To examine the distribution and sources of increased tuberculosis (TB) morbidity in the United States from 1985 through 1992. Design.-Review of TB surveillance data. Participants.-All incident TB cases in the United States reported to the Centers for Disease Control and Prevention from 1980 through 1992. Main Outcome Measures.-Changes in reported number of TB cases from 1985 through 1992 were analyzed by sex, race/ethnicity, age, country of birth (1986 through 1992), site of disease, geographic location; and socioeconomic status (through 1991). From 1985 through 1992, reported number of cases was compared with expected number of cases, extrapolated from 1980 through 1984 trends, to estimate excess cases by sex, race/ethnicity, and age. Results.-Increases in number of cases from 1985 through 1992 were concentrated among racial/ethnic minorities, persons 25 to 44 years of age, males, and the foreign-born. Excess cases occurred in both sexes, all racial/ethnic groups, and all age groups. Foreign-born cases accounted for 60% of the total increase in the number of US cases from 1986 through 1992 and had the greatest impact among Asians, Hispanics, females, and persons other than those 25 to 44 years of age. Human immunodeficiency virus infection had the greatest impact on TB morbidity among whites, blacks, males, and persons 25 to 44 years of age. From 1985 through 1992, the number of cases among children 4 years old or younger increased 36%, suggesting that transmission of TB increased during this period. Conclusions.-Multiple factors contributed to the recent increases in the number of TB cases. The effectiveness of TB screening in immigrants needs further evaluation. Intensified efforts to determine the human immunodeficiency virus status of persons with TB are needed. Screening of subpopulations at increased risk for tuberculous infection or TB should be expanded.	CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,OFF DIRECTOR,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	CANTWELL, MF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,1600 CLIFTON RD,E-10,ATLANTA,GA 30333, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; CAUTHEN GM, 1991, 7TH INT C AIDS FLOR; DRIVER CR, 1992, MAY AM LUNG ASS AM T; GLASSER D, 1978, MARYLAND PHARMAC JUL, P10; KUSHIGEMACHI M, 1984, J CHRON DIS, V37, P853, DOI 10.1016/0021-9681(84)90018-3; MANOFF SB, 1988, 4TH INT C AIDS STOCK; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; ONORATO I, 1993, 33RD INT C ANT AG NE; PITCHENIK AE, 1988, CLIN CHEST MED, V9, P425; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1986, CHEST, V90, P469, DOI 10.1378/chest.90.4.469; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1990, MMWR-MORBID MORTAL W, V39, P1; 1993, HIV AIDS SURVEILLANC, P1; 1992, CURRENT POPULATI P25; 1993, STATISTICAL YB IMMIG; [No title captured]; 1993, MMWR MORBID MORTAL W, V42, P696; 1991, TECHNICAL INSTRUCTIO; 1982, CENSUS POPULATION HO; 1992, AIDS PUBLIC INFORMAT; 1992, MMWR-MORBID MORTAL W, V41, P1	25	336	345	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					535	539		10.1001/jama.272.7.535	http://dx.doi.org/10.1001/jama.272.7.535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046808				2022-12-28	WOS:A1994PB22900031
J	CORR, M; SLANETZ, AE; BOYD, LF; JELONEK, MT; KHILKO, S; ALRAMADI, BK; KIM, YS; MAHER, SE; BOTHWELL, ALM; MARGULIES, DH				CORR, M; SLANETZ, AE; BOYD, LF; JELONEK, MT; KHILKO, S; ALRAMADI, BK; KIM, YS; MAHER, SE; BOTHWELL, ALM; MARGULIES, DH			T-CELL RECEPTOR-MHC CLASS-I PEPTIDE INTERACTIONS - AFFINITY, KINETICS, AND SPECIFICITY	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; BINDING; COMPLEX; ANTIGEN; MOLECULE; RECOGNITION; PROTEINS; ANTISERA	The critical discriminatory event in the activation of T lymphocytes bearing alpha beta T cell receptors (TCRs) is their interaction with a molecular complex consisting of a peptide bound to a major histocompatibility complex (MHC)-encoded class I or class II molecule on the surface of an antigen-presenting cell. The kinetics of binding were measured of a purified TCR to molecular complexes of a purified soluble analog of the murine MHC class I molecule H-2L(d) (sH-2L(d)) and a synthetic octamer peptide p2CL in a direct, real-time assay based on surface plasmon resonance. The kinetic dissociation rate of the MHC-peptide complex from the TCR was rapid (2.6 x 10(-2) second(-1), corresponding to a half-time for dissociation of approximately 27 seconds), and the kinetic association rate was 2.1 x 10(5) M(-1) second(-1). The equilibrium constant for dissociation was approximately 10(-7) M. These values indicate that TCRs must interact with a multivalent array of MHC-peptide complexes to trigger T cell signaling.	NIAID,MOLEC BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT BIOL,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Yale University; Yale University				Margulies, David/0000-0001-8530-7375				Berzofsky Jay A., 1993, P421; BOYD LA, UNPUB; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; CORR M, UNPUB; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; JELONEK MT, UNPUB; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KHILKO S, UNPUB; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUBO RT, 1989, J IMMUNOL, V142, P2736; Margulies David H., 1993, Journal of Molecular Recognition, V6, P59, DOI 10.1002/jmr.300060204; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	30	308	321	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					946	949		10.1126/science.8052850	http://dx.doi.org/10.1126/science.8052850			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052850				2022-12-28	WOS:A1994PB49900040
J	MARTINO, RL; JOHNSON, CA; SUH, EB; TRUS, BL; YAP, TK				MARTINO, RL; JOHNSON, CA; SUH, EB; TRUS, BL; YAP, TK			PARALLEL COMPUTING IN BIOMEDICAL-RESEARCH	SCIENCE			English	Article							RECONSTRUCTION; VIRUS	Scalable parallel computer architectures provide the computational performance needed for advanced biomedical computing problems. The National Institutes of Health have developed a number of parallel algorithms and techniques useful in determining biological structure and function. These applications include processing electron micrographs to determine the three-dimensional structure of viruses, calculating the solvent-accessible surface area of proteins to help predict the three-dimensional conformation of these molecules from their primary structures, and searching for homologous DNA or amino acid sequences in large biological databases. Timing results demonstrate substantial performance improvements with parallel implementations compared with conventional sequential systems.	NIAMSD,STRUCT BIOL RES LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	MARTINO, RL (corresponding author), NIH,DIV COMP RES & TECHNOL,COMPUTAT BIOSCI & ENGN LAB,BETHESDA,MD 20892, USA.							Almasi GS., 1994, HIGHLY PARALLEL COMP, V2nd ed.; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BASKETT F, 1993, SCIENCE, V261, P864, DOI 10.1126/science.261.5123.864; BOOY FP, 1994, P NATL ACAD SCI USA, V91, P5652, DOI 10.1073/pnas.91.12.5652; BURKS C, 1991, NUCLEIC ACIDS RES, V19, P2221, DOI 10.1093/nar/19.suppl.2221; CHAN HS, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881371; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; COVELL DG, 1990, BIOCHEMISTRY-US, V29, P3287, DOI 10.1021/bi00465a020; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DELAGLIO F, COMMUNICATION; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; GUAN X, 1991, 5TH P SIAM C PAR PRO; HILLIS WD, 1993, SCIENCE, V261, P856, DOI 10.1126/science.261.5123.856; HINDS DA, 1992, P NATL ACAD SCI USA, V89, P2536, DOI 10.1073/pnas.89.7.2536; JONES R, 1992, COMPUT APPL BIOSCI, V8, P377; KANG HS, 1993, J MOL BIOL, V229, P448, DOI 10.1006/jmbi.1993.1045; LANGE K, 1984, J COMPUT ASSIST TOMO, V8, P306; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee B., COMMUNICATION; NEWCOMB WW, 1993, J MOL BIOL, V232, P499, DOI 10.1006/jmbi.1993.1406; PILKINGTON TC, 1993, HIGH PERFORMANCE COM; Riefer A., 2013, HIGH PERFORMANCE COM, P93; SITTIG DF, 1991, COMPUT BIOMED RES, V24, P152, DOI 10.1016/0010-4809(91)90027-T; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SUH EB, 1993, 7TH PINT PAR PROC S, P685; YAP TK, IN PRESS HDB PARALLE	28	32	33	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					902	908		10.1126/science.8052847	http://dx.doi.org/10.1126/science.8052847			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052847				2022-12-28	WOS:A1994PB49900030
J	DRIVER, CR; VALWAY, SE; MORGAN, WM; ONORATO, IM; CASTRO, KG				DRIVER, CR; VALWAY, SE; MORGAN, WM; ONORATO, IM; CASTRO, KG			TRANSMISSION OF MYCOBACTERIUM-TUBERCULOSIS ASSOCIATED WITH AIR-TRAVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES-NAVY; OUTBREAK; INFECTION; FLIGHTS	Objective.-To investigate potential transmission of Mycobacterium tuberculosis in aircraft from a crew member with tuberculosis. Design.-Retrospective cohort study and survey. Setting.-A large US airline carrier. Participants.-A total of 212 crew members and 59 passengers who were exposed to a crew member with tuberculosis during a potentially infectious period (May through October 1992). Comparison volunteer sample of 247 unexposed crew members. Main Outcome Measures.-Positive tuberculin skin test (TST) result or tuberculosis. Results.-Rates of positive TST results were higher among foreign-born persons in all study groups. Among US-born comparisons and contacts, rates of positive TST results did not differ between comparisons and contacts exposed from May through July (5.3% vs 5.9%, respectively). However, contacts exposed from August through October had significantly higher rates of positive TST results than did contacts exposed from May through July (30% vs 5.8%, respectively; P<.001); two had documented TST conversions between September 1992 and February 1993. The risk of infection increased with increasing hours of exposure to the index case. Four (6.7%) of 59 frequent flyers were TST-positive; all flew in October. Conclusions.-Data support the conclusion that M tuberculosis was transmitted from an infectious crew member to other Grew members on an aircraft. Because of the clustering of TST-positive frequent flyers in October when the index patient was most infectious, transmission of M tuberculosis to passengers cannot be excluded.	CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	DRIVER, CR (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; CLAYTON AJ, 1976, AVIAT SPACE ENVIR MD, V47, P471; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P572; CROSS ER, 1990, AM J PUBLIC HEALTH, V80, P435, DOI 10.2105/AJPH.80.4.435; DRAKE JW, 1990, AVIAT SPACE ENVIR MD, V61, P531; EISENBERG MS, 1975, LANCET, V2, P595; HARDLE W, 1990, APPLIED NONPARAMETRI, P4; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; NAGDA NL, 1989, DOTP15895 US DEP TRA; PALMER CE, 1956, PUBLIC HEALTH REP, V71, P633, DOI 10.2307/4589488; PEFFERS ASR, 1973, LANCET, V1, P143; RUBEN FL, 1977, AM REV RESPIR DIS, V115, P23; RUST P, 1975, AM J EPIDEMIOL, V101, P311, DOI 10.1093/oxfordjournals.aje.a112099; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; SUTHERLAND I, 1968, 10 YEAR INCIDENCE CL; SUTTON RGA, 1974, J HYG-CAMBRIDGE, V72, P441, DOI 10.1017/S0022172400023688; TAUXE RV, 1987, AM J EPIDEMIOL, V125, P150, DOI 10.1093/oxfordjournals.aje.a114498; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211; 1983, MMWR-MORBID MORTAL W, V32, P210; 1990, MMWR-MORBID MORTAL W, V39, P1; 1976, MMWR-MORBID MORTAL W, V25, P332; 1976, MMWR-MORBID MORTAL W, V25, P317; 1990, AM REV RESPIR DIS, V142, P725; 1992, MMWR-MORBID MORTAL W, V41, P134; 1983, MMWR-MORBID MORTAL W, V32, P215	27	110	112	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1031	1035		10.1001/jama.272.13.1031	http://dx.doi.org/10.1001/jama.272.13.1031			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089885				2022-12-28	WOS:A1994PH77500028
J	RABIN, DL; BOEKELOO, BO; MARX, ES; BOWMAN, MA; RUSSELL, NK; WILLIS, AG				RABIN, DL; BOEKELOO, BO; MARX, ES; BOWMAN, MA; RUSSELL, NK; WILLIS, AG			IMPROVING OFFICE-BASED PHYSICIANS PREVENTION PRACTICES FOR SEXUALLY-TRANSMITTED DISEASES	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY CARE PHYSICIANS; SIMULATED PATIENTS; AIDS; PERFORMANCES; KNOWLEDGE; ATTITUDES	Objective: To determine whether office-based interventions increase primary care physicians' risk assessment of and counseling practices for patients regarding sexually transmitted diseases and the human immunodeficiency virus (HIV). Design: Randomized controlled clinical trial. Setting: Washington, D.C., Metropolitan Statistical Area. Study Participants: Office-based primary care physicians (family or general practice, internal medicine, and obstetrics-gynecology). Intervention: Mailed educational materials alone or coupled with a simulated patient instructor office visit. Measurements: Self-reported and observed frequency of assessing and counseling patients regarding their risk factors for sexually transmitted diseases and HIV infection. Participants were interviewed by telephone before and after the intervention (n = 757). A subset of participants (n = 194) was also observed after the intervention by simulated patient evaluators in blinded office visits. Results: 89% of physicians who received both educational materials and a simulated patient instructor visit reported that they reviewed the educational materials compared with 53% of those who only received the educational materials (P less than or equal to 0.001). Physicians in the combined intervention group had higher self-reported and observed rates for several risk assessment questions and counseling recommendations than did physicians in the control group or the group that only received educational materials. Seventy-three percent of physicians of the combined intervention group reported an increase in counseling patients about reducing risky sexual behavior compared with 53% of the group receiving only educational materials and 42% of the control group (P less than or equal to 0.001). Conclusions: Mailed educational materials combined with an office visit by a simulated patient instructor for role-play and feedback on clinical performance increased the frequency of office-based physicians' risk assessment and risk reduction counseling of patients for sexually transmitted diseases and HIV infection.	GEORGE WASHINGTON UNIV, MED CTR, DEPT HLTH CARE SCI, WASHINGTON, DC 20037 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMMUNITY & FAMILY MED, WINSTON SALEM, NC 27157 USA	George Washington University; Wake Forest University; Wake Forest Baptist Medical Center	RABIN, DL (corresponding author), GEORGETOWN UNIV, SCH MED, DEPT FAMILY MED, 3750 RESERVOIR RD NW, KOBER COGAN ROOM 417, WASHINGTON, DC 20007 USA.		bowman, marjorie a/F-7235-2013	bowman, marjorie a/0000-0002-1945-9212	PHS HHS [R18 A124403] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PF, 1991, VITAL HLTH STAT, V10, P1; AINSWORTH MA, 1991, JAMA-J AM MED ASSOC, V266, P1390, DOI 10.1001/jama.266.10.1390; Boekeloo B O, 1990, Am J Prev Med, V6, P51; BOEKELOO BO, 1991, AM J PUBLIC HEALTH, V81, P1645, DOI 10.2105/AJPH.81.12.1645; BOEKELOO BO, 1993, OBSTET GYNECOL, V81, P131; BOWMAN MA, 1992, ARCH INTERN MED, V152, P1823, DOI 10.1001/archinte.152.9.1823; CALABRESE LH, 1991, ARCH INTERN MED, V151, P1157, DOI 10.1001/archinte.151.6.1157; Carretta R A, 1990, J Community Health, V15, P147, DOI 10.1007/BF01350253; DAWSON DA, 1988, VITAL HLTH STAT, V153, P6; EWART CK, 1983, J MED EDUC, V58, P468; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GERBERT B, 1986, MED CARE, V24, P838, DOI 10.1097/00005650-198609000-00005; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; GONZALEZWILLIS A, 1990, ACAD MED, V65, pS7, DOI 10.1097/00001888-199009000-00018; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; KERN DE, 1990, J GEN INTERN MED, V5, P218, DOI 10.1007/BF02600538; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; LEWIS CE, 1990, AM J PUBLIC HEALTH, V80, P1511, DOI 10.2105/AJPH.80.12.1511; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; NORMAN GR, 1985, J MED EDUC, V60, P925; REDMAN L, 1989, AM J PREV MED, V5, P188; RUSSELL NK, 1991, ACAD MED, V66, pS37, DOI 10.1097/00001888-199109000-00034; RUSSELL NK, 1992, AM J PREV MED, V8, P235, DOI 10.1016/S0749-3797(18)30811-0; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; 1988, SAS STAT USERS GUIDE; 1991, DHHS PHS9150212 PUBL	27	49	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					513	519		10.7326/0003-4819-121-7-199410010-00007	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067649				2022-12-28	WOS:A1994PJ10200007
J	RUTGEERTS, P; LOFBERG, R; MALCHOW, H; LAMERS, C; OLAISON, G; JEWELL, D; DANIELSSON, A; GOEBELL, H; THOMSEN, OO; LORENZMEYER, H; HODGSON, H; PERSSON, T; SEIDEGARD, C				RUTGEERTS, P; LOFBERG, R; MALCHOW, H; LAMERS, C; OLAISON, G; JEWELL, D; DANIELSSON, A; GOEBELL, H; THOMSEN, OO; LORENZMEYER, H; HODGSON, H; PERSSON, T; SEIDEGARD, C			A COMPARISON OF BUDESONIDE WITH PREDNISOLONE FOR ACTIVE CROHNS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDEX	Background. Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low. Methods. We conducted a randomized, double-blind, 10-week trial comparing the efficacy and safety of an oral controlled-release form of budesonide with the efficacy and safety of prednisolone in 176 patients with active ileal or ileocecal Crohn's disease (88 patients in each treatment group). The dose of budesonide was 9 mg per day for eight weeks and then 6 mg per day for two weeks. The dose of prednisolone was 40 mg per day for two weeks, after which it was gradually reduced to 5 mg per day during the last week. Results. At 10 weeks, 53 percent of the patients treated with budesonide were in remission (defined as a score less than or equal to 150 on the Crohn's disease activity index), as compared with 66 percent of those treated with prednisolone (P = 0.12). The mean score on the Crohn's disease activity index decreased from 275 to 175 in the budesonide group and from 279 to 136 in the prednisolone group (P = 0.001). Corticosteroid-associated side effects were significantly less common in the budesonide group (29 vs. 48 patients, P = 0.003). Two patients in the prednisolone group had serious complications (one had intestinal perforation and one an abdominal-wall fistula). The mean morning plasma cortisol concentration was significantly lower in the prednisolone group than in the budesonide group after 4 weeks (P < 0.001) and 8 weeks (P = 0.02) of therapy, but not after 10 weeks. Conclusions. Among patients with active Crohn's disease, both controlled-release budesonide and prednisolone are effective in inducing remission. In this trial, prednisolone reduced scores on the Crohn's disease activity index more, whereas with budesonide there were fewer glucocorticoid-associated side effects and less suppression of pituitary-adrenal function.	HUDDINGE UNIV HOSP,DEPT GASTROENTEROL,HUDDINGE,SWEDEN; UNIV COLOGNE,AKAD LEHRKRANKENHAUS,LEVERKUSEN,GERMANY; LEIDEN UNIV HOSP,DEPT GASTROENTEROL & HEPATOL,LEIDEN,NETHERLANDS; LINKOPING UNIV HOSP,DEPT GASTROENTEROL,LINKOPING,SWEDEN; RADCLIFFE INFIRM,GASTROENTEROL UNIT,OXFORD OX2 6HE,ENGLAND; UMEA UNIV HOSP,DEPT MED,UMEA,SWEDEN; UNIV ESSEN GESAMTHSCH,MED KLIN & POLIKLIN,ESSEN,GERMANY; HERLEV UNIV HOSP,DEPT MED C,HERLEV,DENMARK; STADT KRANKENHAUS FRIEDRICHSHAFEN,FRIEDRICHSHAFEN,GERMANY; HAMMERSMITH HOSP,LONDON,ENGLAND; ASTRO DRACO AB,DEPT BIOSTAT & DATA PROC,LUND,SWEDEN; ASTRO DRACO AB,DEPT CLIN RES & DEV,LUND,SWEDEN	Karolinska Institutet; University of Cologne; Leiden University; Leiden University Medical Center (LUMC); Linkoping University; Radcliffe Infirmary; University of Oxford; Umea University; University of Duisburg Essen; University of Copenhagen; Herlev & Gentofte Hospital; Imperial College London	RUTGEERTS, P (corresponding author), KATHOLIEKE UNIV LEUVEN HOSP,DEPT GASTROENTEROL,B-3000 LOUVAIN,BELGIUM.							BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Brattsand R, 1990, CAN J GASTROENTEROL, V4, P407; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BROGDEN RN, 1992, DRUGS, V44, P1012, DOI 10.1007/BF03259142; BROGDEN RN, 1993, DRUGS, V45, P130, DOI 10.1007/BF03259101; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DAVIS SS, 1986, GUT, V27, P886, DOI 10.1136/gut.27.8.886; EDSBACKER S, 1993, GASTROENTEROLOGY, V104, pA695; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; HARVEY RF, 1980, LANCET, V1, P514; LOFBERG R, 1993, ALIMENT PHARM THERAP, V7, P611; LOFBERG R, 1993, GUT               S1, V34, pS41; MILLER L R, 1989, Gastroenterology, V96, pA344; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; THHOMSEN OO, 1993, GUT S3, V34, pS27; VANDENBERG JHM, 1977, CLIN CHIM ACTA, V78, P165, DOI 10.1016/0009-8981(77)90303-5; 1991, SCAND J GASTROENTERO, V26, P1225	18	495	511	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					842	845		10.1056/NEJM199409293311304	http://dx.doi.org/10.1056/NEJM199409293311304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078530				2022-12-28	WOS:A1994PH53000004
J	LAZAR, J				LAZAR, J			LIVIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					906	906						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084046				2022-12-28	WOS:A1994PG73700002
J	JAN, LY; JAN, YN				JAN, LY; JAN, YN			POTASSIUM CHANNELS AND THEIR EVOLVING GATES	NATURE			English	Article							K+-CHANNEL; CHLORIDE CHANNEL; INWARD RECTIFICATION; ESCHERICHIA-COLI; PORE; INACTIVATION; EXPRESSION; SUBUNIT; VOLTAGE; REGION	Potassium channels allow potassium ions to flow across the membrane and play a key role in maintaining membrane potential. Recent research has begun to reveal how these channels transport potassium in preference to other ions, how their activity is controlled, and how they ate related to other channels.			JAN, LY (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM & PHYSIOL, SAN FRANCISCO, CA 94143 USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KIRSCH GE, 1989, AM J PHYSIOL, V257, pH334, DOI 10.1152/ajpheart.1989.257.1.H334; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCHLOSSER A, 1991, J BACTERIOL, V173, P3170; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOLA, 1994, BIOPHYS J, V66, pA23; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TRUBE G, 1989, SECRETION ITS CONTRO; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	50	259	261	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	1994	371	6493					119	122		10.1038/371119a0	http://dx.doi.org/10.1038/371119a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072541				2022-12-28	WOS:A1994PF19100053
J	MARTINI, CJM; VELOSKI, JJ; BARZANSKY, B; XU, G; FIELDS, SK				MARTINI, CJM; VELOSKI, JJ; BARZANSKY, B; XU, G; FIELDS, SK			MEDICAL-SCHOOL AND STUDENT CHARACTERISTICS THAT INFLUENCE CHOOSING A GENERALIST CAREER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY MEDICINE; PHYSICIANS; NUMBER	Objective.-To identify predictors in medical schools that can be manipulated to affect the proportion of graduates entering generalist practice. Design and Participants.-Cross-sectional and retrospective studies of medical schools and practicing generalist physicians; surveys of MD-granting and DO-granting medical schools; site visits to nine schools with a high proportion of graduates becoming generalist physicians; surveys of national samples of MD and DO generalist physicians. Independent Variables.-Characteristics of medical schools, including structural characteristics, financing, mission, admissions policies, student demographics, curriculum, faculty, and the production of generalist physicians; information on personal characteristics, background, perceptions, and attitudes of practicing generalist physicians. Dependent Variable.-Estimated proportion of graduates of the classes of 1989, 1990, and 1991 in family practice, general internal medicine, and general pediatrics. Results.-Institutional mission, certain admissions policies, characteristics of entering students, and the presence of a primary care-oriented curriculum explained statistically significant variation in the number of physicians choosing generalist careers, even after the structural characteristics of public or private status, age of the school, and class size were controlled for statistically. Conclusions.- Public and institutional policies, where implemented, have had a positive effect on students' choice of generalist careers. The most influential factors under the control of the medical school are the criteria used for admitting students and the design of the curriculum, with particular emphasis on faculty role models. Personal social values was the individual characteristic that most strongly influenced graduates' career choice.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CTR RES MED EDUC & HLTH CARE,PHILADELPHIA,PA 19107; AMER MED ASSOC,OFF VICE PRESIDENT MED EDUC,CHICAGO,IL 60610; AMER MED ASSOC,DIV UNDERGRAD MED EDUC,CHICAGO,IL 60610	Jefferson University; American Medical Association; American Medical Association								Campos-Outcalt D, 1992, Fam Med, V24, P596; CAMPOSOUTCALT D, 1989, ACAD MED, V64, P610, DOI 10.1097/00001888-198910000-00013; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; HENSEL WA, 1993, ACAD MED, V68, P498, DOI 10.1097/00001888-199306000-00007; KASSEBAUM DG, 1992, ACAD MED, V67, P217, DOI 10.1097/00001888-199203000-00018; KASSEBAUM DG, 1994, ACAD MED, V69, P164; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V271, P1505, DOI 10.1001/jama.271.19.1505; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LINZER M, 1994, J GEN INTERN MED, V9, pS14, DOI 10.1007/BF02598114; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; MELNICK A, 1990, ACAD MED, V65, pS87, DOI 10.1097/00001888-199012000-00036; PETERSDORF RG, 1994, ACAD MED, V69, P756; RABINOWITZ HK, 1993, NEW ENGL J MED, V328, P934, DOI 10.1056/NEJM199304013281307; RIVO ML, 1994, JAMA-J AM MED ASSOC, V271, P1499, DOI 10.1001/jama.271.19.1499; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; ROSENBLATT RA, 1993, AM J PUBLIC HEALTH, V83, P322, DOI 10.2105/AJPH.83.3.322; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; WHITCOMB ME, 1992, ACAD MED, V67, P587, DOI 10.1097/00001888-199209000-00009; 1994, 1994 ANN REP C; 1992, 3RD US DEP HLTH HUM, P7; 1994, 1994 NRMP INFORMATIO; 1994, COMP C HLTH SYSTEM R; 1993, FUNCTIONS STRUCTURE	23	130	134	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					661	668		10.1001/jama.272.9.661	http://dx.doi.org/10.1001/jama.272.9.661			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064981				2022-12-28	WOS:A1994PE32700009
J	WHITCOMB, ME				WHITCOMB, ME			THE ROLE OF MEDICAL-SCHOOLS IN GRADUATE MEDICAL-EDUCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WHITCOMB, ME (corresponding author), AMER MED ASSOC,DIV GRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					702	704		10.1001/jama.272.9.702	http://dx.doi.org/10.1001/jama.272.9.702			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	8064986				2022-12-28	WOS:A1994PE32700015
J	HARRISON, WJ; WILLIS, RG; NEAL, DE				HARRISON, WJ; WILLIS, RG; NEAL, DE			ADVERSE REACTIONS TO TIAPROFENIC ACID MIMICKING INTERSTITIAL CYSTITIS	BRITISH MEDICAL JOURNAL			English	Article									FREEMAN RD HOSP,DEPT UROL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; E CUMBERLAND INFIRM,CARLISLE,CUMBRIA,ENGLAND	Newcastle Freeman Hospital				Neal, David/0000-0002-6033-5086				AHMED M, 1991, BRIT MED J, V303, P1376, DOI 10.1136/bmj.303.6814.1376; GHOSE K, 1993, NEW ZEAL MED J, V106, P501; ONEILL GFA, 1994, MED J AUSTRALIA, V160, P123	3	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					574	574		10.1136/bmj.309.6954.574	http://dx.doi.org/10.1136/bmj.309.6954.574			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086944	Green Published			2022-12-28	WOS:A1994PF33000018
J	SHAFI, MI				SHAFI, MI			CONTROVERSIES IN MANAGEMENT - MANAGEMENT OF WOMEN WITH MILD DYSKARYOSIS - CYTOLOGICAL SURVEILLANCE AVOIDS OVERTREATMENT .1.	BRITISH MEDICAL JOURNAL			English	Article							CERVICAL-CANCER; CARCINOMA; SMEARS				SHAFI, MI (corresponding author), DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							BENEDET JL, 1985, OBSTET GYNECOL, V65, P557; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DUNCAN ID, 1992, NHS CERVICAL SCREENI; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MACGREGOR JE, 1994, BMJ-BRIT MED J, V308, P1407, DOI 10.1136/bmj.308.6941.1407; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SEDLACEK TV, 1992, COLPOSCOPIST, V14, P1; 1993, CERVICAL CANCER RES	12	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					590	591		10.1136/bmj.309.6954.590	http://dx.doi.org/10.1136/bmj.309.6954.590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086950	Green Published			2022-12-28	WOS:A1994PF33000027
J	MORGENBESSER, SD; WILLIAMS, BO; JACKS, T; DEPINHO, RA				MORGENBESSER, SD; WILLIAMS, BO; JACKS, T; DEPINHO, RA			P53-DEPENDENT APOPTOSIS PRODUCED BY RB-DEFICIENCY IN THE DEVELOPING MOUSE LENS	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; TRANSGENIC MICE; CELL-DEATH; RAT LENS; GENE; EYE; TRANSFORMATION; KERATINOCYTES; EXPRESSION	THE retinoblastoma tumour-suppressor gene (RB) has been implicated in negative growth regulation, induction of differentiation, and inhibition of cellular transformation(1). Homozygous inactivation of the Rb gene in the mouse leads to mid-gestational lethality with defects in erythropoiesis and neurogenesis(2-4). Here we describe the effects of the Rb-deficient state on the development of the ocular lens. The regional compartmentalization of growth, differentiation and apoptosis in the developing lens provides an ideal system to examine more closely the relationships of these processes in vivo. We demonstrate that loss of Rb function is associated with unchecked proliferation, impaired expression of differentiation markers, and inappropriate apoptosis in lens fibre cells. In addition, we show that ectopic apoptosis in Rb-deficient lenses is dependent on p53, because embryos doubly null for Rb and p53 show a nearly complete suppression of this effect. This developmental system provides a framework for understanding the consequences of the frequent mutation of both RB and p53 in human cancer.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Yeshiva University; Albert Einstein College of Medicine			Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; DePinho, Ronald/0000-0002-5625-577X				BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; ISHAZAKI Y, 1993, J CELL BIOL, V121, P899; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MUNGER K, 1989, J VIROL, V63, P4417; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIELS A, 1991, BIOCHIM BIOPHYS ACTA, V1097, P318, DOI 10.1016/0925-4439(91)90087-P; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, IN PRESS EMBO J; YANCEY SB, 1988, J CELL BIOL, V106, P705, DOI 10.1083/jcb.106.3.705; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	28	576	585	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					72	74		10.1038/371072a0	http://dx.doi.org/10.1038/371072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072529				2022-12-28	WOS:A1994PE38100054
J	PRIVES, C				PRIVES, C			HOW LOOPS, BETA-SHEETS, AND ALPHA-HELICES HELP US TO UNDERSTAND P53	CELL			English	Review							DNA-BINDING FUNCTION; APOPTOSIS; PROTEIN; ACTIVATION; RADIATION; MUTANTS				PRIVES, C (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1994, IN PRESS NUCL ACIDS; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEGROS Y, 1994, IN PRESS ONCOGENE, V9; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; Reed Michael, 1993, Gene Expression, V3, P95; STEPHAN CW, 1990, J MOL BIOL, V225, P577; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1993, ONCOGENE, V8, P2555	27	172	172	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					543	546		10.1016/0092-8674(94)90519-3	http://dx.doi.org/10.1016/0092-8674(94)90519-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069906				2022-12-28	WOS:A1994PD69300003
J	AUSTOKER, J				AUSTOKER, J			CURRENT TRENDS AND SOME PROSPECTS FOR THE FUTURE .2.	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OVARIAN-CANCER; BREAST-CANCER; SURVIVAL; CHEMOPREVENTION; PREVENTION; MORTALITY	Cancer control encompasses the whole spectrum from prevention and early diagnosis to treatment and palliation. The key to the future of cancer control will be to establish multidisciplinary approaches to each type of cancer across this spectrum. For primary prevention this requires some understanding of the causes of each cancer. Although understanding of the aetiology of cancer has greatly improved, prospects for the primary prevention of many common cancers remain remote. Other approaches currently under evaluation,include chemoprevention and the use of biomarkers (discussed last week). The identification of predisposing genes for some of the common cancers may have a considerable impact on the ability to recognise those at risk. Overall,however, mortality trends indicate that reduction of smoking remains the main priority for cancer prevention in the United Kingdom. For primary care teams, brief interventions to reduce smoking are likely to achieve the greatest:benefit. This should be seen as part of broader policies aimed at achieving change in the whole population. The government must acknowledge its major responsibility to cancer prevention by banning all forms of advertising and promotion of tobacco.			AUSTOKER, J (corresponding author), UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, CANC RES CAMPAIGN, PRIMARY CARE EDUC RES GRP, OXFORD OX2 6PE, ENGLAND.							ALTMANN A, 1994, SYMP SOC GEN MICROBI, V51, P71; BAUM M, 1991, BRIT MED BULL, V47, P493, DOI 10.1093/oxfordjournals.bmb.a072487; CALNAN M, 1994, BRIT J GEN PRACT, V44, P224; CALNAN M, 1994, ADV MED SOCIOLOGY, V4, P69; CHARLTON BG, 1994, BRIT MED J, V308, P1019, DOI 10.1136/bmj.308.6935.1019; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; COGGON D, 1994, BRIT MED J, V308, P705, DOI 10.1136/bmj.308.6930.705; COLEMAN MP, 1993, ROY SOC MED INT CONG, V202, P21; DOLL R, 1987, OXFORD TXB MED, V1; EVANS DGR, 1994, BRIT MED J, V308, P183, DOI 10.1136/bmj.308.6922.183; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; HAKAMA M, 1990, EVALUATING EFFECTIVE; HUNT SM, 1987, COMMUNITY MED, V9, P68; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; KREUTER MW, 1993, CANCER, V72, P996, DOI 10.1002/1097-0142(19930801)72:3+<996::AID-CNCR2820721308>3.0.CO;2-O; LERMAN C, IN PRESS ARCH INTERN; LIPPMAN SM, 1993, CANCER, V72, P984, DOI 10.1002/1097-0142(19930801)72:3+<984::AID-CNCR2820721306>3.0.CO;2-0; MANT D, 1994, BRIT J GEN PRACT, V44, P51; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MEYSKENS FL, 1992, JNCI-J NATL CANCER I, V13, P177; MULSHINE JL, 1993, CANCER, V72, P978, DOI 10.1002/1097-0142(19930801)72:3+<978::AID-CNCR2820721305>3.0.CO;2-T; MUNOZ N, 1992, EPIDEMIOLOGY HUMAN P; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PONDER B, 1994, CANCER RES CAMPAIGN; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; PROCHASKA JO, 1992, PREVENTING CANC, P147; RICHARDS MPM, 1993, SOCIOL HEALTH ILL, V15, P567, DOI 10.1111/1467-9566.ep11433335; Rose G., 1992, STRATEGY PREVENTIVE; SPITZ MR, 1993, CANCER-AM CANCER SOC, V72, P991, DOI 10.1002/1097-0142(19930801)72:3+<991::AID-CNCR2820721307>3.0.CO;2-5; STILLER CA, 1989, BRIT MED J, V299, P1058, DOI 10.1136/bmj.299.6707.1058; TOMATIS L, 1990, CANCER CAUSES OCCURR; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23	34	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	1994	309	6953					517	520		10.1136/bmj.309.6953.517	http://dx.doi.org/10.1136/bmj.309.6953.517			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086912	Green Published			2022-12-28	WOS:A1994PD30800026
J	ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J				ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J			DIRECTIONAL MOTION OF BROWNIAN PARTICLES INDUCED BY A PERIODIC ASYMMETRIC POTENTIAL	NATURE			English	Article								STRUCTURES possessing spatial asymmetry should act as pumps in the presence of dissipation alone(1-4), without the need for macroscopic forces or temperature differences(5) to drive vectorial motion. It has been shown theoretically(2-4,6,7) that particles subjected to an asymmetric periodic potential can display net directional motion even if the space-averaged forte is zero. Here we demonstrate such behaviour experimentally. We have studied the behaviour of colloidal particles suspended in solution and exposed to a sawtooth dielectric potential which is turned on and off periodically. The particles exhibit net motion with a velocity that depends on their size, suggesting applications in separation processes for objects in the size range 0.1-5 mu m-a range that includes biological structures such as viruses, cells and chromosomes(8). We furthermore point out the analogy between our device and motor protein assemblies.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEOR GRP, CNRS, URA 1382, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	ROUSSELET, J (corresponding author), CTR RECH PAUL PASCAL, AVE A SCHWEITZER, F-33600 PESSAC, FRANCE.			SALOME, Laurence/0000-0001-9667-4154				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; AJDARI A, 1993, Patent No. 9311346; AJDARI A, 1992, THESIS U PARIS 6; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; CORDOVA NJ, 1991, NATO ADV SCI I B-PHY, V263, P207; Curie P., 1894, J PHYS-PARIS, V3, P393, DOI DOI 10.1051/JPHYSTAP:018940030039300; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; FELICI N, 1971, CR ACAD SCI B PHYS, V273, P1004; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; PESKIN CS, 1994, CELL MECHANICS CELLU; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652	12	575	595	5	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					446	448		10.1038/370446a0	http://dx.doi.org/10.1038/370446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047163				2022-12-28	WOS:A1994PB40700051
J	KIM, DS; BONHOEFFER, T				KIM, DS; BONHOEFFER, T			REVERSE OCCLUSION LEADS TO A PRECISE RESTORATION OF ORIENTATION PREFERENCE MAPS IN VISUAL-CORTEX	NATURE			English	Article							MONOCULAR DEPRIVATION; STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; KITTENS; CAT; ORGANIZATION; SELECTIVITY; DOMAINS; AREA-18	In the visual system of young kittens, the layout of the cortical maps for ocular dominance and orientation preference converges to an equilibrium state within the first few weeks of life and normally remains largely unchanged. If during the critical period, however, patterned visual experience is restricted to only one eye for a few days, cortical neurons lose their ability to respond to stimulation of the deprived eye. We used the 'reverse occlusion' protocol together with chronical optical imaging to investigate how the profound anatomical changes accompanying monocular deprivation(1) affect the spatial pattern of the cortical orientation preference map. We report here that after 1 week of monocular deprivation, cortical orientation maps for the deprived eye had vanished, But we also discovered that after subsequent reverse occlusion the restored orientation maps were very similar to the original maps. This demonstrates that in spite of functional disconnection of one eye after monocular deprivation, the layout of cortical orientation maps, when re-established for this eye, is not formed from scratch but is strongly influenced by previous experience.	MAX PLANCK INST PSYCHIAT,D-82152 MUNCHEN MARTINSRI,GERMANY; MAX PLANCK INST BRAIN RES,D-60528 FRANKFURT,GERMANY	Max Planck Society; Max Planck Society			Bonhoeffer, Tobias/B-9481-2009; Kim, Dae-Shik/C-2071-2011	Bonhoeffer, Tobias/0000-0001-7897-6634; 				ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; FITZPATRICK D, 1993, SOC NEUR ABSTR, V19; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KOSSUT M, 1991, EXP BRAIN RES, V85, P519; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; VANSLUYTERS RC, 1978, J PHYSIOL-LONDON, V284, P1	19	75	75	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					370	372		10.1038/370370a0	http://dx.doi.org/10.1038/370370a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047142				2022-12-28	WOS:A1994PA30400055
J	YOUNG, A; DINAN, S				YOUNG, A; DINAN, S			FITNESS FOR OLDER-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									LONDON CENT YMCA,LONDON,ENGLAND		YOUNG, A (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.								0	19	19	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					331	334		10.1136/bmj.309.6950.331	http://dx.doi.org/10.1136/bmj.309.6950.331			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086874	Green Published			2022-12-28	WOS:A1994PA37300027
J	STOKLAND, E; HELLSTROM, M; HANSSON, S; JODAL, U; ODEN, A; JACOBSSON, B				STOKLAND, E; HELLSTROM, M; HANSSON, S; JODAL, U; ODEN, A; JACOBSSON, B			RELIABILITY OF ULTRASONOGRAPHY IN IDENTIFICATION OF REFLUX NEPHROPATHY IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION; ULTRASOUND; PYELONEPHRITIS; SCINTIGRAPHY; CHILDHOOD	Objective-To assess the ability of ultrasonography to identify reflux nephropathy in children after urinary tract infection. Design-Ten experienced radiologists performed a total of 240 ultrasonographic examinations of kidneys in a one day study. The examiners were unaware of the results of previous radiological and clinical examinations and of the proportions of normal and abnormal kidneys. Urography was used as method of reference, supported by static renal scintigraphy (dimercaptosuccinic acid labelled with technetium-99m) in half of the cases. Setting-Outpatient radiology department. Subjects-25 children aged 2-16 years (20 kidneys with and 30 kidneys without renal scarring). Main outcome measures-Renal scarring. Overall size and length of kidneys. Sensitivity and specificity including receiver operator characteristics and variation between observers. Results-With renal scarring as the diagnostic criterion and including cases classified as abnormal, probably abnormal, and uncertain the sensitivity of ultrasonography was 54% (specificity 80%). Addition of reduced renal size as a diagnostic criterion increased the sensitivity to 64% (specificity 79%). There were, however, wide variations between observers, with sensitivity ranging between 40% and 90% (specificity 94% to 65%). Conclusions-Because of its low sensitivity and specificity and poor agreement between observers, ultrasonography cannot be generally recommended for the detection of reflux nephropathy after urinary tract infection in children.	SAHLGRENS UNIV HOSP,DEPT RADIOL,GOTHENBURG,SWEDEN; EAST HOSP,DEPT PAEDIAT,GOTHENBURG,SWEDEN	Sahlgrenska University Hospital	STOKLAND, E (corresponding author), EAST HOSP,DEPT PAEDIAT RADIOL,S-41685 GOTHENBURG,SWEDEN.		Hellström, Mikael/U-2211-2019	Hellstrom, Mikael/0000-0003-4031-332X				ALON U, 1986, PEDIATRICS, V78, P58; BARR BL, 1991, HDB PEDIATRIC IMAGIN, P239; BJORGVINSSON E, 1991, AM J ROENTGENOL, V157, P539; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; CLAESSON I, 1981, ACTA RADIOL DIAGN, V22, P305, DOI 10.1177/028418518102203B01; CLAESSON I, 1981, ACTA RADIOL DIAGN, V22, P315, DOI 10.1177/028418518102203B02; GARLAND LH, 1959, AMER J ROENTGENOL RA, V82, P25; GELFAND DW, 1985, AM J ROENTGENOL, V144, P1117, DOI 10.2214/ajr.144.6.1117; GLEESON FV, 1991, ARCH DIS CHILD, V66, P1282, DOI 10.1136/adc.66.11.1282; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; HALLER JO, 1987, UROL RADIOL, V9, P99; HAYCOCK GB, 1991, PEDIATR NEPHROL, V5, P401, DOI 10.1007/BF01453665; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; HODSON CJ, 1967, RADIOLOGY, V88, P857, DOI 10.1148/88.5.857; HODSON JC, 1975, BRIT J RADIOL      S, V13, P1; JACOBSON SH, 1989, BMJ-BRIT MED J, V299, P703, DOI 10.1136/bmj.299.6701.703; Jodal U, 1987, Infect Dis Clin North Am, V1, P713; KANGARLOO H, 1985, RADIOLOGY, V154, P367, DOI 10.1148/radiology.154.2.3880909; Macpherson R I, 1986, Semin Urol, V4, P89; MASON WG, 1984, RADIOLOGY, V153, P109, DOI 10.1148/radiology.153.1.6473770; METZ CE, 1986, INVEST RADIOL, V21, P720, DOI 10.1097/00004424-198609000-00009; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; ROSENBERG AR, 1992, J UROLOGY, V148, P1746, DOI 10.1016/S0022-5347(17)37019-2; Schulman Seth L., 1993, Current Opinion in Pediatrics, V5, P191, DOI 10.1097/00008480-199304000-00010; SHEPS SB, 1984, JAMA-J AM MED ASSOC, V252, P2418, DOI 10.1001/jama.252.17.2418; Simpson W, 1989, Clin Radiol, V40, P109, DOI 10.1016/S0009-9260(89)80060-1; TASKER AD, 1993, CLIN RADIOL, V47, P177, DOI 10.1016/S0009-9260(05)81157-2	28	47	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					235	239		10.1136/bmj.309.6949.235	http://dx.doi.org/10.1136/bmj.309.6949.235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069140	Green Published			2022-12-28	WOS:A1994NZ18000016
J	BENMENACHEM, T; FOGEL, R; PATEL, RV; TOUCHETTE, M; ZAROWITZ, BJ; HADZIJAHIC, N; DIVINE, G; VERTER, J; BRESALIER, RS				BENMENACHEM, T; FOGEL, R; PATEL, RV; TOUCHETTE, M; ZAROWITZ, BJ; HADZIJAHIC, N; DIVINE, G; VERTER, J; BRESALIER, RS			PROPHYLAXIS FOR STRESS-RELATED GASTRIC HEMORRHAGE IN THE MEDICAL INTENSIVE-CARE UNIT - A RANDOMIZED, CONTROLLED, SINGLE-BLIND STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						GASTROINTESTINAL HEMORRHAGE; INTENSIVE CARE UNITS; SUCRALFATE; CIMETIDINE; GASTRITIS	CRITICALLY ILL PATIENTS; UPPER GASTROINTESTINAL HEMORRHAGE; ULCER PROPHYLAXIS; CLINICAL-TRIALS; CIMETIDINE PROPHYLAXIS; MECHANICAL VENTILATION; INTRAVENOUS CIMETIDINE; NOSOCOMIAL PNEUMONIA; ANTACID TITRATION; HEAD-INJURY	Objective: To determine the efficacy and safety of cimetidine and sucralfate prophylaxis for stress-related gastrointestinal hemorrhage in patients admitted to a medical intensive care unit. Setting: Medical intensive care unit of a nonprofit, university-affiliate teaching hospital. Patients: 300 patients admitted to the medical intensive care unit during a 10-month period. Design: Randomized, controlled, single-blind clinical trial. Intervention: Patients were assigned to receive no prophylaxis (control), 1 g sucralfate given orally every 6 hours, or continuous intravenous cimetidine titrated to maintain gastric pH at 4.0. Intervention was maintained until the occurrence of clinically severe hemorrhage, onset of drug-related complications, death, or discharge from the medical intensive care unit. Outcome Measures: The primary outcome measure was the incidence of clinically severe hemorrhage from endoscopically verified stress-related gastritis. Other outcome measures were transfusion requirements, duration of medical intensive care unit stay, incidence of nosocomial pneumonia, adverse drug reactions, and death. Results: 100 patients were randomly assigned to each treatment. The three groups were similar with regard to demographic characteristics, intensive care unit admission diagnoses, and APACHE II scores. Stress-related hemorrhage was seen in 6% of control participants and in 5% of those receiving sucralfate or cimetidine (relative risk compared with control, 0.83 for each group; 95% CI, 0.26 to 2.64; P = 0.75). No statistically significant differences were found for transfusion requirements, duration of medical intensive care unit stay, and mortality rates among the three groups. Nosocomial pneumonia was diagnosed in 6%, 12%, and 13% of controls, sucralfate recipients, and cimetidine recipients, respectively (sucralfate: relative risk, 2.0 [CI, 0.79 to 5.01], P = 0.14; cimetidine: relative risk, 2.2 [CI, 0.88 to 5.33], P = 0.09). Prophylaxis caused no definite adverse drug reactions. Conclusions: The observed effects of cimetidine and sucralfate on the incidence and severity of hemorrhage from stress-related gastritis were not significant when compared with no treatment. Routine prophylaxis with these agents for patients entering the medical intensive care unit does not seem warranted.	HENRY FORD HOSP, DIV GASTROENTEROL, DETROIT, MI 48202 USA; HENRY FORD HOSP, DEPT PHARM SERV, DETROIT, MI 48202 USA; HLTH SCI CTR, DETROIT, MI USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital				Bresalier, Robert/0000-0002-9740-281X				BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BRESALIER RS, 1987, AM J MED, V83, P110, DOI 10.1016/0002-9343(87)90839-4; BRESALIER RS, 1991, J CLIN GASTROENTEROL, V13, pS35; Cantu TG, 1991, ANN INTERN MED, V114, P1027, DOI 10.7326/0003-4819-114-12-1027; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; COOK DJ, 1991, AM J MED, V91, P519, DOI 10.1016/0002-9343(91)90189-5; COX DR, 1972, J R STAT SOC B, V34, P187; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FRIEDMAN CJ, 1982, CRIT CARE MED, V10, P316; Friedman LM, 1985, FUNDAMENTALS CLIN TR; GROLL A, 1986, GUT, V27, P135, DOI 10.1136/gut.27.2.135; HALLORAN LG, 1980, AM J SURG, V139, P44, DOI 10.1016/0002-9610(80)90228-7; HALPERIN M, 1982, CONTROL CLIN TRIALS, V3, P311, DOI 10.1016/0197-2456(82)90022-8; HARRIS SK, 1977, CHEST, V72, P301, DOI 10.1378/chest.72.3.301; HASTINGS PR, 1978, NEW ENGL J MED, V298, P1041, DOI 10.1056/NEJM197805112981901; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P75; KAHN F, 1981, CHEST, V79, P409; KAMADA T, 1977, J TRAUMA, V17, P44, DOI 10.1097/00005373-197701000-00006; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MACDOUGALL BRD, 1977, LANCET, V1, P617; MARTIN LF, 1993, CRIT CARE MED, V21, P19, DOI 10.1097/00003246-199301000-00009; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; PEURA DA, 1985, ANN INTERN MED, V103, P173, DOI 10.7326/0003-4819-103-2-173; PEURA DA, 1990, AM J GASTROENTEROL, V85, P935; POLESKI MH, 1986, AM J GASTROENTEROL, V81, P107; PORTER JB, 1986, ARCH INTERN MED, V146, P2237, DOI 10.1001/archinte.146.11.2237; PRIEBE HJ, 1980, NEW ENGL J MED, V302, P426, DOI 10.1056/NEJM198002213020802; REUSSER P, 1990, CRIT CARE MED, V18, P270, DOI 10.1097/00003246-199003000-00004; RICHTER JM, 1989, AM J MED, V87, P278; RUIZSANTANA S, 1991, CRIT CARE MED, V19, P887, DOI 10.1097/00003246-199107000-00011; SCHUSTER DP, 1984, AM J MED, V76, P623, DOI 10.1016/0002-9343(84)90286-9; SCHUSTER DP, 1993, CRIT CARE MED, V21, P4, DOI 10.1097/00003246-199301000-00003; TRYBA M, 1993, DRUGS, V45, P338, DOI 10.2165/00003495-199345030-00003; TRYBA M, 1991, J CLIN GASTROENTEROL, V13, pS44; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; WILCOX CM, 1988, AM J GASTROENTEROL, V83, P1199; ZINNER MJ, 1989, ANN SURG, V210, P590, DOI 10.1097/00000658-198911000-00004; ZINNER MJ, 1981, SURG GYNECOL OBSTET, V153, P214; Zuckerman GR, 1988, INTENS CARE MED, V3, P21; 1989, SAS STAT USERS GUIDE	46	146	152	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					568	+		10.7326/0003-4819-121-8-199410150-00003	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085688				2022-12-28	WOS:A1994PL48600003
J	FISHER, ES; WENNBERG, JE; STUKEL, TA; SHARP, SM				FISHER, ES; WENNBERG, JE; STUKEL, TA; SHARP, SM			HOSPITAL READMISSION RATES FOR COHORTS OF MEDICARE BENEFICIARIES IN BOSTON AND NEW-HAVEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY; SERVICES; MODELS	Background. Geographic variations in the use of hospital services are associated with differences in the availability of hospital beds. There continues to be uncertainty about the extent to which unmeasured case-mix differences explain these findings. Previous research showed that the number of occupied beds per capita in Boston was substantially higher than the number of occupied beds per capita in New Haven, Connecticut, and that overall rates of hospital utilization were higher for Boston residents than for New Haven residents. Methods. We used Medicare claims data to study cohorts of Medicare beneficiaries 65 years of age or older and residing in Boston or New Haven who were initially hospitalized for one of five indications (acute myocardial infarction, stroke, gastrointestinal bleeding, hip fracture, or potentially curative surgery for breast, colon, or lung cancer). Residents of Boston or New Haven who were discharged between October 1, 1987, and September 30, 1989, were enrolled in the cohort corresponding to the earliest such admission and followed for up to 35 months. Results. The relative rate of readmission in Boston as compared with New Haven was 1.64 (95 percent confidence interval, 1.53 to 1.76) for all cohorts combined, with a similarly elevated rate for each of the five clinical cohorts and each age, sex, and race subgroup examined. Hospital-specific readmission rates varied substantially among the hospitals in Boston and were higher than those in New Haven. No relation was found between mortality (during the first 30 days after discharge or over the entire study period) and either community or hospital-specific readmission rates. Conclusions. Regardless of the initial cause of admission, Medicare beneficiaries who were initially hospitalized in Boston had consistently higher rates of readmission than did Medicare beneficiaries hospitalized in New Haven. Differences in the severity of illness are unlikely to explain these findings. One possible explanation is a threshold effect of hospital-bed availability on decisions to admit patients.	VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH; DARTMOUTH COLL SCH MED,CTR EVALUAT CLIN SCI,HANOVER,NH	US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College; Dartmouth College				Stukel, Therese/0000-0002-2951-1360	AHRQ HHS [R18-HS05745] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AITKIN M, 1980, BIOMETRICS, V36, P173, DOI 10.2307/2530509; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COX DR, 1972, J R STAT SOC B, V34, P187; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; FISHER ES, 1992, JAMA-J AM MED ASSOC, V267, P1925, DOI 10.1001/jama.267.14.1925; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Roos N P, 1988, Health Care Financ Rev, V9, P53; STUKEL TA, IN PRESS STAT MED; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1988, AM HOSPITAL ASS GUID; 1989, AM HOSPITAL ASS GUID; 1988, MEDICARE STATISTICAL; 1990, AM HOSPITAL ASS GUID	20	180	180	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					989	995		10.1056/NEJM199410133311506	http://dx.doi.org/10.1056/NEJM199410133311506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	8084356				2022-12-28	WOS:A1994PK50400006
J	KUPERSMITH, MJ; ROSENBERG, C; KLEINBERG, D				KUPERSMITH, MJ; ROSENBERG, C; KLEINBERG, D			VISUAL-LOSS IN PREGNANT-WOMEN WITH PITUITARY-ADENOMAS	ANNALS OF INTERNAL MEDICINE			English	Article						PREGNANCY; PROLACTINOMA; PITUITARY NEOPLASMS; VISION DISORDERS; VISUAL FIELDS	TUMORS; BROMOCRIPTINE; PROLACTIN; HYPERPROLACTINEMIA	Objective: To investigate the potential risk for developing visual loss during single or multiple pregnancies in women with pituitary adenomas. Design: Cohort study. Setting: Referral center of a neuro-ophthalmology service. Patients: 65 consecutive women with pituitary adenomas who had not been previously treated with surgery or radiation were monitored during 111 pregnancies. Sixty had increased levels of serum prolactin or growth hormone and 5 did not. Main Outcome Measures: Visual field or acuity loss was compared with the baseline size of the adenoma measured on the coronal view of the computed tomographic or magnetic resonance image. Results: Computed tomography or magnetic resonance imaging showed a definitive tumor (>0.3 cm, vertical height) in 57 patients, 8 of whom had macroadenomas (greater than or equal to 1.1 cm). Visual field loss occurred in 6 of 8 primiparous patients, all with adenomas greater than 1.1 cm (range, 1.2 to 2.5 cm). None of the 57 patients (95% CI, 0% to 6.3%) with a microadenoma or presumed microadenoma of 1 cm or smaller developed visual loss-after as many as four full-term pregnancies. Conclusions: The risk for developing visual loss during single or multiple pregnancies in patients with microadenomas was small. Six of eight pregnant women with macroadenomas, however, developed visual field loss during pregnancy.	NYU, MED CTR, DEPT NEUROL, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT MED, NEW YORK, NY 10016 USA; DEPT VET AFFAIRS MED CTR, NEW YORK, NY USA	New York University; New York University	KUPERSMITH, MJ (corresponding author), NYU, MED CTR, DEPT OPHTHALMOL, 530 1ST AVE 3B, NEW YORK, NY 10016 USA.							BERGH T, 1982, CLIN ENDOCRINOL, V17, P625, DOI 10.1111/j.1365-2265.1982.tb01636.x; BERGH T, 1978, BRIT MED J, V1, P875, DOI 10.1136/bmj.1.6117.875; BERGH T, 1981, ACTA ENDOCRINOL-COP, V98, P333, DOI 10.1530/acta.0.0980333; BRESLOW NE, 1980, IARC SCI PUBL, V32, P191; CANALES ES, 1981, FERTIL STERIL, V36, P524; CORENBLUM B, 1979, FERTIL STERIL, V32, P183; GEMZELL C, 1979, FERTIL STERIL, V31, P363; GOODMAN L A, 1984, Obstetrics and Gynecology, V64, p2S; KRUPP P, 1987, KLIN WOCHENSCHR, V65, P823, DOI 10.1007/BF01727477; LAMBERTS SWJ, 1979, FERTIL STERIL, V31, P614; MAGYAR DM, 1978, AM J OBSTET GYNECOL, V132, P739, DOI 10.1016/S0002-9378(78)80008-8; MELMED S, 1986, ANN INTERN MED, V105, P238, DOI 10.7326/0003-4819-105-2-238; MOLITCH ME, 1985, NEW ENGL J MED, V312, P1364, DOI 10.1056/NEJM198505233122106; MORNEX R, 1978, J CLIN ENDOCR METAB, V47, P290, DOI 10.1210/jcem-47-2-290; PEILLON F, 1988, ADV PITUITARY ADENOM, P67; RJOSK HK, 1982, ACTA ENDOCRINOL-COP, V100, P337, DOI 10.1530/acta.0.1000337; RUIZVELASCO V, 1984, FERTIL STERIL, V41, P793; SAMAAN NA, 1984, AM J OBSTET GYNECOL, V148, P466, DOI 10.1016/0002-9378(84)90728-2; SHELINE GE, 1984, PROGR ENDOCRINE RES, V1, P93; SHEWCHUK AB, 1980, AM J OBSTET GYNECOL, V136, P659, DOI 10.1016/0002-9378(80)91020-0; THORNER MO, 1979, BRIT MED J, V2, P771, DOI 10.1136/bmj.2.6193.771; THORNER MO, 1981, J CLIN ENDOCR METAB, V53, P480, DOI 10.1210/jcem-53-3-480; VANCE ML, 1987, ENDOCRIN METAB CLIN, V16, P731, DOI 10.1016/S0889-8529(18)30471-7; VANROON E, 1981, FERTIL STERIL, V36, P173; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Zar J., 1984, BIOSTAT ANAL, P261; ZARATE A, 1979, ACTA ENDOCRINOL-COP, V92, P407, DOI 10.1530/acta.0.0920407; 1990, SAS STAT USERS GUIDE, V2, P891	28	86	89	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					473	477		10.7326/0003-4819-121-7-199410010-00001	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067644				2022-12-28	WOS:A1994PJ10200001
J	KEANE, D; JACKSON, G				KEANE, D; JACKSON, G			PERCUTANEOUS BALLOON PULMONARY VALVULOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KEANE, D (corresponding author), GUYS HOSP,LONDON SE1 9RT,ENGLAND.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					846	846						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078531				2022-12-28	WOS:A1994PH53000005
J	LENFANT, C				LENFANT, C			LIFE-STYLE CHANGES, LOW-DOSE DIURETICS SHOULD BE FIRST CHOICE FOR TREATING HYPERTENSION IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI, BLDG 31, ROOM 2B19, BETHESDA, MD 20892 USA.							[Anonymous], 1991, JAMA, V265, P3255; BLACK HR, 1994, HYPERTENSION, V23, P275; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154	3	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					842	842		10.1001/jama.272.11.842	http://dx.doi.org/10.1001/jama.272.11.842			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078153				2022-12-28	WOS:A1994PG18200005
J	CHARLESWORTH, B; SNIEGOWSKI, P; STEPHAN, W				CHARLESWORTH, B; SNIEGOWSKI, P; STEPHAN, W			THE EVOLUTIONARY DYNAMICS OF REPETITIVE DNA IN EUKARYOTES	NATURE			English	Review							ELEMENT COPY NUMBER; GROUP-II INTRON; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENTS; POPULATION-GENETICS; SATELLITE DNA; Y-CHROMOSOME; CENTROMERIC HETEROCHROMATIN; HIGH-FREQUENCY; TANDEM ARRAYS	Repetitive DNA sequences form a large portion of the genomes of eukaryotes. The 'selfish DNA' hypothesis proposes that they are maintained by their ability to replicate within the genome. The behaviour of repetitive sequences can result in mutations that cause genetic diseases, and confer significant fitness losses on the organism. Features of the organization of repetitive sequences in eukaryotic genomes, and their distribution in natural populations, reflect the evolutionary forces acting on selfish DNA.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; UNIV MARYLAND, DEPT ZOOL, COLLEGE PK, MD 20742 USA	Michigan State University; University System of Maryland; University of Maryland College Park	CHARLESWORTH, B (corresponding author), UNIV CHICAGO, DEPT ECOL & EVOLUT, 1101 E 57TH ST, CHICAGO, IL 60637 USA.		Stephan, Wolfgang/GOV-6503-2022					Armour JAL, 1992, CURR OPIN GENET DEV, V2, P850, DOI 10.1016/S0959-437X(05)80106-6; BACHMANN L, 1993, MOL BIOL EVOL, V10, P647; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; BELLIS M, 1987, MOL BIOL EVOL, V4, P351; BENNETT MD, 1972, PROC R SOC SER B-BIO, V181, P109, DOI 10.1098/rspb.1972.0042; Berg DE, 1989, MOBILE DNA; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; BIEMONT C, 1992, GENETICA, V86, P67, DOI 10.1007/BF00133712; Bingham PM, 1989, MOBILE DNA, P485; BLESSMANN H, 1992, EMBO J, V11, P4459; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P5992, DOI 10.1073/pnas.91.13.5992; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; BROOKFIELD JFY, 1991, GENETICS, V128, P471; BRUFORD MW, 1993, CURR OPIN GENET DEV, V3, P939, DOI 10.1016/0959-437X(93)90017-J; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; CABOT EL, 1993, GENETICS, V135, P477; CAMERON JR, 1979, CELL, V16, P739, DOI 10.1016/0092-8674(79)90090-4; Cavalier-Smith T., 1985, P105; Cavalier-Smith T, 1985, EVOLUTION GENOME SIZ; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1992, GENET RES, V60, P103, DOI 10.1017/S0016672300030792; CHARLESWORTH B, 1992, GENET RES, V60, P115, DOI 10.1017/S0016672300030809; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; CHARLESWORTH B, 1986, GENETICS, V112, P947, DOI 10.1093/genetics/112.4.947; Charlesworth B., 1985, POPULATION GENETICS, P213; Crow JF, 1983, GENET BIOL DROSOPHIL, P1; Deininger PL, 1989, MOBILE DNA, P619; DEKA R, 1991, GENOMICS, V11, P83, DOI 10.1016/0888-7543(91)90104-M; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; Dover G. A., 1982, GENOME EVOLUTION; DOWSETT AP, 1982, P NATL ACAD SCI-BIOL, V79, P4570, DOI 10.1073/pnas.79.15.4570; EANES WF, 1992, GENET RES, V59, P1, DOI 10.1017/S0016672300030111; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EICHER EM, 1989, GENETICS, V122, P181; Eickbush Thomas H., 1994, P121; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GANGULY R, 1992, P NATL ACAD SCI USA, V89, P1340, DOI 10.1073/pnas.89.4.1340; GLOOR NB, 1991, SCIENCE, P1110; GRAY IC, 1991, P ROY SOC B-BIOL SCI, V243, P241, DOI 10.1098/rspb.1991.0038; HARDING RM, 1993, GENETICS, V135, P911; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HEY J, 1989, MOL BIOL EVOL, V6, P66; HOCHSTENBACH R, IN PRESS J MOL EVOL; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HUNT JA, 1984, P NATL ACAD SCI-BIOL, V81, P7146, DOI 10.1073/pnas.81.22.7146; JABS EW, 1989, P NATL ACAD SCI USA, V86, P202, DOI 10.1073/pnas.86.1.202; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KIDWELL MG, 1992, GENETICA, V86, P275, DOI 10.1007/BF00133726; KIM A, 1994, P NATL ACAD SCI USA, V91, P1285, DOI 10.1073/pnas.91.4.1285; KRUGER J, 1975, J MOL EVOL, V4, P201, DOI 10.1007/BF01732983; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LANGLEY CH, 1988, GENET RES, V52, P223, DOI 10.1017/S0016672300027695; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LEIGH EG, 1973, GENETICS, V73, P1; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LINDAHL T, 1994, CURR BIOL, V4, P249, DOI 10.1016/S0960-9822(00)00056-7; LOHE AR, 1993, GENETICS, V134, P1149; MACKAY TFC, 1992, GENETICS, V130, P315; MACKAY TFC, 1986, GENET RES, V48, P77, DOI 10.1017/S0016672300024794; MARTIN G, 1983, J MOL EVOL, V19, P203, DOI 10.1007/BF02099967; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MCDONALD JF, 1993, CURR OPIN GENET DEV, V3, P855, DOI 10.1016/0959-437X(93)90005-A; MONTGOMERY E, 1987, GENET RES, V49, P31, DOI 10.1017/S0016672300026707; MONTGOMERY EA, 1991, GENETICS, V129, P1085; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; NEVERS P, 1977, NATURE, V268, P109, DOI 10.1038/268109a0; NUZHDIN SV, IN PRESS MOL BIOL EV; OKUMURA K, 1987, NUCLEIC ACIDS RES, V15, P7477, DOI 10.1093/nar/15.18.7477; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; PAGEL M, 1992, P ROY SOC B-BIOL SCI, V249, P119, DOI 10.1098/rspb.1992.0093; REED KM, 1994, J MOL EVOL, V38, P352, DOI 10.1007/BF00163152; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHAPIRO JA, 1992, GENETICA, V86, P99, DOI 10.1007/BF00133714; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; STEINEMANN M, 1992, P NATL ACAD SCI USA, V89, P7591, DOI 10.1073/pnas.89.16.7591; STEPHAN W, 1989, MOL BIOL EVOL, V6, P198, DOI 10.1093/oxfordjournals.molbev.a040542; STEPHAN W, 1994, GENETICS, V136, P333, DOI 10.1093/genetics/136.1.333; STEPHAN W, 1986, GENET RES, V47, P167, DOI 10.1017/S0016672300023089; STEPHAN W, 1987, GENET RES, V50, P41, DOI 10.1017/S0016672300023326; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SYVANEN M, 1984, ANNU REV GENET, V18, P271, DOI 10.1146/annurev.ge.18.120184.001415; TACHIDA H, 1993, GENETICS, V133, P1023; TYLERSMITH C, 1993, CURR OPIN GENET DEV, V3, P390, DOI 10.1016/0959-437X(93)90110-B; VALDES AM, 1993, GENETICS, V133, P737; VAURY C, 1989, CHROMOSOMA, V98, P215, DOI 10.1007/BF00329686; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WALSH JB, 1987, GENETICS, V115, P553; WARBURTON PE, 1993, MOL CELL BIOL, V13, P6520, DOI 10.1128/MCB.13.10.6520; WEISSENBACH J, 1993, CURR OPIN GENET DEV, V3, P414, DOI 10.1016/0959-437X(93)90114-5; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WICHMAN HA, 1992, GENETICA, V86, P287, DOI 10.1007/BF00133727; WILKE CM, 1992, GENETICA, V86, P155, DOI 10.1007/BF00133718; WU CI, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P177; ZHONG N, 1993, NAT GENET, V5, P248, DOI 10.1038/ng1193-248; [No title captured]	102	1258	1315	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	1994	371	6494					215	220		10.1038/371215a0	http://dx.doi.org/10.1038/371215a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078581				2022-12-28	WOS:A1994PG29000042
J	ROUSSEAU, F; BONAVENTURE, J; LEGEAIMALLET, L; PELET, A; ROZET, JM; MAROTEAUX, P; LEMERRER, M; MUNNICH, A				ROUSSEAU, F; BONAVENTURE, J; LEGEAIMALLET, L; PELET, A; ROZET, JM; MAROTEAUX, P; LEMERRER, M; MUNNICH, A			MUTATIONS IN THE GENE ENCODING FIBROBLAST GROWTH-FACTOR RECEPTOR-3 IN ACHONDROPLASIA	NATURE			English	Article							BIRTH PREVALENCE RATES; TERMINAL DIFFERENTIATION; SKELETAL DYSPLASIAS; SIGNAL TRANSDUCTION; FAMILY	ACHONDROPLASIA, the most common cause of chondrodysplasia in man (1 in 15,000 live births), is a condition of unknown origin characterized by short-limbed dwarfism and macrocephaly(1,2). More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals, suggesting that de novo mutations are of paternal origin. Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (10%)(3-6). In contrast, homozygous achondroplasia is usually lethal in the neonatal period and affects 25% of the offspring of matings between heterozygous achondroplasia parents. The gene responsible for achondroplasia has been mapped to chromosome 4p16.3 (refs 7, 8); the genetic interval encompassing the disease gene contains a member of the fibroblast-growth-factor receptor (FGFR(3)) family which is expressed in articular chondrocytes. Here we report the finding of recurrent missense mutations in a CpG doublet of the transmembrane domain of the FGFR(3) protein (glycine substituted with arginine at residue 380, G380R) in 17 sporadic cases and 6 unrelated familial forms of achondroplasia. We show that the mutant genotype segregates with the disease in these families. Thus it appears that recurrent mutations of a single amino acid in the transmembrane domain of the FGFR(3) protein account for all cases (23/23) of achondroplasia in our series.	HOP NECKER ENFANTS MALAD, INST NECKER, CNRS, ER 88, INSERM, U393, SERV GENET, F-75743 PARIS 15, FRANCE; HOP NECKER ENFANTS MALAD, INST NECKER,CNRS,ER 88,INSERM, U393,UNITE RECH HANDICAPS GENET ENFANT, F-75743 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			ROZET, Jean-Michel/E-5737-2016; Legeai-Mallet, Laurence/E-6112-2016	ROZET, Jean-Michel/0000-0001-7951-7886; Legeai-Mallet, Laurence/0000-0003-4989-5856; PELET, Anastella/0000-0002-8353-1725				EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GARDNER RJM, 1977, CLIN GENET, V11, P31; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; KATO Y, 1990, J BIOL CHEM, V265, P5903; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEMERRER M, 1994, NAT GENET, V6, P318; Maroteaux P, 1964, Clin Orthop Relat Res, V33, P91; MURDOCH JL, 1970, ANN HUM GENET, V33, P227, DOI 10.1111/j.1469-1809.1970.tb01648.x; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORIOLI IM, 1986, J MED GENET, V23, P328, DOI 10.1136/jmg.23.4.328; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; STOLL C, 1989, CLIN GENET, V35, P88; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	18	678	714	5	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	1994	371	6494					252	254		10.1038/371252a0	http://dx.doi.org/10.1038/371252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078586				2022-12-28	WOS:A1994PG29000054
J	KIM, YJ; RAJAPANDI, T; OLIVER, D				KIM, YJ; RAJAPANDI, T; OLIVER, D			SECA PROTEIN IS EXPOSED TO THE PERIPLASMIC SURFACE OF THE ESCHERICHIA-COLI INNER MEMBRANE IN ITS ACTIVE STATE	CELL			English	Article							ESCHERICHIA-COLI; TRANSLOCATION ATPASE; PLASMA-MEMBRANE; PRECURSOR PROTEINS; INVERTED VESICLES; EXPORT; GENE; PHOSPHOLIPIDS; PREPROTEIN; RECONSTITUTION	E. coli cells harboring pCG169 containing the secD secF locus possessed SecA protein almost entirely in an integral membrane form in which it displayed normal protein translocation activity. These results imply that integral membrane SecA is the catalytically active form of this enzyme and that products of the secD secF locus regulate SecA association with the inner membrane. Protease and biotinylation accessibility studies of right side-out and inside-out membrane vesicles derived from this strain revealed that SecA was exposed to the periplasmic surface of the inner membrane. These studies suggest a model of bacterial protein secretion, whereby insertion of SecA into the inner membrane and its association with SecY/E/G promotes assembly of active protein-conducting channels comprised in part of integral membrane SecA protein, and products of the secD secF locus regulate the channel assembly-disassembly reaction by modulating the SecA insertion-deinsertion step.			KIM, YJ (corresponding author), WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BREMER E, 1990, GENE, V96, P59, DOI 10.1016/0378-1119(90)90341-N; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; RAJAPANDI T, 1994, J BACTERIOL, V176, P4444, DOI 10.1128/jb.176.14.4444-4447.1994; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; TAURA T, 1992, MOL GEN GENET, V234, P429, DOI 10.1007/BF00538702; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VANDERPLAS J, 1983, J BACTERIOL, V153, P1027, DOI 10.1128/JB.153.2.1027-1037.1983; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	51	162	163	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					845	853						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087851				2022-12-28	WOS:A1994PG29600013
J	FISHER, RP; MORGAN, DO				FISHER, RP; MORGAN, DO			A NOVEL CYCLIN ASSOCIATES WITH MO15/CDK7 TO FORM THE CDK-ACTIVATING KINASE	CELL			English	Article							PROTEIN-KINASE; DEPENDENT KINASE-2; CATALYTIC SUBUNIT; CELL-CYCLE; PHOSPHORYLATION; YEAST; CDC2; IDENTIFICATION; PURIFICATION; P34(CDC2)	Phosphorylation by the CDK-activating kinase (CAK) is a required step in the activation of cyclin-dependent kinases. We have purified CAK from mammalian cells; the enzyme comprises two major polypeptides of 42 and 37 kDa. Protein sequencing indicates that the 42 kDa subunit is the mammalian homolog of MO15, a protein kinase known to be a component of CAK in amphibians and echinoderms. Cloning of a cDNA encoding the 37 kDa subunit identifies it as a novel cyclin (cyclin H). We have reconstituted CAK in vitro with the MO15 catalytic subunit and cyclin H, demonstrating that MO15 is a cyclin-dependent kinase (CDK7). Like other CDKs, MO15/CDK7 contains a conserved threonine required for full activity; mutation of this residue severely reduces CAK activity. The CAK holoenzyme activates complexes of CDK2 and CDC2 with various cyclins and also phosphorylates CDK2, but not CDC2, in the absence of cyclin. Thus, CAK is a CDK-cyclin complex implicated in the control of multiple cell cycle transitions.			FISHER, RP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Morgan, David/0000-0001-8753-4416				CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MATHUR R, 1984, BIOCHEM J, V222, P261, DOI 10.1042/bj2220261; MOLZ L, 1989, GENETICS, V122, P773; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NUGENT JHA, 1991, J CELL SCI, V99, P669; O'Reilly DR, 1993, BACULOVIRUS EXPRESSI; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	35	565	588	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					713	724		10.1016/0092-8674(94)90535-5	http://dx.doi.org/10.1016/0092-8674(94)90535-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069918				2022-12-28	WOS:A1994PD69300019
J	MASON, IJ				MASON, IJ			THE INS AND OUTS OF FIBROBLAST GROWTH-FACTORS	CELL			English	Editorial Material							GOLGI-COMPLEX; CELL-CYCLE; FACTOR-I; FGF; RECEPTOR; FORMS; DIVERSITY; MESODERM; NUCLEUS; CLONING				MASON, IJ (corresponding author), UNITED MED & DENT SCH,DIV ANAT & CELL BIOL,MRC,BRAIN DEV PROGRAM,LONDON SE1 9RT,ENGLAND.		Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BAIRD A, 1991, ANN NEW YORK ACADEMY, V638; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BORJA AZZ, 1992, DEV BIOL, V157, P110; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; REICHMANFRIED M, 1994, GENE DEV, V8, P828; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VOGEL A, 1993, DEVELOPMENT, V119, P199; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, IN PRESS J BIOL CHEM, V269	36	533	544	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					547	552		10.1016/0092-8674(94)90520-7	http://dx.doi.org/10.1016/0092-8674(94)90520-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069907				2022-12-28	WOS:A1994PD69300004
J	PETER, M; HERSKOWITZ, I				PETER, M; HERSKOWITZ, I			DIRECT INHIBITION OF THE YEAST CYCLIN-DEPENDENT KINASE CDC28-CLN BY FAR1	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CLN2 GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MATING PHEROMONE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; POSITIVE FEEDBACK; G1 CYCLINS; ACTIVATION	Cell cycle arrest of Saccharomyces cerevisiae in G(1) by the antimitogen alpha-factor is mediated by activation of a signal transduction pathway that results in inhibition of the cyclin-dependent kinase Cdc28-Cln. The Farl protein is required for cell cycle arrest and associates with the Cdc28-Cln complex. The kinase activity of Cdc28-Cln was directly inhibited by Far1 both in vivo and in vitro, thus demonstrating that Far1 acts at the final step in the alpha-factor response pathway by inhibiting a G(1) cyclin-dependent kinase.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,GENET PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM31286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CHANG F, 1991, THESIS U CALIFORNIA; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHALES R, COMMUNICATION; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUTCHER BA, 1991, SEMIN CELL BIOL, V2, P205; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HICKS JB, 1976, GENETICS, V83, P245; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEVIN DE, 1993, CURR OPIN CELL BIOL, V5, P245; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETER M, UNPUB; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3111; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SORGER P, COMMUNICATION; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; TYERS M, 1992, EMBO J, V11, P1772; VALDIVIESO MH, 1993, MOL CELL BIOL, V13, P1013, DOI 10.1128/MCB.13.2.1013; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	48	204	208	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1228	1231		10.1126/science.8066461	http://dx.doi.org/10.1126/science.8066461			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066461				2022-12-28	WOS:A1994PD42200036
J	COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC				COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC			ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MAMMOGRAPHIC PARENCHYMAL PATTERNS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; EXOGENOUS ESTROGEN; CONTRACEPTIVE STEROIDS; ADJUVANT CHEMOTHERAPY; TAMOXIFEN THERAPY; HORMONE USE; RISK; CARCINOMA		HEMATOL ONCOL ASSOCIATES, DENVER, CO USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21205 USA; FAIRFAX ONCOL ASSOCIATES, ANNANDALE, VA USA; ALBERT EINSTEIN CANC CTR, BRONX, NY USA; EASTERN COOPERAT ONCOL GRP, OPERAT OFF, DENVER, CO USA; EMORY UNIV, SCH MED, ATLANTA, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Emory University	COBLEIGH, MA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT INTERNAL MED, DIV HEMATOL ONCOL, MED ONCOL SECT, CHICAGO, IL 60612 USA.							ADAMI HO, 1987, NEW ENGL J MED, V316, P752; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; [Anonymous], 1992, Lancet, V339, P1; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BONADONNA G, 1979, ADJUVANT THERAPY CAN, V2, P227; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1993, EPIDEMIOL REV, V15, P233, DOI 10.1093/oxfordjournals.epirev.a036110; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIDSON JA, 1992, MED J AUSTRALIA, V157, P429, DOI 10.5694/j.1326-5377.1992.tb137283.x; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DISAIA PJ, 1993, CANCER-AM CANCER SOC, V71, P1490, DOI 10.1002/cncr.2820710414; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; EDEN JA, IN PRESS MED J AUST; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1989, NEW ENGL J MED, V320, P474; FORNANDER T, 1989, LANCET, V1, P117; GAMBRELL RD, 1984, AM J OBSTET GYNECOL, V150, P119; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON IC, 1993, CANCER-AM CANCER SOC, V71, P2127, DOI 10.1002/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2; HENRICH JB, 1992, JAMA-J AM MED ASSOC, V268, P1900, DOI 10.1001/jama.268.14.1900; HEUSON JC, 1976, CANCER TREAT REP, V60, P1463; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOGSTRATEN B, 1982, CANCER RES, V42, P4788; HOOGSTRATEN B, 1984, CANCER, V54, P2248, DOI 10.1002/1097-0142(19841115)54:10<2248::AID-CNCR2820541031>3.0.CO;2-D; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HUG V, 1985, J CLIN ONCOL, V3, P1672, DOI 10.1200/JCO.1985.3.12.1672; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSONWILLIAMS KA, 1991, YALE J BIOL MED, V64, P607; JORDAN VC, 1987, CANCER RES, V47, P624; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KAUFMAN Z, 1991, CLIN RADIOL, V43, P389, DOI 10.1016/S0009-9260(05)80566-5; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KING RM, 1985, SURG GYNECOL OBSTET, V160, P228; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOBO RA, 1990, OBSTET GYNECOL, V75, pS18; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANDEVILLE R, 1984, EUR J CANCER CLIN ON, V20, P983, DOI 10.1016/0277-5379(84)90174-3; MANNI A, 1980, CANCER TREAT REP, V64, P779; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MARCHANT DJ, 1993, CANCER, V71, P2169, DOI 10.1002/1097-0142(19930315)71:6+<2169::AID-CNCR2820711608>3.0.CO;2-B; MARGREITER R, 1984, BREAST CANCER RES TR, V4, P45, DOI 10.1007/BF01806987; MATTHEWS PN, 1981, BRIT MED J, V282, P774, DOI 10.1136/bmj.282.6266.774; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MEHTA RR, 1992, BREAST CANCER RES TR, V20, P125; MERRILL JM, 1992, JAMA-J AM MED ASSOC, V267, P568; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; OBRIAN CA, 1985, CANCER RES, V45, P2462; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PLANTING AST, 1985, CANCER TREAT REP, V69, P363; POWLES TJ, 1988, LANCET, V2, P344; POWLES TJ, 1990, LANCET, V336, P48, DOI 10.1016/0140-6736(90)91555-O; PRITCHARD KI, 1980, CANCER TREAT REP, V64, P787; RIBEIRO G, 1986, BRIT J SURG, V73, P607, DOI 10.1002/bjs.1800730805; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SAWKA CA, 1986, CANCER RES, V46, P3152; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SHERMAN BM, 1979, J CLIN INVEST, V64, P398, DOI 10.1172/JCI109475; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SPENCER JD, 1978, BRIT MED J, V1, P1024, DOI 10.1136/bmj.1.6119.1024; SPICER DV, 1991, J NATL CANCER I, V83, P63, DOI 10.1093/jnci/83.1.63; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STOLL BA, 1988, LANCET, V1, P1278; STOLL BA, 1967, BRIT MED J, V1, P150, DOI 10.1136/bmj.1.5533.150; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; THERIAULT RL, 1991, ANN ONCOL, V2, P709, DOI 10.1093/oxfordjournals.annonc.a057847; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WADA T, 1981, CANCER TREAT REP, V65, P728; WILE AG, 1993, AM J SURG, V165, P372, DOI 10.1016/S0002-9610(05)80848-7; WILE AG, 1991, P AN M AM SOC CLIN, V10, P58; WILKUND I, 1992, MATURITAS, V14, P211; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YOSHIDA M, 1982, JPN J CLIN ONCOL, V12, P57; 1992, HORMONE REPLACEMENT, P166; 1989, N ENGL JMED, V320, P491	107	135	136	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					540	545		10.1001/jama.272.7.540	http://dx.doi.org/10.1001/jama.272.7.540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046809				2022-12-28	WOS:A1994PB22900032
J	NATHANS, J				NATHANS, J			IN THE EYE OF THE BEHOLDER - VISUAL PIGMENTS AND INHERITED VARIATION IN HUMAN VISION	CELL			English	Review							COLOR-VISION; ABSORPTION-SPECTRA; RETINITIS-PIGMENTOSA; MISSENSE MUTATION; RHODOPSIN GENE; CONE PIGMENTS; RED		JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT OPHTHALMOL,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	NATHANS, J (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; BARLOW HB, 1956, J OPT SOC AM, V46, P634, DOI 10.1364/JOSA.46.000634; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; DRUMMONDBORG M, 1989, P NATL ACAD SCI USA, V86, P983, DOI 10.1073/pnas.86.3.983; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; NATHANS J, 1993, AM J HUM GENET, V53, P987; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, IN PRESS J NEUROSCI; WINDERICKX J, 1992, NAT GENET, V1, P251, DOI 10.1038/ng0792-251; WINDERICKX J, 1992, P NATL ACAD SCI USA, V89, P9710, DOI 10.1073/pnas.89.20.9710; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	20	44	46	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					357	360		10.1016/0092-8674(94)90414-6	http://dx.doi.org/10.1016/0092-8674(94)90414-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062382				2022-12-28	WOS:A1994PC40500002
J	NANKIVELL, BJ; BHANDARI, PK; KOLLER, LJ				NANKIVELL, BJ; BHANDARI, PK; KOLLER, LJ			RHABDOMYOLYSIS INDUCED BY THIORIDAZINE	BRITISH MEDICAL JOURNAL			English	Letter											NANKIVELL, BJ (corresponding author), WESTMEAD HOSP,WESTMEAD,NSW 2145,AUSTRALIA.							CARUANA RJ, 1983, N C MED J, V44, P18; HAAPANEN E, 1988, SCAND J UROL NEPHROL, V22, P305, DOI 10.3109/00365598809180804; PEALMAN C, 1988, AM J PSYCHIAT, V145, P1018	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					378	378						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081139				2022-12-28	WOS:A1994PB31600023
J	HEBERLE, J; RIESLE, J; THIEDEMANN, G; OESTERHELT, D; DENCHER, NA				HEBERLE, J; RIESLE, J; THIEDEMANN, G; OESTERHELT, D; DENCHER, NA			PROTON MIGRATION ALONG THE MEMBRANE-SURFACE AND RETARDED SURFACE TO BULK TRANSFER	NATURE			English	Article							HALOBACTERIUM-HALOBIUM; PURPLE-MEMBRANE; BACTERIORHODOPSIN; WATER; TRANSLOCATION; PHOTOCYCLE	Since the proposal of the chemiosmotic theory(1) there has been a continuing debate about how protons that have been pumped across membranes reach another membrane protein that utilizes the established pH gradient. Evidence has been gathered in favour of a 'delocalized' theory, in which the pumped protons equilibrate with the aqueous bulk phase before being consumed, and a 'localized' one, in which protons move exclusively along the membrane surface(2,3). We report here that after proton release by an integral membrane protein, long-range proton transfer along the membrane surface is faster than proton exchange with the bulk water phase. The rate of lateral proton diffusion can be calculated by considering the buffer capacity of the membrane surface. Our results suggest that protons can efficiently diffuse along the membrane surface between a source and a sink (for example H+-ATP synthase) without dissipation losses into the aqueous bulk.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; TH DARMSTADT, INST BIOCHEM, D-64287 DARMSTADT, GERMANY; HAHN MEITNER INST BERLIN GMBH, D-14109 BERLIN, GERMANY	Max Planck Society; Technical University of Darmstadt; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)			Heberle, Joachim/D-8605-2016; Dencher, Norbert/G-6640-2014	Heberle, Joachim/0000-0001-6321-2615; 				ANTONENKO YN, 1993, BIOCHIM BIOPHYS ACTA, V1150, P45, DOI 10.1016/0005-2736(93)90119-K; BAUER PJ, 1976, BIOPHYS STRUCT MECH, V2, P79, DOI 10.1007/BF00535654; BURGHAUS PA, 1989, ARCH BIOCHEM BIOPHYS, V275, P395, DOI 10.1016/0003-9861(89)90387-1; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; GRZESIEK S, 1986, BIOPHYS J, V50, P265, DOI 10.1016/S0006-3495(86)83460-9; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; GUTMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P391, DOI 10.1016/0005-2728(90)90073-D; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HEBERLE J, 1990, FEBS LETT, V277, P277, DOI 10.1016/0014-5793(90)80864-F; HEBERLE J, 1992, P NATL ACAD SCI USA, V89, P5996, DOI 10.1073/pnas.89.13.5996; HEBERLE J, 1992, NATO ADV SCI I B-PHY, V291, P187; JUNGE W, 1987, BIOCHIM BIOPHYS ACTA, V890, P1, DOI 10.1016/0005-2728(87)90061-2; KASIANOWICZ J, 1987, J MEMBRANE BIOL, V99, P227; LEBERLE K, 1989, BIOPHYS J, V55, P637, DOI 10.1016/S0006-3495(89)82861-9; LECHNER RE, 1994, BIOPHYS CHEM, V49, P91, DOI 10.1016/0301-4622(93)E0086-K; MICHEL H, 1980, BIOCHEMISTRY-US, V19, P4607, DOI 10.1021/bi00561a011; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; OESTERHELT D, 1973, FEBS LETT, V36, P72, DOI 10.1016/0014-5793(73)80339-4; POLLE A, 1989, BIOPHYS J, V56, P27, DOI 10.1016/S0006-3495(89)82649-9; PRATS M, 1986, NATURE, V322, P756, DOI 10.1038/322756a0; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019	21	278	282	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					379	382		10.1038/370379a0	http://dx.doi.org/10.1038/370379a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047144				2022-12-28	WOS:A1994PA30400058
J	WRANA, JL; ATTISANO, L; WIESER, R; VENTURA, F; MASSAGUE, J				WRANA, JL; ATTISANO, L; WIESER, R; VENTURA, F; MASSAGUE, J			MECHANISM OF ACTIVATION OF THE TGF-BETA RECEPTOR	NATURE			English	Article							TRANSFORMING GROWTH-FACTOR; TRANSMEMBRANE SERINE KINASE; EXPRESSION CLONING; ACTIVIN RECEPTOR; II RECEPTORS; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; THREONINE KINASE; IDENTIFICATION; INHIBITION	Transforming growth factor-beta (TGF-beta) signals by contacting two distantly related transmembrane serine/threonine kinases called receptors I and II. The role of these molecules in signalling has now been determined. TGF-beta binds directly to receptor II, which is a constitutively active kinase. Bound TGF-beta is then recognized by receptor I which is recruited into the complex and becomes phosphorylated by receptor II. Phosphorylation allows receptor I to propagate the signal to downstream substrates. This provides a mechanism by which a cytokine can generate the first step of a signalling cascade.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Ventura, Francesc/ABG-2285-2020; Wrana, Jeffrey/F-8857-2013; Ventura, Francesc/K-9700-2014	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Massague, Joan/0000-0001-9324-8408; Wieser, Rotraud/0000-0003-4384-6658				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, IN PRESS MOL CELL BI; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944	43	2049	2145	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	1994	370	6488					341	347		10.1038/370341a0	http://dx.doi.org/10.1038/370341a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047140				2022-12-28	WOS:A1994PA30400046
J	RYAN, KE; MACLENNAN, S; BARBARA, JAJ; HEWITT, PE				RYAN, KE; MACLENNAN, S; BARBARA, JAJ; HEWITT, PE			FOLLOW-UP OF BLOOD-DONORS POSITIVE FOR ANTIBODIES TO HEPATITIS-C VIRUS	BRITISH MEDICAL JOURNAL			English	Article									N LONDON BLOOD TRANSFUS CTR,LONDON NW9 5BG,ENGLAND									AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; MACLENNAN S, IN PRESS TRANSFUSION; 1993, DRUG THER B, V31, P61	4	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					696	697		10.1136/bmj.308.6930.696	http://dx.doi.org/10.1136/bmj.308.6930.696			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8068079	Green Published			2022-12-28	WOS:A1994NA86900022
